<SEC-DOCUMENT>0001055726-20-000052.txt : 20201109
<SEC-HEADER>0001055726-20-000052.hdr.sgml : 20201109
<ACCEPTANCE-DATETIME>20201109155132
ACCESSION NUMBER:		0001055726-20-000052
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201109
DATE AS OF CHANGE:		20201109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		201297475

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ino-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:124dcabe-323e-4d00-a29d-21ddeb618d02,g:528b4586-6faf-4a31-a887-4db858d575b9,d:7b394cbbe15e40f4bfcebd7425a65725--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ino="http://www.inovio.com/20200930" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80L2ZyYWc6YjE4Yjg1YmIwYTExNGRlNGExNWE5Yjg1OWQ0ODlmMTAvdGFibGU6YTAwZjRhYWU5OGYxNGQ2OWIxN2UxNTBhZjc4ODk1YzIvdGFibGVyYW5nZTphMDBmNGFhZTk4ZjE0ZDY5YjE3ZTE1MGFmNzg4OTVjMl80LTEtMS0xLTA_d16689c2-9168-44f1-b55a-1e6a003cc6e4">false</ix:nonNumeric><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80L2ZyYWc6YjE4Yjg1YmIwYTExNGRlNGExNWE5Yjg1OWQ0ODlmMTAvdGFibGU6YTAwZjRhYWU5OGYxNGQ2OWIxN2UxNTBhZjc4ODk1YzIvdGFibGVyYW5nZTphMDBmNGFhZTk4ZjE0ZDY5YjE3ZTE1MGFmNzg4OTVjMl82LTEtMS0xLTA_200b209d-1d6d-4545-b303-52c2b4f2e577">2020</ix:nonNumeric><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80L2ZyYWc6YjE4Yjg1YmIwYTExNGRlNGExNWE5Yjg1OWQ0ODlmMTAvdGFibGU6YTAwZjRhYWU5OGYxNGQ2OWIxN2UxNTBhZjc4ODk1YzIvdGFibGVyYW5nZTphMDBmNGFhZTk4ZjE0ZDY5YjE3ZTE1MGFmNzg4OTVjMl83LTEtMS0xLTA_22d995a2-3265-4f04-bd2c-9b3bf60b875a">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80L2ZyYWc6YjE4Yjg1YmIwYTExNGRlNGExNWE5Yjg1OWQ0ODlmMTAvdGFibGU6YTAwZjRhYWU5OGYxNGQ2OWIxN2UxNTBhZjc4ODk1YzIvdGFibGVyYW5nZTphMDBmNGFhZTk4ZjE0ZDY5YjE3ZTE1MGFmNzg4OTVjMl85LTEtMS0xLTA_58bfb64f-738c-4762-8b0c-c64defd5dc6b">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80L2ZyYWc6YjE4Yjg1YmIwYTExNGRlNGExNWE5Yjg1OWQ0ODlmMTAvdGFibGU6YTAwZjRhYWU5OGYxNGQ2OWIxN2UxNTBhZjc4ODk1YzIvdGFibGVyYW5nZTphMDBmNGFhZTk4ZjE0ZDY5YjE3ZTE1MGFmNzg4OTVjMl8xMC0xLTEtMS0w_b34f13a7-66ce-4f7d-9936-41857fce60d0">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ifb2dc9cc60144c2ca1da77bc87b7812e_D20200101-20200930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfOTk4OQ_0932b4d7-3f73-4fbf-a0c8-940a3372135a">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="idf4033cfc12e48aca490d914c0d2e740_D20200101-20200930" format="ixt-sec:duryear" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81Mi9mcmFnOmIwNzAzYTQ1M2Y1NTQyNDlhZGI4NDg5ZDc1ZTM5NTk3L3RhYmxlOjM2ZjBlMjg5MDhhMjRhNDg5NDM2NjdiZjA5NDJhNmZlL3RhYmxlcmFuZ2U6MzZmMGUyODkwOGEyNGE0ODk0MzY2N2JmMDk0MmE2ZmVfMS0yLTEtMS0w_7961a5c4-2f68-469d-95bf-ec2551f75e40">1</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82NC9mcmFnOjQ4OGVjNmM3ZjM4NzRhZDM4NWNhZmQ2MzhmYTMzNDFlL3RhYmxlOjk5ZTlmZDljZjZiNjQ2NWY5MjU1YjI4NzVhYTFjNmIyL3RhYmxlcmFuZ2U6OTllOWZkOWNmNmI2NDY1ZjkyNTViMjg3NWFhMWM2YjJfMi0xLTEtMS0w_ad36144c-c69c-4ef1-995e-5f6792a7120e">0.1858045</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iff76d992bdba46d5be0328b7a9a8d64c_D20200803-20200803" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82NC9mcmFnOjQ4OGVjNmM3ZjM4NzRhZDM4NWNhZmQ2MzhmYTMzNDFlL3RhYmxlOjk5ZTlmZDljZjZiNjQ2NWY5MjU1YjI4NzVhYTFjNmIyL3RhYmxlcmFuZ2U6OTllOWZkOWNmNmI2NDY1ZjkyNTViMjg3NWFhMWM2YjJfNS0yLTEtMS0w_6f29341b-aff6-41fd-b0e3-30a02d1643ea">0.0002110595</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i8a37a98039ba414db800ad308eb2b02c_D20200803-20200803" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82NC9mcmFnOjQ4OGVjNmM3ZjM4NzRhZDM4NWNhZmQ2MzhmYTMzNDFlL3RhYmxlOjk5ZTlmZDljZjZiNjQ2NWY5MjU1YjI4NzVhYTFjNmIyL3RhYmxlcmFuZ2U6OTllOWZkOWNmNmI2NDY1ZjkyNTViMjg3NWFhMWM2YjJfNy0yLTEtMS0w_aa9852d2-c322-437d-a346-c5a7b4360e16">0.0002756873</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ie4c32c65608040b68dea715a2abffbcd_D20191226-20191226" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82NC9mcmFnOjQ4OGVjNmM3ZjM4NzRhZDM4NWNhZmQ2MzhmYTMzNDFlL3RhYmxlOjk5ZTlmZDljZjZiNjQ2NWY5MjU1YjI4NzVhYTFjNmIyL3RhYmxlcmFuZ2U6OTllOWZkOWNmNmI2NDY1ZjkyNTViMjg3NWFhMWM2YjJfOC0yLTEtMS0w_7bfc3422-899d-4191-981e-1aa042522f96">0.0002147766</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i1abaadc504944f67824cef5b490c4d51_D20191226-20191226" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82NC9mcmFnOjQ4OGVjNmM3ZjM4NzRhZDM4NWNhZmQ2MzhmYTMzNDFlL3RhYmxlOjk5ZTlmZDljZjZiNjQ2NWY5MjU1YjI4NzVhYTFjNmIyL3RhYmxlcmFuZ2U6OTllOWZkOWNmNmI2NDY1ZjkyNTViMjg3NWFhMWM2YjJfOS0yLTEtMS0w_3e1c20cf-d9a7-4052-8331-987df99f27ca">0.0003579611</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i9d03834c753f4461bc91e302fe02118e_I20201105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id34815f9d2a14071b19c7de18cdedc2e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91e7c0f132e34c59bf93da3effb57556_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad00cc94b7054dba89db6de62bd2743e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33802a693628436e990fd03d1c367654_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id37b739c3d7a4609833f69db4559a05d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib74217d38db64ce1adfc9b45c3791fb5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99922d4c4991454fadefaf71d1e588f4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37266a62557f4575b10ba5822c0a691e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbb8d0d9ac154379833cab4cface6fed_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a3e1abbbaad4bd7a9c51a4266035110_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529cf22cf7c34b5cbc581544727e180b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb8e36088aad444883e60bc40d755771_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d20b99727a54a1bb1084d53338a7ac5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a191e57427341858f4afa549fa9f378_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibff05cfee55444728cba8c5821c8cd39_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5255fbfad51c4e9289a4ebb454a733a0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82519fba8e3943dfbc56b64921e0755f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c41f3268694c0eb68fec4dba426315_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd26d40a3bcd4f41a7939cead908de3a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d09d690018a45498dd313c617375257_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5b3fb71885d4741bbd44d4710aafc27_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b80e1cd70cf4455b48eaa840dc9db78_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4baefa69f3a64b9a86686d55294e5ee9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i241bac219d9b4d2cab239b4a93aa2809_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b045061c7ab428582b10f52d98361c4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6edc82bc7b334d5aa607c4be90c9906f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7fd398adc34c49a398e8c5047ce7dca2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a3177da420f419793a90426cdb10103_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i490a2b67f81945fb92911af08177c0d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie245dae4bee84b58843b01eab260ebbe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164d36cfc1194bdfa7a02c7620d6c38f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7da7e536da1348a49003199c51350098_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08deaaf52352444fb06992fafb59e795_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98b336c669ff4c388e47c257d1834054_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia07dddec9a874e3db329127b98b02609_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie23871a5e018407e8d1d917d80671cdf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8eda4ce49e3408f9d4f5308a4037533_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4411f044a3a14ba18265a15b7226653c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i770162b78bb54f1fa1711d54652a4751_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eaf13aa46744705aa06fb61cbe8aa82_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9f754f0888148c498ed9fff863d50dd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47296c4f224f4821b9b5398dff066172_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic38a8356669f4b94a31d4fe6a18ea3c3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5dcbbe8e1f748d0aa61b641b73d3fc4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief04ee355ac748d99c0d4127735597c1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f9c138d29b443f9ed4bc98e732da37_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice079a38e1e1455b9775b3e80821be68_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if181d6b7610d46769fd6e637cc5073f1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0244b4520d04e4e8f59d89ddd1fad54_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie69799d5ae944511ba30c40042a5b329_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7569d7245f540de94c34ea74b24ab62_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb3f93f3c4c744d585e8ee4ebe462d9b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cc6179ba6344761bb813a2e5b312a60_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bf2f09d68754bb1971d7930890683f9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b9c539a1838477abaf6bfa915ee886c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cbfe1fda7da45e895ad0f7797870e3e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i510e75df51764aeab124f1f96a2ce60c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ee3e0978a8246caaaca0810f4cdd6ea_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff71970e3ccb4c1ba1e28e003e256dbb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647bfa57e2c94d82bfe6d0586215e925_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6259481f55947f8a81ad5e6bdf162e0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59f9640746a545989d1bbdb6a45e5c57_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd29250290ea4170b0c3e4f90e4306a9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaae34ec028bf4c5093d8f8caad4165ca_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6465f1fd3deb40cb9065e34705e46564_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978b9d86842c4f2bb0684bfacb1d2f7d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79c71d22c8084831b9423ab29cd4f183_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabe71ccc813949e295ac419f3bf11133_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25f2b47e634f4835ae39efe3509d84cd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e2c3f19273a42778f051025844a72e2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a012f253e8c4f838461bd187a090df3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i101ba48e80cc4d48b6199ad88e5a774a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad543da68a144f83a4d3805ac1f6d89e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id389379a953b4eac99e35c98ee5f565b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica8a6426b215442eb3caef7cecc4c115_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56e81b2a6acf4575b6a2fd1a15aa3a3a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i912f365b06294ab497683dd0247e0307_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e0f2db7f9c1466d884a3ed9d245869e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fca9614850f4094a30e35df9ad3f90d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c34cc69f8ff4a9e9279090d85e2ed1a_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11dd26adaa634c719948d1c87ffa3cb9_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e69cbad70b5452e8efff3fcfbccf5a5_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied96fbdb97a849e49bf60586fe4cae49_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11229e332bfe44958cd20245c914ab26_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia760ea1651944cdda9f87141b2c3b22c_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie93f9f62a04d495caf7d3e9ad734702b_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d984df17864fe6b064ed160b10dbab_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2376931e94a479ab3da18397c83700e_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6ba01cda73b483185d19910f47e556b_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d38c9c361a3445fa534a5a54efca8ce_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68ff5039256e484d8748c537f9e688d9_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62bb952cc15b4e1dbdd165eb7c3dcfbd_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b38bc463ae342a1bc3326ab42796c09_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb02416827ad434aacea7535d3776742_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c7f59d7bc8740db8cb1ae6cde690f43_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971bb2028af54bd38e7112fbc6dabd8a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idac672ec0b2e49d48f658a67d9cf0a81_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01241b5b4e1d44b28b5be3eab2189cf6_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c40c2619a6e4f689eb5e72a7788b8af_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71d44e1083ea450d84f392f8d18c62e9_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78220f5c2a8e4adebfb1017126a472b2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b65c8171f84184a933954da0d120ac_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c14c362804a4c57ba8b3135c378097c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ecc7fb3c1d845e3a86bafa86c697ef4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if02c1be59ab240e5bf65dec5515fa519_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fe6086a20184ba5bede380b65b2eea4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00852cf554364a3aae33ca5c9a00c901_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie69970bd582c4a249c8df8217f771954_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b6031a5c53b40dfbdf167f3ecc7127d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4db23d3c84734d66b66635aa8030bee5_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i679e13f56b134421b5679976e76aa618_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65eb5d78647b4483b008e23b402ec513_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d60de4ea362438a8dce34b8e79c0472_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i362cebf18fb64bc0aeb2df72a45e870e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ea46918d69244b0b92fa827e8689f35_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib64ca090f73d4dd6afb773407d8d39de_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbeadf22b0a640818c2ed7013bf0c883_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i31939003de4d4a3094a1ef0d323e91fb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:VGXAnimalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic34da769042c4f00941ee0248f92939e_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40baaae65a1744768b1b1675f3ad79d0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bda1f1acb9e424588e758c721d6202d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8936c9a775e4048b38647b7b881147d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9481fe2b9b0f4c18b552f08cc3c7e40d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75ad5d40a88941e3a7a873faf3f7eb60_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="i74f44125bc13416a9aeb599f2cb231e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c753a8fdf0f4e7394bef90ba65bc0d2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66d118519dea4ae7bc213714ffeb97a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb2dc9cc60144c2ca1da77bc87b7812e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b8bbe68292646fc920d02bc015f8116_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4058122d38c74b2495974de7f507740b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19efa68d746c41c38d72557926a2c83a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10bdaf5e033f4b6cb32118002bd714d4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1fe60d4ed164b4ba68d097b07daea40_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59afc9c747d34b8c8a09631dec66eae4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb681e91bc24c64b846b49185fe2187_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>ino:investment</xbrli:measure></xbrli:unit><xbrli:context id="i71790af5924c4ddab339efc7f993a154_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5ad4689ec9487e82f66dfbdc7bcff2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6e18e4080084b71847f96b5e9a0e699_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a526030817474ca6bde92e79a78309_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie860f23b62fe487f8c985dd5b2c5316a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf4033cfc12e48aca490d914c0d2e740_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02f68c7b48d744a6a9173080f6c38f09_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i918e4025371f42b5b7b58df82fc10039_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dbb0afb9ddd4315b01e6f4ccb7ca2c6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if795f05efa0445c98031f36131b16eb8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78c105aeef2c41549d702f116ad4f464_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie03669a396f4494cb8682e7da1ca04b4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b71d42002e544b4a463361f34d11920_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e85feb515594f70b6395ddc1f835acc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i151a4fa9e7064eb0913b049b54c5c026_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a11d9344d464d08a2c4860a29929ef9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i038eb61ac20847bb81aa8ef1c87cefbc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ea8a9e591f0496d8673b145a17803fb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id488e43085014ecdb6ffe6983f1f85b9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb90dd8056f43a3ada1c1be4856323f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88d54f6841f54932bc303d237a8609b6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7212a769f73745f29da1c66276126ff3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52399d29eb084b1fba8917f89379b49c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic787e50b63d34253bbe8d56456eb3701_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0dcb790ab6d41bcb0c822ec87057c02_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99efe129ba7f47c493d7948e3488435d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0393158ad254b10ac5bbdca3fffa1c2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i692de2cba0aa4e9bbf5aee0bbed07c99_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e17ec22317c4268b177ef3d384f59b6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic97b736b29264d8aa6220ac0e12c35fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b7d48f9d1074982822fddd2b379a517_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie48be730bf58424b80b0e60560d8fb7e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6f88938286e46c5852675631383c455_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i915d187dcbcc4f6abe0cc0d82477a4dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibea476b8d6cf4060b5668a0a25d5da59_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58ed83b261a747f18822c09954cbbc28_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia54a86390af04834af68005465847e66_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa448e74007b43949527573adaece377_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8de60a0d0457444486d03b56271564bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61b22b095121487092da2a8e6fb84adf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa2966e31f5c4d178bace1c18c46ea63_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5536482a9a094c779a9961b697daaf39_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94285e36aedc4ac6936417abdd4e690c_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie34b833b31b34228ad5580d790df4e4b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f8340ca06974cc4af47f666f30b4427_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35a4423ca3fd4a44b5437b54d8107c3f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i993e6fb6374f485f825fc460f02fba85_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaf790af2a9c4f65a9e9b79b785a3c9f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i595e1f2af87d47f9825e175e8cdbe831_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i629f451db0a646ff9a5db84aee063ff4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i929847a653e343629b9e00d8a43f72a9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55a6a7fc219f409290b994a921f5de9f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9158ca8f497c4770861d6068bf7925f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2914df82e244dcb9b995f1185e3447e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdf052a2e7144cdbbe989052584b4ca0_I20050131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:InovioAsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2005-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4afa819554cd473a95b7517d32ce72f6_I20090630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:VgxPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eca76820add42a0a986a746497d97dd_I20160430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if070ef767938497492f880730056fd65_I20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-19</xbrli:startDate><xbrli:endDate>2019-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3abdef29e774d82a089595d8b564e0f_I20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>ino:day</xbrli:measure></xbrli:unit><xbrli:context id="i172d0673a3194c5580d4987b79a2a44c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if59eceeb9abf42459b9e0b88dc6346ce_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45d4d90e086a49749993964ed0753833_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i590d515cf6de40edb611587951823c62_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d466a48e9e141aa8102e78c3a89cb07_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864892cede774f3eb42a10f60eaf5a21_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0c7c8a510c14ce3ba010b700fac6047_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2393a62fa5e34d739b1a36b6e8df6f31_I20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cec051d961f4164be10ec4cd03c6eb8_D20190801-20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a37a98039ba414db800ad308eb2b02c_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93454515f2814d1aa32809ed291c931a_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i930a152e7e8f41e89ca66ed7945686b3_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if776c09c12d048a8a03158014bdd629b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i069c085bd0884569a0c363b84262b982_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666980e930ca4263a11fb9d67a8ff7a5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i438e7b59c3d54e9e998a30ddc65e87a3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8958471a957c4db3b44209f556886dc5_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8a6a5f3412b4170b586cb0a191c2b65_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30b055a2515244df98c8096ff545da5c_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib669b19a336e48c890a2feda647d2035_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47a612180eaa425693bc6df2815b34a8_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idecb5c7b97f44096ab202e14ea4c5a5c_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5922a465abf4cc1be657156439079c7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34550c65c6944e8290ed1e7c3cc2387d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i321babdbed2a41498f88f960499c9240_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cca53a6bf0849c3a1f4c545316eb5ca_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2b79363a4154026a899e339e36624d9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff76d992bdba46d5be0328b7a9a8d64c_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c32c65608040b68dea715a2abffbcd_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1abaadc504944f67824cef5b490c4d51_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib12d03d2fe7e453ea4f8ccb997e9f525_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09a126e34b741aa9a646f361a9bfa0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2d0bbde4d3e40a9883106a66764b89b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b8d7c533b04e2981466489c552e6c1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14a978d9496a43e7aede0fcbc572e14b_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c298cf37a4848da8778eeafecf73788_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97fe994b743146a2b11f82e54b658475_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id24bddea654742c4b5eecc7be2d6d449_D20200403-20200512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-03</xbrli:startDate><xbrli:endDate>2020-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib23297044af5421488bf606a07fcad5a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c022db15d174f8db8fb571a3e4db2f7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3afac984f9d4d59bbd2907c5bbd7278_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i074731de2992483e840b846807d642f7_I20160513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9835623d0cf40b4861f5c838d46c1a2_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b4928fc44ae4021b15f75edc4b2c760_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc202bd5f1fd4725bdbf57b6065610c3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i186812e80eed40f0bbab169954854146_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5f528ac7ca4891a83906dfc20c1df3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db1b3c721d04b66b6aa18b2614af73a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93b688d453949bda8f80084a4f8c0cf_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44a63daa0269434b8f8645084440149c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5353e9eb3d34cb7a882d3194dc9492f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b9fb3e5b5e4a31a8873ab12cfb64d0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d0b8128b742495c90250bc5b8849172_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e3ca1e82c047479a0c74b2718566f0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06030a312f124dce90532593ecc94dd9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e44945591f04d5da4354f7f7bdd35cd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bdb6a99776a4c4d800ab8e40b952f8d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0194a559551a40c8b27e764106336195_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c5944ef521743b3b9e876883e54f1e5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5a0629abda644218979a5b63841e116_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i860fb08bf8184b179cac33e4192e1816_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide8b04bd4c5e49acb95ba740445e35f4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d3155aacbf84e0b8ce936aae7adf3b9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib68e05e899ac4508aa008ee16595c00c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba702d59c1624ad78cddd0ba1ffc4322_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a56a2b1e29242588c663774b4b5aa76_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i554f1ca12a6049099aa8584a524a2161_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a898fb72f1a49f5bd77c57ed253bd16_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b05350e1bfd4d9ab4452aefb8f891fb_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d59312f204e4b97ab0b449aceeddccb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2861cdc8f69f41d5b5875d02a30fb6a8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia51339b229ef4a62b912b1d36f13eb7a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d7691f080348dea281680ef992b0a6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e404e614cda487ba8a65c024ef8d309_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f1be49da4d049788cefaa0996012c18_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31d99600c91541e08b13dbd22f740ac6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id952f10e76044800b212f242883b868c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39f1040f585a4f308338f4f88079b910_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i289251eaf4234243bc0156afcbc6016e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c12a6f77d0492195c95821a8e4b7b6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3d462cb47b640bf897ca00c25614f47_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a618cdb93274c3cb270ff6bda022556_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af7c35ef173431fb3279d39c0f1d502_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i147548485ecd4491b08aef970e8b6c24_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a5bf1e66b6a422a87b55518b074a975_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6722d5596bb495cb02bbd3e009bb98a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice161059e07d46408a923dd86909c6c9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief5502197e4f432eb1f99435f0610ad2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic129651914c14c8c8f24304e6cea8cf4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c0eec23a36476e8fa9dc64d2143d2b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fb2a364d2a84d27a0a8bb72b4a5d947_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbfbede0bdee4bf2a1144f18c7e235cf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7053c11a98db4096a9e40bd43a3c419b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i195f8d33da5c49f1ad16bb63dfd92fc5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib27721d879d24dc09f0b0eaff7993400_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b70f956f6ba4badbe26e9b1a4182687_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5850434bfd7f47e6aecdd16aac2a9c5e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4b0c15ae5ac4a8e8c3949f8c677e46d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847658eadc124bf3bfa5c9301c21bb42_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffcbbe5f4f454868b69c0a199c847e26_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d9bde506f34a86a79e76444931a225_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id846dd9c3ed6491e8bd1b652cf0299d3_D20200827-20200827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-27</xbrli:startDate><xbrli:endDate>2020-08-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie03bd2679d2e4a7d9318989067e22958_I20200827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3c081d7909a418589d0447afe757e8c_D20100101-20101231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85f7dcb7a22e4903ad067fbb0557bacb_D20140101-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d860bed7f3c477c927663b8fe0f5eee_D20150501-20150531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-01</xbrli:startDate><xbrli:endDate>2015-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bef37dba0d9484fa9ec9f1316d39f3b_D20160101-20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3975abdb45c8440abeef92728a3f628e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecf61220d18043d899fc9e4751d53309_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i790052b1d4424f2eaa1cf12c5cc544e1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40c874fb1aab45f6a0c7ba48d937c1c7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief6a9b5c09ee4b90af8663890af888fa_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49f5bd8f2ce54ea9aac77e18fa6578c7_I20200220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae58b01d628f4694912a6815b3ea0645_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29248800a6f9460c9570869254c619d7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie258d44d8f7c42a788923cec12040ba5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f446d994234ef9aa5a5bc12c0b9dcb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92e675b7850f48a7bd3444a4732e7d6a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57c38a9d213944289a8cdaf81d35f929_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c3f9ed79a4848cab5edbb332f829d5d_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i652ec1b835ac4951b1455fa93ec2220c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0046f92427f94b59992479e7afc4aeab_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c90a066b83c4b8380cb3cd37bc3a09a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7fbaa1c34944d488dabcf367f55d769_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8599ce44e474e488237d3872fc61db9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib51d61f346d74c80bcc530d2cf49fc35_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ifd1bef4535014b23bd76467b4f46b98d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52fd1f860b3e47b3b28f24815064d334_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8e016753b6d49ffa2bed4a3be3bc0ff_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15135c10f2b84613a0bdfc1f99cfb3f9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic81bd389069e417a984bce2bcd1d1063_D20171229-20171229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-29</xbrli:startDate><xbrli:endDate>2017-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47d345bee3e7411d98a3ba44f79db554_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a9ae846802141b899c438da3a7cd430_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d907bd30e814bf1997a9fd3ed4a165b_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcb1a6014bfb4665a8e53fda2328b9fa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d344de8bac24153b97039f4a5da33f7_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i364410dac22d46849150dbb76bf79ea3_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4b9ecc1c92b4eb3b546f10e1fd321ae_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>ino:product</xbrli:measure></xbrli:unit><xbrli:context id="ic3ff9e9dd0e5478f9b9bee7abc6546ca_D20150807-20150807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-07</xbrli:startDate><xbrli:endDate>2015-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i790eb33d2aab4bbb89117717eaf49e43_D20171231-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-31</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc0a0736a3a41e3a718ffe92978cc2d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94a9e28f27b340909b69217c93f1e240_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11fb2d121358429bbb5330755fc13578_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae268d9545fc40279bac5472d53ddf72_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5188afbca0524352a1d0626a807e0bc4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0128722f91943efb7a4bdfdc5335c37_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i006215dec0fa4ecdac01b405a91894bb_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5d7fe092264c2db4c3072992ccce84_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08d25cd3db624f0fa8d5198cf2a38bc6_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c40f03c0b148739b61b7e80708fc06_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b66be9eec75416f98e7e0628e15662f_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2db5556827143cdafe4b46ce571915b_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18456a29ef3c4982b6471ce35dc6e525_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i312dea0c2ff240da9167e27ee1e8868d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id557bc0e9dca48c98443ad742ea2b548_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa238803cd83463bbeb7a595eaa9463c_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e0e25538df447b9b57d8cdb39c3731d_D20190801-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04dd7aeed28047949952a8193bc3f3a4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idac8dcab713949bd94df184fbba19e22_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida003d1fc52d461c9d2031cf761e1268_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01999719b8694f2cb9344f65f0b9b3fc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie814bccba6fe456b84bc2d64be454d97_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8695b2243216498fbd1123097efeb201_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id80ffa0c4fd840e08766b83da4af802f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59cb3488176045c9af0c67101f651fd0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31f8cf75d3184c5385ae2d3930c43939_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icddc6a2b71ac4679b73a1761b7335361_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42731760dc864386b6cc234953ed8db8_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i925dbb99e22c47109cfd6499f718d23f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5310f1c21874dcba016f8044259901b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied249d236e834e95ad34273624d104c1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7a90a05adcc4f638f0b47beed718798_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i869d8bf326be4abfbb1e18a89a00961a_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec2d5f6527c24125972f2622cef53837_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedf6a38f277949399861daef313a0f5d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib53c870fb97b4899bbb5a65108c6bd6d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeddbb99315448e8b2869ef6ad5da9ab_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if383b813ea7a4745bfc01e54b08f32d4_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0362d182781f4ee797f88622a5c045cf_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27451cafe1f2419998b0684fe0a1a45f_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2874a1f41d394187a5752e0fa6598078_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f18198c2b4e4bd8b89b62558865184c_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4859da00a9c04ed2b413734cd6ae17e4_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79ae502b32684fdf8f98b1c19fcf0397_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c98da30e4704069839ed075f3b5a328_D20200601-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10ff0a553ff04929a035481611ba22dc_D20200601-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70b1c5c8e2f24fff8299e8b17608bb18_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i022bb72c504942ac878d6769a4a1b696_D20200601-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05d2269442c846edb144f98b63b06aae_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98c79c39dba34165aa075b540f1c274a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i135db666eca94e468d89995d1fdb8e21_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0df0aeb02416451db34b6235410d3492_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:33.333%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTEx_c50d95ff-2e34-491c-b22d-05858becb83f">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6ODJjMDRmMmI2NDE5NDZmYWJkMTRlNzUxN2Y4ZjJkMGYvdGFibGVyYW5nZTo4MmMwNGYyYjY0MTk0NmZhYmQxNGU3NTE3ZjhmMmQwZl8wLTAtMS0xLTA_9f932e4d-efdb-4c19-905b-beffe7deb4ae">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8xMzA_8d0fddd4-9a10-4a4c-822b-7fe4dc663b8b">SEPTEMBER 30, 2020</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6MzkwM2U4ZTE5ODFlNDU5NDhjNzRjMjNiNTIyOTUxZGMvdGFibGVyYW5nZTozOTAzZThlMTk4MWU0NTk0OGM3NGMyM2I1MjI5NTFkY18wLTAtMS0xLTA_c506faba-d0dd-4ce1-87ec-2a253fd2c197">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">       FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMISSION FILE NO.&#160;<ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTA0_7fd01f4f-b54a-417d-9652-ed3caf77337e">001-14888</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:186.00pt"><tr><td style="width:1.0pt"></td><td style="width:184.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="ino-20200930_g1.jpg" alt="ino-20200930_g1.jpg" style="height:64px;width:204px;"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTE1_0c9b6423-536e-4a8a-8c80-73e8eb8d5436">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6MmY3OGRlMzllNWUwNDY4ODllOTIxZTExMTYyOTA0NzMvdGFibGVyYW5nZToyZjc4ZGUzOWU1ZTA0Njg4OWU5MjFlMTExNjI5MDQ3M18wLTAtMS0xLTA_836bc44f-f09f-40cc-bd77-415dee76c6b4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6MmY3OGRlMzllNWUwNDY4ODllOTIxZTExMTYyOTA0NzMvdGFibGVyYW5nZToyZjc4ZGUzOWU1ZTA0Njg4OWU5MjFlMTExNjI5MDQ3M18wLTItMS0xLTA_1a2fef97-049f-4e61-93ce-35bbe2c9148c">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTA1_612341ff-ab76-4b56-abd6-a0718551e7c0">660 W. GERMANTOWN PIKE, SUITE 110</ix:nonNumeric>  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTA2_abd4581b-761e-4f49-b2e2-9b514fc708c1">PLYMOUTH MEETING</ix:nonNumeric>, <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTA3_5ec4ffed-20a7-4d73-8eb9-14f257155b38">PA</ix:nonNumeric>  <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTA4_91f8aa0f-150c-4014-8df8-d7c70f249f5e">19462</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (<ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTEy_2c0b5ece-001f-49b2-8f74-a315cf718627">267</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTEz_ff07b98d-fac0-4ead-9584-5bb8db4beef6">440-4200</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.069%"><tr><td style="width:1.0%"></td><td style="width:41.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6YTg4MzY1YjlkZWQ1NDVkMTlhNjgyNTRlYjNhNTNhN2UvdGFibGVyYW5nZTphODgzNjViOWRlZDU0NWQxOWE2ODI1NGViM2E1M2E3ZV8xLTAtMS0xLTA_cacb8a9d-9e2b-4c08-b2a5-83945dab9954">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6YTg4MzY1YjlkZWQ1NDVkMTlhNjgyNTRlYjNhNTNhN2UvdGFibGVyYW5nZTphODgzNjViOWRlZDU0NWQxOWE2ODI1NGViM2E1M2E3ZV8xLTEtMS0xLTA_e135143e-e3ba-4663-bc92-509573e40270">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6YTg4MzY1YjlkZWQ1NDVkMTlhNjgyNTRlYjNhNTNhN2UvdGFibGVyYW5nZTphODgzNjViOWRlZDU0NWQxOWE2ODI1NGViM2E1M2E3ZV8xLTItMS0xLTA_e822ed82-8faf-400e-a0de-08bc3c4031f2">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:33.333%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTA5_57524359-8a57-4ced-bcfa-5212e83b4759">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTE0_163c87ff-65af-40b8-a430-276b1a3d643b">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6NTdlZDY0YjQ1NzIwNDk3OTljYTNjNTQzZDRkYmNiN2IvdGFibGVyYW5nZTo1N2VkNjRiNDU3MjA0OTc5OWNhM2M1NDNkNGRiY2I3Yl8wLTMtMS0xLTA_931a8e3f-f15f-4746-af68-87789a684d6f">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6NTdlZDY0YjQ1NzIwNDk3OTljYTNjNTQzZDRkYmNiN2IvdGFibGVyYW5nZTo1N2VkNjRiNDU3MjA0OTc5OWNhM2M1NDNkNGRiY2I3Yl8yLTQtMS0xLTA_4493b166-f7dc-41e8-8f85-024f87143580">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6NTdlZDY0YjQ1NzIwNDk3OTljYTNjNTQzZDRkYmNiN2IvdGFibGVyYW5nZTo1N2VkNjRiNDU3MjA0OTc5OWNhM2M1NDNkNGRiY2I3Yl80LTQtMS0xLTA_1f634d3f-b05c-4d0e-b96e-8c1fd610fd2d">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTEw_085b60e2-e06a-4f58-9fb1-1c223f9acbc6">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">        &#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was <ix:nonFraction unitRef="shares" contextRef="i9d03834c753f4461bc91e302fe02118e_I20201105" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMDkw_4aecf71b-7204-427f-815c-4cebba8e57c9">169,408,979</ix:nonFraction> as of November&#160;5, 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:186.00pt"><tr><td style="width:1.0pt"></td><td style="width:184.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarterly Period Ended September&#160;30, 2020</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_10">Part I.  Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_10">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_13">a) Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_16">b) Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_19">c) Condensed Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_22">d) Condensed Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_25">e) Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_28">f) Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_115">Item&#160;2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_115">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_133">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_133">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_136">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_136">40</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_139">Part II.  Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_139">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_142">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_142">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_145">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_145">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_148">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_148">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_151">Item&#160;3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_151">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_154">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_157">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_157">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_157">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_160">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_160">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_163">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_163">64</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_10"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I.  Financial Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_13"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:74.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNC0xLTEtMS0w_35e10cd0-34c6-48bd-b31f-172338fa3e45">178,700,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNC0zLTEtMS0w_3c3c2692-9685-4191-bd54-c8d1bcd9c992">22,196,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNS0xLTEtMS0w_1b11a39a-e615-4ffa-bae3-a625bd1615d6">158,535,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNS0zLTEtMS0w_371ba72c-4c15-4e3f-8939-4db6aa898feb">67,338,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNi0xLTEtMS0w_b8a9775f-4d53-4d58-96e3-1895b7bc1548">7,692,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNi0zLTEtMS0w_497c94f0-db3e-4c53-a8d7-85185de1a0c5">700,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNy0xLTEtMS0w_7dd1c589-71d6-4e35-a52c-ea943b569cb1">501,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNy0zLTEtMS0w_d5ea0d6c-0a9f-46a5-aae2-488f8a3a2502">1,332,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfOC0xLTEtMS0w_2347429e-9c2a-470e-b226-cd0df83ff37e">31,563,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfOC0zLTEtMS0w_3a19dbf1-c524-484e-8389-5e108d901d80">1,584,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfOS0xLTEtMS0w_483ea264-cd83-406f-a9c1-6454492b7569">70,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfOS0zLTEtMS0w_62a13621-2552-42f0-be0b-7167f116ea99">1,050,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTEtMS0xLTEtMA_3579c4fb-6428-461a-96f0-1f0785d2b45f">377,064,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTEtMy0xLTEtMA_8e4e0cfe-72e1-4d3d-9abb-729584b9332f">94,200,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTItMS0xLTEtMA_7ac09947-089e-4611-85ce-bfe8399c4ec1">11,190,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTItMy0xLTEtMA_81edfc23-dc55-4067-9360-094b27bee2da">12,773,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTMtMS0xLTEtMA_3a02bda9-980f-4273-b561-e601828c778b">4,154,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTMtMy0xLTEtMA_a375a65d-a63e-4b39-8519-cecf99102e24">6,315,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTQtMS0xLTEtMA_c1088788-3433-4a79-a5c4-3ca2fec8dc61">957,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTQtMy0xLTEtMA_a32d421a-3edf-4377-91e6-6d123d54c9c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTUtMS0xLTEtMA_6a4644fc-6ba3-444b-be65-da42160037ea">3,283,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTUtMy0xLTEtMA_95da6a22-7f73-4bb7-b935-8586107e50d2">3,693,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTYtMS0xLTEtMA_b2311d6f-d2e4-4b3e-91b9-cbf97b4bcb66">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTYtMy0xLTEtMA_6c80df62-33de-4319-beeb-e2ad9a14a5ac">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTctMS0xLTEtMA_42b952fe-b70e-426f-9dac-95e33e1e06bc">13,008,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTctMy0xLTEtMA_bf179865-efec-49e2-86c6-2fc12505eb30">13,783,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTgtMS0xLTEtMA_5bf8ac1b-45d7-436e-b018-16ea48a67cb3">17,641,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTgtMy0xLTEtMA_f690e406-4181-40b5-a999-0a2963c8cc98">2,672,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTktMS0xLTEtMA_2c464ccf-d311-4666-ba63-a77d3fd890ae">437,814,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTktMy0xLTEtMA_8f665c1b-e108-4b98-88e7-3ed557f07437">143,951,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjItMS0xLTEtMA_7d123366-da07-46b4-b4b9-dcbdd555ed31">23,533,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjItMy0xLTEtMA_3cceb575-f4f1-49d4-a549-b7d4086dad21">18,237,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjMtMS0xLTEtMA_8511d8e0-8e4c-47ca-accd-f5e656c8c10b">794,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjMtMy0xLTEtMA_796a7268-4d51-4653-9170-2a96b8e36b74">729,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="ino:AccruedClinicalTrialExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjQtMS0xLTEtMA_13149a51-09ed-4175-9bd0-74fe092be75e">5,841,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:AccruedClinicalTrialExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjQtMy0xLTEtMA_4514e086-1715-4d09-bc43-5a152741b30e">4,049,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjYtMS0xLTEtMA_7d3bae54-7d02-4cd2-b5a0-4c7c17678fa7">77,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjYtMy0xLTEtMA_9da7239e-9c38-418a-9b95-01e0d7d9489b">92,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:zerodash" name="ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjctMS0xLTEtMA_c25ba335-3eea-456a-9620-5e0d378d33c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjctMy0xLTEtMA_7adcfa95-b474-47fe-ad95-aab14c330abe">31,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjktMS0xLTEtMA_8deacc81-ae9d-4257-bd6a-3971b1a4c4e5">2,264,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjktMy0xLTEtMA_d56e7dcb-2606-4829-bd0f-56bfb6de5e63">2,074,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzAtMS0xLTEtMA_da9e8821-9af8-4dc5-861a-fca84f8fb66a">8,616,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzAtMy0xLTEtMA_b0497d67-9162-4bbd-8f40-8d62e8ca72f2">6,065,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzEtMS0xLTEtMA_ef4e30a6-939d-4f1f-ba9b-a9e07a11b76f">135,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzEtMy0xLTEtMA_9635ba95-2f1a-40bd-8898-fe4b1bc6e6c5">708,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzMtMS0xLTEtMA_1d829d41-4e47-4850-ba0d-3e5e2d676648">41,263,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzMtMy0xLTEtMA_da5564e2-1671-4eb6-974b-0ed83ce9fd6b">31,989,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzQtMS0xLTEtMA_18399424-b851-42cf-9abe-6d881db858ef">82,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzQtMy0xLTEtMA_43b3fc13-fb83-4178-b8ce-3783e5dc393c">101,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad00cc94b7054dba89db6de62bd2743e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzYtMS0xLTEtMA_7a30f8cc-08af-4a8c-9c1c-e307ee743a73">49,537,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33802a693628436e990fd03d1c367654_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzYtMy0xLTEtMA_83070327-f1b4-4eab-ac4a-d45275021c45">64,180,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37b739c3d7a4609833f69db4559a05d_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzctMS0xLTEtMA_108eea79-91c9-4d08-a514-2b266db350d9">4,151,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib74217d38db64ce1adfc9b45c3791fb5_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzctMy0xLTEtMA_fdeb0bf1-2248-4c51-822c-3bb8bae29037">12,842,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzgtMS0xLTEtMA_a2b3202a-a2e0-4dd5-bdd5-fe0fe9b364d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzgtMy0xLTEtMA_2f6549ac-49b2-4709-959b-536c79342df4">8,819,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDAtMS0xLTEtMA_942e3ae5-2d2f-423a-ae1a-e855a703d298">18,669,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDAtMy0xLTEtMA_10036957-16ba-48e7-bc74-bc6d0490a3e3">20,409,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDEtMS0xLTEtMA_d8c8dd22-aa7b-4362-a2be-5629bf95dd3b">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDEtMy0xLTEtMA_2b4b7cc5-25d9-4bb0-9a7d-e9c644c14038">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entity, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDItMS0xLTEtMA_283a3d6b-a177-4be0-bc49-02332e28c6e4">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDItMy0xLTEtMA_871241fd-03fc-4764-9376-81ccfed359e1">135,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDMtMS0xLTEtMA_a2e178d0-ca8f-46d0-99cf-11fa34275944">39,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDMtMy0xLTEtMA_09423ad2-33c8-4f0a-8d4a-f6737eb62fdb">36,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDQtMS0xLTEtMA_fc0214f4-baeb-46a7-b398-8b47e753a2b9">113,813,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDQtMy0xLTEtMA_58782ff8-33d5-4e2c-a7f6-00708f587187">138,546,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDYtMS0xLTEtMA_e0f0eaec-c10b-466c-8bc4-589f092ff21a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDYtMy0xLTEtMA_d1669de3-da32-431b-878c-097045366fb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDctMS0xLTEtMA_9d2807fd-bc05-4a0c-9129-c12a746b382b">167,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDctMy0xLTEtMA_14e51009-1630-4251-a907-2d14ea2548eb">101,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDgtMS0xLTEtMA_f17e3371-3909-4f97-aa0f-45a4d4740dfb">1,205,842,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDgtMy0xLTEtMA_f4a0f09f-73b8-40d8-b14c-69e823d32bac">742,646,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDktMS0xLTEtMA_64909960-6e45-4e0f-bab3-bb46a4548140">881,858,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDktMy0xLTEtMA_edc023aa-e2f1-42dd-b32a-d319a97e91dd">739,785,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTAtMS0xLTEtMA_2835768b-95a8-454b-88fe-22bb63805e56">247,834</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTAtMy0xLTEtMA_33bbc52d-8d8a-4d8a-ad28-fd4fda76dfc9">472,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTEtMS0xLTEtMA_95d59588-900f-4956-90eb-3d7a8259c07e">323,903,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTEtMy0xLTEtMA_e878abc5-5bef-439d-9b75-67fd622d01c0">3,435,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTItMS0xLTEtMA_87c9c7c5-0055-4b98-9d76-7c35b7b0a3dd">96,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTItMy0xLTEtMA_5fa8bf68-fb63-4497-9955-88cdc6e193aa">1,969,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTMtMS0xLTEtMA_90d7d56a-480c-4326-b9ce-4d173103273a">324,000,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTMtMy0xLTEtMA_24f562ab-6349-4ba4-a142-b688ed174a2c">5,404,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTQtMS0xLTEtMA_63200217-8e6d-4414-9bee-6015bf79907b">437,814,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTQtMy0xLTEtMA_102a3814-aade-4c41-903c-569425e90267">143,951,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99922d4c4991454fadefaf71d1e588f4_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMy0xLTEtMS0w_d61579db-1bd9-4941-aec8-03c033a47f2e">21,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37266a62557f4575b10ba5822c0a691e_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMy0zLTEtMS0w_fc0ce290-a3eb-4b31-ba0d-b4f3e15d17b1">617,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb8d0d9ac154379833cab4cface6fed_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMy01LTEtMS0w_23c8bed7-54ff-4e90-bc2f-fa3bb82b0162">167,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3e1abbbaad4bd7a9c51a4266035110_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMy03LTEtMS0w_1845b0b6-3965-4ebf-bc71-bb9f6081b8f8">3,452,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements with affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529cf22cf7c34b5cbc581544727e180b_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNC0xLTEtMS0w_74136e0b-ea47-4c72-9dc7-950bb5d8a1c7">103,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb8e36088aad444883e60bc40d755771_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNC0zLTEtMS0w_eca16bd8-59d5-4d2b-aba3-e304f1b7d9eb">53,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d20b99727a54a1bb1084d53338a7ac5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNC01LTEtMS0w_f5a5c465-14c6-4953-90f2-eeb899508601">1,370,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a191e57427341858f4afa549fa9f378_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNC03LTEtMS0w_e63cacab-9b33-4e19-beea-2db6a4132a0a">179,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff05cfee55444728cba8c5821c8cd39_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNS0xLTEtMS0w_8328238b-30f8-4e6c-bf7f-7d767c1d07ab">111,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5255fbfad51c4e9289a4ebb454a733a0_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNS0zLTEtMS0w_aa531051-3f31-4c6e-b005-e4cfb03fcea8">196,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82519fba8e3943dfbc56b64921e0755f_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNS01LTEtMS0w_179ca4ed-5000-4780-ac9c-a1aa01860775">292,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12c41f3268694c0eb68fec4dba426315_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNS03LTEtMS0w_2e628ac2-47d1-44bf-9f05-42352fc02b01">200,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfOC0xLTEtMS0w_1195e48a-553c-4a81-8df6-ae230ff99daf">236,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfOC0zLTEtMS0w_583ef0be-10c5-4e78-8aa2-7658cfafccd8">866,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfOC01LTEtMS0w_2cf21f1b-285f-4440-8b97-1c7bbd18b4c7">1,830,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfOC03LTEtMS0w_d6e07fd3-52c0-478b-944f-92cf1c75bac1">3,832,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTAtMS0xLTEtMA_cfb5aa4e-2319-4bd8-93bf-38e56fb34540">26,455,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTAtMy0xLTEtMA_317f4ada-913d-45c8-9a5a-3e20799183d0">19,137,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTAtNS0xLTEtMA_210d5d4c-d536-49ff-8d10-8a046dfa298b">67,942,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTAtNy0xLTEtMA_baddb769-3757-4260-93b4-264d30f49e56">66,013,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTEtMS0xLTEtMA_737f2651-2bf6-4b80-a352-5e7c34b1298c">10,110,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTEtMy0xLTEtMA_811d1f6a-c85b-467f-8c22-8ec4e607fb86">5,681,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTEtNS0xLTEtMA_3ac3f093-a097-423e-a70e-a815a6a0019b">28,630,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTEtNy0xLTEtMA_9407b909-a49f-4fef-8d3e-95c61ffb2713">18,506,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTMtMS0xLTEtMA_3b2e0432-7e1c-4c1c-b8a5-d66f6b028378">36,565,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTMtMy0xLTEtMA_246b4dbf-5c0d-4fb9-b688-18715a68ff8b">24,818,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTMtNS0xLTEtMA_6e0fb4c2-8a9a-4114-a703-a87e986dee49">96,573,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTMtNy0xLTEtMA_240cf126-bed7-4b3e-9712-d49108fef794">84,519,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTQtMS0xLTEtMA_42bb1ccf-03ef-4500-8264-666575b7edad">36,329,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTQtMy0xLTEtMA_1b63f0bc-c883-4215-acbb-1fd61cebc876">23,951,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTQtNS0xLTEtMA_50db5b05-9266-4e42-84bc-c770b391f87d">94,742,606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTQtNy0xLTEtMA_6fffe6aa-a601-40c7-b85f-ec04d63552e6">80,687,492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTYtMS0xLTEtMA_7c898fde-52b3-4f0f-b3c6-8c650670f555">896,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTYtMy0xLTEtMA_930b578f-83d1-40ee-ad06-0298e09b72e2">637,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTYtNS0xLTEtMA_bf4e4a7f-4df3-4d28-a95b-4f36070262af">2,380,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTYtNy0xLTEtMA_3ee85f8f-9ac1-42f6-9c5b-814fc106f9de">2,018,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTctMS0xLTEtMA_568428b3-0a2a-441d-8309-0da8f1181a55">1,984,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTctMy0xLTEtMA_40dd7930-809a-4f4a-989d-8803a08d6033">2,428,671</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTctNS0xLTEtMA_5322c604-cb6b-4252-a90e-772583982caf">7,634,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTctNy0xLTEtMA_53fb4c6a-f758-48eb-a15a-319096bd1332">5,279,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTktMS0xLTEtMA_9e5a025c-90cb-4cda-89ca-b4fa4e6b0338">35,306,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTktMy0xLTEtMA_ef3bdf4e-85a7-4792-b714-87024639f969">2,551,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTktNS0xLTEtMA_db554d67-974d-4391-a079-9b37a95a5605">75,670,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTktNy0xLTEtMA_456e7464-c127-4daf-ba9f-e4a190b0af8b">2,551,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjAtMS0xLTEtMA_b188cdae-c196-4e11-8264-ecd4db7cd042">26,951,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjAtMy0xLTEtMA_7c2bfa49-df60-4742-92b4-067d1af419e1">485,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjAtNS0xLTEtMA_6cc3eea9-b955-4b3d-b990-d191613e1a05">36,250,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjAtNy0xLTEtMA_d2374299-204d-4b51-98a3-b61d532b7322">1,409,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjEtMS0xLTEtMA_4d648c39-f7ad-4b26-af73-5f118f758e30">1,315,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjEtMy0xLTEtMA_b28223f9-fdd3-455e-b1db-1a67c562d0ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjEtNS0xLTEtMA_bc2a38ed-91de-49e0-84e6-2fa9c7b395c6">624,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjEtNy0xLTEtMA_8bc7e2a7-7810-44d0-ba30-c9d00905fea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjItMS0xLTEtMA_06fc5956-93d5-4d3e-acde-3cdad2c02970">136,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjItMy0xLTEtMA_699f2da6-40c9-4dc0-80fe-1d95a9138f5e">140,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjItNS0xLTEtMA_b6abacdd-09c3-418f-b94a-006e175373b2">714,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjItNy0xLTEtMA_9cdde910-7ea6-44d1-9f52-d0582389eabd">232,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjMtMS0xLTEtMA_c741ee06-d15d-499b-9b64-2a10966ec4a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjMtMy0xLTEtMA_c377f49e-8ef7-4ef5-86b0-c707eee6b93f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjMtNS0xLTEtMA_21aed3f8-4eba-43d9-aaff-a8cbd0635ec3">4,121,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjMtNy0xLTEtMA_4dd7244f-47ad-4edb-aeac-3dd8259e92e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd26d40a3bcd4f41a7939cead908de3a_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtMS0xLTEtMzQxNA_240fc44c-53a2-461a-8a42-afe98c200106">8,177,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d09d690018a45498dd313c617375257_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtMy0xLTEtMzQxNA_a51a8add-a37d-4484-88c1-c051756f73b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5b3fb71885d4741bbd44d4710aafc27_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtNS0xLTEtMzQxNA_dee2e69e-c288-4c3a-979c-628a7ed263bf">8,177,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b80e1cd70cf4455b48eaa840dc9db78_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtNy0xLTEtMzQxNA_5cff0ddf-3816-4e1a-b986-521ae42906e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baefa69f3a64b9a86686d55294e5ee9_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtMS0xLTEtMjY1Ng_1b4ee213-1173-484a-b531-f8c39bdd85d6">3,087,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i241bac219d9b4d2cab239b4a93aa2809_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtMy0xLTEtMjY1Ng_97ec855f-0e36-42a5-bc44-98932b61558c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b045061c7ab428582b10f52d98361c4_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtNS0xLTEtMjY2MA_dcdd53d9-0f9d-482a-bef3-16cb2c555fd7">3,087,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edc82bc7b334d5aa607c4be90c9906f_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtNy0xLTEtMjY2MA_b64bdb8d-b555-45b3-841f-1d57d70d4fba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) before income tax benefit and share in net loss of Geneos</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjUtMS0xLTEtMA_a96ecd5e-64ef-4048-abd1-b52b3d4b4fd6">20,931,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjUtMy0xLTEtMA_419163f0-8953-4445-a261-b748c7d12f9c">23,536,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjUtNS0xLTEtMA_014a1631-9429-40c0-8d68-6ba66d878fd3">140,475,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjUtNy0xLTEtMA_a0a62e14-fe67-4f65-8099-5c69ba85d9e1">82,573,966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjYtMS0xLTEtMA_91efe0cb-21a0-48e6-af1e-95c154e41b05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjYtMy0xLTEtMA_d0964e29-c351-4234-b806-826a116eb8dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjYtNS0xLTEtMA_93617016-0a7d-448b-95ab-e8b012d61c0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjYtNy0xLTEtMA_e75f8d2e-7a22-48f0-a89f-2cb993c449d4">169,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjctMS0xLTEtMA_0aa4faa4-7d98-42e3-aed7-fd9236a2c55f">1,759,674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjctMy0xLTEtMA_22ec30b1-f513-4e7b-a2c3-5b5e05ceb634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjctNS0xLTEtMA_c49cffc2-5f5c-4939-aecf-56812416bbda">2,661,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjctNy0xLTEtMA_5a441648-5734-4e8c-826f-729897d1b7de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjgtMS0xLTEtMA_2007f201-22b9-4170-a80d-1f9f66bd817d">19,171,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjgtMy0xLTEtMA_f215d454-94cf-4d87-a470-437958597bfa">23,536,452</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjgtNS0xLTEtMA_63f59cfd-fe8b-43c7-ad3f-269bdeb37083">143,136,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjgtNy0xLTEtMA_bb3987f6-cb88-433d-8663-750280404b4f">82,404,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjktMS0xLTEtMA_f22b6d1d-908c-495b-99e9-780dff37c75c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjktMy0xLTEtMA_92844d51-559c-4dda-aecf-d480729954df">445,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjktNS0xLTEtMA_2bee6905-42bc-4e78-aaaf-e57f599a4da0">1,063,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjktNy0xLTEtMA_08d08761-cf57-4945-80f0-6e206df52866">707,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzAtMS0xLTEtMA_0bfa0ac8-8cb1-43c7-b734-f71986d7d3e3">19,171,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzAtMy0xLTEtMA_9b9c316e-7dfc-419d-ae8b-0ba03bec5f40">23,090,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzAtNS0xLTEtMA_2e0bd7c1-1ac6-4793-99f8-3e2980ee2a22">142,072,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzAtNy0xLTEtMA_082153ca-a9a5-4286-a31b-d713f89ecf58">81,697,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share attributable to Inovio Pharmaceuticals, Inc. stockholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzItMS0xLTEtMA_c2698ebe-acb2-407a-8caa-45f42acad8bb">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzItMy0xLTEtMA_bd8edfdb-172f-433d-b319-b8d742c6d28d">0.23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzItNS0xLTEtMA_b1897623-eade-42bd-a66e-e12308943de4">0.96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzItNy0xLTEtMA_ab06bbd1-b29c-4d73-8449-37dc8cbf4d2c">0.83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzMtMS0xLTEtMA_7caf4cc4-ade2-4cfe-9b19-d59587d4424d">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzMtMy0xLTEtMA_6c659dc8-0420-4bc9-8a7b-0fd1e9c2f9d7">0.25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzMtNS0xLTEtMA_f9a1bfe0-d5e9-4824-91f6-4e195c7ca550">0.96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzMtNy0xLTEtMA_28626379-1eb2-43b2-836a-37c529cf765b">0.83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzUtMS0xLTEtMA_c6304a22-f3b8-461d-b403-4f4ec744a0f9">165,355,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzUtMy0xLTEtMA_8d91140c-c799-4348-ac3c-8602148f1b68">99,007,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzUtNS0xLTEtMA_bc0cef19-c5b4-481d-a97e-f6b3cab199fa">148,656,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzUtNy0xLTEtMA_4d48c5e8-dbf5-4ef2-ab2c-db30658f5d46">98,204,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzYtMS0xLTEtMA_a724ef56-ce85-4089-aa3e-4e109e6b5d77">174,376,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzYtMy0xLTEtMA_8ee36f70-c834-4d99-9ca5-7e6d8d35f7f5">102,807,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzYtNS0xLTEtMA_01e48dec-de47-4388-9ded-038874cdc737">148,656,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzYtNy0xLTEtMA_112916ee-0743-4470-af65-461a3798db6e">98,204,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMi0xLTEtMS0w_6459d7bd-da41-4a07-97e0-4a0328e02899">19,171,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMi0zLTEtMS0w_351b4c46-8413-4220-a97e-3e128a9abdb9">23,536,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMi01LTEtMS0w_8ddc5759-4292-410c-b537-8d57c78a4c71">143,136,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMi03LTEtMS0w_c549c4ff-e3cc-4b58-8916-85d7d532a47c">82,404,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNS0xLTEtMS0w_bc3e861c-7265-4e1b-b77f-f15555ac0b3a">6,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNS0zLTEtMS0w_03acff56-f3df-4e0f-a2e0-33dd8801c0f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNS01LTEtMS0w_c566f498-a415-4888-9d10-f1ed1f444827">6,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNS03LTEtMS0w_f407e2ca-7af1-4db9-baa7-b5961e9fc77f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Unrealized gain (loss) on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNi0xLTEtMS0w_d55a156b-1550-4da4-b46a-f15d0ed6ca7e">356,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNi0zLTEtMS0w_cb33104e-1d18-4840-8f9a-32f61a4d74cc">31,457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNi01LTEtMS0w_08975d55-a579-4dc6-b405-c69b070f4ac2">726,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNi03LTEtMS0w_211e8bda-2ff2-4091-8774-99a64120fe3b">1,229,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfOS0xLTEtMS0w_94f0b15e-1d11-40c2-ab9b-767273a92826">19,533,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfOS0zLTEtMS0w_5710eac8-7f5a-40b1-b5af-9a442084b33c">23,567,909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfOS01LTEtMS0w_058f18eb-e6b9-4461-b903-cc6341f60890">143,856,976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfOS03LTEtMS0w_6de75e5c-1533-4f3b-a6a1-0ab18ac20079">81,175,130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Comprehensive loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTAtMS0xLTEtMA_ee0e2b81-9ed4-4618-a26a-f742d4c5b5d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTAtMy0xLTEtMA_cf97f880-cb27-4167-bde9-ec9fe9c239ec">445,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTAtNS0xLTEtMA_f0979cc4-6a1b-4252-9af5-43a4afdeff6c">1,063,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTAtNy0xLTEtMA_b226f088-3580-4bda-8fae-176ed5133af2">707,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income (loss) attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTEtMS0xLTEtMA_25ea5889-e0a6-443d-8f96-3a2b9ed85afd">19,533,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTEtMy0xLTEtMA_ef49ceda-1922-41d8-a1fe-4dc082b03eb5">23,122,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTEtNS0xLTEtMA_45385dc7-aee7-406a-a51b-85d7609f1ee1">142,793,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTEtNy0xLTEtMA_4f584f39-9071-4f77-a68f-62df382ce58d">80,467,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.567%"><tr><td style="width:1.0%"></td><td style="width:27.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fd398adc34c49a398e8c5047ce7dca2_I20191231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtMS0xLTEtMA_611bae79-4a2f-45ee-8b86-ba65db48296d">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fd398adc34c49a398e8c5047ce7dca2_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtMy0xLTEtMA_2ccd9bdb-b7fb-4903-9a59-eed4809d318c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a3177da420f419793a90426cdb10103_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtNS0xLTEtMA_3c82bfe9-9fd0-49a9-92c7-91e96ede8a0b">101,361,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3177da420f419793a90426cdb10103_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtNy0xLTEtMA_adec0aad-b607-4f04-b9c0-9d0cd9c67825">101,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490a2b67f81945fb92911af08177c0d3_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtOS0xLTEtMA_3c841a92-5d88-480f-842d-b6d6d7c53ca1">742,646,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie245dae4bee84b58843b01eab260ebbe_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtMTEtMS0xLTA_ddd454ee-2b7c-4978-b1fc-f2031b40e6da">739,785,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164d36cfc1194bdfa7a02c7620d6c38f_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtMTMtMS0xLTA_ac43d301-7c93-4231-86b7-25a3aaa5cfc8">472,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7da7e536da1348a49003199c51350098_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtMTUtMS0xLTA_9e9ef60e-d5fe-49ee-bf32-b232280ff56a">1,969,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtMTctMS0xLTA_99e3b9a1-c1f2-48b4-a25f-6e77c3e47650">5,404,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08deaaf52352444fb06992fafb59e795_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzQtNS0xLTEtMA_89d4a965-74f5-4505-9c83-241bdfbb350d">43,148,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08deaaf52352444fb06992fafb59e795_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzQtNy0xLTEtMA_f7af7cc8-a82b-4fc0-af71-5ea2754e25bd">43,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b336c669ff4c388e47c257d1834054_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzQtOS0xLTEtMA_048a0d46-f0c9-41da-8d76-5271ce0ca65a">208,198,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07dddec9a874e3db329127b98b02609_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzQtMTctMS0xLTA_b4662f88-d6e3-4d7f-9040-d1d16e16ded3">208,241,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08deaaf52352444fb06992fafb59e795_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzUtNS0xLTEtMA_7c89e730-04fc-40dc-8558-a67ec6d71f58">1,405,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08deaaf52352444fb06992fafb59e795_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzUtNy0xLTEtMA_41d6ab6b-49f4-458a-bdd2-02e45a5ca126">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b336c669ff4c388e47c257d1834054_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzUtOS0xLTEtMA_482206a2-65af-4d12-a9ba-4108e2fa6491">3,099,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07dddec9a874e3db329127b98b02609_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzUtMTctMS0xLTA_4dad75e3-773e-4b8c-9a24-406b3c1ab1e1">3,100,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b336c669ff4c388e47c257d1834054_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzYtOS0xLTEtMA_063757b4-bf13-4110-bf1a-044ff9d25b6c">4,017,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie23871a5e018407e8d1d917d80671cdf_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzYtMTUtMS0xLTA_7ea46483-7207-414e-84b3-b442da30d7cd">16,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07dddec9a874e3db329127b98b02609_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzYtMTctMS0xLTA_f7b64f15-acb9-4a74-962e-efc6799bfb67">4,001,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie23871a5e018407e8d1d917d80671cdf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzctMTUtMS0xLTA_8d6214b1-2417-49bf-91f5-824aa5160a68">2,169,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07dddec9a874e3db329127b98b02609_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzctMTctMS0xLTA_4099b5ff-7517-4d9c-9d63-006ffc1af040">2,169,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8eda4ce49e3408f9d4f5308a4037533_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzgtMTEtMS0xLTA_1893e972-cd7d-4e8f-9acd-e76cc1a21838">32,541,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie23871a5e018407e8d1d917d80671cdf_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzgtMTUtMS0xLTA_69dfd6c6-54dc-4e70-96e2-fa2386cc5912">594,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia07dddec9a874e3db329127b98b02609_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzgtMTctMS0xLTA_a3f73f6d-6902-4389-9fec-f4a0057cec2c">33,135,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4411f044a3a14ba18265a15b7226653c_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzktMTMtMS0xLTA_640a6f51-d816-48b3-9138-3b376cdc613d">1,929,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia07dddec9a874e3db329127b98b02609_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzktMTctMS0xLTA_23f64f82-ec95-4b3a-9b57-f9093ce9d8f2">1,929,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i770162b78bb54f1fa1711d54652a4751_I20200331" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtMS0xLTEtMA_d675fea4-3a13-4ee3-9ca1-febec176c9b7">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770162b78bb54f1fa1711d54652a4751_I20200331" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtMy0xLTEtMA_74657b7f-83b2-4e84-9e0d-54e2e61558c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6eaf13aa46744705aa06fb61cbe8aa82_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtNS0xLTEtMA_978283a3-fe5a-4fc9-a079-38096b71d598">145,915,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eaf13aa46744705aa06fb61cbe8aa82_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtNy0xLTEtMA_e058e5a7-351c-44ae-8745-7525fc8d1fb1">145,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9f754f0888148c498ed9fff863d50dd_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtOS0xLTEtMA_270e6d01-be67-4159-8e98-899f34c02305">957,962,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47296c4f224f4821b9b5398dff066172_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtMTEtMS0xLTA_ef953f46-6fbf-440d-bee8-a1d4aab243e1">772,326,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic38a8356669f4b94a31d4fe6a18ea3c3_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtMTMtMS0xLTA_a6a69ccb-c4a3-4efd-8188-ef3bf2acc458">1,456,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5dcbbe8e1f748d0aa61b641b73d3fc4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtMTUtMS0xLTA_aac4d2c2-8983-4e61-957c-62ca55eda645">3,529,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief04ee355ac748d99c0d4127735597c1_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtMTctMS0xLTA_616618a6-ab1f-42d0-8ed7-69041f750eff">187,854,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDEtNS0xLTEtMA_b39f204b-863f-4880-8e68-ca7dda0795ff">12,041,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDEtNy0xLTEtMA_7f77bdf9-2d3a-4be2-9be4-449e4d052b16">12,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f9c138d29b443f9ed4bc98e732da37_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDEtOS0xLTEtMA_33623aeb-e48b-468e-950e-5659955fca00">121,706,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDEtMTctMS0xLTA_f5a1de24-b2d1-4bd7-ad60-3464b72ca1bf">121,718,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ice079a38e1e1455b9775b3e80821be68_D20200401-20200630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDItMS0xLTEtMA_b8415b24-67d3-406a-9f7a-ca58d6f37799">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDItNS0xLTEtMA_3041a4c3-19e4-4274-ba78-1cc8ac0c1672">5,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDItNy0xLTEtMA_96d33978-67eb-4fc5-a916-5229820009f4">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83f9c138d29b443f9ed4bc98e732da37_D20200401-20200630" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDItOS0xLTEtMA_13583b53-90f9-4c3d-823e-6e4bcf2b4d97">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDItMTctMS0xLTA_fca98f45-1fd1-490b-b926-8ce43e9a553e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDMtNS0xLTEtMA_40a2a5ca-e8d6-4833-af43-64873a211ba4">794,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDMtNy0xLTEtMA_0cb453c0-c562-4b19-a43f-a58d8153080d">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f9c138d29b443f9ed4bc98e732da37_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDMtOS0xLTEtMA_daf945fd-8d2d-44e4-8077-698186046aad">4,421,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDMtMTctMS0xLTA_30784aca-7c4f-4b50-90a0-c0cf8a015385">4,422,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f9c138d29b443f9ed4bc98e732da37_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDQtOS0xLTEtMA_321135a4-314c-4105-9423-ed0be5a8c322">3,654,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if181d6b7610d46769fd6e637cc5073f1_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDQtMTUtMS0xLTA_f091bd26-a849-4c22-b14e-826861c68325">8,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDQtMTctMS0xLTA_90a72e74-c810-455a-a03d-eba0b681231b">3,662,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if181d6b7610d46769fd6e637cc5073f1_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDUtMTUtMS0xLTA_2d1a95c9-8f1f-41f0-9525-e85d4adc8cfc">209,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDUtMTctMS0xLTA_842818de-74ad-4cbe-a7aa-d0d4b4da9e0f">209,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if181d6b7610d46769fd6e637cc5073f1_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDYtMTUtMS0xLTA_449a2e94-3567-4279-807f-dac5f63611e1">3,181,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDYtMTctMS0xLTA_fd6da11f-4938-426e-8ea5-e803ce3001af">3,181,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0244b4520d04e4e8f59d89ddd1fad54_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDctMTEtMS0xLTA_ad113136-ec92-4fed-86e4-83876a4c38d5">128,703,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if181d6b7610d46769fd6e637cc5073f1_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDctMTUtMS0xLTA_32443370-e4c6-4df1-be54-5405fb8185f2">469,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDctMTctMS0xLTA_5b22a93c-003b-4fcf-b70f-a7c6146e3352">129,172,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie69799d5ae944511ba30c40042a5b329_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDgtMTMtMS0xLTA_3e70fb16-8b2b-49be-9a22-240abf8a31e0">846,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDgtMTctMS0xLTA_3a62be3e-4b06-4d18-b69f-f78e99cdae9e">846,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7569d7245f540de94c34ea74b24ab62_I20200630" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktMS0xLTEtMA_b34f036a-99d6-4754-8612-ffd70c664d01">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7569d7245f540de94c34ea74b24ab62_I20200630" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktMy0xLTEtMA_fd0d35f9-ff18-4d1e-900f-86667569fc2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb3f93f3c4c744d585e8ee4ebe462d9b_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktNS0xLTEtMA_6acdee8a-6ba5-45f4-973e-b31939219ea1">158,756,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3f93f3c4c744d585e8ee4ebe462d9b_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktNy0xLTEtMA_077e3f13-539c-4c5f-8aaf-a21705fd13fb">158,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc6179ba6344761bb813a2e5b312a60_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktOS0xLTEtMA_21164d70-a567-46f6-a5fb-6ef94fb3d20e">1,087,745,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf2f09d68754bb1971d7930890683f9_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktMTEtMS0xLTA_99fdbc6a-680b-424d-a02d-e39ffc96a0fd">901,029,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b9c539a1838477abaf6bfa915ee886c_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktMTMtMS0xLTA_d1278ff1-6ab3-494b-9582-5b92b8ca6c43">610,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cbfe1fda7da45e895ad0f7797870e3e_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktMTUtMS0xLTA_3f3a10f1-ff30-4420-a7f8-9d53834f71ec">96,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i510e75df51764aeab124f1f96a2ce60c_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktMTctMS0xLTA_dbee7f88-b29b-47f6-8d34-c3765fbed183">186,360,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of senior notes to common stock</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ee3e0978a8246caaaca0810f4cdd6ea_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTEtNS0xLTEtMTQ2_36292741-e99a-4bed-9e5d-4d749fa581eb">3,546,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee3e0978a8246caaaca0810f4cdd6ea_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTEtNy0xLTEtMTQ2_2adaf028-b5a0-4d43-b508-c84dcec47ccc">3,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff71970e3ccb4c1ba1e28e003e256dbb_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTEtOS0xLTEtMTQ2_cb940532-3118-476d-aa93-0d0b153f7055">12,967,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baefa69f3a64b9a86686d55294e5ee9_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTEtMTctMS0xLTE0Ng_2cebe323-5bf8-4ed4-8ade-80b9905fdb2c">12,971,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of August 2019 Bonds to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i647bfa57e2c94d82bfe6d0586215e925_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItNS0xLTEtMjYyNA_0f95684d-f9bb-4709-bf09-8391a8a0996b">4,962,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i647bfa57e2c94d82bfe6d0586215e925_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItNy0xLTEtMjYyNA_fd418145-9cea-4101-a515-f2f9a2234b46">4,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6259481f55947f8a81ad5e6bdf162e0_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItOS0xLTEtMjYyNA_2abd5513-669b-41ca-b46a-d41514b63c6f">102,666,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f9640746a545989d1bbdb6a45e5c57_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItMTctMS0xLTI2MjQ_19f1eb86-7614-49e0-9c40-4b89312884ec">102,671,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd29250290ea4170b0c3e4f90e4306a9_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItNS0xLTEtMTQ2_fd3d1797-0cca-4f05-a035-b80393f9294b">263,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd29250290ea4170b0c3e4f90e4306a9_D20200701-20200930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItNy0xLTEtMTQ2_dba317a9-4900-4161-beaa-1392594133ee">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaae34ec028bf4c5093d8f8caad4165ca_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItOS0xLTEtMTQ2_e0228477-69a2-47bc-b295-54e824e78469">1,695,315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItMTctMS0xLTE0Ng_4bcc7d53-b8bf-43af-b6aa-c9179756834a">1,695,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaae34ec028bf4c5093d8f8caad4165ca_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTMtOS0xLTEtMTQ2_3da95b84-7b72-4ca9-902a-d2faef06535a">4,158,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTMtMTctMS0xLTE0Ng_202b1c7b-ef32-4337-ac02-ab4b06798ade">4,158,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6465f1fd3deb40cb9065e34705e46564_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTYtMTEtMS0xLTE0Ng_7878a616-8308-4812-8545-2fc1f04abce5">19,171,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTYtMTctMS0xLTE0Ng_648c5814-a9ef-4e80-881f-f0adc60d4a51">19,171,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i978b9d86842c4f2bb0684bfacb1d2f7d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTctMTMtMS0xLTE0Ng_f4a51971-8acb-4c10-b149-4e28fe7f05db">356,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTctMTctMS0xLTE0Ng_07baffba-c316-4cbb-a710-f5e103ae7f7f">356,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i978b9d86842c4f2bb0684bfacb1d2f7d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMTMtMS0xLTIyNzM_ea428d49-bfdb-4418-8f89-fc228706cc7f">6,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMTctMS0xLTIyNzM_2046380b-a104-42a4-81b3-ba0f5d4a7561">6,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79c71d22c8084831b9423ab29cd4f183_I20200930" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMS0xLTEtMTQ2_fa274ee8-f185-4e67-a2af-b07cca1c05db">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79c71d22c8084831b9423ab29cd4f183_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMy0xLTEtMTQ2_24c00caa-3c21-4ae4-a9ac-0ed7a5a74629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabe71ccc813949e295ac419f3bf11133_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtNS0xLTEtMTQ2_aa181eff-984d-4e3f-8d17-82c95a0361f0">167,528,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe71ccc813949e295ac419f3bf11133_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtNy0xLTEtMTQ2_1f59b338-7100-49a5-a2c9-a2ffc6e2623f">167,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f2b47e634f4835ae39efe3509d84cd_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtOS0xLTEtMTQ2_98cae067-dd4b-43c2-9f54-68efca3a5ff8">1,205,842,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e2c3f19273a42778f051025844a72e2_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMTEtMS0xLTE0Ng_8cd47788-b4b5-4169-b021-0e48ccfd25fb">881,858,432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a012f253e8c4f838461bd187a090df3_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMTMtMS0xLTE0Ng_ef34db95-26ac-429a-bf12-9e422d060572">247,834</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101ba48e80cc4d48b6199ad88e5a774a_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMTUtMS0xLTE0Ng_6bcb8e42-b3dc-466d-bd83-4e1c8d083bc1">96,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMTctMS0xLTE0Ng_3b60804f-630a-4b38-9a9b-a3378eb967e2">324,000,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:26.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad543da68a144f83a4d3805ac1f6d89e_I20181231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtMS0xLTEtMA_bbe56e19-0837-40ce-a4e1-e33e5548b735">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad543da68a144f83a4d3805ac1f6d89e_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtMy0xLTEtMA_1a0b96a0-a8a2-4c85-9062-5914cc69a12a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id389379a953b4eac99e35c98ee5f565b_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtNS0xLTEtMA_16724202-7a14-4a8e-93e4-94f24b236fbc">97,225,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id389379a953b4eac99e35c98ee5f565b_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtNy0xLTEtMA_be4fd13e-399b-4801-b6b2-99264cc81cbe">97,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica8a6426b215442eb3caef7cecc4c115_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtOS0xLTEtMA_80aec2ef-a049-413a-a262-b9d8fe8655e2">707,794,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56e81b2a6acf4575b6a2fd1a15aa3a3a_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtMTEtMS0xLTA_bebeb908-5fcc-4b9a-9488-430e2754c6d0">620,426,436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i912f365b06294ab497683dd0247e0307_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtMTMtMS0xLTA_24546fc1-cae3-49dc-98ea-f0d3b7d70d89">528,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0f2db7f9c1466d884a3ed9d245869e_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtMTUtMS0xLTA_9a2e330a-6d25-4ca4-9bd5-231fe8d66c0f">96,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fca9614850f4094a30e35df9ad3f90d_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtMTctMS0xLTA_06dcb3a3-a767-446a-a2b8-da6866c7825c">87,032,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c34cc69f8ff4a9e9279090d85e2ed1a_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzItNS0xLTEtMA_135ec7c1-9eca-4338-9611-40fafc0906c4">183,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c34cc69f8ff4a9e9279090d85e2ed1a_D20190101-20190331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzItNy0xLTEtMA_25360122-0931-4485-aef1-a45a9e451785">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11dd26adaa634c719948d1c87ffa3cb9_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzItOS0xLTEtMA_ac20c111-f986-4dc1-a54a-869af12a1ca6">907,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzItMTctMS0xLTA_0cffe1fd-129f-4ad8-8937-80070bace3d1">907,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c34cc69f8ff4a9e9279090d85e2ed1a_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzMtNS0xLTEtMA_18843091-07ca-4382-81db-c02c7d61db39">525,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c34cc69f8ff4a9e9279090d85e2ed1a_D20190101-20190331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzMtNy0xLTEtMA_618232ce-d391-44d4-b98f-baaf8edcef34">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11dd26adaa634c719948d1c87ffa3cb9_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzMtOS0xLTEtMA_a2614a1b-1af1-4191-9097-a17eb79e8b93">719,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzMtMTctMS0xLTA_1e14a02a-5128-4ea8-86bd-3c8643f9e1a6">719,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity component of issuance of convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11dd26adaa634c719948d1c87ffa3cb9_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzQtOS0xLTEtMA_03206657-3cb6-43ef-874e-5fd73985ca4b">15,752,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzQtMTctMS0xLTA_7ab5ec07-ead9-44d6-acf4-ea63345daf70">15,752,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11dd26adaa634c719948d1c87ffa3cb9_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzUtOS0xLTEtMA_b314ff7e-6038-41ee-9c81-7d818e350dd4">3,432,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzUtMTctMS0xLTA_dd2011bd-066e-4b2d-986c-2e41db1440bc">3,432,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e69cbad70b5452e8efff3fcfbccf5a5_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzYtMTUtMS0xLTA_2e3441ff-e045-4cd7-bcf4-ecb4f29bd50c">3,030,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzYtMTctMS0xLTA_ea307189-d8c5-4352-a308-71e4cc743572">3,030,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied96fbdb97a849e49bf60586fe4cae49_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzctMTEtMS0xLTA_dc4a8a80-00c4-4d23-92fc-2e14f52ab86a">29,219,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e69cbad70b5452e8efff3fcfbccf5a5_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzctMTUtMS0xLTA_b2dd0503-9e40-49e5-a769-ae9be2f3424e">69,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzctMTctMS0xLTA_a161f2de-0907-4413-b79c-cfe0e8528800">29,288,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11229e332bfe44958cd20245c914ab26_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzgtMTMtMS0xLTA_3dee6946-d829-4390-86b7-62d6b279bfbf">819,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzgtMTctMS0xLTA_5f230253-b347-4cd1-8de8-708ad0b5e6dc">819,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia760ea1651944cdda9f87141b2c3b22c_I20190331" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktMS0xLTEtMA_e61b60de-a863-4732-8e9a-164df201b720">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia760ea1651944cdda9f87141b2c3b22c_I20190331" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktMy0xLTEtMA_e5871f9e-b9d6-41a8-b62a-59a53df68533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie93f9f62a04d495caf7d3e9ad734702b_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktNS0xLTEtMA_352b6223-3699-43a3-963c-fe3a0dec3c22">97,934,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93f9f62a04d495caf7d3e9ad734702b_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktNy0xLTEtMA_66d9eaee-2fd6-448c-822f-f9497e47629e">97,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d984df17864fe6b064ed160b10dbab_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktOS0xLTEtMA_78beebfe-fe8e-4c43-96b7-524fd2d4eef9">727,166,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2376931e94a479ab3da18397c83700e_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktMTEtMS0xLTA_fc0bbafc-3c75-4973-b4bf-58dc3ac92ed3">649,645,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ba01cda73b483185d19910f47e556b_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktMTMtMS0xLTA_05550e41-efe1-456f-a5fb-11f552879556">290,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d38c9c361a3445fa534a5a54efca8ce_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktMTUtMS0xLTA_1434fa15-fb1d-4748-81e5-19242adc64e3">3,056,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ff5039256e484d8748c537f9e688d9_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktMTctMS0xLTA_384fb060-326a-45dd-9d7b-15351bf5455b">80,966,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62bb952cc15b4e1dbdd165eb7c3dcfbd_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDAtNS0xLTEtMA_bd75b4a7-9786-45c5-84a5-26b6e0f08b5c">476,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62bb952cc15b4e1dbdd165eb7c3dcfbd_D20190401-20190630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDAtNy0xLTEtMA_6ac74f53-4579-450a-a50c-05f46229adcb">476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b38bc463ae342a1bc3326ab42796c09_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDAtOS0xLTEtMA_671122cd-278f-481b-a990-2209b7154453">1,388,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDAtMTctMS0xLTA_e1e4efd6-6569-4504-a3d3-413e0ebdc42a">1,388,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62bb952cc15b4e1dbdd165eb7c3dcfbd_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDEtNS0xLTEtMA_3b7c4d11-457d-4bc7-a084-3068e0ddfe69">173,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62bb952cc15b4e1dbdd165eb7c3dcfbd_D20190401-20190630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDEtNy0xLTEtMA_e37b5fd5-0d5f-4d9f-b6d7-e0915e3c5841">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b38bc463ae342a1bc3326ab42796c09_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDEtOS0xLTEtMA_afe18ddb-86f2-4de7-af92-0a23adbb6e69">81,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDEtMTctMS0xLTA_b8b449b0-4bb3-4abe-819f-f78b03d4506c">81,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b38bc463ae342a1bc3326ab42796c09_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDMtOS0xLTEtMA_33ad5b0d-051c-42c2-a7fa-ce853d159a2b">3,345,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb02416827ad434aacea7535d3776742_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDMtMTUtMS0xLTA_e37c9f69-0fd7-4aac-8b91-72d76a8999c1">9,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDMtMTctMS0xLTA_618374a2-06b7-4201-994d-b0b99d3a69f9">3,355,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of acquisition of non-controlling interest in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb02416827ad434aacea7535d3776742_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDQtMTUtMS0xLTA_755bb20a-fe77-42af-bf0c-e5fd75a1942e">13,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDQtMTctMS0xLTA_44166f28-cbb6-4afc-a134-413a2dbcfd20">13,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c7f59d7bc8740db8cb1ae6cde690f43_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDUtMTEtMS0xLTA_33c92f20-0047-46c3-8f31-5c192f9966d3">29,387,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb02416827ad434aacea7535d3776742_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDUtMTUtMS0xLTA_f65078b1-43fa-428c-b698-19f1d6b43f2d">191,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDUtMTctMS0xLTA_9fbd27b4-676d-4101-9658-f8d5c6bc782d">29,579,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971bb2028af54bd38e7112fbc6dabd8a_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDYtMTMtMS0xLTA_f4c881c1-0de4-4954-a9e0-b485181c1039">441,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDYtMTctMS0xLTA_d9b2cf88-8dcd-4a28-bf37-1e37ca9fc112">441,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idac672ec0b2e49d48f658a67d9cf0a81_I20190630" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctMS0xLTEtMA_87bdd3a2-6202-4c46-8ae4-817d584e58ff">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac672ec0b2e49d48f658a67d9cf0a81_I20190630" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctMy0xLTEtMA_45f35091-961f-434b-955f-b42d0a6bbd86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01241b5b4e1d44b28b5be3eab2189cf6_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctNS0xLTEtMA_0520af0c-7e23-476d-8651-eb77ae205f66">98,584,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01241b5b4e1d44b28b5be3eab2189cf6_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctNy0xLTEtMA_dd2a844d-e4eb-421e-ad66-f59d3b32b09b">98,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c40c2619a6e4f689eb5e72a7788b8af_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctOS0xLTEtMA_6cbb590c-194a-495f-a304-f548eb75e37a">731,819,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71d44e1083ea450d84f392f8d18c62e9_I20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctMTEtMS0xLTA_19444b39-16bd-4c6f-94b7-fdd7615fa73b">679,032,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78220f5c2a8e4adebfb1017126a472b2_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctMTMtMS0xLTA_e1bae20f-9b64-4358-b948-6f2065bd0bc5">731,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b65c8171f84184a933954da0d120ac_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctMTUtMS0xLTA_a1174d8a-0a09-4832-a9ce-2ccc8e202f6f">2,861,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c14c362804a4c57ba8b3135c378097c_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctMTctMS0xLTA_6f9a7c63-1086-4283-a3f9-3dd54d4bcaf9">56,478,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ecc7fb3c1d845e3a86bafa86c697ef4_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDgtNS0xLTEtMTEy_79c93631-2108-4cab-87fc-39d93c1cbd61">382,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ecc7fb3c1d845e3a86bafa86c697ef4_D20190701-20190930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDgtNy0xLTEtMTEy_5ec84261-edd8-41f8-ae7b-355e1539872f">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02c1be59ab240e5bf65dec5515fa519_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDgtOS0xLTEtMTEy_d0058f92-4a9f-4922-80f9-bbd2ceb5f0d3">1,128,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDgtMTctMS0xLTExMg_0e06a1d7-9ad7-490e-a77b-0371eae47e66">1,128,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ecc7fb3c1d845e3a86bafa86c697ef4_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDktNS0xLTEtMTEy_3e7cdb20-1cc1-498f-978c-9df9220180d4">78,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ecc7fb3c1d845e3a86bafa86c697ef4_D20190701-20190930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDktNy0xLTEtMTEy_bec1dd2f-bbae-4bd8-8858-7d725e45c559">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if02c1be59ab240e5bf65dec5515fa519_D20190701-20190930" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDktOS0xLTEtMTEy_8abc793c-39f6-47f7-88ce-16e9e1d92783">79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDktMTctMS0xLTExMg_a22339c2-0ec0-4d65-915d-ea1221b4efa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02c1be59ab240e5bf65dec5515fa519_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTAtOS0xLTEtMTEy_a666c7bc-2ae7-4098-92e5-ab379afabe77">2,070,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe6086a20184ba5bede380b65b2eea4_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTAtMTUtMS0xLTExMg_4a077310-87a2-43ca-a584-e61990491951">9,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTAtMTctMS0xLTExMg_a7475523-6e64-459c-8932-ff664f8f2782">2,079,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00852cf554364a3aae33ca5c9a00c901_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTEtMTEtMS0xLTExMg_13e8a7fc-e2b4-4510-bb49-484883cd0665">23,090,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fe6086a20184ba5bede380b65b2eea4_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTEtMTUtMS0xLTExMg_742eec73-3836-4a17-b430-0e1a17bd34a5">445,759</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTEtMTctMS0xLTExMg_c74a9ed0-7d56-4b93-a3c5-836bc31c4f0b">23,536,452</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie69970bd582c4a249c8df8217f771954_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTItMTMtMS0xLTExMg_fb3d8d4c-201d-4166-b244-80de0dd222ab">31,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTItMTctMS0xLTExMg_9ce7deb1-6f9f-4660-9252-74ffce6f9fdb">31,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b6031a5c53b40dfbdf167f3ecc7127d_I20190930" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtMS0xLTEtMTEy_8e86b551-0b5f-4829-a684-d9976d28b0fa">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b6031a5c53b40dfbdf167f3ecc7127d_I20190930" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtMy0xLTEtMTEy_71682749-03e2-4a22-b225-968a70901130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4db23d3c84734d66b66635aa8030bee5_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtNS0xLTEtMTEy_cf987c82-4618-4455-956b-f24dfe0ee91c">99,046,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db23d3c84734d66b66635aa8030bee5_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtNy0xLTEtMTEy_0073346b-6317-4f92-9f25-49d35e6e49c7">99,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i679e13f56b134421b5679976e76aa618_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtOS0xLTEtMTEy_d43f9593-0100-4ec1-b950-7846a09add74">735,017,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65eb5d78647b4483b008e23b402ec513_I20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtMTEtMS0xLTExMg_ff2b507b-b7c3-467d-8f02-8b6089d23046">702,123,617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d60de4ea362438a8dce34b8e79c0472_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtMTMtMS0xLTExMg_b06b21ca-63d5-435f-b122-854d99bc4fc1">700,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i362cebf18fb64bc0aeb2df72a45e870e_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtMTUtMS0xLTExMg_c696b98c-eee2-47f9-a50f-f90134047ef3">2,425,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea46918d69244b0b92fa827e8689f35_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtMTctMS0xLTExMg_c582ea9e-b51e-46b3-812f-c89c999341b6">36,118,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_25"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMy0xLTEtMS0w_9e528b2f-fe92-4c6a-8c2e-90f3faa80a8b">143,136,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMy0zLTEtMS0w_e00d8a54-533d-467c-9f0b-d83967d06e56">82,404,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNS0xLTEtMS0w_a78d4cf9-da0f-4b51-bbbd-af6585976d7b">2,323,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNS0zLTEtMS0w_0b783d6a-ddc0-499e-9922-8155782d42ad">2,746,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNi0xLTEtMS0w_00ab7c93-ffb7-406c-b199-a70b253b8b3d">410,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNi0zLTEtMS0w_6414555f-1685-4e93-bfef-294d3976d03b">799,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfOC0xLTEtMS0w_0500edea-cd55-4c38-be6e-e359db9aac68">75,670,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfOC0zLTEtMS0w_9433be2a-73d5-4fe8-8580-d93f4f57370e">2,551,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfOS0xLTEtMS0w_ecb74dba-b18f-45f2-b26a-25da9e52e939">11,822,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfOS0zLTEtMS0w_e8656bde-1e06-449f-814f-6bef771c2bf4">8,867,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="ino:NonCashInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTItMS0xLTEtMA_cf024bc0-fa05-4532-8d3d-142f5f1adfa2">3,019,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="ino:NonCashInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTItMy0xLTEtMA_9330cfd1-2183-4e0f-ab90-17b094503928">2,587,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:zerodash" name="ino:InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTMtMS0xLTEtMA_bdfe295c-5f92-4175-b53c-a230639e275e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="ino:InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTMtMy0xLTEtMA_85c30e56-6307-4eb8-a1f9-54259b309db4">1,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTQtMS0xLTEtMA_32dedae4-fb84-4381-8ae4-49d2cebd8b98">571,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTQtMy0xLTEtMA_f571b222-6ac4-47bb-83b1-e8ba92c35200">238,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of receivable with shares of common stock from affiliated entity (PLS)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTYtMS0xLTEtMA_a2c78872-a6e6-461d-800b-a29a6f966825">1,713,770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTYtMy0xLTEtMA_02023f82-22ff-4a06-b4a8-5008e0c55659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTctMS0xLTEtMA_85b62ca0-138b-41a1-aea1-e09c700b72e8">4,121,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTctMy0xLTEtMA_4c52949d-546e-4144-b3ac-2f383e9177a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on equity investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTgtMS0xLTEtMA_441b9801-f251-4f7d-9820-1f75573848e3">36,250,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTgtMy0xLTEtMA_94d3c59c-cfae-409d-b678-8ae56bbd7074">1,409,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share of net loss in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTktMS0xLTEtMA_09526c1c-9945-4362-95c5-1f312e42704b">2,661,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTktMy0xLTEtMA_9b65a8ca-daaa-4aec-bdb2-f0aaac235347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible August 2019 bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib64ca090f73d4dd6afb773407d8d39de_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjAtMS0xLTEtMjYzNg_2effc3b3-6c64-4bff-a5a6-5087c3550c4f">8,177,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbeadf22b0a640818c2ed7013bf0c883_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjAtMy0xLTEtMjYzNg_9cdd47a0-d5a3-4b0c-8009-484ed0be4e4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b045061c7ab428582b10f52d98361c4_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjEtMS0xLTEtMjYzNg_3d910385-292e-4440-92d1-5903e4202791">3,087,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edc82bc7b334d5aa607c4be90c9906f_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjEtMy0xLTEtMjYzNg_d8f65a4c-3507-41a2-ae35-5666ae38ba56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjAtMS0xLTEtMA_f412913f-38e7-4710-b128-66f0a9e18186">624,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjAtMy0xLTEtMA_13cddefe-c44c-4ff8-9537-e033599b53ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="ino:OperatingLeaseNonCashLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjEtMS0xLTEtMA_69c7be3d-3627-464e-b6c3-349ab9f5f915">774,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="ino:OperatingLeaseNonCashLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjEtMy0xLTEtMA_b86f7ee2-8a2e-4282-9010-86322d78c292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from other unrealized gains on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:zerodash" name="ino:TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjItMS0xLTEtMA_cd4ada8a-9a20-46f2-b02d-542049c0a1bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjItMy0xLTEtMA_f33b954c-78f3-4aa9-8e24-1311ffcdba32">335,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized transaction loss on foreign-currency denominated debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjMtMS0xLTEtMA_23acf12a-343f-4e33-b347-6d097d0ff620">290,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjMtMy0xLTEtMA_81d7056d-4cfe-4aca-8fb2-17004ebfdc08">183,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjUtMS0xLTEtMA_dc817550-a53c-4a06-9c0b-6ab6b04651a1">6,992,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjUtMy0xLTEtMA_de960711-8a06-4d89-a037-fefd722e3202">2,540,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjYtMS0xLTEtMA_1715930e-029f-4a3a-b3d2-63a762e79b31">846,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjYtMy0xLTEtMA_892e4c9d-d0b1-4adb-8d19-194e44d774bb">239,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjctMS0xLTEtMA_22c2f9fc-dba7-4616-a7c3-0b38712ac5c8">30,055,813</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjctMy0xLTEtMA_6a635f73-3193-4651-a252-af1172ba16b0">271,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjgtMS0xLTEtMA_3b5fa024-f519-42a9-ac6b-f8ccac69e9a3">409,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjgtMy0xLTEtMA_372497c5-d0ee-4ef3-adc8-3688a9a96f04">460,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzAtMS0xLTEtMA_78cc2ec7-8f63-4989-a18b-ceb4835f2ada">14,969,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzAtMy0xLTEtMA_f1c24c05-387f-41b4-88f0-179a1498c123">61,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzEtMS0xLTEtMA_47e64a57-b39a-4aa8-a346-dc5f1067d4b6">5,383,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzEtMy0xLTEtMA_9790e97d-19f7-40c3-a2d3-158740eb37c9">12,791,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzItMS0xLTEtMA_7bffd068-0a5e-4ecc-8bf0-7a9e453f71ea">1,853,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzItMy0xLTEtMA_5d36794c-50d5-4719-ae30-9e8dcf257563">1,170,866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzMtMS0xLTEtMA_9546451e-662a-46ba-8caa-35a5e115ec87">287,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzMtMy0xLTEtMA_8c8a6c5d-daed-4ef4-8406-525ca00b38c4">515,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzQtMS0xLTEtMA_73ec5136-e0c0-40ff-b347-7d5354573b28">33,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzQtMy0xLTEtMA_9770a7bd-1c35-48cb-b691-7f89bebd04c6">144,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzUtMS0xLTEtMA_91f8ad02-0724-467f-8333-9a54d2c29f5e">31,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzUtMy0xLTEtMA_adb21b26-2d7f-43d9-8037-6190f1ba7173">31,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzctMS0xLTEtMA_133d2a27-f112-4796-ac27-fa39a180bff3">1,550,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzctMy0xLTEtMA_18e98cb0-7d35-42f3-9b8f-1cc9b142b0eb">622,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzgtMS0xLTEtMA_243c7898-8274-4016-a45d-b513a31c7c1f">2,551,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzgtMy0xLTEtMA_d570b079-19d7-4ad0-a53f-a0660b5e06e6">2,269,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzktMS0xLTEtMA_2dd2ba75-fce3-4ded-a1f2-e8915c8fbe2b">670,925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzktMy0xLTEtMA_56723891-7225-4c21-a349-fc1a8f184c6a">828,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDEtMS0xLTEtMA_6095dfca-7ed5-4514-97b8-66fb6ea3d965">2,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDEtMy0xLTEtMA_fa60c99a-8032-41e1-9caa-c1f5c605bf08">35,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDItMS0xLTEtMA_e863e58d-c75b-4146-ba63-2eebb887deb4">126,762,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDItMy0xLTEtMA_5b8e06f7-d7fa-443a-9685-4823263c6bc5">84,112,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDQtMS0xLTEtMA_2ea27b38-3eb7-4638-9460-b23949b425af">153,135,274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDQtMy0xLTEtMA_7d027afd-9c4e-470d-b835-ca5563130cc4">86,950,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDUtMS0xLTEtMA_562b9431-b5cd-4ba1-82c9-610084cea909">61,263,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDUtMy0xLTEtMA_a985933e-54b9-440e-b213-e1bba9358a09">68,344,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of capital assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDYtMS0xLTEtMA_09ef56c0-b561-4708-a699-23d5fbeda84a">558,588</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDYtMy0xLTEtMA_7eb2f652-8c38-4ff1-898f-aa1ca524bb7e">873,484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of investment in GeneOne</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDktMS0xLTEtMA_94cfbfff-23b5-43b0-9fae-c4ddcbc2e2d5">40,125,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsForProceedsFromInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDktMy0xLTEtMA_76a16ae9-3390-479a-aee7-81da9eb057ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashDivestedFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTEtMS0xLTEtMA_ec981302-c083-47a2-a21c-55f1ad993be4">2,774,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:CashDivestedFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTEtMy0xLTEtMA_535553eb-b0c0-4e38-adbb-80afc172023a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTItMS0xLTEtMA_197b28ad-cc5b-40cd-adf4-0aa7bf49971f">55,079,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTItMy0xLTEtMA_1a825ff3-0e80-46a4-a408-a944e0d28d8d">19,479,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of convertible senior notes and convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTQtMS0xLTEtMA_099f2ec6-0468-4a05-8df5-89444a8ce91e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTQtMy0xLTEtMA_90298c24-442d-42ab-a6a5-093528cdeae3">93,425,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs related to issuance of convertible senior notes and convertible bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTUtMS0xLTEtMA_cd555f84-edf6-4ea1-93a8-1f0075a2710a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTUtMy0xLTEtMA_f40e9929-6bdd-41c5-9b5d-c49142ba64c4">3,314,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTYtMS0xLTEtMA_8433c268-f774-47ba-ace7-267862f9d2a6">329,960,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTYtMy0xLTEtMA_7144311b-6835-4f58-b0d8-c5d487b93376">3,425,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTctMS0xLTEtMA_3c051403-e390-42e5-8231-2ef18d0ab996">9,856,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTctMy0xLTEtMA_9148fa2c-8a2c-4ec0-8472-860b8b2700a4">92,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTgtMS0xLTEtMA_b860cae4-b098-43e1-9868-69335417e5ea">4,028,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTgtMy0xLTEtMA_d9fa8490-e919-43b0-b26c-bcd2fa359ed8">892,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTktMS0xLTEtMA_87928cfc-408f-4455-be6e-e438a2e167f5">2,379,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTktMy0xLTEtMA_5676c1cc-1c4e-49a8-80d4-6919a0632004">3,016,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from Geneos issuance of note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjAtMS0xLTEtMA_12432ffb-4001-4b39-9cfb-cd98e8f9e7e3">171,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjAtMy0xLTEtMA_6d7dac48-e75c-4ba0-bfab-3d4c5f896dcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjEtMS0xLTEtMA_5a9608c3-acbb-449e-916b-387022c2ca8c">338,340,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjEtMy0xLTEtMA_53d1ed76-bc4e-44be-9d69-31db5121ad0b">95,752,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjItMS0xLTEtMA_81734494-bd2e-4e0c-9c23-55baba6afeec">6,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjItMy0xLTEtMA_4549b8e0-c029-4f63-8223-0f2ed78b6ae5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjMtMS0xLTEtMA_fab51f60-63d7-4934-96f7-df0e9c13c8c7">156,504,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjMtMy0xLTEtMA_b0995f82-8218-4f42-9b75-c8575dc62acf">7,840,397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjQtMS0xLTEtMA_bc9029ec-bcb1-4056-b480-2d03d8245efd">22,196,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fca9614850f4094a30e35df9ad3f90d_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjQtMy0xLTEtMA_641c324c-1a1a-4f2d-988e-4e2f66f02417">23,693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjUtMS0xLTEtMA_96bd059c-26b4-4b5a-ac3d-3ee6fb1c8284">178,700,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea46918d69244b0b92fa827e8689f35_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjUtMy0xLTEtMA_df539d59-7789-4390-9989-9de5fbba3e7d">15,853,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts accrued for purchases of property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjgtMS0xLTEtMA_bcc7f536-f022-46b6-8276-2368e001fb6c">198,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjgtMy0xLTEtMA_974e1732-8fc5-45d4-9451-4cf1cf6559ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjktMS0xLTEtMA_2abcf3ba-bd58-4c8c-a55a-a17fd6020a80">4,614,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjktMy0xLTEtMA_92d62166-8049-4bc4-9247-c575cfc6e0ff">2,692,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNzEtMS0xLTEtMA_61da154c-8067-41a0-aed8-1045b1d801d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNzEtMy0xLTEtMA_e6fa7604-e6b1-40a2-83a2-88cc02a16e66">14,634,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_31"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">1. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zMS9mcmFnOjRlMTk4MzViZTE5NjQ1YTRhOWE2YjEwOWU1Yzc0YmI5L3RleHRyZWdpb246NGUxOTgzNWJlMTk2NDVhNGE5YTZiMTA5ZTVjNzRiYjlfMzMxNw_a45fcb53-51c7-4448-8769-89b8e3bac1c0" continuedAt="i16077b789c954b41ae7eb9c314c26d3b" escape="true">Organization and Operations</ix:nonNumeric></span></div><ix:continuation id="i16077b789c954b41ae7eb9c314c26d3b"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Inovio&#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The Company's DNA medicine pipeline is comprised of three types of candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, Inovio has demonstrated that a DNA medicine can be delivered directly into cells in the body via its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's novel DNA medicines are made using its proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person's immune system recognize and destroy cancerous or virally infected cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio's hand-held CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human data to date have shown a favorable safety profile of Inovio&#8217;s DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery device in more than 6,000 administrations across more than 2,000 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio's corporate strategy is to advance, protect, and provide its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), The U.S. Department of Defense (DoD), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), International Vaccine Institute (IVI), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Thermo Fisher Scientific, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_34"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNzE0NjgyNTU5ODI2MQ_965a4228-cb50-49a1-b6f2-605a896a4a73" continuedAt="i84ac30a0fdcc4612ba53ad1cbb6fe117" escape="true">Basis of Presentation, Liquidity and Risks and Uncertainties</ix:nonNumeric></span></div><ix:continuation id="i84ac30a0fdcc4612ba53ad1cbb6fe117" continuedAt="i1ebeb413db034fedadd5ee8459ed8530"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNzE0NjgyNTU5ODI2MA_2af6bab3-2409-4188-b9a0-bd88448c1ae8" continuedAt="ibb764a38fc9c428e9839223a8bdbf652" escape="true">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of September&#160;30, 2020, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2020 and 2019 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three and nine months ended September 30, 2020 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2019, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_7">Table of Contents</a></span></div></div><ix:continuation id="i1ebeb413db034fedadd5ee8459ed8530" continuedAt="id59fe8def439423b91ec521873f588a8"><ix:continuation id="ibb764a38fc9c428e9839223a8bdbf652" continuedAt="i57193b0360504deb9067a9656e3c1aa7"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange Commission (&#8220;SEC&#8221;) on March&#160;12, 2020. The balance sheet at December&#160;31, 2019 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc., VGX Pharmaceuticals, Inc. ("VGX") and Inovio Asia LLC, and records a <ix:nonFraction unitRef="number" contextRef="i31939003de4d4a3094a1ef0d323e91fb_I20200930" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMjM4Mw_d5f25ab7-a301-4190-b140-ac3757ce5ffe">15</ix:nonFraction>% non-controlling interest for its subsidiary VGX Animal Health, Inc., a subsidiary of VGX.  All intercompany accounts and transactions have been eliminated upon consolidation.  As of June 1, 2020, the Company deconsolidated its subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest, retaining <ix:nonFraction unitRef="number" contextRef="ic34da769042c4f00941ee0248f92939e_I20200601" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMjczNg_7f4097b0-ea92-4079-ac2a-7b120d4641b7">47</ix:nonFraction>% of the outstanding equity on an as-converted to common stock basis. Refer to Footnote 17 for further discussion.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio incurred a net income (loss) attributable to common stockholders of $<ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMjkxOA_7595789f-b2c5-468b-a34c-818c48a7a242">19.2</ix:nonFraction> million and $(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMjkyNQ_c2777f4e-d1b5-4504-ae5d-702a7f51356f">142.1</ix:nonFraction>) million for the three and nine months ended September 30, 2020, respectively. Inovio had working capital of $<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Capital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMjk4NA_57349dbb-f1a6-4996-8752-9bc31389ce49">335.8</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMzAxOA_146f8e7d-270f-42c5-9a28-34b58735b5c8">881.9</ix:nonFraction> million as of September&#160;30, 2020. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMzM2NQ_62306840-4a82-4e92-8692-20b28500456b">337.2</ix:nonFraction> million as of September&#160;30, 2020, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of its current or potential future At-the-Market Equity Offering Sales Agreements (each, a &#8220;Sales Agreement&#8221; and collectively, the &#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds under the Sales Agreements of $<ix:nonFraction unitRef="usd" contextRef="i40baaae65a1744768b1b1675f3ad79d0_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDA5OA_837de2b1-5272-4465-b511-ea83a14ef95a">330.0</ix:nonFraction> million d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uring the nine months ended September 30, 2020, and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0bda1f1acb9e424588e758c721d6202d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDE1MA_489f0601-ce39-4f49-a8cf-7a4e6d7675f1">9.1</ix:nonFraction> million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic8936c9a775e4048b38647b7b881147d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDI2MA_3a4888a9-d5de-4ff0-9f1f-9823162da776">75.7</ix:nonFraction> million from a private placement of <ix:nonFraction unitRef="number" contextRef="i9481fe2b9b0f4c18b552f08cc3c7e40d_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDI5MQ_1e1ca9d5-1eee-4b7d-9d1f-e84d05a78cff">6.50</ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i75ad5d40a88941e3a7a873faf3f7eb60_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDM1OQ_bcb4a7a0-f121-4706-a809-f3aaca099fac">14.5</ix:nonFraction> million from the private placement of <ix:nonFraction unitRef="krw" contextRef="i74f44125bc13416a9aeb599f2cb231e1_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDM5Mg_a86efe4a-4da1-4e45-8acb-bbfc5cea35da">18</ix:nonFraction> billion Korean Won (KRW) (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i74f44125bc13416a9aeb599f2cb231e1_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDQzMQ_b6d4c9b3-0cbd-44ad-baec-157fcf1ba028">15.0</ix:nonFraction> million based on the exchange rate on the date of issuance) aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i74f44125bc13416a9aeb599f2cb231e1_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDUyMA_49b74752-0308-4569-8136-0daab1a0aa68">1.0</ix:nonFraction>% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i2c753a8fdf0f4e7394bef90ba65bc0d2_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDYwNA_856ced4f-c7d2-4968-95ef-cdd613b82739">4.0</ix:nonFraction> million from the private placement of <ix:nonFraction unitRef="krw" contextRef="i66d118519dea4ae7bc213714ffeb97a2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDYzNw_4cd638dd-1ea0-4cf3-b6df-2d118391b4ae">4.7</ix:nonFraction> billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i66d118519dea4ae7bc213714ffeb97a2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDY2Mw_ff65595d-a5a8-4b47-a3ec-c1c0f6d3e25e">4.1</ix:nonFraction> million based on the exchange rate on the date of issuance) aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i66d118519dea4ae7bc213714ffeb97a2_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDc1Mg_e0d13221-3ac9-45fc-b27f-3a91bc26f740">1.0</ix:nonFraction>% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#8220;Bonds&#8221;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#8217;s condensed consolidated financial statements as of and for the three and nine months ended September 30, 2020 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="id59fe8def439423b91ec521873f588a8" continuedAt="i5fad0456de764dc1a4353a3d19142ac5"><ix:continuation id="i57193b0360504deb9067a9656e3c1aa7" continuedAt="i5968ab45c6dc495b94384ed02b079d86">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </ix:continuation></ix:continuation></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i5fad0456de764dc1a4353a3d19142ac5"><ix:continuation id="i5968ab45c6dc495b94384ed02b079d86">The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will impact the Company's business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, that are highly uncertain.</ix:continuation></ix:continuation> </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_37"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMTk_74a101c1-50fd-442a-bf80-57da07e8aae6" continuedAt="id79e01cabde14b2c998d83756de3b6a7" escape="true">Critical Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="id79e01cabde14b2c998d83756de3b6a7" continuedAt="i38e4e208530a42fbab17c6a5da8935f7"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMTA_6cb64307-f8ff-4273-93a1-1e6f5694b35a" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgxOTY_83257ff9-4229-46f2-bb4c-41b8d7c451cf" continuedAt="i02bf0061f24e419f927152775570fff4" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_7">Table of Contents</a></span></div></div><ix:continuation id="i38e4e208530a42fbab17c6a5da8935f7" continuedAt="i12cc88f1202f47d5afd92224f2babb40"><ix:continuation id="i02bf0061f24e419f927152775570fff4"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="ino:GrantPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMjg_ebb55d54-efb8-41d1-89ed-09ea62f64895" continuedAt="i9ef59746f51442138150aa94f969e8aa" escape="true">Grants</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="i9ef59746f51442138150aa94f969e8aa" continuedAt="i6437c19a6e684eb7ac776551427777e0"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6437c19a6e684eb7ac776551427777e0">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMTM_61770758-aa29-4c67-bead-4b3a70415dad" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMjc_3796dda7-d8b6-4381-bd4d-e50e94287c7f" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMDc_e2ffc7ee-d4d0-40d0-96bc-8612d3a3aa4f" continuedAt="id8cb5a00f46e4e06b774c933d22b1453" escape="true">Valuation of Intangible Assets and Goodwill</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_7">Table of Contents</a></span></div></div><ix:continuation id="i12cc88f1202f47d5afd92224f2babb40" continuedAt="i95d91618ea1e4646aa4ddbfd8e0d6c98"><ix:continuation id="id8cb5a00f46e4e06b774c933d22b1453" continuedAt="ib99d6e1675694add9c97f326384a0f69"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfOTk4OQ_0932b4d7-3f73-4fbf-a0c8-940a3372135a">two</span> to <ix:nonNumeric contextRef="i6b8bbe68292646fc920d02bc015f8116_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfOTk5NQ_7e4441ee-66dc-496e-af7d-d1e82c30a943">18</ix:nonNumeric>&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTA4Njk_218245e9-f4fb-4cf3-9415-d8190b075625">3.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTA4Nzc_6b3db6ed-8319-4b21-a8ea-1af1b623c4a0">3.7</ix:nonFraction> million, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through September&#160;30, 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any.  The Company performed its annual assessment for goodwill impairment as of November 30, 2019, identifying no impairment.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib99d6e1675694add9c97f326384a0f69">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.</ix:continuation> See Note&#160;8 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgxOTk_34d17d06-1444-4150-9c28-226d6cdb94e9" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company&#8217;s financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the condensed consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMTY_ffb665e5-5031-4d0c-a88b-c3d514044631" continuedAt="i6c7847b100c243c7b31daff2aaf318a5" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_7">Table of Contents</a></span></div></div><ix:continuation id="i95d91618ea1e4646aa4ddbfd8e0d6c98" continuedAt="i478d93f6101d4c35ae0f0adedbc37880"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6c7847b100c243c7b31daff2aaf318a5">in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.</ix:continuation></span></div><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgxOTQ_f90101a3-7750-42bf-a38c-5a93ef6699bb" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMjU_63f3cf16-1e67-4b8f-8466-77ab1b89258d" continuedAt="i3cdd8c9c4cd041bfb72c64b330e0e747" escape="true">Equity Investments</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="i478d93f6101d4c35ae0f0adedbc37880" continuedAt="i738b1651f5b34ac08a6c1952c6d26076"><ix:continuation id="i3cdd8c9c4cd041bfb72c64b330e0e747" continuedAt="id15903f0315b43e3a906a393892c1976"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i738b1651f5b34ac08a6c1952c6d26076"><ix:continuation id="id15903f0315b43e3a906a393892c1976"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</ix:continuation></ix:continuation>&#160;</span></div><div style="margin-top:5pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_43"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80My9mcmFnOmM4NzJjODg0MGFjODQzYTg5Mzg2OWUzZWM0ZWViZTY0L3RleHRyZWdpb246Yzg3MmM4ODQwYWM4NDNhODkzODY5ZTNlYzRlZWJlNjRfNTE3Mg_13b44aa7-8876-460a-ae42-13307f66cfaf" continuedAt="i8045e114e63b4cc3b7196b60a3e69892" escape="true">Impact of Recently Issued Accounting Standards </ix:nonNumeric></span></div><ix:continuation id="i8045e114e63b4cc3b7196b60a3e69892" continuedAt="iad16707fcd2f485195112fea5c2a24d3"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80My9mcmFnOmM4NzJjODg0MGFjODQzYTg5Mzg2OWUzZWM0ZWViZTY0L3RleHRyZWdpb246Yzg3MmM4ODQwYWM4NDNhODkzODY5ZTNlYzRlZWJlNjRfNTE3Nw_d39b97e4-07bb-48b3-a486-628db5b511e3" continuedAt="i63bb57d4ca364341883862b25434fb1a" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Recently Adopted</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2019-12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adoption. As of September 30, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended September 30, 2020. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2016-13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its condensed consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#8220;COVID-19&#8221;) outbreak on expected credit losses.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2018-13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends certain disclosure requirements over fair value measurements.  Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (see Note 7 for more information about the Company&#8217;s fair value classifications).</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><ix:continuation id="iad16707fcd2f485195112fea5c2a24d3" continuedAt="i55e7c89dba754a98943b988d264ee9f5"><ix:continuation id="i63bb57d4ca364341883862b25434fb1a" continuedAt="iabf1cf77a36743bb8b9a524146d5eb45"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2018-18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarified the interaction between Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.</span></ix:continuation></ix:continuation></div><div style="text-indent:27pt"><ix:continuation id="i55e7c89dba754a98943b988d264ee9f5" continuedAt="i607a0ea30baf4689a6ee2666c019c0bf"><ix:continuation id="iabf1cf77a36743bb8b9a524146d5eb45" continuedAt="ib2b43ec93e1e4771a328e23b476de700"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2017-04.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2017, the FASB issued ASU 2017-04,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i607a0ea30baf4689a6ee2666c019c0bf"><ix:continuation id="ib2b43ec93e1e4771a328e23b476de700">("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_46"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfNTYw_9e0ca8b6-40fc-4f39-83e7-17afff946704" continuedAt="idac9cdccc671446e96e83e730dcbb04a" escape="true">Revenue Recognition  </ix:nonNumeric></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idac9cdccc671446e96e83e730dcbb04a">During the three and nine months ended September 30, 2020, the Company recognized total revenue under collaborative research and development and other agreements of $<ix:nonFraction unitRef="usd" contextRef="i4058122d38c74b2495974de7f507740b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMTUx_018d0911-06c7-4a1f-a698-883dcc9760cd">83,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i19efa68d746c41c38d72557926a2c83a_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMTU4_64d2308f-1930-4502-a1c5-fcedf0a3ecb1">1.3</ix:nonFraction> million, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS"), $<ix:nonFraction unitRef="usd" contextRef="i10bdaf5e033f4b6cb32118002bd714d4_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMjQy_a454fc94-daaf-4332-9b19-f94bd826ec91">21,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id1fe60d4ed164b4ba68d097b07daea40_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMjQ5_832d0a8f-fd65-4b68-a63f-3854539f5b07">167,000</ix:nonFraction>, respectively, from AstraZeneca and $<ix:nonFraction unitRef="usd" contextRef="i59afc9c747d34b8c8a09631dec66eae4_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMjg4_7fd975b6-41a2-40a5-bb64-d1d55469d8fb">132,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0cb681e91bc24c64b846b49185fe2187_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMjk1_50e5df11-7f82-4ea2-b765-e8f9b1e95e92">364,000</ix:nonFraction>, respectively, from various other contracts. Of the total revenue recognized during the three and nine months ended September 30, 2020, $<ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMzkw_36d82f7e-ab7c-4bde-b10e-bb5ef3726e31">4,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMzk3_6354fcaf-ab5c-479e-b927-44472208524a">127,000</ix:nonFraction>, respectively, were in deferred revenue as of December 31, 2019. Performance obligations are generally satisfied within 12 months of the initial contract date.</ix:continuation></span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_49"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMzMzNQ_90633b10-80cf-4fb4-8e1e-a22453e61965" continuedAt="ied6307792a4b490cb490e085f696869b" escape="true">Short-term Investments</ix:nonNumeric></span></div><ix:continuation id="ied6307792a4b490cb490e085f696869b" continuedAt="iec943d8eeea146319133b757b9f421b5"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments at September&#160;30, 2020 consisted of mutual funds, U.S. treasury securities, corporate debt securities, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments at December&#160;31, 2019 consisted of mutual funds. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the condensed consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. During the three and nine months ended September 30, 2020, the Company recorded gross realized gain on investments of $<ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfODUy_2a72af3d-54b1-4898-97e7-619dea1d2cad">105,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfODU5_424bd361-ade4-431d-86bc-af6a2ba6bceb">741,000</ix:nonFraction>, respectively, and gross realized loss on investments of $<ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfOTE5_18ef944d-3281-4bbf-9c35-7339ce74de07">101,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfOTI2_5a5698bb-106a-464e-9f9d-4ce1e48a77b6">1.3</ix:nonFraction> million, respectively. During the three and nine months ended September 30, 2019, the Company recorded gross realized gain on investments of $<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTAyNg_701853a8-31ed-4eee-a4be-1c7ae1bbfb00">155,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTAzMw_6e700ea2-f773-49b4-a3cc-cf2bbda98a50">330,000</ix:nonFraction>, respectively, and gross realized loss on investments of $<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTA5Mw_a6236517-f93a-4679-800a-343720b86679">11,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTEwMA_abe52c67-c988-46bc-8b12-33d408c6ff84">93,000</ix:nonFraction>, respectively. During the three and nine months ended September 30, 2020, the Company recorded net unrealized gain on available-for-sale equity securities of $<ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTIyNA_348f9baa-ec62-4a1d-9c41-23acaca4333e">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTIzMQ_60cde111-3a25-424c-a24b-2f898b0387f4">625,000</ix:nonFraction>, respectively. There was <ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTI1OQ_5735ebcd-f8b8-4e2a-a6b4-2af04a917840"><ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTI1OQ_98a10ffb-c516-4d71-a468-ae54e0ca9d9c">no</ix:nonFraction></ix:nonFraction> material unrealized gain or loss on available-for-sale equity securities recorded during the three and nine months ended September 30, 2019. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of September&#160;30, 2020, the Company had&#160;<ix:nonFraction unitRef="investment" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTY1NQ_0c7b54a0-bca9-4491-9fda-fd7e75c9f36d">11</ix:nonFraction> available-for-sale securities in an unrealized loss position, of which <ix:nonFraction unitRef="investment" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTcyOQ_65e90730-6b91-4543-a2c6-90d83615c829">none</ix:nonFraction> were in such position for longer than 12 months.</span></div><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfNzE0NjgyNTU4NTc4NA_177e55b7-6444-4c32-ba5a-455b46f61620" continuedAt="i3f10338d7d8042db80b9088075e63d5f" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71790af5924c4ddab339efc7f993a154_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMi0zLTEtMS0w_b6c0ae83-06bf-49f1-8143-26ac8cdbd12d">152,177,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71790af5924c4ddab339efc7f993a154_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMi01LTEtMS0w_263ead61-9048-46e7-9273-26e0c01d92cc">1,752,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71790af5924c4ddab339efc7f993a154_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMi03LTEtMS0w_d8aa8e97-23af-453e-a0b2-ba6af003ee91">1,128,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71790af5924c4ddab339efc7f993a154_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMi05LTEtMS0w_9e46f92f-8dee-4d21-9b7c-21f196792b61">152,802,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice5ad4689ec9487e82f66dfbdc7bcff2_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMy0zLTEtMS0w_daea4fd2-b53f-444c-a17d-00718947b80a">1,200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice5ad4689ec9487e82f66dfbdc7bcff2_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMy01LTEtMS0w_ae8b5d6d-30ee-42a6-abff-a85bd9c70cf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice5ad4689ec9487e82f66dfbdc7bcff2_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMy03LTEtMS0w_5063211f-ee23-480f-97d1-8619dc876f74">27,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice5ad4689ec9487e82f66dfbdc7bcff2_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMy05LTEtMS0w_b0cfde96-a8c9-4ddb-9f82-cb7ebb652974">1,172,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e18e4080084b71847f96b5e9a0e699_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNC0zLTEtMS0w_8325a305-741b-4542-b30b-ae435a5c9bba">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e18e4080084b71847f96b5e9a0e699_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNC01LTEtMS0w_a728f95c-8b1d-4ffd-9da8-0c668b2321b2">32,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e18e4080084b71847f96b5e9a0e699_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNC03LTEtMS0w_9a1970d0-2076-4a89-af1d-8b617b150ad8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e18e4080084b71847f96b5e9a0e699_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNC05LTEtMS0w_438c84e2-328e-49c5-9fb0-9069ec15e0c5">3,032,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a526030817474ca6bde92e79a78309_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS0zLTEtMS0xNDcx_28721a6d-2f7f-405b-ad12-97c1bb31eb14">1,529,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a526030817474ca6bde92e79a78309_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS01LTEtMS0xNDcx_8cb210ae-007b-46df-a9d5-c65cce1bebac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96a526030817474ca6bde92e79a78309_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS03LTEtMS0xNDcx_2cb7267a-1b7e-4f36-87b2-b9862813ffb5">1,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a526030817474ca6bde92e79a78309_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS05LTEtMS0xNDcx_f33101d7-9b65-432a-8673-17f7ad41e612">1,528,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS0zLTEtMS0w_64066398-8e55-489e-b7f2-d7c115e4049a">157,907,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS01LTEtMS0w_21f1a912-f1a7-4029-9896-d8a0354b126f">1,785,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS03LTEtMS0w_6ba3b879-2ae0-4e7b-9b38-95520727614d">1,157,214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS05LTEtMS0w_d77d26de-35ba-43a3-ac46-3f632667c271">158,535,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iec943d8eeea146319133b757b9f421b5"><ix:continuation id="i3f10338d7d8042db80b9088075e63d5f"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie860f23b62fe487f8c985dd5b2c5316a_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmY5N2MwMzBhOTNjYzRmOTJiY2FkYjUyOWMwYzYxYjMxL3RhYmxlcmFuZ2U6Zjk3YzAzMGE5M2NjNGY5MmJjYWRiNTI5YzBjNjFiMzFfMi0zLTEtMS0w_d7e71d1e-7ee6-420e-9dae-ffa3e748b98d">66,599,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie860f23b62fe487f8c985dd5b2c5316a_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmY5N2MwMzBhOTNjYzRmOTJiY2FkYjUyOWMwYzYxYjMxL3RhYmxlcmFuZ2U6Zjk3YzAzMGE5M2NjNGY5MmJjYWRiNTI5YzBjNjFiMzFfMi01LTEtMS0w_56e618ce-e17c-4f6d-a30f-3f4fb932b2d3">754,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie860f23b62fe487f8c985dd5b2c5316a_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmY5N2MwMzBhOTNjYzRmOTJiY2FkYjUyOWMwYzYxYjMxL3RhYmxlcmFuZ2U6Zjk3YzAzMGE5M2NjNGY5MmJjYWRiNTI5YzBjNjFiMzFfMi03LTEtMS0w_bc9b3c35-1d9b-42d3-b2df-dd1af082327f">15,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie860f23b62fe487f8c985dd5b2c5316a_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmY5N2MwMzBhOTNjYzRmOTJiY2FkYjUyOWMwYzYxYjMxL3RhYmxlcmFuZ2U6Zjk3YzAzMGE5M2NjNGY5MmJjYWRiNTI5YzBjNjFiMzFfMi05LTEtMS0w_188a410a-3b9d-4045-a2d6-dc53c99fa914">67,338,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;September&#160;30, 2020&#160;were primarily due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the COVID-19 global pandemic, and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at September&#160;30, 2020, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div></ix:continuation><div><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_55"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RleHRyZWdpb246YTZmMzEwMGY0ZGE0NDM1MWI5MGY1NGJmNTNlOTM1MWJfNTMxOA_481b624e-5cfd-4dc1-ae34-24b5b3313c74" continuedAt="i443d5789fca94fc8a4e9f583bccce8c7" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i443d5789fca94fc8a4e9f583bccce8c7" continuedAt="i7b0d67d5183c4638bfe87125822f9d64"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets are, and prior to September 30, 2020 liabilities were, classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the nine months ended September 30, 2020 or 2019. All liabilities in the fair value hierarchy were extinguished as of September 30, 2020 as described below.</span></div><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RleHRyZWdpb246YTZmMzEwMGY0ZGE0NDM1MWI5MGY1NGJmNTNlOTM1MWJfNTMzNQ_bb6b5f42-3c76-40fa-b576-a6ee3caca95e" continuedAt="ifdaf4eaa24cc446b845bbb2387a02fdb" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of September&#160;30, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f68c7b48d744a6a9173080f6c38f09_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy0xLTEtMS00Nzcw_d7304245-0236-44ed-a873-77d0b1a086b8">99,985,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i918e4025371f42b5b7b58df82fc10039_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy0zLTEtMS00Nzcw_b827ea44-1a2c-4234-94d7-824caf8ee43e">99,985,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dbb0afb9ddd4315b01e6f4ccb7ca2c6_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy01LTEtMS00Nzcw_b3c9a983-4876-4aa6-b46d-026bbba9b345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if795f05efa0445c98031f36131b16eb8_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy03LTEtMS00Nzcw_e197b418-9244-412a-a7f8-8a75e7afe511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c105aeef2c41549d702f116ad4f464_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS0xLTEtMS00ODYx_41cf95d8-04ff-46a6-9fe1-6b0024ef6b59">152,802,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie03669a396f4494cb8682e7da1ca04b4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS0zLTEtMS00ODYx_936838a1-b1d5-485e-b7df-3a0c9eb67b7f">152,802,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b71d42002e544b4a463361f34d11920_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS01LTEtMS00ODYx_0b9777e1-88e5-4694-b380-cd8c0e7a70fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e85feb515594f70b6395ddc1f835acc_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS03LTEtMS00ODYx_64b0799c-1d90-4831-a9d5-3f19cdc55535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151a4fa9e7064eb0913b049b54c5c026_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNi0xLTEtMS0w_89ed84d1-4a18-4955-81b2-eb585cbe4c26">1,172,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice5ad4689ec9487e82f66dfbdc7bcff2_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNi0zLTEtMS0w_b0cfde96-a8c9-4ddb-9f82-cb7ebb652974">1,172,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a11d9344d464d08a2c4860a29929ef9_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNi01LTEtMS0w_396e0ae6-e05f-46f2-8104-f75a1072f0b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i038eb61ac20847bb81aa8ef1c87cefbc_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNi03LTEtMS0w_bdac37ba-6845-444d-88fc-85cde1ee1b3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea8a9e591f0496d8673b145a17803fb_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy0xLTEtMS0w_a9ac5efa-067b-4917-8a71-afcc53489a1f">3,032,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id488e43085014ecdb6ffe6983f1f85b9_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy0zLTEtMS0w_c4c075c7-aef4-4bc3-81e6-582b2aa57b34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb90dd8056f43a3ada1c1be4856323f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy01LTEtMS0w_e2a0e8aa-23f3-42b9-86e6-fa148d5580a1">3,032,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d54f6841f54932bc303d237a8609b6_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy03LTEtMS0w_a00d4cac-19a1-4483-899b-4cb792fff348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7212a769f73745f29da1c66276126ff3_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOC0xLTEtMS0w_add1110a-9b0a-4484-ac2c-aff0e5b118f2">1,528,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52399d29eb084b1fba8917f89379b49c_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOC0zLTEtMS0w_4d804762-0827-4ebe-af19-f0407c108582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic787e50b63d34253bbe8d56456eb3701_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOC01LTEtMS0w_aa632023-45f9-4f57-b23f-9e3fe2fe3277">1,528,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0dcb790ab6d41bcb0c822ec87057c02_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOC03LTEtMS0w_6b7e7c46-e597-45ad-8e2a-06925839e591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99efe129ba7f47c493d7948e3488435d_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTMtMS0xLTEtNDg4OA_afe47f26-6339-4bc8-aa14-4fb2a506f697">158,535,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0393158ad254b10ac5bbdca3fffa1c2_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTMtMy0xLTEtNDg4OQ_5b60c7f5-6a0a-48f1-932c-750c5424768d">153,974,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i692de2cba0aa4e9bbf5aee0bbed07c99_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTMtNS0xLTEtNDg5Mg_c4b49d1b-6752-4402-a31c-f4924d961be1">4,561,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e17ec22317c4268b177ef3d384f59b6_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTMtNy0xLTEtNDg5Mw_c9057f42-3e23-4a61-a313-1159945d5041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99efe129ba7f47c493d7948e3488435d_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS0xLTEtMS0w_1b20dd96-9927-48f2-a8c1-2728f6e8e1a5">4,154,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0393158ad254b10ac5bbdca3fffa1c2_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS0zLTEtMS0w_0dbd8715-0a7e-4b94-ac3a-b9cee5e936d6">4,154,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i692de2cba0aa4e9bbf5aee0bbed07c99_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS01LTEtMS0w_6f7b07de-eeee-40c9-abb7-7af1a5a94327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e17ec22317c4268b177ef3d384f59b6_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS03LTEtMS0w_bdcbb0ea-56dc-436a-95f6-3c7844c67995">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99efe129ba7f47c493d7948e3488435d_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTEtMS0xLTEtMA_cd0b248e-939e-4963-99ee-8b63d35cc014">262,674,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0393158ad254b10ac5bbdca3fffa1c2_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTEtMy0xLTEtMA_e2b504f7-cc19-456b-91d9-743e0173d33f">258,113,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i692de2cba0aa4e9bbf5aee0bbed07c99_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTEtNS0xLTEtMA_db4b95dd-0a33-402e-9e66-b4602817b630">4,561,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e17ec22317c4268b177ef3d384f59b6_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTEtNy0xLTEtMA_34bbb189-c3f4-422a-9adc-bc950570659d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7b0d67d5183c4638bfe87125822f9d64" continuedAt="i813f2ec898e64347b27a4dd5e14ac0bc"><ix:continuation id="ifdaf4eaa24cc446b845bbb2387a02fdb"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2019:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97b736b29264d8aa6220ac0e12c35fe_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNC0xLTEtMS0w_b5c619e3-a83f-44a8-8673-db05c6560199">2,349,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7d48f9d1074982822fddd2b379a517_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNC0zLTEtMS0w_3da6716f-2d23-4591-976f-e4a758ef60e5">2,349,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48be730bf58424b80b0e60560d8fb7e_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNC01LTEtMS0w_8fb368c9-d8e8-46d8-afd5-8a3d461a02b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f88938286e46c5852675631383c455_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNC03LTEtMS0w_961d64dc-6371-478d-9b15-f5a8b1575f41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915d187dcbcc4f6abe0cc0d82477a4dd_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNS0xLTEtMS0w_4977f9be-c6b9-47e4-937e-ee8b3e21a73d">67,338,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea476b8d6cf4060b5668a0a25d5da59_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNS0zLTEtMS0w_136e220f-8874-4fcb-9e48-90680b027043">67,338,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ed83b261a747f18822c09954cbbc28_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNS01LTEtMS0w_d86fa28e-5883-4445-a6bb-3f6bb4ce08b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54a86390af04834af68005465847e66_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNS03LTEtMS0w_69957494-8e48-4bd1-8d69-ebf6a410ea15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa448e74007b43949527573adaece377_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfOS0xLTEtMS0w_0aa90296-fad7-4042-a62e-e94ea6265ca2">6,315,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de60a0d0457444486d03b56271564bc_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfOS0zLTEtMS0w_ab2f602d-36ac-4555-aa37-5b74f50c442e">6,315,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b22b095121487092da2a8e6fb84adf_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfOS01LTEtMS0w_4178db82-faea-48ef-b5b7-cefd1a1cfeb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2966e31f5c4d178bace1c18c46ea63_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfOS03LTEtMS0w_120c47e4-8f9d-4c1e-9e76-efefc0f34afe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa448e74007b43949527573adaece377_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTEtMS0xLTEtMA_30613ce1-4766-4ca3-9989-cbeffb4ef957">76,003,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de60a0d0457444486d03b56271564bc_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTEtMy0xLTEtMA_3aa791a3-7031-4628-9243-dca2c049582b">76,003,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b22b095121487092da2a8e6fb84adf_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTEtNS0xLTEtMA_52d1580f-0014-4d25-bf35-984b11ec4a14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2966e31f5c4d178bace1c18c46ea63_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTEtNy0xLTEtMA_aaafb57a-17a1-4da6-b0ac-9edf18ef1405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability (Note 9)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa448e74007b43949527573adaece377_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTMtMS0xLTEtMA_5c6d02de-b4c2-4fb8-9e04-668bc0cc76e6">8,819,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de60a0d0457444486d03b56271564bc_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTMtMy0xLTEtMA_4ea15148-d679-415e-8765-ffaf6b38cf7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b22b095121487092da2a8e6fb84adf_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTMtNS0xLTEtMA_8ed9996d-a535-4e28-a3ad-d8e9b240ac3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2966e31f5c4d178bace1c18c46ea63_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTMtNy0xLTEtMA_09bb77e8-c524-479d-90ae-c87c5f0c845d">8,819,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa448e74007b43949527573adaece377_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTQtMS0xLTEtMA_3e2d3630-30b2-4f0e-b27d-f4c24e8c9cb4">8,819,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de60a0d0457444486d03b56271564bc_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTQtMy0xLTEtMA_d494a697-c79e-47a0-ba23-d66830c61146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b22b095121487092da2a8e6fb84adf_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTQtNS0xLTEtMA_73b7fb9f-5ede-4111-b675-6fdc0804d8b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2966e31f5c4d178bace1c18c46ea63_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTQtNy0xLTEtMA_f530a838-5bb4-4b81-8de4-14e86f5fc946">8,819,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at September&#160;30, 2020 consisted of mutual funds, corporate debt securities and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in <ix:nonFraction unitRef="shares" contextRef="i5536482a9a094c779a9961b697daaf39_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RleHRyZWdpb246YTZmMzEwMGY0ZGE0NDM1MWI5MGY1NGJmNTNlOTM1MWJfMTkxMA_edf74d0f-7bc3-4835-b2e8-cebcc0366696">597,808</ix:nonFraction> common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the condensed consolidated statement of operations as a gain (loss) on investment in affiliated entities. In August 2020, the Company sold its investment in <ix:nonFraction unitRef="shares" contextRef="i94285e36aedc4ac6936417abdd4e690c_I20200831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RleHRyZWdpb246YTZmMzEwMGY0ZGE0NDM1MWI5MGY1NGJmNTNlOTM1MWJfOTM0NTg0ODg0MzI4Mw_c399129b-513b-4d9c-9583-e90c39af87e0">1,644,155</ix:nonFraction> common shares of its affiliated entity GeneOne. Previously, the Company accounted for its investment in GeneOne based on the closing price of the shares on the KOSDAQ Market of the Korea Exchange (KOSDAQ) on the applicable balance sheet date. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at September&#160;30, 2020 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets at September&#160;30, 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 liabilities at September 30, 2020 due to the full conversion of the August 2019 Bonds into shares of the Company's common stock (see Note 9 below for more information). Level 3 liabilities held as of December 31, 2019 consisted of the embedded conversion option contained in the August 2019 Bonds that met the criteria to be bifurcated and accounted for separately from the August 2019 Bonds (the "derivative liability"). The derivative liability was recorded at fair value of $<ix:nonFraction unitRef="usd" contextRef="ie34b833b31b34228ad5580d790df4e4b_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RleHRyZWdpb246YTZmMzEwMGY0ZGE0NDM1MWI5MGY1NGJmNTNlOTM1MWJfMzg0Nw_51e6559f-4294-4a63-904c-c9c36da5ab92">7.1</ix:nonFraction> million upon the issuance of the August 2019 Bonds, and was subsequently remeasured to fair value at each reporting period until conversion. The derivative liability was initially valued and remeasured using a "with-and-without" method. The "with-and-without" methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the embedded conversion option. The difference between the entire instrument with the embedded conversion option compared to the instrument without the embedded conversion option is the fair value of the derivative, recorded as the derivative liability. There was no derivative liability associated with the issuance of the December 2019 Bonds.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i813f2ec898e64347b27a4dd5e14ac0bc"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the August 2019 Bonds with the conversion option was estimated using a Monte Carlo simulation approach. The key inputs to valuing the August 2019 Bonds with the conversion option on the date of issuance and as of the August 3, 2020 conversion date, include the Company&#8217;s stock price on the valuation date; the expected annual volatility of the Company&#8217;s common stock, and the discount yield, which was derived by making the fair value of the August 2019 Bonds equal to the face value on the issuance date. Fair value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value. </span></div><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RleHRyZWdpb246YTZmMzEwMGY0ZGE0NDM1MWI5MGY1NGJmNTNlOTM1MWJfNTM0Ng_8a7d08e5-d2cf-40d3-92b3-0ae34d5dd19f" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company's derivative liability for the nine months ended September 30, 2020: </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:79.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBiYjcxNDM5NTdmZjQ3MDE4MDdjY2FjNjkzMjEyNzViL3RhYmxlcmFuZ2U6MGJiNzE0Mzk1N2ZmNDcwMTgwN2NjYWM2OTMyMTI3NWJfMC0xLTEtMS0w_c4b19473-d45e-4620-bd61-69cc5a2d542c">8,819,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBiYjcxNDM5NTdmZjQ3MDE4MDdjY2FjNjkzMjEyNzViL3RhYmxlcmFuZ2U6MGJiNzE0Mzk1N2ZmNDcwMTgwN2NjYWM2OTMyMTI3NWJfMS0xLTEtMS0w_140baf10-f00c-413f-9030-edd4e34cd04a">75,670,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Derecognition of the derivative liability upon conversion </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBiYjcxNDM5NTdmZjQ3MDE4MDdjY2FjNjkzMjEyNzViL3RhYmxlcmFuZ2U6MGJiNzE0Mzk1N2ZmNDcwMTgwN2NjYWM2OTMyMTI3NWJfMi0xLTEtMS0xNzY3_6aaf060e-bb54-456a-971f-790280fab4e9">84,490,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBiYjcxNDM5NTdmZjQ3MDE4MDdjY2FjNjkzMjEyNzViL3RhYmxlcmFuZ2U6MGJiNzE0Mzk1N2ZmNDcwMTgwN2NjYWM2OTMyMTI3NWJfMi0xLTEtMS0w_10fb9d44-8586-4736-9905-4b7c6a38770a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_58"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfOTg1_15b6c997-e90a-4046-b843-66bf3182675e" continuedAt="i990010bb92d04538ab5a24d57e5c637e" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i990010bb92d04538ab5a24d57e5c637e" continuedAt="i9395aab0f78e458896543c18e6bc5c1b"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfOTcx_3a0f882f-8790-4b61-b7d4-2cd7e3d27656" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.918%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GoodwillGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMy0zLTEtMS0w_b6e63e11-5062-4de6-aaff-dd04644c8bc4">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMy03LTEtMS0w_f3625c97-2ffd-473d-9d89-ca874b12740a">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GoodwillGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMy05LTEtMS0w_4af353c1-1480-45ec-8fbc-6b04a06f70ab">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMy0xMy0xLTEtMA_cd711c7f-aac7-43c3-9657-50954515e081">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f8340ca06974cc4af47f666f30b4427_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi0xLTEtMS0w_7d2ffa6f-0722-44db-97b8-ee6a8627d400">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a4423ca3fd4a44b5437b54d8107c3f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi0zLTEtMS0w_e35273f1-5822-430a-8404-80891e2730e0">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35a4423ca3fd4a44b5437b54d8107c3f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi01LTEtMS0w_f4d6251d-f9a1-4fb1-a9c2-f375fc7a062b">1,269,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a4423ca3fd4a44b5437b54d8107c3f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi03LTEtMS0w_4f47d7f0-458a-469d-b1e2-52dc2cedcbe5">54,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i993e6fb6374f485f825fc460f02fba85_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi05LTEtMS0w_e72ecf78-89b1-497e-bd20-8fb6bc2cc480">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i993e6fb6374f485f825fc460f02fba85_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi0xMS0xLTEtMA_19b68e28-6efa-4ded-b08c-8e9ec31cc1ee">1,248,104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i993e6fb6374f485f825fc460f02fba85_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi0xMy0xLTEtMA_ba99df38-d4b9-4fa1-bff0-1fc973f21c54">75,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icaf790af2a9c4f65a9e9b79b785a3c9f_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS0xLTEtMS0w_8eb1b7f0-3771-4c30-82b0-038b0193df7c">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595e1f2af87d47f9825e175e8cdbe831_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS0zLTEtMS0w_b4f66df4-6b36-4617-804d-a2ca1d688f3d">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i595e1f2af87d47f9825e175e8cdbe831_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS01LTEtMS0w_c0c92cd9-901a-4de7-9e53-978c3f91a39b">2,395,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595e1f2af87d47f9825e175e8cdbe831_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS03LTEtMS0w_f70b99e7-7962-497c-ad8a-e4e8cf4c4ece">2,704,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629f451db0a646ff9a5db84aee063ff4_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS05LTEtMS0w_f5ebed6a-8fc2-44aa-8c0e-d416094b1fe8">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i629f451db0a646ff9a5db84aee063ff4_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS0xMS0xLTEtMA_bc5ad8f4-9cb2-4249-b2f5-c503c2b8d3a1">2,175,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629f451db0a646ff9a5db84aee063ff4_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS0xMy0xLTEtMA_ef01b9db-c3c7-43e7-9f05-a36438737168">2,924,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i929847a653e343629b9e00d8a43f72a9_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtMS0xLTEtMA_c14a1424-6c0b-4217-93e6-68eebde29db5">18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a6a7fc219f409290b994a921f5de9f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtMy0xLTEtMA_be69e823-785e-4427-8035-c607e8f76fea">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55a6a7fc219f409290b994a921f5de9f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtNS0xLTEtMA_8294af77-7bd5-4f75-ba7c-4fb3463eb6c9">3,525,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a6a7fc219f409290b994a921f5de9f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtNy0xLTEtMA_ffefab38-b500-4307-8a4e-f3747ced3ac0">525,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9158ca8f497c4770861d6068bf7925f9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtOS0xLTEtMA_d263b217-2d56-4655-ab3f-5d415d98865a">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9158ca8f497c4770861d6068bf7925f9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtMTEtMS0xLTA_46a1f7d4-94c5-48f1-85f1-8598662f46c8">3,356,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9158ca8f497c4770861d6068bf7925f9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtMTMtMS0xLTA_6126e5ef-e4b2-4e53-b5c2-39d61fc8a9c6">693,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2914df82e244dcb9b995f1185e3447e_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtMS0xLTEtMA_0d492c4a-fbb3-43fd-824f-9cb6a5f5f928">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtMy0xLTEtMA_5c8d322f-42dd-403f-a3ef-b7930f830b01">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtNS0xLTEtMA_e1e541a2-2d19-486e-bf45-5793a47815c1">7,190,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtNy0xLTEtMA_4531f82b-a283-428c-8b3d-dc19a19239cb">3,283,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtOS0xLTEtMA_c3ef73c4-b1b3-4455-bae8-df64457565ee">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtMTEtMS0xLTA_b855399e-7b00-4c70-99f5-245166790438">6,779,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtMTMtMS0xLTA_10a623b8-58d3-4778-93b2-0a8fedddcb91">3,693,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTItMy0xLTEtMA_45defaa5-ac60-45fa-81e3-c849da7b4ef9">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTItNS0xLTEtMA_923961f0-381d-4f56-aead-650279d2c9b5">7,190,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTItNy0xLTEtMA_f7753d4a-5213-48a3-9567-5bcc1fedd93c">13,796,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTItOS0xLTEtMA_6239eb97-aa66-4919-b5b4-6f9d2662b2dd">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTItMTEtMS0xLTA_5f9f9aeb-ffb2-4304-8193-2dc377ec0e86">6,779,910</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTItMTMtMS0xLTA_0d638010-59f2-4514-9d01-5c7a74aba74a">14,207,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for $<ix:nonFraction unitRef="usd" contextRef="ibdf052a2e7144cdbbe989052584b4ca0_I20050131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfMjgz_41655890-0e30-4efe-8ffc-dbeb96ff9d8f">3.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i4afa819554cd473a95b7517d32ce72f6_I20090630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfMjg3_8156bcae-d364-4c90-8b38-5ba50f926a7e">6.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2eca76820add42a0a986a746497d97dd_I20160430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfMjk0_0a7ccab1-8636-46d1-996e-c8567778b819">400,000</ix:nonFraction>, respectively.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9395aab0f78e458896543c18e6bc5c1b">Aggregate amortization expense on intangible assets for the three and nine months ended September 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfNjcx_36bc85da-47c7-43b1-882c-c25af9c6f167">137,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfNjc4_1738c169-cd9f-4071-9eae-643a20b1191d">410,000</ix:nonFraction>, respectively. Aggregate amortization expense on intangible assets for the three and nine months ended September 30, 2019 was $<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfNzYz_2eeea8e4-5375-4c16-9242-05a6f7d2f829">267,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfNzcw_bf9c4eb3-3058-46d7-abb7-5c68c3edc9f7">800,000</ix:nonFraction>, respectively. Estimated aggregate amortization expense is $<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfODMz_0f422dfd-0170-409e-be10-680442b4df94">137,000</ix:nonFraction> for the remainder of fiscal year 2020, $<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfODcz_ee9ad503-2856-4aec-af5e-6e8d232428eb">520,000</ix:nonFraction> for 2021, $<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfODg1_7c6eea95-64d9-4316-ae11-4c4854967893">493,000</ix:nonFraction> for 2022, $<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfODk3_87d5fece-299a-40da-98ee-30753b6247f4">276,000</ix:nonFraction> for 2023, $<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfOTA5_1e47ef92-f45c-40ad-af98-cc06fd4418f4">253,000</ix:nonFraction> for 2024 and $<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfOTI0_fd4b95c0-496b-41f7-a661-c40f0bc86325">1.6</ix:nonFraction> million for 2025 and subsequent years combined.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_61"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNzY5NjU4MTQxMzcxOA_7b5ad682-c868-41b3-862f-13608d817163" continuedAt="i015b061b38d649b7848063ba34e8a57c" escape="true">Convertible Debt</ix:nonNumeric></span></div><ix:continuation id="i015b061b38d649b7848063ba34e8a57c" continuedAt="i6671481579a9472fbe8f6d27f1ce5ba5"><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="if070ef767938497492f880730056fd65_I20190301" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTM3_fdda763b-b704-4b55-a23a-f5ba2b7fc612">78.5</ix:nonFraction> million aggregate principal amount of the Notes to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzMy_0f9464f5-6996-48e4-8420-a33a59da856f">75.7</ix:nonFraction> million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6671481579a9472fbe8f6d27f1ce5ba5" continuedAt="ic7adcf34f35e4a04b891663b03108b50"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of <ix:nonFraction unitRef="number" contextRef="if070ef767938497492f880730056fd65_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNTQx_2529f425-54d2-4c22-beb9-a5180b13939e">6.50</ix:nonFraction>% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ib3abdef29e774d82a089595d8b564e0f_I20190301" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTM1Mw_9edc2863-4776-444b-a774-de99a858e31c">5.38</ix:nonFraction> per share), subject to adjustment upon the occurrence of specified events.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds <ix:nonFraction unitRef="number" contextRef="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTY2NQ_ed28a8df-2730-4bd0-9ba6-f3841e26edb9">130</ix:nonFraction>% of the conversion price on (i) each of at least <ix:nonFraction unitRef="day" contextRef="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTcxNg_d6c35feb-c021-48c2-b6e0-863a179a4894">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="day" contextRef="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTc3Mg_5a9dd708-ee79-47e8-b9df-a513c4df813b">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to <ix:nonFraction unitRef="number" contextRef="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMjA0Mw_8672a970-452f-4afb-96b9-a182dd6fc07d">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its condensed consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $<ix:nonFraction unitRef="usd" contextRef="if070ef767938497492f880730056fd65_I20190301" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMjU4Mg_9ffb28bd-885b-49e9-9686-e3db8a044586">78.5</ix:nonFraction> million are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion featu</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">res. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $<ix:nonFraction unitRef="usd" contextRef="if070ef767938497492f880730056fd65_I20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMjg5OA_a906bfcc-1bd3-42fd-9c27-0f0f879cf597">62.2</ix:nonFraction> million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $<ix:nonFraction unitRef="usd" contextRef="if070ef767938497492f880730056fd65_I20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzExMA_b0f2ba0e-2be3-4d4f-a77e-afc6e2c6ef4e">2.8</ix:nonFraction> million are allocated to the liability and equity component in the same proportion as the issuance proceeds. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $<ix:nonFraction unitRef="usd" contextRef="if070ef767938497492f880730056fd65_I20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzg0ODI5MDczMDc4Mw_8c60b77c-b48b-4239-8b48-d6075c26abb5">18.6</ix:nonFraction> million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is <ix:nonFraction unitRef="number" contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzg0ODI5MDczMDc4Nw_15333902-0d35-4f1d-bb55-3b6572773dc5">13.1</ix:nonFraction>%. </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, the Company received notices for the conversion of $<ix:nonFraction unitRef="usd" contextRef="if59eceeb9abf42459b9e0b88dc6346ce_D20200701-20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzg0ODI5MDcyODg2NA_83985d19-3f26-48be-8a5a-f2bb2881bd55">19.1</ix:nonFraction>&#160;million of principal amount of the Notes, which were settled in July 2020 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">into an aggregate of <ix:nonFraction unitRef="shares" contextRef="if59eceeb9abf42459b9e0b88dc6346ce_D20200701-20200731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzg0ODI5MDcyODg3OQ_d251db2e-bc2a-44d3-aebd-f1a4740ae503">3,546,074</ix:nonFraction> shares of the Company's common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The fair value of the Notes at the date of conversion was $<ix:nonFraction unitRef="usd" contextRef="i45d4d90e086a49749993964ed0753833_I20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkyNzY2Nw_6548f24a-61c3-4dd0-b48a-6a6fc9d91f31">13.0</ix:nonFraction>&#160;million compared to the carrying value of $<ix:nonFraction unitRef="usd" contextRef="i45d4d90e086a49749993964ed0753833_I20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkyNzY4Mg_85204c11-78ab-45d8-90c4-a26b606aa346">16.1</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="if59eceeb9abf42459b9e0b88dc6346ce_D20200701-20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzg0ODI5MDcyOTc0MA_af0f4d48-cfae-4b65-9636-9c41d6a30229">3.1</ix:nonFraction> million gain on extinguishment of debt. This gain was recorded in the condensed consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.</span></div><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ4MTU_63a9339f-8867-43dc-98ff-1f98d2630467" continuedAt="iafdc9152d9654c638a08651cfa57df7f" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad00cc94b7054dba89db6de62bd2743e_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmEwOTIwZjIwYmZiYzQzY2U4M2M3MTgxOGZjOWJiZWRhL3RhYmxlcmFuZ2U6YTA5MjBmMjBiZmJjNDNjZTgzYzcxODE4ZmM5YmJlZGFfMC0xLTEtMS0w_decf31a6-6024-4fd1-ba8f-739dfb907726">78,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="0" format="ixt:numdotdecimal" name="ino:DebtInstrumentConvertibleDebtConvertedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmEwOTIwZjIwYmZiYzQzY2U4M2M3MTgxOGZjOWJiZWRhL3RhYmxlcmFuZ2U6YTA5MjBmMjBiZmJjNDNjZTgzYzcxODE4ZmM5YmJlZGFfMS0xLTEtMS0zMDYw_10ff3d59-799c-45e1-a761-e9aca177957a">19,085,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad00cc94b7054dba89db6de62bd2743e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmEwOTIwZjIwYmZiYzQzY2U4M2M3MTgxOGZjOWJiZWRhL3RhYmxlcmFuZ2U6YTA5MjBmMjBiZmJjNDNjZTgzYzcxODE4ZmM5YmJlZGFfMS0xLTEtMS0w_088012aa-7fe6-4963-91cf-1b27a6f2e22f">8,965,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad00cc94b7054dba89db6de62bd2743e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmEwOTIwZjIwYmZiYzQzY2U4M2M3MTgxOGZjOWJiZWRhL3RhYmxlcmFuZ2U6YTA5MjBmMjBiZmJjNDNjZTgzYzcxODE4ZmM5YmJlZGFfMi0xLTEtMS0w_b5b2f8bf-e591-47e1-a359-076a9f6b3f0a">1,233,978</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad00cc94b7054dba89db6de62bd2743e_I20200930" decimals="0" format="ixt:numdotdecimal" name="ino:DebtInstrumentAccruedInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmEwOTIwZjIwYmZiYzQzY2U4M2M3MTgxOGZjOWJiZWRhL3RhYmxlcmFuZ2U6YTA5MjBmMjBiZmJjNDNjZTgzYzcxODE4ZmM5YmJlZGFfMy0xLTEtMS0w_ca6dc4e6-b001-43a7-b75c-f670e3cc2a83">321,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad00cc94b7054dba89db6de62bd2743e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmEwOTIwZjIwYmZiYzQzY2U4M2M3MTgxOGZjOWJiZWRhL3RhYmxlcmFuZ2U6YTA5MjBmMjBiZmJjNDNjZTgzYzcxODE4ZmM5YmJlZGFfNC0xLTEtMS0w_18c0f9d8-c4c9-4ca0-baec-0ad413c1bcb1">49,537,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2020,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i590d515cf6de40edb611587951823c62_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDA5Mw_c211056a-b409-4cff-983d-23c638c2fb72">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9d466a48e9e141aa8102e78c3a89cb07_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDEwMA_e4c4495e-d8ff-4dc2-a2b3-0af9674cbc83">5.9</ix:nonFraction> million, respectively, of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="i590d515cf6de40edb611587951823c62_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDE2OQ_131e4e3c-da28-4db5-9356-9ddae22d0fe5">996,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9d466a48e9e141aa8102e78c3a89cb07_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDE3Ng_5684095d-2377-4760-8b83-ac7bfe08e04a">3.5</ix:nonFraction> million, respectively, related to the contractual interest coupon. For the three and nine months ended September 30, 2019,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i864892cede774f3eb42a10f60eaf5a21_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDMxMQ_70745f3b-c67e-4c50-a29b-f12da0af895c">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib0c7c8a510c14ce3ba010b700fac6047_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDMxOA_f292f7b6-e360-4b4d-9ea9-bd1be6fa37e3">4.9</ix:nonFraction> million, respectively, of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="i864892cede774f3eb42a10f60eaf5a21_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDM4Nw_fab485e9-fa21-43fc-9ce3-ea187e9b1b22">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib0c7c8a510c14ce3ba010b700fac6047_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDM5NA_d8bff692-ab69-42b9-a86f-2f00198b2ad7">3.1</ix:nonFraction> million, respectively, related to the contractual interest coupon. As descr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ibed in Note 18 below, subsequent to September 30, 2020, certain holders converted an additional portion of the Notes into shares of the Company's common stock.  </span></div></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic7adcf34f35e4a04b891663b03108b50" continuedAt="i19cd4408da684cafae5afdb0d52b1b88"><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2019 Convertible Bonds</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2019, the Company closed a private placem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent of the August 2019 Bonds with an aggregate principal amount of <ix:nonFraction unitRef="krw" contextRef="i2393a62fa5e34d739b1a36b6e8df6f31_I20190801" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDgzNQ_3cd280e5-ce1f-4dc1-b465-eeb9696671c0">18</ix:nonFraction> billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i2393a62fa5e34d739b1a36b6e8df6f31_I20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDg3NA_471b5361-e7a6-4f98-8778-89f40d8b5ea1">15.0</ix:nonFraction> million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i5cec051d961f4164be10ec4cd03c6eb8_D20190801-20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNTEyNQ_865cc452-d8e7-43d4-995f-d27c60fb3602">14.5</ix:nonFraction> million. The Company also announced its intent to pursue a listing of its securities on the KOSDAQ in the form of Korean Depositary Receipts (KDRs) representing shares of common stock. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of <ix:nonFraction unitRef="number" contextRef="i2393a62fa5e34d739b1a36b6e8df6f31_I20190801" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNTQ4Nw_89b782d9-00de-4e21-ba94-e44a45473124">1.00</ix:nonFraction>% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020 the August 2019 Bonds were converted in full into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i8a37a98039ba414db800ad308eb2b02c_D20200803-20200803" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkyNjg3MA_188bd3ea-a1ff-4f62-a59e-30c42ab9006d">4,962,364</ix:nonFraction> shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="i93454515f2814d1aa32809ed291c931a_I20200803" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkyNjkwMg_3c352d3d-4acb-4c4e-bea3-8558dc7c1c05">4.00</ix:nonFraction> per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.6873 shares per KRW 1,000,000 in principal amount (equivalent to a conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="i930a152e7e8f41e89ca66ed7945686b3_I20200803" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkyNjkxMQ_260bd875-6402-4f5a-b387-9be3a61d341e">3.04</ix:nonFraction> per share based on the exchange rate as of August 3, 2020).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i2393a62fa5e34d739b1a36b6e8df6f31_I20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNzAzNw_fcd7a1b7-d975-47b3-a28d-0eda5d619ddb">7.1</ix:nonFraction> million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the condensed consolidated&#160;statements of operations.  </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $<ix:nonFraction unitRef="usd" contextRef="i2393a62fa5e34d739b1a36b6e8df6f31_I20190801" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfODE1Nw_e2b45c4a-d9b4-4159-8f4c-c607cd1eb195">7.3</ix:nonFraction> million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022.&#160;The effective interest rate of the August 2019 Bonds was <ix:nonFraction unitRef="number" contextRef="if776c09c12d048a8a03158014bdd629b_I20200930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfODM5Mw_23e7b0ca-1289-4d47-af4d-57423b7112b6">29.4</ix:nonFraction>%. For the three and nine months ended September 30, 2020,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i069c085bd0884569a0c363b84262b982_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfODQzMg_6eb399a7-37ad-4169-b3c1-1aebd032ab3e">238,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i666980e930ca4263a11fb9d67a8ff7a5_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfODQzOQ_4f9b2298-c6c6-4f36-92bf-e63204d7e989">1.6</ix:nonFraction> million, respectively, of interest expense related to the August 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="i069c085bd0884569a0c363b84262b982_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfODUyOA_b5968a3a-96b2-46c9-aa49-ce477af01acc">13,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i666980e930ca4263a11fb9d67a8ff7a5_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfODUzNQ_8f85d13b-b6d3-45ac-8486-82061f634d5d">87,000</ix:nonFraction>, respectively, related to the contractual interest coupon. For the nine months ended September 30, 2019, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i438e7b59c3d54e9e998a30ddc65e87a3_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMjc0ODc3OTA5NjY4MQ_5f7adb45-2165-4bb1-bb96-6de038e9f432">374,000</ix:nonFraction> of interest expense related to the August 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="i438e7b59c3d54e9e998a30ddc65e87a3_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMjc0ODc3OTA5NjY5MQ_1193c0e4-eaa1-469a-a668-62fcc6dcc6da">26,000</ix:nonFraction> related to the contractual interest coupon.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, all outstanding August 2019 Bonds were converted into common stock. Immediately prior to the conversion, the derivative liability was revalued at $<ix:nonFraction unitRef="usd" contextRef="i8958471a957c4db3b44209f556886dc5_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkwNDY2NQ_9c9a7d7a-20b9-4e95-a19f-bad81d96da55">84.5</ix:nonFraction> million. The changes in fair value of the derivative liability were a decrease of $<ix:nonFraction unitRef="usd" contextRef="i069c085bd0884569a0c363b84262b982_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkwNDczNw_abda83a1-a6b8-48ff-ad2b-abe571f86fd3">35.3</ix:nonFraction> million and an increase of $<ix:nonFraction unitRef="usd" contextRef="i666980e930ca4263a11fb9d67a8ff7a5_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkwNDc0NQ_650c7043-f179-4220-86d6-e8b2511a3b2d">75.7</ix:nonFraction> million, which were recorded on the condensed consolidated statement of operations for the three and nine months ended September 30, 2020, respectively. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, a loss on extinguishment of $<ix:nonFraction unitRef="usd" contextRef="i069c085bd0884569a0c363b84262b982_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfOTM0NTg0ODg1OTAxMA_ce3eeb60-bc88-4ef1-81b1-55921c3748c1">8.2</ix:nonFraction>&#160;million was recorded on the condensed consolidated statement of operations for the three months ended September 30, 2020. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the <ix:nonFraction unitRef="shares" contextRef="ib8a6a5f3412b4170b586cb0a191c2b65_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkwNjAzMg_d88f73db-62c9-46c3-b4bb-3d6fc35cc3db">4,692,364</ix:nonFraction> shares of the Company's common stock issued upon conversion.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of <ix:nonFraction unitRef="krw" contextRef="i30b055a2515244df98c8096ff545da5c_I20191226" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfOTE5MA_a37835fd-85d3-4ad6-bb9e-fec28f3348bc">4.7</ix:nonFraction> billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i30b055a2515244df98c8096ff545da5c_I20191226" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfOTIxNg_f60251e3-4bc4-4057-ab99-bd74cc9509a6">4.1</ix:nonFraction> million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="ib669b19a336e48c890a2feda647d2035_D20191226-20191226" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfOTM2OQ_1c1943fb-9fe2-4dea-b686-ba1c75e38a27">4.0</ix:nonFraction> million.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which are unsecured obligations of the Company, were issued on December&#160;31, 2019 and will accrue interest at a coupon rate of <ix:nonFraction unitRef="number" contextRef="i30b055a2515244df98c8096ff545da5c_I20191226" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfOTUyNg_3ff45a31-636b-41f0-8489-671254c52850">1.00</ix:nonFraction>% per annum, payable quarterly. The December 2019 Bonds will mature on December&#160;31, 2024, unless earlier converted or repurchased. The outstanding December 2019 Bonds will be repaid at maturity </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i19cd4408da684cafae5afdb0d52b1b88" continuedAt="i9bdbfa14de5f49bc848036ff25dcc78c"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of <ix:nonFraction unitRef="number" contextRef="i30b055a2515244df98c8096ff545da5c_I20191226" decimals="INF" name="ino:DebtInstrumentConvertibleInternalRateOfReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfOTg5MA_6190cffc-dad7-4d2f-8745-47d3c7273d00">6.00</ix:nonFraction>%. Commencing on December&#160;31, 2020, the December 2019 Bonds will be convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver KDRs, if the Company has any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock of the Company. The initial conversion rate is 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="i47a612180eaa425693bc6df2815b34a8_I20191226" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTAzNDM_59b061b4-e6e1-4868-a0dc-02383e7afc17">4.00</ix:nonFraction> per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. The conversion rate is subject to reset on July&#160;2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed 357.9611 shares per KRW1,000,000 (equivalent to a conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="idecb5c7b97f44096ab202e14ea4c5a5c_I20191226" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTA4MzQ_9ec66c3d-f452-4149-8442-47ec6776dc61">2.40</ix:nonFraction> per share based on the exchange rate as of December&#160;19, 2019). The conversion rate has not been reset as of September 30, 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including December&#160;31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the December 2019 Bonds to be repurchased plus a premium on the Bonds in order to ensure an internal rate of return with respect to the Bonds equal to <ix:nonFraction unitRef="number" contextRef="i30b055a2515244df98c8096ff545da5c_I20191226" decimals="INF" name="ino:DebtInstrumentConvertibleInternalRateOfReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTEyOTg_9ef41fc3-7f87-4c2d-aae7-986b3716e846">6.00</ix:nonFraction>%. In addition, upon the occurrence of a fundamental change (as defined in the Subscription Agreement) the Company will be required to offer to repurchase the Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon to but excluding the applicable repurchase date. If certain bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding December 2019 Bonds shall automatically become due and payable. If any other event of default occurs and is continuing, the holders of at least <ix:nonFraction unitRef="number" contextRef="ib669b19a336e48c890a2feda647d2035_D20191226-20191226" decimals="INF" name="ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTE5MTA_98257092-3ce2-419c-bc9d-bb01902fa655">25</ix:nonFraction>% of the in aggregate principal amount of the December 2019 Bonds by notice to the Company may declare the principal of, and accrued and unpaid interest on, all of the then-outstanding December 2019 Bonds to be due and payable.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds are denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario is fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency does not impact the settlement of the conversion option. Further, as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><ix:continuation id="iafdc9152d9654c638a08651cfa57df7f"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the December 2019 Bonds at September&#160;30, 2020 was as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5922a465abf4cc1be657156439079c7_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmM5NWMxNzEzYjdhYTQzYzZhZGFiMmY4YzdjODQyZmJiL3RhYmxlcmFuZ2U6Yzk1YzE3MTNiN2FhNDNjNmFkYWIyZjhjN2M4NDJmYmJfMC0xLTEtMS0w_4fe42c9e-ceb8-4aca-93f3-83c79c513f97">4,030,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5922a465abf4cc1be657156439079c7_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmM5NWMxNzEzYjdhYTQzYzZhZGFiMmY4YzdjODQyZmJiL3RhYmxlcmFuZ2U6Yzk1YzE3MTNiN2FhNDNjNmFkYWIyZjhjN2M4NDJmYmJfMi0xLTEtMS0w_8a3f9cb2-20db-42d8-8a6e-8c71817f93d7">37,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of premium associated with the December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5922a465abf4cc1be657156439079c7_I20200930" decimals="0" format="ixt:numdotdecimal" name="ino:DebtInstrumentAccretionOfPremium" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmM5NWMxNzEzYjdhYTQzYzZhZGFiMmY4YzdjODQyZmJiL3RhYmxlcmFuZ2U6Yzk1YzE3MTNiN2FhNDNjNmFkYWIyZjhjN2M4NDJmYmJfMy0xLTEtMS0w_486fef24-55ac-4176-9a35-719cc86913d8">148,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5922a465abf4cc1be657156439079c7_I20200930" decimals="0" format="ixt:numdotdecimal" name="ino:DebtInstrumentAccruedInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmM5NWMxNzEzYjdhYTQzYzZhZGFiMmY4YzdjODQyZmJiL3RhYmxlcmFuZ2U6Yzk1YzE3MTNiN2FhNDNjNmFkYWIyZjhjN2M4NDJmYmJfNC0xLTEtMS0w_a5273bef-9d8e-4743-b69a-950c1fecfb3c">10,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5922a465abf4cc1be657156439079c7_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmM5NWMxNzEzYjdhYTQzYzZhZGFiMmY4YzdjODQyZmJiL3RhYmxlcmFuZ2U6Yzk1YzE3MTNiN2FhNDNjNmFkYWIyZjhjN2M4NDJmYmJfNS0xLTEtMS0w_6de48090-7310-48ff-b458-61debca04fe3">4,151,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represents the point at which the December 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is <ix:nonFraction unitRef="number" contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQwMzQ_240f4e3e-65c7-407a-8622-99b9086512e1">6.2</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the three and nine months ended September 30, 2020,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i321babdbed2a41498f88f960499c9240_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQwNzM_092fe4f6-a93f-41ee-ba18-e8cb20dab5bf">63,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2cca53a6bf0849c3a1f4c545316eb5ca_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQwODA_09afc7ba-95d6-4ada-8344-06897e93c5d7">185,000</ix:nonFraction>, respectively, of interest expense related to the December 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="i321babdbed2a41498f88f960499c9240_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQxNjM_f97ddd0d-a3e8-4c2a-874e-309ec8eb5d88">10,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2cca53a6bf0849c3a1f4c545316eb5ca_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQxNzA_5df53fe6-bc30-492b-8706-3eb165095c82">30,000</ix:nonFraction>, respectively, related to the contractual interest coupon. As of September&#160;30, 2020, there had not been any conversions or redemptions of the December 2019 Bonds.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ4MjU_a196a25b-f3e7-4215-a8be-5435150c3ebb" continuedAt="id5e384261393498eb6ecd42e49c43119" escape="true"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, future minimum payments due under the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> convertible debt instruments are as follows:</span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9bdbfa14de5f49bc848036ff25dcc78c" continuedAt="i45cdd81631c3468bb82771ce9947d8b7"><ix:continuation id="id5e384261393498eb6ecd42e49c43119" continuedAt="i16b40ab5564b40a39e280b73ff8e785c"><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:58.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible Notes (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 2019 Bonds (2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfMi0yLTEtMS0w_74f2e76f-0392-4352-9380-d39831cc5c52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfMi02LTEtMS0w_4a425f96-877d-41e6-aa33-6243e69aa811">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b79363a4154026a899e339e36624d9_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfMi04LTEtMS0w_67244b12-7b5b-4783-a2a0-f20eeb36887f">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfMy0yLTEtMS0w_8792ee92-6ad6-4812-9f6c-8642c8044834">3,862,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfMy02LTEtMS0w_3c151d58-4b9c-4437-a416-66cd5469f958">40,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b79363a4154026a899e339e36624d9_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfMy04LTEtMS0w_4afe5a67-3442-4525-b101-218e226ab0a0">3,902,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNC0yLTEtMS0w_ce35c640-d662-481f-9632-a041c48dd098">3,862,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNC02LTEtMS0w_2b0c9827-2c35-483f-8777-5057105fd613">40,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b79363a4154026a899e339e36624d9_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNC04LTEtMS0w_0f3afbd7-3eb6-42dd-8104-246105e1f506">3,902,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNS0yLTEtMS0w_f7ddab2d-69d9-46c1-8009-b8950baa6b27">3,862,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNS02LTEtMS0w_f5abfc32-15ec-4f85-98c8-efc46181c061">40,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b79363a4154026a899e339e36624d9_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNS04LTEtMS0w_f9da9fa9-a002-481f-8072-9a80bb2b3e06">3,902,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNi0yLTEtMS0w_4b909771-ae04-46aa-a2eb-342b7e673f15">61,346,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNi02LTEtMS0w_43f3effa-1372-4e9e-9eb9-56b035c93750">5,189,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b79363a4154026a899e339e36624d9_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNi04LTEtMS0w_da96dec0-9195-47b1-9adb-2511fede3f18">66,535,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNy0yLTEtMS0w_e1bbe110-8204-4c66-9cc0-d3af7f4487d4">72,932,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNy02LTEtMS0w_e17277eb-4c91-4bdc-847e-86f1ee86cb6e">5,319,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b79363a4154026a899e339e36624d9_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNy04LTEtMS0w_f655b102-65cb-4fb2-b771-3b01139b9be9">78,251,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:22.5pt"><span><br/></span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of <ix:nonFraction unitRef="number" contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ1MzQ_969655d1-9a14-4b04-96c0-e6a7ed7e67d4">6.5</ix:nonFraction>% per year. </span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i45cdd81631c3468bb82771ce9947d8b7"><ix:continuation id="i16b40ab5564b40a39e280b73ff8e785c">(2) Amounts represent amounts due under the December 2019 Bonds, including interest based on the fixed rate of <ix:nonFraction unitRef="number" contextRef="if776c09c12d048a8a03158014bdd629b_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ2ODc_1d7b09c1-7787-4d0c-a2c7-b09a9832d460"><ix:nonFraction unitRef="number" contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ2ODc_20feba89-2692-4a79-b39b-814a6f4a23fc">1</ix:nonFraction></ix:nonFraction>% per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of <ix:nonFraction unitRef="number" contextRef="if776c09c12d048a8a03158014bdd629b_I20200930" decimals="INF" name="ino:DebtInstrumentConvertibleInternalRateOfReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ3OTY_a514010a-4f62-4647-9804-62d58778dada"><ix:nonFraction unitRef="number" contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930" decimals="INF" name="ino:DebtInstrumentConvertibleInternalRateOfReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ3OTY_c10a9b78-e152-48e7-a3cf-5d9d94990b2d">6</ix:nonFraction></ix:nonFraction>% at maturity.</ix:continuation></ix:continuation> </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_67"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNTIwOA_a42bd28c-3bfb-4bc8-803f-b9ea9bea8925" continuedAt="ic272e505977d4cb28f01e690319a7830" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="ic272e505977d4cb28f01e690319a7830" continuedAt="i4a8aa1cc02e2489b8c1f39261fbc0245"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNTIxNQ_69215c6b-0653-48af-8d96-d11bc73067f9" escape="true"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of September&#160;30, 2020 and December&#160;31, 2019: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:42.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfMi0wLTEtMS00NTc0L3RleHRyZWdpb246NGJkNDhlOTU1MDAzNDgxNDk2OThmZGI4ZmNmMDVhMGNfNDM5ODA0NjUxMTE1NA_93c9e4ad-047a-4713-9be8-ae8306030b2e"><ix:nonFraction unitRef="usdPerShare" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfMi0wLTEtMS00NTc0L3RleHRyZWdpb246NGJkNDhlOTU1MDAzNDgxNDk2OThmZGI4ZmNmMDVhMGNfNDM5ODA0NjUxMTE1NA_c8f9c690-e463-4b30-858b-25f7d05dd9d1">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfMi0xLTEtMS0w_1754db3a-78c8-48f4-b2fc-10fdcff6e01e">600,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfMi0zLTEtMS0w_c58e6cad-7c67-466d-9e0d-acf74acfb375">167,528,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfMi01LTEtMS0w_917bd309-63b1-4299-af9b-c35ae988c7a9">167,528,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfMi03LTEtMS0w_14c46c93-90f6-487a-aa19-bad3de420924">101,361,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ib12d03d2fe7e453ea4f8ccb997e9f525_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfNS0wLTEtMS00NTc3L3RleHRyZWdpb246ZTM2YmM5NjFmNDY1NDI0ZjkwOWQ2ODZhNzgxMjZkYjlfNDM5ODA0NjUxMTE2Ng_68d440ea-2e98-452b-9628-6172e275217d"><ix:nonFraction unitRef="usdPerShare" contextRef="ie09a126e34b741aa9a646f361a9bfa0d_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfNS0wLTEtMS00NTc3L3RleHRyZWdpb246ZTM2YmM5NjFmNDY1NDI0ZjkwOWQ2ODZhNzgxMjZkYjlfNDM5ODA0NjUxMTE2Ng_7b5dcd07-341a-4f92-ae20-62e70b6b0522">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib12d03d2fe7e453ea4f8ccb997e9f525_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfNS0xLTEtMS0w_a3f21f8d-3c0a-4f99-b8a6-b637b1ead955">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib12d03d2fe7e453ea4f8ccb997e9f525_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfNS0zLTEtMS0w_f2f88a63-8d6c-46e8-a694-f8f20bacc3d3">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib12d03d2fe7e453ea4f8ccb997e9f525_I20200930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfNS01LTEtMS0w_5ca67fb4-4926-468e-bbd7-10cd81c2bde8">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie09a126e34b741aa9a646f361a9bfa0d_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfNS03LTEtMS0w_89590134-8eab-4fcc-89f9-91e21a708aa3">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, <ix:nonFraction unitRef="shares" contextRef="ie2d0bbde4d3e40a9883106a66764b89b_D20200101-20200630" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjA0_433b31d8-1324-49dd-a261-6a97f7355097">14</ix:nonFraction> shares of the Company&#8217;s Series&#160;C preferred stock were converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="id6b8d7c533b04e2981466489c552e6c1_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjky_99ba26f2-9976-475c-86d2-2a87df6e07bf">5,147</ix:nonFraction> shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#8220;Placement Agent&#8221;) to sell shares of its common stock with aggregate gross proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="i14a978d9496a43e7aede0fcbc572e14b_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNTMy_329b1388-107b-4ef7-845b-950eecc61c57">100.0</ix:nonFraction> million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent would act as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from $<ix:nonFraction unitRef="usd" contextRef="i14a978d9496a43e7aede0fcbc572e14b_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfOTE2_8bd912ac-5216-413c-8d8c-2259e3c03507">100.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i9c298cf37a4848da8778eeafecf73788_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfOTIy_17f67251-0e87-4faa-901a-68feca0c48ab">250.0</ix:nonFraction> million. As of March 31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i97fe994b743146a2b11f82e54b658475_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="ino:StockSalesAgreementRemainingAuthorizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfOTU4_d6112818-4e58-49d9-bffa-911efacff313">no</ix:nonFraction> remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="id24bddea654742c4b5eecc7be2d6d449_D20200403-20200512" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMTM3Ng_34e83f79-8a5d-4014-ace5-d1a07c8d1826">250.0</ix:nonFraction> million. Under the New Sales Agreement, the Company sets the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The New Sales Agreement provides that the Placement Agent is entitled to compensation for its services in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="id24bddea654742c4b5eecc7be2d6d449_D20200403-20200512" decimals="INF" name="ino:StockSalesAgreementAgentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMTgzNg_bb4e6e5b-25a8-45ea-af54-98b6a276b2b7">3.0</ix:nonFraction>% of the gross proceeds from the sales of shares sold through the Placement Agent under the New Sales Agreement. The Company has no obligation to sell any shares under the New Sales Agreement, and could at any time suspend solicitation and offers under the New Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i9c298cf37a4848da8778eeafecf73788_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjE3OA_7ec4d0ce-3377-4aca-a2a5-f62243ec95ab">43,148,952</ix:nonFraction> shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9c298cf37a4848da8778eeafecf73788_D20200101-20200331" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjI5Mg_35b8274a-02fa-4182-8e28-4d244ee56575">4.92</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9c298cf37a4848da8778eeafecf73788_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjM0NQ_a4ec63d9-742e-407f-b21f-d3a79f88dee7">208.2</ix:nonFraction> million. As of March 31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i97fe994b743146a2b11f82e54b658475_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="ino:StockSalesAgreementRemainingAuthorizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjM4Mg_0c5ec82f-d159-4776-84f9-f1d80237e3b8">no</ix:nonFraction> remaining capacity under the Prior Sales Agreement.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended June 30, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="ib23297044af5421488bf606a07fcad5a_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjQ5OQ_41f62272-7d9b-4802-a19f-cd15e38ccb2f">12,041,178</ix:nonFraction> shares of its common stock under the New Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib23297044af5421488bf606a07fcad5a_D20200401-20200630" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjYxMQ_ef87229e-90dc-424f-83c6-6689dd517db4">10.26</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib23297044af5421488bf606a07fcad5a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjY2NA_07231815-b081-4f90-bfc9-72d792294de0">121.7</ix:nonFraction> million. There were <ix:nonFraction unitRef="shares" contextRef="i4c022db15d174f8db8fb571a3e4db2f7_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMzI5ODUzNDg4ODc4NQ_47a1ef3f-6de8-4e34-a982-359a1f232124">no</ix:nonFraction> shares sold during the three months ended September 30, 2020 under the New Sales Agreement. As of September 30, 2020, the Company may sell up to $<ix:nonFraction unitRef="usd" contextRef="ic3afac984f9d4d59bbd2907c5bbd7278_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjcxNg_b2367db2-14aa-43df-a0b1-5aca645794e7">126.4</ix:nonFraction> million in gross proceeds of shares of Common Stock under the New Sales Agreement before it would be required to file a new prospectus supplement with the SEC to sell additional shares pursuant to the New Sales Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4a8aa1cc02e2489b8c1f39261fbc0245" continuedAt="if832df5219a440fa9b969ab807f72058"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. The maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan may not exceed <ix:nonFraction unitRef="shares" contextRef="i074731de2992483e840b846807d642f7_I20160513" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMzY3OQ_17c0ec24-ecf6-435e-b2fa-b516c2fc6480">18,000,000</ix:nonFraction> shares, provided that commencing with the first business day of each calendar year beginning January&#160;1, 2020, such maximum number of shares shall be increased by&#160;<ix:nonFraction unitRef="shares" contextRef="i074731de2992483e840b846807d642f7_I20160513" decimals="INF" format="ixt:numdotdecimal" name="ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMzg0NA_06ddbe98-8cac-40b1-b1ba-3f1b5187f7cd">2,000,000</ix:nonFraction> shares of common stock unless the Company's Board of Directors determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2020, the maximum number of shares to be issued increased by <ix:nonFraction unitRef="shares" contextRef="ia9835623d0cf40b4861f5c838d46c1a2_I20200101" decimals="INF" format="ixt:numdotdecimal" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDE2NA_f7516159-a6f7-4873-975d-576e5b31b97a">2,000,000</ix:nonFraction>. At September&#160;30, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i4b4928fc44ae4021b15f75edc4b2c760_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDE4Ng_8c6cc182-22cf-44fd-9a93-8c53eb5a4c3a">18,000,000</ix:nonFraction> shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At September&#160;30, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="i4b4928fc44ae4021b15f75edc4b2c760_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDM2NA_93446c94-d6f1-4c49-aed9-767baa7ce36f">6,785,707</ix:nonFraction> shares of common stock available for future grant under the 2016 Incentive Plan, <ix:nonFraction unitRef="shares" contextRef="i4b4928fc44ae4021b15f75edc4b2c760_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDQ0OA_93dcdec0-b09f-49c9-9640-3b6cefc910b0">2,586,915</ix:nonFraction> shares underlying outstanding but unvested restricted stock units and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i4b4928fc44ae4021b15f75edc4b2c760_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDU1Mw_0bc90871-3a97-4700-b2f5-04b65fb4405a">5,878,252</ix:nonFraction> shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over <ix:nonNumeric contextRef="ibc202bd5f1fd4725bdbf57b6065610c3_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDcxMA_fe648544-44cb-4e77-9dbd-8f132fd87054">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="ibc202bd5f1fd4725bdbf57b6065610c3_D20200101-20200930" format="ixt-sec:durwordsen" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDc1Mg_1175a030-f12f-4c97-b772-077c158c318e">ten years</ix:nonNumeric>. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if832df5219a440fa9b969ab807f72058">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At September&#160;30, 2020, the Company had options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i186812e80eed40f0bbab169954854146_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNTAzNQ_d03af92c-0b04-46bd-a2e5-ead0d262ee91">3,412,095</ix:nonFraction> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over <ix:nonNumeric contextRef="ice5f528ac7ca4891a83906dfc20c1df3_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNTE2MQ_95574122-9672-4739-a640-e83c8fe2f470">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="ice5f528ac7ca4891a83906dfc20c1df3_D20200101-20200930" format="ixt-sec:durwordsen" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNTIwMw_1f0d6817-1290-49fc-a441-1fbae85a1b54">ten years</ix:nonNumeric>.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_73"></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.  <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RleHRyZWdpb246MmIwMjQxODZjMzc5NDY3NzgzODBmYTU0YTJkZDBmOTJfMTA4Ng_acb9efe2-78a2-4a5a-9737-cd298ac0de61" continuedAt="i009d71dc4e5a40f18736c31e06b2e521" escape="true">Net Income (Loss) Per Share </ix:nonNumeric></span></div><ix:continuation id="i009d71dc4e5a40f18736c31e06b2e521" continuedAt="iaab6b8ce102741d0950b0583f86610af"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method.  The calculation of diluted net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net income (loss) per share for the period, an adjustment to the net income (loss) used in the calculation is required to remove the change in fair value of such securities from the numerator for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the nine months ended September 30, 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options and restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are anti-dilutive.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RleHRyZWdpb246MmIwMjQxODZjMzc5NDY3NzgzODBmYTU0YTJkZDBmOTJfMTQyOTM2NTExNjMyMjk_d0560128-1fa0-49d6-8c0d-7aaf0f00c49d" continuedAt="i09a8241db4124918b57907161bcb6204" escape="true">The following tables reconcile the components of the numerator and denominator included in the calculation of diluted net income (loss) per share:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iaab6b8ce102741d0950b0583f86610af" continuedAt="i1c7df5461a09434e87f3e366f0ebaa3e"><ix:continuation id="i09a8241db4124918b57907161bcb6204"><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net income (loss) per share)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMy0yLTEtMS04MDA_1eda2347-eed7-4807-802b-d70d270168e7">19,171,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMy00LTEtMS02ODE_5e677090-9f8a-4c60-8b74-910ff7dd3f0f">23,090,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment for decrease in fair value of derivative liability and interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfNC0yLTEtMS04MDA_5ef1e5ea-5ff3-4dcb-bd0f-aa96c18ed5b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfNC00LTEtMS02ODE_7503887a-7300-42a3-be81-66b36c398c98">2,177,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for use in diluted income (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfNS0yLTEtMS04MDA_29fca9f5-1145-4b6d-82ff-9b42d6b6e775">19,171,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfNS00LTEtMS02ODE_4db3270b-5fc2-4696-bc9e-f016cff144cc">25,267,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding (denominator for use in basic net income (loss) per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfOC0yLTEtMS04MDQ_c65d8409-6338-4b15-9806-28d5d97d677c">165,355,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfOC00LTEtMS02ODY_3ba5f022-98ea-4069-9714-64af200e01ba">99,007,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive potential common shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfOS0yLTEtMS04MDQ_c62d271a-fd2c-4c6a-b02b-3e12274eb7b7">9,020,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfOS00LTEtMS02ODY_7c3d47fb-2e52-4398-a7da-397b3d304c7a">3,799,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for use in diluted net income (loss) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMTAtMi0xLTEtODA0_f32d77ef-7f75-44c7-b077-2d94601bade6">174,376,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMTAtNC0xLTEtNjg2_818fc062-6567-4540-a1a3-c1b30a6d1f82">102,807,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMTItMi0xLTEtODA4_20d9a5d1-0e71-41f5-88fa-86bb5fc54256">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMTItNC0xLTEtNjkw_98958ec6-6d05-44e4-a582-7f8dc902c900">0.25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMTQtMi0xLTEtODA4_3373ed3b-482f-47d8-9337-ce8e16369ae3">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMTQtNC0xLTEtNjk0_b8f4ebd6-9e20-44bf-95f8-47accaf657e8">0.23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net loss per share)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMy0yLTEtMS04MTY_2ddc94ed-4319-4c1a-80af-b0f6bedaefbe">142,072,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMy00LTEtMS03MDI_6ec22dfa-34e0-4b70-b31a-a39aa82fcff3">81,697,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment for decrease in fair value of derivative liability and interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfNC0yLTEtMS04MTY_3e6112f6-83c5-436d-9390-8ddb91d7b824">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfNC00LTEtMS03MDI_02f7e7e3-60ef-43ca-8bdf-0f2cbdaf0d96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for use in diluted loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfNS0yLTEtMS04MTY_efe2c766-04dd-435a-b030-c0d55bb65c77">142,072,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfNS00LTEtMS03MDI_c3c7df64-87ba-42a6-865c-b39f3d3fe4a2">81,697,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding (denominator for use in basic net loss per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfOC0yLTEtMS04MjA_9a407f15-ba88-471c-86e4-c4a2e579920e">148,656,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfOC00LTEtMS03MDY_93f9c7d3-ac8f-49c2-9d26-5b6e36eb8da4">98,204,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive potential common shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfOS0yLTEtMS04MjA_e66bab30-f02f-4ced-acf4-f7005a3f1bca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfOS00LTEtMS03MDY_8ce40eb4-fc67-4de4-ab21-a9255d7d5a84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for use in diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMTAtMi0xLTEtODIw_f670bcbd-9dcd-4d52-a9cb-b94e92e3f7a4">148,656,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMTAtNC0xLTEtNzA2_8f34063f-476a-41c9-a936-f15d5cd9f113">98,204,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMTItMi0xLTEtODI5_4fc8e332-a33c-46b4-90e0-ced6523f82c4">0.96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMTItNC0xLTEtNzA5_d16d351d-bad9-4fe6-8443-e932c22fb33f">0.83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMTQtMi0xLTEtODI5_5018f8eb-50b8-4c97-b32f-8c82202836a1">0.96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMTQtNC0xLTEtNzA5_9cf1c2bf-8393-4321-afca-caa027dc84bd">0.83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RleHRyZWdpb246MmIwMjQxODZjMzc5NDY3NzgzODBmYTU0YTJkZDBmOTJfMTA5Ng_adc18d85-9603-41e4-9826-57271ad62e51" continuedAt="i93cacd5061b34466b712a4cd08baf5ae" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net income (loss) per share calculation because of their anti-dilutive effect for the three months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6db1b3c721d04b66b6aa18b2614af73a_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfMi0xLTEtMS03MzQ_af234fb8-e495-474a-a6d7-82ea641b9549">119,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia93b688d453949bda8f80084a4f8c0cf_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfMi0zLTEtMS03MzQ_ad20ce8c-642d-4c49-9af4-e8016a9c7839">9,971,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44a63daa0269434b8f8645084440149c_D20200701-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNC0xLTEtMS03MzQ_5642887c-08ca-4d6d-b2c1-f6dff924d9f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5353e9eb3d34cb7a882d3194dc9492f_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNC0zLTEtMS03MzQ_2622ef0c-0fb7-4ecc-a96f-b1cad04465d1">2,121,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51b9fb3e5b5e4a31a8873ab12cfb64d0_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNS0xLTEtMS03MzQ_520b3371-1224-4b59-99e8-5c26b187845d">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d0b8128b742495c90250bc5b8849172_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNS0zLTEtMS03MzQ_22ba4e91-669a-4ac9-b35a-6c5b240a70d6">8,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02e3ca1e82c047479a0c74b2718566f0_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNi0xLTEtMS03MzQ_4fbc1fad-c278-4ece-b838-12b2d2d8905a">11,039,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06030a312f124dce90532593ecc94dd9_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNi0zLTEtMS03MzQ_d0252535-85bd-42fd-9978-905993d76cab">14,585,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e44945591f04d5da4354f7f7bdd35cd_D20200701-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNy0xLTEtMS03MzQ_89dc742f-9bb6-48ff-aaee-55ba9851c271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bdb6a99776a4c4d800ab8e40b952f8d_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNy0zLTEtMS03MzQ_4bd65025-4aad-41f2-b856-a6097787d5ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0194a559551a40c8b27e764106336195_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfOC0xLTEtMS03MzQ_0a9dc992-9a8d-4164-bd9c-918bba66b16b">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c5944ef521743b3b9e876883e54f1e5_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfOC0zLTEtMS03MzQ_3382d926-5460-4bf2-9211-166d58b2e6b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfOS0xLTEtMS0xMDI2_ba3dc349-d95a-4aa4-9fd0-9808642dbc0a">12,171,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfOS0zLTEtMS0xMDI4_10163ca8-c1ad-47ae-9224-056797f8499e">26,686,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1c7df5461a09434e87f3e366f0ebaa3e"><ix:continuation id="i93cacd5061b34466b712a4cd08baf5ae"><div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the nine months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5a0629abda644218979a5b63841e116_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfMi0xLTEtMS0w_88ac0bc0-1c88-4f7b-9b7b-358e1b1d6d34">9,290,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i860fb08bf8184b179cac33e4192e1816_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfMi0zLTEtMS0w_bc19c8f6-92b9-4408-b903-e94351963e94">9,971,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide8b04bd4c5e49acb95ba740445e35f4_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNC0xLTEtMS0w_bfbef89a-a15c-4c1d-bbcb-183286be997e">2,586,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d3155aacbf84e0b8ce936aae7adf3b9_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNC0zLTEtMS0w_8a881066-8b5b-45d1-93ce-ed38f92bfa5f">2,121,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib68e05e899ac4508aa008ee16595c00c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNS0xLTEtMS0zNTAz_343098d2-405b-4bcc-84ad-3ce0f1cedf3c">663,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba702d59c1624ad78cddd0ba1ffc4322_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNS0zLTEtMS0zNTAz_092ef479-6d55-48ba-8654-2a03f0f831f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a56a2b1e29242588c663774b4b5aa76_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNS0xLTEtMS0w_111ee040-69f8-472a-ab68-5e33b26db6d4">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i554f1ca12a6049099aa8584a524a2161_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNS0zLTEtMS0w_956a66c2-b19a-4668-b5f3-59c9c5d65cef">8,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a898fb72f1a49f5bd77c57ed253bd16_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNi0xLTEtMS0w_17379152-1a8f-4f94-a297-b2898f447af3">11,039,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b05350e1bfd4d9ab4452aefb8f891fb_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNi0zLTEtMS0w_6ef721fa-2f2f-4ad5-90f4-fdbeef8cd866">14,585,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d59312f204e4b97ab0b449aceeddccb_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNy0xLTEtMS0w_7f61a5b2-de76-48b1-ae3c-dcf7ac0e6b59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2861cdc8f69f41d5b5875d02a30fb6a8_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNy0zLTEtMS0w_f5238f86-19ea-4f4b-90a9-edca9ec6c33e">3,799,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia51339b229ef4a62b912b1d36f13eb7a_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfOC0xLTEtMS0w_180f55ce-cfd3-4643-bcab-242449147504">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65d7691f080348dea281680ef992b0a6_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfOC0zLTEtMS0w_8734b096-62d8-4078-b2cd-67165dbbee29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfOS0xLTEtMS0w_461769bd-5991-4afd-a47c-dbe906c1ff4a">24,592,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfOS0zLTEtMS0w_ceeb80c0-b2d8-4450-a597-828010216074">30,485,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_79"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.  <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfNzE0NjgyNTU4NzQzNA_23af9e96-f547-4cb2-9f34-e01e393cd40b" continuedAt="i9a8f0f0fe2884a3f829a8319d1efaeb5" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i9a8f0f0fe2884a3f829a8319d1efaeb5" continuedAt="iab5b42ce5ac6491ab36268b0873fe51d"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span></div><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzMzNw_9a3761c2-5dfa-4440-b916-bb3e92ddc4bf" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:57.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.652%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.652%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:2.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e404e614cda487ba8a65c024ef8d309_D20200701-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMi0xLTEtMS0w_a09bea8f-2039-49fe-b96d-a78e58caf232">0.35</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f1be49da4d049788cefaa0996012c18_D20190701-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMi0zLTEtMS0w_46d473f0-0e2d-4823-b07c-b76e0e92156c">1.75</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31d99600c91541e08b13dbd22f740ac6_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMi0xMC0xLTEtMA_28912d7f-a29e-47d6-866f-43c4627c9759">0.64</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id952f10e76044800b212f242883b868c_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMi0xMi0xLTEtMA_ac2ea61e-bcef-4768-ab22-41821121e2b7">2.43</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e404e614cda487ba8a65c024ef8d309_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMy0xLTEtMS0w_64f1d9f9-d413-4c32-b805-6d09158f0b7b">85</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f1be49da4d049788cefaa0996012c18_D20190701-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMy0zLTEtMS0w_f8eace4f-4709-491c-bdde-9eb7c68b1918">65</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31d99600c91541e08b13dbd22f740ac6_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMy0xMC0xLTEtMA_3351d335-4efc-4b0a-8240-f7d5f59a1a80">77</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id952f10e76044800b212f242883b868c_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMy0xMi0xLTEtMA_e24efdbc-a0b7-4e99-b4ec-80e217d6df82">70</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2e404e614cda487ba8a65c024ef8d309_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNC0xLTEtMS0w_b4fcd1ea-73b8-4737-bec0-d6ab1a4f26d1">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f1be49da4d049788cefaa0996012c18_D20190701-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNC0zLTEtMS0w_43949fed-8a5c-4f10-8fe4-133ac79aee2f">6.1</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i31d99600c91541e08b13dbd22f740ac6_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNC0xMC0xLTEtMA_42bd8892-da45-405b-b00b-9e0fab7b646b">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id952f10e76044800b212f242883b868c_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNC0xMi0xLTEtMA_bf99bc2e-e7fc-4fb6-aa34-844e2269f226">6.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e404e614cda487ba8a65c024ef8d309_D20200701-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNS0xLTEtMS0w_395728ed-ff90-4267-9dbd-1bc5acefa60d">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f1be49da4d049788cefaa0996012c18_D20190701-20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNS0zLTEtMS0w_9ac6b908-5303-4f13-bceb-28d4eaffe26e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31d99600c91541e08b13dbd22f740ac6_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNS0xMC0xLTEtMA_5c9ca40d-2aa7-4bca-a842-ad1ee7324c06">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id952f10e76044800b212f242883b868c_D20190101-20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNS0xMi0xLTEtMA_2d634a41-341e-4f97-9b14-a627297c2402">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i39f1040f585a4f308338f4f88079b910_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTUyOA_a9ab7ff3-80aa-4c46-8d97-60d7711235b7">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i289251eaf4234243bc0156afcbc6016e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTUzNQ_6d9d7e30-fb51-4a69-ae8b-5ad088ad821b">11.0</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i06c12a6f77d0492195c95821a8e4b7b6_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTU2Mw_f83721d1-5332-4647-a0cf-006c1b6035da">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie3d462cb47b640bf897ca00c25614f47_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTU3MA_f448946f-26ef-43ee-af1e-28eba9080143">6.2</ix:nonFraction> million, respectively, was included in research and development expenses, and $<ix:nonFraction unitRef="usd" contextRef="i7a618cdb93274c3cb270ff6bda022556_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTY0NA_de6f0462-b9cc-4af9-b85b-b3db618c8c9d">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7af7c35ef173431fb3279d39c0f1d502_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTY1MQ_80a0dd04-7766-40e1-ba06-576a134c50c1">4.8</ix:nonFraction> million, respectively, was included in general and administrative expenses.</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i147548485ecd4491b08aef970e8b6c24_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTg2NA_42db9746-c3f7-4b24-8807-4fd5d0c1ac80">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5a5bf1e66b6a422a87b55518b074a975_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTg3MQ_768a93d6-ede4-48ce-8c6d-5a2ab563352e">8.1</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="ib6722d5596bb495cb02bbd3e009bb98a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTg5OA_b47c277f-276f-435b-8a68-e74309d33091">922,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ice161059e07d46408a923dd86909c6c9_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTkwNQ_6a818d93-d724-492f-a613-8517a09b32d2">5.1</ix:nonFraction> million, respectively, was included in research and development expenses, and $<ix:nonFraction unitRef="usd" contextRef="ief5502197e4f432eb1f99435f0610ad2_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTk3OA_ecc8614d-4e82-4fc6-90d6-4b3fb159dcc4">885,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic129651914c14c8c8f24304e6cea8cf4_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTk4NQ_18d9e2e0-e637-4254-b605-0a0eba75dc4b">3.0</ix:nonFraction> million, respectively, was included in general and administrative expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjA3Mw_3ce17db0-8caa-49ca-b3de-b720c5d39c64">9.7</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjIyMw_edd92fe5-af76-489a-b4b1-20e912285869">2.2</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $<ix:nonFraction unitRef="usdPerShare" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjM0Mg_96f07396-9a79-4cbe-aba5-4276b2ec0161">12.09</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjM0OQ_083313de-63c9-46ec-b59b-1cdb1ff8b27d">6.78</ix:nonFraction> for employee and director stock options granted during the three and nine months ended September 30, 2020, respectively, and $<ix:nonFraction unitRef="usdPerShare" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjQzMw_2e87b0ad-4754-4ce4-9ec9-5dcea6d63233">1.65</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjQ0MA_92433fc1-cb9d-4da4-9753-f8d03aa3ac25">2.20</ix:nonFraction> for employee and director stock options granted during the three and nine months ended September 30, 2019, respectively. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="ia9c0eec23a36476e8fa9dc64d2143d2b_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjUzOA_043e4561-8a5a-4e73-9976-f4f87e3ea4a1">13.0</ix:nonFraction> million of total unrecognized compensation expense related to unvested restricted stock units ("RSUs"), which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i4fb2a364d2a84d27a0a8bb72b4a5d947_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjY5Nw_48e30711-b319-407e-9d01-2e0f7a4af678">2.1</ix:nonNumeric> years.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iab5b42ce5ac6491ab36268b0873fe51d"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i4fb2a364d2a84d27a0a8bb72b4a5d947_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjc3Mw_ff29532c-ecb0-40aa-a775-b2e06b4e0cd1">9.12</ix:nonFraction> for RSUs granted during the nine months ended September 30, 2020. There were <ix:nonFraction unitRef="shares" contextRef="icbfbede0bdee4bf2a1144f18c7e235cf_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjc0ODc3OTA3NjIyMQ_1bcab3eb-1429-4237-b8f3-381696f5680a">no</ix:nonFraction> RSUs granted during the three months ended September 30, 2020. The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7053c11a98db4096a9e40bd43a3c419b_D20190701-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjg0NA_3e3cc25c-bbc3-41d5-9e96-ec499dbc37da">2.68</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i195f8d33da5c49f1ad16bb63dfd92fc5_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjg1MQ_765d3f39-a206-46f7-a34d-a6b76b9e4a8f">3.09</ix:nonFraction> for RSUs granted during the three and nine months ended September 30, 2019, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and nine months ended September 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ib27721d879d24dc09f0b0eaff7993400_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzE1Mg_4b425a34-b021-4a90-87c5-ba7afb495d78">278,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3b70f956f6ba4badbe26e9b1a4182687_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzE1OQ_279d2754-7407-40e7-ac4c-e6d1fac0875d">884,000</ix:nonFraction>, respectively. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and nine months ended September 30, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i5850434bfd7f47e6aecdd16aac2a9c5e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzMwMQ_986cedf7-34a0-4b63-8f67-a9d1d115e476">264,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie4b0c15ae5ac4a8e8c3949f8c677e46d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzMwOA_67928e24-ed81-46b6-a77b-40a7c09e2186">744,000</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="i847658eadc124bf3bfa5c9301c21bb42_D20200828-20200828" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzI5ODUzNDg4OTYxMw_48e33903-45c0-453d-b5fe-3967bb05bed2">663,353</ix:nonFraction> performance-based RSUs to key employees under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: <ix:nonFraction unitRef="number" contextRef="iffcbbe5f4f454868b69c0a199c847e26_D20200828-20200828" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzI5ODUzNDg4OTYyMg_c9614bf6-82d2-42df-ac21-829e61a7880f">50</ix:nonFraction>% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining <ix:nonFraction unitRef="number" contextRef="i67d9bde506f34a86a79e76444931a225_D20200828-20200828" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzI5ODUzNDg4OTY1NA_282698d6-8a38-4a87-96ab-1a1b558fb048">50</ix:nonFraction>% of the shares in each tranche will vest upon subsequent completion of a <ix:nonNumeric contextRef="i67d9bde506f34a86a79e76444931a225_D20200828-20200828" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfNDM5ODA0NjUxNzk4NA_8e06cece-57b1-4ccd-8723-fb3bf06821c1">one-year</ix:nonNumeric> service period. The grant date fair value of the performance-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="i847658eadc124bf3bfa5c9301c21bb42_D20200828-20200828" decimals="-5" format="ixt:numdotdecimal" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzI5ODUzNDg4OTY2MA_2acc1614-021d-4c93-ba2a-bad84d7760a9">8.0</ix:nonFraction>&#160;million based on the grant date closing price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i847658eadc124bf3bfa5c9301c21bb42_D20200828-20200828" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfNDM5ODA0NjUxNzk4Nw_b1aad977-94b8-467c-91a3-f982cfa8a6f2">12.06</ix:nonFraction>. As of September 30, 2020, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSU's for the three and nine months then ended.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_82"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.  <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzg1MQ_6a14241d-e0ca-422b-b46e-26f47053f0ae" continuedAt="i976bd503c93d4073a50d986505398cda" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i976bd503c93d4073a50d986505398cda" continuedAt="i945c82a7ae284fd89f7b4aa52208a6d2"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Life Sciences </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 27, 2020, the Company so</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ld <ix:nonFraction unitRef="shares" contextRef="id846dd9c3ed6491e8bd1b652cf0299d3_D20200827-20200827" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzc_3fb37fea-e865-4018-836c-628b95a01add">1,644,155</ix:nonFraction> sh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ares of common stock in GeneOne for net proceeds of approximately <ix:nonFraction unitRef="krw" contextRef="id846dd9c3ed6491e8bd1b652cf0299d3_D20200827-20200827" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfOTM0NTg0ODg0NTQ5OA_cb0ebc9c-8941-4fc8-9e34-0ae9b5d20b91">47.4</ix:nonFraction>&#160;billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="id846dd9c3ed6491e8bd1b652cf0299d3_D20200827-20200827" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfOTM0NTg0ODg0NTUxMg_ae17b3f8-c090-469b-99e0-aadb31c53699">40.1</ix:nonFraction>&#160;million based on the exchange rate on the date of sale). The Company no longer holds an investment in GeneOne shares and GeneOne is no longer considered a related party to the Company under ASC 850. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he Company's condensed consolidated balance sheet as of September 30, 2020 no longer reflects GeneOne&#8217;s portion in accounts receivable and accounts payable and accrued expenses with affiliated entities whereas the Company&#8217;s balance sheet as of December 31, 2019 reflects $<ix:nonFraction unitRef="usd" contextRef="ie03bd2679d2e4a7d9318989067e22958_I20200827" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfMzg0ODI5MDcwODk3NQ_4f7dea93-51f7-4951-8156-6e686d5780f1">128,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie03bd2679d2e4a7d9318989067e22958_I20200827" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfOTg5NTYwNDY2MjAyNA_4eb1a53a-f353-41c6-bb00-efd4ed35de8c">511,000</ix:nonFraction> in a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ccounts receivable and accounts payable and accrued expenses with affiliated entities, respectively, related to GeneOne. Revenues recognized from GeneOne will no longer be presented as revenue with affiliated entity on the consolidated statement of operations after the change in related party designation in August 2020. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, the Company entered into a collaboration and license agreement (the &#8220;GeneOne Agreement&#8221;) with GeneOne. Under the GeneOne Agreement, the Company granted GeneOne an exclusive license to the Company's SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> universal influenza vaccine delivered with electroporation to be developed in certain countries in Asia (the &#8220;Product&#8221;). As consideration for the license granted to GeneOne, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia3c081d7909a418589d0447afe757e8c_D20100101-20101231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNjQ2_a99e774a-1c01-4d30-9c01-26915281ee7a">3.0</ix:nonFraction> million, and is entitled to receive research support, annual license maintenance fees and royalties on net Product sales. The GeneOne Agreement also provides the Company with exclusive rights to supply devices for clinical and commercial purposes (including single use components) to GeneOne for use in the Product. The term of the GeneOne Agreement commenced upon execution and will extend on a country by country basis until the last to expire of all Royalty Periods for the territory (as such term is defined in the GeneOne Agreement) for any Product in that country, unless the GeneOne Agreement is terminated earlier in accordance with its provisions as a result of breach, by mutual agreement, or by GeneOne's right to terminate without cause upon prior written notice. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, the Company entered into a collaborative development and license agreement (the &#8220;Hep Agreement&#8221;) with GeneOne. Under the Hep Agreement, as originally executed, the Company and GeneOne agreed to co-develop the Company&#8217;s SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapeutic vaccines for hepatitis B and C infections (the &#8220;Hep Products&#8221;). Under the terms of the Hep Agreement, GeneOne will receive marketing rights for the Products in Asia, excluding Japan, and in return will fully fund IND-enabling and initial Phase 1 and 2 clinical studies with respect to the Hep Products. The Company will receive from GeneOne payments based on the achievement of clinical milestones and royalties based on sales of the Hep Products in the licensed territories, retaining all commercial rights to the Hep Products in all other territories. In 2013, the Company amended the Hep Agreement to grant back to the Company the SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapeutic vaccines targeting hepatitis B, along with all associated rights, from the collaboration in return for certain remuneration including a percentage of license fees. In 2013, the Company further amended the Hep Agreement to in part provide exclusive patent rights to IL-28 technology for use with the Hep Products in Asia, excluding Japan. The Hep Agreement shall terminate upon the later of the expiration or abandonment of the last patent that is a component of the rights or <ix:nonNumeric contextRef="i85f7dcb7a22e4903ad067fbb0557bacb_D20140101-20140331" format="ixt-sec:duryear" name="ino:CollaborativeArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfMjc5Ng_5d5c2627-c9a5-4221-b41a-708f6fb2f2c1">20</ix:nonNumeric> years after the effective date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2015, the Company entered into a Collaborative Development Agreement with GeneOne to co-develop a DNA vaccine for MERS through Phase 1 clinical trials.&#160;Under the terms of the agreement, GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a <ix:nonFraction unitRef="number" contextRef="i1d860bed7f3c477c927663b8fe0f5eee_D20150501-20150531" decimals="INF" name="ino:MilestoneBasedOwnershipTarget" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfMzE1OA_4ec64452-6968-4069-8b38-592de780ce2d">35</ix:nonFraction>% milestone-based ownership interest in the MERS immunotherapy upon achievement of the last milestone event of completion of the Phase 1 safety and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i945c82a7ae284fd89f7b4aa52208a6d2"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunogenicity study.&#160;The collaborative research program shall terminate upon the completion of activities under the development plan, unless sooner terminated.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the Company and GeneOne amended the Collaborative Development Agreement for MERS to expand the agreement to test and advance the Company's DNA-based vaccine for preventing and treating Zika virus.&#160;GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a <ix:nonFraction unitRef="number" contextRef="i3bef37dba0d9484fa9ec9f1316d39f3b_D20160101-20160131" decimals="INF" name="ino:MilestoneBasedOwnershipTarget" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfMzgxNg_1ad89c00-e144-4e40-902b-9c0f29f80539">35</ix:nonFraction>% milestone-based ownership interest in the Zika immunotherapy upon achievement of the last milestone event of the completion of the Phase 1 safety and immunogenicity study. All other agreement terms remain the same.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from GeneOne consisted of patent and device maintenance fees. For both the three and nine months ended September 30, 2020 and 2019, the Company recognized revenue from GeneOne of $<ix:nonFraction unitRef="usd" contextRef="i3975abdb45c8440abeef92728a3f628e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDE4OA_1fde7c39-c830-4f2f-88c0-2a2f6a0c02c4"><ix:nonFraction unitRef="usd" contextRef="iecf61220d18043d899fc9e4751d53309_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDE4OA_fb109133-a963-40d9-bd90-64c5524d42e7">31,000</ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i790052b1d4424f2eaa1cf12c5cc544e1_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfMjc0ODc3OTA4MjQ1MQ_84fde5f2-3514-4250-baf2-1466d2c5d8e6"><ix:nonFraction unitRef="usd" contextRef="i40c874fb1aab45f6a0c7ba48d937c1c7_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfMjc0ODc3OTA4MjQ1MQ_a3f2767d-c057-4e5f-8ca3-9b73d83a64bd">94,000</ix:nonFraction></ix:nonFraction>, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses recorded from transactions with GeneOne related primarily to biologics manufacturing were $<ix:nonFraction unitRef="usd" contextRef="i790052b1d4424f2eaa1cf12c5cc544e1_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDMyMg_5c29509e-b6a2-480b-a4dc-a145ac805060">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iecf61220d18043d899fc9e4751d53309_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDMyOQ_b1263ed9-4baf-4359-a374-0eb41c193027">4.4</ix:nonFraction> million for the three and nine months ended September 30, 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i40c874fb1aab45f6a0c7ba48d937c1c7_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDM2Mg_44d7c3e2-fe38-4cdf-823f-3baf56aa6b0d">232,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3975abdb45c8440abeef92728a3f628e_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDM2OQ_f35966fb-21f1-414b-bb77-7d224f2727ef">2.1</ix:nonFraction> million for the three and nine months ended September 30, 2019, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns <ix:nonFraction unitRef="shares" contextRef="ief6a9b5c09ee4b90af8663890af888fa_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDgyNQ_5077866f-3fd5-406e-a9eb-17ee36cc2795">597,808</ix:nonFraction> shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of September&#160;30, 2020 and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February 20, 2020, the Company entered into a Debt and Share Subscription Agreement with PLS under which the Company received <ix:nonFraction unitRef="shares" contextRef="i49f5bd8f2ce54ea9aac77e18fa6578c7_I20200220" decimals="INF" format="ixt:numdotdecimal" name="ino:InvestmentOwnedAdditionalSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTExNw_a701bc85-21ce-4a09-b3e9-a02a01b8e255">202,050</ix:nonFraction> shares of PLS common stock in exchange for a portion of the outstanding accounts receivable balance due from PLS. Following the issuance of these shares and as of September&#160;30, 2020, the Company held a <ix:nonFraction unitRef="number" contextRef="iae58b01d628f4694912a6815b3ea0645_I20200930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTMwNg_99a6f0a2-bd7c-49cf-9d5e-c7fbb7c5d714">19.9</ix:nonFraction>% ownership interest in PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the three and nine months ended September 30, 2020, the Company recognized revenue from PLS of $<ix:nonFraction unitRef="usd" contextRef="i4058122d38c74b2495974de7f507740b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTQ2Nw_018d0911-06c7-4a1f-a698-883dcc9760cd">83,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i19efa68d746c41c38d72557926a2c83a_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTQ3NA_64d2308f-1930-4502-a1c5-fcedf0a3ecb1">1.3</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i29248800a6f9460c9570869254c619d7_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTQ5Ng_48bbbae7-79e4-48ec-9b71-ffc50346a4eb">22,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie258d44d8f7c42a788923cec12040ba5_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTUwMw_4c13ab36-ccff-4514-ba8e-3f700f951540">86,000</ix:nonFraction> for the three and nine months ended September 30, 2019, respectively. At September&#160;30, 2020 and December&#160;31, 2019, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="ib9f446d994234ef9aa5a5bc12c0b9dcb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTU5Ng_85e602c7-2848-4d4a-b86c-79faee3988b2">40,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i92e675b7850f48a7bd3444a4732e7d6a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTYwMw_b03576c1-f5d6-4508-9544-b669ff0b51b3">589,000</ix:nonFraction>, respectively, related to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="i57c38a9d213944289a8cdaf81d35f929_D20160301-20160331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementExpensesToReimburse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNjI1OQ_66173599-1ff3-4454-9f03-a94e1317cb60">3.1</ix:nonFraction> million during the <ix:nonNumeric contextRef="i57c38a9d213944289a8cdaf81d35f929_D20160301-20160331" format="ixt-sec:durwordsen" name="ino:CollaborativeArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDM5ODA0NjUyNDM3Nw_85d33986-b946-450d-90a4-ea0081585d76">five-year</ix:nonNumeric> term of the agreement.  The Company will have the exclusive right to in-license new intellectual property developed under the agreement.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company received a&#160;$<ix:nonFraction unitRef="usd" contextRef="i8c3f9ed79a4848cab5edbb332f829d5d_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAwardedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNjQ2MQ_f702d8e9-fb71-449b-af90-694c13aae2db">6.1</ix:nonFraction> million&#160;sub-grant through Wistar to develop a DNA-based monoclonal antibody against the Zika infection, with funding through December 2020. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three and nine months ended September 30, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i652ec1b835ac4951b1455fa93ec2220c_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNjk4NQ_a412fa6a-bbe1-4c1e-871b-9172db5ccd04">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0046f92427f94b59992479e7afc4aeab_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNjk5Mg_a7003baf-fdfb-4678-bb05-7c30619780c7">1.7</ix:nonFraction> million, respectively, and for the three and nine months ended September 30, 2019 the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i3c90a066b83c4b8380cb3cd37bc3a09a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzA0Ng_f2b14089-4552-40b2-80d2-93fe306d10a1">482,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if7fbaa1c34944d488dabcf367f55d769_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzA1Mw_901092d6-0792-4d9b-8faf-ba0c97fd17a0">1.7</ix:nonFraction> million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill and Melinda Gates Foundation and CEPI (see Note 15). Research and development expenses recorded from Wistar for the three and nine months ended September 30, 2020 were $<ix:nonFraction unitRef="usd" contextRef="i652ec1b835ac4951b1455fa93ec2220c_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzQxMw_925c9fa4-8460-4de3-a59c-0ec4cbde6c5e">411,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0046f92427f94b59992479e7afc4aeab_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzQyMA_82ace16d-ab99-4601-bfe9-6063d2b13a1b">1.2</ix:nonFraction> million, respectively. Research and development expenses recorded from Wistar for the three and nine months ended September 30, 2019 were $<ix:nonFraction unitRef="usd" contextRef="i3c90a066b83c4b8380cb3cd37bc3a09a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzUwOQ_e1ad97c8-165c-4167-a813-47c5e376b1b4">313,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if7fbaa1c34944d488dabcf367f55d769_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzUxNg_4920905c-dacc-4cea-ab02-15905d8e7aba">1.1</ix:nonFraction> million, respectively. At September&#160;30, 2020 and December&#160;31, 2019, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="if8599ce44e474e488237d3872fc61db9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzU5OA_f42439bf-f85a-4553-8cfb-a11bdda61879">443,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib51d61f346d74c80bcc530d2cf49fc35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzYwNQ_eae58b52-d3b0-4bf0-b27e-12d7798427dd">616,000</ix:nonFraction>, respectively, and an accounts payable and accrued liability balance of $<ix:nonFraction unitRef="usd" contextRef="if8599ce44e474e488237d3872fc61db9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzY4MA_d00d294d-9441-40c0-8f76-5986ec8d0c24">795,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib51d61f346d74c80bcc530d2cf49fc35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzY4Nw_e035ca85-9dad-47c0-bf31-ec9399793ae9">219,000</ix:nonFraction>, respectively, related to Wistar. As of September&#160;30, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="if8599ce44e474e488237d3872fc61db9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzc1MA_ff97ba5b-de18-4781-be18-75d422c7d0ce">173,000</ix:nonFraction> recorded as deferred grant funding on the condensed consolidated balance sheet related to Wistar.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_88"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.  <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMzAwOQ_4bce9322-92d9-4929-8655-faae0241ca22" continuedAt="i699525ef47634cc99c778bff5f922985" escape="true">Leases                                                  </ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i699525ef47634cc99c778bff5f922985" continuedAt="i8bb03fb15f1a4fd296356c4acb16e0f1">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="ifd1bef4535014b23bd76467b4f46b98d_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMTAw_f93a961b-223d-4f14-9c40-ed4dc7816ade">82,200</ix:nonFraction> square feet of office, laboratory, and manufacturing space in San Diego, California and <ix:nonFraction unitRef="sqft" contextRef="i52fd1f860b3e47b3b28f24815064d334_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMTkx_e47e9064-c172-4d1e-84bf-79e3612d8829">57,360</ix:nonFraction> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8bb03fb15f1a4fd296356c4acb16e0f1"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lease agreements with remaining lease terms as of September&#160;30, 2020 of <ix:nonNumeric contextRef="if8e016753b6d49ffa2bed4a3be3bc0ff_I20200930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMzYz_b7732709-88d6-466f-ae8b-3a230de11f3a">3.2</ix:nonNumeric> to <ix:nonNumeric contextRef="i15135c10f2b84613a0bdfc1f99cfb3f9_I20200930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMzY5_0e0bff23-2829-4789-b7ab-854b3b2cede7">9.3</ix:nonNumeric> years, which represent the non-cancellable periods of the leases.  The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMzAxMQ_17bfe4eb-6995-4979-a247-33882ad1a29b" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of September&#160;30, 2020, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMC0xLTEtMS0w_93d4a890-cdc5-4aa7-9cab-84e5fa2e01b4">985,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMS0xLTEtMS0w_24b2889e-5d05-42f4-bbb3-8f511b8051af">3,968,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMi0xLTEtMS0w_c18788f7-b47a-4471-88a9-6d9e69d26899">4,045,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMy0xLTEtMS0w_3b45d750-9df2-453f-82f7-d0d4b28015e4">4,023,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfNC0xLTEtMS0w_27f65f2b-d662-4bd3-8bf2-c2744c9c81ef">3,001,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfNS0xLTEtMS0w_32ebce35-5da5-4720-aac3-92a1c02448bf">12,951,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfNi0xLTEtMS0w_f9896d16-72e5-453b-8069-fe40fa74cfaf">28,973,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfNy0xLTEtMS0w_e4c6cee7-e1d7-40e8-8b18-03bf12755a67">8,039,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfOC0xLTEtMS0w_2aa672e8-66e5-453a-9c90-d788550f6962">20,934,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfOS0xLTEtMS0w_704ac43c-43be-4b9a-ba93-69e1c57a71aa">2,264,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMTAtMS0xLTEtMA_cff6d480-bf5c-4ee5-9ba4-f5e74fd1e843">18,670,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMTItMS0xLTEtMA_a774b2b1-3d4b-4e04-b982-d8009bc16b32">7.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMTMtMS0xLTEtMA_c3e1ae19-b669-41d2-b34f-bf718f09618c">8.4</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 were $<ix:nonFraction unitRef="usd" contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMjAzMw_8246740a-aa1d-4bd6-9936-64c46ed29ad1">836,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMjA0MA_47ee721d-9e29-4e92-802c-7b5b6fe33c22">2.5</ix:nonFraction> million, respectively. Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and nine months ended September 30, 2019 were $<ix:nonFraction unitRef="usd" contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMjE4MA_e784ec41-dcf1-4ae3-b307-9e8f56b00f18">820,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMjE4Nw_9e5cea95-1b73-4e93-8397-a7ae8101d5f6">2.5</ix:nonFraction> million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_91"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNzY5NjU4MTQwNzExNw_af284cb9-6b5d-4991-96ec-b6ec3d7c8462" continuedAt="iec3ab2d3848b44ba924c24054b2e419a" escape="true">Collaborative Agreements</ix:nonNumeric></span></div><ix:continuation id="iec3ab2d3848b44ba924c24054b2e419a" continuedAt="i66aaff0cffde4b6781e325053a33f0db"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and potentially Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the <ix:nonNumeric contextRef="ic81bd389069e417a984bce2bcd1d1063_D20171229-20171229" format="ixt-sec:durwordsen" name="ino:CollaborationAgreementTerritoryExpansionOptionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjU5_27890fac-3cc6-4e75-ab90-895d94284000">three years</ix:nonNumeric> following the effective date of the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ApolloBio Agreement, the Company received proceeds of $<ix:nonFraction unitRef="usd" contextRef="i47d345bee3e7411d98a3ba44f79db554_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:ProceedsFromCollaborativeAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNzgz_fc37106c-fc7d-4591-88d4-47616d73239f">19.4</ix:nonFraction> million in March 2018 which comprised the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i66aaff0cffde4b6781e325053a33f0db" continuedAt="i98f457e86ff44a15815a9f1982be9574"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i47d345bee3e7411d98a3ba44f79db554_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODM5_22a0df79-385f-45b8-9cf0-6839fb5c70d9">23.0</ix:nonFraction> million less $<ix:nonFraction unitRef="usd" contextRef="i0a9ae846802141b899c438da3a7cd430_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementCorporateIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODQ3_142819e0-bba0-474b-a0e1-553b383a5739">2.2</ix:nonFraction> million in foreign income taxes and $<ix:nonFraction unitRef="usd" contextRef="i0a9ae846802141b899c438da3a7cd430_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementForeignNonIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODc4_aeee2f90-e69c-4f58-9c45-d758487f705e">1.4</ix:nonFraction> million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the condensed consolidated statement of operations. The Company also incurred advisory fees of $<ix:nonFraction unitRef="usd" contextRef="i0d907bd30e814bf1997a9fd3ed4a165b_I20180331" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAdvisoryFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTE3NQ_6da11376-81a3-41b6-b677-db95df4ca025">960,000</ix:nonFraction> in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="idcb1a6014bfb4665a8e53fda2328b9fa_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTc2Mw_9474c272-f5ba-413a-8db7-e0e848ca1b5e">20.0</ix:nonFraction> million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for <ix:nonNumeric contextRef="idcb1a6014bfb4665a8e53fda2328b9fa_D20200101-20200930" format="ixt-sec:duryear" name="ino:CollaborationAgreementRoyaltyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMjMwNA_0afaf9f6-1930-4d34-b613-9bf924bb4857">10</ix:nonNumeric> years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement.  The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $<ix:nonFraction unitRef="usd" contextRef="idcb1a6014bfb4665a8e53fda2328b9fa_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMjkzOQ_d786bcfc-2f56-4a80-a3db-48298d5a9915">23.0</ix:nonFraction> million upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning <ix:nonNumeric contextRef="idcb1a6014bfb4665a8e53fda2328b9fa_D20200101-20200930" format="ixt-sec:durwordsen" name="ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNDE3MA_11cf6018-8c24-4409-958b-4416745e251e">one year</ix:nonNumeric> after the effective date for any reason upon <ix:nonNumeric contextRef="idcb1a6014bfb4665a8e53fda2328b9fa_D20200101-20200930" format="ixt-sec:durday" name="ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNDIxOA_04a3da0d-4621-49bc-9b7f-da0ca8facca2">90</ix:nonNumeric> days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $<ix:nonFraction unitRef="usd" contextRef="i2d344de8bac24153b97039f4a5da33f7_D20180401-20180630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNDMwNg_1f729642-2f75-4bdb-8d89-c7a8f2fb76e2">23.0</ix:nonFraction> million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. The Company has recorded the gross upfront payment received from ApolloBio of $<ix:nonFraction unitRef="usd" contextRef="i2d344de8bac24153b97039f4a5da33f7_D20180401-20180630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNDYwOQ_3656aa40-64c4-4b0c-88cf-ccf7cc690d11">23.0</ix:nonFraction> million as revenue under collaborative research and development arrangements on the condensed consolidated statement of operations during the three months ended June 30, 2018.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i364410dac22d46849150dbb76bf79ea3_D20150901-20150930" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNTI2Mg_378dba6f-1d6f-4afa-8d77-d48cfb5a961c">27.5</ix:nonFraction> million to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to $<ix:nonFraction unitRef="usd" contextRef="ie4b9ecc1c92b4eb3b546f10e1fd321ae_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNTQzMQ_e86b0140-7434-4593-b51d-bf5dd1aee1d3">125</ix:nonFraction> million and potential future commercial event-based payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="ie4b9ecc1c92b4eb3b546f10e1fd321ae_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNTUwMg_30a09309-ea67-4622-a8fe-29efcd2ba24b">115</ix:nonFraction> million, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement.  </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the broader collaboration, AstraZeneca had rights to co-develop up to <ix:nonFraction unitRef="product" contextRef="ic3ff9e9dd0e5478f9b9bee7abc6546ca_D20150807-20150807" decimals="INF" format="ixt-sec:numwordsen" name="ino:NumberOfAdditionalProducts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjE0OA_90f05673-94cd-4e1e-ac2a-4588cd031089">two</ix:nonFraction> additional DNA-based cancer vaccine product candidates not included in the Company's current product pipeline. The Company has received notice that AstraZeneca intends to discontinue activities with respect to the research collaboration programs, other than MEDI0457, that were covered by the collaboration agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2017, the Company had recognized all of the $<ix:nonFraction unitRef="usd" contextRef="i790eb33d2aab4bbb89117717eaf49e43_D20171231-20171231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjUzMw_396532d3-f7b1-43d9-8e7d-af04324881f6">27.5</ix:nonFraction> million upfront payment as revenue, as all identified material performance obligations had been met with respect to that payment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020, the Company recognized revenues of $<ix:nonFraction unitRef="usd" contextRef="i10bdaf5e033f4b6cb32118002bd714d4_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjcwOA_a454fc94-daaf-4332-9b19-f94bd826ec91">21,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id1fe60d4ed164b4ba68d097b07daea40_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjcxNQ_832d0a8f-fd65-4b68-a63f-3854539f5b07">167,000</ix:nonFraction>, respectively, from AstraZeneca primarily for </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i98f457e86ff44a15815a9f1982be9574" continuedAt="i0c43f8cdaa464c18a8be84e93dbf2e08"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing services. During the three and nine months ended September 30, 2019, the Company recognized revenues of $<ix:nonFraction unitRef="usd" contextRef="i1dc0a0736a3a41e3a718ffe92978cc2d_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjgzOA_10072395-e770-456d-9a2e-e5ec574f8b33">255,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i94a9e28f27b340909b69217c93f1e240_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjg0NQ_172b7702-5f32-4d6e-bd49-f1ebe6342e61">3.0</ix:nonFraction> million, respectively, from AstraZeneca primarily from a milestone achieved in the first quarter of 2019 triggered by the initiation of a Phase 2 portion of an ongoing clinical trial in the third major indication, as well as for manufacturing services.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i11fb2d121358429bbb5330755fc13578_D20200401-20200430" decimals="-6" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNzc1Mg_bf1c64b6-406d-4b90-ad6b-543096bb593b">56</ix:nonFraction> million of costs over a <ix:nonNumeric contextRef="i11fb2d121358429bbb5330755fc13578_D20200401-20200430" format="ixt-sec:durwordsen" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNDM5ODA0NjUyNDUzOQ_87c02297-baa7-4189-bfdb-91af0faf8bb3">five-year</ix:nonNumeric> period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three and nine months ended September 30, 2020, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="iae268d9545fc40279bac5472d53ddf72_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODAzOA_43bfc394-c75c-40ad-a5fd-848276b80bbd">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5188afbca0524352a1d0626a807e0bc4_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODA0NQ_22767ae3-4c95-44ff-bc50-d9974b1d4cbb">4.6</ix:nonFraction> million, respectively, related to the CEPI Lassa fever and MERS grants and recorded such amounts as contra-research and development expense. During the three and nine months ended September 30, 2019, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="ia0128722f91943efb7a4bdfdc5335c37_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODIyOA_263fe420-fa5e-4de4-9f52-e4bde1dde2c8">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i006215dec0fa4ecdac01b405a91894bb_D20190101-20190930" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODIzNQ_c6fc8d55-26bf-4c1d-a716-4ed06e2605a2">4.6</ix:nonFraction> million, respectively, related to these grants and recorded such amounts as contra-research and development expense. As of September&#160;30, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i3a5d7fe092264c2db4c3072992ccce84_I20200930" decimals="-5" name="ino:DeferredGrantFundingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODM4MQ_f521235a-1c86-4920-a320-a1f59d879af7">3.7</ix:nonFraction> million recorded as deferred grant funding on the condensed consolidated balance sheet related to these CEPI grants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $<ix:nonFraction unitRef="usd" contextRef="i08d25cd3db624f0fa8d5198cf2a38bc6_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODU2MQ_0ce009fc-1ac9-4e2e-943c-386c43a1effd">9.0</ix:nonFraction> million to develop a vaccine against COVID-19. This initial CEPI funding is intended to support preclinical and clinical development through Phase 1 human testing in the United States of INO-4800, the Company's COVID-19 vaccine candidate against COVID-19. In April 2020, CEPI awarded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="i99c40f03c0b148739b61b7e80708fc06_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODg2Mw_016e86cd-ee71-4a21-8b42-a9b5af088897">6.9</ix:nonFraction> million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $<ix:nonFraction unitRef="usd" contextRef="i3b66be9eec75416f98e7e0628e15662f_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfOTA0MQ_5e042dfe-0b0e-4e56-90ae-234cc1666f94">5.0</ix:nonFraction> million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $<ix:nonFraction unitRef="usd" contextRef="ia2db5556827143cdafe4b46ce571915b_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfOTIyMw_703b390d-0d6d-413a-b503-59e0829d1454">1.3</ix:nonFraction> million to support large-scale manufacturing of INO-4800. During the three and nine months ended September 30, 2020, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="i18456a29ef3c4982b6471ce35dc6e525_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfOTMyMw_8938f0bd-e16a-4cdc-aef1-18a1a765bc4a">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i312dea0c2ff240da9167e27ee1e8868d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfOTMzMA_a8df7d33-4558-4526-8c9e-086d2d2d5e0d">9.5</ix:nonFraction> million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of September&#160;30, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="id557bc0e9dca48c98443ad742ea2b548_I20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfOTUzMg_5821b3a7-55fe-4cac-b058-7f30c1813183">1.1</ix:nonFraction> million recorded as deferred grant funding on the condensed consolidated balance sheet related to the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Bill &amp; Melinda Gates Foundation (&#8220;Gates&#8221;) awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="ifa238803cd83463bbeb7a595eaa9463c_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfOTc5Ng_fd2273a2-3bc5-4f9a-ad13-fc4740054d94">2.2</ix:nonFraction> million to advance the development of DNA-encoded monoclonal antibody technology (&#8220;dMAb&#8221;) to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $<ix:nonFraction unitRef="usd" contextRef="i7e0e25538df447b9b57d8cdb39c3731d_D20190801-20190830" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTAyMDU_fadade22-1532-467f-ba86-25eb4ff1301e">1.1</ix:nonFraction> million for the project. During the three and nine months ended September 30, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i04dd7aeed28047949952a8193bc3f3a4_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTAyNjE_b5ec8ba6-b20b-4ff8-95c9-dd25974086db">164,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idac8dcab713949bd94df184fbba19e22_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTAyNjg_92c9b23a-2c4c-4e23-abe7-437977aee382">334,000</ix:nonFraction>, respectively, and during the three and nine months ended September 30, 2019 recorded $<ix:nonFraction unitRef="usd" contextRef="ida003d1fc52d461c9d2031cf761e1268_D20190701-20190930" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTAzMTM_ffb1f029-4c6a-4b6c-b0b1-1b922a4145c4">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i01999719b8694f2cb9344f65f0b9b3fc_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTAzMjA_35900bd5-f57c-4272-a59e-4fcd747f08b3">4.6</ix:nonFraction> million, respectively, as contra-research and development expense related to the Gates dMAb grant. As of September&#160;30, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="ie814bccba6fe456b84bc2d64be454d97_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTA0NDA_eb8f1f6a-f519-4d13-8b61-2f60c927c813">703,000</ix:nonFraction> recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="i8695b2243216498fbd1123097efeb201_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTA2MDc_bad0eee0-0c37-4541-900b-59cc250f9870">5.0</ix:nonFraction> million to accelerate the development of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the three and nine months ended September 30, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="id80ffa0c4fd840e08766b83da4af802f_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTA3NDg_364d1a87-563f-487a-8a67-bb55f74816f6">943,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i59cb3488176045c9af0c67101f651fd0_D20200101-20200930" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTA3NTU_35ca45c0-6a3b-4b2e-a46e-eceb93c3f7b6">1.9</ix:nonFraction> million, respectively, as contra-research and development expense and had $<ix:nonFraction unitRef="usd" contextRef="i31f8cf75d3184c5385ae2d3930c43939_I20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTA4MjQ_a0e02e1a-7b27-456c-9aec-c6950dc190e1">3.1</ix:nonFraction> million recorded as deferred grant funding on the condensed consolidated balance sheet related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the U.S. Department of Defense (the "DoD"), to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately $<ix:nonFraction unitRef="usd" contextRef="icddc6a2b71ac4679b73a1761b7335361_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTE5MDE_568784e2-807b-4ec3-a967-8561d4dd70f2">54.5</ix:nonFraction> million. The Company has determined that the OTA Agreement does not represent revenue under ASC 606, therefore will record contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses are incurred. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="i0c43f8cdaa464c18a8be84e93dbf2e08" continuedAt="i15849770ca9d443b95323104882e4b94"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $<ix:nonFraction unitRef="usd" contextRef="i42731760dc864386b6cc234953ed8db8_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTIyOTU_ad879b5d-1cdb-448d-8c3c-82aa6efe72f8">16.6</ix:nonFraction> million. The Company has determined that the Procurement Contract does not currently fall under the scope of ASC 606 as contingencies remain regarding INO-4800 which does not give the Company the ability to satisfy its obligations under the arrangement.</span></ix:continuation></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i15849770ca9d443b95323104882e4b94">During the three and nine months ended September 30, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i925dbb99e22c47109cfd6499f718d23f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODc5NjA5MzAzNTEwMw_38bc52af-bc98-40fe-af29-8d35a575c57f"><ix:nonFraction unitRef="usd" contextRef="if5310f1c21874dcba016f8044259901b_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODc5NjA5MzAzNTEwMw_ee3746c4-a742-4a9c-b568-4f3683e137f8">7.7</ix:nonFraction></ix:nonFraction>&#160;million as contra-research and development expense related to these agreements with the DoD.  As of September&#160;30, 2020, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="ied249d236e834e95ad34273624d104c1_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMjc0ODc3OTA4MjExMg_f92f1532-ced3-4f78-b381-3d57fe829bc2">7.7</ix:nonFraction>&#160;million on the condensed consolidated balance sheet</ix:continuation> from the DoD.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_97"></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85Ny9mcmFnOjdlODY2ZGYxZGNjYjQ3OGM5NjAwMDQzN2ZiYzJhZGMwL3RleHRyZWdpb246N2U4NjZkZjFkY2NiNDc4Yzk2MDAwNDM3ZmJjMmFkYzBfMTg1MA_b4f22249-4fc5-45c2-8323-bad4569c06f0" continuedAt="ib522a6cc9f614ff79c77b9880fac3e28" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="ib522a6cc9f614ff79c77b9880fac3e28"><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act).&#160; The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19.&#160;The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic; some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act.&#160;At September&#160;30, 2020, the Company has not recorded any income tax provision/(benefit) for the impact for the CARES Act due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets. The Company will continue to analyze the impact that the CARES Act will have, if any, on its financial position, results of operations or cash flows.</span></div></ix:continuation><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_100"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzc3NDU_78231bb0-d6e8-460d-b4ae-1eb388eec482" continuedAt="i707cc3dbf3fd4922a028de95cf2225ef" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><ix:continuation id="i707cc3dbf3fd4922a028de95cf2225ef" continuedAt="ifbd5e3238992437ab536a635d48e9234"><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company formed Geneos, to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;preferred stock financing. The Company invested&#160;$<ix:nonFraction unitRef="usd" contextRef="ic7a90a05adcc4f638f0b47beed718798_D20190201-20190228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzM3MQ_8122acb9-cfa0-4619-9132-b64812335c07">1.2</ix:nonFraction> million&#160;in the preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="i869d8bf326be4abfbb1e18a89a00961a_I20190228" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzQ5Mg_0fe756f0-913b-4bae-a529-d9a641478e86">61</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;preferred stock financing, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="iec2d5f6527c24125972f2622cef53837_I20200131" decimals="-3" format="ixt:numdotdecimal" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzc3Nw_d936af2f-41bf-4b84-a7e4-1c07c40b86a6">800,000</ix:nonFraction>. Following this transaction, as of March 31, 2020, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="iedf6a38f277949399861daef313a0f5d_I20200331" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzg0OA_49826704-3904-424c-ab28-95e09094c8d9">52</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;preferred stock financing round, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="ib53c870fb97b4899bbb5a65108c6bd6d_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzEwOTA_daefe267-ddd9-48d1-8f36-82e96d78b0aa">800,000</ix:nonFraction>.  Following this transaction, the Company no longer held a controlling financial interest as the Company, owned <ix:nonFraction unitRef="number" contextRef="iaeddbb99315448e8b2869ef6ad5da9ab_I20200930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzEyMDk_e4fefa44-9cee-45ca-b646-d6bc4b15bc0c">47</ix:nonFraction>% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support.  However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="if383b813ea7a4745bfc01e54b08f32d4_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzE4MDM_8d453e34-8b96-4fe9-ae46-fc39e77bab15">4.1</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="if383b813ea7a4745bfc01e54b08f32d4_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzE4MTY_034ae0c5-6800-48ea-b3a6-37a2876627c9">2.4</ix:nonFraction> million related to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's condensed consolidated statement of operations.  <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzc3NDY_58577b96-156d-4bf7-a9c5-914d2f8eb6ed" continuedAt="i75c8c02b511e40e28cd87683d9280495" escape="true">The following table shows the amounts related to the deconsolidation accounting: </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifbd5e3238992437ab536a635d48e9234" continuedAt="i1bbcdc4ffd8b4289a8bfc9fe28365de3"><ix:continuation id="i75c8c02b511e40e28cd87683d9280495" continuedAt="icf8e693a4d7e413cbd46ff8b39a11a52"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601" decimals="0" format="ixt:numdotdecimal" name="ino:WorkingCapitalExcludingCash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzAtMS0xLTEtMA_68707ad0-a8e0-4581-a731-5d2512480292">59,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzEtMS0xLTEtMA_bb88c313-1612-4f5e-9eae-8b26c9c7e282">171,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzItMS0xLTEtMA_fd058aa3-243f-4bf0-9b9e-2201254421b7">16,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzMtMS0xLTEtMA_c715b2a7-2374-480e-86fb-f88791fe2aa3">3,181,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedInterestFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzQtMS0xLTEtMA_49c01f12-86ee-4ad5-af66-351ae69373cb">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if383b813ea7a4745bfc01e54b08f32d4_D20200601-20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzUtMS0xLTEtMA_2ce83779-2dc4-4f83-99cb-cc8f3b220e7e">4,121,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if383b813ea7a4745bfc01e54b08f32d4_D20200601-20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashDivestedFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzYtMS0xLTEtMA_cfe9293a-1fc0-4bce-be5f-21af0f19f676">2,774,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="iaeddbb99315448e8b2869ef6ad5da9ab_I20200930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzIxNTc_58a0e4e4-04c3-4662-b164-c078ef112c55">47</ix:nonFraction>% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27451cafe1f2419998b0684fe0a1a45f_I20200601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzEtMS0xLTEtMA_402c45ec-ba45-45a7-962e-f30ef8eb52c1">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27451cafe1f2419998b0684fe0a1a45f_I20200601" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzEtMy0xLTEtMA_5edb0ed6-2e66-41b5-b30b-7555566fc990">0.273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27451cafe1f2419998b0684fe0a1a45f_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzEtNS0xLTEtMA_bb58541f-b48d-43ac-bb6d-5705777e7c55">819,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2874a1f41d394187a5752e0fa6598078_I20200601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzItMS0xLTEtMA_001db53a-6411-4476-80d5-e8f0116b757d">2,113,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2874a1f41d394187a5752e0fa6598078_I20200601" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzItMy0xLTEtMA_b7b3234f-befe-470f-8da8-fb11b7bea8c3">1.325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2874a1f41d394187a5752e0fa6598078_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzItNS0xLTEtMA_f02fc8c2-56ca-4555-9a2d-92b1453f8bd2">2,799,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzMtMS0xLTEtMA_c584883c-ccd8-434f-b2b7-155198b28a80">5,113,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzMtNS0xLTEtMA_feb02bb8-930f-42d4-ac5f-0205e9f5726c">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for Geneos&#8217; common stock.  Geneos&#8217; enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving Geneos&#8217; own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#8217;s exercise price was based on Geneos&#8217; total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of Geneos&#8217; estimated time to their next financing and successful exit timing assumption.  The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#8217;s common stock is classified as a Level 3 financial instrument. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzc3NDg_d87cc92e-3a00-4e7c-949a-a5dcd89ea143" continuedAt="i933151510d92447182918a2a214e690b" escape="true">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><ix:continuation id="i933151510d92447182918a2a214e690b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1f18198c2b4e4bd8b89b62558865184c_D20200601-20200601" format="ixt-sec:duryear" name="ino:AlternativeInvestmentMeasurementInputTerm" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo5ZjgzNWZmMTFkMTY0YjBlODI4MWYxMjUyZjU0YjhmZC90YWJsZXJhbmdlOjlmODM1ZmYxMWQxNjRiMGU4MjgxZjEyNTJmNTRiOGZkXzAtMS0xLTEtMA_559ebc62-ae9f-45d3-94df-aeafbbaaaf50">2.92</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4859da00a9c04ed2b413734cd6ae17e4_I20200601" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo5ZjgzNWZmMTFkMTY0YjBlODI4MWYxMjUyZjU0YjhmZC90YWJsZXJhbmdlOjlmODM1ZmYxMWQxNjRiMGU4MjgxZjEyNTJmNTRiOGZkXzEtMS0xLTEtMA_4bdf7f0e-29af-41ad-b26c-8a9af94e56a5">70</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79ae502b32684fdf8f98b1c19fcf0397_I20200601" decimals="4" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo5ZjgzNWZmMTFkMTY0YjBlODI4MWYxMjUyZjU0YjhmZC90YWJsZXJhbmdlOjlmODM1ZmYxMWQxNjRiMGU4MjgxZjEyNTJmNTRiOGZkXzItMS0xLTEtMA_e7350ef8-667d-44b0-897d-54b0c597e235">2.46</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601" decimals="-3" format="ixt:numdotdecimal" name="ino:EquityMethodInvestmentEnterpriseValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo5ZjgzNWZmMTFkMTY0YjBlODI4MWYxMjUyZjU0YjhmZC90YWJsZXJhbmdlOjlmODM1ZmYxMWQxNjRiMGU4MjgxZjEyNTJmNTRiOGZkXzMtMS0xLTEtMA_ee39a5ba-df03-428a-bc70-9df42ca59232">4,966,531</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock.  Since the Company&#8217;s preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company has determined that its preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1bbcdc4ffd8b4289a8bfc9fe28365de3" continuedAt="ib6d5d3778f2d4ad8b6f8cda5e4e05ea5"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the period from June 1, 2020 through September 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i9c98da30e4704069839ed075f3b5a328_D20200601-20200930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzY5ODM_f89b6864-ecd2-4e8b-8c6e-ecfc4c86b6fb">2.7</ix:nonFraction> million. Of this amount, $<ix:nonFraction unitRef="usd" contextRef="i10ff0a553ff04929a035481611ba22dc_D20200601-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzcwMDQ_f61e4df3-6846-4b2d-ae30-355883127859">819,000</ix:nonFraction> has been allocated to the equity method investment, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="i70b1c5c8e2f24fff8299e8b17608bb18_I20200930" decimals="INF" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzcwOTE_55e21efd-9e92-4aa3-8858-2f5973298bed">0</ix:nonFraction> as of September 30, 2020. <ix:continuation id="icf8e693a4d7e413cbd46ff8b39a11a52" continuedAt="ia7192086cdcf4284bd85ed03e8738450">The remaining $<ix:nonFraction unitRef="usd" contextRef="i022bb72c504942ac878d6769a4a1b696_D20200601-20200930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzcxMzA_32170909-857c-4727-9d65-e63cd1679b5d">1.8</ix:nonFraction> million loss has been allocated to the Company&#8217;s preferred stock investment in Geneos, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="i05d2269442c846edb144f98b63b06aae_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzQzOTgwNDY1MjA0MDc_d1a8ea7a-1bfa-4fa7-97ef-5519c25151af">958,000</ix:nonFraction> as of September 30, 2020 as shown in the table below:</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:5pt"><ix:continuation id="ia7192086cdcf4284bd85ed03e8738450"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTpiNGFkYTY4Y2ZkMmU0MzFmYjZhOWRmZTUxZjcyOWIxZS90YWJsZXJhbmdlOmI0YWRhNjhjZmQyZTQzMWZiNmE5ZGZlNTFmNzI5YjFlXzEtMi0xLTEtNDY5Ng_3f656931-f788-42a0-881e-4d02f460bebd">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c98da30e4704069839ed075f3b5a328_D20200601-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTpiNGFkYTY4Y2ZkMmU0MzFmYjZhOWRmZTUxZjcyOWIxZS90YWJsZXJhbmdlOmI0YWRhNjhjZmQyZTQzMWZiNmE5ZGZlNTFmNzI5YjFlXzItMi0xLTEtNDY5Ng_bb57dd07-ea12-4e0c-bf3f-5e4c40e3dd7f">2,661,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c79c39dba34165aa075b540f1c274a_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTpiNGFkYTY4Y2ZkMmU0MzFmYjZhOWRmZTUxZjcyOWIxZS90YWJsZXJhbmdlOmI0YWRhNjhjZmQyZTQzMWZiNmE5ZGZlNTFmNzI5YjFlXzMtMi0xLTEtNDY5Ng_cfb82fbf-c8ee-4ded-9d2e-56a60e437f79">957,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="ib6d5d3778f2d4ad8b6f8cda5e4e05ea5" continuedAt="ie047a5ff494043a0880e605f70555990"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie047a5ff494043a0880e605f70555990">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</ix:continuation>  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_103"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDMvZnJhZzo2ZWQ3YmFkZjQ4NDM0OTM2YmQwYTMxYzEwOGE3ZTc0MS90ZXh0cmVnaW9uOjZlZDdiYWRmNDg0MzQ5MzZiZDBhMzFjMTA4YTdlNzQxXzU4NQ_4a14a22b-33f0-4d47-a017-40bd2f404ff6" continuedAt="i3fcaed8c313c478b9bec768e624388a2" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3fcaed8c313c478b9bec768e624388a2">In October 2020, certain holders converted an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i135db666eca94e468d89995d1fdb8e21_D20201001-20201031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDMvZnJhZzo2ZWQ3YmFkZjQ4NDM0OTM2YmQwYTMxYzEwOGE3ZTc0MS90ZXh0cmVnaW9uOjZlZDdiYWRmNDg0MzQ5MzZiZDBhMzFjMTA4YTdlNzQxXzEwMA_bea0819f-b029-4c52-b1b2-9087e83622ea">10.0</ix:nonFraction> million of Notes into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i0df0aeb02416451db34b6235410d3492_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDMvZnJhZzo2ZWQ3YmFkZjQ4NDM0OTM2YmQwYTMxYzEwOGE3ZTc0MS90ZXh0cmVnaW9uOjZlZDdiYWRmNDg0MzQ5MzZiZDBhMzFjMTA4YTdlNzQxXzEzMw_659273bd-fbc0-4a0d-b219-c574f0ecc884">1,858,044</ix:nonFraction> shares of the Company's common stock.</ix:continuation>  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Quarterly Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes and other financial information appearing elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes for the year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission, or SEC, on March 12, 2020 (our &#8220;2019 Annual Report&#8221;). Readers are also urged to carefully review and consider the various disclosures made by us that attempt to advise interested parties of the factors that affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;II of this Quarterly Report under the captions &#8220;Risk Factors&#8221; and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and the disclosures made in our 2019 Annual Report under the caption &#8220;Risk Factors&#8221; and in our audited consolidated financial statements and related notes. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that preclinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibody product candidates, or dMABS, may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture vaccine candidates, either on our own or with third parties; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; the impact of government healthcare proposals; and the impact of COVID-19 on us and our third-party contractors and suppliers.</span></div><div style="margin-top:9pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_118"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Our DNA medicine pipeline is comprised of three types of product candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, we have demonstrated that a DNA medicine can be delivered directly into cells in the body via our proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our novel DNA medicine candidates are made using our proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person's immune system recognize and destroy cancerous or virally infected cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hand-held CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of our DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human data to date have shown a favorable safety profile of our DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device in more than 6,000 administrations across more than 2,000 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate strategy is to advance, protect, and provide our novel DNA medicines to meet urgent and emerging global health needs. We continue to advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. We aim to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), International Vaccine Institute (IVI), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators are currently conducting or planning clinical studies of our DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome, or MERS; Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development agreements. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we had an accumulated deficit of $881.9 million. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impacts of COVID-19 on Our Business</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has had a number of significant impacts on our business during 2020.  Most notably, in the United States, South Korea and China, we have accelerated the clinical development of INO-4800, our DNA vaccine candidate matched to the outbreak strain of SARS-CoV-2, the virus that causes COVID-19. In January, we received initial grant funding from CEPI to advance INO-4800 into preclinical studies and clinical development through Phase 1 human testing. We had previously been awarded grants from CEPI for the development of other DNA vaccines against Lassa fever and Middle East Respiratory Syndrome, MERS, which is also caused by a coronavirus like COVID-19. We commenced a Phase 1 clinical trial in the United States in April, and in June we reported positive interim data from the first two cohorts of the trial. In addition, INO-4800 was selected to participate in a non-human primate (NHP) challenge study as part of the U.S. government's Operation Warp Speed, a national program aiming to provide substantial quantities of safe, effective COVID-19 vaccine for Americans by January 2021. We recently expanded our Phase 1 trial to add older participants in additional cohorts and intend to initiate a Phase 2/3 efficacy trial if and when the FDA allows us to proceed. In September 2020, the FDA notified us that the planned Phase 2/3 clinical trial remains on partial clinical hold pending resolution of certain items identified by the FDA. We responded to the FDA&#8217;s questions in October 2020, and the FDA has up to 30 days following our response to notify us of its decision as to whether the Phase 2/3 trial may proceed. In the meantime, we may continue our expanded Phase 1 clinical trial as previously authorized. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also initiated clinical trials of INO-4800 in South Korea and China. In April, CEPI awarded us a grant of $6.9 million to work with International Vaccine Institute and the Korea National Institute of Health to conduct a Phase 1/2 trial, which is the first COVID-19 vaccine clinical trial approved in South Korea. In China, we are collaborating with Beijing Advaccine Biotechnology Co. to conduct a Phase 1 trial, the initiation of which was approved by regulatory authorities in July. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In parallel with our accelerated clinical development efforts, we have engaged a network of partners for the planned large-scale manufacturing of INO-4800 if it achieves regulatory approval. In March, the U.S. Department of Defense, or DoD, awarded Ology Bioservices Inc. a contract to manufacture INO-4800 for the DoD to be used in upcoming clinical trials. In April, we entered into an agreement with the German contract manufacturer Richter-Helm BioLogics GmbH &amp; Co. KG and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expanded our preexisting manufacturing partnership to support large-scale manufacturing of INO-4800. In March, we also received a grant from the Bill and Melinda Gates Foundation for accelerated testing and scale up of our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP proprietary smart device for the intradermal delivery of INO-4800. In June, the DoD awarded us $71 million to support the large-scale manufacture of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP and the procurement of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2000 devices that are used to deliver INO-4800 intradermally.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With this growing coalition of partners and funders, and with our existing capacity and current and planned contract resources, our goal is to produce up to one million doses of INO-4800 by the end of 2020 and additional doses in 2021. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operationally, we have not experienced significant disruptions to date as a result of the COVID-19 pandemic.  In response to the outbreak, a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. We have implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. Business travel has been suspended, and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our liquidity has also not been negatively impacted by the pandemic. During the nine months ended September 30, 2020, we have raised $330.0 million in net proceeds from the sale of shares of our common stock, which has further enhanced our liquidity and capital resources. As of September&#160;30, 2020, our cash and cash equivalents and short-term investments </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were $337.2 million, co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mpared to $89.5 million as of December 31, 2019. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are closely monitoring the impact of the COVID-19 pandemic on our employees, collaborators and service providers. The extent to which the pandemic will impact our business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, that are highly uncertain. For additional information on the potential effects of the COVID-19 pandemic on our business, financial condition and results of operations, see the &#8220;Risk Factors&#8221; section below in Part II, Item 1A of this Form 10-Q.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_121"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to our critical accounting policies since December 31, 2019, other than our adoption of Accounting Standards Update ("ASU") No. 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 1, 2020. For a description of our critical accounting policies that affect our significant judgments and estimates used in the preparation of our condensed consolidated financial statements, refer to Note 3 to our Condensed Consolidated Financial Statements included in this Quarterly Report, as well as Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2019 Annual Report and Note 2 to our audited Consolidated Financial Statements contained in our 2019 Annual Report. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_124"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding recent accounting pronouncements is contained in Note&#160;4 to the Condensed Consolidated Financial Statements, included in this Quarterly Report.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_127"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue was $236,000 and $1.8 million, respectively, for the three and nine months ended September 30, 2020, as compared to $867,000 and $3.8 million, respectively, for the three and nine months ended September 30, 2019. Revenue primarily consisted of revenues under collaborative research and development arrangements, including arrangements with affiliated entities, for the three and nine months ended September 30, 2020 and 2019. The decrease in revenue for the nine-month period year over year was primarily due to less revenue recognized from our collaboration with AstraZeneca, offset by milestone revenue earned from our affiliated entity PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the three and nine months ended September 30, 2020 were $26.5 million and $67.9 million, respectively, as compared to $19.1 million and $66.0 million, respectively, for the three and nine months ended September 30, 2019. The increase for the three-month period year over year was primarily due to higher drug manufacturing expenses related to our INO-4800, VGX-3100 and other clinical trials of $4.3 million, an increase in engineering services related to our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device array automation project of $3.9 million, higher employee and contractor compensation expense of $3.5 million, an increase in consulting services related to COVID-19 of $2.1 million, higher device inventory expense of $1.6 million, and higher employee stock-based compensation expense of $1.1 million. These increases were offset by an increase in contra-research and development expense recorded from grant </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements of $10.1 million, among other variances. The increase for the nine-month period year over year was primarily due to higher drug manufacturing expenses and outside services related to our INO-4800 clinical trials of $9.3 million, an increase in engineering services related to our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device array automation project of $4.2 million, higher device inventory expense of $3.0 million and higher drug manufacturing expenses related to our VGX-3100 clinical trials of $2.3 million. These increases were offset by an increase in contra-research and development expense recorded from grant agreements of $17.7 million, among other variances.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $12.9 million and $26.9 million, respectively, for the three and nine months ended September 30, 2020 as compared to $2.8 million and $9.2 million, respectively, for the three and nine months ended September 30, 2019. The increase for the three-month period year over year was primarily due to increases of $7.7 million, $1.3 million and $943,000 earned under grants from the DoD, CEPI and Gates, respectively, for our INO-4800 and device development activities, among other variances. The increase for the nine-month period year over year was primarily due to increases of $9.5 million, $7.7 million and $1.9 million earned under grants from CEPI, DoD and Gates, respectively, related to our INO-4800 and device development activities, partially offset by a decrease of $1.7 million earned from the Gates grant related to our dMAb technology, among other variances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses, which include business development expenses, the amortization of intangible assets and patent expenses, were $10.1 million and $28.6 million, respectively, for the three and nine months ended September 30, 2020, as compared to $5.7 million and $18.5 million, respectively, for the three and nine months ended September 30, 2019. The increase for the three-month period year over year was primarily related to an increase in legal expenses of $2.3 million related to the legal proceedings described elsewhere in this report, higher employee and consultant stock-based compensation expense of $951,000, and higher employee compensation of $698,000, among other variances. The increase for the nine-month period year over year was primarily related to an increase in legal expenses of $3.8 million, an increase in expenses for work performed related to corporate marketing and communications of $3.0 million, higher employee and consultant stock-based compensation expense of $2.2 million, and higher employee compensation of $1.1 million, among other variances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite vesting period. Total employee and director stock-based compensation expense for the three and nine months ended September 30, 2020 was $3.9 million and $11.0 million, respectively. Of these amounts, $2.1 million and $6.2 million, respectively, was included in research and development expenses, and $1.8 million and $4.8 million, respectively, was included in general and administrative expenses. Total employee and director stock-based compensation expense for the three and nine months ended September 30, 2019 was $1.8 million and $8.1 million, respectively. Of these amounts, $922,000 and $5.1 million, respectively, was included in research and development expenses, and $885,000 and $3.0 million, respectively, was included in general and administrative expenses. The year over year increase was primarily related to a higher weighted average grant date fair value for the awards granted in 2020, offset in part by the reversal of previously recorded stock option expense due to the reduction in force in the third quarter of 2019 and an option modification expense recorded in the second quarter of 2019.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three and nine months ended September 30, 2020 was $897,000 and $2.4 million, respectively, as compared to $637,000 and $2.0 million, respectively, for the three and nine months ended September 30, 2019. The increase was related to higher interest earned on our higher balance of short-term investment holdings.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three and nine months ended September 30, 2020 was $2.0 million and $7.6 million, respectively, as compared to $2.4 million and $5.3 million, respectively, for the three and nine months ended September 30, 2019. The decrease for the three-month period year over year was due to less interest expense recorded for our convertible senior notes, or the Notes, due to the partial conversion of the Notes into shares of our common stock in July 2020, as well as less interest  expense recorded on our August 2019 Bonds due to their full conversion into shares of our common stock in August 2020. The increase for the nine-month period year over year was due to higher interest expense recorded on the Notes, which were issued during the first quarter of 2019, as well as interest expense from our August 2019 Bonds and December 2019 Bonds, which were issued during the third and fourth quarters of 2019, respectively. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in fair value of derivative liability.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The change in fair value of derivative liability for the three and nine months ended September 30, 2020 was a decrease of $35.3 million and an increase of $75.7 million, respectively. The change in fair value of derivative liability for both the three and nine months ended September 30, 2019 was a decrease of $2.6 million. We determined that our August 2019 Bonds included an embedded conversion feature that was considered to be a derivative liability requiring bifurcation from the debt instrument and separate recognition in our financial statements. The conversion feature was revalued at the end of each reporting period and immediately prior to the conversion of the August 2019 Bonds in August 2020, with&#160;the resulting changes in fair value reflected in the condensed consolidated&#160;statements of operations. The derivative liability was derecognized upon the conversion in full of the August 2019 Bonds.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain (loss) on investment in affiliated entities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain (loss) results from the change in the fair market value of the investments in GeneOne and PLS for a gain of $27.0 million and $36.3 million, respectively, for the three and nine months ended September 30, 2020 as compared to a loss of $486,000 and $1.4 million, respectively, for the three and nine months ended September 30, 2019. During the three months ended September 30, 2020, we sold our full equity interest in GeneOne. We record our investment in PLS at its market value based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the condensed consolidated statements of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net unrealized gain on available-for-sale equity securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gain on available-for-sale equity securities for the three and nine months ended September 30, 2020 of $1.3 million and $625,000, respectively, results from a change in the fair market value of the investments as of September&#160;30, 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on deconsolidation of Geneos. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain recorded represents the excess of the fair value of our retained noncontrolling investment in Geneos and the carrying amount of the non-controlling interest over the carrying amount of Geneos' assets and liabilities as of June 1, 2020, the date of deconsolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on extinguishment of convertible bonds. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the full conversion of our August 2019 Bonds, a loss of $8.2&#160;million was recorded for the difference between the fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component, and the fair value of our common stock issued upon conversion.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on extinguishment of convertible senior notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a result of the partial conversions of the Notes in July 2020, we recorded a $3.1 million gain on extinguishment calculated as the difference between the estimated fair value of the debt and the carrying value of the Notes as of the conversion dates. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share in net loss of Geneos.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The share in net loss of Geneos represents our share of Geneos' losses during the period after deconsolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income tax benefit/(Provision for income taxes). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit of $0 and $170,000 recorded for the three and nine months ended September 30, 2019, respectively, reflected our application of the intraperiod tax allocation rules under which we are required to record a tax benefit in continuing operations to offset the tax provision we recorded directly to other comprehensive income (loss) related to unrealized gains on our short-term investments. There was no income tax benefit or provision recorded for the three and nine months ended September 30, 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_130"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities in the oncology, DNA vaccines and other immunotherapy areas of our business. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital and Liquidity</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had cash, cash equivalents and short-term investments of $337.2 million and working capital of $335.8 million, as compared to $89.5 million and $62.2 million, respectively, as of December&#160;31, 2019. The increase in cash and short-term investments during the nine months ended September&#160;30, 2020 was primarily due to the net proceeds from the sale of our common stock under at-the-market, or ATM, sales agreements, offset by expenditures related to our research and development activities, clinical trials and various general and administrative expenses related to legal, consultants, accounting and audit, and corporate development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $126.8 million and $84.1 million for the nine months ended September 30, 2020 and 2019, respectively. Net cash used in operating activities for the nine months ended September 30, 2020 consisted of net loss of&#160;$143.1 million, less use of net cash in operating assets and liabilities of&#160;$43.0 million partially offset by net non-cash adjustments of&#160;$59.3 million. The net cash used in operating activities included a $30.1 million increase in prepaid expenses and other current assets and a $15.0 million increase in other assets, primarily made up of prepayments for facilities, equipment and manufacturing related to INO-4800. The primary non-cash adjustments to net loss included the increase in fair value of derivative liability of $75.7 million prior to its derecognition, stock-based compensation of&#160;$11.8 million, net loss on extinguishment of convertible debt of $5.1 million, interest expense of $3.0 million, depreciation and amortization of $2.7 million and shares of net loss in Geneos of $2.7 million, offset by gain on investment in affiliated entities of $36.3 million and gain on deconsolidation of Geneos of $4.1 million, among other items. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the nine months ended September 30, 2019 consisted of net loss of&#160;$82.4 million,&#160;less use of net cash in operating assets and liabilities of&#160;$15.2 million, partially offset by net non-cash adjustments of&#160;$13.5 million. The primary non-cash expenses added back to net loss included stock-based compensation of&#160;$8.9 million, interest expense of $2.6 million and depreciation and amortization of&#160;$3.5 million.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $55.1 million and $19.5 million for the nine months ended September 30, 2020 and 2019, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities, offset by the proceeds from the sale of our investment in GeneOne of $40.1 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $338.3 million and $95.8 million for the nine months ended September 30, 2020 and 2019, respectively. The variance was primarily due to the significantly higher net proceeds from the sale of common stock under the ATM sales agreement as well as proceeds from stock option exercises in 2020, offset by the net proceeds received from the issuance of Notes and August 2019 Bonds.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances of Notes and Bonds</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we completed a private placement of our 1.0% convertible bonds due December 2024, or the December 2019 Bonds, to an institutional investor in Korea for an aggregate principal amount of 4.7 billion Korean Won (KRW) (approximately USD $4.1 million based on the exchange rate on the date of issuance). Net proceeds from the offering were $4.0 million, after deducting the offering expenses payable by us. See Note 9 to the condensed consolidated financial statements included in this report for further discussion. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we completed a private placement of aggregate principal amount of 18 billion KRW (approximately USD $15.0 million based on the exchange rate on the date of issuance) of August 2019 Bonds issued to institutional investors led by Korea Investment Partners. Net proceeds from the offering were $14.5 million, after deducting the offering expen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ses payable by us. See Note 9 to the condensed consolidated financial statements included in this report for further discussion. In August 2020, the August 2019 Bonds were fully converted into 4,962,364 shares of our common stock.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2019, we completed a private placement of $78.5 million aggregate principal amount of Notes, sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million, after deducting the initial purchasers' discount and offering expen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ses payable by us. See Note 9 to the condensed consolidated financial statements included in this report for further discussion. In July 2020, certain holders of the Notes converted principal amount of $19.1 million into an aggregate of 3,546,074 shares of our common stock. In October 2020, certain holders of the Notes converted additional principal amount of $10.0 million into an aggregate of 1,858,044 shares of common stock.  </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Issuances of Common Stock</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into an At-the-Market Equity Offering Sales Agreement, or the Sales Agreement, with an outside placement agent, or the Placement Agent, to sell shares of our common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent would act as sales agent. During the year ended December&#160;31, 2019, we sold 3,340,678 shares of common stock under the Sales Agreement for aggregate net proceeds of $9.1 million. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we entered into amendments to the&#160;Sales Agreement to increase the amount of our common stock that could be sold through the Placement Agent under the Sales Agreement to an aggregate offering price of up to $250.0 million. During the three months ended March 31, 2020, we sold 43,148,952 shares of common stock under the Sales Agreement for aggregate net proceeds of $208.2 million. Following these sales, there was no remaining capacity under this Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020, we entered into a new sales agreement, or the New Sales Agreement, with the same Placement Agent to sell shares of our common stock. On that same day, we filed a prospectus supplement pursuant to the New Sales Agreement for the offer and sale of our common stock for aggregate gross proceeds of up to $150.0 million. On May 12, 2020 we filed an additional prospectus supplement pursuant to the New Sales Agreement for the offer and sale of our common stock for an additional $100.0 million of gross proceeds, bringing the maximum gross proceeds of sales under the New Sales Agreement to $250.0 million. Through September 30, 2020, we have sold 12,041,178 shares of common stock under the New Sales Agreement for aggregate net proceeds of $121.7 million.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, stock options to purchase 1,723,626 shares of common stock were exercised for aggregate net proceeds to us of $9.9 million. During the nine months ended September 30, 2019, stock options to purchase 33,594 shares of common stock were exercised for aggregate net proceeds of $92,000.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had an accumulated deficit of $881.9 million. We expect to continue to operate at a loss for some time. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. If these activities are successful and if we receive approval from the FDA to market any of our DNA </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vaccines, DNA immunotherapies or dMAB product candidates, then we will need to raise additional funding to market and sell the approved vaccine products and equipment. We cannot predict the outcome of the above matters at this time. We are evaluating potential collaborations as an additional way to fund operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months from the date this Quarterly Report is filed.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_133"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk represents the risk of loss that may impact our consolidated financial position, results of operations or cash flows due to adverse changes in financial and commodity market prices and rates. We are exposed to market risk primarily in the area of changes in United States interest rates and conditions in the credit markets, and the recent fluctuations in interest rates and availability of funding in the credit markets primarily impact the performance of our investments. We do not have any material foreign currency or other derivative financial instruments. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities.  Due to the short-term maturities of our cash equivalents and the low risk profile of our investments at September&#160;30, 2020, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on our indebtedness, consisting of the Notes and Bonds, is fixed and not subject to fluctuations in interest rates.</span></div><div><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment in affiliated entity at September 30, 2020 represents our ownership interest in the Korean-based company PLS. We report this investment at fair value on the condensed consolidated balance sheet using the closing price of PLS shares of common stock as reported on the date of determination on the Korea New Exchange Market.</span></div><div style="margin-top:14pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and most transactions during the nine months ended September 30, 2020 were made in United States dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations, with the exception of the sale of our investment in GeneOne, which was denominated in South Korean Won, the issuance of the August 2019 and December 2019 Bonds, which were and are denominated in South Korean Won, and the valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars. We do not have any foreign currency hedging instruments in place. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_136"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_7">Table of Contents</a></span></div></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation carried out as of the end of the period covered by this Quarterly Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of September&#160;30, 2020 at the reasonable assurance level. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting that occurred during the quarter ended September&#160;30, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_142"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Securities Litigation</span></div><div style="margin-top:5.2pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;12, 2020, a purported shareholder class action complaint,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the United States District Court for the Eastern District of Pennsylvania, naming us and J. Joseph Kim, our Chief Executive Officer, as defendants. The lawsuit alleges that we made materially false and misleading statements regarding our development of a vaccine for&#160;COVID-19 in our public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On June 18, 2020, the court appointed Manuel Williams to serve as lead plaintiff.&#160;On August 3, 2020, the plaintiff filed a consolidated complaint, naming us and three of our officers as defendants. On September 21, 2020, the plaintiff filed his first amended complaint, naming us and three of our officers as defendants. Defendants will file a motion to dismiss plaintiff&#8217;s first amended complaint on November 5, 2020.</span></div><div style="margin-top:5.2pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Behesti v. Kim, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses our board of directors of failing to exercise reasonable and prudent supervision over our management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of us as well as governance reforms. On June 5, 2020, the court stayed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beheshti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay.</span></div><div style="margin-top:5pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 12 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isman v. Benito</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Devarakonda et al. v Kim, et. al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160; The complaints assert substantially similar claims as the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beheshti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action and name our current directors as defendants.&#160;The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Devarakonda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint also names one of our former directors as a defendant.&#160; On July 21, 2020, the court consolidated the three derivative cases under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Inovio Pharmaceuticals, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160; The consolidated action is stayed pending resolution of a forthcoming motion to dismiss the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">McDermid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> securities class action or until any party provides notice that they no longer consent to the stay.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 7, 2020, a fourth shareholder derivative complaint, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fettig v. Kim et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The complaint asserts substantially similar claims as those in the consolidated derivative action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to defend these actions vigorously.</span></div><div style="margin-top:5.2pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">VGXI Litigation </span></div><div style="margin-top:5pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 3, 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI.  On June 3, 2020, we filed a petition for preliminary injunction, which was denied on June 25, 2020.  On June 26, 2020, we filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.  </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> On July 7, 2020, VGXI filed an answer, new matter and counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment.  The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us.  Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, we filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.  </span></div><div style="margin-top:5pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims.  </span></div><div style="margin-top:5pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_145"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;  RISK FACTORS</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to numerous risks. You should carefully consider and evaluate each of the following factors as well as the other information in this Quarterly Report on Form&#160;10-Q, including our financial statements and the related notes, the risk factors discussed in our 2019 Annual Report, which we filed with the SEC on March 12, 2020 in evaluating our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">business and prospects. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impair our business operations. If any of the following risks actually occur, our business and financial results could be harmed. In that case, the trading price of our common stock could decline. You should also consider the more detailed description of our business contained in our 2019 Annual Report. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus, since named SARS-CoV-2, causing the disease known as COVID-19, was reported in China. Since then, COVID-19 has spread globally, resulting in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a &#8220;pandemic&#8221; in March 2020 and United States also declaring a national emergency. In response to the COVID-19 pandemic, a number of governmental orders and other public health guidance measures have been implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines could be negatively affected by COVID-19, which could then materially and adversely affect our business, financial condition and results of operations. Further, we have implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. Business travel has been suspended, and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission. Our increased reliance on personnel working from home may negatively impact our productivity, or could disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories could be delayed.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as local jurisdictions continue to put restrictions in place, our ability to continue to conduct and enroll patients in our clinical trials, manufacture our product candidates and pursue collaborations may also be limited. Such events may result in a period of business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, could also affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has resulted in significant disruption of global financial markets, which could reduce our ability to access capital, including a potential secondary listing of our equity securities on the KOSDAQ Market of the Korea Exchange. Although we have raised a substantial sum of funds from the sale of our common stock in the public markets in 2020, there can be no guarantee that we will be able to continue to so, which could negative affect our future liquidity. In addition, if a global economic recession results following the spread of COVID-19, its impact could materially affect our business and the value of our common stock.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continued spread of COVID-19 globally has and could continue to adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. For example, COVID-19 has adversely impacted the timeline for data collection for our VGX-3100 program. An increasing number of trial participants are either not able or do not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for this trial. These concerns are magnified by increasing COVID-19 infection rates, surges in cases globally, and lockdowns now occurring in Europe. As a result, it is taking longer than anticipated to complete the data collection process. Further, the COVID-19 outbreak could result in delays in our clinical trials due to prioritization of hospital resources toward the outbreak, restrictions in travel, potential unwillingness of patients to enroll in trials, patients withdrawing from trials following enrollment as a result of contracting COVID-19 or other health conditions, or the inability of patients to comply with clinical trial protocols as quarantines and travel restrictions impede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. These restrictions may delay the conduct of multiple clinical trials including our Phase 1 through 3 clinical trials.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, COVID-19 may also result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees, and refusals to accept data from clinical trials conducted in these affected geographies.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global outbreak of COVID-19 continues to rapidly evolve. The extent to which COVID-19 may impact our business, operations and clinical trials will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, the effectiveness of actions taken in the United States and other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">countries to contain and treat the disease and whether the United States and additional countries are required to move to complete lock-down status. The ultimate long-term impact of COVID-19 is highly uncertain and cannot be predicted with confidence.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred losses since inception, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant operating losses to date; as of September&#160;30, 2020, our accumulated deficit was approximately $881.9 million. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA vaccine, DNA immunotherapy and dMAB product candidates or electroporation-based synthetic vaccine delivery technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, during 2020, numerous purported shareholder class action complaints have been filed against us, naming us and our directors and executive officers as defendants, and alleging that we made materially false and misleading statements regarding the development of our INO-4800 vaccine candidate against COVID-19 in violation of certain federal securities laws. We may also become party to litigation with third parties as a result of our business activities. For example, in June 2020 we filed a lawsuit against VGXI, one of our contract manufacturers, seeking to compel VGXI to facilitate the transfer of manufacturing methods, using VGXI&#8217;s technology, which would for the large-scale manufacture of INO-4800 by other third-party contract manufacturers that we have engaged and are seeking to engage. In July 2020, VGXI filed a counterclaim against us alleging that we had breached our contract with them, among other claims. Even though we intend to vigorously defend ourselves in the shareholder class action and the litigation with VGXI, there can be no assurance that we will ultimately prevail. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our consolidated financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sources of revenue and our success is dependent on our ability to develop our DNA vaccines, DNA immunotherapies, dMAB and electroporation equipment. </span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not sell any products and may not have any other products commercially available for several years, if at all. Our ability to generate future revenues depends heavily on our success in: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">developing and securing United States and/or foreign regulatory approvals for our product candidates, including securing regulatory approval for conducting clinical trials with product candidates; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">developing our electroporation-based DNA delivery technology; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our electroporation equipment and product candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our electroporation equipment and product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of electroporation equipment and products, and we may not be able to continue our operations. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">None of our human vaccine candidates, including INO-4800, or our immunotherapy and DNA encoded monoclonal antibody product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or monoclonal antibody products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human vaccine programs, which includes our COVID-19 vaccine candidate INO-4800, and our immunotherapy programs and our DNA encoded monoclonal antibodies program are in various stages of research and development, and currently include product candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of synthetic vaccine candidates and immunotherapy candidates compared with conventional vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our vaccine product candidates, including INO-4800. The success of our efforts to develop and commercialize our product candidates, including INO-4800, could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our product candidates could be found to be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. The ability to manufacture sufficient quantities of a COVID-19 vaccine candidate, like INO-4800, on a large scale is particularly challenging and will require substantial resources and the engagement of third parties, which we may not be able to obtain on a timely basis, or at all</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our substantial indebtedness could limit the cash flow available for our operations and could expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we sold $78.5 million aggregate principal amount of 6.50% convertible senior notes due 2024, or the Notes, as well as $4.1 million aggregate principal amount of 1.0% convertible bonds due December 2024, or the December 2019 Bonds.  We also sold $15.0 million of convertible bonds in August 2019 which we fully converted into shares of our common stock in August 2020. A portion of the Notes were also converted into shares of our common stock in July 2020 and October 2020, although the substantial majority of the Notes remain outstanding as of the date of this report. We may incur additional indebtedness to meet our future financing needs. Our existing indebtedness and potential future indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">increasing our vulnerability to adverse economic and industry conditions;</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">limiting our ability to obtain additional financing;</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">limiting our flexibility to plan for, or react to, changes in our business;</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">diluting the interests of our existing stockholders if we issue additional shares of our common stock upon conversion of any convertible debt, such as the Notes and the December 2019 Bonds, in accordance with their respective terms; and</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under the Notes and the December 2019 Bonds and any additional indebtedness that we may incur. In addition, our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The conditional conversion features of the Notes, if triggered, may adversely affect our financial condition, operating results, or liquidity.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the conditional conversion feature of the Notes is triggered, holders of the Notes will be entitled to convert their Notes into shares of our common stock at any time during specified periods at their option. If one or more of the holders of the Notes elects to convert their Notes, unless we satisfy our conversion obligation by delivering only shares of our common stock, we would be required to settle all or a portion of our conversion obligation through the payment of cash, which could adversely affect our liquidity. The conditional convertibility of the Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of the Notes and/or the December 2019 Bonds will dilute the ownership interest of existing stockholders, and may otherwise depress the price of our common stock.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion of some or all of the Notes and/or December 2019 Bonds will dilute the ownership interests of existing stockholders to the extent we deliver shares of our common stock upon conversion of any of the Notes. The Notes may become in the future convertible at the option of the holders of the Notes prior to November 1, 2023 under certain circumstances as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided in the indenture governing the Notes. The December 2019 Bonds may become in the future convertible at the option of the holders of the December 2019 Bonds starting December 31, 2020. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress the price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to develop our DNA vaccine, DNA immunotherapy and dMAB programs and electroporation delivery technology.</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our product candidates and delivery technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the progress of our current and new product development programs; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the progress, scope and results of our pre-clinical and clinical testing; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the time and cost involved in obtaining regulatory approvals; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the cost of manufacturing our products and product candidates; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div><div style="padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:12.25pt">debt service obligations on the Notes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> and the December 2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Bonds;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">competing technological and market developments; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our ability and costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility and turmoil, particularly in light of the COVID-19 pandemic, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through the sale of equity securities, as we have done in 2020 through our &#8220;at-the-market&#8221; sales agreement, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Fluctuating interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and product candidates. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense and increasing competition and many of our competitors have significantly greater resources and experience. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our products, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive, or result in treatments or cures superior to ours.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many other companies are pursuing other forms of treatment or prevention for diseases that we target. For example, many of our competitors are working on developing and testing COVID-19 vaccines, cancer vaccines and immunotherapies, and several products such as the CAR-Ts developed by our competitors have been approved for human use. Our competitors and potential competitors include large pharmaceutical and more established biotechnology companies. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. Small companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive.</span></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our product candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to enter into agreements with other highly-regarded organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A small number of licensing partners and government contracts account for a substantial portion of our revenue. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and in the past we have derived, a significant portion of our revenue from a limited number of licensing partners and government grants and contracts. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with government agencies, which are subject to termination and uncertain future funding. </span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with government agencies, such as the NIAID, DARPA and the DoD, and we intend to continue entering into these types of agreements in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">variations in the level of expenses related to our electroporation equipment, product candidates or future development programs; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">expenses related to corporate transactions, including ones not fully completed; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">addition or termination of clinical trials or funding support; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">any intellectual property infringement lawsuit in which we may become involved; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">any legal claims that may be asserted against us or any of our officers; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">regulatory developments affecting our electroporation equipment and product candidates or those of our competitors; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">debt service obligations on the Notes and the December 2019 Bonds;</span></div><div style="padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:12.25pt">changes in the fair value of our investments, including investments in affiliated entities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">if any of our products receives regulatory approval, the levels of underlying demand for our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain FDA approval of our products, we will not be able to commercialize them in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our electroporation equipment and product candidates in the United States. If we fail to obtain FDA approval to market our electroporation equipment and product candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our products as well as the evaluation of our manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our electroporation equipment and product candidates are both safe and effective for each indication for which approval is sought. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our electroporation equipment and any of our product candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our electroporation equipment and product candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our products or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our products may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products could fail to complete the clinical trial process for many reasons, including the following:</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our electroporation equipment or product candidate is safe and effective for any indication; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">we may be unable to demonstrate that our electroporation equipment or product candidate's clinical and other benefits outweigh its safety risks; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">we may be unable to demonstrate that our electroporation equipment or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of us or third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the QSR or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in the commencement or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">obtaining regulatory approval to commence a clinical trial; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">adverse results from third party clinical trials involving gene-based therapies and the regulatory response thereto; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">future bans or stricter standards imposed on clinical trials of gene-based therapy; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">manufacturing sufficient quantities of our electroporation equipment and product candidates for use in clinical trials; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">collecting, reviewing and analyzing our clinical trial data; and</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">global unrest, global pathogen outbreaks or pandemics, terrorist activities, and economic and other external factors.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described elsewhere in this report, our planned clinical development of INO-4800 as a potential COVID-19 vaccine has been placed on partial clinical hold by the FDA. We may not commence our planned Phase 2/3 clinical trial of INO-4800 until we satisfactorily resolve the FDA&#8217;s questions regarding the trial. There can be no assurance that we will be successful in obtaining FDA approval to proceed.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">unforeseen safety issues; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">lack of adequate funding to continue the clinical trial. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect the trading price of our common stock. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our electroporation equipment and product candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our product candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if United States regulatory approval is obtained, the FDA may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">issue Warning Letters or untitled letters; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">impose civil or criminal penalties; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">suspend regulatory approval; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">suspend any ongoing clinical trials; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">refuse to approve pending applications or supplements to applications filed by us; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">seize or detain products or require us to initiate a product recall. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any electroporation equipment and product candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our electroporation equipment and DNA vaccine, DNA immunotherapy and dMAB candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">decreased demand for our product candidates; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">impairment of our business reputation; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">costs of related litigation; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">distraction of management's attention from our primary business; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">substantial monetary awards to patients or other claimants; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">loss of revenues; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">inability to commercialize our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have a sales organization for the marketing, sales and distribution of our electroporation equipment and product candidates. In order to commercialize any products, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of our own sales force to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In addition, we may have little or no control over the sales efforts of third parties involved in our commercialization efforts. In the event we are unable to develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our product candidates which would negatively impact our ability to generate product revenues. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our products for which we receive regulatory approval does not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our electroporation equipment and product candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our ability to provide acceptable evidence of safety and efficacy; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the relative convenience and ease of administration; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the prevalence and severity of any actual or perceived adverse side effects; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">availability of alternative treatments; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">pricing and cost effectiveness; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our electroporation equipment and product candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our product candidates, could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our electroporation equipment and product candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that drug products have been approved for marketing by the FDA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our product candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our product candidates or procedures using our product candidates, could reduce physician utilization of our products once approved.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably.&#160;In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA.   Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposed an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, although the effective rate paid may be lower. Under the Consolidated Appropriations Act of 2016, the excise tax was suspended through December&#160;31, 2017, and under the continuing resolution on appropriations for fiscal year 2018, or 2018 Appropriations Resolution, signed by President Trump on January&#160;22, 2018, was further suspended through December&#160;31, 2019;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded the entities eligible for discounts under the Public Health program;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a licensure framework for follow on biologic products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance and delaying the implementation of certain ACA-mandated fees. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2027 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, the Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. On January 31, 2019, the U.S. Department of Health and Human Services, Office of Inspector General, proposed modifications to the federal healthcare program Anti-Kickback Statute discount safe harbor for the purpose of reducing the cost of drug products to consumers which, among other things, if finalized, will affect discounts paid by manufacturers to Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these organizations. While some of these and other proposed measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our ability to set a price we believe is fair for our products; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our ability to generate revenues and achieve or maintain profitability; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the availability of capital; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our ability to obtain timely approval of our products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the Physician Payments Sunshine Act, created under the ACA, which requires pharmaceutical companies to record any transfers of value made to doctors and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members, and to annually report such data to CMS;</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and the contract manufacturers upon whom we rely fail to produce our electroporation devices and product candidates in the volumes that we require on a timely basis, or at all, or fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture some components of our electroporation devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our product candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our product candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and product candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our electroporation equipment to our partners and to supply product candidates for clinical trials or to commercially launch a product would be jeopardized. For example, we have in the past relied on VGXI to manufacture DNA plasmids for our product candidates, including our COVID-19 vaccine candidate INO-4800. Due to the urgency of the COVID-19 pandemic, we previously announced our goal of having up to one million doses of INO-4800 available by the end of 2020. VGXI notified us that they would be unable to produce the necessary plasmids to meet this timeline due to a lack of manufacturing capacity. As a result, we have sought to engage additional third-party contract manufacturers to support the large-scale manufacturing of INO-4800. However, there can be no assurance that we will be able to secure this additional manufacturing capacity on commercially reasonable terms, if at all. In addition, VGXI has to date refused to permit the transfer of its proprietary methods and technology to third parties for the potential manufacture of INO-4800, something we believe VGXI is contractually obligated to do under our agreement with them. If we are unable to compel VGXI to provide the requested manufacturing methods, it could impair our ability to effectively engage additional third-party manufacturers or could delay the expected timeline for manufacturing sufficient quantities of INO-4800, either of which would adversely affect our commercialization plans and could also harm our reputation.    </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any delay or interruption in the supply of clinical trial supplies for INO-4800 or any of our other product candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">exposure to unknown liabilities; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">higher than expected acquisition and integration costs; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">increased amortization expenses; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, including COVID-19, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption in or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential information, and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. A significant breakdown, invasion, corruption, destruction or interruption of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices. We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. While we have invested in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Tax Cuts and Jobs Act of 2017 was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code.&#160;The new federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions).&#160;Notwithstanding the reduction in the corporate income tax rate, the overall impact of the federal tax law is uncertain and our business and financial condition could be adversely affected.&#160;In addition, it is uncertain if and to what extent various states will conform to the federal tax law.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could hinder our ability to hire and retain key leadership and other personnel, or otherwise prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our electroporation equipment and product candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">pending patent applications may not result in issued patents; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">we may not develop or acquire additional proprietary technologies that are patentable; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our trademarks may be invalid or subject to a third party's prior use; or </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Global Select Market, we cannot assure you that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock may be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price may be highly volatile and can be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations, particularly developments concerning the prospects of INO-4800 as a potential vaccine candidate against COVID-19;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">fluctuating public or scientific interest in the potential for COVID-19 and other pandemic or other applications for our vaccine or other product candidates; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">fluctuations in our operating results; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">announcements of technological innovations; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">new products or services that we or our competitors offer; </span></div><div style="padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:12.25pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">regulatory developments in the United States and other countries; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">negative perception of gene-based therapy; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">additions or departures of key personnel; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">sales or other transactions involving our common stock; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">changes in our capital structure;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">sales or other transactions by executive officers or directors involving our common stock; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">changes in accounting principles; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">global unrest, terrorist activities, and economic and other external factors; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">catastrophic weather and/or global disease pandemics, such as the recent COVID-19 outbreak. </span></div><div style="margin-top:9.5pt;padding-right:15.75pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general has recently experienced relatively large price and volume fluctuations, particularly in response to the COVID-19 outbreak during 2020. In particular, the market prices of securities of smaller biotechnology and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9.5pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the elimination of cumulative voting. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_148"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In July 2020, certain holders of the Notes converted principal amount of $19.1 million into an aggregate of 3,546,074 shares of our common stock. </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In August 2020, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">the August 2019 Bonds were fully converted into 4,962,364 shares of our common stock.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Each of the foregoing issuances of shares of common stock were made in reliance upon the exemption set forth in Section 3(a)(9) of the Securities Act of 1933, as amended, for securities exchanged by the registrant and existing security holders where no commission or other remuneration is paid or given directly or indirectly by the registrant for soliciting such exchange.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_151"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_154"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_157"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_160"></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7b394cbbe15e40f4bfcebd7425a65725_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-93020x10qex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-93020x10qex311.htm">Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-93020x10qex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-93020x10qex312.htm">Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-93020x10qex321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-93020x10qex321.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.&#160;Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).*</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This exhibit shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. </span></div><div style="margin-top:7.5pt;padding-left:11.25pt;text-indent:-11.25pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i7b394cbbe15e40f4bfcebd7425a65725_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J. JOSEPH KIM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">J. Joseph Kim</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                                                                                         (On Behalf of the Registrant)</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER KIES&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter Kies </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer                                                                         (Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ino-93020x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i290f6e63f57b4a7ca5bb4b530127bd7a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, J. Joseph Kim, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:5pt;margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;J. J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OSEPH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">J. Joseph Kim</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                       (Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ino-93020x10qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i98cd4f4400ef4b1590291741d3fbcd18_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Kies, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="margin-top:9pt;padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer                                                                    (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ino-93020x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iff667a7dbc6144dd826f758570811b6c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ending September&#160;30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;J. J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OSEPH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">J. Joseph Kim</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and is not filed with the Securities and Exchange Commission as part of the Form&#160;10-Q or as a separate disclosure document and is not incorporated by reference into any filing of Inovio Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ino-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:124dcabe-323e-4d00-a29d-21ddeb618d02,g:528b4586-6faf-4a31-a887-4db858d575b9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.inovio.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandOperations" roleURI="http://www.inovio.com/role/OrganizationandOperations">
        <link:definition>2101101 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertainties" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties">
        <link:definition>2102102 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies">
        <link:definition>2203201 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesDetails" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails">
        <link:definition>2404401 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CriticalAccountingPolicies" roleURI="http://www.inovio.com/role/CriticalAccountingPolicies">
        <link:definition>2105103 - Disclosure - Critical Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CriticalAccountingPoliciesDetails" roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails">
        <link:definition>2406402 - Disclosure - Critical Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpactofRecentlyIssuedAccountingStandards" roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards">
        <link:definition>2107104 - Disclosure - Impact of Recently Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.inovio.com/role/RevenueRecognition">
        <link:definition>2108105 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>2409403 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestments" roleURI="http://www.inovio.com/role/ShorttermInvestments">
        <link:definition>2110106 - Disclosure - Short-term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsTables" roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables">
        <link:definition>2311301 - Disclosure - Short-term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsNarrativeDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails">
        <link:definition>2412404 - Disclosure - Short-term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails">
        <link:definition>2413405 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.inovio.com/role/FairValueMeasurements">
        <link:definition>2114107 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.inovio.com/role/FairValueMeasurementsTables">
        <link:definition>2315302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2416406 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2417407 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails">
        <link:definition>2418408 - Disclosure - Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets">
        <link:definition>2119108 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2320303 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails">
        <link:definition>2421409 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>2422410 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>2123109 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtTables" roleURI="http://www.inovio.com/role/ConvertibleDebtTables">
        <link:definition>2324304 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNarrativeDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails">
        <link:definition>2425411 - Disclosure - Convertible Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails">
        <link:definition>2426412 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtScheduleofMaturitiesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails">
        <link:definition>2427413 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>2128110 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>2329305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails">
        <link:definition>2430414 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2431415 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShare" roleURI="http://www.inovio.com/role/NetIncomeLossPerShare">
        <link:definition>2132111 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.inovio.com/role/NetLossPerShareTables">
        <link:definition>2333306 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails" roleURI="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails">
        <link:definition>2434416 - Disclosure - Net Income (Loss) Per Share - Schedule of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails" roleURI="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails">
        <link:definition>2435417 - Disclosure - Net Income (Loss) Per Share - Schedule of Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.inovio.com/role/StockBasedCompensation">
        <link:definition>2136112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.inovio.com/role/StockBasedCompensationTables">
        <link:definition>2337307 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationDetails">
        <link:definition>2438418 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>2139113 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>2440419 - Disclosure - Related Party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.inovio.com/role/Leases">
        <link:definition>2141114 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.inovio.com/role/LeasesTables">
        <link:definition>2342308 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.inovio.com/role/LeasesNarrativeDetails">
        <link:definition>2443420 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofFutureMinimumLeasePaymentsDetails" roleURI="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails">
        <link:definition>2444421 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>2145115 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>2446422 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>2147116 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>2148117 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncTables" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables">
        <link:definition>2349309 - Disclosure - Geneos Therapeutics, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncNarrativeDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails">
        <link:definition>2450423 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncDeconsolidationAccountingDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails">
        <link:definition>2451424 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncInvestmentInGeneosDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails">
        <link:definition>2452425 - Disclosure - Geneos Therapeutics, Inc. - Investment In Geneos (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncFairValueAssumptionsDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails">
        <link:definition>2453426 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncPreferredstockInvestmentDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails">
        <link:definition>2454427 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.inovio.com/role/SubsequentEvents">
        <link:definition>2155118 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.inovio.com/role/SubsequentEventsDetails">
        <link:definition>2456428 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" abstract="false" name="ContractWithCustomerLiabilityAffiliatedEntityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleDebtConvertedAmount" abstract="false" name="DebtInstrumentConvertibleDebtConvertedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OtherCounterpartyMember" abstract="true" name="OtherCounterpartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" abstract="false" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2016IncentivePlanMember" abstract="true" name="A2016IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesMember" abstract="true" name="PlumblineLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DebtInstrumentAccruedInterest" abstract="false" name="DebtInstrumentAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GeneOneLifeSciencesMember" abstract="true" name="GeneOneLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_VGXAnimalHealthIncMember" abstract="true" name="VGXAnimalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_BiojectMember" abstract="true" name="BiojectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" abstract="false" name="CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedAmount" abstract="false" name="CollaborativeAgreementAwardedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" abstract="false" name="NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NumberOfAdditionalProducts" abstract="false" name="NumberOfAdditionalProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" abstract="false" name="SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" abstract="false" name="IncreaseDecreaseInDeferredRevenueFromRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateNoncurrent" abstract="false" name="DeferredGrantFundingFromAffiliateNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ApolloBioMember" abstract="true" name="ApolloBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DepartmentOfDefenceMember" abstract="true" name="DepartmentOfDefenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_SalesAgreementsMember" abstract="true" name="SalesAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_INO4800Member" abstract="true" name="INO4800Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementCorporateIncomeTax" abstract="false" name="CollaborativeAgreementCorporateIncomeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleInternalRateOfReturn" abstract="false" name="DebtInstrumentConvertibleInternalRateOfReturn" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ino_LassaFeverAndMERSVaccineMember" abstract="true" name="LassaFeverAndMERSVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_RelatedPartyTransactionsTextualAbstract" abstract="true" name="RelatedPartyTransactionsTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_AfterJuly22020ConversionPriceMember" abstract="true" name="AfterJuly22020ConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_PriorSalesAgreementMember" abstract="true" name="PriorSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_AlternativeInvestmentMeasurementInputTerm" abstract="false" name="AlternativeInvestmentMeasurementInputTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_DebtInstrumentAccretionOfPremium" abstract="false" name="DebtInstrumentAccretionOfPremium" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SanDiegoOfficeMember" abstract="true" name="SanDiegoOfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementForeignNonIncomeTaxes" abstract="false" name="CollaborativeAgreementForeignNonIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EquityMethodInvestmentEnterpriseValue" abstract="false" name="EquityMethodInvestmentEnterpriseValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_WorkingCapitalExcludingCash" abstract="false" name="WorkingCapitalExcludingCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LicensewithAffiliatedEntitiesMember" abstract="true" name="LicensewithAffiliatedEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsNet" abstract="false" name="GoodwillAndIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NewSalesAgreementMember" abstract="true" name="NewSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementAdvisoryFees" abstract="false" name="CollaborativeAgreementAdvisoryFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" abstract="false" name="DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ino_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateCurrent" abstract="false" name="DeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ConvertibleBondsMember" abstract="true" name="ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" abstract="false" name="StockPurchaseAgreementCommitmentOfAdditionalInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" abstract="false" name="TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingReceived" abstract="false" name="CollaborativeAgreementFundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliate" abstract="false" name="DeferredGrantFundingFromAffiliate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_InovioAsMember" abstract="true" name="InovioAsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_VgxPharmaceuticalsMember" abstract="true" name="VgxPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" abstract="false" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" abstract="false" name="CollaborativeAgreementPeriodFromEffectiveDateForTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_GrantPolicyPolicyTextBlock" abstract="false" name="GrantPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ino_StockSalesAgreementRemainingAuthorizedAmount" abstract="false" name="StockSalesAgreementRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" abstract="true" name="MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlymouthMeetingPennsylvaniaMember" abstract="true" name="PlymouthMeetingPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_December2019ConvertibleBondsMember" abstract="true" name="December2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_GeneosTherapeuticsInc.Member" abstract="true" name="GeneosTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" abstract="false" name="CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" abstract="false" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementExpensesToReimburse" abstract="false" name="CollaborativeAgreementExpensesToReimburse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CELLECTRA2000DeviceMember" abstract="true" name="CELLECTRA2000DeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_InitialConversionPriceMember" abstract="true" name="InitialConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" abstract="false" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" abstract="false" name="CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsGross" abstract="false" name="GoodwillAndIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_InvestmentOwnedAdditionalSharesAcquired" abstract="false" name="InvestmentOwnedAdditionalSharesAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLeaseNonCashLeaseExpense" abstract="false" name="OperatingLeaseNonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementTerritoryExpansionOptionPeriod" abstract="false" name="CollaborationAgreementTerritoryExpansionOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" abstract="false" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" abstract="false" name="InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" abstract="true" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" abstract="false" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_August2019ConvertibleBondsMember" abstract="true" name="August2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_ProceedsFromCollaborativeAgreement" abstract="false" name="ProceedsFromCollaborativeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2007IncentivePlanMember" abstract="true" name="A2007IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementRoyaltyPeriod" abstract="false" name="CollaborationAgreementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CELLECTRA3PSPProprietarySmartDeviceMember" abstract="true" name="CELLECTRA3PSPProprietarySmartDeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" abstract="false" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_A6.50ConvertibleSeniorNotesDue2024Member" abstract="true" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborativeArrangementFixedPriceContractAmountAwarded" abstract="false" name="CollaborativeArrangementFixedPriceContractAmountAwarded" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_MilestoneBasedOwnershipTarget" abstract="false" name="MilestoneBasedOwnershipTarget" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ino_CoalitionforEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_StockSalesAgreementAgentFee" abstract="false" name="StockSalesAgreementAgentFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" abstract="false" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_GrantProceedsReceived" abstract="false" name="GrantProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingToBeReceived" abstract="false" name="CollaborativeAgreementFundingToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" abstract="false" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementWeightedAveragePricePerShare" abstract="false" name="StockSaleAgreementWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" abstract="false" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="ino_SARSCoV2COVID19VaccineMember" abstract="true" name="SARSCoV2COVID19VaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ino-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:124dcabe-323e-4d00-a29d-21ddeb618d02,g:528b4586-6faf-4a31-a887-4db858d575b9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a15f8865-7325-4f60-aba5-1e6bee64bddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d7e187e0-dc70-4f4d-bdc9-85a08308a665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a15f8865-7325-4f60-aba5-1e6bee64bddd" xlink:to="loc_us-gaap_Liabilities_d7e187e0-dc70-4f4d-bdc9-85a08308a665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_419447e5-2c53-4335-bc1a-07cc085bf4fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a15f8865-7325-4f60-aba5-1e6bee64bddd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_419447e5-2c53-4335-bc1a-07cc085bf4fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a8834b7-e308-49fe-ab6b-f0211db02f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b2dcbbe7-6aed-4af5-93c3-286134a4ab95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1a8834b7-e308-49fe-ab6b-f0211db02f76" xlink:to="loc_us-gaap_PreferredStockValue_b2dcbbe7-6aed-4af5-93c3-286134a4ab95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_74c43a58-760f-454b-9f86-02ddc6445395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1a8834b7-e308-49fe-ab6b-f0211db02f76" xlink:to="loc_us-gaap_CommonStockValue_74c43a58-760f-454b-9f86-02ddc6445395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_271bec9e-e1bc-4fa7-b884-bb7bc099fb34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1a8834b7-e308-49fe-ab6b-f0211db02f76" xlink:to="loc_us-gaap_AdditionalPaidInCapital_271bec9e-e1bc-4fa7-b884-bb7bc099fb34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3a696a6c-c57e-46e1-bfeb-e47671b31460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1a8834b7-e308-49fe-ab6b-f0211db02f76" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3a696a6c-c57e-46e1-bfeb-e47671b31460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_441c5675-888d-4764-8fde-45767386fdb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1a8834b7-e308-49fe-ab6b-f0211db02f76" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_441c5675-888d-4764-8fde-45767386fdb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_312a135c-3a0a-4951-bb55-fbb3d210c895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c3d72f33-c2b1-4f71-a481-b5b863c8cda8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_312a135c-3a0a-4951-bb55-fbb3d210c895" xlink:to="loc_us-gaap_LiabilitiesCurrent_c3d72f33-c2b1-4f71-a481-b5b863c8cda8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9c310aeb-e444-4391-bde2-016501eda071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_312a135c-3a0a-4951-bb55-fbb3d210c895" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9c310aeb-e444-4391-bde2-016501eda071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_d567ab7c-cfcd-4b2a-9140-677c646db731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_312a135c-3a0a-4951-bb55-fbb3d210c895" xlink:to="loc_us-gaap_ConvertibleDebt_d567ab7c-cfcd-4b2a-9140-677c646db731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_08756e68-6ff8-468a-9a65-5f532074278f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_312a135c-3a0a-4951-bb55-fbb3d210c895" xlink:to="loc_us-gaap_DerivativeLiabilities_08756e68-6ff8-468a-9a65-5f532074278f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b21dfbdc-966d-4b99-9640-aa634df8e277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_312a135c-3a0a-4951-bb55-fbb3d210c895" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b21dfbdc-966d-4b99-9640-aa634df8e277" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0010e3a6-261c-4757-8b22-5ab2c033aa00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_312a135c-3a0a-4951-bb55-fbb3d210c895" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0010e3a6-261c-4757-8b22-5ab2c033aa00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_548fe0fb-fd50-4ac1-9d09-8697d3db1b24" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_312a135c-3a0a-4951-bb55-fbb3d210c895" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_548fe0fb-fd50-4ac1-9d09-8697d3db1b24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_22e82306-3f48-40f5-925f-b39e4ec9af8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_312a135c-3a0a-4951-bb55-fbb3d210c895" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_22e82306-3f48-40f5-925f-b39e4ec9af8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee90c9f2-41cd-4246-bae3-ba9d54eb67c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_28aa3077-e926-42be-b1cb-f0295d378202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee90c9f2-41cd-4246-bae3-ba9d54eb67c7" xlink:to="loc_us-gaap_StockholdersEquity_28aa3077-e926-42be-b1cb-f0295d378202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_11fac027-e2d9-46ee-b55d-3a697826088f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee90c9f2-41cd-4246-bae3-ba9d54eb67c7" xlink:to="loc_us-gaap_MinorityInterest_11fac027-e2d9-46ee-b55d-3a697826088f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1bb3ac7e-509b-4d43-a470-ea34afd461c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a88e6741-c500-4b4a-be26-6e537561ae7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1bb3ac7e-509b-4d43-a470-ea34afd461c5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a88e6741-c500-4b4a-be26-6e537561ae7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_5ba7b60b-2301-442c-968f-022cea0f5424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1bb3ac7e-509b-4d43-a470-ea34afd461c5" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_5ba7b60b-2301-442c-968f-022cea0f5424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_0ee78ea0-273f-494c-844d-445509af0d02" xlink:href="ino-20200930.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1bb3ac7e-509b-4d43-a470-ea34afd461c5" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_0ee78ea0-273f-494c-844d-445509af0d02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_247e3e0c-f404-4e66-82d8-a2f8e5d10aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1bb3ac7e-509b-4d43-a470-ea34afd461c5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_247e3e0c-f404-4e66-82d8-a2f8e5d10aea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_48750afa-a4c9-426e-8b77-1dc87db565dd" xlink:href="ino-20200930.xsd#ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1bb3ac7e-509b-4d43-a470-ea34afd461c5" xlink:to="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_48750afa-a4c9-426e-8b77-1dc87db565dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e5ebc22d-c2f1-4ab1-a667-5a614ada7aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1bb3ac7e-509b-4d43-a470-ea34afd461c5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e5ebc22d-c2f1-4ab1-a667-5a614ada7aa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_fa046738-9624-43d1-95dc-c87d16c04a45" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1bb3ac7e-509b-4d43-a470-ea34afd461c5" xlink:to="loc_ino_DeferredGrantFundingCurrent_fa046738-9624-43d1-95dc-c87d16c04a45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_1bfd1026-9e7c-4adb-8b6a-a56aedf34326" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1bb3ac7e-509b-4d43-a470-ea34afd461c5" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_1bfd1026-9e7c-4adb-8b6a-a56aedf34326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d78782dc-0972-4c99-963a-e732392abac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_777846ac-69f6-4f5e-9876-7350934c633e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d78782dc-0972-4c99-963a-e732392abac9" xlink:to="loc_us-gaap_AssetsCurrent_777846ac-69f6-4f5e-9876-7350934c633e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0978c275-8940-4072-9768-b837ed58129d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d78782dc-0972-4c99-963a-e732392abac9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0978c275-8940-4072-9768-b837ed58129d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_cc847d22-4390-43c4-a4a1-2d2ea649d2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d78782dc-0972-4c99-963a-e732392abac9" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_cc847d22-4390-43c4-a4a1-2d2ea649d2f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_dcf4bc5c-77b4-4330-b9ef-663266739e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d78782dc-0972-4c99-963a-e732392abac9" xlink:to="loc_us-gaap_EquityMethodInvestments_dcf4bc5c-77b4-4330-b9ef-663266739e91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2d7f87f1-3b10-4faa-be51-74a9691704c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d78782dc-0972-4c99-963a-e732392abac9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2d7f87f1-3b10-4faa-be51-74a9691704c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_179d7ed1-fdac-4a08-ab5e-4c8edf02f5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d78782dc-0972-4c99-963a-e732392abac9" xlink:to="loc_us-gaap_Goodwill_179d7ed1-fdac-4a08-ab5e-4c8edf02f5e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cdd1fe86-3387-42d1-bf20-5e95e20ce88e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d78782dc-0972-4c99-963a-e732392abac9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cdd1fe86-3387-42d1-bf20-5e95e20ce88e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b82dbce3-1c1d-4cb1-858e-3896f438f7c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d78782dc-0972-4c99-963a-e732392abac9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b82dbce3-1c1d-4cb1-858e-3896f438f7c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c0e3a0af-b7e3-4eb0-a0b3-3c2419557991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5df2cff4-ef53-4a24-86a8-3201b551f3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c0e3a0af-b7e3-4eb0-a0b3-3c2419557991" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5df2cff4-ef53-4a24-86a8-3201b551f3c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_11eafd30-b79d-448c-bf66-511f0c538f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c0e3a0af-b7e3-4eb0-a0b3-3c2419557991" xlink:to="loc_us-gaap_ShortTermInvestments_11eafd30-b79d-448c-bf66-511f0c538f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ce21f004-314d-4175-894b-8833e42c7570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c0e3a0af-b7e3-4eb0-a0b3-3c2419557991" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ce21f004-314d-4175-894b-8833e42c7570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_b0614b05-4a52-4ed2-80ab-342cd2521492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c0e3a0af-b7e3-4eb0-a0b3-3c2419557991" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_b0614b05-4a52-4ed2-80ab-342cd2521492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29c605c0-a97a-4438-8a2a-7dcad348d0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c0e3a0af-b7e3-4eb0-a0b3-3c2419557991" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29c605c0-a97a-4438-8a2a-7dcad348d0d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_012bc020-5874-4420-bfd9-25004037115e" xlink:href="ino-20200930.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c0e3a0af-b7e3-4eb0-a0b3-3c2419557991" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_012bc020-5874-4420-bfd9-25004037115e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_56ddd172-7b4e-44be-94b4-f2baed09df8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6fd99ef4-c880-47e6-bda5-65b10e99cab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_56ddd172-7b4e-44be-94b4-f2baed09df8e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6fd99ef4-c880-47e6-bda5-65b10e99cab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6b2ea3a3-f9a1-4d05-8036-c247bfdf84ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_56ddd172-7b4e-44be-94b4-f2baed09df8e" xlink:to="loc_us-gaap_OperatingExpenses_6b2ea3a3-f9a1-4d05-8036-c247bfdf84ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_78fc9a74-53f5-437e-96dd-961b69ffac31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ae3c5f5a-5a92-447c-bf69-dd39ef7c4db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_78fc9a74-53f5-437e-96dd-961b69ffac31" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ae3c5f5a-5a92-447c-bf69-dd39ef7c4db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_51912729-bb1b-4237-bd05-ed527e3909a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_78fc9a74-53f5-437e-96dd-961b69ffac31" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_51912729-bb1b-4237-bd05-ed527e3909a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51135a1c-ebf6-4590-b63e-21df5f9b05c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_be631250-054d-47f0-b705-10d2e4f429c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51135a1c-ebf6-4590-b63e-21df5f9b05c6" xlink:to="loc_us-gaap_OperatingIncomeLoss_be631250-054d-47f0-b705-10d2e4f429c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_c4851556-145d-41b6-baa1-6d829724e27f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51135a1c-ebf6-4590-b63e-21df5f9b05c6" xlink:to="loc_us-gaap_InterestIncomeOperating_c4851556-145d-41b6-baa1-6d829724e27f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e497509f-762f-4cef-b0cf-de9996fd0314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51135a1c-ebf6-4590-b63e-21df5f9b05c6" xlink:to="loc_us-gaap_InterestExpense_e497509f-762f-4cef-b0cf-de9996fd0314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_3a22e551-742e-4d5d-ad62-80cf8ea423d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51135a1c-ebf6-4590-b63e-21df5f9b05c6" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_3a22e551-742e-4d5d-ad62-80cf8ea423d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_93e8bfb9-e5c6-4182-b1a7-5702682edbdf" xlink:href="ino-20200930.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51135a1c-ebf6-4590-b63e-21df5f9b05c6" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_93e8bfb9-e5c6-4182-b1a7-5702682edbdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1dc43c2a-5688-44fd-a845-c4de3edbd0ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51135a1c-ebf6-4590-b63e-21df5f9b05c6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1dc43c2a-5688-44fd-a845-c4de3edbd0ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_dc7ef1fe-d590-4cbb-a4e8-7312cbe26034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51135a1c-ebf6-4590-b63e-21df5f9b05c6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_dc7ef1fe-d590-4cbb-a4e8-7312cbe26034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_7203a4e5-fda7-4570-a230-9e6a19ab2f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51135a1c-ebf6-4590-b63e-21df5f9b05c6" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_7203a4e5-fda7-4570-a230-9e6a19ab2f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a918d74a-e27a-4074-b950-7cceb5689793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51135a1c-ebf6-4590-b63e-21df5f9b05c6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a918d74a-e27a-4074-b950-7cceb5689793" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_58f452a9-7cc3-4cc6-887b-422c9b767f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_802058c3-2424-40c5-8415-fd738f4c654a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_58f452a9-7cc3-4cc6-887b-422c9b767f1c" xlink:to="loc_us-gaap_ProfitLoss_802058c3-2424-40c5-8415-fd738f4c654a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a0e21054-aa55-42db-868d-df819403dbf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_58f452a9-7cc3-4cc6-887b-422c9b767f1c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a0e21054-aa55-42db-868d-df819403dbf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_75e6943c-ab1e-4551-bb3d-a56918f4c467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e5c83137-83eb-4ed0-97c4-f61190895378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_75e6943c-ab1e-4551-bb3d-a56918f4c467" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e5c83137-83eb-4ed0-97c4-f61190895378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0d3849c3-d34b-47a9-b09e-06d8a647eb24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_75e6943c-ab1e-4551-bb3d-a56918f4c467" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0d3849c3-d34b-47a9-b09e-06d8a647eb24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e11e3e2a-6e07-438c-80d7-8a4109e95d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_75e6943c-ab1e-4551-bb3d-a56918f4c467" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e11e3e2a-6e07-438c-80d7-8a4109e95d1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_936825fa-1667-4820-a8a8-bdcce3fd592d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ef739a25-c359-40ef-b571-ca97c9e96f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_936825fa-1667-4820-a8a8-bdcce3fd592d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ef739a25-c359-40ef-b571-ca97c9e96f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ff1f80dc-fac7-4000-86c8-cba45bd98b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_936825fa-1667-4820-a8a8-bdcce3fd592d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ff1f80dc-fac7-4000-86c8-cba45bd98b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2733abb8-25a0-4429-a4a7-f5cdd742de60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d7d5d243-df45-447b-9417-4a0cfa05cc38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2733abb8-25a0-4429-a4a7-f5cdd742de60" xlink:to="loc_us-gaap_ProfitLoss_d7d5d243-df45-447b-9417-4a0cfa05cc38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_72a9209e-772a-4c9b-bb78-c6433698a506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2733abb8-25a0-4429-a4a7-f5cdd742de60" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_72a9209e-772a-4c9b-bb78-c6433698a506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32f405b9-fc55-4eb7-94b0-d3e70d3bf5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2733abb8-25a0-4429-a4a7-f5cdd742de60" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32f405b9-fc55-4eb7-94b0-d3e70d3bf5a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_881c541d-8eed-49b1-8e3e-a32de9148c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a12fa013-b41e-41d1-9dbc-134fac4e9a28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_881c541d-8eed-49b1-8e3e-a32de9148c6f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a12fa013-b41e-41d1-9dbc-134fac4e9a28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9bb41ca4-365e-4fbb-8acb-f0cea439f602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_881c541d-8eed-49b1-8e3e-a32de9148c6f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9bb41ca4-365e-4fbb-8acb-f0cea439f602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca06cfe0-e344-4863-869b-f09f5c25dbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_881c541d-8eed-49b1-8e3e-a32de9148c6f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca06cfe0-e344-4863-869b-f09f5c25dbd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_81ed5ea8-664f-427c-8af0-31ced1a00c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_881c541d-8eed-49b1-8e3e-a32de9148c6f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_81ed5ea8-664f-427c-8af0-31ced1a00c0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82d96759-3ab6-499b-876f-65dabc7d5aff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b786b40c-81ba-40dd-9d18-f45dc6d876bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82d96759-3ab6-499b-876f-65dabc7d5aff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b786b40c-81ba-40dd-9d18-f45dc6d876bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f2137fb3-12dc-465b-a4e7-63098c143e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82d96759-3ab6-499b-876f-65dabc7d5aff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f2137fb3-12dc-465b-a4e7-63098c143e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_90af2420-c7eb-4c4b-975c-aa34c9283e8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82d96759-3ab6-499b-876f-65dabc7d5aff" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_90af2420-c7eb-4c4b-975c-aa34c9283e8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_24606f82-b199-484c-a62b-387768d363bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82d96759-3ab6-499b-876f-65dabc7d5aff" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_24606f82-b199-484c-a62b-387768d363bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_1a3593fe-2edd-492b-b63d-05ae8d7ae5b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82d96759-3ab6-499b-876f-65dabc7d5aff" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_1a3593fe-2edd-492b-b63d-05ae8d7ae5b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_8bfe5a8b-4d95-447b-bb5f-291a975adbd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82d96759-3ab6-499b-876f-65dabc7d5aff" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_8bfe5a8b-4d95-447b-bb5f-291a975adbd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e8a84896-91b5-4932-ace9-13bac4caa104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82d96759-3ab6-499b-876f-65dabc7d5aff" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e8a84896-91b5-4932-ace9-13bac4caa104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1ef2ff1f-438a-4801-9bcf-b1d132b38aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_ProfitLoss_1ef2ff1f-438a-4801-9bcf-b1d132b38aa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6c995559-d46b-4e94-a84a-38419f4ab01f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_Depreciation_6c995559-d46b-4e94-a84a-38419f4ab01f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9e158c70-61bb-4510-ba97-83e0d160b535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9e158c70-61bb-4510-ba97-83e0d160b535" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_5faff644-2287-453e-a373-81cd42d7898d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_5faff644-2287-453e-a373-81cd42d7898d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b0c23748-7974-4d49-a7c8-49de0b09d437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_ShareBasedCompensation_b0c23748-7974-4d49-a7c8-49de0b09d437" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense_fcae30d7-31cc-43f1-bc90-858fafbc56d2" xlink:href="ino-20200930.xsd#ino_NonCashInterestExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_ino_NonCashInterestExpense_fcae30d7-31cc-43f1-bc90-858fafbc56d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_031190ec-713e-440f-a7ff-271c85036ab8" xlink:href="ino-20200930.xsd#ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_031190ec-713e-440f-a7ff-271c85036ab8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_71fd0957-c048-45bf-b71a-eef029d8e6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_GainLossOnInvestments_71fd0957-c048-45bf-b71a-eef029d8e6df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_112ef43e-1fd3-447f-a802-a0aefedd72b6" xlink:href="ino-20200930.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_112ef43e-1fd3-447f-a802-a0aefedd72b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_c8ae4b93-308d-44f7-90ad-9bfed22ccf62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_c8ae4b93-308d-44f7-90ad-9bfed22ccf62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_c3353093-64c3-4985-8b66-ff49b2afd13b" xlink:href="ino-20200930.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_c3353093-64c3-4985-8b66-ff49b2afd13b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c321c4d0-df7d-4a05-b459-316b44f88430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c321c4d0-df7d-4a05-b459-316b44f88430" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_26931d47-dd0d-42f1-a9a6-90c6a4432927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_26931d47-dd0d-42f1-a9a6-90c6a4432927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_c1db9a2d-e1e9-4d17-b3f9-7f1ec5293c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_c1db9a2d-e1e9-4d17-b3f9-7f1ec5293c1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense_41e178d2-650d-457c-aa0d-ddac132d7790" xlink:href="ino-20200930.xsd#ino_OperatingLeaseNonCashLeaseExpense"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_ino_OperatingLeaseNonCashLeaseExpense_41e178d2-650d-457c-aa0d-ddac132d7790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_43944501-5a73-409e-8ea4-45c9cc93f880" xlink:href="ino-20200930.xsd#ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_43944501-5a73-409e-8ea4-45c9cc93f880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7d59b963-d157-4a8b-a975-f9f8da24937e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7d59b963-d157-4a8b-a975-f9f8da24937e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_89c2dd2a-9eb9-4a92-9288-f289d207a613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_89c2dd2a-9eb9-4a92-9288-f289d207a613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_24760100-17b6-47c0-908d-a6accf7966e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_24760100-17b6-47c0-908d-a6accf7966e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99bcf93f-412c-487a-ba8a-42a1b17031a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99bcf93f-412c-487a-ba8a-42a1b17031a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_21965308-6da6-410b-bc9d-ca66cb1fe658" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_21965308-6da6-410b-bc9d-ca66cb1fe658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b94ef280-03d5-4511-97eb-1c6d4a110616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b94ef280-03d5-4511-97eb-1c6d4a110616" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a9483349-e163-4daa-8c4a-f5113997621a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="23" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a9483349-e163-4daa-8c4a-f5113997621a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_982fb6c1-c43c-4e8c-9290-690d4b1214e8" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:calculationArc order="24" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_982fb6c1-c43c-4e8c-9290-690d4b1214e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_6687a26c-37a0-4f6d-b1a6-1c14abfa831f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:calculationArc order="25" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_6687a26c-37a0-4f6d-b1a6-1c14abfa831f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2ad1ba16-8a20-4881-884d-4c1de0780632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="26" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2ad1ba16-8a20-4881-884d-4c1de0780632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_3801e8a5-5e0a-431a-8f9a-af6a82a3521f" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:calculationArc order="27" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_3801e8a5-5e0a-431a-8f9a-af6a82a3521f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_8e39d458-a709-45df-922e-ec9006985dc7" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:calculationArc order="28" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_8e39d458-a709-45df-922e-ec9006985dc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_fc70a542-0793-451f-bdef-f02cc4afa49f" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:calculationArc order="29" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_fc70a542-0793-451f-bdef-f02cc4afa49f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_95347f24-1257-4ab6-92ea-d1e1fe37dee2" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="30" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_95347f24-1257-4ab6-92ea-d1e1fe37dee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_134e875e-734d-436c-b882-659d0d58a20f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="31" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b6642fb-7231-4ef8-99c9-c31fc9bd271b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_134e875e-734d-436c-b882-659d0d58a20f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_63837ec6-df14-411c-bf93-c9b335ef86f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_b7c1e451-0320-42cf-bc16-af60318ef707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_63837ec6-df14-411c-bf93-c9b335ef86f4" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_b7c1e451-0320-42cf-bc16-af60318ef707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_934ffc7f-0e23-425f-8ad7-b52dff21342d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_63837ec6-df14-411c-bf93-c9b335ef86f4" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_934ffc7f-0e23-425f-8ad7-b52dff21342d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_96b9df3f-2299-4045-9034-bf2d0b05c676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_63837ec6-df14-411c-bf93-c9b335ef86f4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_96b9df3f-2299-4045-9034-bf2d0b05c676" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_e1e6c8f0-1a89-40df-bcc3-23b9815f62c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_63837ec6-df14-411c-bf93-c9b335ef86f4" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_e1e6c8f0-1a89-40df-bcc3-23b9815f62c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_1dd2649d-3a3f-462e-a0d3-d5521bb70237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_63837ec6-df14-411c-bf93-c9b335ef86f4" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_1dd2649d-3a3f-462e-a0d3-d5521bb70237" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="ino-20200930.xsd#OrganizationandOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/OrganizationandOperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="simple" xlink:href="ino-20200930.xsd#BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="simple" xlink:href="ino-20200930.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="simple" xlink:href="ino-20200930.xsd#CriticalAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#CriticalAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="ino-20200930.xsd#ImpactofRecentlyIssuedAccountingStandards"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ino-20200930.xsd#RevenueRecognition"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="ino-20200930.xsd#ShorttermInvestments"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="ino-20200930.xsd#ShorttermInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ShorttermInvestmentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_477a4e7b-aa3c-434f-a39f-e43d6f2db08b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0956964e-f376-48e9-9856-1c603039f011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_477a4e7b-aa3c-434f-a39f-e43d6f2db08b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0956964e-f376-48e9-9856-1c603039f011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3182d057-7a29-46d6-a7f2-aacf6e43288b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_477a4e7b-aa3c-434f-a39f-e43d6f2db08b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3182d057-7a29-46d6-a7f2-aacf6e43288b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d7a062c6-0e2f-43dd-953e-e80181e9780e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_477a4e7b-aa3c-434f-a39f-e43d6f2db08b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d7a062c6-0e2f-43dd-953e-e80181e9780e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_295be955-aeeb-4827-94dd-749bcb8f22ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_925f1d6d-cf44-45c8-81ab-578a46f7be94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_295be955-aeeb-4827-94dd-749bcb8f22ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_925f1d6d-cf44-45c8-81ab-578a46f7be94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fce83e3d-fe73-4813-9de8-7d9feb10339a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_295be955-aeeb-4827-94dd-749bcb8f22ab" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fce83e3d-fe73-4813-9de8-7d9feb10339a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_04b40f17-66b4-4ed2-9398-4a72780c182c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_295be955-aeeb-4827-94dd-749bcb8f22ab" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_04b40f17-66b4-4ed2-9398-4a72780c182c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_75c82ee3-aacd-48cb-a45e-ccf2eb0edf2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5881b056-efe3-4ec7-8217-adad97249f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_75c82ee3-aacd-48cb-a45e-ccf2eb0edf2d" xlink:to="loc_us-gaap_DerivativeLiabilities_5881b056-efe3-4ec7-8217-adad97249f0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20200930.xsd#GoodwillandIntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20200930.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_97c36044-81ca-42e5-8d27-1ef1e97b7e6d" xlink:href="ino-20200930.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_2365e955-23c1-485a-ae61-91572197fcdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_97c36044-81ca-42e5-8d27-1ef1e97b7e6d" xlink:to="loc_us-gaap_GoodwillGross_2365e955-23c1-485a-ae61-91572197fcdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0d76550a-00a6-4652-b813-8d9cbb53580f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_97c36044-81ca-42e5-8d27-1ef1e97b7e6d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0d76550a-00a6-4652-b813-8d9cbb53580f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_92e44d1e-229f-4355-bff2-038b0ff60b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_161f627f-7da1-4a66-bb1e-e99880c8986a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_92e44d1e-229f-4355-bff2-038b0ff60b99" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_161f627f-7da1-4a66-bb1e-e99880c8986a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fcf92418-89c8-4316-9f90-eb478d59c70c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_92e44d1e-229f-4355-bff2-038b0ff60b99" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fcf92418-89c8-4316-9f90-eb478d59c70c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_7ae80a2c-af79-44d8-8b73-86a112aa9e0d" xlink:href="ino-20200930.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f74ec19d-b854-4c60-9ed1-009ad9156d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_7ae80a2c-af79-44d8-8b73-86a112aa9e0d" xlink:to="loc_us-gaap_Goodwill_f74ec19d-b854-4c60-9ed1-009ad9156d50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6756914a-5676-416d-a31a-3596b8f7fed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_7ae80a2c-af79-44d8-8b73-86a112aa9e0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6756914a-5676-416d-a31a-3596b8f7fed4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3233352c-f8db-40f6-be4c-c34b46661715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_6f315993-c618-4f86-abaf-558117ff8f29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Goodwill_3233352c-f8db-40f6-be4c-c34b46661715" xlink:to="loc_us-gaap_GoodwillGross_6f315993-c618-4f86-abaf-558117ff8f29" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebt"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebtTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_41f04113-4104-402c-bef9-9f65b3405d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0a6af454-d7d9-4af9-9f57-60e3f5adde22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_41f04113-4104-402c-bef9-9f65b3405d76" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0a6af454-d7d9-4af9-9f57-60e3f5adde22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7bcbfeee-49b7-4a5a-9046-0f870da1cd17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_41f04113-4104-402c-bef9-9f65b3405d76" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7bcbfeee-49b7-4a5a-9046-0f870da1cd17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_3991b5a5-055a-45e0-b7a0-3190ae1b8a48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_41f04113-4104-402c-bef9-9f65b3405d76" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_3991b5a5-055a-45e0-b7a0-3190ae1b8a48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_b7f15143-1909-459e-be1e-8915d20a6d90" xlink:href="ino-20200930.xsd#ino_DebtInstrumentAccretionOfPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_41f04113-4104-402c-bef9-9f65b3405d76" xlink:to="loc_ino_DebtInstrumentAccretionOfPremium_b7f15143-1909-459e-be1e-8915d20a6d90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_54567662-1606-46af-81cf-799c2f78db12" xlink:href="ino-20200930.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_41f04113-4104-402c-bef9-9f65b3405d76" xlink:to="loc_ino_DebtInstrumentAccruedInterest_54567662-1606-46af-81cf-799c2f78db12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_ef40ab6f-0235-4571-acc7-921b588a7246" xlink:href="ino-20200930.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_41f04113-4104-402c-bef9-9f65b3405d76" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_ef40ab6f-0235-4571-acc7-921b588a7246" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2245527a-521d-411e-accb-77928f80fd61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_40216dfe-248c-43d4-8b04-613911a285a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2245527a-521d-411e-accb-77928f80fd61" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_40216dfe-248c-43d4-8b04-613911a285a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_967c889f-47c5-4fd3-81d7-f6d5e3a4922b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2245527a-521d-411e-accb-77928f80fd61" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_967c889f-47c5-4fd3-81d7-f6d5e3a4922b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2453fd0d-2a31-4501-bddb-bac4ac68ded8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2245527a-521d-411e-accb-77928f80fd61" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2453fd0d-2a31-4501-bddb-bac4ac68ded8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1ee6b1c4-773a-406b-bb5a-5fd5da38e0e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2245527a-521d-411e-accb-77928f80fd61" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1ee6b1c4-773a-406b-bb5a-5fd5da38e0e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_69607458-2595-4e58-ae68-84106b6523e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2245527a-521d-411e-accb-77928f80fd61" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_69607458-2595-4e58-ae68-84106b6523e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20200930.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20200930.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/NetIncomeLossPerShare" xlink:type="simple" xlink:href="ino-20200930.xsd#NetIncomeLossPerShare"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/NetIncomeLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ino-20200930.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b5b4df43-7bc8-4825-ae15-ac5387648816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f8114874-5a6b-4118-a098-11550136d6e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b5b4df43-7bc8-4825-ae15-ac5387648816" xlink:to="loc_us-gaap_NetIncomeLoss_f8114874-5a6b-4118-a098-11550136d6e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_50f0c726-bae0-4795-b3bc-b70b5c1ccb8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b5b4df43-7bc8-4825-ae15-ac5387648816" xlink:to="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_50f0c726-bae0-4795-b3bc-b70b5c1ccb8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_279f3eef-23c6-4bb1-b982-de402726e83b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_82cd5070-5b37-4e17-bf35-352a62936e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_279f3eef-23c6-4bb1-b982-de402726e83b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_82cd5070-5b37-4e17-bf35-352a62936e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ac0161ee-3873-4e75-a381-e0f8f1f7d00c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_279f3eef-23c6-4bb1-b982-de402726e83b" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ac0161ee-3873-4e75-a381-e0f8f1f7d00c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ino-20200930.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ino-20200930.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#StockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20200930.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:type="simple" xlink:href="ino-20200930.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:type="simple" xlink:href="ino-20200930.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#LeasesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5cc76ec1-0c48-4023-a0cf-2781d5e4c8e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_efdd42a8-04ac-4795-a0e1-38d95ff55f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5cc76ec1-0c48-4023-a0cf-2781d5e4c8e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_efdd42a8-04ac-4795-a0e1-38d95ff55f67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6fa10da7-7c43-4ccb-961b-4736e2a5c9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5cc76ec1-0c48-4023-a0cf-2781d5e4c8e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6fa10da7-7c43-4ccb-961b-4736e2a5c9fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b6c01623-6c8e-4ba2-a3df-84e4ea98417c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5cc76ec1-0c48-4023-a0cf-2781d5e4c8e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b6c01623-6c8e-4ba2-a3df-84e4ea98417c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dd446fbc-9ba0-47e8-a770-a3768c3ae377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5cc76ec1-0c48-4023-a0cf-2781d5e4c8e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dd446fbc-9ba0-47e8-a770-a3768c3ae377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c49c2db9-bfe4-4318-a7dd-911190b887e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5cc76ec1-0c48-4023-a0cf-2781d5e4c8e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c49c2db9-bfe4-4318-a7dd-911190b887e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_edc51f6d-9306-4745-8daa-b1cfb12dfd3a" xlink:href="ino-20200930.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5cc76ec1-0c48-4023-a0cf-2781d5e4c8e3" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_edc51f6d-9306-4745-8daa-b1cfb12dfd3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b207780f-0dbf-4d76-819f-ea8f1bd92b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d1aca265-55bc-40fb-b920-0930de999ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b207780f-0dbf-4d76-819f-ea8f1bd92b0c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d1aca265-55bc-40fb-b920-0930de999ecf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_857e1366-914f-4840-9455-fb5d71a72f60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b207780f-0dbf-4d76-819f-ea8f1bd92b0c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_857e1366-914f-4840-9455-fb5d71a72f60" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20200930.xsd#CollaborativeAgreements"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#CollaborativeAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20200930.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsInc"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncInvestmentInGeneosDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncPreferredstockInvestmentDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ino-20200930.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ino-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:124dcabe-323e-4d00-a29d-21ddeb618d02,g:528b4586-6faf-4a31-a887-4db858d575b9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended" id="i0504ff7e39a34b6c81d13d9aab5d25d4_CoverPage"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i1ffda60683374410a56398b2079f9a92_CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a24386dc-c737-4439-8399-ff173db692a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a24386dc-c737-4439-8399-ff173db692a8" xlink:to="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d8de50b3-a840-4552-b9d9-bcf85c633990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d8de50b3-a840-4552-b9d9-bcf85c633990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_6aa2826a-37f3-470a-8453-900400e5d0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_us-gaap_ShortTermInvestments_6aa2826a-37f3-470a-8453-900400e5d0cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_030f4a29-157e-4568-ad14-a52d16316690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_030f4a29-157e-4568-ad14-a52d16316690" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_15acd447-95d4-425b-b462-9c691caa60b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_15acd447-95d4-425b-b462-9c691caa60b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f4a931e2-7d97-4860-bcc8-182ac4607d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f4a931e2-7d97-4860-bcc8-182ac4607d7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_62769c24-c4c4-4402-a07d-114278b4e52c" xlink:href="ino-20200930.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_62769c24-c4c4-4402-a07d-114278b4e52c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9b120c70-9d6a-426d-8ce5-ae7e7201504c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_us-gaap_AssetsCurrent_9b120c70-9d6a-426d-8ce5-ae7e7201504c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_03387781-f2ef-4ea1-b712-a67c4dcaef62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_03387781-f2ef-4ea1-b712-a67c4dcaef62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c8b64d2f-5cc8-47f7-bb65-09f1c448d82c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c8b64d2f-5cc8-47f7-bb65-09f1c448d82c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c3fc6848-45a7-45f7-bce7-5411381ec1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_EquityMethodInvestments_c3fc6848-45a7-45f7-bce7-5411381ec1d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_590c5a66-baac-4a24-9112-0764ffa13a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_590c5a66-baac-4a24-9112-0764ffa13a7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b3d7fe9e-6ead-4032-a3ef-aff04a99329d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_Goodwill_b3d7fe9e-6ead-4032-a3ef-aff04a99329d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ef7be706-17a0-46a3-a586-6c056ba3e2d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ef7be706-17a0-46a3-a586-6c056ba3e2d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_59090a4a-9c44-45a3-957a-2e42c661704b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_59090a4a-9c44-45a3-957a-2e42c661704b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_66c404d6-6eb0-419a-829d-6e62446ec600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_Assets_66c404d6-6eb0-419a-829d-6e62446ec600" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a24386dc-c737-4439-8399-ff173db692a8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aa347da-b8f7-4f59-9273-065ec7a441e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aa347da-b8f7-4f59-9273-065ec7a441e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_a5f7701a-2c8c-4ab7-8daf-d67ced7d4414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_a5f7701a-2c8c-4ab7-8daf-d67ced7d4414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_b7398346-2f91-49cd-98cd-c2c929644cb9" xlink:href="ino-20200930.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_b7398346-2f91-49cd-98cd-c2c929644cb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_edfd72a3-74ae-4faa-8c20-9943a6b133c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_edfd72a3-74ae-4faa-8c20-9943a6b133c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_0f9fb81a-d7d4-4a23-9e65-6bd34d8033ef" xlink:href="ino-20200930.xsd#ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_0f9fb81a-d7d4-4a23-9e65-6bd34d8033ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_738a0f4a-9b90-4c84-80f1-0d0b4b84b12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_738a0f4a-9b90-4c84-80f1-0d0b4b84b12e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_1da00414-2825-483e-992e-e77548f9fc24" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_ino_DeferredGrantFundingCurrent_1da00414-2825-483e-992e-e77548f9fc24" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_63ac5f2c-2766-4717-99a2-4d7894dfd400" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_63ac5f2c-2766-4717-99a2-4d7894dfd400" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2e0ac536-f182-429f-a1e1-64ee5f074e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_us-gaap_LiabilitiesCurrent_2e0ac536-f182-429f-a1e1-64ee5f074e2f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_77f18c48-f0d5-4b37-b491-f6d067f7ebf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_77f18c48-f0d5-4b37-b491-f6d067f7ebf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_b94bbcc8-bf03-41b8-a558-f6f848190af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_ConvertibleDebt_b94bbcc8-bf03-41b8-a558-f6f848190af2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d3452878-f4ff-4467-a45e-c820f46b7d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_DerivativeLiabilities_d3452878-f4ff-4467-a45e-c820f46b7d5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cef44ef0-8eb8-49fe-a18c-5d5c66481cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cef44ef0-8eb8-49fe-a18c-5d5c66481cef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_915450fa-9780-4768-b611-aa2105bae1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_915450fa-9780-4768-b611-aa2105bae1eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_ff245663-0d55-42d1-a680-8e83a332053a" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_ff245663-0d55-42d1-a680-8e83a332053a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a9d8cfa7-40d5-495b-bb36-5c0548e61dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a9d8cfa7-40d5-495b-bb36-5c0548e61dff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8d58e463-21f3-4af3-a840-03fafe9328a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_Liabilities_8d58e463-21f3-4af3-a840-03fafe9328a8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d21dc963-d243-48dc-b010-e30c562b6200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_PreferredStockValue_d21dc963-d243-48dc-b010-e30c562b6200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e117c82b-5c6f-4d96-9b69-34cc6f6d3a47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_CommonStockValue_e117c82b-5c6f-4d96-9b69-34cc6f6d3a47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f797a800-4e55-4d01-8e67-3e82b01c1751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f797a800-4e55-4d01-8e67-3e82b01c1751" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6964f726-00f6-4b46-86aa-c8233ced6096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6964f726-00f6-4b46-86aa-c8233ced6096" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84e89af4-2f04-4cb8-91d3-3d2423044571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84e89af4-2f04-4cb8-91d3-3d2423044571" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_71c0b2f6-b9f0-43e1-9c15-f2c5f58f8e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_StockholdersEquity_71c0b2f6-b9f0-43e1-9c15-f2c5f58f8e42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_11fb1a28-ef85-4e2b-abd2-d05cac32f8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_MinorityInterest_11fb1a28-ef85-4e2b-abd2-d05cac32f8b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dbf5ca9a-35a0-47e7-b487-90cccedbac31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dbf5ca9a-35a0-47e7-b487-90cccedbac31" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cfa9a676-d3b8-48b9-8405-006781068fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_cfa9a676-d3b8-48b9-8405-006781068fc1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_268959a9-5c3f-4b00-a417-1621150c188f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a24386dc-c737-4439-8399-ff173db692a8" xlink:to="loc_us-gaap_StatementTable_268959a9-5c3f-4b00-a417-1621150c188f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cba733f0-37e6-4e95-b8e2-35142ddf07af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_268959a9-5c3f-4b00-a417-1621150c188f" xlink:to="loc_us-gaap_DebtInstrumentAxis_cba733f0-37e6-4e95-b8e2-35142ddf07af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cba733f0-37e6-4e95-b8e2-35142ddf07af_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_cba733f0-37e6-4e95-b8e2-35142ddf07af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cba733f0-37e6-4e95-b8e2-35142ddf07af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_46da3e59-5f8d-4b70-916a-f83b6e16a310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_cba733f0-37e6-4e95-b8e2-35142ddf07af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_46da3e59-5f8d-4b70-916a-f83b6e16a310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_4f58bac9-a785-478a-b7b2-0157757bcc31" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46da3e59-5f8d-4b70-916a-f83b6e16a310" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_4f58bac9-a785-478a-b7b2-0157757bcc31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_d5b946bb-336e-44d8-83ef-8607c1e21960" xlink:href="ino-20200930.xsd#ino_ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46da3e59-5f8d-4b70-916a-f83b6e16a310" xlink:to="loc_ino_ConvertibleBondsMember_d5b946bb-336e-44d8-83ef-8607c1e21960" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i2164eda442d548a2b17cea838f5a3ad0_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6a2c74d8-efd5-4889-80c5-a70d2b451cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_RevenuesAbstract_6a2c74d8-efd5-4889-80c5-a70d2b451cf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1abd4f29-50fe-41ca-9939-18165a076f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_6a2c74d8-efd5-4889-80c5-a70d2b451cf1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1abd4f29-50fe-41ca-9939-18165a076f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6e87fedb-3d89-42c2-af72-e1036b860d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6e87fedb-3d89-42c2-af72-e1036b860d3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b2432005-9759-452d-83e2-e60894e4afcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6e87fedb-3d89-42c2-af72-e1036b860d3f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b2432005-9759-452d-83e2-e60894e4afcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d20a432c-1c24-4791-afea-4349463516bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6e87fedb-3d89-42c2-af72-e1036b860d3f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d20a432c-1c24-4791-afea-4349463516bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1b5be67a-28fc-4223-bb89-c42e354afc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6e87fedb-3d89-42c2-af72-e1036b860d3f" xlink:to="loc_us-gaap_OperatingExpenses_1b5be67a-28fc-4223-bb89-c42e354afc1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7ea21ca6-c2cb-4bff-843a-cbba1b5218e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_OperatingIncomeLoss_7ea21ca6-c2cb-4bff-843a-cbba1b5218e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_2cb5ad5b-51a0-48ac-b189-58d8ee0f1777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_InterestIncomeOperating_2cb5ad5b-51a0-48ac-b189-58d8ee0f1777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fbee854d-8750-4ed7-bf51-c409095c2f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_InterestExpense_fbee854d-8750-4ed7-bf51-c409095c2f26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_d26f607b-2ae3-43d1-8117-29c9dfa9e643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_d26f607b-2ae3-43d1-8117-29c9dfa9e643" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_779c0a8e-7b35-4262-b533-84110b1402e5" xlink:href="ino-20200930.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_779c0a8e-7b35-4262-b533-84110b1402e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9d39a8eb-748f-4e4d-8f7d-291a404fd604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9d39a8eb-748f-4e4d-8f7d-291a404fd604" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f63cd696-d3e1-42e0-9063-18ef3f1e8bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f63cd696-d3e1-42e0-9063-18ef3f1e8bd5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_71c15888-705e-4de1-84c3-df73de9b959a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_71c15888-705e-4de1-84c3-df73de9b959a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_705c256b-f4ca-4a31-bdb8-c0890e569000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_705c256b-f4ca-4a31-bdb8-c0890e569000" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2fcf6600-922e-4e08-b0fe-65c623fc4e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2fcf6600-922e-4e08-b0fe-65c623fc4e7e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3ef08559-4c05-45c5-8cc1-f2f17d63393f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3ef08559-4c05-45c5-8cc1-f2f17d63393f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e9190dc6-fdac-45b9-9a5e-74b292d6381d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e9190dc6-fdac-45b9-9a5e-74b292d6381d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_18c2ecf4-a97d-48f0-aa20-26ce4b102281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_ProfitLoss_18c2ecf4-a97d-48f0-aa20-26ce4b102281" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1b00295d-ebb2-42d0-833b-983d0fd5858e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1b00295d-ebb2-42d0-833b-983d0fd5858e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f43c247-0b35-4cc0-b1ae-27175609046d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_NetIncomeLoss_2f43c247-0b35-4cc0-b1ae-27175609046d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_04413aed-5531-4ffa-9121-77c6fdb3d95c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_04413aed-5531-4ffa-9121-77c6fdb3d95c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_caac7945-2338-4d94-9510-f14764cbd629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_04413aed-5531-4ffa-9121-77c6fdb3d95c" xlink:to="loc_us-gaap_EarningsPerShareBasic_caac7945-2338-4d94-9510-f14764cbd629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5fed0d78-780a-4beb-86d8-9aa89ce82cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_04413aed-5531-4ffa-9121-77c6fdb3d95c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5fed0d78-780a-4beb-86d8-9aa89ce82cdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_71fad07f-3d74-4089-bac5-add5bc058c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_71fad07f-3d74-4089-bac5-add5bc058c5b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d680ac7e-cae6-4f3d-9c55-d283a3f06f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_71fad07f-3d74-4089-bac5-add5bc058c5b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d680ac7e-cae6-4f3d-9c55-d283a3f06f7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_af9cfcba-8d30-4521-a62c-a1420c7c97ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_71fad07f-3d74-4089-bac5-add5bc058c5b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_af9cfcba-8d30-4521-a62c-a1420c7c97ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c780ae54-0b64-48e8-9388-fab14395bcaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_StatementTable_c780ae54-0b64-48e8-9388-fab14395bcaf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fc27353b-03ac-4206-97f3-82e1bde1f41f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c780ae54-0b64-48e8-9388-fab14395bcaf" xlink:to="loc_srt_ProductOrServiceAxis_fc27353b-03ac-4206-97f3-82e1bde1f41f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc27353b-03ac-4206-97f3-82e1bde1f41f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fc27353b-03ac-4206-97f3-82e1bde1f41f" xlink:to="loc_srt_ProductsAndServicesDomain_fc27353b-03ac-4206-97f3-82e1bde1f41f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a85ee2ad-c913-4ddc-8b7c-e61ca3edd905" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fc27353b-03ac-4206-97f3-82e1bde1f41f" xlink:to="loc_srt_ProductsAndServicesDomain_a85ee2ad-c913-4ddc-8b7c-e61ca3edd905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_010557e5-7010-4114-a0fb-6a5b8c1c6139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a85ee2ad-c913-4ddc-8b7c-e61ca3edd905" xlink:to="loc_us-gaap_LicenseMember_010557e5-7010-4114-a0fb-6a5b8c1c6139" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_d8a021e2-d664-4370-968b-7f9707c04634" xlink:href="ino-20200930.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a85ee2ad-c913-4ddc-8b7c-e61ca3edd905" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_d8a021e2-d664-4370-968b-7f9707c04634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9a3f6fdb-15f6-4f8f-be07-26f6379a41b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a85ee2ad-c913-4ddc-8b7c-e61ca3edd905" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9a3f6fdb-15f6-4f8f-be07-26f6379a41b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d2c774ad-95b6-46f4-adc0-623448768d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c780ae54-0b64-48e8-9388-fab14395bcaf" xlink:to="loc_us-gaap_DebtInstrumentAxis_d2c774ad-95b6-46f4-adc0-623448768d80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d2c774ad-95b6-46f4-adc0-623448768d80_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d2c774ad-95b6-46f4-adc0-623448768d80" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d2c774ad-95b6-46f4-adc0-623448768d80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a97dedfe-40f6-4d12-a5ea-8e7ef3c1892d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d2c774ad-95b6-46f4-adc0-623448768d80" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a97dedfe-40f6-4d12-a5ea-8e7ef3c1892d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_fdc00eb3-1bd2-4ea7-8513-0f27c3a38dac" xlink:href="ino-20200930.xsd#ino_ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a97dedfe-40f6-4d12-a5ea-8e7ef3c1892d" xlink:to="loc_ino_ConvertibleBondsMember_fdc00eb3-1bd2-4ea7-8513-0f27c3a38dac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ce4f4b85-dc83-4e24-a52c-5b68854f1fa4" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a97dedfe-40f6-4d12-a5ea-8e7ef3c1892d" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ce4f4b85-dc83-4e24-a52c-5b68854f1fa4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended" id="ie2d945ccf62c4ce4b12f7e0974b8ffb2_CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ib944ad70af4f487d9f523e24fe1e8f40_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_01ace31d-a78c-4192-b742-c49612a9d89f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_SharesIssued_01ace31d-a78c-4192-b742-c49612a9d89f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81f4818b-0a57-4f6a-a6e4-304753621dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81f4818b-0a57-4f6a-a6e4-304753621dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_452f2d1c-4a65-4e94-bd60-fc55e1c2c8ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_452f2d1c-4a65-4e94-bd60-fc55e1c2c8ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c247571e-9089-4351-9185-78ebad01e469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c247571e-9089-4351-9185-78ebad01e469" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0d6ff104-7cf3-4351-8659-7e9805b28ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0d6ff104-7cf3-4351-8659-7e9805b28ec5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e8803a94-7e26-4420-ac64-6b336c8cc226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e8803a94-7e26-4420-ac64-6b336c8cc226" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ded4b54b-2bc6-43bd-8aab-210639109c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ded4b54b-2bc6-43bd-8aab-210639109c82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0a64ca07-2a32-45b5-9500-dd283ec9881b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0a64ca07-2a32-45b5-9500-dd283ec9881b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_1fdf774f-d613-4bbb-8529-4d969fa2406f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_1fdf774f-d613-4bbb-8529-4d969fa2406f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d75d6dc7-30d6-45f3-9f8f-68de0b81a3aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d75d6dc7-30d6-45f3-9f8f-68de0b81a3aa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_50cb56b0-6c4d-49f1-a48f-b886a34a4f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_50cb56b0-6c4d-49f1-a48f-b886a34a4f0e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_637c842f-2ca5-4abb-a280-8385ee91a05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_637c842f-2ca5-4abb-a280-8385ee91a05d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_cc54b1a5-a886-4a56-ab2e-7cde92eee0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_cc54b1a5-a886-4a56-ab2e-7cde92eee0a4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_986e3cc3-6da1-4c78-a99d-a06c7e7e792b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_ProfitLoss_986e3cc3-6da1-4c78-a99d-a06c7e7e792b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ac441418-86f9-41dc-8f3e-96f88f637e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ac441418-86f9-41dc-8f3e-96f88f637e54" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2155fc14-41d2-461a-9094-c9de199462a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2155fc14-41d2-461a-9094-c9de199462a4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a62d0b40-2801-4878-a3ab-eb069e6e6a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_425978da-67d4-43fa-9ecd-322c507db383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ef07239e-38e2-4ddc-9013-7c26de034f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StatementTable_ef07239e-38e2-4ddc-9013-7c26de034f39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a45b4947-9183-48c2-b967-3cc3a2144432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ef07239e-38e2-4ddc-9013-7c26de034f39" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a45b4947-9183-48c2-b967-3cc3a2144432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a45b4947-9183-48c2-b967-3cc3a2144432_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a45b4947-9183-48c2-b967-3cc3a2144432" xlink:to="loc_us-gaap_EquityComponentDomain_a45b4947-9183-48c2-b967-3cc3a2144432_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a45b4947-9183-48c2-b967-3cc3a2144432" xlink:to="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_0ef979ce-9b21-4309-a456-0445a74ae4f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:to="loc_us-gaap_PreferredStockMember_0ef979ce-9b21-4309-a456-0445a74ae4f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bf0fd859-4cb4-4983-8f53-09f63c1e57d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:to="loc_us-gaap_CommonStockMember_bf0fd859-4cb4-4983-8f53-09f63c1e57d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9ff946d7-9f6e-41ab-a9c7-7653019426fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9ff946d7-9f6e-41ab-a9c7-7653019426fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2f045fd7-a89e-4731-a780-623f34280784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:to="loc_us-gaap_RetainedEarningsMember_2f045fd7-a89e-4731-a780-623f34280784" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2878b24f-6b69-4fe7-891c-44e8f23e44ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2878b24f-6b69-4fe7-891c-44e8f23e44ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_49fe68c6-3951-4379-a897-af07a57b6ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_49fe68c6-3951-4379-a897-af07a57b6ead" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aac49bbe-ed73-42af-8f94-58391f4bd79e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ef07239e-38e2-4ddc-9013-7c26de034f39" xlink:to="loc_us-gaap_DebtInstrumentAxis_aac49bbe-ed73-42af-8f94-58391f4bd79e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aac49bbe-ed73-42af-8f94-58391f4bd79e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_aac49bbe-ed73-42af-8f94-58391f4bd79e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aac49bbe-ed73-42af-8f94-58391f4bd79e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_389808f0-c258-4c0a-adc5-65ec6d47c604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_aac49bbe-ed73-42af-8f94-58391f4bd79e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_389808f0-c258-4c0a-adc5-65ec6d47c604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_08aabcb2-6068-4ada-a4c9-8ef32bc56a6b" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_389808f0-c258-4c0a-adc5-65ec6d47c604" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_08aabcb2-6068-4ada-a4c9-8ef32bc56a6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_866cb5fe-8e66-4483-a6dd-004beb931881" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_389808f0-c258-4c0a-adc5-65ec6d47c604" xlink:to="loc_ino_August2019ConvertibleBondsMember_866cb5fe-8e66-4483-a6dd-004beb931881" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="ic8e1b270234047ae8e45d82a6e2c9412_CondensedConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7722c31f-dc75-420b-88c4-8300952001de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7722c31f-dc75-420b-88c4-8300952001de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cc2291ca-db44-4f88-89ac-3763a7246f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7722c31f-dc75-420b-88c4-8300952001de" xlink:to="loc_us-gaap_ProfitLoss_cc2291ca-db44-4f88-89ac-3763a7246f38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7722c31f-dc75-420b-88c4-8300952001de" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_911537a9-b426-4f3a-986a-aa45af161708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_Depreciation_911537a9-b426-4f3a-986a-aa45af161708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2d333faf-6c8a-448d-9cfd-67a0494e4c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2d333faf-6c8a-448d-9cfd-67a0494e4c98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_01c2a4bb-dc97-4cae-a8ab-67d164fa0002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_01c2a4bb-dc97-4cae-a8ab-67d164fa0002" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1ec1ae8d-ec8c-43c3-9de8-00572aadcc8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_ShareBasedCompensation_1ec1ae8d-ec8c-43c3-9de8-00572aadcc8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense_7cd02d6a-9082-4685-bbbe-55572060f04e" xlink:href="ino-20200930.xsd#ino_NonCashInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_ino_NonCashInterestExpense_7cd02d6a-9082-4685-bbbe-55572060f04e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_28f5625a-ff72-459f-b0e1-cfe5f5b1ae9f" xlink:href="ino-20200930.xsd#ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_28f5625a-ff72-459f-b0e1-cfe5f5b1ae9f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_096d6499-65a5-4d71-9fb3-209c006bae89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_GainLossOnInvestments_096d6499-65a5-4d71-9fb3-209c006bae89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_c071d9e1-7108-49a6-b32a-e778fb8e1793" xlink:href="ino-20200930.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_c071d9e1-7108-49a6-b32a-e778fb8e1793" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_dc5b76f4-d88a-4fc3-9adf-21800850fbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_dc5b76f4-d88a-4fc3-9adf-21800850fbd6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_16ce473e-b0a0-493b-99f7-65ac348b69a4" xlink:href="ino-20200930.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_16ce473e-b0a0-493b-99f7-65ac348b69a4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d2d185d0-eae6-40bc-9ea1-eaa2f9265026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d2d185d0-eae6-40bc-9ea1-eaa2f9265026" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2663a727-6014-4c44-a212-46b5e0abbd05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2663a727-6014-4c44-a212-46b5e0abbd05" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_29e181ac-187e-4ccf-9f2e-a83f70e38a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_29e181ac-187e-4ccf-9f2e-a83f70e38a05" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense_c6de4693-9e36-4cd3-8be9-28cc7d88cf5b" xlink:href="ino-20200930.xsd#ino_OperatingLeaseNonCashLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_ino_OperatingLeaseNonCashLeaseExpense_c6de4693-9e36-4cd3-8be9-28cc7d88cf5b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_16b0cdb8-8902-4a85-8bbd-deef97cea25f" xlink:href="ino-20200930.xsd#ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_16b0cdb8-8902-4a85-8bbd-deef97cea25f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_edd59058-9255-4c83-8d2f-2d2636e6da48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_edd59058-9255-4c83-8d2f-2d2636e6da48" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f17919b7-5a58-4aec-9748-6ea4593785f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f17919b7-5a58-4aec-9748-6ea4593785f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_af988d71-cc56-4b4d-aba0-41f90d0befcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_af988d71-cc56-4b4d-aba0-41f90d0befcf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4b0ed0c6-d402-4010-aeae-e286238acbee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4b0ed0c6-d402-4010-aeae-e286238acbee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_1eed8557-fdf8-4a82-9ac2-f13e62ee77b1" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_1eed8557-fdf8-4a82-9ac2-f13e62ee77b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b7a3b0ac-b156-4ab6-9687-4a43f14f975a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b7a3b0ac-b156-4ab6-9687-4a43f14f975a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5e3fb7af-48a8-4eeb-8333-7a00799781c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5e3fb7af-48a8-4eeb-8333-7a00799781c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_519e42c3-3fab-47b7-891a-a3c57f8745e1" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_519e42c3-3fab-47b7-891a-a3c57f8745e1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_727801c4-00f2-4d07-83ab-19c477593dda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_727801c4-00f2-4d07-83ab-19c477593dda" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_95dffdb3-4942-4b61-a075-f05b06837090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_95dffdb3-4942-4b61-a075-f05b06837090" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_408b557e-1169-46d3-a3e8-1f0e0ca52241" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_408b557e-1169-46d3-a3e8-1f0e0ca52241" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_29b269ac-6619-43bd-ba28-60d1201a192b" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_29b269ac-6619-43bd-ba28-60d1201a192b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_1708b2ef-de35-462a-81d5-a20ed0aca3ae" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_1708b2ef-de35-462a-81d5-a20ed0aca3ae" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_501e71a6-1fba-4a4a-a4a7-27686803289d" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_501e71a6-1fba-4a4a-a4a7-27686803289d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a941954-020d-43cd-bd73-bd963918b58e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a941954-020d-43cd-bd73-bd963918b58e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36ab75e0-680c-46ce-9872-8981514e8fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7722c31f-dc75-420b-88c4-8300952001de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36ab75e0-680c-46ce-9872-8981514e8fb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_77e5f39f-aed0-42da-9669-27bfad887f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_77e5f39f-aed0-42da-9669-27bfad887f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_7976474d-28a5-4952-88ed-ec54519eb3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_7976474d-28a5-4952-88ed-ec54519eb3ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_265bad5e-a900-4553-ae33-49d3c61abde7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_265bad5e-a900-4553-ae33-49d3c61abde7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_1222549d-93ae-4b13-b894-59f2f1e81887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_1222549d-93ae-4b13-b894-59f2f1e81887" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_d958f9b6-a4b6-4a9b-ba88-8a1bcb52274c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_d958f9b6-a4b6-4a9b-ba88-8a1bcb52274c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e7ab5b1-bf48-456e-a837-927a6cdb15f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e7ab5b1-bf48-456e-a837-927a6cdb15f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b15dfa14-1132-490c-81a6-fda54a84bddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b15dfa14-1132-490c-81a6-fda54a84bddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_efe11a49-1e30-4ecc-8566-1c8899c87612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_efe11a49-1e30-4ecc-8566-1c8899c87612" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b33a21c8-fdd6-4e14-9e6c-937f616f4a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b33a21c8-fdd6-4e14-9e6c-937f616f4a65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9e86feaa-a7ea-4dc0-bfe5-c4b29ddf0d32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9e86feaa-a7ea-4dc0-bfe5-c4b29ddf0d32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_381d5441-e65d-4e76-94ff-a5bce7a9acdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_381d5441-e65d-4e76-94ff-a5bce7a9acdb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_6a8a0798-a5fd-425b-b616-d6d69662cd76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_6a8a0798-a5fd-425b-b616-d6d69662cd76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_62437cf7-5d81-4dcb-bfdd-4da81a28f7c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_62437cf7-5d81-4dcb-bfdd-4da81a28f7c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c11c0416-2899-4754-b048-c9d91a9006e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c11c0416-2899-4754-b048-c9d91a9006e3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e55c3fc-6782-4c60-aa6d-4ae49bebff29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e55c3fc-6782-4c60-aa6d-4ae49bebff29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd5b9662-9974-48ae-bf00-f51401b2a6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd5b9662-9974-48ae-bf00-f51401b2a6e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afa89acf-760e-497b-b6f8-1248886bcdc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afa89acf-760e-497b-b6f8-1248886bcdc6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ff791b1-c6f4-4e39-b7a8-917db0779fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_dbe742f9-aa4e-4020-9c56-2848b264a75c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_dbe742f9-aa4e-4020-9c56-2848b264a75c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2337bb6a-c5c3-4c26-b41c-22361b31547b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dbe742f9-aa4e-4020-9c56-2848b264a75c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2337bb6a-c5c3-4c26-b41c-22361b31547b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a3eb431b-ff16-48c6-8ede-768311a0051e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dbe742f9-aa4e-4020-9c56-2848b264a75c" xlink:to="loc_us-gaap_InterestPaidNet_a3eb431b-ff16-48c6-8ede-768311a0051e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fd2150ce-a2a5-449d-ab9a-98f8183e68d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dbe742f9-aa4e-4020-9c56-2848b264a75c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fd2150ce-a2a5-449d-ab9a-98f8183e68d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7a5f91fc-6b3c-4168-b241-a77bda61d715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_StatementTable_7a5f91fc-6b3c-4168-b241-a77bda61d715" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1989bc47-5c8d-44eb-ac36-0a659741b6af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7a5f91fc-6b3c-4168-b241-a77bda61d715" xlink:to="loc_us-gaap_DebtInstrumentAxis_1989bc47-5c8d-44eb-ac36-0a659741b6af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1989bc47-5c8d-44eb-ac36-0a659741b6af_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1989bc47-5c8d-44eb-ac36-0a659741b6af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1989bc47-5c8d-44eb-ac36-0a659741b6af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_58f6170e-d523-4713-a61d-da231056b596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1989bc47-5c8d-44eb-ac36-0a659741b6af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_58f6170e-d523-4713-a61d-da231056b596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_1ded161e-639d-4144-9a43-0b84f54f1565" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_58f6170e-d523-4713-a61d-da231056b596" xlink:to="loc_ino_August2019ConvertibleBondsMember_1ded161e-639d-4144-9a43-0b84f54f1565" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_84a7dd4a-e3e8-458c-95db-aef49407afad" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_58f6170e-d523-4713-a61d-da231056b596" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_84a7dd4a-e3e8-458c-95db-aef49407afad" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="ino-20200930.xsd#OrganizationandOperations"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/OrganizationandOperations" xlink:type="extended" id="i5e21252e742b425293c61da0f124a73c_OrganizationandOperations"/>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="simple" xlink:href="ino-20200930.xsd#BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="extended" id="i776b01eebd05402c90f4f6fb5a427f2a_BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="simple" xlink:href="ino-20200930.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="extended" id="i7253a229ccff4cecbca819cab0866fdc_BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended" id="i43be27e23a8e41e59d9196a29ba746a7_BasisofPresentationLiquidityandRisksandUncertaintiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_25a8cf11-0aab-42ef-b50c-d5c59a1b6343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_25a8cf11-0aab-42ef-b50c-d5c59a1b6343" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e614d1d-4056-4126-9786-44a73f58fbee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_NetIncomeLoss_3e614d1d-4056-4126-9786-44a73f58fbee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Capital_72a8b70f-ed40-4b00-9ac5-bf90406218bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Capital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_Capital_72a8b70f-ed40-4b00-9ac5-bf90406218bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12b9cd21-8988-4071-81bd-62ef19bacfa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12b9cd21-8988-4071-81bd-62ef19bacfa8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b3d261d9-6120-437e-9a1d-01c2ab4e6c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b3d261d9-6120-437e-9a1d-01c2ab4e6c8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1b3765a3-a07e-43ac-923f-1fb73294d23c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1b3765a3-a07e-43ac-923f-1fb73294d23c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2a601c87-86c4-48ba-a5cc-fe4af6c0782a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2a601c87-86c4-48ba-a5cc-fe4af6c0782a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_035b8cc3-3648-4135-acdf-4b5455c4c7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_035b8cc3-3648-4135-acdf-4b5455c4c7cf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_912da54f-1721-45d0-b3e4-878e0c312fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_912da54f-1721-45d0-b3e4-878e0c312fee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b83b4fc3-7f30-4b35-943e-b570a0f0217f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:to="loc_srt_OwnershipAxis_b83b4fc3-7f30-4b35-943e-b570a0f0217f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b83b4fc3-7f30-4b35-943e-b570a0f0217f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_b83b4fc3-7f30-4b35-943e-b570a0f0217f" xlink:to="loc_srt_OwnershipDomain_b83b4fc3-7f30-4b35-943e-b570a0f0217f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1088de5a-7df5-42c7-afc2-d00ed96b385e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_b83b4fc3-7f30-4b35-943e-b570a0f0217f" xlink:to="loc_srt_OwnershipDomain_1088de5a-7df5-42c7-afc2-d00ed96b385e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_VGXAnimalHealthIncMember_88cccc0f-1f24-431b-899e-ebe07a799826" xlink:href="ino-20200930.xsd#ino_VGXAnimalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1088de5a-7df5-42c7-afc2-d00ed96b385e" xlink:to="loc_ino_VGXAnimalHealthIncMember_88cccc0f-1f24-431b-899e-ebe07a799826" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_92e9655b-ea28-4caa-8b2a-e7c8c718e9da" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1088de5a-7df5-42c7-afc2-d00ed96b385e" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_92e9655b-ea28-4caa-8b2a-e7c8c718e9da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3efa2338-5676-4380-b7bb-86c830a51b01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:to="loc_us-gaap_DebtInstrumentAxis_3efa2338-5676-4380-b7bb-86c830a51b01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3efa2338-5676-4380-b7bb-86c830a51b01_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3efa2338-5676-4380-b7bb-86c830a51b01" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3efa2338-5676-4380-b7bb-86c830a51b01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_00c15a9a-7a4f-4680-bafa-5c8dc9a987f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3efa2338-5676-4380-b7bb-86c830a51b01" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_00c15a9a-7a4f-4680-bafa-5c8dc9a987f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_95724c24-395b-40ca-aa4f-5a4a757740a0" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_00c15a9a-7a4f-4680-bafa-5c8dc9a987f7" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_95724c24-395b-40ca-aa4f-5a4a757740a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_4f2a2491-cf3d-4eab-a576-9d7ac1ad240c" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_00c15a9a-7a4f-4680-bafa-5c8dc9a987f7" xlink:to="loc_ino_August2019ConvertibleBondsMember_4f2a2491-cf3d-4eab-a576-9d7ac1ad240c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_a4012608-9e68-4a84-be87-a66a04e4e566" xlink:href="ino-20200930.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_00c15a9a-7a4f-4680-bafa-5c8dc9a987f7" xlink:to="loc_ino_December2019ConvertibleBondsMember_a4012608-9e68-4a84-be87-a66a04e4e566" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6e849cbf-e895-4bf3-b848-bff3f2da6d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6e849cbf-e895-4bf3-b848-bff3f2da6d9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6e849cbf-e895-4bf3-b848-bff3f2da6d9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6e849cbf-e895-4bf3-b848-bff3f2da6d9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6e849cbf-e895-4bf3-b848-bff3f2da6d9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c6a110d3-fcce-4b51-a96a-975c78eba9ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6e849cbf-e895-4bf3-b848-bff3f2da6d9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c6a110d3-fcce-4b51-a96a-975c78eba9ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_98f6dcd4-021e-49dc-b069-55f1678ede29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c6a110d3-fcce-4b51-a96a-975c78eba9ad" xlink:to="loc_us-gaap_ConvertibleDebtMember_98f6dcd4-021e-49dc-b069-55f1678ede29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9c70c2b4-ecc9-4a0f-89c3-5b3912f47a88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9c70c2b4-ecc9-4a0f-89c3-5b3912f47a88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9c70c2b4-ecc9-4a0f-89c3-5b3912f47a88_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9c70c2b4-ecc9-4a0f-89c3-5b3912f47a88" xlink:to="loc_us-gaap_ClassOfStockDomain_9c70c2b4-ecc9-4a0f-89c3-5b3912f47a88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bee60569-ab96-4419-b7b6-9d1fcfb6dc17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9c70c2b4-ecc9-4a0f-89c3-5b3912f47a88" xlink:to="loc_us-gaap_ClassOfStockDomain_bee60569-ab96-4419-b7b6-9d1fcfb6dc17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2e7e5b1d-a330-4ef8-9428-7bf076a62377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bee60569-ab96-4419-b7b6-9d1fcfb6dc17" xlink:to="loc_us-gaap_CommonStockMember_2e7e5b1d-a330-4ef8-9428-7bf076a62377" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3885f060-e488-40e8-b7d4-15faa7113eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3885f060-e488-40e8-b7d4-15faa7113eb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3885f060-e488-40e8-b7d4-15faa7113eb2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3885f060-e488-40e8-b7d4-15faa7113eb2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3885f060-e488-40e8-b7d4-15faa7113eb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87e40f20-1e1b-42ac-bdb1-b063866f79a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3885f060-e488-40e8-b7d4-15faa7113eb2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87e40f20-1e1b-42ac-bdb1-b063866f79a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember_f07e56e9-f907-43fb-b685-12dbcc40388c" xlink:href="ino-20200930.xsd#ino_SalesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87e40f20-1e1b-42ac-bdb1-b063866f79a5" xlink:to="loc_ino_SalesAgreementsMember_f07e56e9-f907-43fb-b685-12dbcc40388c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="simple" xlink:href="ino-20200930.xsd#CriticalAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended" id="ia859b013199b4048894e16479a37c970_CriticalAccountingPolicies"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#CriticalAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="extended" id="i6fb84de19b414a4dafddf735bfd63f09_CriticalAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9cb9316a-3ea4-4a7d-825f-bab0a88aecf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cb356edc-f1f0-4df2-9263-b6aab911f016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9cb9316a-3ea4-4a7d-825f-bab0a88aecf1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cb356edc-f1f0-4df2-9263-b6aab911f016" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_11c00cb5-55aa-457a-aee9-3562f827092e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9cb9316a-3ea4-4a7d-825f-bab0a88aecf1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_11c00cb5-55aa-457a-aee9-3562f827092e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b33d381f-f21e-4d96-b80f-0a8317f4d3f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9cb9316a-3ea4-4a7d-825f-bab0a88aecf1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b33d381f-f21e-4d96-b80f-0a8317f4d3f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_727d2691-04fd-48a2-b026-b154a4879ef6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b33d381f-f21e-4d96-b80f-0a8317f4d3f9" xlink:to="loc_srt_RangeAxis_727d2691-04fd-48a2-b026-b154a4879ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_727d2691-04fd-48a2-b026-b154a4879ef6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_727d2691-04fd-48a2-b026-b154a4879ef6" xlink:to="loc_srt_RangeMember_727d2691-04fd-48a2-b026-b154a4879ef6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e20623d-969c-4c67-84ee-ff6d32e45729" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_727d2691-04fd-48a2-b026-b154a4879ef6" xlink:to="loc_srt_RangeMember_7e20623d-969c-4c67-84ee-ff6d32e45729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4f069639-5688-4675-b67d-e405d5564848" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7e20623d-969c-4c67-84ee-ff6d32e45729" xlink:to="loc_srt_MinimumMember_4f069639-5688-4675-b67d-e405d5564848" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f7e2af8e-b9a4-44e5-9db5-84d26f85b11b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7e20623d-969c-4c67-84ee-ff6d32e45729" xlink:to="loc_srt_MaximumMember_f7e2af8e-b9a4-44e5-9db5-84d26f85b11b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="ino-20200930.xsd#ImpactofRecentlyIssuedAccountingStandards"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="extended" id="i879fad70a06b4a7c9d6d13689c5250fd_ImpactofRecentlyIssuedAccountingStandards"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ino-20200930.xsd#RevenueRecognition"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended" id="i462319b7edd547a280a1b80938d2cd23_RevenueRecognition"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" id="i65187dcef8fc49438b1656ea454b8ccb_RevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bd787205-a1eb-4d50-ae2b-bb3f29c81a09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19578ece-f4c2-493e-b38e-4d8f8f834d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bd787205-a1eb-4d50-ae2b-bb3f29c81a09" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19578ece-f4c2-493e-b38e-4d8f8f834d5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8623004c-2740-4fdc-918a-16d8408f7340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bd787205-a1eb-4d50-ae2b-bb3f29c81a09" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8623004c-2740-4fdc-918a-16d8408f7340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ed6b55d7-4e08-422a-8c5e-16e4d94f6747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bd787205-a1eb-4d50-ae2b-bb3f29c81a09" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ed6b55d7-4e08-422a-8c5e-16e4d94f6747" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_78e52d25-5056-4a4f-a606-31733b31fa8f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ed6b55d7-4e08-422a-8c5e-16e4d94f6747" xlink:to="loc_srt_CounterpartyNameAxis_78e52d25-5056-4a4f-a606-31733b31fa8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78e52d25-5056-4a4f-a606-31733b31fa8f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_78e52d25-5056-4a4f-a606-31733b31fa8f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78e52d25-5056-4a4f-a606-31733b31fa8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b6c5e04-6fa8-46f7-b18b-4b559174ecba" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_78e52d25-5056-4a4f-a606-31733b31fa8f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b6c5e04-6fa8-46f7-b18b-4b559174ecba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_8ae63e95-fd37-4a41-90ef-1672b56b12c3" xlink:href="ino-20200930.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b6c5e04-6fa8-46f7-b18b-4b559174ecba" xlink:to="loc_ino_PlumblineLifeSciencesMember_8ae63e95-fd37-4a41-90ef-1672b56b12c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_22f84bf9-ec7e-4b56-b685-15ac5c9e57d2" xlink:href="ino-20200930.xsd#ino_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b6c5e04-6fa8-46f7-b18b-4b559174ecba" xlink:to="loc_ino_AstraZenecaMember_22f84bf9-ec7e-4b56-b685-15ac5c9e57d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember_3631a94d-cb93-407b-b432-470d9a6cfdc8" xlink:href="ino-20200930.xsd#ino_OtherCounterpartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b6c5e04-6fa8-46f7-b18b-4b559174ecba" xlink:to="loc_ino_OtherCounterpartyMember_3631a94d-cb93-407b-b432-470d9a6cfdc8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="ino-20200930.xsd#ShorttermInvestments"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestments" xlink:type="extended" id="ic9911d807e18443f8f1303efa0fa54f7_ShorttermInvestments"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="ino-20200930.xsd#ShorttermInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="extended" id="i109dcb4b7726484fa52f2a6f802a41c9_ShorttermInvestmentsTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ShorttermInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="extended" id="i558970818e5a4d47a9234154deaf7d50_ShorttermInvestmentsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended" id="i5dde38245ffb4422868d452a21041fef_ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb354097-f332-4056-9af8-9ec65529597f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_2a69d5ce-4887-4581-ba86-a3400cae9728" xlink:href="ino-20200930.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb354097-f332-4056-9af8-9ec65529597f" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_2a69d5ce-4887-4581-ba86-a3400cae9728" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2dc31c0c-4cae-459d-a7cd-e0eef46b11dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb354097-f332-4056-9af8-9ec65529597f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2dc31c0c-4cae-459d-a7cd-e0eef46b11dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a49f53ff-28cb-4a83-8ea6-547f4a8caac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2dc31c0c-4cae-459d-a7cd-e0eef46b11dd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a49f53ff-28cb-4a83-8ea6-547f4a8caac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ec4ab24d-ccb6-465a-aa0e-d48c49449b3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2dc31c0c-4cae-459d-a7cd-e0eef46b11dd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ec4ab24d-ccb6-465a-aa0e-d48c49449b3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e41b582-1bb3-4d74-9193-637b4957f211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2dc31c0c-4cae-459d-a7cd-e0eef46b11dd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e41b582-1bb3-4d74-9193-637b4957f211" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_171ceaf9-8510-4aa0-8bb9-e5774e04e0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2dc31c0c-4cae-459d-a7cd-e0eef46b11dd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_171ceaf9-8510-4aa0-8bb9-e5774e04e0ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7f9887a3-37eb-4eec-9e8b-0d03566e97ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb354097-f332-4056-9af8-9ec65529597f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7f9887a3-37eb-4eec-9e8b-0d03566e97ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_98e53777-51ab-4c3d-93e3-97b515253d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7f9887a3-37eb-4eec-9e8b-0d03566e97ee" xlink:to="loc_us-gaap_FinancialInstrumentAxis_98e53777-51ab-4c3d-93e3-97b515253d41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e53777-51ab-4c3d-93e3-97b515253d41_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_98e53777-51ab-4c3d-93e3-97b515253d41" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e53777-51ab-4c3d-93e3-97b515253d41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3258e03d-8d99-4428-b1d7-87c3347139fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_98e53777-51ab-4c3d-93e3-97b515253d41" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3258e03d-8d99-4428-b1d7-87c3347139fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_93cb2657-40b6-4dba-90c1-90d2fc8b2773" xlink:href="ino-20200930.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3258e03d-8d99-4428-b1d7-87c3347139fa" xlink:to="loc_ino_MutualFundsMember_93cb2657-40b6-4dba-90c1-90d2fc8b2773" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_41eb4a3c-7369-41ec-a730-cc9d802914a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3258e03d-8d99-4428-b1d7-87c3347139fa" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_41eb4a3c-7369-41ec-a730-cc9d802914a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_915da6e7-8bfd-4a99-9ae8-c13ea10f439a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3258e03d-8d99-4428-b1d7-87c3347139fa" xlink:to="loc_us-gaap_CertificatesOfDepositMember_915da6e7-8bfd-4a99-9ae8-c13ea10f439a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3366a05e-cd4f-4037-96a0-7901f1c14fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3258e03d-8d99-4428-b1d7-87c3347139fa" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3366a05e-cd4f-4037-96a0-7901f1c14fee" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended" id="i1333575e797e413091e6fccf979d465d_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i02d9ad4eea96470fbfe00e962098ae9b_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i3417f80d158645928dd9db4e297f5e71_FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3636ea2a-c7a3-47de-ac42-c78f28db5567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_93fbee79-89e5-4421-8591-f952fec446f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3636ea2a-c7a3-47de-ac42-c78f28db5567" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_93fbee79-89e5-4421-8591-f952fec446f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ef325d24-4686-4edb-a6a9-539dd31ed261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93fbee79-89e5-4421-8591-f952fec446f7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ef325d24-4686-4edb-a6a9-539dd31ed261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_227d4965-057c-4afb-8d04-894a7195fe5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93fbee79-89e5-4421-8591-f952fec446f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_227d4965-057c-4afb-8d04-894a7195fe5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_1280e3f5-27c2-425c-8807-ef457f33655a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93fbee79-89e5-4421-8591-f952fec446f7" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_1280e3f5-27c2-425c-8807-ef457f33655a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b75daeb0-20e9-4da7-9912-56eaba41fbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93fbee79-89e5-4421-8591-f952fec446f7" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b75daeb0-20e9-4da7-9912-56eaba41fbcc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e933691f-016e-476b-85ff-39a130fbea7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3636ea2a-c7a3-47de-ac42-c78f28db5567" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e933691f-016e-476b-85ff-39a130fbea7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_77ee2dfa-ac39-49a2-a149-99ab14b733f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e933691f-016e-476b-85ff-39a130fbea7e" xlink:to="loc_us-gaap_DerivativeLiabilities_77ee2dfa-ac39-49a2-a149-99ab14b733f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_96aff2e0-1fa9-43f9-a447-66a050246a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e933691f-016e-476b-85ff-39a130fbea7e" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_96aff2e0-1fa9-43f9-a447-66a050246a4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_acfb1a71-2d51-439e-b251-2bb354ae218f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3636ea2a-c7a3-47de-ac42-c78f28db5567" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_acfb1a71-2d51-439e-b251-2bb354ae218f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfc9527d-3898-4246-9f34-a56bc7de5524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_acfb1a71-2d51-439e-b251-2bb354ae218f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfc9527d-3898-4246-9f34-a56bc7de5524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bfc9527d-3898-4246-9f34-a56bc7de5524_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfc9527d-3898-4246-9f34-a56bc7de5524" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bfc9527d-3898-4246-9f34-a56bc7de5524_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_133ddbb3-9e18-41b1-b1eb-8ec539de5864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfc9527d-3898-4246-9f34-a56bc7de5524" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_133ddbb3-9e18-41b1-b1eb-8ec539de5864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_488df57c-0fbc-4f5c-96f0-0f57347e3998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_133ddbb3-9e18-41b1-b1eb-8ec539de5864" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_488df57c-0fbc-4f5c-96f0-0f57347e3998" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_53b796ec-b9f2-4f2e-81b4-83a605266ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_acfb1a71-2d51-439e-b251-2bb354ae218f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_53b796ec-b9f2-4f2e-81b4-83a605266ea6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53b796ec-b9f2-4f2e-81b4-83a605266ea6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_53b796ec-b9f2-4f2e-81b4-83a605266ea6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53b796ec-b9f2-4f2e-81b4-83a605266ea6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_53b796ec-b9f2-4f2e-81b4-83a605266ea6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_47279dd2-8b67-4b0a-9db7-383e0b25625b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_47279dd2-8b67-4b0a-9db7-383e0b25625b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_f45f2004-d704-496c-9e27-5645ab7956a0" xlink:href="ino-20200930.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:to="loc_ino_MutualFundsMember_f45f2004-d704-496c-9e27-5645ab7956a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_21b6b585-9526-4d22-b5df-be4ff1479c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_21b6b585-9526-4d22-b5df-be4ff1479c3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_02037aec-d343-4061-8bd7-7f87a115f3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:to="loc_us-gaap_CertificatesOfDepositMember_02037aec-d343-4061-8bd7-7f87a115f3a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5d531fc4-d8b2-406f-96ef-733b4ac48a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5d531fc4-d8b2-406f-96ef-733b4ac48a7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_49d6007d-bb6e-4cb8-ace9-37e518bd7d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_49d6007d-bb6e-4cb8-ace9-37e518bd7d77" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b057df6-8be3-4779-8b44-741d5598c511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_acfb1a71-2d51-439e-b251-2bb354ae218f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b057df6-8be3-4779-8b44-741d5598c511" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b057df6-8be3-4779-8b44-741d5598c511_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b057df6-8be3-4779-8b44-741d5598c511" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b057df6-8be3-4779-8b44-741d5598c511_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d67a3e52-bd9d-48c5-ba3f-6960dfe941d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b057df6-8be3-4779-8b44-741d5598c511" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d67a3e52-bd9d-48c5-ba3f-6960dfe941d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_53b7806d-3ea3-4098-90df-10e89deba508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d67a3e52-bd9d-48c5-ba3f-6960dfe941d7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_53b7806d-3ea3-4098-90df-10e89deba508" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cd9bc4f9-cdb6-43b3-9e89-3d9b4c73e455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d67a3e52-bd9d-48c5-ba3f-6960dfe941d7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cd9bc4f9-cdb6-43b3-9e89-3d9b4c73e455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0e5d1c8d-4f05-412d-904a-12473d5ffa64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d67a3e52-bd9d-48c5-ba3f-6960dfe941d7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0e5d1c8d-4f05-412d-904a-12473d5ffa64" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="ifb760bfcd6aa4e5db269c7b341b8eb5e_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7136ce2c-25ce-4fab-a394-395515b0e677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_ca34f725-e3a6-400a-9666-3828b76e464b" xlink:href="ino-20200930.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7136ce2c-25ce-4fab-a394-395515b0e677" xlink:to="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_ca34f725-e3a6-400a-9666-3828b76e464b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_73ae2e9c-c12a-4dcc-bd03-5cd7b8b767d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_ca34f725-e3a6-400a-9666-3828b76e464b" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_73ae2e9c-c12a-4dcc-bd03-5cd7b8b767d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_59239009-e0b9-40c4-84d8-36132833536d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_ca34f725-e3a6-400a-9666-3828b76e464b" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_59239009-e0b9-40c4-84d8-36132833536d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_1eb314c8-f1b7-4c7f-97f5-dc1486c68fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_ca34f725-e3a6-400a-9666-3828b76e464b" xlink:to="loc_us-gaap_DerivativeLiabilities_1eb314c8-f1b7-4c7f-97f5-dc1486c68fe5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_7a59114c-f698-4121-a46f-9349170143b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7136ce2c-25ce-4fab-a394-395515b0e677" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_7a59114c-f698-4121-a46f-9349170143b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4d507cd8-167d-49fa-92d2-02f5d820388a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_7a59114c-f698-4121-a46f-9349170143b7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4d507cd8-167d-49fa-92d2-02f5d820388a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4d507cd8-167d-49fa-92d2-02f5d820388a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4d507cd8-167d-49fa-92d2-02f5d820388a" xlink:to="loc_us-gaap_ClassOfStockDomain_4d507cd8-167d-49fa-92d2-02f5d820388a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4721210a-d06c-4302-896f-69036eb76be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4d507cd8-167d-49fa-92d2-02f5d820388a" xlink:to="loc_us-gaap_ClassOfStockDomain_4721210a-d06c-4302-896f-69036eb76be3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d56bbd44-6f2b-40b0-a8e5-65018a40547b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4721210a-d06c-4302-896f-69036eb76be3" xlink:to="loc_us-gaap_CommonStockMember_d56bbd44-6f2b-40b0-a8e5-65018a40547b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64c1d9da-20bc-4bd6-b730-cc8d78819619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_7a59114c-f698-4121-a46f-9349170143b7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64c1d9da-20bc-4bd6-b730-cc8d78819619" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_64c1d9da-20bc-4bd6-b730-cc8d78819619_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64c1d9da-20bc-4bd6-b730-cc8d78819619" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_64c1d9da-20bc-4bd6-b730-cc8d78819619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9a96635-9e50-4d1d-9573-2989158091c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64c1d9da-20bc-4bd6-b730-cc8d78819619" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9a96635-9e50-4d1d-9573-2989158091c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cd46dac2-33fb-44ca-9538-eed3fa301a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9a96635-9e50-4d1d-9573-2989158091c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cd46dac2-33fb-44ca-9538-eed3fa301a34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_845f0dd1-3750-40d4-b118-ef7b65431e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9a96635-9e50-4d1d-9573-2989158091c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_845f0dd1-3750-40d4-b118-ef7b65431e8b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" xlink:type="extended" id="i3350a2b9d337465296bf60acb4fa10ac_FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20200930.xsd#GoodwillandIntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended" id="i50205111f7c243d695757fe4a96ccd70_GoodwillandIntangibleAssets"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20200930.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended" id="ic1fa4111e2284bf68e0dda5d9f01e502_GoodwillandIntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended" id="iaeb4e788c5db4aceb3a1ffa3f34c41cb_GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_d2d5cdc2-6d08-4169-a1d4-2fdbd21a3be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6054d623-2ee8-4281-81eb-73a45b588c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_d2d5cdc2-6d08-4169-a1d4-2fdbd21a3be2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6054d623-2ee8-4281-81eb-73a45b588c98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e4665e80-6b6d-4829-bb98-843fb36a6801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6054d623-2ee8-4281-81eb-73a45b588c98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e4665e80-6b6d-4829-bb98-843fb36a6801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_ffe3def1-b81f-4d20-8230-1ebc4873b753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e4665e80-6b6d-4829-bb98-843fb36a6801" xlink:to="loc_us-gaap_GoodwillGross_ffe3def1-b81f-4d20-8230-1ebc4873b753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f6d83184-9d7a-40e5-b291-0af38050f231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e4665e80-6b6d-4829-bb98-843fb36a6801" xlink:to="loc_us-gaap_Goodwill_f6d83184-9d7a-40e5-b291-0af38050f231" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_06f104ea-58cb-429c-bd0c-e99e505cfedb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6054d623-2ee8-4281-81eb-73a45b588c98" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_06f104ea-58cb-429c-bd0c-e99e505cfedb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_11d945f2-96a6-4526-9a6f-6bed1d55cf33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_06f104ea-58cb-429c-bd0c-e99e505cfedb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_11d945f2-96a6-4526-9a6f-6bed1d55cf33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9ff28384-2bea-4a29-9b18-b0d1e3883d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_06f104ea-58cb-429c-bd0c-e99e505cfedb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9ff28384-2bea-4a29-9b18-b0d1e3883d5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4ad67e80-81a5-479d-bd2e-c5cd0b554bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_06f104ea-58cb-429c-bd0c-e99e505cfedb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4ad67e80-81a5-479d-bd2e-c5cd0b554bac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0f28b367-342c-4395-88bb-fad51fcafa4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_06f104ea-58cb-429c-bd0c-e99e505cfedb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0f28b367-342c-4395-88bb-fad51fcafa4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_b30d3161-2b8e-49ea-bc24-3676514523bb" xlink:href="ino-20200930.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6054d623-2ee8-4281-81eb-73a45b588c98" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_b30d3161-2b8e-49ea-bc24-3676514523bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_0162f448-3701-46cc-830a-36024f4e649e" xlink:href="ino-20200930.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6054d623-2ee8-4281-81eb-73a45b588c98" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_0162f448-3701-46cc-830a-36024f4e649e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_8295a967-f9d0-4b44-bdea-f239564ac8f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_d2d5cdc2-6d08-4169-a1d4-2fdbd21a3be2" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_8295a967-f9d0-4b44-bdea-f239564ac8f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_14137d0e-51d5-4550-9683-3974a191282d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_8295a967-f9d0-4b44-bdea-f239564ac8f7" xlink:to="loc_srt_RangeAxis_14137d0e-51d5-4550-9683-3974a191282d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_14137d0e-51d5-4550-9683-3974a191282d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_14137d0e-51d5-4550-9683-3974a191282d" xlink:to="loc_srt_RangeMember_14137d0e-51d5-4550-9683-3974a191282d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac684458-c8cc-4a05-aa0b-6694c50d3f17" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_14137d0e-51d5-4550-9683-3974a191282d" xlink:to="loc_srt_RangeMember_ac684458-c8cc-4a05-aa0b-6694c50d3f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_b355dc2b-6330-4ef2-b85a-00c95bc82e62" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ac684458-c8cc-4a05-aa0b-6694c50d3f17" xlink:to="loc_srt_WeightedAverageMember_b355dc2b-6330-4ef2-b85a-00c95bc82e62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3fe2458d-5467-4555-9dc0-653a233f6dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_8295a967-f9d0-4b44-bdea-f239564ac8f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3fe2458d-5467-4555-9dc0-653a233f6dab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3fe2458d-5467-4555-9dc0-653a233f6dab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3fe2458d-5467-4555-9dc0-653a233f6dab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3fe2458d-5467-4555-9dc0-653a233f6dab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e628676-1d82-44b6-aac1-b270601e948d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3fe2458d-5467-4555-9dc0-653a233f6dab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e628676-1d82-44b6-aac1-b270601e948d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_784bbbd5-da01-4a63-a792-60faa88a9138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e628676-1d82-44b6-aac1-b270601e948d" xlink:to="loc_us-gaap_LicensingAgreementsMember_784bbbd5-da01-4a63-a792-60faa88a9138" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_254b84bf-85d8-443e-a766-6144ed420aff" xlink:href="ino-20200930.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e628676-1d82-44b6-aac1-b270601e948d" xlink:to="loc_ino_BiojectMember_254b84bf-85d8-443e-a766-6144ed420aff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_50a48614-3a93-453a-a3b8-2febc674b2f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e628676-1d82-44b6-aac1-b270601e948d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_50a48614-3a93-453a-a3b8-2febc674b2f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f249b645-9abc-4348-902d-0c2ea15c82d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_8295a967-f9d0-4b44-bdea-f239564ac8f7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f249b645-9abc-4348-902d-0c2ea15c82d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f249b645-9abc-4348-902d-0c2ea15c82d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f249b645-9abc-4348-902d-0c2ea15c82d3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f249b645-9abc-4348-902d-0c2ea15c82d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b3d8b3-9904-4200-ae1f-b4c5a3f2643c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f249b645-9abc-4348-902d-0c2ea15c82d3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b3d8b3-9904-4200-ae1f-b4c5a3f2643c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InovioAsMember_13bdbd0c-77eb-470d-a8dd-85888a338152" xlink:href="ino-20200930.xsd#ino_InovioAsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b3d8b3-9904-4200-ae1f-b4c5a3f2643c" xlink:to="loc_ino_InovioAsMember_13bdbd0c-77eb-470d-a8dd-85888a338152" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_VgxPharmaceuticalsMember_804ebb3b-cddb-47e5-b6e7-8a175cfca176" xlink:href="ino-20200930.xsd#ino_VgxPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b3d8b3-9904-4200-ae1f-b4c5a3f2643c" xlink:to="loc_ino_VgxPharmaceuticalsMember_804ebb3b-cddb-47e5-b6e7-8a175cfca176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_34d64a40-c200-49de-b987-5c160f78aa24" xlink:href="ino-20200930.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b3d8b3-9904-4200-ae1f-b4c5a3f2643c" xlink:to="loc_ino_BiojectMember_34d64a40-c200-49de-b987-5c160f78aa24" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended" id="i21ef252b5bec410e80baf901d6870110_GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebt"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended" id="id526733466914bf483da1a111fa97d7b_ConvertibleDebt"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebtTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended" id="i8c4ca68a8ddd4ed1831a7070a219fbbd_ConvertibleDebtTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended" id="i6b13ddbd7f244de8aaf94ba5d4b3d18a_ConvertibleDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_04496411-0a83-4313-bd44-626f9d37c6e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_04496411-0a83-4313-bd44-626f9d37c6e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_b3b02ead-81ee-42fd-9d7e-c3730b229145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_b3b02ead-81ee-42fd-9d7e-c3730b229145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2e4808ee-a653-4e09-8c12-ef1007ebc37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2e4808ee-a653-4e09-8c12-ef1007ebc37c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_092bea08-5ef2-48c6-b0f0-c40ed2127db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_092bea08-5ef2-48c6-b0f0-c40ed2127db2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c70737bc-964e-4bcd-9ccb-138ea5fad916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c70737bc-964e-4bcd-9ccb-138ea5fad916" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90537cee-77be-4056-bb15-fe279710ff40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90537cee-77be-4056-bb15-fe279710ff40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_26ff4210-11cc-4c5b-b16d-a2a38fd62efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_26ff4210-11cc-4c5b-b16d-a2a38fd62efc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_292fe375-7ccb-4771-8c58-f530e7038abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_292fe375-7ccb-4771-8c58-f530e7038abc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a310f210-61df-4031-85de-89a044f1223a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a310f210-61df-4031-85de-89a044f1223a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_b1fdba16-d6bd-44c3-a573-cc9f5a7dad3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_b1fdba16-d6bd-44c3-a573-cc9f5a7dad3f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a004f6fd-95f4-4622-aab5-cb0393fc797a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a004f6fd-95f4-4622-aab5-cb0393fc797a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7d8953f1-6153-417f-936c-9faef0036820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7d8953f1-6153-417f-936c-9faef0036820" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9a446a4d-be1d-41e4-896c-b3ab3ff3a830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9a446a4d-be1d-41e4-896c-b3ab3ff3a830" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_aa989968-1a6f-463b-b059-9069c32b7bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_aa989968-1a6f-463b-b059-9069c32b7bc7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_09d46f5d-89f6-46ac-b1d1-8908ed531047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_09d46f5d-89f6-46ac-b1d1-8908ed531047" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_5dd1dce3-b471-4a9a-abbd-d9807f237efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentFairValue_5dd1dce3-b471-4a9a-abbd-d9807f237efa" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92e3bd44-8a1e-46ef-899b-02c48043a505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92e3bd44-8a1e-46ef-899b-02c48043a505" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_17eb72a0-80dd-4a49-8106-72fd02cb7147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_InterestExpense_17eb72a0-80dd-4a49-8106-72fd02cb7147" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_abcb74a6-5423-4435-a805-0e9ed350c38c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_InterestExpenseDebt_abcb74a6-5423-4435-a805-0e9ed350c38c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_86263e77-dc13-44e7-b3bf-8baa023ad06b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_86263e77-dc13-44e7-b3bf-8baa023ad06b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a9a16fcc-95e1-4364-b057-61a2564e6df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a9a16fcc-95e1-4364-b057-61a2564e6df8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_c0027556-212c-4f5f-a9d7-4fed7654bc5c" xlink:href="ino-20200930.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_c0027556-212c-4f5f-a9d7-4fed7654bc5c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_db2d8f19-dd3d-4ae2-bd53-6a2c1f482c1e" xlink:href="ino-20200930.xsd#ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_db2d8f19-dd3d-4ae2-bd53-6a2c1f482c1e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_027bc935-1d0e-4bc3-b668-89f77422c131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_027bc935-1d0e-4bc3-b668-89f77422c131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_027bc935-1d0e-4bc3-b668-89f77422c131_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_027bc935-1d0e-4bc3-b668-89f77422c131" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_027bc935-1d0e-4bc3-b668-89f77422c131_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_05ea133e-579c-46d4-9116-5bea4904fa91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_027bc935-1d0e-4bc3-b668-89f77422c131" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_05ea133e-579c-46d4-9116-5bea4904fa91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_3f0231bc-6ca4-4c7e-b70e-9ce2d8137b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_05ea133e-579c-46d4-9116-5bea4904fa91" xlink:to="loc_us-gaap_ConvertibleDebtMember_3f0231bc-6ca4-4c7e-b70e-9ce2d8137b8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c2d9b631-3212-4c04-ae08-2ed0080d9d00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:to="loc_us-gaap_DebtInstrumentAxis_c2d9b631-3212-4c04-ae08-2ed0080d9d00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c2d9b631-3212-4c04-ae08-2ed0080d9d00_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c2d9b631-3212-4c04-ae08-2ed0080d9d00" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c2d9b631-3212-4c04-ae08-2ed0080d9d00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7e006777-e708-4fa9-995f-8b5505ac1eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c2d9b631-3212-4c04-ae08-2ed0080d9d00" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7e006777-e708-4fa9-995f-8b5505ac1eef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b4e7411a-23e2-4f78-8a6f-58d92127b4dc" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e006777-e708-4fa9-995f-8b5505ac1eef" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b4e7411a-23e2-4f78-8a6f-58d92127b4dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_7598140b-1cc5-4c0f-a01a-e61db918cb57" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e006777-e708-4fa9-995f-8b5505ac1eef" xlink:to="loc_ino_August2019ConvertibleBondsMember_7598140b-1cc5-4c0f-a01a-e61db918cb57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_bb74c44b-bd70-489d-9c95-b6e6a2b012bc" xlink:href="ino-20200930.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e006777-e708-4fa9-995f-8b5505ac1eef" xlink:to="loc_ino_December2019ConvertibleBondsMember_bb74c44b-bd70-489d-9c95-b6e6a2b012bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b7cbff08-9ec3-40df-b5e7-a56589a1e1c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b7cbff08-9ec3-40df-b5e7-a56589a1e1c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_b7cbff08-9ec3-40df-b5e7-a56589a1e1c5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b7cbff08-9ec3-40df-b5e7-a56589a1e1c5" xlink:to="loc_us-gaap_DebtConversionNameDomain_b7cbff08-9ec3-40df-b5e7-a56589a1e1c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_26bf3b40-d48e-468a-8c5a-f60c461420e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b7cbff08-9ec3-40df-b5e7-a56589a1e1c5" xlink:to="loc_us-gaap_DebtConversionNameDomain_26bf3b40-d48e-468a-8c5a-f60c461420e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember_a5a140e5-239b-42ed-b12e-50b7719efcd6" xlink:href="ino-20200930.xsd#ino_InitialConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_26bf3b40-d48e-468a-8c5a-f60c461420e6" xlink:to="loc_ino_InitialConversionPriceMember_a5a140e5-239b-42ed-b12e-50b7719efcd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember_4a58b5b5-df55-429f-8b8e-ad62433c61d1" xlink:href="ino-20200930.xsd#ino_AfterJuly22020ConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_26bf3b40-d48e-468a-8c5a-f60c461420e6" xlink:to="loc_ino_AfterJuly22020ConversionPriceMember_4a58b5b5-df55-429f-8b8e-ad62433c61d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eafad1f4-5d72-4b12-ba9f-77da99d996cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:to="loc_srt_RangeAxis_eafad1f4-5d72-4b12-ba9f-77da99d996cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eafad1f4-5d72-4b12-ba9f-77da99d996cb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eafad1f4-5d72-4b12-ba9f-77da99d996cb" xlink:to="loc_srt_RangeMember_eafad1f4-5d72-4b12-ba9f-77da99d996cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_534fb9fa-f7ef-475b-a2cf-4c42ca77a3df" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eafad1f4-5d72-4b12-ba9f-77da99d996cb" xlink:to="loc_srt_RangeMember_534fb9fa-f7ef-475b-a2cf-4c42ca77a3df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e0bb5db8-eb4c-4a7c-9f78-7fe371c20ff4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_534fb9fa-f7ef-475b-a2cf-4c42ca77a3df" xlink:to="loc_srt_MaximumMember_e0bb5db8-eb4c-4a7c-9f78-7fe371c20ff4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a3218d5a-6ffe-4129-babb-12e97251bd0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a3218d5a-6ffe-4129-babb-12e97251bd0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a3218d5a-6ffe-4129-babb-12e97251bd0e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a3218d5a-6ffe-4129-babb-12e97251bd0e" xlink:to="loc_us-gaap_ClassOfStockDomain_a3218d5a-6ffe-4129-babb-12e97251bd0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6c892904-156c-4b35-83f7-9757012d3dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a3218d5a-6ffe-4129-babb-12e97251bd0e" xlink:to="loc_us-gaap_ClassOfStockDomain_6c892904-156c-4b35-83f7-9757012d3dc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cfea6207-ca17-4611-9a4a-9c688d2bc80c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6c892904-156c-4b35-83f7-9757012d3dc2" xlink:to="loc_us-gaap_CommonStockMember_cfea6207-ca17-4611-9a4a-9c688d2bc80c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended" id="i749ebe8a5d1e4150a2d58fd522d87cf8_ConvertibleDebtBalanceofConvertibleBondsandNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_709ca87e-3f1a-458e-952b-5241f0a2d745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_709ca87e-3f1a-458e-952b-5241f0a2d745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_89a1ed1a-c5fc-4612-b506-0245517b2816" xlink:href="ino-20200930.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_89a1ed1a-c5fc-4612-b506-0245517b2816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a8dddd6f-a6e1-4844-85e6-b66466c3402c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a8dddd6f-a6e1-4844-85e6-b66466c3402c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_8e4fe759-a76e-41b9-87ff-bd18d45134e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_8e4fe759-a76e-41b9-87ff-bd18d45134e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_dc48ca22-65b0-41c3-8a30-5c59816e5e4b" xlink:href="ino-20200930.xsd#ino_DebtInstrumentAccretionOfPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_ino_DebtInstrumentAccretionOfPremium_dc48ca22-65b0-41c3-8a30-5c59816e5e4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_72407a5c-a2c8-4e2e-aa82-daa58319e63b" xlink:href="ino-20200930.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_ino_DebtInstrumentAccruedInterest_72407a5c-a2c8-4e2e-aa82-daa58319e63b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b37cfcd3-1013-4251-8cd1-1ec5b0fc19cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_us-gaap_LongTermDebt_b37cfcd3-1013-4251-8cd1-1ec5b0fc19cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7fb8fa38-0e68-40e8-9778-3cdc6d305508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_us-gaap_DebtInstrumentTable_7fb8fa38-0e68-40e8-9778-3cdc6d305508" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_78128e86-f5ad-427e-b341-6aeb54ecb2da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7fb8fa38-0e68-40e8-9778-3cdc6d305508" xlink:to="loc_us-gaap_DebtInstrumentAxis_78128e86-f5ad-427e-b341-6aeb54ecb2da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_78128e86-f5ad-427e-b341-6aeb54ecb2da_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_78128e86-f5ad-427e-b341-6aeb54ecb2da" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_78128e86-f5ad-427e-b341-6aeb54ecb2da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c9d87362-d479-439c-875b-787b21ff4f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_78128e86-f5ad-427e-b341-6aeb54ecb2da" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c9d87362-d479-439c-875b-787b21ff4f92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_6868f1d7-ce0b-46a5-a028-f83ff1555ad8" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c9d87362-d479-439c-875b-787b21ff4f92" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_6868f1d7-ce0b-46a5-a028-f83ff1555ad8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_dba7e5e3-7d99-4747-8b47-d81d6beb968e" xlink:href="ino-20200930.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c9d87362-d479-439c-875b-787b21ff4f92" xlink:to="loc_ino_December2019ConvertibleBondsMember_dba7e5e3-7d99-4747-8b47-d81d6beb968e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended" id="ied5ef89db82543e4ab424de800c0b483_ConvertibleDebtScheduleofMaturitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_79fa6f25-f301-425f-81d9-d6abd6f01bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_79fa6f25-f301-425f-81d9-d6abd6f01bd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bacbc304-6959-4e11-b3f7-6fe320b9bb26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bacbc304-6959-4e11-b3f7-6fe320b9bb26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_211ca0ae-a499-4f54-94ac-84bdec8a17e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_211ca0ae-a499-4f54-94ac-84bdec8a17e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_169e6614-5d11-4369-b529-dd1bc2510e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_169e6614-5d11-4369-b529-dd1bc2510e80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9377329a-f569-4c1b-8bd3-3a40fed4b4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9377329a-f569-4c1b-8bd3-3a40fed4b4c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9112240b-9180-4772-a40f-45281a732206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_LongTermDebt_9112240b-9180-4772-a40f-45281a732206" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5937a1f5-96da-4e1f-b380-dccdab139e84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5937a1f5-96da-4e1f-b380-dccdab139e84" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_68c5b48a-449e-47de-b1ce-460218136b03" xlink:href="ino-20200930.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_68c5b48a-449e-47de-b1ce-460218136b03" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4cc6257e-7696-4f8e-a9c2-541981581188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_DebtInstrumentTable_4cc6257e-7696-4f8e-a9c2-541981581188" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c87ef424-0731-4aec-b514-8b74fb167f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4cc6257e-7696-4f8e-a9c2-541981581188" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c87ef424-0731-4aec-b514-8b74fb167f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c87ef424-0731-4aec-b514-8b74fb167f17_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c87ef424-0731-4aec-b514-8b74fb167f17" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c87ef424-0731-4aec-b514-8b74fb167f17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_430c14ed-3070-4ad0-ab0f-3f8e682f592d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c87ef424-0731-4aec-b514-8b74fb167f17" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_430c14ed-3070-4ad0-ab0f-3f8e682f592d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_51fab071-44fb-4abb-b62c-d6635e2811e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_430c14ed-3070-4ad0-ab0f-3f8e682f592d" xlink:to="loc_us-gaap_ConvertibleDebtMember_51fab071-44fb-4abb-b62c-d6635e2811e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4e285924-8a6c-4be5-8a58-4846efad0634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4cc6257e-7696-4f8e-a9c2-541981581188" xlink:to="loc_us-gaap_DebtInstrumentAxis_4e285924-8a6c-4be5-8a58-4846efad0634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e285924-8a6c-4be5-8a58-4846efad0634_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e285924-8a6c-4be5-8a58-4846efad0634" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e285924-8a6c-4be5-8a58-4846efad0634_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cc3f733d-303b-4f43-a2af-c87e1372da82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e285924-8a6c-4be5-8a58-4846efad0634" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cc3f733d-303b-4f43-a2af-c87e1372da82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_d6eded22-437d-4c23-b912-c54f198620f3" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cc3f733d-303b-4f43-a2af-c87e1372da82" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_d6eded22-437d-4c23-b912-c54f198620f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_84199c59-4b38-4f40-925f-df457fe40f29" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cc3f733d-303b-4f43-a2af-c87e1372da82" xlink:to="loc_ino_August2019ConvertibleBondsMember_84199c59-4b38-4f40-925f-df457fe40f29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_8cf8b9a4-7e51-4f33-8558-16c43fc833fd" xlink:href="ino-20200930.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cc3f733d-303b-4f43-a2af-c87e1372da82" xlink:to="loc_ino_December2019ConvertibleBondsMember_8cf8b9a4-7e51-4f33-8558-16c43fc833fd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20200930.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended" id="i9960990775224a23bdd3dcd4322feb4c_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20200930.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended" id="i8af69b107d99431c9b95e98535aeb83b_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended" id="i3e08baf5017a42a48ec134163a37c79d_StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9da6cd6a-351c-476f-bf47-e0c5882c88f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9da6cd6a-351c-476f-bf47-e0c5882c88f2" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0774e159-1221-47e5-b5d1-97234f1910b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0774e159-1221-47e5-b5d1-97234f1910b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_42a9d4cf-ab38-4792-82dd-50097d13c17a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_42a9d4cf-ab38-4792-82dd-50097d13c17a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c2ff27fa-3f7c-4459-94fe-90f27d4752f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_CommonStockSharesIssued_c2ff27fa-3f7c-4459-94fe-90f27d4752f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7eb61bcb-0952-4b1f-b277-86fa3c5179a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7eb61bcb-0952-4b1f-b277-86fa3c5179a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_be38ddcb-047a-40d4-a7d6-69b2149c33b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_be38ddcb-047a-40d4-a7d6-69b2149c33b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_772bc1ca-54cc-4fe2-a306-f1c98a1e6496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_772bc1ca-54cc-4fe2-a306-f1c98a1e6496" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d64dd358-6317-4894-922b-029fd2880bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d64dd358-6317-4894-922b-029fd2880bf7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a069c012-6875-490c-9325-2c0cc8b6d610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a069c012-6875-490c-9325-2c0cc8b6d610" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a3d740b7-afe2-4d61-a539-ada0f54775c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9da6cd6a-351c-476f-bf47-e0c5882c88f2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a3d740b7-afe2-4d61-a539-ada0f54775c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2cb69151-3518-411c-9df7-69fe63972a18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a3d740b7-afe2-4d61-a539-ada0f54775c3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2cb69151-3518-411c-9df7-69fe63972a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2cb69151-3518-411c-9df7-69fe63972a18_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2cb69151-3518-411c-9df7-69fe63972a18" xlink:to="loc_us-gaap_ClassOfStockDomain_2cb69151-3518-411c-9df7-69fe63972a18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_85789339-cca1-4c33-9952-c355788ae437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2cb69151-3518-411c-9df7-69fe63972a18" xlink:to="loc_us-gaap_ClassOfStockDomain_85789339-cca1-4c33-9952-c355788ae437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_b943aeaf-b7bd-4692-a0c1-553c5e6ef409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_85789339-cca1-4c33-9952-c355788ae437" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_b943aeaf-b7bd-4692-a0c1-553c5e6ef409" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="idc96dc15889a457fb2ff5bd55878931f_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_185309a6-c9e4-4681-9a96-16b9d899d421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_185309a6-c9e4-4681-9a96-16b9d899d421" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_86c9bea7-9f0f-4943-baa1-ecadcfc7be6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_86c9bea7-9f0f-4943-baa1-ecadcfc7be6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_03c62156-db87-41b7-a72c-ce089252a614" xlink:href="ino-20200930.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_03c62156-db87-41b7-a72c-ce089252a614" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_ddca37a0-5ba1-4787-8265-67031e12edbc" xlink:href="ino-20200930.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_ddca37a0-5ba1-4787-8265-67031e12edbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementAgentFee_3508a22d-76d1-4eea-b937-756e976f138c" xlink:href="ino-20200930.xsd#ino_StockSalesAgreementAgentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_StockSalesAgreementAgentFee_3508a22d-76d1-4eea-b937-756e976f138c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_1b6e9e92-1a10-4002-9e69-873fba5ab5d2" xlink:href="ino-20200930.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_1b6e9e92-1a10-4002-9e69-873fba5ab5d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_8ca1f57a-98aa-447f-ae57-f78a21675a65" xlink:href="ino-20200930.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_8ca1f57a-98aa-447f-ae57-f78a21675a65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_bbc5a5ea-8bf4-4385-a0ea-c93860846852" xlink:href="ino-20200930.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_bbc5a5ea-8bf4-4385-a0ea-c93860846852" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ed95817-48f0-4d31-a5ab-c6b49abdb705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ed95817-48f0-4d31-a5ab-c6b49abdb705" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_80f6afdd-1222-4087-98d7-0336d54df5d0" xlink:href="ino-20200930.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_80f6afdd-1222-4087-98d7-0336d54df5d0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_966aa2cf-40ca-4234-b4dd-d91042d5e045" xlink:href="ino-20200930.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_966aa2cf-40ca-4234-b4dd-d91042d5e045" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3074ddf8-51cf-4016-be37-4683267611ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3074ddf8-51cf-4016-be37-4683267611ce" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dccfe110-6cbd-4ca2-bd90-fc57ce3d4908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dccfe110-6cbd-4ca2-bd90-fc57ce3d4908" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_a90c5948-50dd-476c-8ba7-3d4024b895d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_a90c5948-50dd-476c-8ba7-3d4024b895d2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c469d7ae-5f48-4fe5-8b80-8c58d275b6d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c469d7ae-5f48-4fe5-8b80-8c58d275b6d9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_cb2e4b14-f2a8-4f7f-aab7-88bbbbf975f3" xlink:href="ino-20200930.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_cb2e4b14-f2a8-4f7f-aab7-88bbbbf975f3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bdb222c9-d7c9-419c-a620-e803c95e710e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bdb222c9-d7c9-419c-a620-e803c95e710e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f551ac57-2ec8-4101-acdb-dc2858aa91c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bdb222c9-d7c9-419c-a620-e803c95e710e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f551ac57-2ec8-4101-acdb-dc2858aa91c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f551ac57-2ec8-4101-acdb-dc2858aa91c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f551ac57-2ec8-4101-acdb-dc2858aa91c6" xlink:to="loc_us-gaap_ClassOfStockDomain_f551ac57-2ec8-4101-acdb-dc2858aa91c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_52dbb8b4-8fe0-43e6-a0b5-552176f8511d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f551ac57-2ec8-4101-acdb-dc2858aa91c6" xlink:to="loc_us-gaap_ClassOfStockDomain_52dbb8b4-8fe0-43e6-a0b5-552176f8511d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_d8c82214-1291-4447-822d-f5e1f1e7d186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_52dbb8b4-8fe0-43e6-a0b5-552176f8511d" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_d8c82214-1291-4447-822d-f5e1f1e7d186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ac1aa77d-4006-40f6-a637-96c26f60f998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_52dbb8b4-8fe0-43e6-a0b5-552176f8511d" xlink:to="loc_us-gaap_CommonStockMember_ac1aa77d-4006-40f6-a637-96c26f60f998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3e40a531-e839-4980-941f-07d74a84eeef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bdb222c9-d7c9-419c-a620-e803c95e710e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3e40a531-e839-4980-941f-07d74a84eeef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e40a531-e839-4980-941f-07d74a84eeef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3e40a531-e839-4980-941f-07d74a84eeef" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e40a531-e839-4980-941f-07d74a84eeef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80bc5a88-f9e4-4311-b552-c8527cfcbc16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3e40a531-e839-4980-941f-07d74a84eeef" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80bc5a88-f9e4-4311-b552-c8527cfcbc16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember_70f4a751-3f72-47d0-a05b-34e3d42097ee" xlink:href="ino-20200930.xsd#ino_PriorSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80bc5a88-f9e4-4311-b552-c8527cfcbc16" xlink:to="loc_ino_PriorSalesAgreementMember_70f4a751-3f72-47d0-a05b-34e3d42097ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember_e1df6839-1901-4d08-ae2f-35eece627c0b" xlink:href="ino-20200930.xsd#ino_NewSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80bc5a88-f9e4-4311-b552-c8527cfcbc16" xlink:to="loc_ino_NewSalesAgreementMember_e1df6839-1901-4d08-ae2f-35eece627c0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_555ad61d-7adc-472c-9104-e0ece544c5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bdb222c9-d7c9-419c-a620-e803c95e710e" xlink:to="loc_us-gaap_PlanNameAxis_555ad61d-7adc-472c-9104-e0ece544c5c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_555ad61d-7adc-472c-9104-e0ece544c5c1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_555ad61d-7adc-472c-9104-e0ece544c5c1" xlink:to="loc_us-gaap_PlanNameDomain_555ad61d-7adc-472c-9104-e0ece544c5c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_eab86ab9-5967-4eca-89c2-0c6f73bb3c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_555ad61d-7adc-472c-9104-e0ece544c5c1" xlink:to="loc_us-gaap_PlanNameDomain_eab86ab9-5967-4eca-89c2-0c6f73bb3c45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_de100784-3167-461f-b884-df6a75ff614d" xlink:href="ino-20200930.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_eab86ab9-5967-4eca-89c2-0c6f73bb3c45" xlink:to="loc_ino_A2016IncentivePlanMember_de100784-3167-461f-b884-df6a75ff614d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_31a2f9f0-0ed1-405b-8c58-c24bd75391be" xlink:href="ino-20200930.xsd#ino_A2007IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_eab86ab9-5967-4eca-89c2-0c6f73bb3c45" xlink:to="loc_ino_A2007IncentivePlanMember_31a2f9f0-0ed1-405b-8c58-c24bd75391be" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetIncomeLossPerShare" xlink:type="simple" xlink:href="ino-20200930.xsd#NetIncomeLossPerShare"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetIncomeLossPerShare" xlink:type="extended" id="i77141eb803c749b193212826dcddbf64_NetIncomeLossPerShare"/>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ino-20200930.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended" id="i9ec8c6cceba9438b961c3eeacd4f18fc_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails" xlink:type="extended" id="i26ec335bfda7469d8dfae89393c00be1_NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended" id="i0e588e277162497893e491e4fc20786c_NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_def33ea2-6ba5-49e6-bf06-b7db6f18f219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0458f84a-a015-4f86-983e-8e30ee8d0d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_def33ea2-6ba5-49e6-bf06-b7db6f18f219" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0458f84a-a015-4f86-983e-8e30ee8d0d3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3fcc437a-d207-4a82-9c9b-16a5f0c0cb1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_def33ea2-6ba5-49e6-bf06-b7db6f18f219" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3fcc437a-d207-4a82-9c9b-16a5f0c0cb1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_62a53729-2776-4546-b405-f1057cf12529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3fcc437a-d207-4a82-9c9b-16a5f0c0cb1e" xlink:to="loc_us-gaap_DebtInstrumentAxis_62a53729-2776-4546-b405-f1057cf12529" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_62a53729-2776-4546-b405-f1057cf12529_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_62a53729-2776-4546-b405-f1057cf12529" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_62a53729-2776-4546-b405-f1057cf12529_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5489d9fb-9931-4580-8792-b792875d33f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_62a53729-2776-4546-b405-f1057cf12529" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5489d9fb-9931-4580-8792-b792875d33f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_2aed3122-3e83-45f5-8015-ae27be26703d" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5489d9fb-9931-4580-8792-b792875d33f5" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_2aed3122-3e83-45f5-8015-ae27be26703d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_d1475230-58d0-4474-b45e-0fb46cad622a" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5489d9fb-9931-4580-8792-b792875d33f5" xlink:to="loc_ino_August2019ConvertibleBondsMember_d1475230-58d0-4474-b45e-0fb46cad622a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_3b2533c9-3603-4102-bc80-dc7923bdc67d" xlink:href="ino-20200930.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5489d9fb-9931-4580-8792-b792875d33f5" xlink:to="loc_ino_December2019ConvertibleBondsMember_3b2533c9-3603-4102-bc80-dc7923bdc67d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3306b085-53a0-414a-ad07-d99c24d89d98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3fcc437a-d207-4a82-9c9b-16a5f0c0cb1e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3306b085-53a0-414a-ad07-d99c24d89d98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3306b085-53a0-414a-ad07-d99c24d89d98_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3306b085-53a0-414a-ad07-d99c24d89d98" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3306b085-53a0-414a-ad07-d99c24d89d98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3306b085-53a0-414a-ad07-d99c24d89d98" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e6d98965-a86c-46e2-b807-5a54a9532578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e6d98965-a86c-46e2-b807-5a54a9532578" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_ce53422f-5f93-4942-9ec8-6759fc707c3e" xlink:href="ino-20200930.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_ce53422f-5f93-4942-9ec8-6759fc707c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_110951a3-85e7-4af4-b958-60e7f763b264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_110951a3-85e7-4af4-b958-60e7f763b264" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_edbf9fd5-2455-41d7-b131-42321e35c200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_edbf9fd5-2455-41d7-b131-42321e35c200" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_1dab2f57-614a-418d-ae4b-820281a24d36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_1dab2f57-614a-418d-ae4b-820281a24d36" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ino-20200930.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended" id="i6f815b616f43456789fce91bbeae09ad_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ino-20200930.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended" id="i64756781b0da4dbabf69e496ba2f5c9d_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#StockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended" id="i34d97799bd7e40818408465c4dadeb00_StockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_535c21ce-fea6-4a7c-b4c7-95b83bff0ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_535c21ce-fea6-4a7c-b4c7-95b83bff0ad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7025520f-3590-494b-aa20-509d8af4dd2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7025520f-3590-494b-aa20-509d8af4dd2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_441407e5-3bab-4608-9a51-acb71791ad01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_441407e5-3bab-4608-9a51-acb71791ad01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfd32dba-8e82-4956-9412-767005b838f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfd32dba-8e82-4956-9412-767005b838f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e73ecee8-c588-48e8-b58d-9f93bdc03265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensation_e73ecee8-c588-48e8-b58d-9f93bdc03265" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_957d8db1-3fef-4062-96c6-2e6c2b33418a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_957d8db1-3fef-4062-96c6-2e6c2b33418a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_25b9f252-0cdf-4515-9481-4c607d1b883f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_25b9f252-0cdf-4515-9481-4c607d1b883f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6abe7eba-3850-45e3-9e19-013c7915b97a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6abe7eba-3850-45e3-9e19-013c7915b97a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_81405008-ea3c-4918-92df-5e5a8c8cc808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_81405008-ea3c-4918-92df-5e5a8c8cc808" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1f66ec8e-0f09-45df-bf52-e2c515266b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1f66ec8e-0f09-45df-bf52-e2c515266b2a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f53ed78b-c2cf-4be5-9aad-dc0c28ebc04c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f53ed78b-c2cf-4be5-9aad-dc0c28ebc04c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1e2c8067-4717-46d7-947d-e988a6c2e8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1e2c8067-4717-46d7-947d-e988a6c2e8d6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b2535b31-42eb-4be8-bef5-acdf9cb2be27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b2535b31-42eb-4be8-bef5-acdf9cb2be27" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_61da35ce-99f2-481d-ae22-b4e52e292848" xlink:href="ino-20200930.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_61da35ce-99f2-481d-ae22-b4e52e292848" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_127255eb-8619-4f15-a125-395b3bde8c65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:to="loc_srt_TitleOfIndividualAxis_127255eb-8619-4f15-a125-395b3bde8c65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_127255eb-8619-4f15-a125-395b3bde8c65_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_127255eb-8619-4f15-a125-395b3bde8c65" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_127255eb-8619-4f15-a125-395b3bde8c65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4c6dd009-c954-4979-964f-8f25b3d33505" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_127255eb-8619-4f15-a125-395b3bde8c65" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4c6dd009-c954-4979-964f-8f25b3d33505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_beeee2c5-b1e4-4194-a20b-c76b73d7de98" xlink:href="ino-20200930.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4c6dd009-c954-4979-964f-8f25b3d33505" xlink:to="loc_ino_EmployeesAndDirectorsMember_beeee2c5-b1e4-4194-a20b-c76b73d7de98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_ba424e2f-d351-45b3-9d6c-685b7a0b614b" xlink:href="ino-20200930.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4c6dd009-c954-4979-964f-8f25b3d33505" xlink:to="loc_ino_NonEmployeeMember_ba424e2f-d351-45b3-9d6c-685b7a0b614b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3c5d58a0-28f2-44ae-a0ec-a3928c12529b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:to="loc_us-gaap_PlanNameAxis_3c5d58a0-28f2-44ae-a0ec-a3928c12529b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3c5d58a0-28f2-44ae-a0ec-a3928c12529b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3c5d58a0-28f2-44ae-a0ec-a3928c12529b" xlink:to="loc_us-gaap_PlanNameDomain_3c5d58a0-28f2-44ae-a0ec-a3928c12529b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8bc89707-cacb-43a1-83fc-10adb5f2d1e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3c5d58a0-28f2-44ae-a0ec-a3928c12529b" xlink:to="loc_us-gaap_PlanNameDomain_8bc89707-cacb-43a1-83fc-10adb5f2d1e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_74285977-4503-4c20-a5f6-0b9cbe42af1a" xlink:href="ino-20200930.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8bc89707-cacb-43a1-83fc-10adb5f2d1e2" xlink:to="loc_ino_A2016IncentivePlanMember_74285977-4503-4c20-a5f6-0b9cbe42af1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_21318c64-78ec-412b-8132-f680aa7bbacb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_21318c64-78ec-412b-8132-f680aa7bbacb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_21318c64-78ec-412b-8132-f680aa7bbacb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_21318c64-78ec-412b-8132-f680aa7bbacb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_21318c64-78ec-412b-8132-f680aa7bbacb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6f765ad6-c393-47af-88ce-10f8ca1aa6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_21318c64-78ec-412b-8132-f680aa7bbacb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6f765ad6-c393-47af-88ce-10f8ca1aa6d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2e08105d-0c43-43e3-a8be-1bfcb736f8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6f765ad6-c393-47af-88ce-10f8ca1aa6d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2e08105d-0c43-43e3-a8be-1bfcb736f8b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_83040202-f63f-4a7e-9ea6-23880bacd5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6f765ad6-c393-47af-88ce-10f8ca1aa6d4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_83040202-f63f-4a7e-9ea6-23880bacd5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_df17e808-e817-4baa-aca1-c09b5d1d52aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:to="loc_us-gaap_AwardTypeAxis_df17e808-e817-4baa-aca1-c09b5d1d52aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df17e808-e817-4baa-aca1-c09b5d1d52aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_df17e808-e817-4baa-aca1-c09b5d1d52aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df17e808-e817-4baa-aca1-c09b5d1d52aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cef16bda-0de0-49a8-a68e-6a687a49f92d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_df17e808-e817-4baa-aca1-c09b5d1d52aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cef16bda-0de0-49a8-a68e-6a687a49f92d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9fecea11-51f5-4b25-8eab-326361c00a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cef16bda-0de0-49a8-a68e-6a687a49f92d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9fecea11-51f5-4b25-8eab-326361c00a2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_18af882e-af32-4a21-993e-540ec847df5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cef16bda-0de0-49a8-a68e-6a687a49f92d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_18af882e-af32-4a21-993e-540ec847df5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_23a49616-67f5-4786-8331-f838e66cdab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:to="loc_us-gaap_VestingAxis_23a49616-67f5-4786-8331-f838e66cdab9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_23a49616-67f5-4786-8331-f838e66cdab9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_23a49616-67f5-4786-8331-f838e66cdab9" xlink:to="loc_us-gaap_VestingDomain_23a49616-67f5-4786-8331-f838e66cdab9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_c03ed166-784a-42f9-b14b-8b749d064ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_23a49616-67f5-4786-8331-f838e66cdab9" xlink:to="loc_us-gaap_VestingDomain_c03ed166-784a-42f9-b14b-8b749d064ea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a3a9c7fd-3efd-4fe4-b587-fe2959d607c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_c03ed166-784a-42f9-b14b-8b749d064ea1" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a3a9c7fd-3efd-4fe4-b587-fe2959d607c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9728d8de-4c52-413b-ae8f-acbd46c603f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_c03ed166-784a-42f9-b14b-8b749d064ea1" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9728d8de-4c52-413b-ae8f-acbd46c603f1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20200930.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended" id="i947973a72fab46678fbc28175f51e6fc_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended" id="i75f325c9bf9e42279cfeb7170f4ff0b0_RelatedPartyTransactionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0db9c53f-3028-4289-8429-bb4f9f6471be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:href="ino-20200930.xsd#ino_RelatedPartyTransactionsTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0db9c53f-3028-4289-8429-bb4f9f6471be" xlink:to="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f8442810-4d18-4831-a92a-da08d29ed019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f8442810-4d18-4831-a92a-da08d29ed019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d530decd-ee8d-4d58-9c0c-6cd7112f6814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d530decd-ee8d-4d58-9c0c-6cd7112f6814" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_11a9ca91-eb08-4afe-8639-dbad70e2552f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_11a9ca91-eb08-4afe-8639-dbad70e2552f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_66865eb7-ba30-4fb3-a993-d1ed2de5d7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_66865eb7-ba30-4fb3-a993-d1ed2de5d7e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_f2fb7220-d092-4e90-8f55-ebf93a29d1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_f2fb7220-d092-4e90-8f55-ebf93a29d1c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_a3f113e5-d8c0-4eb1-8006-5eac12ca3db4" xlink:href="ino-20200930.xsd#ino_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_CollaborativeArrangementTerm_a3f113e5-d8c0-4eb1-8006-5eac12ca3db4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MilestoneBasedOwnershipTarget_e69db619-df84-4cfb-bce8-801e21f2635a" xlink:href="ino-20200930.xsd#ino_MilestoneBasedOwnershipTarget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_MilestoneBasedOwnershipTarget_e69db619-df84-4cfb-bce8-801e21f2635a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b43df9b-d13c-43b2-856a-3c95dfde2a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b43df9b-d13c-43b2-856a-3c95dfde2a1b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_e7300718-971f-4b0e-9bb5-ef130b2ac023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_e7300718-971f-4b0e-9bb5-ef130b2ac023" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_2af10790-ba18-4de3-aa1d-aa2ceb888dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_2af10790-ba18-4de3-aa1d-aa2ceb888dd2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InvestmentOwnedAdditionalSharesAcquired_d6ae1732-6ced-486f-9bcc-9fe624b5012a" xlink:href="ino-20200930.xsd#ino_InvestmentOwnedAdditionalSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_InvestmentOwnedAdditionalSharesAcquired_d6ae1732-6ced-486f-9bcc-9fe624b5012a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_93b517e9-0d76-4c7c-a061-51406cdecab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_93b517e9-0d76-4c7c-a061-51406cdecab5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_f2908dab-b67c-4168-bb6c-60a0b15a5210" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_f2908dab-b67c-4168-bb6c-60a0b15a5210" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_73b68394-7004-45f0-b2e1-9b5b2f38b2e5" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_73b68394-7004-45f0-b2e1-9b5b2f38b2e5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_27c53ab0-f0ab-4c32-9a27-7b4a8f8afcc8" xlink:href="ino-20200930.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_GrantProceedsReceived_27c53ab0-f0ab-4c32-9a27-7b4a8f8afcc8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_5696d988-90d3-42a0-9f6f-1a23836ebe71" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_5696d988-90d3-42a0-9f6f-1a23836ebe71" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0db9c53f-3028-4289-8429-bb4f9f6471be" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58622611-a12c-4c3a-89ec-4a6a73da9dbd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58622611-a12c-4c3a-89ec-4a6a73da9dbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_58622611-a12c-4c3a-89ec-4a6a73da9dbd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58622611-a12c-4c3a-89ec-4a6a73da9dbd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_58622611-a12c-4c3a-89ec-4a6a73da9dbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1da1fa6c-0708-40e8-aca0-948ba90693b6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58622611-a12c-4c3a-89ec-4a6a73da9dbd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1da1fa6c-0708-40e8-aca0-948ba90693b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_8ecd0a33-295d-45a9-9ab2-3dd6b1e3365d" xlink:href="ino-20200930.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1da1fa6c-0708-40e8-aca0-948ba90693b6" xlink:to="loc_ino_PlumblineLifeSciencesMember_8ecd0a33-295d-45a9-9ab2-3dd6b1e3365d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e987f1bd-b21c-4320-9456-021c2d4079a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e987f1bd-b21c-4320-9456-021c2d4079a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e987f1bd-b21c-4320-9456-021c2d4079a0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e987f1bd-b21c-4320-9456-021c2d4079a0" xlink:to="loc_us-gaap_RelatedPartyDomain_e987f1bd-b21c-4320-9456-021c2d4079a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9b02f3d2-1a30-40a6-8c1e-272a4dde3644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e987f1bd-b21c-4320-9456-021c2d4079a0" xlink:to="loc_us-gaap_RelatedPartyDomain_9b02f3d2-1a30-40a6-8c1e-272a4dde3644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_4c7a43f8-1465-4102-967f-b21b36915270" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9b02f3d2-1a30-40a6-8c1e-272a4dde3644" xlink:to="loc_srt_DirectorMember_4c7a43f8-1465-4102-967f-b21b36915270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1fd99e2d-12ec-437c-868a-f2fa55038fcd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:to="loc_srt_CounterpartyNameAxis_1fd99e2d-12ec-437c-868a-f2fa55038fcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1fd99e2d-12ec-437c-868a-f2fa55038fcd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1fd99e2d-12ec-437c-868a-f2fa55038fcd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1fd99e2d-12ec-437c-868a-f2fa55038fcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe1ce6bf-6d4c-4ca6-997e-fb2137c13d0f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1fd99e2d-12ec-437c-868a-f2fa55038fcd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe1ce6bf-6d4c-4ca6-997e-fb2137c13d0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneOneLifeSciencesMember_56b3e9a1-673c-47a9-b57b-b5769c4f10ea" xlink:href="ino-20200930.xsd#ino_GeneOneLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe1ce6bf-6d4c-4ca6-997e-fb2137c13d0f" xlink:to="loc_ino_GeneOneLifeSciencesMember_56b3e9a1-673c-47a9-b57b-b5769c4f10ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_e8bcff9f-f863-46bd-8fc9-fcc6e29900d3" xlink:href="ino-20200930.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe1ce6bf-6d4c-4ca6-997e-fb2137c13d0f" xlink:to="loc_ino_PlumblineLifeSciencesMember_e8bcff9f-f863-46bd-8fc9-fcc6e29900d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6f4d7b3b-c4d0-4429-a9ef-23a4d53794a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6f4d7b3b-c4d0-4429-a9ef-23a4d53794a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_6f4d7b3b-c4d0-4429-a9ef-23a4d53794a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6f4d7b3b-c4d0-4429-a9ef-23a4d53794a3" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_6f4d7b3b-c4d0-4429-a9ef-23a4d53794a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_30e23edd-13a4-4d31-a350-fb85e2fecd7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6f4d7b3b-c4d0-4429-a9ef-23a4d53794a3" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_30e23edd-13a4-4d31-a350-fb85e2fecd7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_dce99994-4c7a-4147-85a0-ae380c11adda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_30e23edd-13a4-4d31-a350-fb85e2fecd7d" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_dce99994-4c7a-4147-85a0-ae380c11adda" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:type="simple" xlink:href="ino-20200930.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended" id="i6d56f71e46704687b956d288dcbebbb2_Leases"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:type="simple" xlink:href="ino-20200930.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended" id="i7e0a3055f9de425f9c320d0a565a18a5_LeasesTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i656ea1bfa9254437b77a7f9dee7de217_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb8aa28a-d825-4ab6-9aac-5dd9ea6a7acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_4c16c77c-5e83-4165-9cae-e0c4bc6ab17a" xlink:href="ino-20200930.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb8aa28a-d825-4ab6-9aac-5dd9ea6a7acd" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_4c16c77c-5e83-4165-9cae-e0c4bc6ab17a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ad5a4f76-9cd0-43ac-995b-7c6d8e053a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb8aa28a-d825-4ab6-9aac-5dd9ea6a7acd" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ad5a4f76-9cd0-43ac-995b-7c6d8e053a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c9b2abdd-b5c4-4d15-b3ff-bede1586357f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb8aa28a-d825-4ab6-9aac-5dd9ea6a7acd" xlink:to="loc_us-gaap_LeaseCost_c9b2abdd-b5c4-4d15-b3ff-bede1586357f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_807b9a6b-3c97-4ab9-a20e-ac4238fd6a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb8aa28a-d825-4ab6-9aac-5dd9ea6a7acd" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_807b9a6b-3c97-4ab9-a20e-ac4238fd6a34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0976cac8-b0e4-4a85-957b-24b6a9570d6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_807b9a6b-3c97-4ab9-a20e-ac4238fd6a34" xlink:to="loc_srt_RangeAxis_0976cac8-b0e4-4a85-957b-24b6a9570d6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0976cac8-b0e4-4a85-957b-24b6a9570d6f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0976cac8-b0e4-4a85-957b-24b6a9570d6f" xlink:to="loc_srt_RangeMember_0976cac8-b0e4-4a85-957b-24b6a9570d6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad61f0d4-ef7b-4fc5-96eb-b666f3d61fe2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0976cac8-b0e4-4a85-957b-24b6a9570d6f" xlink:to="loc_srt_RangeMember_ad61f0d4-ef7b-4fc5-96eb-b666f3d61fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_146e584b-42b7-455c-91ed-40999c600bb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ad61f0d4-ef7b-4fc5-96eb-b666f3d61fe2" xlink:to="loc_srt_MinimumMember_146e584b-42b7-455c-91ed-40999c600bb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0669935c-866b-4558-a438-689c4a5bd007" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ad61f0d4-ef7b-4fc5-96eb-b666f3d61fe2" xlink:to="loc_srt_MaximumMember_0669935c-866b-4558-a438-689c4a5bd007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5962c4c4-aa2a-4e48-a1fd-438c6ffb8754" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_807b9a6b-3c97-4ab9-a20e-ac4238fd6a34" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5962c4c4-aa2a-4e48-a1fd-438c6ffb8754" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5962c4c4-aa2a-4e48-a1fd-438c6ffb8754_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5962c4c4-aa2a-4e48-a1fd-438c6ffb8754" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5962c4c4-aa2a-4e48-a1fd-438c6ffb8754_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_302366c4-5cdd-45fe-ad48-e20ef308df24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5962c4c4-aa2a-4e48-a1fd-438c6ffb8754" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_302366c4-5cdd-45fe-ad48-e20ef308df24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_53f8b242-5e0a-452a-894c-ab43ad8a0bfc" xlink:href="ino-20200930.xsd#ino_SanDiegoOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_302366c4-5cdd-45fe-ad48-e20ef308df24" xlink:to="loc_ino_SanDiegoOfficeMember_53f8b242-5e0a-452a-894c-ab43ad8a0bfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_24872629-ed30-497b-a8ee-06144494fe09" xlink:href="ino-20200930.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_302366c4-5cdd-45fe-ad48-e20ef308df24" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_24872629-ed30-497b-a8ee-06144494fe09" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#LeasesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended" id="if3550862d8c140269cab38bf55944caa_LeasesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20200930.xsd#CollaborativeAgreements"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended" id="i263093eeee5047cab46a2c4746a1a9d8_CollaborativeAgreements"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended" id="ieb46053cfded45f38a7137302881dfd0_CollaborativeAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_20adc0bb-9916-4ca0-8602-ab7fc1f78ee0" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_20adc0bb-9916-4ca0-8602-ab7fc1f78ee0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_ee0fcf4e-824c-497c-85d1-c7c98fa2b716" xlink:href="ino-20200930.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_ee0fcf4e-824c-497c-85d1-c7c98fa2b716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_544db971-d886-44dd-97b2-6fca0e2b9531" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_544db971-d886-44dd-97b2-6fca0e2b9531" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_9ea8027d-09ba-4a07-8d00-1874ba46da77" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_9ea8027d-09ba-4a07-8d00-1874ba46da77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_51dbbaf8-71fe-4359-aedf-e4b1c2736aa2" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_51dbbaf8-71fe-4359-aedf-e4b1c2736aa2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_3b55eb3f-063e-4665-903b-6fedb3135c6c" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_3b55eb3f-063e-4665-903b-6fedb3135c6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_f8937e84-52d3-40e0-8de7-1b8b53d2d7fd" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_f8937e84-52d3-40e0-8de7-1b8b53d2d7fd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_193c236c-45c9-4471-a654-e791af770562" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_193c236c-45c9-4471-a654-e791af770562" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_61446b50-e245-4a43-a774-62027d7553a2" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_61446b50-e245-4a43-a774-62027d7553a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_09cccec7-62fa-4c4b-a147-c3fad9890bf3" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_09cccec7-62fa-4c4b-a147-c3fad9890bf3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_8e859b54-9fbd-4031-bc38-e66217ac6705" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_8e859b54-9fbd-4031-bc38-e66217ac6705" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_746a04ce-0c1e-4a10-b480-4c0354502717" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_746a04ce-0c1e-4a10-b480-4c0354502717" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfAdditionalProducts_5a70da81-71e3-4607-b2a0-4d022c819d69" xlink:href="ino-20200930.xsd#ino_NumberOfAdditionalProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_NumberOfAdditionalProducts_5a70da81-71e3-4607-b2a0-4d022c819d69" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a1313f5f-cce2-430c-be74-461d5ea784ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a1313f5f-cce2-430c-be74-461d5ea784ff" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_f31705e6-0ad9-4182-b4ed-2dbed35e30dd" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_f31705e6-0ad9-4182-b4ed-2dbed35e30dd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_96b133db-8133-4d66-8b5d-0c78140a29da" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_96b133db-8133-4d66-8b5d-0c78140a29da" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_2ac1cd51-2179-4f0e-8936-9ca838fe61b4" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_DeferredGrantFundingCurrent_2ac1cd51-2179-4f0e-8936-9ca838fe61b4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_f9c0a1c0-faea-4d7e-8314-5bf60209868f" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_f9c0a1c0-faea-4d7e-8314-5bf60209868f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_6667faa0-da78-49c1-8a5d-c32e9a498953" xlink:href="ino-20200930.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_6667faa0-da78-49c1-8a5d-c32e9a498953" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_b9408c92-c3a7-491b-a83a-b68c79927cd2" xlink:href="ino-20200930.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_GrantProceedsReceived_b9408c92-c3a7-491b-a83a-b68c79927cd2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_4521a82d-7a9f-4025-ae75-2ff2c0d107b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_4521a82d-7a9f-4025-ae75-2ff2c0d107b4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b7206c68-51ab-4145-a0f1-b0f927b82377" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:to="loc_srt_CounterpartyNameAxis_b7206c68-51ab-4145-a0f1-b0f927b82377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7206c68-51ab-4145-a0f1-b0f927b82377_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b7206c68-51ab-4145-a0f1-b0f927b82377" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7206c68-51ab-4145-a0f1-b0f927b82377_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b7206c68-51ab-4145-a0f1-b0f927b82377" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_9b2b7f7e-4a5f-4d4f-8b4f-af0059216fc4" xlink:href="ino-20200930.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:to="loc_ino_ApolloBioMember_9b2b7f7e-4a5f-4d4f-8b4f-af0059216fc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_b3fdcc84-a078-4d8b-8232-7c0fe74e43b5" xlink:href="ino-20200930.xsd#ino_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:to="loc_ino_AstraZenecaMember_b3fdcc84-a078-4d8b-8232-7c0fe74e43b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_b46f20bd-534c-43c7-af5d-fbc68d4e8ed1" xlink:href="ino-20200930.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_b46f20bd-534c-43c7-af5d-fbc68d4e8ed1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_a4110739-a8ae-4a20-b53e-e6901401f0de" xlink:href="ino-20200930.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_a4110739-a8ae-4a20-b53e-e6901401f0de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_9a02a0f7-baa1-439e-9552-6b72d03422b5" xlink:href="ino-20200930.xsd#ino_DepartmentOfDefenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:to="loc_ino_DepartmentOfDefenceMember_9a02a0f7-baa1-439e-9552-6b72d03422b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a84b7649-7d14-42b4-b3e5-ada391048b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a84b7649-7d14-42b4-b3e5-ada391048b00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a84b7649-7d14-42b4-b3e5-ada391048b00_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a84b7649-7d14-42b4-b3e5-ada391048b00" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a84b7649-7d14-42b4-b3e5-ada391048b00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86a0fcb1-1f71-4116-977b-b1302d5a2587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a84b7649-7d14-42b4-b3e5-ada391048b00" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86a0fcb1-1f71-4116-977b-b1302d5a2587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_07d4599b-1b2d-4253-803a-26d33adebbd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86a0fcb1-1f71-4116-977b-b1302d5a2587" xlink:to="loc_us-gaap_CollaborativeArrangementMember_07d4599b-1b2d-4253-803a-26d33adebbd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e6ec984b-56b8-4177-9dc5-e812c8074852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e6ec984b-56b8-4177-9dc5-e812c8074852" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e6ec984b-56b8-4177-9dc5-e812c8074852_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e6ec984b-56b8-4177-9dc5-e812c8074852" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e6ec984b-56b8-4177-9dc5-e812c8074852_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_61531691-c4af-4f20-ad96-d800a4d2414f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e6ec984b-56b8-4177-9dc5-e812c8074852" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_61531691-c4af-4f20-ad96-d800a4d2414f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_51311681-9bef-4ee3-8651-37cd2672c509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_61531691-c4af-4f20-ad96-d800a4d2414f" xlink:to="loc_us-gaap_ForeignCountryMember_51311681-9bef-4ee3-8651-37cd2672c509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0484c4f2-0d35-4db1-b588-dec82cfb26c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:to="loc_srt_ProductOrServiceAxis_0484c4f2-0d35-4db1-b588-dec82cfb26c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0484c4f2-0d35-4db1-b588-dec82cfb26c7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0484c4f2-0d35-4db1-b588-dec82cfb26c7" xlink:to="loc_srt_ProductsAndServicesDomain_0484c4f2-0d35-4db1-b588-dec82cfb26c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0484c4f2-0d35-4db1-b588-dec82cfb26c7" xlink:to="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_1cc75be2-844e-4888-bbc3-d8a07ab58361" xlink:href="ino-20200930.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_1cc75be2-844e-4888-bbc3-d8a07ab58361" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_cc61647c-d8e4-4d8d-ae5b-30c0839577b8" xlink:href="ino-20200930.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_cc61647c-d8e4-4d8d-ae5b-30c0839577b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_89cf797c-7447-4f51-b5b4-a39768c45f10" xlink:href="ino-20200930.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_89cf797c-7447-4f51-b5b4-a39768c45f10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_77a1f1ba-d246-47b2-8823-4898fd559a50" xlink:href="ino-20200930.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_77a1f1ba-d246-47b2-8823-4898fd559a50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_65b3e611-95d3-42a9-8d95-365ce00abb6c" xlink:href="ino-20200930.xsd#ino_INO4800Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:to="loc_ino_INO4800Member_65b3e611-95d3-42a9-8d95-365ce00abb6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember_07ab3f92-ac0a-450a-812e-c28d3ae224f6" xlink:href="ino-20200930.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:to="loc_ino_CELLECTRA2000DeviceMember_07ab3f92-ac0a-450a-812e-c28d3ae224f6" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20200930.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended" id="i8de625db158c49328783356e351ec08f_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsInc"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended" id="i09f26fca91524f8f928ff4d7849dec5d_GeneosTherapeuticsInc"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended" id="i9642f80f6418458dafae3ca569ee2355_GeneosTherapeuticsIncTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended" id="i5ccd8c284d1c41fc8a30d1d1a85915eb_GeneosTherapeuticsIncNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ff152401-bd31-4176-a82e-bbfd4eda905f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ff152401-bd31-4176-a82e-bbfd4eda905f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_c0c3f476-1203-420b-8ee3-b8a96f6b2608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_c0c3f476-1203-420b-8ee3-b8a96f6b2608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_89f7a009-2356-43fd-b29f-ed938ca94ec6" xlink:href="ino-20200930.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_89f7a009-2356-43fd-b29f-ed938ca94ec6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_83d34e9e-a312-45d7-b079-dc9bd6f40d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_83d34e9e-a312-45d7-b079-dc9bd6f40d18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_3413d83a-d340-45ea-bea1-34bbd947dfc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_3413d83a-d340-45ea-bea1-34bbd947dfc0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_399cf48f-7b84-4e2f-a49e-03c58d889283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_399cf48f-7b84-4e2f-a49e-03c58d889283" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_298ccefe-6f99-4cbb-96dd-2e8023a260ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_298ccefe-6f99-4cbb-96dd-2e8023a260ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c02257b3-d4ae-4efc-ae71-56b295e09425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_EquityMethodInvestments_c02257b3-d4ae-4efc-ae71-56b295e09425" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_2185d9a6-8f7e-4f83-a3dc-47f45f8581a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_MinorityInterestTable_2185d9a6-8f7e-4f83-a3dc-47f45f8581a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d0a52bfa-7865-470e-8294-a6027d334487" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_2185d9a6-8f7e-4f83-a3dc-47f45f8581a1" xlink:to="loc_srt_CounterpartyNameAxis_d0a52bfa-7865-470e-8294-a6027d334487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0a52bfa-7865-470e-8294-a6027d334487_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d0a52bfa-7865-470e-8294-a6027d334487" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0a52bfa-7865-470e-8294-a6027d334487_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5cd9612-55f4-4906-9c59-b0fe366e7fc6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d0a52bfa-7865-470e-8294-a6027d334487" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5cd9612-55f4-4906-9c59-b0fe366e7fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_8df4da20-dec2-4525-bd9f-9a2be0ae689c" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5cd9612-55f4-4906-9c59-b0fe366e7fc6" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_8df4da20-dec2-4525-bd9f-9a2be0ae689c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_9df40370-63aa-46c0-b1d9-3dfe6c6492ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_2185d9a6-8f7e-4f83-a3dc-47f45f8581a1" xlink:to="loc_srt_OwnershipAxis_9df40370-63aa-46c0-b1d9-3dfe6c6492ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9df40370-63aa-46c0-b1d9-3dfe6c6492ea_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_9df40370-63aa-46c0-b1d9-3dfe6c6492ea" xlink:to="loc_srt_OwnershipDomain_9df40370-63aa-46c0-b1d9-3dfe6c6492ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7f1ea7c8-bc51-45b5-94a2-420e67abcea6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_9df40370-63aa-46c0-b1d9-3dfe6c6492ea" xlink:to="loc_srt_OwnershipDomain_7f1ea7c8-bc51-45b5-94a2-420e67abcea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_c5603cdc-93eb-46c3-994d-7c08f162ba2a" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_7f1ea7c8-bc51-45b5-94a2-420e67abcea6" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_c5603cdc-93eb-46c3-994d-7c08f162ba2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dc28704e-24e4-466d-a61c-4bfec61664c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_2185d9a6-8f7e-4f83-a3dc-47f45f8581a1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dc28704e-24e4-466d-a61c-4bfec61664c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dc28704e-24e4-466d-a61c-4bfec61664c9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dc28704e-24e4-466d-a61c-4bfec61664c9" xlink:to="loc_us-gaap_ClassOfStockDomain_dc28704e-24e4-466d-a61c-4bfec61664c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c46bfe37-19ee-4ca0-a64e-5483228755a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dc28704e-24e4-466d-a61c-4bfec61664c9" xlink:to="loc_us-gaap_ClassOfStockDomain_c46bfe37-19ee-4ca0-a64e-5483228755a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cd2ef110-0b4c-4105-b0b7-c8ccc9f202ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c46bfe37-19ee-4ca0-a64e-5483228755a2" xlink:to="loc_us-gaap_CommonStockMember_cd2ef110-0b4c-4105-b0b7-c8ccc9f202ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_31af79c5-77c3-4e7e-a0ab-d7330be76837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c46bfe37-19ee-4ca0-a64e-5483228755a2" xlink:to="loc_us-gaap_PreferredStockMember_31af79c5-77c3-4e7e-a0ab-d7330be76837" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended" id="i7956229fba9640459dd2ef3e57081645_GeneosTherapeuticsIncDeconsolidationAccountingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash_0a719684-90c3-4f6b-86a5-d5eb3f7174a5" xlink:href="ino-20200930.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_ino_WorkingCapitalExcludingCash_0a719684-90c3-4f6b-86a5-d5eb3f7174a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_de2030c1-0d65-4305-a819-8b161018abf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_NotesPayable_de2030c1-0d65-4305-a819-8b161018abf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4368c86a-762c-4a7e-8309-1d4c65c3b40e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4368c86a-762c-4a7e-8309-1d4c65c3b40e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_1af56b05-03fc-4ad3-8469-26ce6f89602c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_MinorityInterest_1af56b05-03fc-4ad3-8469-26ce6f89602c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_9740fc50-7594-4a36-b714-97232a4f3d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_RetainedInterestFairValueDisclosure_9740fc50-7594-4a36-b714-97232a4f3d62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_824c4eb0-c7ff-441b-a70e-f6a295a38599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_824c4eb0-c7ff-441b-a70e-f6a295a38599" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_6780e57f-5a7d-40eb-91a8-779674fc7fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_6780e57f-5a7d-40eb-91a8-779674fc7fd0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_f1b98eab-b433-4c72-a589-9657d9890db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_MinorityInterestTable_f1b98eab-b433-4c72-a589-9657d9890db7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d2f512b6-ef01-4d6f-9592-a30dda7f2a6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_f1b98eab-b433-4c72-a589-9657d9890db7" xlink:to="loc_srt_CounterpartyNameAxis_d2f512b6-ef01-4d6f-9592-a30dda7f2a6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2f512b6-ef01-4d6f-9592-a30dda7f2a6e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d2f512b6-ef01-4d6f-9592-a30dda7f2a6e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2f512b6-ef01-4d6f-9592-a30dda7f2a6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1de92262-3c51-4233-81bc-23c10dcaec92" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d2f512b6-ef01-4d6f-9592-a30dda7f2a6e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1de92262-3c51-4233-81bc-23c10dcaec92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_2f1b3cad-e2ee-4f85-9751-28954a567e36" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1de92262-3c51-4233-81bc-23c10dcaec92" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_2f1b3cad-e2ee-4f85-9751-28954a567e36" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncInvestmentInGeneosDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="extended" id="i1da3c3ae65b94e49b2ca7c5749b9fa9f_GeneosTherapeuticsIncInvestmentInGeneosDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_69274274-4667-428a-9f16-6debb253eb80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_bf468404-d60f-4fe4-9f5c-3b6c3ef1a694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_69274274-4667-428a-9f16-6debb253eb80" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_bf468404-d60f-4fe4-9f5c-3b6c3ef1a694" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_3ed61c49-5340-47c2-bbff-b65f386576a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_69274274-4667-428a-9f16-6debb253eb80" xlink:to="loc_us-gaap_SharePrice_3ed61c49-5340-47c2-bbff-b65f386576a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_527c1ca2-acc7-450c-b7bc-20ea8e379a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_69274274-4667-428a-9f16-6debb253eb80" xlink:to="loc_us-gaap_EquityMethodInvestments_527c1ca2-acc7-450c-b7bc-20ea8e379a19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_de8f4c6a-fb01-423b-9e61-9bf58afd41c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_69274274-4667-428a-9f16-6debb253eb80" xlink:to="loc_us-gaap_MinorityInterestTable_de8f4c6a-fb01-423b-9e61-9bf58afd41c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7c2aea13-fb55-435e-8e26-9e72e2de9386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_de8f4c6a-fb01-423b-9e61-9bf58afd41c3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7c2aea13-fb55-435e-8e26-9e72e2de9386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7c2aea13-fb55-435e-8e26-9e72e2de9386_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7c2aea13-fb55-435e-8e26-9e72e2de9386" xlink:to="loc_us-gaap_ClassOfStockDomain_7c2aea13-fb55-435e-8e26-9e72e2de9386_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5704b635-b9df-4165-ad01-f6114312ba9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7c2aea13-fb55-435e-8e26-9e72e2de9386" xlink:to="loc_us-gaap_ClassOfStockDomain_5704b635-b9df-4165-ad01-f6114312ba9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_759bbde2-d6c4-45a0-9021-56d9f87029ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5704b635-b9df-4165-ad01-f6114312ba9b" xlink:to="loc_us-gaap_CommonStockMember_759bbde2-d6c4-45a0-9021-56d9f87029ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_092aeb95-13cd-4b6a-aa15-850c224127c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5704b635-b9df-4165-ad01-f6114312ba9b" xlink:to="loc_us-gaap_PreferredStockMember_092aeb95-13cd-4b6a-aa15-850c224127c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b670e600-fc15-47be-81b3-a9ab674eff77" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_de8f4c6a-fb01-423b-9e61-9bf58afd41c3" xlink:to="loc_srt_CounterpartyNameAxis_b670e600-fc15-47be-81b3-a9ab674eff77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b670e600-fc15-47be-81b3-a9ab674eff77_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b670e600-fc15-47be-81b3-a9ab674eff77" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b670e600-fc15-47be-81b3-a9ab674eff77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aee78f3e-0e2b-4979-b90e-9d786f47101c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b670e600-fc15-47be-81b3-a9ab674eff77" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aee78f3e-0e2b-4979-b90e-9d786f47101c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_5bf93f7c-1bc2-419e-94b0-6b65447b2ba4" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aee78f3e-0e2b-4979-b90e-9d786f47101c" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_5bf93f7c-1bc2-419e-94b0-6b65447b2ba4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended" id="i7a6751e307174f51a49d15a4309cf4eb_GeneosTherapeuticsIncFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_1c6030d9-c386-41c6-8b56-fb071c452c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_e3f2e167-7148-46e3-9bff-8c44b2f12849" xlink:href="ino-20200930.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c6030d9-c386-41c6-8b56-fb071c452c7a" xlink:to="loc_ino_AlternativeInvestmentMeasurementInputTerm_e3f2e167-7148-46e3-9bff-8c44b2f12849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_712ddc96-74a6-4879-85f3-0685f7eee022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c6030d9-c386-41c6-8b56-fb071c452c7a" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_712ddc96-74a6-4879-85f3-0685f7eee022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_1f6a7600-c0e0-4391-ac85-313446197529" xlink:href="ino-20200930.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c6030d9-c386-41c6-8b56-fb071c452c7a" xlink:to="loc_ino_EquityMethodInvestmentEnterpriseValue_1f6a7600-c0e0-4391-ac85-313446197529" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_3a8ad1e9-725b-43f5-bffd-3c35d2472ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c6030d9-c386-41c6-8b56-fb071c452c7a" xlink:to="loc_us-gaap_MinorityInterestTable_3a8ad1e9-725b-43f5-bffd-3c35d2472ae6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3aba1439-476e-4710-8f6e-a3b291f6688c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_3a8ad1e9-725b-43f5-bffd-3c35d2472ae6" xlink:to="loc_srt_CounterpartyNameAxis_3aba1439-476e-4710-8f6e-a3b291f6688c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3aba1439-476e-4710-8f6e-a3b291f6688c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3aba1439-476e-4710-8f6e-a3b291f6688c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3aba1439-476e-4710-8f6e-a3b291f6688c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45acc914-eeaf-4822-a331-698c5f5cf302" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3aba1439-476e-4710-8f6e-a3b291f6688c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45acc914-eeaf-4822-a331-698c5f5cf302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_a427955b-8a3f-4602-b744-0fcaba3089c3" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45acc914-eeaf-4822-a331-698c5f5cf302" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_a427955b-8a3f-4602-b744-0fcaba3089c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_350128a2-0d1a-434e-aca2-8d60d093bde8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_3a8ad1e9-725b-43f5-bffd-3c35d2472ae6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_350128a2-0d1a-434e-aca2-8d60d093bde8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_350128a2-0d1a-434e-aca2-8d60d093bde8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_350128a2-0d1a-434e-aca2-8d60d093bde8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_350128a2-0d1a-434e-aca2-8d60d093bde8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f22b0ae0-1e80-4126-afb8-11e3f0172016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_350128a2-0d1a-434e-aca2-8d60d093bde8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f22b0ae0-1e80-4126-afb8-11e3f0172016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_78bc1099-101e-4f99-b6d7-39a9685cdc50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f22b0ae0-1e80-4126-afb8-11e3f0172016" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_78bc1099-101e-4f99-b6d7-39a9685cdc50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_861b9ffb-4f74-4305-beae-a16378094ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f22b0ae0-1e80-4126-afb8-11e3f0172016" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_861b9ffb-4f74-4305-beae-a16378094ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_362b9193-4efc-4221-89e0-d38510048df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f22b0ae0-1e80-4126-afb8-11e3f0172016" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_362b9193-4efc-4221-89e0-d38510048df4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncPreferredstockInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="extended" id="ic7a3fe8f9c5a4fe89c57baa1a72889ef_GeneosTherapeuticsIncPreferredstockInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_1c6c9f09-77ff-461b-9e17-83df089a65c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_344c1c7f-573b-4ecd-839b-630e2a15c6ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c6c9f09-77ff-461b-9e17-83df089a65c5" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_344c1c7f-573b-4ecd-839b-630e2a15c6ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_54a4627c-2917-43fe-a9ca-f55c3ab98b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_344c1c7f-573b-4ecd-839b-630e2a15c6ec" xlink:to="loc_us-gaap_EquityMethodInvestments_54a4627c-2917-43fe-a9ca-f55c3ab98b92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c4184fd5-1927-4036-8ea0-4c6aba97d41b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_344c1c7f-573b-4ecd-839b-630e2a15c6ec" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c4184fd5-1927-4036-8ea0-4c6aba97d41b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2b4616e5-b9bb-4e01-84a7-12ecea85beba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_babb1456-45bc-40c8-904b-fbeb12a47bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c6c9f09-77ff-461b-9e17-83df089a65c5" xlink:to="loc_us-gaap_MinorityInterestTable_babb1456-45bc-40c8-904b-fbeb12a47bdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0e8c28b3-29ff-4531-8237-00d1bf896399" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_babb1456-45bc-40c8-904b-fbeb12a47bdd" xlink:to="loc_srt_CounterpartyNameAxis_0e8c28b3-29ff-4531-8237-00d1bf896399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e8c28b3-29ff-4531-8237-00d1bf896399_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0e8c28b3-29ff-4531-8237-00d1bf896399" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e8c28b3-29ff-4531-8237-00d1bf896399_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90a02ea5-e308-4f09-b19a-35d454355f93" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0e8c28b3-29ff-4531-8237-00d1bf896399" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90a02ea5-e308-4f09-b19a-35d454355f93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_81925496-90ad-4cbd-9c07-41463a5774f4" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90a02ea5-e308-4f09-b19a-35d454355f93" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_81925496-90ad-4cbd-9c07-41463a5774f4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ino-20200930.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended" id="ie235ec65d2c349b5b71bd86d0a4c94de_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended" id="i014ecf75a4ff4f70879218d9f2dee9fd_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_67d7f388-e336-4d93-a32d-a563e670cb31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_fa45bce6-3cb3-4aa1-a14c-46bf23cc9e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_67d7f388-e336-4d93-a32d-a563e670cb31" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_fa45bce6-3cb3-4aa1-a14c-46bf23cc9e91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_88275ea3-af6c-4986-8ee5-0954975f929d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_67d7f388-e336-4d93-a32d-a563e670cb31" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_88275ea3-af6c-4986-8ee5-0954975f929d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_7cb65c05-cd6c-43f4-ae79-5bada40572ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_67d7f388-e336-4d93-a32d-a563e670cb31" xlink:to="loc_us-gaap_SubsequentEventTable_7cb65c05-cd6c-43f4-ae79-5bada40572ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f5835208-45ff-440c-98e2-696530c4abf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7cb65c05-cd6c-43f4-ae79-5bada40572ea" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f5835208-45ff-440c-98e2-696530c4abf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f5835208-45ff-440c-98e2-696530c4abf8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f5835208-45ff-440c-98e2-696530c4abf8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f5835208-45ff-440c-98e2-696530c4abf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3ad23261-1b0c-4f70-ab48-b1c46b28ed52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f5835208-45ff-440c-98e2-696530c4abf8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3ad23261-1b0c-4f70-ab48-b1c46b28ed52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_58a7aad8-9b67-4ebd-a58d-a465d6c85a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3ad23261-1b0c-4f70-ab48-b1c46b28ed52" xlink:to="loc_us-gaap_ConvertibleDebtMember_58a7aad8-9b67-4ebd-a58d-a465d6c85a69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_db91e23c-d727-4c46-8f90-39bc7f1fcc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7cb65c05-cd6c-43f4-ae79-5bada40572ea" xlink:to="loc_us-gaap_StatementClassOfStockAxis_db91e23c-d727-4c46-8f90-39bc7f1fcc4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_db91e23c-d727-4c46-8f90-39bc7f1fcc4e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_db91e23c-d727-4c46-8f90-39bc7f1fcc4e" xlink:to="loc_us-gaap_ClassOfStockDomain_db91e23c-d727-4c46-8f90-39bc7f1fcc4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_275fc9d4-0e8b-4a51-84d6-67101a73193a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_db91e23c-d727-4c46-8f90-39bc7f1fcc4e" xlink:to="loc_us-gaap_ClassOfStockDomain_275fc9d4-0e8b-4a51-84d6-67101a73193a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a5745123-cb1f-4db9-ad14-20fcd1a2d3e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_275fc9d4-0e8b-4a51-84d6-67101a73193a" xlink:to="loc_us-gaap_CommonStockMember_a5745123-cb1f-4db9-ad14-20fcd1a2d3e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b919b49e-03a4-4638-959e-76daef7156f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7cb65c05-cd6c-43f4-ae79-5bada40572ea" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b919b49e-03a4-4638-959e-76daef7156f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b919b49e-03a4-4638-959e-76daef7156f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b919b49e-03a4-4638-959e-76daef7156f4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b919b49e-03a4-4638-959e-76daef7156f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_93e7cea9-5155-491e-aed3-932ed2ae700a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b919b49e-03a4-4638-959e-76daef7156f4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_93e7cea9-5155-491e-aed3-932ed2ae700a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_67247a37-ed1a-43f0-8ea4-ef99aa6e0e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_93e7cea9-5155-491e-aed3-932ed2ae700a" xlink:to="loc_us-gaap_SubsequentEventMember_67247a37-ed1a-43f0-8ea4-ef99aa6e0e13" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ino-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:124dcabe-323e-4d00-a29d-21ddeb618d02,g:528b4586-6faf-4a31-a887-4db858d575b9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_91f96237-e6ca-402e-af88-de3230a5ef2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e9ef676c-09cc-4fe0-8ed2-88b3ed825aa8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8ee0ca5a-a784-49d0-be62-d5ee83743e96_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_a7941016-420f-4eb3-bfaf-40e630c6f553_negatedLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_790a25aa-b335-48f0-8a85-be9a424148e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derecognition of the derivative liability upon conversion</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e558fe2a-6f56-457b-a016-321997d0038f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4ed36374-855f-4fad-953b-8f8785aadedb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_580baebb-8ff0-4f54-bc0d-ce528d706b16_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_05a7cfd4-1223-4249-8681-039a52fed8eb_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_1212e899-345c-44d1-8ea2-26dad00cb7a4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_35ff5f3f-91dd-4ad9-8d95-d0e0712d379b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5d4d8acd-1674-4a15-a51b-0cf957fd6225_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_de646a5c-a683-4fdd-a888-53d4052b9c46_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_db228797-d25a-4c23-b492-47c9bb5e3e28_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_8f312a4f-dbef-4952-a481-96abd0696183_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entity, net of current portion</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_0a94bf26-e9c4-4605-96eb-58e3964f4a4a_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses related to affiliated entity</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5ad18450-fa21-417f-896f-2486afab7d9f_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite lived:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_e7110230-a32d-4a1a-a0a8-728444412a4e_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2260701c-147f-487d-b556-cec9913ebfcb_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ed8214a-142f-45c4-bebe-2f33ef3f871e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dc237e3-0747-4fd7-b0cb-ef3cfb66d11c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_5e81a877-8262-4f57-8fea-77561be8aa10_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_7c3e1fbf-9d24-49cd-9601-f560a8e5d459_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_ef9965ca-8f9b-456d-9651-7214afe012a3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_363dbe63-5e1a-4bb5-bc79-63d5ded9aba0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_16d5c9e0-4f98-45c2-bc48-fc6925b9f1ed_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0ad90c45-ee39-4085-ab28-55614c42454b_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2e5b7884-f060-4e0d-8b48-840d59ac1e16_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_d598f6ee-1626-4612-abb6-194d635421e9_terseLabel_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under share based compensation plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_label_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_documentation_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:href="ino-20200930.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:to="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2007IncentivePlanMember_ddddbf88-de89-449e-8d6b-9fe2fa62e8bd_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember" xlink:href="ino-20200930.xsd#ino_A2007IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember" xlink:to="lab_ino_A2007IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ece8dca4-151c-4aec-acea-4017cf25a82c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible senior notes and convertible bonds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1cf13eee-92e6-4d29-8c86-973b0d332000_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_eb42b86d-afe6-4cd1-a392-80a46599862c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs related to issuance of convertible senior notes and convertible bonds</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3fe919ff-a9d0-4331-8626-23fdf911319e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_f06183eb-26a4-4604-afaa-94033c13d1fb_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign corporate income taxes reducing upfront payment</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_label_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementCorporateIncomeTax" xlink:to="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1e5189a2-dafb-4937-961c-c2e1dcc3d17e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantProceedsReceived_cffbc317-d08e-48b6-ae41-76ff7463bfe6_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contra-research and development expense</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_label_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived" xlink:href="ino-20200930.xsd#ino_GrantProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived" xlink:to="lab_ino_GrantProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d4832889-8f0c-43bc-9eac-f2865dda9e02_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_cb68397d-fe44-4f3a-9852-1db6e22552e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized loss on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_953e2ebb-e8bd-46a6-9ccc-5ed8b5f317e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_bc89b11e-663f-45bc-a70a-bfa32d1b95ff_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, net book value</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Net</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:href="ino-20200930.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:to="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_fd7f9da4-3303-4895-955f-ebd05191fa7b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_79b964d0-d07f-46fb-b0a7-b457ae59db9f_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ec354adf-05e7-46d1-8f72-885945933728_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4476e355-2771-4034-ab97-818aa22cb661_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ba55f572-342c-4bb9-8d51-97deea43df55_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8826f8ef-329e-4218-abc1-7f10a4a77c59_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_a407e9a9-2054-4b9d-a9f6-2f7d1307ef10_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f61e896f-4cd7-442b-ab5b-23ddc84603c1_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_e6bd3a29-9c85-413f-8536-41d4c42487e7_terseLabel_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2025</link:label>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ino-20200930.xsd#ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d8ed44d5-4bfb-4a4f-9dee-05f369a18e70_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f397be5a-c0d7-41c6-be08-6ae826f6468f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4cd9381d-3ccb-4533-a96f-1b36bf1bb547_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2e89dda3-c24e-4079-a034-a7a312e638d7_netLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e35b95d7-3100-467c-9090-882aa3ceec3d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_317efc6a-e42b-4fce-90e2-dba6f3a883c8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_3bfee11b-66c3-4aa9-bf9c-4708268a1d16_terseLabel_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, measurement input, expected term</link:label>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_label_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input, Term</link:label>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_documentation_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm" xlink:href="ino-20200930.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AlternativeInvestmentMeasurementInputTerm" xlink:to="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_8069a806-ce07-4f62-a789-d3fbdafe4007_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Territory expansion option period</link:label>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Territory Expansion Option Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Territory Expansion Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:to="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_38ba42c8-b2df-46a3-a445-8bd21b2dab0b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_e2cc007b-ea84-4b62-9a6c-ff196205224f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_858c4756-c79d-48b3-bc01-35fb9400ca1e_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_c273a679-8bdd-4b15-a0b5-5cab2ade8a3e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_bf222c95-3c97-4ccc-a23c-6153f5c2b3ed_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d61723ab-98b9-4c79-a802-0d5feb9a984f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_10ee7b6c-aaa9-40aa-91a3-97711bb22565_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DepartmentOfDefenceMember_0bf33d39-30f0-4a7a-8b13-b8e93a7dfaf2_terseLabel_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defence</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_label_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_documentation_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember" xlink:href="ino-20200930.xsd#ino_DepartmentOfDefenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DepartmentOfDefenceMember" xlink:to="lab_ino_DepartmentOfDefenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_368a7d7a-0869-4191-99d4-3a1702e28f8a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_95b24939-77ba-40f1-bad6-e37bfea0385d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_32cf858f-65c1-4abc-b901-1399f0b1e6a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_801f15f3-aa7c-4df7-bfe5-16eebfc51140_terseLabel_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Bonds</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember" xlink:href="ino-20200930.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2019ConvertibleBondsMember" xlink:to="lab_ino_December2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_eec0d335-2605-47f2-a103-dd2bcee1f570_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_606888fa-30e4-42b5-9874-05c02bd0bf9c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_5ff5558f-358f-4e3e-969b-23fc67c98ba2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_36cd5346-8df0-4c44-b8e5-337bb5803868_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_35bce8ca-e347-4c4c-abfa-2306357aabb0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6b6afd1a-bfae-4928-8391-76f107119745_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2040272d-e774-434b-b1d3-2a0d5170504e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_99b20b64-94b1-4258-a89c-3bd15c704258_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MutualFundsMember_cacd94e1-54c3-461c-8076-8eb343aa5709_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_efc7d494-c6f7-414a-98f1-90e771ad347f_terseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_label_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_documentation_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember" xlink:href="ino-20200930.xsd#ino_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember" xlink:to="lab_ino_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d096fc0c-68ab-4e9c-b29c-4b740be09def_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO4800Member_4eac8a5f-cb39-4774-9ced-052ababb2a45_terseLabel_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800</link:label>
    <link:label id="lab_ino_INO4800Member_label_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:label id="lab_ino_INO4800Member_documentation_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member" xlink:href="ino-20200930.xsd#ino_INO4800Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO4800Member" xlink:to="lab_ino_INO4800Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5d9ef535-7224-4e5a-87a6-ab57251cb5d8_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a7b62b77-a48b-408a-aeac-1d0ed0aae803_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eecfc16a-e8c6-4310-8979-fc5bf8509395_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_00d8fbaa-8798-4570-9c0c-4b1ff85b2b72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c610c37e-10fa-4fd2-8178-a4d3b654a320_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_501ac6e5-312a-4208-bb42-45d09e0e8eaf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2db9e74c-c652-4a29-9e1f-3b258bc0df6f_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_bc19ef5c-f1c7-40bb-8056-206ba0b01106_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_690c7737-4f3d-49b4-85ce-95fd1cc901f8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_8dac8a83-ab1d-4dd2-8b86-f35f9a0d5ec1_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BiojectMember_17fd3dbf-ee04-49a3-b056-d9dc6f679e32_terseLabel_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject</link:label>
    <link:label id="lab_ino_BiojectMember_label_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:label id="lab_ino_BiojectMember_documentation_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember" xlink:href="ino-20200930.xsd#ino_BiojectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BiojectMember" xlink:to="lab_ino_BiojectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_94dc1451-7acf-434c-a7ba-19f6d8df9677_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_7c6e9cfb-42ea-4ff5-b9d0-95046dc98491_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_45fe7f08-3f57-47dc-a30a-451fcef7396e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_479a510d-3672-4a5d-9b0c-c73950c702e2_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_85547e95-62f1-4ebe-b30b-a106b458eff4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_14db0233-4b67-4deb-895e-658bd18ae814_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_57e758d2-7e10-40cc-8e58-3b1617a09497_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f7c8b8dd-6369-4ce7-993b-bfd6c0035011_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share attributable to Inovio Pharmaceuticals, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_89264ba2-c161-494f-87d4-2f2fdf2be149_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received in upfront payment</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_label_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_documentation_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement" xlink:href="ino-20200930.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromCollaborativeAgreement" xlink:to="lab_ino_ProceedsFromCollaborativeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c0380ecc-d5d9-4ede-9a25-a105b81360b8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2d265575-ab68-4788-9882-6ce74e69f2b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_3a7fa8b7-aecf-41a9-a4c0-49c0b81ebd73_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneOneLifeSciencesMember_a6880d53-77a3-487d-8fb1-e5b488f03404_terseLabel_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GeneOne Life Sciences</link:label>
    <link:label id="lab_ino_GeneOneLifeSciencesMember_label_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GeneOne Life Sciences [Member]</link:label>
    <link:label id="lab_ino_GeneOneLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GeneOne Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneOneLifeSciencesMember" xlink:href="ino-20200930.xsd#ino_GeneOneLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneOneLifeSciencesMember" xlink:to="lab_ino_GeneOneLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9ce4407c-3d46-46d9-97e6-2a3aa676cb20_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_6361350d-7661-470e-a5d3-8f43b6f287ce_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_4a274345-3455-499b-b772-fa2c3547105b_terseLabel_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement, commitment of additional investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_label_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_documentation_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:href="ino-20200930.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:to="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_b57a7bd9-d171-4a97-b061-500dd9072106_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedInterestFairValueDisclosure_ab23b347-afe5-4bb2-8ede-a3c6c621b5f2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investment in Geneos retained</link:label>
    <link:label id="lab_us-gaap_RetainedInterestFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Interest, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedInterestFairValueDisclosure" xlink:to="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_85144767-373a-4a42-8550-58825998a816_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:href="ino-20200930.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_a6e41fc7-0646-4cc6-a41c-a129e68dbf20_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of date conversion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_a44f4972-1a10-43b4-8f61-a4542b33dcb4_verboseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based restricted stock units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20200930.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e871e313-fb00-4907-8eb6-18f3945f330d_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_d0ea5a79-9a62-4576-b0d0-6b6a7058cef7_negatedTerseLabel_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital (excluding cash)</link:label>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_label_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital, Excluding Cash</link:label>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_documentation_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital, Excluding Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash" xlink:href="ino-20200930.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapitalExcludingCash" xlink:to="lab_ino_WorkingCapitalExcludingCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_a47a0d50-d304-4e85-a8ee-bd357f672545_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_3ddaacde-d589-43bc-8879-0817b7540246_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_f8dd1c64-b4c7-40a5-8134-e67cdd1fb895_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment for decrease in fair value of derivative liability and interest expense</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_44e99727-8485-41d2-92d6-93d48bc79e3d_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_32f5d8fd-27f2-4f3f-bb8f-4b889719b4b5_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember" xlink:href="ino-20200930.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_f22f7691-9e94-48c8-a312-e77d208b1adc_terseLabel_en-US" xlink:label="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums on investments</link:label>
    <link:label id="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_label_en-US" xlink:label="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Accrued On Short Term Investments Certificates Of Deposit</link:label>
    <link:label id="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_documentation_en-US" xlink:label="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Accrued On Short Term Investments Certificates Of Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" xlink:href="ino-20200930.xsd#ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" xlink:to="lab_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_827c4d76-c761-4c61-b479-9917b23a8ddc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ef22c0a4-63eb-4b1a-9a73-63e5ef86fbe2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22bd5a67-4e85-43f3-980a-4b79a52b89ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_389ad0c7-189b-422d-8970-33a75947baf7_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advisory fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAdvisoryFees" xlink:to="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_eea2a2c0-0adc-4a0c-a257-e7bfe3b4da0e_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:href="ino-20200930.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_4b8cf946-cdfc-4a08-823f-1c603bdea105_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Product</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_424bf4f9-acdf-4e87-8f40-c918676dc897_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1d9d75a2-6e58-40a5-8117-caaf13642815_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_85ba9136-273a-41d1-b673-556e3df36fcb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_93e28a87-4e9c-41db-80a0-6ffa94383a78_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eb8097f7-efa9-41a7-aa33-14678016d147_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c895c6c0-fa13-40cb-933a-dc159590168e_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7d7aebf7-8c50-4c70-a5ea-c7a1c4d43fec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6276e9c7-0e1d-4ddd-a088-734d631651fb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1f8d21a7-47f5-486b-8f25-f4b8380295e6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_858b7afa-ddfd-4173-8058-83bfbae8deef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_3506bdde-bece-4fbd-acf3-56fd1a486d6b_negatedLabel_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of receivable with shares of common stock from affiliated entity (PLS)</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_label_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_documentation_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:href="ino-20200930.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:to="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_02c7e578-adaa-40bb-a782-3a5ee36d3d65_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_20821bf1-9121-446b-8c2c-fd7a310617cf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_89932c52-f531-4883-945f-de5cb19886c0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_e63c8d8a-99f4-4cf1-9e3e-e80b760970e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_a4ef8a1a-2446-4725-94bf-fdcb6f8d0506_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81fd462e-c780-4b7e-bf13-da7a556d4800_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb5cb26f-8384-4bf6-a09a-c4ea6830bdd8_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7338ea44-dce0-4435-84f7-edb1127ccab7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SalesAgreementsMember_2b0e197d-3311-4eda-8174-f0b88b26bb7a_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements</link:label>
    <link:label id="lab_ino_SalesAgreementsMember_label_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementsMember_documentation_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember" xlink:href="ino-20200930.xsd#ino_SalesAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementsMember" xlink:to="lab_ino_SalesAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_e371deb1-c355-4200-b86b-6e4227c0c8a3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_2c08a9c0-d85a-485c-8c5b-984b24be497f_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a9ff0117-7b55-40a1-a2a8-b3e68857a77b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_e06314f0-c31a-4d80-a388-8116fd6de67d_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:href="ino-20200930.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:to="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_136a83f3-9bf0-4bc5-a857-321e9b78b668_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a8f0d03d-d769-4494-a110-a40487e48c51_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_af9a7438-2d1a-450f-a2b7-2b4e13720e12_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_644f6593-8129-487c-a11e-5f3d3ff44435_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_0bf49c57-f58e-444e-b0aa-9f147b668599_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember" xlink:href="ino-20200930.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember" xlink:to="lab_ino_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_df83eb11-88c1-41c1-a156-d45046e20151_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_5dccba86-0ee1-45fc-a9b4-6fb5c3442f3c_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value</link:label>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_57a659a7-2a8e-4427-a1be-b7a3875c055a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive potential common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_46810314-d0f1-468a-bdbd-7b74afa87059_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_7aa4e936-e731-4837-a2db-863701c51c2c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_474ae015-bc6c-49e1-9d1d-0cfb69b5567e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_447ebffd-a941-45fb-b838-3e457804f6c3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_5b92ab65-74f3-469e-b385-13347c71658b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_7b276ba7-4284-4d26-a339-4dcc67a96bca_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_d6cbbfaf-dcf6-4c33-aa10-b164808b7737_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares held in an affiliated entity (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advances to Affiliates, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_bb7ea20e-eee6-4eef-ae1e-96ed82d47910_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_dff9d055-44ac-4b22-966d-4eefc285ac16_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amortization expense on intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_03919e82-1d2c-43cd-8cf3-b0057401e2db_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4309957c-b700-4ddd-b5ff-f515dd118e01_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3a5796b1-981d-4874-a1e3-c0f8bc15320a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_9db2c4ab-d691-4046-9706-b15587fcdae2_verboseLabel_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos enterprise value</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_label_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Enterprise Value</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_documentation_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Enterprise Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue" xlink:href="ino-20200930.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EquityMethodInvestmentEnterpriseValue" xlink:to="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_510aa13a-75af-48a6-8039-55c8cf894240_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_0ddea4e4-6861-4563-8269-abe4ed54c608_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_53e724fd-a1ed-4dd0-a27f-11f4bd160e4c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_85c2fc31-89a4-46d1-bf2c-954d4286206f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument principal amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_dd55e195-f20c-4c33-9933-15790a11f129_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_b84bda9f-d2f0-4eb3-b349-24893fd7bc63_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_9c8491fa-2575-43c8-9c6a-35c78fe2f228_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:href="ino-20200930.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_deeddc45-4fb3-4c65-b3a2-397aa884cfb3_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_688268e6-246c-4bab-a482-d991e6dd7891_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6ce025c2-fa97-4c21-9bdf-30c9a8e90f90_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_38586599-e3ed-4a38-94be-112f814e4b9b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, contractual interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2570ffa3-27f4-4a3c-9186-584afd109608_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of unvested restricted stock units and options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_8099bf4f-46e6-45d6-b792-2f310a5836b7_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:href="ino-20200930.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_6d6f9955-8ada-4bb6-a352-4a997b32b378_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_35dc15fa-71a0-4981-87c5-d4c2b4459b4e_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net book value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e45a3567-bc4d-4476-84d8-b25664f8f018_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_aebac8bd-6e09-4b8a-a3cd-89dd48f68528_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_df385f14-12d1-493c-8570-24a1779358f4_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_cef73013-dab1-4382-bf67-e141fc54ed40_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a398b767-22db-451a-b1c7-8efa1348e19f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_10c9de38-7654-43e6-8732-159e7e06fab2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dbc5226f-699d-444c-940e-83b4d1746698_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_21ac8762-df1d-4060-a79d-883248b4b599_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Liquidity and Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ba77de10-8933-4f38-80f5-7de06030f9b5_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_ba2a6b2e-205b-4d2b-83d6-9efe04b19076_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_514b0ce6-3167-439b-8ee4-dddbd3a0c81f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_56351eb7-eb6a-417d-8620-1a2f7f2b5eea_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_17905d65-d690-42ef-9d31-21b35521013f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_cccf92e6-be47-46a5-bdba-0f98cf1d4d9c_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_d19d28b3-d396-4d08-88ba-ef8ab0777cdc_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding, from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_3b0b3f8f-c528-4088-a254-b9bf8747f85e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f091bcc7-22ae-46a6-889b-4a2d89dd090e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a320f0a2-77e8-4a10-8b0c-7888e3755812_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_5d83b2d9-2c55-439c-9926-198b47299ba1_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_bd66baa3-feb1-4eef-aef6-250c6737c305_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3f31580a-d3da-4c2e-b90e-b4ce4c3105ae_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_78baedcc-d1d2-4b46-972a-1eb2bf427dcf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_eee6d76c-411b-4a05-9d82-09d4abc4d989_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Geneos issuance of note payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_788af53f-dd60-4891-be14-40c8b30b3903_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1b92808b-5ac7-41fc-820b-7c89b60d8591_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d8df2336-6c16-4fee-af5e-6ff788d5979a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c412a2c3-7f65-41f7-babb-79e51d356224_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_61995de4-900a-4fb6-bb26-e263bfef77c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b4292f70-01f8-46a9-86e9-d5458fa5c30d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from deferred revenue beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7f2331c0-8055-4b4e-adb0-43fd14f8d36d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7ffe6b2b-c0fd-4e26-b84c-8969aaaacd64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_15fa4470-c7d0-4102-9d4b-9057590d5a68_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_69fb208a-0438-49e0-b912-180f2263dc8e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, other shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_73140ccb-7794-4711-9278-8998dcd8486f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b39e6118-ab02-4e51-8cd3-284660718229_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ino-20200930.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_346129b8-52fc-4b79-829a-5e9113ceaf14_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_621a366c-ae7a-4631-9e0d-8d5bbac9be72_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_c5761a82-8024-4234-af4b-52d09ba11899_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_9ffc48c0-17c8-40fa-8d06-c0fdd0a8678a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input, expected term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1ae4088d-0388-4c8d-a765-2917779056af_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ConvertibleBondsMember_854c2c06-0901-42d8-aa7b-caec539139c6_terseLabel_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible bonds</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember" xlink:href="ino-20200930.xsd#ino_ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertibleBondsMember" xlink:to="lab_ino_ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_97e1b688-19fa-4dc8-88b3-d244045aab0a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_a48959b0-7842-4c69-9568-a42f15a819cd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_1f9e9975-de69-408b-b08a-f688697b4169_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_9e059680-7487-4228-bcfd-b5d574a5166d_terseLabel_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After July 2, 2020 Conversion Price</link:label>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_label_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After July 2, 2020 Conversion Price [Member]</link:label>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_documentation_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After July 2, 2020 Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember" xlink:href="ino-20200930.xsd#ino_AfterJuly22020ConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AfterJuly22020ConversionPriceMember" xlink:to="lab_ino_AfterJuly22020ConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8a05a94-af05-4a5a-bc21-1da083288590_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_313ac285-b748-40b9-a835-ba495ea7d2ec_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_0ac03f7e-6b1f-4f35-a87c-8bb38093b605_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_e42a0583-f35b-4e29-9a3e-ba4000e51132_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_c6ec3bf7-de38-483d-9b1c-3ec6e8894f71_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability (Note 9)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_fdd9120f-d78d-4af0-aa19-9363232f97b5_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_4641c70b-1d9a-42c3-9780-ca96696660f6_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:href="ino-20200930.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_c03f398e-2d42-4a53-8591-3409dbeb2b75_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position for more than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7d1a2935-2d7e-4fc2-9ddb-a4f08b21090c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_73c1cdd0-5bf4-402c-8744-9a0a4f5327c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of acquisition of non-controlling interest in Geneos</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_72f8ab4b-636d-40f2-96dd-8c14ba7cfb8d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_ee14969f-c7a2-4e1d-b93c-180b20246df5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_6493c6b4-123b-4906-aa29-09e732ca5022_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_82654e72-af28-4434-9136-9effab07bdd1_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos upon deconsolidation</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_271a5529-65d1-4fa8-a73c-3e8147f55e77_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos as of September 30, 2020</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_7868787c-9cad-4b24-84f7-85aca66147c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_417f3863-e1a1-41a7-b685-bccc1b95f8d5_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_InovioAsMember_41818659-1f3c-47b8-a9c9-3cf8a7098dad_verboseLabel_en-US" xlink:label="lab_ino_InovioAsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inovio AS</link:label>
    <link:label id="lab_ino_InovioAsMember_label_en-US" xlink:label="lab_ino_InovioAsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inovio As [Member]</link:label>
    <link:label id="lab_ino_InovioAsMember_documentation_en-US" xlink:label="lab_ino_InovioAsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inovio AS.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InovioAsMember" xlink:href="ino-20200930.xsd#ino_InovioAsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InovioAsMember" xlink:to="lab_ino_InovioAsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_f0567e1f-b7e7-49f2-82c4-a150aa1709ad_terseLabel_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_label_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine [Member]</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_documentation_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember" xlink:href="ino-20200930.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SARSCoV2COVID19VaccineMember" xlink:to="lab_ino_SARSCoV2COVID19VaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f42df905-caf4-428a-907d-e81174087749_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_2aae7132-7b1a-47f7-aa1c-22e7f709086e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_a9dc790e-9d84-44a1-bcd3-41da658bdcae_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_label_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued Interest</link:label>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_documentation_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest" xlink:href="ino-20200930.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentAccruedInterest" xlink:to="lab_ino_DebtInstrumentAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_57cc05e5-0787-429f-af66-c219596de246_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_524341a3-b1b2-49b5-96e3-e84fb6ba7390_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_8ef8bdff-9e36-4ebd-a356-46e9635b746d_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonEmployeeMember_1c49c62e-3a44-49bb-9fe1-37c2203f7594_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_label_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember" xlink:href="ino-20200930.xsd#ino_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember" xlink:to="lab_ino_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_f4bc27da-7028-4bf2-87ed-89024b40ae5a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a9ea97de-35e5-4ee2-8647-0fa3f31a4798_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ee538e0-e950-47be-8af7-013e722dd7b7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_d75e15e8-3b23-4f01-a80a-f6675995231c_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual maturity (less than)</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:href="ino-20200930.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_598f6348-e9e1-4a5e-a78d-8ee0898d1843_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5e8385a9-bfad-4883-aaf1-f54e06f3e145_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6631d642-332c-4009-b14c-93a5825d15f6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c363b694-33fd-4ea9-a663-65be3af1f0d0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ffffcebf-01fc-416f-813f-a465efb4c225_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fa068349-ec56-4d7d-967b-0a1757765998_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_89ae9d86-3af8-49c9-983c-44e22aff41ff_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_4dbfb2d3-ce37-43b1-b72c-b7614d812843_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b81512b1-1957-44ea-b8fd-c3eb1511fd1b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentAccretionOfPremium_e59d50f8-08fa-43f4-af6c-ace4aa674e65_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentAccretionOfPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of premium associated with the December 2019 Bonds</link:label>
    <link:label id="lab_ino_DebtInstrumentAccretionOfPremium_label_en-US" xlink:label="lab_ino_DebtInstrumentAccretionOfPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accretion Of Premium</link:label>
    <link:label id="lab_ino_DebtInstrumentAccretionOfPremium_documentation_en-US" xlink:label="lab_ino_DebtInstrumentAccretionOfPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accretion Of Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium" xlink:href="ino-20200930.xsd#ino_DebtInstrumentAccretionOfPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentAccretionOfPremium" xlink:to="lab_ino_DebtInstrumentAccretionOfPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_017d41a7-b85a-4d2c-bbc6-0cd492ea5611_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionNameDomain" xlink:to="lab_us-gaap_DebtConversionNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_0172de8d-cbda-4976-a820-03b47427dc57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_50152630-4bfb-4baa-a6e9-0c38385707c3_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_ff523adc-2764-4894-ad0b-91e9631fa21a_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, gross</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5f1f750f-182c-40f5-a091-143b63d2b2de_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_48a906db-abb8-4024-ae8a-43bbd70a7ff8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d8dc44de-ed0f-4fc0-806b-e9bbe02b89b2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e82a41d4-787d-4116-b98a-7486aca044dd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_0b69363e-b882-436d-a978-f38a3c189d2e_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ba2aa8d9-472a-4a4d-8254-92d018b77795_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_28d23ce0-093f-413c-b48c-05ca5c2f5711_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonCashInterestExpense_64fab17c-4365-4096-80cb-59f9eb390f94_terseLabel_en-US" xlink:label="lab_ino_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_ino_NonCashInterestExpense_label_en-US" xlink:label="lab_ino_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:label id="lab_ino_NonCashInterestExpense_documentation_en-US" xlink:label="lab_ino_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense" xlink:href="ino-20200930.xsd#ino_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestExpense" xlink:to="lab_ino_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_64917ebc-fd99-4853-8d06-9a2e48b3a33d_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_373b0e71-3a98-46e9-b854-07fb8c085e54_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_58f49e17-1d73-45ea-8eb1-62db78801988_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2b693590-ae85-494e-9c74-aac7bb7f6751_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_f26d63b3-c2e3-4c10-bec5-037e83451217_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_d17d3c0d-4a5a-4afe-868d-23ee10ba8979_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_84cdbfbb-2542-4e79-9c12-757f6e2d102a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_31e83c05-a634-43bf-af40-e30be4fb5f5c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of net loss in Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_8dc77a40-402b-474a-906b-4fed84737d1e_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_09121ef4-ed41-4bb0-a068-3977663d1943_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_568c750e-3341-4d70-9966-bc354436422a_netLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_29bb0d89-a50c-4670-a60f-c01ffcfb929b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_138266a4-66c6-4cc3-94df-ab8ea4fadb30_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_8d0a82fb-d5cb-496d-92c9-9a53acca9cb5_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member" xlink:to="lab_ino_GeneosTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8f8f809f-c23a-4213-9842-c180dab3f721_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) before income tax benefit and share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5163d530-9f27-46ee-b322-e55d179734ec_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_cdbcb737-7f3c-4733-9b2d-ca1b29318090_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_67428f33-4841-4b0e-b436-b3d58c3cd272_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_97be4a35-acbd-4753-9f5a-9458fbfc5add_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_0cbafc1a-7a8d-461c-b97f-b731af35e4cc_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliated entities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_d8a03b83-6b3b-43c2-8027-bc362b08520a_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_5a139c1e-76b9-405e-bb21-8d694d7af19d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9f29483a-8432-4887-ae67-d4dc1c434f0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_f01c0e0f-7a2a-4618-8a9b-b51ed0dbeb55_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_d0b15a16-34f5-4971-8151-88217c5ee14f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_8c21835e-747e-47ff-8002-def4b29c096b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_b5b9f5da-7780-45bd-a5b8-0f78663bb8ce_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:href="ino-20200930.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_58c8160b-449f-48ee-9fc1-0a539c77d3f7_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_f3d37d3b-fe07-4672-a786-69fc0bf0584f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_dbcba7ac-d29f-4e0a-846c-ba3a1bc758ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_fd5ca41a-44f5-455b-8062-7616c520f052_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_250c0153-4722-4831-834f-90acbbf62a6b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_2cc275c5-c809-4135-94e0-7a7a4df9bf95_terseLabel_en-US" xlink:label="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from other unrealized gains on short-term investments</link:label>
    <link:label id="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_label_en-US" xlink:label="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefit From Unrealized Gains (Losses) On Short-Term Investments</link:label>
    <link:label id="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_documentation_en-US" xlink:label="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefit From Unrealized Gains (Losses) On Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" xlink:href="ino-20200930.xsd#ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" xlink:to="lab_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_16a88286-fbfc-4cc2-a4a4-e94a5413123d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_66aa0740-8627-4df6-81fa-664487702ee6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair&#160;Market&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb05d989-bca2-4aa7-99f6-72270d033403_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available for sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_0940defe-fbbe-4416-9b18-151e193322d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_992da2f3-6fed-4862-bb2b-abcfbbdfb3da_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2f334065-ac7e-4b8b-b5a6-20a6128e33b7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e20bc5e-6a63-486d-a400-2cadc7bcca81_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6d6e2682-ab16-4577-a254-245ffb64e33f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d14bb91b-1da3-4f85-bd3f-01b307900c78_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_bb851439-f8b6-4ee7-82ac-57cb9d2b275f_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_97a46e18-f411-4fa3-8437-9473bb6d7120_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_dceee864-3804-4024-8ee2-372e5380d9da_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_821ba688-c032-45c0-9cc8-9955d90c3d2e_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_32f7b26d-be3e-49b0-95f6-2f5729e57991_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated development and regulatory event based payment receivable milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_label_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:to="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a041d4e9-fb53-4f37-a353-a577ec15978c_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_dbb545e5-d111-4e4a-94e9-224c53106ba1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_7a831df3-3fc6-48fb-9934-c9e05a7ab80a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e7980567-b43d-4b90-8b48-8def91b11e8d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed064458-f0ae-41ce-8e07-4fd512981c74_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_eba287f0-22d4-499b-a471-77013eb38fec_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfAdditionalProducts_12e7b949-f95c-45c2-a7a8-381b7a81fcc1_terseLabel_en-US" xlink:label="lab_ino_NumberOfAdditionalProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional products to be developed</link:label>
    <link:label id="lab_ino_NumberOfAdditionalProducts_label_en-US" xlink:label="lab_ino_NumberOfAdditionalProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Additional Products</link:label>
    <link:label id="lab_ino_NumberOfAdditionalProducts_documentation_en-US" xlink:label="lab_ino_NumberOfAdditionalProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Additional Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfAdditionalProducts" xlink:href="ino-20200930.xsd#ino_NumberOfAdditionalProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfAdditionalProducts" xlink:to="lab_ino_NumberOfAdditionalProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoOfficeMember_bc9cea7c-5f49-4793-863d-c93410d62352_terseLabel_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_label_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_documentation_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember" xlink:href="ino-20200930.xsd#ino_SanDiegoOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoOfficeMember" xlink:to="lab_ino_SanDiegoOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_70d3ebbd-f88c-464e-927f-1111e6bb7700_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for remainder of 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_4c03992f-7390-4de5-985f-ece43b972567_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area leased (in square feet)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:href="ino-20200930.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PriorSalesAgreementMember_37f12190-db85-4c42-8261-2dfba274e3df_verboseLabel_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement</link:label>
    <link:label id="lab_ino_PriorSalesAgreementMember_label_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_PriorSalesAgreementMember_documentation_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember" xlink:href="ino-20200930.xsd#ino_PriorSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PriorSalesAgreementMember" xlink:to="lab_ino_PriorSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_66f11a87-51e4-49c6-9fe6-31318641d48e_verboseLabel_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_label_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_documentation_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract" xlink:href="ino-20200930.xsd#ino_RelatedPartyTransactionsTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_3a47eca5-0c50-452f-ae0e-12d4445fb92c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_253eca91-7ea7-47f2-8752-b2ecdc90b4a7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_43c580a6-ca0a-4910-b1f3-0163271983ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_24fcfe5e-180a-4fb1-ae45-f5ebcc7caf42_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_67a468a6-dc65-412f-9f0a-e09423840caa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AstraZenecaMember_5f65a06c-c156-4768-a594-d2a650fe05c1_terseLabel_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ino_AstraZenecaMember_label_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_ino_AstraZenecaMember_documentation_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember" xlink:href="ino-20200930.xsd#ino_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AstraZenecaMember" xlink:to="lab_ino_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_c65a9f9f-edcc-4041-86d9-4f45e54725ec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_f5ebfc7c-24a4-4a4c-bae2-94020962dfa9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_0d01b629-f80c-486b-ac50-552fb7902ee6_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:href="ino-20200930.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_2f65bbe6-8284-40ad-a4c8-076f6b8223dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3e5c3d76-56ed-4a68-a3d0-e16a9e39aa6c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c8c107d1-97df-4580-a6d1-ae0a4cc737ca_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherCounterpartyMember_7018b6ac-d9d6-418d-98de-f6e39cbecff4_terseLabel_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_label_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_documentation_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember" xlink:href="ino-20200930.xsd#ino_OtherCounterpartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherCounterpartyMember" xlink:to="lab_ino_OtherCounterpartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_12760c2f-956f-454c-b668-b6539e0d0c66_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_770d3f0c-944d-458a-8143-ccd441bd8d52_terseLabel_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Bonds</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_August2019ConvertibleBondsMember" xlink:to="lab_ino_August2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7ba832f1-2fbf-4585-b12a-33ba68ef45a7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_f5a93f3b-9551-415e-b658-003fa54bc721_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a86ce683-b5d3-4b8d-887c-154f58be431e_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_dd628ffb-6c15-479f-8a1c-91296e17c18d_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_c8c4def3-9571-471e-ad2f-e35d4ad324fe_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_de3a0e39-ce52-4200-b848-ac0f19828251_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price, procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_label_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:href="ino-20200930.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:to="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_6acffc3d-1625-42fb-9279-78cbada5048c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_53333bbb-e8e8-4934-89a7-f078f5593c3b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b5cacfd0-cd17-4efd-b377-8d662b829a42_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fb988d97-fcf6-4d46-ad80-5ae0459ef0c5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5fe21969-29e9-42f9-b033-388b39fb0a3e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_1949aa6c-75c1-44a7-9702-ce86f63153e4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_2a2a2020-cab3-4d64-8496-b1813461b279_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period from effective date for termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:to="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_76734fa0-102a-49d7-9f7a-0057661fa845_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_63462eac-e8f1-4023-a429-ad1b8b80d5e0_totalLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, net book value</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_dce4a366-27d0-4188-9609-a700c0d87a24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b224e8be-950c-4764-8c20-b10e843039b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromInvestments_ef02f3a8-ee9f-4eea-8c55-6cc780e64579_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of investment in GeneOne</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromInvestments" xlink:to="lab_us-gaap_PaymentsForProceedsFromInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_55be40d5-430e-4c32-9853-cbb5af0110f0_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a46812d1-355e-494e-a829-4629562e2a49_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_431b5e1f-84a6-4763-88fa-d8f96c1e7519_verboseLabel_en-US" xlink:label="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue from affiliated entities</link:label>
    <link:label id="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_label_en-US" xlink:label="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Affiliated Entity, Current</link:label>
    <link:label id="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_documentation_en-US" xlink:label="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:href="ino-20200930.xsd#ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:to="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_e9a3a564-1363-4890-afcf-79e498e0c41e_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate proceeds</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:href="ino-20200930.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_7f6a376f-ed63-4f15-ad70-57d1b03cd151_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_3761b753-3d90-41f8-9a66-f6105e225f3b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_20714912-e5fd-4ebe-a9b7-a4bf4f5ac759_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Unobservable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_f7939b78-12e4-4b22-918f-1d6bed1c92b8_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:href="ino-20200930.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:to="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_9de0378c-906b-4cab-ab37-800a86160976_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_ddc7a4f5-0600-465f-a59c-b54a401320a2_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_5f54670b-7599-40f0-ab79-437599073596_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_00d8b4ed-77fc-4a53-86b0-f40a9a579d1c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_23fb0ba0-759b-4169-b067-e718e5bfa40c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_aadd0190-3957-49f7-b794-af0f6e231889_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5a8b4c2f-6385-4f6d-944d-35738e63515c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_07810112-962a-4a5a-a141-ae8d432d5ef2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_de438d10-250f-441c-b810-16f6616828f5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_60cc3c4d-307d-4be2-b003-fd7c7025e751_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Intangible Assets by Major Asset Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_61f4bfed-06d5-4dcb-95d8-92e5ccd744ca_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_924ee17c-4212-4107-b48d-8eae10ae2e5e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_daccd687-9acc-4ac2-abca-07b2c7a50c6f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_7fe97f9d-302e-407e-b2c1-86eb8db50b8f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3d888e9f-af80-4e7d-a879-2ee7795227cb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f700b573-6f5e-4394-9a15-ce7f304938e0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5d70edf3-3ce0-41e3-89e9-f5d84fadda19_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for use in diluted net income (loss) per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9b4939ee-b2df-4e50-ae03-17f45bfb1c46_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_64737693-7d2a-4ab1-87bf-d62ba8bc6eac_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_57669811-4332-498f-b2e7-7a131c0aadf4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_f0856e7a-b04a-4f5c-9b96-6c19bcf219ee_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment received for license granted</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_841594a9-10c9-4d40-8f07-63a90d9d64b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f42576b5-2be7-4274-bdb4-26801bce5103_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_4c9b6fd1-a99a-48c2-9be1-ea0c97551d94_verboseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in Deferred Revenue From Related Parties</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:to="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_1e094ea2-ac39-4ef6-af51-fb16d444e566_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:href="ino-20200930.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_20d03f42-3dbf-4486-b9c3-4a3bc0c2bc7e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_0c82906d-b319-4a4f-b0eb-46d0eb6c26fa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_4d73e2ac-829d-409c-90a2-2641ae993a7d_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, internal rate of return</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Internal Rate Of Return</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Internal Rate Of Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:href="ino-20200930.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:to="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6dbc1a30-3c15-4b50-98e5-1221682fff65_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_dafb957e-3c73-4633-9ba0-1cd766af932e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ad32f99f-0850-479a-bdb5-8b4361a28f92_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_9b85a5a0-02d6-438e-adb9-7926a57a4d5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ff00538-c9e0-414d-b860-e725af9e6c20_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_ffdd876a-fa70-4b28-8d13-e7ce5ca0085b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b1be4757-04e0-46f6-9e19-6eff94165899_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_6957873f-c893-4e3e-befa-e0324f1f50d4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c289bc4d-7c2f-4434-b6a4-321fa3a67123_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_00d28389-fd2c-43e1-86ae-730f4836cf14_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input, price volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_7fde61c7-a8ef-4359-9b5b-43e581443776_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_c8bab701-6377-41ee-bf30-2639a96bc19c_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_84990dab-95c8-4489-906a-1ec21f4764f6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_fcb62ed4-fb9a-4fef-95c2-19f59fb53f57_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_967139ab-1686-4b5d-b9f7-4dfa0b7d63c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_a4fbd44b-7c2d-42ad-9fee-557f3c4387cc_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_dd12740a-4068-4d74-9fd1-1c12bbfe7d8f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eb6b720f-dd4f-46b8-8d3b-5325cec86586_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, restricted stock units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_23a2833c-33c4-49cc-8c20-6d279caeabf6_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_adf88e71-af49-45b5-8b16-557d36e5b093_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_a5485a0c-6d4a-49a6-991b-680d58fdf1c3_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f507877a-51c7-43a0-ac00-c1322ba43b2a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f92f42b1-acd8-4b82-885f-02d8a74234b6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_feb9b854-da51-45d0-a9c0-8c1d95cfdf36_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_ba8dc950-a962-47e0-a12a-dd146e0bdcb2_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:href="ino-20200930.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_b2a7b40f-f047-4eaa-a77a-d9583245f4b6_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_9c5dca03-4001-4f6e-ba3e-124317701890_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_ea5f1447-f210-40d3-a53a-97d32b16770d_verboseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of investment</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_7cf36b50-1aa8-489d-826a-4de1d70eeb47_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input, risk free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_e2086a1f-8a21-4506-b58f-33a63d927749_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NewSalesAgreementMember_91d1fbca-3c9b-404e-ab1d-81378440636e_terseLabel_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement</link:label>
    <link:label id="lab_ino_NewSalesAgreementMember_label_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_NewSalesAgreementMember_documentation_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember" xlink:href="ino-20200930.xsd#ino_NewSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NewSalesAgreementMember" xlink:to="lab_ino_NewSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_cb412a1d-ee7b-476f-aae8-7259af0e22c9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantPolicyPolicyTextBlock_63495e3e-d005-4c27-885c-3f7d2319b14e_terseLabel_en-US" xlink:label="lab_ino_GrantPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_ino_GrantPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ino_GrantPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Policy [Policy Text Block]</link:label>
    <link:label id="lab_ino_GrantPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ino_GrantPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantPolicyPolicyTextBlock" xlink:href="ino-20200930.xsd#ino_GrantPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantPolicyPolicyTextBlock" xlink:to="lab_ino_GrantPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLeaseNonCashLeaseExpense_a3adbf07-a253-4227-83c1-87178e9668c4_terseLabel_en-US" xlink:label="lab_ino_OperatingLeaseNonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_ino_OperatingLeaseNonCashLeaseExpense_label_en-US" xlink:label="lab_ino_OperatingLeaseNonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Non-Cash Lease Expense</link:label>
    <link:label id="lab_ino_OperatingLeaseNonCashLeaseExpense_documentation_en-US" xlink:label="lab_ino_OperatingLeaseNonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense" xlink:href="ino-20200930.xsd#ino_OperatingLeaseNonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLeaseNonCashLeaseExpense" xlink:to="lab_ino_OperatingLeaseNonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_edf59723-67c2-4b7b-aefc-99372ceb0ff2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_4db1175e-084c-4c4b-934e-66ff41ac8ddd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2b3acd35-2d2d-4145-86b4-271f9a6b88b9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7b4d495b-db7b-4432-b7ae-9cbab32db9c0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_42c94f38-713c-4e41-adc4-e2fca7932db2_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_VGXAnimalHealthIncMember_c80d3656-84ca-4687-825f-c5249d8a8703_terseLabel_en-US" xlink:label="lab_ino_VGXAnimalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VGX Animal Health, Inc</link:label>
    <link:label id="lab_ino_VGXAnimalHealthIncMember_label_en-US" xlink:label="lab_ino_VGXAnimalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VGX Animal Health, Inc [Member]</link:label>
    <link:label id="lab_ino_VGXAnimalHealthIncMember_documentation_en-US" xlink:label="lab_ino_VGXAnimalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VGX Animal Health, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_VGXAnimalHealthIncMember" xlink:href="ino-20200930.xsd#ino_VGXAnimalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_VGXAnimalHealthIncMember" xlink:to="lab_ino_VGXAnimalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_be0d45b7-1671-418e-ac7c-45ff8fc49757_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, measurement input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8fe6e5cf-d089-452c-8013-7626178ef331_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b156873e-fa1e-4202-88c9-0973d736356b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_34f542d9-1f31-418f-a675-9c6c91652ad9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_f163ebaa-da5f-4445-b945-d9a72873e210_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_a3d0a852-0a69-4d37-9d46-d187e3edf15e_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign non-corporate income taxes reducing upfront payment</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_label_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Foreign Non-Income Taxes</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Non-Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:to="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0015bb85-530a-4ff7-9d83-4b52ef715e61_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_c2bdd6e4-d1f3-4f86-9a72-684f6d02dabb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6d6137e8-27b8-4bfa-922b-100cdb0906aa_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8d631825-ffa8-4057-a084-2bc8b6936569_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d124ce62-c5ee-4822-a9d9-95eba94e1950_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c278b276-4172-4e32-9546-7f5e22d23c32_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_e8085838-f6a7-4482-b9b9-972eee6fbdc7_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c780cf29-c454-4417-902b-1d609a8923d1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_InvestmentOwnedAdditionalSharesAcquired_8caf095d-5bf5-45ec-b31c-949c21eb93e6_terseLabel_en-US" xlink:label="lab_ino_InvestmentOwnedAdditionalSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment owned, additional shares acquired (in shares)</link:label>
    <link:label id="lab_ino_InvestmentOwnedAdditionalSharesAcquired_label_en-US" xlink:label="lab_ino_InvestmentOwnedAdditionalSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Additional Shares Acquired</link:label>
    <link:label id="lab_ino_InvestmentOwnedAdditionalSharesAcquired_documentation_en-US" xlink:label="lab_ino_InvestmentOwnedAdditionalSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Additional Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InvestmentOwnedAdditionalSharesAcquired" xlink:href="ino-20200930.xsd#ino_InvestmentOwnedAdditionalSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InvestmentOwnedAdditionalSharesAcquired" xlink:to="lab_ino_InvestmentOwnedAdditionalSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0db3188d-069d-4c51-925a-cb1a92dd9031_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_54f6f165-7f12-4b3c-96e4-be60c4b9b909_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_a57a62e4-cc2d-4361-8ce3-0ccd02549e27_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9ad4a5e0-afbc-4627-9e29-7829ceae9173_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_aa8309df-30e2-4bbe-a549-abd8b9b7b856_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e1585615-37f7-4f67-8b6d-9aa6487df27d_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f120a972-f5a3-478b-a049-ecd9f690f2bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_99251f84-0e37-438b-98e1-92bf06d949f5_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9ba66a1b-9fb0-4905-9288-158b19019299_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_ec382332-0177-447e-a52b-907d4c58e821_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_169349f9-ecf5-44b4-9ed4-5c4cda5ffd3c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_56adc92d-619e-4be9-a543-061e83fa2565_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6c6e461c-0ddf-46b8-b275-962666c6b43f_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f8eba133-dcf9-41b9-b9ec-cff9e01485fc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net income (loss) per share)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_26ca3b93-3e4b-4453-a8bc-f4bd1d11328f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_2b0c4d3b-1493-4825-8e07-c566834ed130_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated commercial event based payment receivable milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_label_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:to="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2d314e1-2883-4f18-b7cc-2461ce1e40c4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_8248fb62-fb39-4aed-9c50-115acbfc98db_verboseLabel_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20200930.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_40497f05-139e-4fa4-9854-0c9ab7d588cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1f9c4a57-e786-4a4d-962a-1d732d791a9d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_28af9afc-c9c2-41b0-9baf-c6b102de0742_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_7f37ed31-43d0-48e4-9024-a46e98ff2b53_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_2bda6441-0d23-4b1f-8673-7006fba3ac59_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent" xlink:to="lab_ino_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_b6afa1e3-0ed4-4749-b20b-4d36828d1e17_verboseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingReceived" xlink:to="lab_ino_CollaborativeAgreementFundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_1f983d6c-d193-462d-ba23-4b09c2f90668_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f1e9a345-bbf0-4209-83b8-fb9d8ea298c1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_edb09f16-29a7-4960-aeac-e341bb65ff9f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_d10e079a-ddfd-452e-8e69-621233f8f086_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d1912f1e-bea9-4eb4-b61d-4bf3b65fe2b4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_aa81eb57-23d0-4379-8a88-1a39127d3bab_negatedTerseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount converted into common shares</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:href="ino-20200930.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:to="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33860b08-7bb7-45d3-87e4-6da7022bf699_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_c7c388f3-61ef-4b66-a222-318429a1f6d7_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest in Geneos</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementTerm_8329b07c-f2de-4cb6-ba48-21fe0771a8c9_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm" xlink:href="ino-20200930.xsd#ino_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm" xlink:to="lab_ino_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7dfbffdf-df1d-490c-ba00-52139343c7b7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_d0f0e618-a72f-4506-84d5-5e575a09df58_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_952fd0f2-51b4-4dad-a357-2268632ba192_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_bb1517a2-1006-41b1-bef6-eddc341493aa_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_VgxPharmaceuticalsMember_fdd896ab-ddf1-4a15-917a-bb0174777a1b_verboseLabel_en-US" xlink:label="lab_ino_VgxPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VGX</link:label>
    <link:label id="lab_ino_VgxPharmaceuticalsMember_label_en-US" xlink:label="lab_ino_VgxPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VGX Pharmaceuticals [Member]</link:label>
    <link:label id="lab_ino_VgxPharmaceuticalsMember_documentation_en-US" xlink:label="lab_ino_VgxPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VGX pharmaceuticals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_VgxPharmaceuticalsMember" xlink:href="ino-20200930.xsd#ino_VgxPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_VgxPharmaceuticalsMember" xlink:to="lab_ino_VgxPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_d4b71c97-e1d3-48c6-9ad2-bba9e9069899_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_23663f22-ae88-4c47-bc1e-e1c552f42384_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f62a8542-5df3-43ee-b5e1-ac3dc6777ed4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_95a26ee4-0a84-4f5b-a74f-cf748f882542_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator for use in diluted income (loss) per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_fc357aa7-c333-4bae-96db-f42464e9fd11_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_22bd6026-7450-41f1-b2e9-175d23c566f3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_dc1cfaeb-13bf-4e71-b047-30e25280ecde_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d1f4e10c-7d4c-4db3-9c74-aba7a9f0e4b6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a7352e89-e3f5-4aac-9870-f1afebcd7579_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_30d0d2a7-4639-43e6-acf3-7d26fbe0030a_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device</link:label>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember" xlink:href="ino-20200930.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA2000DeviceMember" xlink:to="lab_ino_CELLECTRA2000DeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_646c8b6c-7bde-469c-b046-97736efca40e_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable/accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_29d742ff-9f9c-465a-80b2-dd169b16a437_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_62f39f88-c839-4eb7-96b6-fd1df649e1e3_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contractual term (in years)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:href="ino-20200930.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f9a56808-498c-4adb-ab2c-142caf31d361_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_3dd005c9-f26b-4b13-840c-e3661dd91e2f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_edb69001-ad9c-4cbd-889c-1e5c2949c3a3_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_1797a627-97ed-48b1-b424-226b140a2d5f_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_4176332c-4a66-43c3-8e81-a90fafc4d5af_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_56cef60e-ffe8-4fde-89f2-0f47ac074233_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_861844c3-17e4-4fae-971a-66e8a8d98b42_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_744c6bae-d601-40bc-ac0a-f21bbe097231_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1b39c22e-0fcb-4499-a84f-b4ce34b68bbc_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_770dc1b9-2986-4dc5-923b-06c42199059f_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:href="ino-20200930.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_ff12e17d-11dc-48bb-a91b-764aeb076daa_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e6d93cd-b610-493e-8092-419c0bdfd147_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_bedfe7fd-5ed6-4c89-b9aa-c8932f0c469d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0a4af623-3c36-46e9-9ea2-4dc61c01aa67_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_faf049dd-14c1-43ce-86c1-fffacaf2c834_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d9bc02cc-fea8-4137-b6d9-8027d40febdd_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_37271b75-b7de-4226-8136-4311ebf811ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_12d4d114-a334-4f48-89ac-e89b9cf8fa57_terseLabel_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements with affiliated entities</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_label_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_documentation_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:href="ino-20200930.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:to="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9ddbe416-9736-4399-8721-c9853e5a2c21_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c8e10895-8cba-43d5-8da0-68c8e93eaf95_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding (denominator for use in basic net income (loss per share) (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_f72396bf-bfe5-4886-9b2c-8538724705de_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_80cc992e-8905-48e9-b435-17d750706277_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_6fb6df59-e7d1-4387-9420-23127f9de8ce_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_2763359f-bc85-4714-8260-5b76ec34134f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_b6ab662a-3aa0-4668-971a-717e5d5b98c6_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_310da653-3b03-4f8d-9189-cc4f36be48d2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_60e743f1-e92f-48e0-85ed-afe076fba3f6_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities (VIE)</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1133f154-91e0-42b1-a9ed-ffef9263938c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_93395637-e40e-429d-b94c-d4aff7651043_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_bad1a0b6-8f69-46e7-beae-908d16131a36_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1ecdd92f-70c1-478d-af4e-7812f56e1abc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_12eabf2b-05ec-41eb-85ef-b335d0ad1488_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_27a9fb65-fc61-475a-8418-5725d4f47c29_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_f01fbdcc-c35d-4d19-9bec-4027036ddd77_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05d0a8a0-1a96-45ea-948e-b1d411e108a2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1fd6999c-c1db-492c-87d9-8b6d8bbabe10_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84c35372-df7e-4ce3-b288-08e446aa0d04_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_435e0d7c-7873-4805-b8fe-92b83a312211_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_aaae4e6a-a612-4f3d-b852-936d55dc6c12_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_a10bf576-1dc9-4a36-ae9f-83a72650084a_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days written notice before termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:to="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_4c9be5be-313e-4eba-9948-03119845f256_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2aec8293-6e34-4fe1-929c-b08a383e42a5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_359d28ff-ee88-465c-92f8-3a107750ef9c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2027aa4e-b34b-41c2-bcf3-6a850e022e7f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized transaction loss on foreign-currency denominated debt</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cae9a4ee-7915-4353-999a-a14e2df3390b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_524bdcc6-5b14-4524-8b1a-225cff9a3a61_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8b92d62-3f5f-42af-a5d5-6f619f0bdd82_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementAgentFee_669f14c3-b072-473b-8ff5-e1cb63bfbb28_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementAgentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agent fee</link:label>
    <link:label id="lab_ino_StockSalesAgreementAgentFee_label_en-US" xlink:label="lab_ino_StockSalesAgreementAgentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Agent Fee</link:label>
    <link:label id="lab_ino_StockSalesAgreementAgentFee_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementAgentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Agent Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementAgentFee" xlink:href="ino-20200930.xsd#ino_StockSalesAgreementAgentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementAgentFee" xlink:to="lab_ino_StockSalesAgreementAgentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_18a69431-3045-4f92-9230-54775ba513fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_d534f4e3-dd22-4455-8064-1ca8bf91f63e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1107848c-8ac3-4719-9a25-d682723fa6e8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_bc0c6484-a926-4f6c-8b8f-f89ac5d85e3f_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_fbdffa2e-1a65-47dc-8be8-0ecf7a320a38_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_71bb8a09-1ff7-43a6-a7bd-d3ffa21aba31_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_868a14ec-73b2-4ba5-b13d-d8429852aa65_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_f54967be-8655-44b5-8449-ac36a10f0c8e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3813c1ba-81e4-4f2c-8137-357a8a0a5575_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_d8b79c18-fcdf-4ccb-a28e-4329112350d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_7a3b054e-d9f9-450a-a7d7-b89ff7f2af3b_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, required bondholder approval, percentage</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Required Bondholder Approval, Percentage</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Required Bondholder Approval, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:href="ino-20200930.xsd#ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:to="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_bdac417e-7468-4ba3-a44b-25331f13473e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2016IncentivePlanMember_6f033e76-b16c-4817-a508-84300de28b8c_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember" xlink:href="ino-20200930.xsd#ino_A2016IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember" xlink:to="lab_ino_A2016IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a8109250-ce72-4f1c-8007-2884340fc97e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of the Company's Derivative Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_56506e91-9684-49c3-84dd-9bba7fb911c2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f8fd67c8-b65c-4b8d-bce5-0517dcaa341e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_a45ff018-b3d3-444e-a22d-6febdda6094d_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_7af1ddd6-41b0-4931-a392-91f69ca086ea_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_a1f5d757-d9c1-4c96-b49d-3435a54402b3_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember" xlink:href="ino-20200930.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember" xlink:to="lab_ino_PlumblineLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_fdcfe233-df76-4e0b-96fc-277136784f41_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MilestoneBasedOwnershipTarget_0b0de785-e3bc-4678-8a66-8f8128c73b77_terseLabel_en-US" xlink:label="lab_ino_MilestoneBasedOwnershipTarget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone-based ownership target</link:label>
    <link:label id="lab_ino_MilestoneBasedOwnershipTarget_label_en-US" xlink:label="lab_ino_MilestoneBasedOwnershipTarget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone-Based Ownership Target</link:label>
    <link:label id="lab_ino_MilestoneBasedOwnershipTarget_documentation_en-US" xlink:label="lab_ino_MilestoneBasedOwnershipTarget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone-Based Ownership Target</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MilestoneBasedOwnershipTarget" xlink:href="ino-20200930.xsd#ino_MilestoneBasedOwnershipTarget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MilestoneBasedOwnershipTarget" xlink:to="lab_ino_MilestoneBasedOwnershipTarget" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_e5c51cf6-c2bb-4f7e-aff2-0abff3463136_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_33b74fc8-f036-4a67-875c-91f68bbb9619_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6fa472bf-5531-4dfb-9e89-632e5ccb8ec7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Capital_c4d8b21e-a681-4d1d-bf08-18ad8f6a1205_terseLabel_en-US" xlink:label="lab_us-gaap_Capital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_us-gaap_Capital_label_en-US" xlink:label="lab_us-gaap_Capital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banking Regulation, Total Capital, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Capital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Capital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Capital" xlink:to="lab_us-gaap_Capital" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_abe557ec-afc9-436a-8b43-972dec816370_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sale agreement weighted average price per share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Weighted Average Price Per Share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement Weighted Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:href="ino-20200930.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:to="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioMember_1490d23b-a72b-4297-8cb8-9e6d84394364_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_label_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_documentation_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember" xlink:href="ino-20200930.xsd#ino_ApolloBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember" xlink:to="lab_ino_ApolloBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_dcdeb6d3-2ee2-486e-b93b-5c5710cd8fcc_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_InitialConversionPriceMember_0e8ef738-43c9-4d41-910c-87e72fbdede7_terseLabel_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_label_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_documentation_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember" xlink:href="ino-20200930.xsd#ino_InitialConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InitialConversionPriceMember" xlink:to="lab_ino_InitialConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cf05c0d7-5342-405d-b82c-b0b43ea50e2e_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_253bc5c7-2dba-44e7-97c0-6706745cc190_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0a3794cb-19c4-4682-ac2c-0288c06bce2c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_14305251-0301-49ba-905e-328974f77e95_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_53c095a5-a7b3-49e9-a1c6-9c6d609bae39_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_904f9ea2-5923-48f6-88c7-1d07e6dd7ad1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_9f89f999-bbb7-4849-b8ef-736aa3c12e42_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_246ab527-d451-4b01-a7c3-9732d8ed9fcc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_dfe4514f-07b3-4062-a938-ce861767313b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_3840ad28-3169-44d9-b486-6f7f05dc23b0_verboseLabel_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and Fair Value Measurements (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_label_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and Fair Value Measurements (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_documentation_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities and fair value measurements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:href="ino-20200930.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:to="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e187b187-322a-48a2-a945-232165159324_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0610d075-3e69-436b-aa30-3c6b7fff60b5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_775e6aa6-ad42-441b-addc-4ef7f5749478_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_401fd502-32bb-4938-8986-2c30c5ff572a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_52baf160-f4f6-4916-9363-cd0039333128_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_406c9bdc-d30e-4934-b660-4e9f183837d6_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0f234f12-a9b0-4e98-a49b-611aa0d13416_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_16cccceb-1c3c-4166-ac7f-71158f92c661_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash resulting from the deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_910beba9-1f55-4d32-b12e-efb6f1df6f3c_terseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash resulting from the deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_1d58cb51-4524-4407-b6d2-30b562bd0b13_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_694bdef5-3081-4373-aef8-89ac336ae421_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1cb9ee07-01f5-4901-8d2e-6d09794dfbb8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20977748-a905-464a-890f-eafa3273c4d0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_21cf079a-e10b-477a-aca8-17946b613dc3_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_fe09faee-9c67-4009-8740-e8fe8ddfa266_terseLabel_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_label_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_documentation_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember" xlink:href="ino-20200930.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LassaFeverAndMERSVaccineMember" xlink:to="lab_ino_LassaFeverAndMERSVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_53cfcbb5-22ac-4444-940c-1440f258422b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a498fd38-d3ed-4cd1-87ac-f36e77acb455_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_75519754-0667-4459-ab75-ebe09144cafe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_81cc0448-6205-4b28-a579-707e2429f099_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ino-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:124dcabe-323e-4d00-a29d-21ddeb618d02,g:528b4586-6faf-4a31-a887-4db858d575b9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_86e3439c-a408-4a64-a33a-a50ac4c69095" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_DocumentType_86e3439c-a408-4a64-a33a-a50ac4c69095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_8339f88a-10d1-4079-aaf3-a815f6413b3b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_DocumentQuarterlyReport_8339f88a-10d1-4079-aaf3-a815f6413b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_530fe30d-111b-4b4a-a7a6-b833eefb6ffa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_DocumentPeriodEndDate_530fe30d-111b-4b4a-a7a6-b833eefb6ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6375be6c-82b2-4722-b0a9-78e70b3abe9d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_DocumentTransitionReport_6375be6c-82b2-4722-b0a9-78e70b3abe9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4951f9b6-295f-4258-a509-50e929f42aec" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityFileNumber_4951f9b6-295f-4258-a509-50e929f42aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_619a777a-eece-401b-a9fe-d3c68bae61fa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityRegistrantName_619a777a-eece-401b-a9fe-d3c68bae61fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0870d1ec-4927-42b7-9d20-c699c3b7d0d1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0870d1ec-4927-42b7-9d20-c699c3b7d0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_17413b1f-e0b7-4e16-ad09-099e7b7111c0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityTaxIdentificationNumber_17413b1f-e0b7-4e16-ad09-099e7b7111c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_69231cba-0c2c-466d-b5d7-b22daaa54d03" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityAddressAddressLine1_69231cba-0c2c-466d-b5d7-b22daaa54d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_dfe0e835-3ec7-451e-89d1-b49ff56f3745" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityAddressCityOrTown_dfe0e835-3ec7-451e-89d1-b49ff56f3745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_95ff1809-d748-4284-b636-009e553aa696" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityAddressStateOrProvince_95ff1809-d748-4284-b636-009e553aa696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_03a7d1f3-f025-4973-a437-1e9d84b9ad8e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityAddressPostalZipCode_03a7d1f3-f025-4973-a437-1e9d84b9ad8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4a649001-7f4c-4b86-b7c1-f77f49cc14fc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_CityAreaCode_4a649001-7f4c-4b86-b7c1-f77f49cc14fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_88fbf3b0-5888-49c8-a102-391394273984" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_LocalPhoneNumber_88fbf3b0-5888-49c8-a102-391394273984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1b22f078-f829-4778-9c2a-6c66be007607" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_Security12bTitle_1b22f078-f829-4778-9c2a-6c66be007607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d067a8fb-026b-4688-b484-1ff6660e5a3c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_TradingSymbol_d067a8fb-026b-4688-b484-1ff6660e5a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c9f2bd2d-687b-4486-8bd0-7f86473e39d8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_SecurityExchangeName_c9f2bd2d-687b-4486-8bd0-7f86473e39d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_07f05c5e-627a-4e39-bc38-960650980fe9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityCurrentReportingStatus_07f05c5e-627a-4e39-bc38-960650980fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_30a325b7-81de-42de-9e44-158e346f721d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityInteractiveDataCurrent_30a325b7-81de-42de-9e44-158e346f721d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_18e0c6b9-d409-4508-9c7d-0843692dffef" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityFilerCategory_18e0c6b9-d409-4508-9c7d-0843692dffef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6d94077b-db54-43a9-8086-dc325c10eec2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntitySmallBusiness_6d94077b-db54-43a9-8086-dc325c10eec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_55dde394-52d7-459c-b4a0-f9c21b5a405b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityEmergingGrowthCompany_55dde394-52d7-459c-b4a0-f9c21b5a405b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_45826451-4cd6-4b2e-8996-3949ae25243e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityShellCompany_45826451-4cd6-4b2e-8996-3949ae25243e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a634acf1-930d-47de-b82c-131325d53a04" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a634acf1-930d-47de-b82c-131325d53a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c0846585-9645-42bd-b170-312033e6ac37" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_AmendmentFlag_c0846585-9645-42bd-b170-312033e6ac37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_127aa8ba-90c9-44cd-b53d-207b97744661" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_DocumentFiscalYearFocus_127aa8ba-90c9-44cd-b53d-207b97744661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d9f6fea1-5cef-498b-b69b-e8bce6a8f6cf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d9f6fea1-5cef-498b-b69b-e8bce6a8f6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_74778986-f668-4553-862f-17213dea7910" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_EntityCentralIndexKey_74778986-f668-4553-862f-17213dea7910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_91f94bda-24ce-4015-8771-53ea50c9e9f6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a113bfc7-5de3-48bd-9f01-57596017d4bd" xlink:to="loc_dei_CurrentFiscalYearEndDate_91f94bda-24ce-4015-8771-53ea50c9e9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_34c33748-e97e-4787-b4c8-aba940692f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_268959a9-5c3f-4b00-a417-1621150c188f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34c33748-e97e-4787-b4c8-aba940692f07" xlink:to="loc_us-gaap_StatementTable_268959a9-5c3f-4b00-a417-1621150c188f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cba733f0-37e6-4e95-b8e2-35142ddf07af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_268959a9-5c3f-4b00-a417-1621150c188f" xlink:to="loc_us-gaap_DebtInstrumentAxis_cba733f0-37e6-4e95-b8e2-35142ddf07af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_46da3e59-5f8d-4b70-916a-f83b6e16a310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_cba733f0-37e6-4e95-b8e2-35142ddf07af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_46da3e59-5f8d-4b70-916a-f83b6e16a310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_4f58bac9-a785-478a-b7b2-0157757bcc31" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46da3e59-5f8d-4b70-916a-f83b6e16a310" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_4f58bac9-a785-478a-b7b2-0157757bcc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_d5b946bb-336e-44d8-83ef-8607c1e21960" xlink:href="ino-20200930.xsd#ino_ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46da3e59-5f8d-4b70-916a-f83b6e16a310" xlink:to="loc_ino_ConvertibleBondsMember_d5b946bb-336e-44d8-83ef-8607c1e21960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a24386dc-c737-4439-8399-ff173db692a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_268959a9-5c3f-4b00-a417-1621150c188f" xlink:to="loc_us-gaap_StatementLineItems_a24386dc-c737-4439-8399-ff173db692a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a24386dc-c737-4439-8399-ff173db692a8" xlink:to="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d8de50b3-a840-4552-b9d9-bcf85c633990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d8de50b3-a840-4552-b9d9-bcf85c633990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_6aa2826a-37f3-470a-8453-900400e5d0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_us-gaap_ShortTermInvestments_6aa2826a-37f3-470a-8453-900400e5d0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_030f4a29-157e-4568-ad14-a52d16316690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_030f4a29-157e-4568-ad14-a52d16316690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_15acd447-95d4-425b-b462-9c691caa60b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_15acd447-95d4-425b-b462-9c691caa60b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f4a931e2-7d97-4860-bcc8-182ac4607d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f4a931e2-7d97-4860-bcc8-182ac4607d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_62769c24-c4c4-4402-a07d-114278b4e52c" xlink:href="ino-20200930.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_62769c24-c4c4-4402-a07d-114278b4e52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9b120c70-9d6a-426d-8ce5-ae7e7201504c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fb600ccf-6fdf-4881-9186-a1f4cfbaab6d" xlink:to="loc_us-gaap_AssetsCurrent_9b120c70-9d6a-426d-8ce5-ae7e7201504c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_03387781-f2ef-4ea1-b712-a67c4dcaef62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_03387781-f2ef-4ea1-b712-a67c4dcaef62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c8b64d2f-5cc8-47f7-bb65-09f1c448d82c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c8b64d2f-5cc8-47f7-bb65-09f1c448d82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c3fc6848-45a7-45f7-bce7-5411381ec1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_EquityMethodInvestments_c3fc6848-45a7-45f7-bce7-5411381ec1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_590c5a66-baac-4a24-9112-0764ffa13a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_590c5a66-baac-4a24-9112-0764ffa13a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b3d7fe9e-6ead-4032-a3ef-aff04a99329d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_Goodwill_b3d7fe9e-6ead-4032-a3ef-aff04a99329d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ef7be706-17a0-46a3-a586-6c056ba3e2d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ef7be706-17a0-46a3-a586-6c056ba3e2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_59090a4a-9c44-45a3-957a-2e42c661704b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_59090a4a-9c44-45a3-957a-2e42c661704b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_66c404d6-6eb0-419a-829d-6e62446ec600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85c24061-b5dc-4c8a-a3c0-060ab1af8f6b" xlink:to="loc_us-gaap_Assets_66c404d6-6eb0-419a-829d-6e62446ec600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a24386dc-c737-4439-8399-ff173db692a8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aa347da-b8f7-4f59-9273-065ec7a441e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9aa347da-b8f7-4f59-9273-065ec7a441e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_a5f7701a-2c8c-4ab7-8daf-d67ced7d4414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_a5f7701a-2c8c-4ab7-8daf-d67ced7d4414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_b7398346-2f91-49cd-98cd-c2c929644cb9" xlink:href="ino-20200930.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_b7398346-2f91-49cd-98cd-c2c929644cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_edfd72a3-74ae-4faa-8c20-9943a6b133c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_edfd72a3-74ae-4faa-8c20-9943a6b133c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_0f9fb81a-d7d4-4a23-9e65-6bd34d8033ef" xlink:href="ino-20200930.xsd#ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_0f9fb81a-d7d4-4a23-9e65-6bd34d8033ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_738a0f4a-9b90-4c84-80f1-0d0b4b84b12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_738a0f4a-9b90-4c84-80f1-0d0b4b84b12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_1da00414-2825-483e-992e-e77548f9fc24" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_ino_DeferredGrantFundingCurrent_1da00414-2825-483e-992e-e77548f9fc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_63ac5f2c-2766-4717-99a2-4d7894dfd400" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_63ac5f2c-2766-4717-99a2-4d7894dfd400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2e0ac536-f182-429f-a1e1-64ee5f074e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7fff4282-017d-4fff-bfc7-de35c53c7253" xlink:to="loc_us-gaap_LiabilitiesCurrent_2e0ac536-f182-429f-a1e1-64ee5f074e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_77f18c48-f0d5-4b37-b491-f6d067f7ebf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_77f18c48-f0d5-4b37-b491-f6d067f7ebf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_b94bbcc8-bf03-41b8-a558-f6f848190af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_ConvertibleDebt_b94bbcc8-bf03-41b8-a558-f6f848190af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d3452878-f4ff-4467-a45e-c820f46b7d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_DerivativeLiabilities_d3452878-f4ff-4467-a45e-c820f46b7d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cef44ef0-8eb8-49fe-a18c-5d5c66481cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cef44ef0-8eb8-49fe-a18c-5d5c66481cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_915450fa-9780-4768-b611-aa2105bae1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_915450fa-9780-4768-b611-aa2105bae1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_ff245663-0d55-42d1-a680-8e83a332053a" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_ff245663-0d55-42d1-a680-8e83a332053a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a9d8cfa7-40d5-495b-bb36-5c0548e61dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a9d8cfa7-40d5-495b-bb36-5c0548e61dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8d58e463-21f3-4af3-a840-03fafe9328a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_Liabilities_8d58e463-21f3-4af3-a840-03fafe9328a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d21dc963-d243-48dc-b010-e30c562b6200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_PreferredStockValue_d21dc963-d243-48dc-b010-e30c562b6200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e117c82b-5c6f-4d96-9b69-34cc6f6d3a47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_CommonStockValue_e117c82b-5c6f-4d96-9b69-34cc6f6d3a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f797a800-4e55-4d01-8e67-3e82b01c1751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f797a800-4e55-4d01-8e67-3e82b01c1751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6964f726-00f6-4b46-86aa-c8233ced6096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6964f726-00f6-4b46-86aa-c8233ced6096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84e89af4-2f04-4cb8-91d3-3d2423044571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84e89af4-2f04-4cb8-91d3-3d2423044571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_71c0b2f6-b9f0-43e1-9c15-f2c5f58f8e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_StockholdersEquity_71c0b2f6-b9f0-43e1-9c15-f2c5f58f8e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_11fb1a28-ef85-4e2b-abd2-d05cac32f8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_MinorityInterest_11fb1a28-ef85-4e2b-abd2-d05cac32f8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dbf5ca9a-35a0-47e7-b487-90cccedbac31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4fec76cc-5a5c-4cbc-a043-8d41ddf43dc0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dbf5ca9a-35a0-47e7-b487-90cccedbac31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cfa9a676-d3b8-48b9-8405-006781068fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4396037c-08ef-474a-bada-97f4f492788b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_cfa9a676-d3b8-48b9-8405-006781068fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_7f153209-4c92-4b78-b493-cc535ac4aec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c780ae54-0b64-48e8-9388-fab14395bcaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7f153209-4c92-4b78-b493-cc535ac4aec0" xlink:to="loc_us-gaap_StatementTable_c780ae54-0b64-48e8-9388-fab14395bcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fc27353b-03ac-4206-97f3-82e1bde1f41f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c780ae54-0b64-48e8-9388-fab14395bcaf" xlink:to="loc_srt_ProductOrServiceAxis_fc27353b-03ac-4206-97f3-82e1bde1f41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a85ee2ad-c913-4ddc-8b7c-e61ca3edd905" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fc27353b-03ac-4206-97f3-82e1bde1f41f" xlink:to="loc_srt_ProductsAndServicesDomain_a85ee2ad-c913-4ddc-8b7c-e61ca3edd905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_010557e5-7010-4114-a0fb-6a5b8c1c6139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a85ee2ad-c913-4ddc-8b7c-e61ca3edd905" xlink:to="loc_us-gaap_LicenseMember_010557e5-7010-4114-a0fb-6a5b8c1c6139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_d8a021e2-d664-4370-968b-7f9707c04634" xlink:href="ino-20200930.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a85ee2ad-c913-4ddc-8b7c-e61ca3edd905" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_d8a021e2-d664-4370-968b-7f9707c04634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9a3f6fdb-15f6-4f8f-be07-26f6379a41b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a85ee2ad-c913-4ddc-8b7c-e61ca3edd905" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9a3f6fdb-15f6-4f8f-be07-26f6379a41b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d2c774ad-95b6-46f4-adc0-623448768d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c780ae54-0b64-48e8-9388-fab14395bcaf" xlink:to="loc_us-gaap_DebtInstrumentAxis_d2c774ad-95b6-46f4-adc0-623448768d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a97dedfe-40f6-4d12-a5ea-8e7ef3c1892d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d2c774ad-95b6-46f4-adc0-623448768d80" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a97dedfe-40f6-4d12-a5ea-8e7ef3c1892d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_fdc00eb3-1bd2-4ea7-8513-0f27c3a38dac" xlink:href="ino-20200930.xsd#ino_ConvertibleBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a97dedfe-40f6-4d12-a5ea-8e7ef3c1892d" xlink:to="loc_ino_ConvertibleBondsMember_fdc00eb3-1bd2-4ea7-8513-0f27c3a38dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ce4f4b85-dc83-4e24-a52c-5b68854f1fa4" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a97dedfe-40f6-4d12-a5ea-8e7ef3c1892d" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ce4f4b85-dc83-4e24-a52c-5b68854f1fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c780ae54-0b64-48e8-9388-fab14395bcaf" xlink:to="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6a2c74d8-efd5-4889-80c5-a70d2b451cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_RevenuesAbstract_6a2c74d8-efd5-4889-80c5-a70d2b451cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1abd4f29-50fe-41ca-9939-18165a076f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_6a2c74d8-efd5-4889-80c5-a70d2b451cf1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1abd4f29-50fe-41ca-9939-18165a076f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6e87fedb-3d89-42c2-af72-e1036b860d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6e87fedb-3d89-42c2-af72-e1036b860d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b2432005-9759-452d-83e2-e60894e4afcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6e87fedb-3d89-42c2-af72-e1036b860d3f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b2432005-9759-452d-83e2-e60894e4afcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d20a432c-1c24-4791-afea-4349463516bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6e87fedb-3d89-42c2-af72-e1036b860d3f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d20a432c-1c24-4791-afea-4349463516bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1b5be67a-28fc-4223-bb89-c42e354afc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6e87fedb-3d89-42c2-af72-e1036b860d3f" xlink:to="loc_us-gaap_OperatingExpenses_1b5be67a-28fc-4223-bb89-c42e354afc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7ea21ca6-c2cb-4bff-843a-cbba1b5218e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_OperatingIncomeLoss_7ea21ca6-c2cb-4bff-843a-cbba1b5218e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_2cb5ad5b-51a0-48ac-b189-58d8ee0f1777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_InterestIncomeOperating_2cb5ad5b-51a0-48ac-b189-58d8ee0f1777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fbee854d-8750-4ed7-bf51-c409095c2f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_InterestExpense_fbee854d-8750-4ed7-bf51-c409095c2f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_d26f607b-2ae3-43d1-8117-29c9dfa9e643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_d26f607b-2ae3-43d1-8117-29c9dfa9e643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_779c0a8e-7b35-4262-b533-84110b1402e5" xlink:href="ino-20200930.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_779c0a8e-7b35-4262-b533-84110b1402e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9d39a8eb-748f-4e4d-8f7d-291a404fd604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9d39a8eb-748f-4e4d-8f7d-291a404fd604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f63cd696-d3e1-42e0-9063-18ef3f1e8bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f63cd696-d3e1-42e0-9063-18ef3f1e8bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_71c15888-705e-4de1-84c3-df73de9b959a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_71c15888-705e-4de1-84c3-df73de9b959a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_705c256b-f4ca-4a31-bdb8-c0890e569000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_705c256b-f4ca-4a31-bdb8-c0890e569000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2fcf6600-922e-4e08-b0fe-65c623fc4e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2fcf6600-922e-4e08-b0fe-65c623fc4e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3ef08559-4c05-45c5-8cc1-f2f17d63393f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3ef08559-4c05-45c5-8cc1-f2f17d63393f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e9190dc6-fdac-45b9-9a5e-74b292d6381d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e9190dc6-fdac-45b9-9a5e-74b292d6381d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_18c2ecf4-a97d-48f0-aa20-26ce4b102281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_ProfitLoss_18c2ecf4-a97d-48f0-aa20-26ce4b102281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1b00295d-ebb2-42d0-833b-983d0fd5858e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1b00295d-ebb2-42d0-833b-983d0fd5858e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f43c247-0b35-4cc0-b1ae-27175609046d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_08b11557-f908-42c8-a346-3b4568cb8364" xlink:to="loc_us-gaap_NetIncomeLoss_2f43c247-0b35-4cc0-b1ae-27175609046d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_04413aed-5531-4ffa-9121-77c6fdb3d95c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_04413aed-5531-4ffa-9121-77c6fdb3d95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_caac7945-2338-4d94-9510-f14764cbd629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_04413aed-5531-4ffa-9121-77c6fdb3d95c" xlink:to="loc_us-gaap_EarningsPerShareBasic_caac7945-2338-4d94-9510-f14764cbd629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5fed0d78-780a-4beb-86d8-9aa89ce82cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_04413aed-5531-4ffa-9121-77c6fdb3d95c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5fed0d78-780a-4beb-86d8-9aa89ce82cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_71fad07f-3d74-4089-bac5-add5bc058c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0626791a-7dba-4285-9ebd-8431583f479f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_71fad07f-3d74-4089-bac5-add5bc058c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d680ac7e-cae6-4f3d-9c55-d283a3f06f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_71fad07f-3d74-4089-bac5-add5bc058c5b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d680ac7e-cae6-4f3d-9c55-d283a3f06f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_af9cfcba-8d30-4521-a62c-a1420c7c97ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_71fad07f-3d74-4089-bac5-add5bc058c5b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_af9cfcba-8d30-4521-a62c-a1420c7c97ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_88d4e4cf-ea84-4cc3-987c-7ed926ac980e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_47b5d5ca-95a3-48b9-b029-60ce2e1c1c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_88d4e4cf-ea84-4cc3-987c-7ed926ac980e" xlink:to="loc_us-gaap_ProfitLoss_47b5d5ca-95a3-48b9-b029-60ce2e1c1c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f303f31c-ac23-4df2-8a92-7ba9e54ba98a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_88d4e4cf-ea84-4cc3-987c-7ed926ac980e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f303f31c-ac23-4df2-8a92-7ba9e54ba98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bc3048a4-0b77-4706-8045-1780d5e8c50c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f303f31c-ac23-4df2-8a92-7ba9e54ba98a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bc3048a4-0b77-4706-8045-1780d5e8c50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_015b8579-1acd-40fd-b888-7d89b3cc8720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f303f31c-ac23-4df2-8a92-7ba9e54ba98a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_015b8579-1acd-40fd-b888-7d89b3cc8720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a703f3fe-d971-4682-879d-64436c8cf426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_88d4e4cf-ea84-4cc3-987c-7ed926ac980e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a703f3fe-d971-4682-879d-64436c8cf426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f8a8e579-400c-479b-9a43-831d4f96be06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_88d4e4cf-ea84-4cc3-987c-7ed926ac980e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f8a8e579-400c-479b-9a43-831d4f96be06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_95a90e12-9ed1-4015-a9de-47ede9fcc68c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_88d4e4cf-ea84-4cc3-987c-7ed926ac980e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_95a90e12-9ed1-4015-a9de-47ede9fcc68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cc264abb-769e-433a-9ca7-ef1d61014f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ef07239e-38e2-4ddc-9013-7c26de034f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cc264abb-769e-433a-9ca7-ef1d61014f65" xlink:to="loc_us-gaap_StatementTable_ef07239e-38e2-4ddc-9013-7c26de034f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a45b4947-9183-48c2-b967-3cc3a2144432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ef07239e-38e2-4ddc-9013-7c26de034f39" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a45b4947-9183-48c2-b967-3cc3a2144432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a45b4947-9183-48c2-b967-3cc3a2144432" xlink:to="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_0ef979ce-9b21-4309-a456-0445a74ae4f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:to="loc_us-gaap_PreferredStockMember_0ef979ce-9b21-4309-a456-0445a74ae4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bf0fd859-4cb4-4983-8f53-09f63c1e57d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:to="loc_us-gaap_CommonStockMember_bf0fd859-4cb4-4983-8f53-09f63c1e57d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9ff946d7-9f6e-41ab-a9c7-7653019426fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9ff946d7-9f6e-41ab-a9c7-7653019426fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2f045fd7-a89e-4731-a780-623f34280784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:to="loc_us-gaap_RetainedEarningsMember_2f045fd7-a89e-4731-a780-623f34280784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2878b24f-6b69-4fe7-891c-44e8f23e44ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2878b24f-6b69-4fe7-891c-44e8f23e44ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_49fe68c6-3951-4379-a897-af07a57b6ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_060af33b-0b4c-4db1-a45c-3d66ff9da42f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_49fe68c6-3951-4379-a897-af07a57b6ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aac49bbe-ed73-42af-8f94-58391f4bd79e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ef07239e-38e2-4ddc-9013-7c26de034f39" xlink:to="loc_us-gaap_DebtInstrumentAxis_aac49bbe-ed73-42af-8f94-58391f4bd79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_389808f0-c258-4c0a-adc5-65ec6d47c604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_aac49bbe-ed73-42af-8f94-58391f4bd79e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_389808f0-c258-4c0a-adc5-65ec6d47c604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_08aabcb2-6068-4ada-a4c9-8ef32bc56a6b" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_389808f0-c258-4c0a-adc5-65ec6d47c604" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_08aabcb2-6068-4ada-a4c9-8ef32bc56a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_866cb5fe-8e66-4483-a6dd-004beb931881" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_389808f0-c258-4c0a-adc5-65ec6d47c604" xlink:to="loc_ino_August2019ConvertibleBondsMember_866cb5fe-8e66-4483-a6dd-004beb931881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ef07239e-38e2-4ddc-9013-7c26de034f39" xlink:to="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_01ace31d-a78c-4192-b742-c49612a9d89f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_SharesIssued_01ace31d-a78c-4192-b742-c49612a9d89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81f4818b-0a57-4f6a-a6e4-304753621dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81f4818b-0a57-4f6a-a6e4-304753621dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_452f2d1c-4a65-4e94-bd60-fc55e1c2c8ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_452f2d1c-4a65-4e94-bd60-fc55e1c2c8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c247571e-9089-4351-9185-78ebad01e469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c247571e-9089-4351-9185-78ebad01e469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0d6ff104-7cf3-4351-8659-7e9805b28ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0d6ff104-7cf3-4351-8659-7e9805b28ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e8803a94-7e26-4420-ac64-6b336c8cc226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e8803a94-7e26-4420-ac64-6b336c8cc226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ded4b54b-2bc6-43bd-8aab-210639109c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ded4b54b-2bc6-43bd-8aab-210639109c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0a64ca07-2a32-45b5-9500-dd283ec9881b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0a64ca07-2a32-45b5-9500-dd283ec9881b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_1fdf774f-d613-4bbb-8529-4d969fa2406f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_1fdf774f-d613-4bbb-8529-4d969fa2406f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d75d6dc7-30d6-45f3-9f8f-68de0b81a3aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d75d6dc7-30d6-45f3-9f8f-68de0b81a3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_50cb56b0-6c4d-49f1-a48f-b886a34a4f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_50cb56b0-6c4d-49f1-a48f-b886a34a4f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_637c842f-2ca5-4abb-a280-8385ee91a05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_637c842f-2ca5-4abb-a280-8385ee91a05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_cc54b1a5-a886-4a56-ab2e-7cde92eee0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_cc54b1a5-a886-4a56-ab2e-7cde92eee0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_986e3cc3-6da1-4c78-a99d-a06c7e7e792b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_ProfitLoss_986e3cc3-6da1-4c78-a99d-a06c7e7e792b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ac441418-86f9-41dc-8f3e-96f88f637e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ac441418-86f9-41dc-8f3e-96f88f637e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2155fc14-41d2-461a-9094-c9de199462a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2155fc14-41d2-461a-9094-c9de199462a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a62d0b40-2801-4878-a3ab-eb069e6e6a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_SharesIssued_a62d0b40-2801-4878-a3ab-eb069e6e6a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_425978da-67d4-43fa-9ecd-322c507db383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2668a4d7-80cf-42a4-9cee-afd058ea4ae7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_425978da-67d4-43fa-9ecd-322c507db383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b2ca79a1-a760-4083-be24-047a399f654d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7a5f91fc-6b3c-4168-b241-a77bda61d715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b2ca79a1-a760-4083-be24-047a399f654d" xlink:to="loc_us-gaap_StatementTable_7a5f91fc-6b3c-4168-b241-a77bda61d715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1989bc47-5c8d-44eb-ac36-0a659741b6af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7a5f91fc-6b3c-4168-b241-a77bda61d715" xlink:to="loc_us-gaap_DebtInstrumentAxis_1989bc47-5c8d-44eb-ac36-0a659741b6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_58f6170e-d523-4713-a61d-da231056b596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1989bc47-5c8d-44eb-ac36-0a659741b6af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_58f6170e-d523-4713-a61d-da231056b596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_1ded161e-639d-4144-9a43-0b84f54f1565" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_58f6170e-d523-4713-a61d-da231056b596" xlink:to="loc_ino_August2019ConvertibleBondsMember_1ded161e-639d-4144-9a43-0b84f54f1565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_84a7dd4a-e3e8-458c-95db-aef49407afad" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_58f6170e-d523-4713-a61d-da231056b596" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_84a7dd4a-e3e8-458c-95db-aef49407afad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7a5f91fc-6b3c-4168-b241-a77bda61d715" xlink:to="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7722c31f-dc75-420b-88c4-8300952001de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7722c31f-dc75-420b-88c4-8300952001de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cc2291ca-db44-4f88-89ac-3763a7246f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7722c31f-dc75-420b-88c4-8300952001de" xlink:to="loc_us-gaap_ProfitLoss_cc2291ca-db44-4f88-89ac-3763a7246f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7722c31f-dc75-420b-88c4-8300952001de" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_911537a9-b426-4f3a-986a-aa45af161708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_Depreciation_911537a9-b426-4f3a-986a-aa45af161708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2d333faf-6c8a-448d-9cfd-67a0494e4c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2d333faf-6c8a-448d-9cfd-67a0494e4c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_01c2a4bb-dc97-4cae-a8ab-67d164fa0002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_01c2a4bb-dc97-4cae-a8ab-67d164fa0002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1ec1ae8d-ec8c-43c3-9de8-00572aadcc8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_ShareBasedCompensation_1ec1ae8d-ec8c-43c3-9de8-00572aadcc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense_7cd02d6a-9082-4685-bbbe-55572060f04e" xlink:href="ino-20200930.xsd#ino_NonCashInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_ino_NonCashInterestExpense_7cd02d6a-9082-4685-bbbe-55572060f04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_28f5625a-ff72-459f-b0e1-cfe5f5b1ae9f" xlink:href="ino-20200930.xsd#ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit_28f5625a-ff72-459f-b0e1-cfe5f5b1ae9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_096d6499-65a5-4d71-9fb3-209c006bae89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_GainLossOnInvestments_096d6499-65a5-4d71-9fb3-209c006bae89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_c071d9e1-7108-49a6-b32a-e778fb8e1793" xlink:href="ino-20200930.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_c071d9e1-7108-49a6-b32a-e778fb8e1793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_dc5b76f4-d88a-4fc3-9adf-21800850fbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_dc5b76f4-d88a-4fc3-9adf-21800850fbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_16ce473e-b0a0-493b-99f7-65ac348b69a4" xlink:href="ino-20200930.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_16ce473e-b0a0-493b-99f7-65ac348b69a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d2d185d0-eae6-40bc-9ea1-eaa2f9265026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d2d185d0-eae6-40bc-9ea1-eaa2f9265026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2663a727-6014-4c44-a212-46b5e0abbd05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2663a727-6014-4c44-a212-46b5e0abbd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_29e181ac-187e-4ccf-9f2e-a83f70e38a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_29e181ac-187e-4ccf-9f2e-a83f70e38a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense_c6de4693-9e36-4cd3-8be9-28cc7d88cf5b" xlink:href="ino-20200930.xsd#ino_OperatingLeaseNonCashLeaseExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_ino_OperatingLeaseNonCashLeaseExpense_c6de4693-9e36-4cd3-8be9-28cc7d88cf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_16b0cdb8-8902-4a85-8bbd-deef97cea25f" xlink:href="ino-20200930.xsd#ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments_16b0cdb8-8902-4a85-8bbd-deef97cea25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_edd59058-9255-4c83-8d2f-2d2636e6da48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_edd59058-9255-4c83-8d2f-2d2636e6da48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04a221c0-1a72-4e47-bee6-9ee97796678e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f17919b7-5a58-4aec-9748-6ea4593785f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f17919b7-5a58-4aec-9748-6ea4593785f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_af988d71-cc56-4b4d-aba0-41f90d0befcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_af988d71-cc56-4b4d-aba0-41f90d0befcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4b0ed0c6-d402-4010-aeae-e286238acbee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4b0ed0c6-d402-4010-aeae-e286238acbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_1eed8557-fdf8-4a82-9ac2-f13e62ee77b1" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_1eed8557-fdf8-4a82-9ac2-f13e62ee77b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b7a3b0ac-b156-4ab6-9687-4a43f14f975a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b7a3b0ac-b156-4ab6-9687-4a43f14f975a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5e3fb7af-48a8-4eeb-8333-7a00799781c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5e3fb7af-48a8-4eeb-8333-7a00799781c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_519e42c3-3fab-47b7-891a-a3c57f8745e1" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_519e42c3-3fab-47b7-891a-a3c57f8745e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_727801c4-00f2-4d07-83ab-19c477593dda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_727801c4-00f2-4d07-83ab-19c477593dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_95dffdb3-4942-4b61-a075-f05b06837090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_95dffdb3-4942-4b61-a075-f05b06837090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_408b557e-1169-46d3-a3e8-1f0e0ca52241" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_408b557e-1169-46d3-a3e8-1f0e0ca52241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_29b269ac-6619-43bd-ba28-60d1201a192b" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_29b269ac-6619-43bd-ba28-60d1201a192b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_1708b2ef-de35-462a-81d5-a20ed0aca3ae" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_1708b2ef-de35-462a-81d5-a20ed0aca3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_501e71a6-1fba-4a4a-a4a7-27686803289d" xlink:href="ino-20200930.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_501e71a6-1fba-4a4a-a4a7-27686803289d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a941954-020d-43cd-bd73-bd963918b58e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d83657d7-2142-44e8-90ac-d823372acad0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a941954-020d-43cd-bd73-bd963918b58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36ab75e0-680c-46ce-9872-8981514e8fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7722c31f-dc75-420b-88c4-8300952001de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36ab75e0-680c-46ce-9872-8981514e8fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_77e5f39f-aed0-42da-9669-27bfad887f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_77e5f39f-aed0-42da-9669-27bfad887f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_7976474d-28a5-4952-88ed-ec54519eb3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_7976474d-28a5-4952-88ed-ec54519eb3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_265bad5e-a900-4553-ae33-49d3c61abde7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_265bad5e-a900-4553-ae33-49d3c61abde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_1222549d-93ae-4b13-b894-59f2f1e81887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_1222549d-93ae-4b13-b894-59f2f1e81887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_d958f9b6-a4b6-4a9b-ba88-8a1bcb52274c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_d958f9b6-a4b6-4a9b-ba88-8a1bcb52274c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e7ab5b1-bf48-456e-a837-927a6cdb15f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0676b377-7f1d-45ba-964b-92b548b3b99c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e7ab5b1-bf48-456e-a837-927a6cdb15f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b15dfa14-1132-490c-81a6-fda54a84bddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b15dfa14-1132-490c-81a6-fda54a84bddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_efe11a49-1e30-4ecc-8566-1c8899c87612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_efe11a49-1e30-4ecc-8566-1c8899c87612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b33a21c8-fdd6-4e14-9e6c-937f616f4a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b33a21c8-fdd6-4e14-9e6c-937f616f4a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9e86feaa-a7ea-4dc0-bfe5-c4b29ddf0d32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9e86feaa-a7ea-4dc0-bfe5-c4b29ddf0d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_381d5441-e65d-4e76-94ff-a5bce7a9acdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_381d5441-e65d-4e76-94ff-a5bce7a9acdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_6a8a0798-a5fd-425b-b616-d6d69662cd76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_6a8a0798-a5fd-425b-b616-d6d69662cd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_62437cf7-5d81-4dcb-bfdd-4da81a28f7c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_62437cf7-5d81-4dcb-bfdd-4da81a28f7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c11c0416-2899-4754-b048-c9d91a9006e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ac80635-0236-4ff8-b15a-e6654590ea19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c11c0416-2899-4754-b048-c9d91a9006e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e55c3fc-6782-4c60-aa6d-4ae49bebff29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e55c3fc-6782-4c60-aa6d-4ae49bebff29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd5b9662-9974-48ae-bf00-f51401b2a6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd5b9662-9974-48ae-bf00-f51401b2a6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afa89acf-760e-497b-b6f8-1248886bcdc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afa89acf-760e-497b-b6f8-1248886bcdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ff791b1-c6f4-4e39-b7a8-917db0779fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ff791b1-c6f4-4e39-b7a8-917db0779fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_dbe742f9-aa4e-4020-9c56-2848b264a75c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108b3dae-620c-4212-8ac1-70b6742801da" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_dbe742f9-aa4e-4020-9c56-2848b264a75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2337bb6a-c5c3-4c26-b41c-22361b31547b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dbe742f9-aa4e-4020-9c56-2848b264a75c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2337bb6a-c5c3-4c26-b41c-22361b31547b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a3eb431b-ff16-48c6-8ede-768311a0051e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dbe742f9-aa4e-4020-9c56-2848b264a75c" xlink:to="loc_us-gaap_InterestPaidNet_a3eb431b-ff16-48c6-8ede-768311a0051e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fd2150ce-a2a5-449d-ab9a-98f8183e68d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dbe742f9-aa4e-4020-9c56-2848b264a75c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fd2150ce-a2a5-449d-ab9a-98f8183e68d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="ino-20200930.xsd#OrganizationandOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/OrganizationandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb85c46a-0125-4640-a71d-64f5dacb4943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_8320d010-3947-43ca-ad24-b441c9124955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb85c46a-0125-4640-a71d-64f5dacb4943" xlink:to="loc_us-gaap_NatureOfOperations_8320d010-3947-43ca-ad24-b441c9124955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="simple" xlink:href="ino-20200930.xsd#BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0ceb1357-78a3-4d45-81d1-43af99d3fb35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_43832a70-a447-4f81-9a0c-ff3892945f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ceb1357-78a3-4d45-81d1-43af99d3fb35" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_43832a70-a447-4f81-9a0c-ff3892945f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="simple" xlink:href="ino-20200930.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6b7e309b-c39a-4acf-b384-4146586d9a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6b7e309b-c39a-4acf-b384-4146586d9a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_f8fc4ebf-5bd0-49aa-8121-259d9c9fbfa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_f8fc4ebf-5bd0-49aa-8121-259d9c9fbfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f570dd7b-beed-4083-9be5-e8edea2ec4af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f570dd7b-beed-4083-9be5-e8edea2ec4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantPolicyPolicyTextBlock_510871a7-8d26-4515-a937-e82fffede9dd" xlink:href="ino-20200930.xsd#ino_GrantPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:to="loc_ino_GrantPolicyPolicyTextBlock_510871a7-8d26-4515-a937-e82fffede9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_ad56a070-9151-4e6a-a114-3cd99952f881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_ad56a070-9151-4e6a-a114-3cd99952f881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_29e04158-5b37-4e72-85df-3ab9442e6068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_29e04158-5b37-4e72-85df-3ab9442e6068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_ef1ddd7a-aee5-4245-b72f-f378e6a852bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_ef1ddd7a-aee5-4245-b72f-f378e6a852bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_789a46dd-1209-4c73-9cc0-2e44d5448e51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_789a46dd-1209-4c73-9cc0-2e44d5448e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_6ed6732e-3dcf-462a-8181-332015409219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_6ed6732e-3dcf-462a-8181-332015409219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_c3707b3a-cecb-4528-b910-67fee00ba6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_c3707b3a-cecb-4528-b910-67fee00ba6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_823a7d0f-14a2-4cba-b122-888d2cefecf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_823a7d0f-14a2-4cba-b122-888d2cefecf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55a931b7-3107-4d88-b591-a78c05ff147b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1903b48-a3bd-4225-9508-c7e45e907a0f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55a931b7-3107-4d88-b591-a78c05ff147b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_98113ebd-b9f2-4391-aef0-7446a9c01b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98113ebd-b9f2-4391-aef0-7446a9c01b81" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b83b4fc3-7f30-4b35-943e-b570a0f0217f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:to="loc_srt_OwnershipAxis_b83b4fc3-7f30-4b35-943e-b570a0f0217f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1088de5a-7df5-42c7-afc2-d00ed96b385e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_b83b4fc3-7f30-4b35-943e-b570a0f0217f" xlink:to="loc_srt_OwnershipDomain_1088de5a-7df5-42c7-afc2-d00ed96b385e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_VGXAnimalHealthIncMember_88cccc0f-1f24-431b-899e-ebe07a799826" xlink:href="ino-20200930.xsd#ino_VGXAnimalHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1088de5a-7df5-42c7-afc2-d00ed96b385e" xlink:to="loc_ino_VGXAnimalHealthIncMember_88cccc0f-1f24-431b-899e-ebe07a799826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_92e9655b-ea28-4caa-8b2a-e7c8c718e9da" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1088de5a-7df5-42c7-afc2-d00ed96b385e" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_92e9655b-ea28-4caa-8b2a-e7c8c718e9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3efa2338-5676-4380-b7bb-86c830a51b01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:to="loc_us-gaap_DebtInstrumentAxis_3efa2338-5676-4380-b7bb-86c830a51b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_00c15a9a-7a4f-4680-bafa-5c8dc9a987f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3efa2338-5676-4380-b7bb-86c830a51b01" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_00c15a9a-7a4f-4680-bafa-5c8dc9a987f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_95724c24-395b-40ca-aa4f-5a4a757740a0" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_00c15a9a-7a4f-4680-bafa-5c8dc9a987f7" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_95724c24-395b-40ca-aa4f-5a4a757740a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_4f2a2491-cf3d-4eab-a576-9d7ac1ad240c" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_00c15a9a-7a4f-4680-bafa-5c8dc9a987f7" xlink:to="loc_ino_August2019ConvertibleBondsMember_4f2a2491-cf3d-4eab-a576-9d7ac1ad240c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_a4012608-9e68-4a84-be87-a66a04e4e566" xlink:href="ino-20200930.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_00c15a9a-7a4f-4680-bafa-5c8dc9a987f7" xlink:to="loc_ino_December2019ConvertibleBondsMember_a4012608-9e68-4a84-be87-a66a04e4e566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6e849cbf-e895-4bf3-b848-bff3f2da6d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6e849cbf-e895-4bf3-b848-bff3f2da6d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c6a110d3-fcce-4b51-a96a-975c78eba9ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6e849cbf-e895-4bf3-b848-bff3f2da6d9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c6a110d3-fcce-4b51-a96a-975c78eba9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_98f6dcd4-021e-49dc-b069-55f1678ede29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c6a110d3-fcce-4b51-a96a-975c78eba9ad" xlink:to="loc_us-gaap_ConvertibleDebtMember_98f6dcd4-021e-49dc-b069-55f1678ede29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9c70c2b4-ecc9-4a0f-89c3-5b3912f47a88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9c70c2b4-ecc9-4a0f-89c3-5b3912f47a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bee60569-ab96-4419-b7b6-9d1fcfb6dc17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9c70c2b4-ecc9-4a0f-89c3-5b3912f47a88" xlink:to="loc_us-gaap_ClassOfStockDomain_bee60569-ab96-4419-b7b6-9d1fcfb6dc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2e7e5b1d-a330-4ef8-9428-7bf076a62377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bee60569-ab96-4419-b7b6-9d1fcfb6dc17" xlink:to="loc_us-gaap_CommonStockMember_2e7e5b1d-a330-4ef8-9428-7bf076a62377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3885f060-e488-40e8-b7d4-15faa7113eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3885f060-e488-40e8-b7d4-15faa7113eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87e40f20-1e1b-42ac-bdb1-b063866f79a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3885f060-e488-40e8-b7d4-15faa7113eb2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87e40f20-1e1b-42ac-bdb1-b063866f79a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember_f07e56e9-f907-43fb-b685-12dbcc40388c" xlink:href="ino-20200930.xsd#ino_SalesAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87e40f20-1e1b-42ac-bdb1-b063866f79a5" xlink:to="loc_ino_SalesAgreementsMember_f07e56e9-f907-43fb-b685-12dbcc40388c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7a7c84f4-284b-486c-8d3d-d87dacf23aba" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_25a8cf11-0aab-42ef-b50c-d5c59a1b6343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_25a8cf11-0aab-42ef-b50c-d5c59a1b6343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e614d1d-4056-4126-9786-44a73f58fbee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_NetIncomeLoss_3e614d1d-4056-4126-9786-44a73f58fbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Capital_72a8b70f-ed40-4b00-9ac5-bf90406218bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Capital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_Capital_72a8b70f-ed40-4b00-9ac5-bf90406218bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12b9cd21-8988-4071-81bd-62ef19bacfa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12b9cd21-8988-4071-81bd-62ef19bacfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b3d261d9-6120-437e-9a1d-01c2ab4e6c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b3d261d9-6120-437e-9a1d-01c2ab4e6c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1b3765a3-a07e-43ac-923f-1fb73294d23c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1b3765a3-a07e-43ac-923f-1fb73294d23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2a601c87-86c4-48ba-a5cc-fe4af6c0782a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2a601c87-86c4-48ba-a5cc-fe4af6c0782a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_035b8cc3-3648-4135-acdf-4b5455c4c7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_035b8cc3-3648-4135-acdf-4b5455c4c7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_912da54f-1721-45d0-b3e4-878e0c312fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8d625f7a-edd3-419e-b9f6-06f5cd43b748" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_912da54f-1721-45d0-b3e4-878e0c312fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="simple" xlink:href="ino-20200930.xsd#CriticalAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c2376cf2-d1f2-45f7-b97d-ab9d506ad41d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4c97faf5-74f7-4711-94ab-94c9f0079059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c2376cf2-d1f2-45f7-b97d-ab9d506ad41d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4c97faf5-74f7-4711-94ab-94c9f0079059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#CriticalAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b4e53c98-34b7-4611-84f6-9385e296acd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b33d381f-f21e-4d96-b80f-0a8317f4d3f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b4e53c98-34b7-4611-84f6-9385e296acd5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b33d381f-f21e-4d96-b80f-0a8317f4d3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_727d2691-04fd-48a2-b026-b154a4879ef6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b33d381f-f21e-4d96-b80f-0a8317f4d3f9" xlink:to="loc_srt_RangeAxis_727d2691-04fd-48a2-b026-b154a4879ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e20623d-969c-4c67-84ee-ff6d32e45729" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_727d2691-04fd-48a2-b026-b154a4879ef6" xlink:to="loc_srt_RangeMember_7e20623d-969c-4c67-84ee-ff6d32e45729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4f069639-5688-4675-b67d-e405d5564848" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7e20623d-969c-4c67-84ee-ff6d32e45729" xlink:to="loc_srt_MinimumMember_4f069639-5688-4675-b67d-e405d5564848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f7e2af8e-b9a4-44e5-9db5-84d26f85b11b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7e20623d-969c-4c67-84ee-ff6d32e45729" xlink:to="loc_srt_MaximumMember_f7e2af8e-b9a4-44e5-9db5-84d26f85b11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9cb9316a-3ea4-4a7d-825f-bab0a88aecf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b33d381f-f21e-4d96-b80f-0a8317f4d3f9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9cb9316a-3ea4-4a7d-825f-bab0a88aecf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cb356edc-f1f0-4df2-9263-b6aab911f016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9cb9316a-3ea4-4a7d-825f-bab0a88aecf1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cb356edc-f1f0-4df2-9263-b6aab911f016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_11c00cb5-55aa-457a-aee9-3562f827092e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9cb9316a-3ea4-4a7d-825f-bab0a88aecf1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_11c00cb5-55aa-457a-aee9-3562f827092e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="ino-20200930.xsd#ImpactofRecentlyIssuedAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e1a0e652-bfca-485e-89b9-9814cbbdfbaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_7cec3080-fb98-4681-9ee3-dc4518c4c656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e1a0e652-bfca-485e-89b9-9814cbbdfbaf" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_7cec3080-fb98-4681-9ee3-dc4518c4c656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ino-20200930.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3f07608a-7647-4bec-8306-525d645f4cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5e6fe039-ed4f-48f1-898f-5d4b69aa1544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3f07608a-7647-4bec-8306-525d645f4cf6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5e6fe039-ed4f-48f1-898f-5d4b69aa1544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6e1b5df6-45e1-4edb-8ea3-163b8ad0a186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ed6b55d7-4e08-422a-8c5e-16e4d94f6747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6e1b5df6-45e1-4edb-8ea3-163b8ad0a186" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ed6b55d7-4e08-422a-8c5e-16e4d94f6747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_78e52d25-5056-4a4f-a606-31733b31fa8f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ed6b55d7-4e08-422a-8c5e-16e4d94f6747" xlink:to="loc_srt_CounterpartyNameAxis_78e52d25-5056-4a4f-a606-31733b31fa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b6c5e04-6fa8-46f7-b18b-4b559174ecba" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_78e52d25-5056-4a4f-a606-31733b31fa8f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b6c5e04-6fa8-46f7-b18b-4b559174ecba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_8ae63e95-fd37-4a41-90ef-1672b56b12c3" xlink:href="ino-20200930.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b6c5e04-6fa8-46f7-b18b-4b559174ecba" xlink:to="loc_ino_PlumblineLifeSciencesMember_8ae63e95-fd37-4a41-90ef-1672b56b12c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_22f84bf9-ec7e-4b56-b685-15ac5c9e57d2" xlink:href="ino-20200930.xsd#ino_AstraZenecaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b6c5e04-6fa8-46f7-b18b-4b559174ecba" xlink:to="loc_ino_AstraZenecaMember_22f84bf9-ec7e-4b56-b685-15ac5c9e57d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember_3631a94d-cb93-407b-b432-470d9a6cfdc8" xlink:href="ino-20200930.xsd#ino_OtherCounterpartyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2b6c5e04-6fa8-46f7-b18b-4b559174ecba" xlink:to="loc_ino_OtherCounterpartyMember_3631a94d-cb93-407b-b432-470d9a6cfdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bd787205-a1eb-4d50-ae2b-bb3f29c81a09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ed6b55d7-4e08-422a-8c5e-16e4d94f6747" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_bd787205-a1eb-4d50-ae2b-bb3f29c81a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19578ece-f4c2-493e-b38e-4d8f8f834d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bd787205-a1eb-4d50-ae2b-bb3f29c81a09" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19578ece-f4c2-493e-b38e-4d8f8f834d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8623004c-2740-4fdc-918a-16d8408f7340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bd787205-a1eb-4d50-ae2b-bb3f29c81a09" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8623004c-2740-4fdc-918a-16d8408f7340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="ino-20200930.xsd#ShorttermInvestments"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_73c21053-7553-41bb-b00d-491967397982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_8c5d0b24-a2c7-4df7-895a-d1c8d30f0820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_73c21053-7553-41bb-b00d-491967397982" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_8c5d0b24-a2c7-4df7-895a-d1c8d30f0820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="ino-20200930.xsd#ShorttermInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_20f400c0-65ce-4823-9057-2379be5b4a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f8656984-5d17-422a-945a-85f7f3b41823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_20f400c0-65ce-4823-9057-2379be5b4a4c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f8656984-5d17-422a-945a-85f7f3b41823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ShorttermInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff03446e-922f-4a65-a808-de65a87bc31b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_7a956fb4-98bb-4a63-9c07-33db8c4d0eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff03446e-922f-4a65-a808-de65a87bc31b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_7a956fb4-98bb-4a63-9c07-33db8c4d0eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_83dd7ee3-6d11-464e-8280-db82e4f0e83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff03446e-922f-4a65-a808-de65a87bc31b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_83dd7ee3-6d11-464e-8280-db82e4f0e83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_88802d1b-b7d2-4a07-bf7f-5fce5c0449cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff03446e-922f-4a65-a808-de65a87bc31b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_88802d1b-b7d2-4a07-bf7f-5fce5c0449cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_7f38d361-f458-460c-ba08-02826756fa69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff03446e-922f-4a65-a808-de65a87bc31b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_7f38d361-f458-460c-ba08-02826756fa69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_d1149abd-007e-4217-aa1d-6d74475e73fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff03446e-922f-4a65-a808-de65a87bc31b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_d1149abd-007e-4217-aa1d-6d74475e73fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_425fce6d-1693-4746-8899-1e5526cd5743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7f9887a3-37eb-4eec-9e8b-0d03566e97ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_425fce6d-1693-4746-8899-1e5526cd5743" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7f9887a3-37eb-4eec-9e8b-0d03566e97ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_98e53777-51ab-4c3d-93e3-97b515253d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7f9887a3-37eb-4eec-9e8b-0d03566e97ee" xlink:to="loc_us-gaap_FinancialInstrumentAxis_98e53777-51ab-4c3d-93e3-97b515253d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3258e03d-8d99-4428-b1d7-87c3347139fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_98e53777-51ab-4c3d-93e3-97b515253d41" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3258e03d-8d99-4428-b1d7-87c3347139fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_93cb2657-40b6-4dba-90c1-90d2fc8b2773" xlink:href="ino-20200930.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3258e03d-8d99-4428-b1d7-87c3347139fa" xlink:to="loc_ino_MutualFundsMember_93cb2657-40b6-4dba-90c1-90d2fc8b2773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_41eb4a3c-7369-41ec-a730-cc9d802914a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3258e03d-8d99-4428-b1d7-87c3347139fa" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_41eb4a3c-7369-41ec-a730-cc9d802914a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_915da6e7-8bfd-4a99-9ae8-c13ea10f439a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3258e03d-8d99-4428-b1d7-87c3347139fa" xlink:to="loc_us-gaap_CertificatesOfDepositMember_915da6e7-8bfd-4a99-9ae8-c13ea10f439a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3366a05e-cd4f-4037-96a0-7901f1c14fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3258e03d-8d99-4428-b1d7-87c3347139fa" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3366a05e-cd4f-4037-96a0-7901f1c14fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb354097-f332-4056-9af8-9ec65529597f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7f9887a3-37eb-4eec-9e8b-0d03566e97ee" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb354097-f332-4056-9af8-9ec65529597f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_2a69d5ce-4887-4581-ba86-a3400cae9728" xlink:href="ino-20200930.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb354097-f332-4056-9af8-9ec65529597f" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_2a69d5ce-4887-4581-ba86-a3400cae9728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2dc31c0c-4cae-459d-a7cd-e0eef46b11dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb354097-f332-4056-9af8-9ec65529597f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2dc31c0c-4cae-459d-a7cd-e0eef46b11dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a49f53ff-28cb-4a83-8ea6-547f4a8caac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2dc31c0c-4cae-459d-a7cd-e0eef46b11dd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a49f53ff-28cb-4a83-8ea6-547f4a8caac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ec4ab24d-ccb6-465a-aa0e-d48c49449b3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2dc31c0c-4cae-459d-a7cd-e0eef46b11dd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ec4ab24d-ccb6-465a-aa0e-d48c49449b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e41b582-1bb3-4d74-9193-637b4957f211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2dc31c0c-4cae-459d-a7cd-e0eef46b11dd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e41b582-1bb3-4d74-9193-637b4957f211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_171ceaf9-8510-4aa0-8bb9-e5774e04e0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2dc31c0c-4cae-459d-a7cd-e0eef46b11dd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_171ceaf9-8510-4aa0-8bb9-e5774e04e0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8964bb1e-cc26-4d34-af3c-deff309de0d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_944a4c01-7630-4fe3-8cd1-898e8924c82e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8964bb1e-cc26-4d34-af3c-deff309de0d0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_944a4c01-7630-4fe3-8cd1-898e8924c82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_52ad5cc0-88c3-49eb-96fd-91f32ca87b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4ca6f693-3b63-4bee-80ec-4d4d11127853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52ad5cc0-88c3-49eb-96fd-91f32ca87b3b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4ca6f693-3b63-4bee-80ec-4d4d11127853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1490e851-4b67-421e-80ba-d5836af3159e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52ad5cc0-88c3-49eb-96fd-91f32ca87b3b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1490e851-4b67-421e-80ba-d5836af3159e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d36d59ca-1b1a-4c68-a506-562770126bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_acfb1a71-2d51-439e-b251-2bb354ae218f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d36d59ca-1b1a-4c68-a506-562770126bdd" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_acfb1a71-2d51-439e-b251-2bb354ae218f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfc9527d-3898-4246-9f34-a56bc7de5524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_acfb1a71-2d51-439e-b251-2bb354ae218f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfc9527d-3898-4246-9f34-a56bc7de5524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_133ddbb3-9e18-41b1-b1eb-8ec539de5864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfc9527d-3898-4246-9f34-a56bc7de5524" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_133ddbb3-9e18-41b1-b1eb-8ec539de5864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_488df57c-0fbc-4f5c-96f0-0f57347e3998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_133ddbb3-9e18-41b1-b1eb-8ec539de5864" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_488df57c-0fbc-4f5c-96f0-0f57347e3998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_53b796ec-b9f2-4f2e-81b4-83a605266ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_acfb1a71-2d51-439e-b251-2bb354ae218f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_53b796ec-b9f2-4f2e-81b4-83a605266ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_53b796ec-b9f2-4f2e-81b4-83a605266ea6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_47279dd2-8b67-4b0a-9db7-383e0b25625b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_47279dd2-8b67-4b0a-9db7-383e0b25625b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_f45f2004-d704-496c-9e27-5645ab7956a0" xlink:href="ino-20200930.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:to="loc_ino_MutualFundsMember_f45f2004-d704-496c-9e27-5645ab7956a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_21b6b585-9526-4d22-b5df-be4ff1479c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_21b6b585-9526-4d22-b5df-be4ff1479c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_02037aec-d343-4061-8bd7-7f87a115f3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:to="loc_us-gaap_CertificatesOfDepositMember_02037aec-d343-4061-8bd7-7f87a115f3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5d531fc4-d8b2-406f-96ef-733b4ac48a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5d531fc4-d8b2-406f-96ef-733b4ac48a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_49d6007d-bb6e-4cb8-ace9-37e518bd7d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9f7d4f95-2360-4f73-aeae-7ec277775407" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_49d6007d-bb6e-4cb8-ace9-37e518bd7d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b057df6-8be3-4779-8b44-741d5598c511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_acfb1a71-2d51-439e-b251-2bb354ae218f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b057df6-8be3-4779-8b44-741d5598c511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d67a3e52-bd9d-48c5-ba3f-6960dfe941d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b057df6-8be3-4779-8b44-741d5598c511" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d67a3e52-bd9d-48c5-ba3f-6960dfe941d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_53b7806d-3ea3-4098-90df-10e89deba508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d67a3e52-bd9d-48c5-ba3f-6960dfe941d7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_53b7806d-3ea3-4098-90df-10e89deba508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cd9bc4f9-cdb6-43b3-9e89-3d9b4c73e455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d67a3e52-bd9d-48c5-ba3f-6960dfe941d7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cd9bc4f9-cdb6-43b3-9e89-3d9b4c73e455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0e5d1c8d-4f05-412d-904a-12473d5ffa64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d67a3e52-bd9d-48c5-ba3f-6960dfe941d7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0e5d1c8d-4f05-412d-904a-12473d5ffa64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3636ea2a-c7a3-47de-ac42-c78f28db5567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_acfb1a71-2d51-439e-b251-2bb354ae218f" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3636ea2a-c7a3-47de-ac42-c78f28db5567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_93fbee79-89e5-4421-8591-f952fec446f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3636ea2a-c7a3-47de-ac42-c78f28db5567" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_93fbee79-89e5-4421-8591-f952fec446f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ef325d24-4686-4edb-a6a9-539dd31ed261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93fbee79-89e5-4421-8591-f952fec446f7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ef325d24-4686-4edb-a6a9-539dd31ed261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_227d4965-057c-4afb-8d04-894a7195fe5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93fbee79-89e5-4421-8591-f952fec446f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_227d4965-057c-4afb-8d04-894a7195fe5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_1280e3f5-27c2-425c-8807-ef457f33655a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93fbee79-89e5-4421-8591-f952fec446f7" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_1280e3f5-27c2-425c-8807-ef457f33655a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b75daeb0-20e9-4da7-9912-56eaba41fbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_93fbee79-89e5-4421-8591-f952fec446f7" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b75daeb0-20e9-4da7-9912-56eaba41fbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e933691f-016e-476b-85ff-39a130fbea7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3636ea2a-c7a3-47de-ac42-c78f28db5567" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e933691f-016e-476b-85ff-39a130fbea7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_77ee2dfa-ac39-49a2-a149-99ab14b733f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e933691f-016e-476b-85ff-39a130fbea7e" xlink:to="loc_us-gaap_DerivativeLiabilities_77ee2dfa-ac39-49a2-a149-99ab14b733f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_96aff2e0-1fa9-43f9-a447-66a050246a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e933691f-016e-476b-85ff-39a130fbea7e" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_96aff2e0-1fa9-43f9-a447-66a050246a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5f000ba6-d538-4808-9400-bddfe0bf454c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_7a59114c-f698-4121-a46f-9349170143b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5f000ba6-d538-4808-9400-bddfe0bf454c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_7a59114c-f698-4121-a46f-9349170143b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4d507cd8-167d-49fa-92d2-02f5d820388a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_7a59114c-f698-4121-a46f-9349170143b7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4d507cd8-167d-49fa-92d2-02f5d820388a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4721210a-d06c-4302-896f-69036eb76be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4d507cd8-167d-49fa-92d2-02f5d820388a" xlink:to="loc_us-gaap_ClassOfStockDomain_4721210a-d06c-4302-896f-69036eb76be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d56bbd44-6f2b-40b0-a8e5-65018a40547b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4721210a-d06c-4302-896f-69036eb76be3" xlink:to="loc_us-gaap_CommonStockMember_d56bbd44-6f2b-40b0-a8e5-65018a40547b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64c1d9da-20bc-4bd6-b730-cc8d78819619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_7a59114c-f698-4121-a46f-9349170143b7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64c1d9da-20bc-4bd6-b730-cc8d78819619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9a96635-9e50-4d1d-9573-2989158091c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64c1d9da-20bc-4bd6-b730-cc8d78819619" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9a96635-9e50-4d1d-9573-2989158091c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cd46dac2-33fb-44ca-9538-eed3fa301a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9a96635-9e50-4d1d-9573-2989158091c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cd46dac2-33fb-44ca-9538-eed3fa301a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_845f0dd1-3750-40d4-b118-ef7b65431e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f9a96635-9e50-4d1d-9573-2989158091c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_845f0dd1-3750-40d4-b118-ef7b65431e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7136ce2c-25ce-4fab-a394-395515b0e677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_7a59114c-f698-4121-a46f-9349170143b7" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7136ce2c-25ce-4fab-a394-395515b0e677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_ca34f725-e3a6-400a-9666-3828b76e464b" xlink:href="ino-20200930.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7136ce2c-25ce-4fab-a394-395515b0e677" xlink:to="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_ca34f725-e3a6-400a-9666-3828b76e464b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_73ae2e9c-c12a-4dcc-bd03-5cd7b8b767d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_ca34f725-e3a6-400a-9666-3828b76e464b" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_73ae2e9c-c12a-4dcc-bd03-5cd7b8b767d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_59239009-e0b9-40c4-84d8-36132833536d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_ca34f725-e3a6-400a-9666-3828b76e464b" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_59239009-e0b9-40c4-84d8-36132833536d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_1eb314c8-f1b7-4c7f-97f5-dc1486c68fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_ca34f725-e3a6-400a-9666-3828b76e464b" xlink:to="loc_us-gaap_DerivativeLiabilities_1eb314c8-f1b7-4c7f-97f5-dc1486c68fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1a946712-d092-4cc9-846b-fbacce9425e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5d7be1d7-a00f-46ee-b65b-f6699ac4cc7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1a946712-d092-4cc9-846b-fbacce9425e3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5d7be1d7-a00f-46ee-b65b-f6699ac4cc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_09c08329-ce59-431e-a9f6-6ccc9cf921e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5d7be1d7-a00f-46ee-b65b-f6699ac4cc7a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_09c08329-ce59-431e-a9f6-6ccc9cf921e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_fa743d93-84f7-4b31-97e9-7bcf6f1f0c57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5d7be1d7-a00f-46ee-b65b-f6699ac4cc7a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_fa743d93-84f7-4b31-97e9-7bcf6f1f0c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_967c63bf-f7f9-4adb-b8a6-f6e53a5fd72d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5d7be1d7-a00f-46ee-b65b-f6699ac4cc7a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_967c63bf-f7f9-4adb-b8a6-f6e53a5fd72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bad6e485-ea3a-4be4-88a4-6cec72199fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5d7be1d7-a00f-46ee-b65b-f6699ac4cc7a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bad6e485-ea3a-4be4-88a4-6cec72199fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20200930.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e2be6d9d-24ee-4888-928c-3b8cdab12093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e7876ae8-c9aa-43b3-86e5-3a43a55130af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e2be6d9d-24ee-4888-928c-3b8cdab12093" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e7876ae8-c9aa-43b3-86e5-3a43a55130af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20200930.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9b3440cb-279c-4952-821e-27e8dd80f3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7efe65cb-21a5-488e-9ee4-594e04791df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9b3440cb-279c-4952-821e-27e8dd80f3fe" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7efe65cb-21a5-488e-9ee4-594e04791df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3e1a2c9a-b127-434f-8da9-512cc59e757a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_8295a967-f9d0-4b44-bdea-f239564ac8f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3e1a2c9a-b127-434f-8da9-512cc59e757a" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_8295a967-f9d0-4b44-bdea-f239564ac8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_14137d0e-51d5-4550-9683-3974a191282d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_8295a967-f9d0-4b44-bdea-f239564ac8f7" xlink:to="loc_srt_RangeAxis_14137d0e-51d5-4550-9683-3974a191282d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac684458-c8cc-4a05-aa0b-6694c50d3f17" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14137d0e-51d5-4550-9683-3974a191282d" xlink:to="loc_srt_RangeMember_ac684458-c8cc-4a05-aa0b-6694c50d3f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_b355dc2b-6330-4ef2-b85a-00c95bc82e62" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ac684458-c8cc-4a05-aa0b-6694c50d3f17" xlink:to="loc_srt_WeightedAverageMember_b355dc2b-6330-4ef2-b85a-00c95bc82e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3fe2458d-5467-4555-9dc0-653a233f6dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_8295a967-f9d0-4b44-bdea-f239564ac8f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3fe2458d-5467-4555-9dc0-653a233f6dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e628676-1d82-44b6-aac1-b270601e948d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3fe2458d-5467-4555-9dc0-653a233f6dab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e628676-1d82-44b6-aac1-b270601e948d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_784bbbd5-da01-4a63-a792-60faa88a9138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e628676-1d82-44b6-aac1-b270601e948d" xlink:to="loc_us-gaap_LicensingAgreementsMember_784bbbd5-da01-4a63-a792-60faa88a9138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_254b84bf-85d8-443e-a766-6144ed420aff" xlink:href="ino-20200930.xsd#ino_BiojectMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e628676-1d82-44b6-aac1-b270601e948d" xlink:to="loc_ino_BiojectMember_254b84bf-85d8-443e-a766-6144ed420aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_50a48614-3a93-453a-a3b8-2febc674b2f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e628676-1d82-44b6-aac1-b270601e948d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_50a48614-3a93-453a-a3b8-2febc674b2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f249b645-9abc-4348-902d-0c2ea15c82d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_8295a967-f9d0-4b44-bdea-f239564ac8f7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f249b645-9abc-4348-902d-0c2ea15c82d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b3d8b3-9904-4200-ae1f-b4c5a3f2643c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f249b645-9abc-4348-902d-0c2ea15c82d3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b3d8b3-9904-4200-ae1f-b4c5a3f2643c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InovioAsMember_13bdbd0c-77eb-470d-a8dd-85888a338152" xlink:href="ino-20200930.xsd#ino_InovioAsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b3d8b3-9904-4200-ae1f-b4c5a3f2643c" xlink:to="loc_ino_InovioAsMember_13bdbd0c-77eb-470d-a8dd-85888a338152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_VgxPharmaceuticalsMember_804ebb3b-cddb-47e5-b6e7-8a175cfca176" xlink:href="ino-20200930.xsd#ino_VgxPharmaceuticalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b3d8b3-9904-4200-ae1f-b4c5a3f2643c" xlink:to="loc_ino_VgxPharmaceuticalsMember_804ebb3b-cddb-47e5-b6e7-8a175cfca176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_34d64a40-c200-49de-b987-5c160f78aa24" xlink:href="ino-20200930.xsd#ino_BiojectMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b3d8b3-9904-4200-ae1f-b4c5a3f2643c" xlink:to="loc_ino_BiojectMember_34d64a40-c200-49de-b987-5c160f78aa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_d2d5cdc2-6d08-4169-a1d4-2fdbd21a3be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_8295a967-f9d0-4b44-bdea-f239564ac8f7" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_d2d5cdc2-6d08-4169-a1d4-2fdbd21a3be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6054d623-2ee8-4281-81eb-73a45b588c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_d2d5cdc2-6d08-4169-a1d4-2fdbd21a3be2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6054d623-2ee8-4281-81eb-73a45b588c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e4665e80-6b6d-4829-bb98-843fb36a6801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6054d623-2ee8-4281-81eb-73a45b588c98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e4665e80-6b6d-4829-bb98-843fb36a6801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_ffe3def1-b81f-4d20-8230-1ebc4873b753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e4665e80-6b6d-4829-bb98-843fb36a6801" xlink:to="loc_us-gaap_GoodwillGross_ffe3def1-b81f-4d20-8230-1ebc4873b753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f6d83184-9d7a-40e5-b291-0af38050f231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e4665e80-6b6d-4829-bb98-843fb36a6801" xlink:to="loc_us-gaap_Goodwill_f6d83184-9d7a-40e5-b291-0af38050f231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_06f104ea-58cb-429c-bd0c-e99e505cfedb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6054d623-2ee8-4281-81eb-73a45b588c98" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_06f104ea-58cb-429c-bd0c-e99e505cfedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_11d945f2-96a6-4526-9a6f-6bed1d55cf33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_06f104ea-58cb-429c-bd0c-e99e505cfedb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_11d945f2-96a6-4526-9a6f-6bed1d55cf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9ff28384-2bea-4a29-9b18-b0d1e3883d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_06f104ea-58cb-429c-bd0c-e99e505cfedb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9ff28384-2bea-4a29-9b18-b0d1e3883d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4ad67e80-81a5-479d-bd2e-c5cd0b554bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_06f104ea-58cb-429c-bd0c-e99e505cfedb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4ad67e80-81a5-479d-bd2e-c5cd0b554bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0f28b367-342c-4395-88bb-fad51fcafa4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_06f104ea-58cb-429c-bd0c-e99e505cfedb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0f28b367-342c-4395-88bb-fad51fcafa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_b30d3161-2b8e-49ea-bc24-3676514523bb" xlink:href="ino-20200930.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6054d623-2ee8-4281-81eb-73a45b588c98" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_b30d3161-2b8e-49ea-bc24-3676514523bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_0162f448-3701-46cc-830a-36024f4e649e" xlink:href="ino-20200930.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6054d623-2ee8-4281-81eb-73a45b588c98" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_0162f448-3701-46cc-830a-36024f4e649e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64b5b278-ff41-4d53-8b85-0de0839db129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5b651f1a-80b5-40b4-ab8d-480395881504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64b5b278-ff41-4d53-8b85-0de0839db129" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5b651f1a-80b5-40b4-ab8d-480395881504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1cd4b043-a846-4f67-880f-ced0f8aaa8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64b5b278-ff41-4d53-8b85-0de0839db129" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1cd4b043-a846-4f67-880f-ced0f8aaa8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_22d3081b-1e11-4700-9934-5de017b207a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64b5b278-ff41-4d53-8b85-0de0839db129" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_22d3081b-1e11-4700-9934-5de017b207a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_989ab4d8-6923-4aaa-8f44-cea23372aa3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64b5b278-ff41-4d53-8b85-0de0839db129" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_989ab4d8-6923-4aaa-8f44-cea23372aa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5709895e-f6fe-4c1e-96fe-ca966d7e4730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64b5b278-ff41-4d53-8b85-0de0839db129" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5709895e-f6fe-4c1e-96fe-ca966d7e4730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a25e78b2-6865-44d4-8799-64662015c7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64b5b278-ff41-4d53-8b85-0de0839db129" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a25e78b2-6865-44d4-8799-64662015c7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_e3e7257b-a191-4e37-8fbf-e7009c1bed84" xlink:href="ino-20200930.xsd#ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64b5b278-ff41-4d53-8b85-0de0839db129" xlink:to="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_e3e7257b-a191-4e37-8fbf-e7009c1bed84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebt"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5d3aed3a-47f3-48f9-b444-3e5abceb90be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4ec2c91f-db2b-4695-a05f-0635861f0edc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5d3aed3a-47f3-48f9-b444-3e5abceb90be" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4ec2c91f-db2b-4695-a05f-0635861f0edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebtTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a7e4d66c-484f-46c8-b624-9d27f85e0742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_6cce57d5-1649-4138-ad6f-91089b5f8f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a7e4d66c-484f-46c8-b624-9d27f85e0742" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_6cce57d5-1649-4138-ad6f-91089b5f8f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_128a4c93-0193-4f9c-925b-af9d8b5704bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a7e4d66c-484f-46c8-b624-9d27f85e0742" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_128a4c93-0193-4f9c-925b-af9d8b5704bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_34a59935-0f5f-4b91-9502-8628ba51c4af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_34a59935-0f5f-4b91-9502-8628ba51c4af" xlink:to="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_027bc935-1d0e-4bc3-b668-89f77422c131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_027bc935-1d0e-4bc3-b668-89f77422c131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_05ea133e-579c-46d4-9116-5bea4904fa91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_027bc935-1d0e-4bc3-b668-89f77422c131" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_05ea133e-579c-46d4-9116-5bea4904fa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_3f0231bc-6ca4-4c7e-b70e-9ce2d8137b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_05ea133e-579c-46d4-9116-5bea4904fa91" xlink:to="loc_us-gaap_ConvertibleDebtMember_3f0231bc-6ca4-4c7e-b70e-9ce2d8137b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c2d9b631-3212-4c04-ae08-2ed0080d9d00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:to="loc_us-gaap_DebtInstrumentAxis_c2d9b631-3212-4c04-ae08-2ed0080d9d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7e006777-e708-4fa9-995f-8b5505ac1eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c2d9b631-3212-4c04-ae08-2ed0080d9d00" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7e006777-e708-4fa9-995f-8b5505ac1eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b4e7411a-23e2-4f78-8a6f-58d92127b4dc" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e006777-e708-4fa9-995f-8b5505ac1eef" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b4e7411a-23e2-4f78-8a6f-58d92127b4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_7598140b-1cc5-4c0f-a01a-e61db918cb57" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e006777-e708-4fa9-995f-8b5505ac1eef" xlink:to="loc_ino_August2019ConvertibleBondsMember_7598140b-1cc5-4c0f-a01a-e61db918cb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_bb74c44b-bd70-489d-9c95-b6e6a2b012bc" xlink:href="ino-20200930.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e006777-e708-4fa9-995f-8b5505ac1eef" xlink:to="loc_ino_December2019ConvertibleBondsMember_bb74c44b-bd70-489d-9c95-b6e6a2b012bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b7cbff08-9ec3-40df-b5e7-a56589a1e1c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b7cbff08-9ec3-40df-b5e7-a56589a1e1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_26bf3b40-d48e-468a-8c5a-f60c461420e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b7cbff08-9ec3-40df-b5e7-a56589a1e1c5" xlink:to="loc_us-gaap_DebtConversionNameDomain_26bf3b40-d48e-468a-8c5a-f60c461420e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember_a5a140e5-239b-42ed-b12e-50b7719efcd6" xlink:href="ino-20200930.xsd#ino_InitialConversionPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_26bf3b40-d48e-468a-8c5a-f60c461420e6" xlink:to="loc_ino_InitialConversionPriceMember_a5a140e5-239b-42ed-b12e-50b7719efcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember_4a58b5b5-df55-429f-8b8e-ad62433c61d1" xlink:href="ino-20200930.xsd#ino_AfterJuly22020ConversionPriceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_26bf3b40-d48e-468a-8c5a-f60c461420e6" xlink:to="loc_ino_AfterJuly22020ConversionPriceMember_4a58b5b5-df55-429f-8b8e-ad62433c61d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eafad1f4-5d72-4b12-ba9f-77da99d996cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:to="loc_srt_RangeAxis_eafad1f4-5d72-4b12-ba9f-77da99d996cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_534fb9fa-f7ef-475b-a2cf-4c42ca77a3df" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eafad1f4-5d72-4b12-ba9f-77da99d996cb" xlink:to="loc_srt_RangeMember_534fb9fa-f7ef-475b-a2cf-4c42ca77a3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e0bb5db8-eb4c-4a7c-9f78-7fe371c20ff4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_534fb9fa-f7ef-475b-a2cf-4c42ca77a3df" xlink:to="loc_srt_MaximumMember_e0bb5db8-eb4c-4a7c-9f78-7fe371c20ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a3218d5a-6ffe-4129-babb-12e97251bd0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a3218d5a-6ffe-4129-babb-12e97251bd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6c892904-156c-4b35-83f7-9757012d3dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a3218d5a-6ffe-4129-babb-12e97251bd0e" xlink:to="loc_us-gaap_ClassOfStockDomain_6c892904-156c-4b35-83f7-9757012d3dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cfea6207-ca17-4611-9a4a-9c688d2bc80c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6c892904-156c-4b35-83f7-9757012d3dc2" xlink:to="loc_us-gaap_CommonStockMember_cfea6207-ca17-4611-9a4a-9c688d2bc80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48376fc5-029c-470a-a8b7-089468218e58" xlink:to="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_04496411-0a83-4313-bd44-626f9d37c6e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_04496411-0a83-4313-bd44-626f9d37c6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_b3b02ead-81ee-42fd-9d7e-c3730b229145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_b3b02ead-81ee-42fd-9d7e-c3730b229145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2e4808ee-a653-4e09-8c12-ef1007ebc37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2e4808ee-a653-4e09-8c12-ef1007ebc37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_092bea08-5ef2-48c6-b0f0-c40ed2127db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_092bea08-5ef2-48c6-b0f0-c40ed2127db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c70737bc-964e-4bcd-9ccb-138ea5fad916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c70737bc-964e-4bcd-9ccb-138ea5fad916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90537cee-77be-4056-bb15-fe279710ff40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90537cee-77be-4056-bb15-fe279710ff40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_26ff4210-11cc-4c5b-b16d-a2a38fd62efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_26ff4210-11cc-4c5b-b16d-a2a38fd62efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_292fe375-7ccb-4771-8c58-f530e7038abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_292fe375-7ccb-4771-8c58-f530e7038abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a310f210-61df-4031-85de-89a044f1223a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a310f210-61df-4031-85de-89a044f1223a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_b1fdba16-d6bd-44c3-a573-cc9f5a7dad3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_b1fdba16-d6bd-44c3-a573-cc9f5a7dad3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a004f6fd-95f4-4622-aab5-cb0393fc797a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a004f6fd-95f4-4622-aab5-cb0393fc797a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7d8953f1-6153-417f-936c-9faef0036820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7d8953f1-6153-417f-936c-9faef0036820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9a446a4d-be1d-41e4-896c-b3ab3ff3a830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9a446a4d-be1d-41e4-896c-b3ab3ff3a830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_aa989968-1a6f-463b-b059-9069c32b7bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_aa989968-1a6f-463b-b059-9069c32b7bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_09d46f5d-89f6-46ac-b1d1-8908ed531047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_09d46f5d-89f6-46ac-b1d1-8908ed531047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_5dd1dce3-b471-4a9a-abbd-d9807f237efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_DebtInstrumentFairValue_5dd1dce3-b471-4a9a-abbd-d9807f237efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92e3bd44-8a1e-46ef-899b-02c48043a505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92e3bd44-8a1e-46ef-899b-02c48043a505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_17eb72a0-80dd-4a49-8106-72fd02cb7147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_InterestExpense_17eb72a0-80dd-4a49-8106-72fd02cb7147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_abcb74a6-5423-4435-a805-0e9ed350c38c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_InterestExpenseDebt_abcb74a6-5423-4435-a805-0e9ed350c38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_86263e77-dc13-44e7-b3bf-8baa023ad06b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_86263e77-dc13-44e7-b3bf-8baa023ad06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a9a16fcc-95e1-4364-b057-61a2564e6df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a9a16fcc-95e1-4364-b057-61a2564e6df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_c0027556-212c-4f5f-a9d7-4fed7654bc5c" xlink:href="ino-20200930.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_c0027556-212c-4f5f-a9d7-4fed7654bc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_db2d8f19-dd3d-4ae2-bd53-6a2c1f482c1e" xlink:href="ino-20200930.xsd#ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_56f17434-4d51-433e-9e60-f2a6c02773ea" xlink:to="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_db2d8f19-dd3d-4ae2-bd53-6a2c1f482c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7706bf7f-28a5-4a86-a983-20bf9f586b3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7fb8fa38-0e68-40e8-9778-3cdc6d305508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7706bf7f-28a5-4a86-a983-20bf9f586b3d" xlink:to="loc_us-gaap_DebtInstrumentTable_7fb8fa38-0e68-40e8-9778-3cdc6d305508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_78128e86-f5ad-427e-b341-6aeb54ecb2da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7fb8fa38-0e68-40e8-9778-3cdc6d305508" xlink:to="loc_us-gaap_DebtInstrumentAxis_78128e86-f5ad-427e-b341-6aeb54ecb2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c9d87362-d479-439c-875b-787b21ff4f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_78128e86-f5ad-427e-b341-6aeb54ecb2da" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c9d87362-d479-439c-875b-787b21ff4f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_6868f1d7-ce0b-46a5-a028-f83ff1555ad8" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c9d87362-d479-439c-875b-787b21ff4f92" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_6868f1d7-ce0b-46a5-a028-f83ff1555ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_dba7e5e3-7d99-4747-8b47-d81d6beb968e" xlink:href="ino-20200930.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c9d87362-d479-439c-875b-787b21ff4f92" xlink:to="loc_ino_December2019ConvertibleBondsMember_dba7e5e3-7d99-4747-8b47-d81d6beb968e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7fb8fa38-0e68-40e8-9778-3cdc6d305508" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_709ca87e-3f1a-458e-952b-5241f0a2d745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_709ca87e-3f1a-458e-952b-5241f0a2d745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_89a1ed1a-c5fc-4612-b506-0245517b2816" xlink:href="ino-20200930.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_89a1ed1a-c5fc-4612-b506-0245517b2816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a8dddd6f-a6e1-4844-85e6-b66466c3402c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a8dddd6f-a6e1-4844-85e6-b66466c3402c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_8e4fe759-a76e-41b9-87ff-bd18d45134e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_8e4fe759-a76e-41b9-87ff-bd18d45134e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_dc48ca22-65b0-41c3-8a30-5c59816e5e4b" xlink:href="ino-20200930.xsd#ino_DebtInstrumentAccretionOfPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_ino_DebtInstrumentAccretionOfPremium_dc48ca22-65b0-41c3-8a30-5c59816e5e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_72407a5c-a2c8-4e2e-aa82-daa58319e63b" xlink:href="ino-20200930.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_ino_DebtInstrumentAccruedInterest_72407a5c-a2c8-4e2e-aa82-daa58319e63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b37cfcd3-1013-4251-8cd1-1ec5b0fc19cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a4695d4-7758-43be-ac75-908dc0179a87" xlink:to="loc_us-gaap_LongTermDebt_b37cfcd3-1013-4251-8cd1-1ec5b0fc19cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ff949b86-acfb-498e-9598-3fd80f4dc923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4cc6257e-7696-4f8e-a9c2-541981581188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ff949b86-acfb-498e-9598-3fd80f4dc923" xlink:to="loc_us-gaap_DebtInstrumentTable_4cc6257e-7696-4f8e-a9c2-541981581188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c87ef424-0731-4aec-b514-8b74fb167f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4cc6257e-7696-4f8e-a9c2-541981581188" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c87ef424-0731-4aec-b514-8b74fb167f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_430c14ed-3070-4ad0-ab0f-3f8e682f592d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c87ef424-0731-4aec-b514-8b74fb167f17" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_430c14ed-3070-4ad0-ab0f-3f8e682f592d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_51fab071-44fb-4abb-b62c-d6635e2811e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_430c14ed-3070-4ad0-ab0f-3f8e682f592d" xlink:to="loc_us-gaap_ConvertibleDebtMember_51fab071-44fb-4abb-b62c-d6635e2811e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4e285924-8a6c-4be5-8a58-4846efad0634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4cc6257e-7696-4f8e-a9c2-541981581188" xlink:to="loc_us-gaap_DebtInstrumentAxis_4e285924-8a6c-4be5-8a58-4846efad0634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cc3f733d-303b-4f43-a2af-c87e1372da82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e285924-8a6c-4be5-8a58-4846efad0634" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cc3f733d-303b-4f43-a2af-c87e1372da82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_d6eded22-437d-4c23-b912-c54f198620f3" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cc3f733d-303b-4f43-a2af-c87e1372da82" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_d6eded22-437d-4c23-b912-c54f198620f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_84199c59-4b38-4f40-925f-df457fe40f29" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cc3f733d-303b-4f43-a2af-c87e1372da82" xlink:to="loc_ino_August2019ConvertibleBondsMember_84199c59-4b38-4f40-925f-df457fe40f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_8cf8b9a4-7e51-4f33-8558-16c43fc833fd" xlink:href="ino-20200930.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cc3f733d-303b-4f43-a2af-c87e1372da82" xlink:to="loc_ino_December2019ConvertibleBondsMember_8cf8b9a4-7e51-4f33-8558-16c43fc833fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4cc6257e-7696-4f8e-a9c2-541981581188" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_79fa6f25-f301-425f-81d9-d6abd6f01bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_79fa6f25-f301-425f-81d9-d6abd6f01bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bacbc304-6959-4e11-b3f7-6fe320b9bb26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bacbc304-6959-4e11-b3f7-6fe320b9bb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_211ca0ae-a499-4f54-94ac-84bdec8a17e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_211ca0ae-a499-4f54-94ac-84bdec8a17e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_169e6614-5d11-4369-b529-dd1bc2510e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_169e6614-5d11-4369-b529-dd1bc2510e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9377329a-f569-4c1b-8bd3-3a40fed4b4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9377329a-f569-4c1b-8bd3-3a40fed4b4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9112240b-9180-4772-a40f-45281a732206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_LongTermDebt_9112240b-9180-4772-a40f-45281a732206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5937a1f5-96da-4e1f-b380-dccdab139e84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5937a1f5-96da-4e1f-b380-dccdab139e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_68c5b48a-449e-47de-b1ce-460218136b03" xlink:href="ino-20200930.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd19f2ea-1eff-42fe-81ed-8e27e448014c" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_68c5b48a-449e-47de-b1ce-460218136b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20200930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6dd7fdbf-04ae-4047-a1cd-3c32f28fb464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ae37de8d-4273-4f95-abf4-b4ab3463b7ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6dd7fdbf-04ae-4047-a1cd-3c32f28fb464" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ae37de8d-4273-4f95-abf4-b4ab3463b7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20200930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_9654a285-c85b-48cf-ac67-933def0f5b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_92072da1-23fc-4fc0-b8a5-f602f4ebb5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9654a285-c85b-48cf-ac67-933def0f5b1a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_92072da1-23fc-4fc0-b8a5-f602f4ebb5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_48b767fe-205b-4832-bc24-f6d836fd15ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a3d740b7-afe2-4d61-a539-ada0f54775c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_48b767fe-205b-4832-bc24-f6d836fd15ba" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a3d740b7-afe2-4d61-a539-ada0f54775c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2cb69151-3518-411c-9df7-69fe63972a18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a3d740b7-afe2-4d61-a539-ada0f54775c3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2cb69151-3518-411c-9df7-69fe63972a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_85789339-cca1-4c33-9952-c355788ae437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2cb69151-3518-411c-9df7-69fe63972a18" xlink:to="loc_us-gaap_ClassOfStockDomain_85789339-cca1-4c33-9952-c355788ae437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_b943aeaf-b7bd-4692-a0c1-553c5e6ef409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_85789339-cca1-4c33-9952-c355788ae437" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_b943aeaf-b7bd-4692-a0c1-553c5e6ef409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9da6cd6a-351c-476f-bf47-e0c5882c88f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a3d740b7-afe2-4d61-a539-ada0f54775c3" xlink:to="loc_us-gaap_ClassOfStockLineItems_9da6cd6a-351c-476f-bf47-e0c5882c88f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9da6cd6a-351c-476f-bf47-e0c5882c88f2" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0774e159-1221-47e5-b5d1-97234f1910b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0774e159-1221-47e5-b5d1-97234f1910b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_42a9d4cf-ab38-4792-82dd-50097d13c17a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_42a9d4cf-ab38-4792-82dd-50097d13c17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c2ff27fa-3f7c-4459-94fe-90f27d4752f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_CommonStockSharesIssued_c2ff27fa-3f7c-4459-94fe-90f27d4752f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7eb61bcb-0952-4b1f-b277-86fa3c5179a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7eb61bcb-0952-4b1f-b277-86fa3c5179a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_be38ddcb-047a-40d4-a7d6-69b2149c33b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_be38ddcb-047a-40d4-a7d6-69b2149c33b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_772bc1ca-54cc-4fe2-a306-f1c98a1e6496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_772bc1ca-54cc-4fe2-a306-f1c98a1e6496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d64dd358-6317-4894-922b-029fd2880bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d64dd358-6317-4894-922b-029fd2880bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a069c012-6875-490c-9325-2c0cc8b6d610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f7f91d68-fdc4-4fe9-9e98-e8762d09e533" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a069c012-6875-490c-9325-2c0cc8b6d610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_9e6a75f0-61ed-465f-9fbb-f9f0fbbda49f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bdb222c9-d7c9-419c-a620-e803c95e710e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9e6a75f0-61ed-465f-9fbb-f9f0fbbda49f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bdb222c9-d7c9-419c-a620-e803c95e710e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f551ac57-2ec8-4101-acdb-dc2858aa91c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bdb222c9-d7c9-419c-a620-e803c95e710e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f551ac57-2ec8-4101-acdb-dc2858aa91c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_52dbb8b4-8fe0-43e6-a0b5-552176f8511d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f551ac57-2ec8-4101-acdb-dc2858aa91c6" xlink:to="loc_us-gaap_ClassOfStockDomain_52dbb8b4-8fe0-43e6-a0b5-552176f8511d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_d8c82214-1291-4447-822d-f5e1f1e7d186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_52dbb8b4-8fe0-43e6-a0b5-552176f8511d" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_d8c82214-1291-4447-822d-f5e1f1e7d186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ac1aa77d-4006-40f6-a637-96c26f60f998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_52dbb8b4-8fe0-43e6-a0b5-552176f8511d" xlink:to="loc_us-gaap_CommonStockMember_ac1aa77d-4006-40f6-a637-96c26f60f998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3e40a531-e839-4980-941f-07d74a84eeef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bdb222c9-d7c9-419c-a620-e803c95e710e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3e40a531-e839-4980-941f-07d74a84eeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80bc5a88-f9e4-4311-b552-c8527cfcbc16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3e40a531-e839-4980-941f-07d74a84eeef" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80bc5a88-f9e4-4311-b552-c8527cfcbc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember_70f4a751-3f72-47d0-a05b-34e3d42097ee" xlink:href="ino-20200930.xsd#ino_PriorSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80bc5a88-f9e4-4311-b552-c8527cfcbc16" xlink:to="loc_ino_PriorSalesAgreementMember_70f4a751-3f72-47d0-a05b-34e3d42097ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember_e1df6839-1901-4d08-ae2f-35eece627c0b" xlink:href="ino-20200930.xsd#ino_NewSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80bc5a88-f9e4-4311-b552-c8527cfcbc16" xlink:to="loc_ino_NewSalesAgreementMember_e1df6839-1901-4d08-ae2f-35eece627c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_555ad61d-7adc-472c-9104-e0ece544c5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bdb222c9-d7c9-419c-a620-e803c95e710e" xlink:to="loc_us-gaap_PlanNameAxis_555ad61d-7adc-472c-9104-e0ece544c5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_eab86ab9-5967-4eca-89c2-0c6f73bb3c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_555ad61d-7adc-472c-9104-e0ece544c5c1" xlink:to="loc_us-gaap_PlanNameDomain_eab86ab9-5967-4eca-89c2-0c6f73bb3c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_de100784-3167-461f-b884-df6a75ff614d" xlink:href="ino-20200930.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_eab86ab9-5967-4eca-89c2-0c6f73bb3c45" xlink:to="loc_ino_A2016IncentivePlanMember_de100784-3167-461f-b884-df6a75ff614d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_31a2f9f0-0ed1-405b-8c58-c24bd75391be" xlink:href="ino-20200930.xsd#ino_A2007IncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_eab86ab9-5967-4eca-89c2-0c6f73bb3c45" xlink:to="loc_ino_A2007IncentivePlanMember_31a2f9f0-0ed1-405b-8c58-c24bd75391be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bdb222c9-d7c9-419c-a620-e803c95e710e" xlink:to="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_185309a6-c9e4-4681-9a96-16b9d899d421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_185309a6-c9e4-4681-9a96-16b9d899d421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_86c9bea7-9f0f-4943-baa1-ecadcfc7be6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_86c9bea7-9f0f-4943-baa1-ecadcfc7be6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_03c62156-db87-41b7-a72c-ce089252a614" xlink:href="ino-20200930.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_03c62156-db87-41b7-a72c-ce089252a614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_ddca37a0-5ba1-4787-8265-67031e12edbc" xlink:href="ino-20200930.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_ddca37a0-5ba1-4787-8265-67031e12edbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementAgentFee_3508a22d-76d1-4eea-b937-756e976f138c" xlink:href="ino-20200930.xsd#ino_StockSalesAgreementAgentFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_StockSalesAgreementAgentFee_3508a22d-76d1-4eea-b937-756e976f138c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_1b6e9e92-1a10-4002-9e69-873fba5ab5d2" xlink:href="ino-20200930.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_1b6e9e92-1a10-4002-9e69-873fba5ab5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_8ca1f57a-98aa-447f-ae57-f78a21675a65" xlink:href="ino-20200930.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_8ca1f57a-98aa-447f-ae57-f78a21675a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_bbc5a5ea-8bf4-4385-a0ea-c93860846852" xlink:href="ino-20200930.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_bbc5a5ea-8bf4-4385-a0ea-c93860846852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ed95817-48f0-4d31-a5ab-c6b49abdb705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ed95817-48f0-4d31-a5ab-c6b49abdb705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_80f6afdd-1222-4087-98d7-0336d54df5d0" xlink:href="ino-20200930.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_80f6afdd-1222-4087-98d7-0336d54df5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_966aa2cf-40ca-4234-b4dd-d91042d5e045" xlink:href="ino-20200930.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_966aa2cf-40ca-4234-b4dd-d91042d5e045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3074ddf8-51cf-4016-be37-4683267611ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3074ddf8-51cf-4016-be37-4683267611ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dccfe110-6cbd-4ca2-bd90-fc57ce3d4908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dccfe110-6cbd-4ca2-bd90-fc57ce3d4908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_a90c5948-50dd-476c-8ba7-3d4024b895d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_a90c5948-50dd-476c-8ba7-3d4024b895d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c469d7ae-5f48-4fe5-8b80-8c58d275b6d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c469d7ae-5f48-4fe5-8b80-8c58d275b6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_cb2e4b14-f2a8-4f7f-aab7-88bbbbf975f3" xlink:href="ino-20200930.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd33a1e-23ef-48ed-9349-41aa7d8ebe6e" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_cb2e4b14-f2a8-4f7f-aab7-88bbbbf975f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetIncomeLossPerShare" xlink:type="simple" xlink:href="ino-20200930.xsd#NetIncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetIncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_82008cad-b844-4e64-86a8-dbda4db480da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c8446e56-f6a1-45ff-aa9b-d1d43d6f1d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_82008cad-b844-4e64-86a8-dbda4db480da" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c8446e56-f6a1-45ff-aa9b-d1d43d6f1d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ino-20200930.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_927f8da5-d825-4ba6-bc0f-24caedc0b49b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_2db00be2-cee4-4dba-aeb0-352138da7f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_927f8da5-d825-4ba6-bc0f-24caedc0b49b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_2db00be2-cee4-4dba-aeb0-352138da7f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f7d74808-f1c7-41e9-94db-f62d7ec71cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_927f8da5-d825-4ba6-bc0f-24caedc0b49b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f7d74808-f1c7-41e9-94db-f62d7ec71cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5a988b51-b899-4177-a2c9-77d8d4317013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_3f9b96c7-47d4-465f-bc31-38c891856031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a988b51-b899-4177-a2c9-77d8d4317013" xlink:to="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_3f9b96c7-47d4-465f-bc31-38c891856031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c8db146a-30d9-485f-a6fb-652690581c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_3f9b96c7-47d4-465f-bc31-38c891856031" xlink:to="loc_us-gaap_NetIncomeLoss_c8db146a-30d9-485f-a6fb-652690581c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_56d156a7-3bb7-40d5-abc8-2bcabc89fcaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_3f9b96c7-47d4-465f-bc31-38c891856031" xlink:to="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_56d156a7-3bb7-40d5-abc8-2bcabc89fcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cdc72ad5-b6c9-4d22-9847-04133fbea35a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_3f9b96c7-47d4-465f-bc31-38c891856031" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cdc72ad5-b6c9-4d22-9847-04133fbea35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9ff4ecdf-f930-4509-8feb-fde5d6694fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a988b51-b899-4177-a2c9-77d8d4317013" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9ff4ecdf-f930-4509-8feb-fde5d6694fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_253fde3c-8989-4cce-8918-ae153e3342b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9ff4ecdf-f930-4509-8feb-fde5d6694fd5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_253fde3c-8989-4cce-8918-ae153e3342b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_757b08ab-2242-4e83-9a40-b8e3cec51a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9ff4ecdf-f930-4509-8feb-fde5d6694fd5" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_757b08ab-2242-4e83-9a40-b8e3cec51a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_47477ecf-3b7c-43d1-b4a6-f096dc35ef44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9ff4ecdf-f930-4509-8feb-fde5d6694fd5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_47477ecf-3b7c-43d1-b4a6-f096dc35ef44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f2f86d53-1920-426d-b376-e5445331028b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a988b51-b899-4177-a2c9-77d8d4317013" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f2f86d53-1920-426d-b376-e5445331028b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_49c3b932-0cc7-4748-9a4c-1b299e9fb2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a988b51-b899-4177-a2c9-77d8d4317013" xlink:to="loc_us-gaap_EarningsPerShareBasic_49c3b932-0cc7-4748-9a4c-1b299e9fb2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1c7eb199-8ab8-4b90-b727-3700aa548020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3fcc437a-d207-4a82-9c9b-16a5f0c0cb1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1c7eb199-8ab8-4b90-b727-3700aa548020" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3fcc437a-d207-4a82-9c9b-16a5f0c0cb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_62a53729-2776-4546-b405-f1057cf12529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3fcc437a-d207-4a82-9c9b-16a5f0c0cb1e" xlink:to="loc_us-gaap_DebtInstrumentAxis_62a53729-2776-4546-b405-f1057cf12529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5489d9fb-9931-4580-8792-b792875d33f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_62a53729-2776-4546-b405-f1057cf12529" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5489d9fb-9931-4580-8792-b792875d33f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_2aed3122-3e83-45f5-8015-ae27be26703d" xlink:href="ino-20200930.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5489d9fb-9931-4580-8792-b792875d33f5" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_2aed3122-3e83-45f5-8015-ae27be26703d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_d1475230-58d0-4474-b45e-0fb46cad622a" xlink:href="ino-20200930.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5489d9fb-9931-4580-8792-b792875d33f5" xlink:to="loc_ino_August2019ConvertibleBondsMember_d1475230-58d0-4474-b45e-0fb46cad622a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_3b2533c9-3603-4102-bc80-dc7923bdc67d" xlink:href="ino-20200930.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5489d9fb-9931-4580-8792-b792875d33f5" xlink:to="loc_ino_December2019ConvertibleBondsMember_3b2533c9-3603-4102-bc80-dc7923bdc67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3306b085-53a0-414a-ad07-d99c24d89d98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3fcc437a-d207-4a82-9c9b-16a5f0c0cb1e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3306b085-53a0-414a-ad07-d99c24d89d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3306b085-53a0-414a-ad07-d99c24d89d98" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e6d98965-a86c-46e2-b807-5a54a9532578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e6d98965-a86c-46e2-b807-5a54a9532578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_ce53422f-5f93-4942-9ec8-6759fc707c3e" xlink:href="ino-20200930.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_ce53422f-5f93-4942-9ec8-6759fc707c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_110951a3-85e7-4af4-b958-60e7f763b264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_110951a3-85e7-4af4-b958-60e7f763b264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_edbf9fd5-2455-41d7-b131-42321e35c200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_edbf9fd5-2455-41d7-b131-42321e35c200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_1dab2f57-614a-418d-ae4b-820281a24d36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2689cdba-3107-44da-81d4-231f51299dff" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_1dab2f57-614a-418d-ae4b-820281a24d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_def33ea2-6ba5-49e6-bf06-b7db6f18f219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3fcc437a-d207-4a82-9c9b-16a5f0c0cb1e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_def33ea2-6ba5-49e6-bf06-b7db6f18f219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0458f84a-a015-4f86-983e-8e30ee8d0d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_def33ea2-6ba5-49e6-bf06-b7db6f18f219" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0458f84a-a015-4f86-983e-8e30ee8d0d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ino-20200930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b8e0ee5-9e8f-43fb-9d76-465d0cadde99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7ec77059-6580-4d1d-bf6f-204b0e612400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b8e0ee5-9e8f-43fb-9d76-465d0cadde99" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7ec77059-6580-4d1d-bf6f-204b0e612400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ino-20200930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b2506cca-c93d-4666-a02e-33eb88df45be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9d7039f0-86e7-4c8e-822c-3703cd594ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b2506cca-c93d-4666-a02e-33eb88df45be" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9d7039f0-86e7-4c8e-822c-3703cd594ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#StockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88fc348f-a468-4b8a-a50a-e413417cf52d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88fc348f-a468-4b8a-a50a-e413417cf52d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_127255eb-8619-4f15-a125-395b3bde8c65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:to="loc_srt_TitleOfIndividualAxis_127255eb-8619-4f15-a125-395b3bde8c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4c6dd009-c954-4979-964f-8f25b3d33505" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_127255eb-8619-4f15-a125-395b3bde8c65" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4c6dd009-c954-4979-964f-8f25b3d33505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_beeee2c5-b1e4-4194-a20b-c76b73d7de98" xlink:href="ino-20200930.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4c6dd009-c954-4979-964f-8f25b3d33505" xlink:to="loc_ino_EmployeesAndDirectorsMember_beeee2c5-b1e4-4194-a20b-c76b73d7de98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_ba424e2f-d351-45b3-9d6c-685b7a0b614b" xlink:href="ino-20200930.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4c6dd009-c954-4979-964f-8f25b3d33505" xlink:to="loc_ino_NonEmployeeMember_ba424e2f-d351-45b3-9d6c-685b7a0b614b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3c5d58a0-28f2-44ae-a0ec-a3928c12529b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:to="loc_us-gaap_PlanNameAxis_3c5d58a0-28f2-44ae-a0ec-a3928c12529b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8bc89707-cacb-43a1-83fc-10adb5f2d1e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3c5d58a0-28f2-44ae-a0ec-a3928c12529b" xlink:to="loc_us-gaap_PlanNameDomain_8bc89707-cacb-43a1-83fc-10adb5f2d1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_74285977-4503-4c20-a5f6-0b9cbe42af1a" xlink:href="ino-20200930.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8bc89707-cacb-43a1-83fc-10adb5f2d1e2" xlink:to="loc_ino_A2016IncentivePlanMember_74285977-4503-4c20-a5f6-0b9cbe42af1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_21318c64-78ec-412b-8132-f680aa7bbacb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_21318c64-78ec-412b-8132-f680aa7bbacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6f765ad6-c393-47af-88ce-10f8ca1aa6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_21318c64-78ec-412b-8132-f680aa7bbacb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6f765ad6-c393-47af-88ce-10f8ca1aa6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2e08105d-0c43-43e3-a8be-1bfcb736f8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6f765ad6-c393-47af-88ce-10f8ca1aa6d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2e08105d-0c43-43e3-a8be-1bfcb736f8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_83040202-f63f-4a7e-9ea6-23880bacd5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6f765ad6-c393-47af-88ce-10f8ca1aa6d4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_83040202-f63f-4a7e-9ea6-23880bacd5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_df17e808-e817-4baa-aca1-c09b5d1d52aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:to="loc_us-gaap_AwardTypeAxis_df17e808-e817-4baa-aca1-c09b5d1d52aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cef16bda-0de0-49a8-a68e-6a687a49f92d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_df17e808-e817-4baa-aca1-c09b5d1d52aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cef16bda-0de0-49a8-a68e-6a687a49f92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9fecea11-51f5-4b25-8eab-326361c00a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cef16bda-0de0-49a8-a68e-6a687a49f92d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9fecea11-51f5-4b25-8eab-326361c00a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_18af882e-af32-4a21-993e-540ec847df5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cef16bda-0de0-49a8-a68e-6a687a49f92d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_18af882e-af32-4a21-993e-540ec847df5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_23a49616-67f5-4786-8331-f838e66cdab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:to="loc_us-gaap_VestingAxis_23a49616-67f5-4786-8331-f838e66cdab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_c03ed166-784a-42f9-b14b-8b749d064ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_23a49616-67f5-4786-8331-f838e66cdab9" xlink:to="loc_us-gaap_VestingDomain_c03ed166-784a-42f9-b14b-8b749d064ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a3a9c7fd-3efd-4fe4-b587-fe2959d607c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_c03ed166-784a-42f9-b14b-8b749d064ea1" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a3a9c7fd-3efd-4fe4-b587-fe2959d607c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9728d8de-4c52-413b-ae8f-acbd46c603f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_c03ed166-784a-42f9-b14b-8b749d064ea1" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9728d8de-4c52-413b-ae8f-acbd46c603f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d2023e9-acd4-4579-96c4-b84c317b2d74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_535c21ce-fea6-4a7c-b4c7-95b83bff0ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_535c21ce-fea6-4a7c-b4c7-95b83bff0ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7025520f-3590-494b-aa20-509d8af4dd2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7025520f-3590-494b-aa20-509d8af4dd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_441407e5-3bab-4608-9a51-acb71791ad01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_441407e5-3bab-4608-9a51-acb71791ad01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfd32dba-8e82-4956-9412-767005b838f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cfd32dba-8e82-4956-9412-767005b838f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e73ecee8-c588-48e8-b58d-9f93bdc03265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensation_e73ecee8-c588-48e8-b58d-9f93bdc03265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_957d8db1-3fef-4062-96c6-2e6c2b33418a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_957d8db1-3fef-4062-96c6-2e6c2b33418a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_25b9f252-0cdf-4515-9481-4c607d1b883f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_25b9f252-0cdf-4515-9481-4c607d1b883f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6abe7eba-3850-45e3-9e19-013c7915b97a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6abe7eba-3850-45e3-9e19-013c7915b97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_81405008-ea3c-4918-92df-5e5a8c8cc808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_81405008-ea3c-4918-92df-5e5a8c8cc808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1f66ec8e-0f09-45df-bf52-e2c515266b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1f66ec8e-0f09-45df-bf52-e2c515266b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f53ed78b-c2cf-4be5-9aad-dc0c28ebc04c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f53ed78b-c2cf-4be5-9aad-dc0c28ebc04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1e2c8067-4717-46d7-947d-e988a6c2e8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1e2c8067-4717-46d7-947d-e988a6c2e8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b2535b31-42eb-4be8-bef5-acdf9cb2be27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b2535b31-42eb-4be8-bef5-acdf9cb2be27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_61da35ce-99f2-481d-ae22-b4e52e292848" xlink:href="ino-20200930.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e5f3cd4-f119-4ac2-93ac-5ae7a21f76af" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_61da35ce-99f2-481d-ae22-b4e52e292848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20200930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_7d0d59f0-089c-42b4-b531-d5a2cccf18ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d396715f-9b3a-4d3d-b53e-cb1deb2c5209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_7d0d59f0-089c-42b4-b531-d5a2cccf18ae" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d396715f-9b3a-4d3d-b53e-cb1deb2c5209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_47c51785-ac0e-45ac-9012-a789034f4d78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_47c51785-ac0e-45ac-9012-a789034f4d78" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58622611-a12c-4c3a-89ec-4a6a73da9dbd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58622611-a12c-4c3a-89ec-4a6a73da9dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1da1fa6c-0708-40e8-aca0-948ba90693b6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_58622611-a12c-4c3a-89ec-4a6a73da9dbd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1da1fa6c-0708-40e8-aca0-948ba90693b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_8ecd0a33-295d-45a9-9ab2-3dd6b1e3365d" xlink:href="ino-20200930.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1da1fa6c-0708-40e8-aca0-948ba90693b6" xlink:to="loc_ino_PlumblineLifeSciencesMember_8ecd0a33-295d-45a9-9ab2-3dd6b1e3365d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e987f1bd-b21c-4320-9456-021c2d4079a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e987f1bd-b21c-4320-9456-021c2d4079a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9b02f3d2-1a30-40a6-8c1e-272a4dde3644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e987f1bd-b21c-4320-9456-021c2d4079a0" xlink:to="loc_us-gaap_RelatedPartyDomain_9b02f3d2-1a30-40a6-8c1e-272a4dde3644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_4c7a43f8-1465-4102-967f-b21b36915270" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9b02f3d2-1a30-40a6-8c1e-272a4dde3644" xlink:to="loc_srt_DirectorMember_4c7a43f8-1465-4102-967f-b21b36915270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1fd99e2d-12ec-437c-868a-f2fa55038fcd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:to="loc_srt_CounterpartyNameAxis_1fd99e2d-12ec-437c-868a-f2fa55038fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe1ce6bf-6d4c-4ca6-997e-fb2137c13d0f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1fd99e2d-12ec-437c-868a-f2fa55038fcd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe1ce6bf-6d4c-4ca6-997e-fb2137c13d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneOneLifeSciencesMember_56b3e9a1-673c-47a9-b57b-b5769c4f10ea" xlink:href="ino-20200930.xsd#ino_GeneOneLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe1ce6bf-6d4c-4ca6-997e-fb2137c13d0f" xlink:to="loc_ino_GeneOneLifeSciencesMember_56b3e9a1-673c-47a9-b57b-b5769c4f10ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_e8bcff9f-f863-46bd-8fc9-fcc6e29900d3" xlink:href="ino-20200930.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe1ce6bf-6d4c-4ca6-997e-fb2137c13d0f" xlink:to="loc_ino_PlumblineLifeSciencesMember_e8bcff9f-f863-46bd-8fc9-fcc6e29900d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6f4d7b3b-c4d0-4429-a9ef-23a4d53794a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6f4d7b3b-c4d0-4429-a9ef-23a4d53794a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_30e23edd-13a4-4d31-a350-fb85e2fecd7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6f4d7b3b-c4d0-4429-a9ef-23a4d53794a3" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_30e23edd-13a4-4d31-a350-fb85e2fecd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_dce99994-4c7a-4147-85a0-ae380c11adda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_30e23edd-13a4-4d31-a350-fb85e2fecd7d" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_dce99994-4c7a-4147-85a0-ae380c11adda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0db9c53f-3028-4289-8429-bb4f9f6471be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_22320e28-dfa2-47bf-9ee2-8a689eb46c81" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_0db9c53f-3028-4289-8429-bb4f9f6471be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:href="ino-20200930.xsd#ino_RelatedPartyTransactionsTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0db9c53f-3028-4289-8429-bb4f9f6471be" xlink:to="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f8442810-4d18-4831-a92a-da08d29ed019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f8442810-4d18-4831-a92a-da08d29ed019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d530decd-ee8d-4d58-9c0c-6cd7112f6814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d530decd-ee8d-4d58-9c0c-6cd7112f6814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_11a9ca91-eb08-4afe-8639-dbad70e2552f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_11a9ca91-eb08-4afe-8639-dbad70e2552f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_66865eb7-ba30-4fb3-a993-d1ed2de5d7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_66865eb7-ba30-4fb3-a993-d1ed2de5d7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_f2fb7220-d092-4e90-8f55-ebf93a29d1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_f2fb7220-d092-4e90-8f55-ebf93a29d1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_a3f113e5-d8c0-4eb1-8006-5eac12ca3db4" xlink:href="ino-20200930.xsd#ino_CollaborativeArrangementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_CollaborativeArrangementTerm_a3f113e5-d8c0-4eb1-8006-5eac12ca3db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MilestoneBasedOwnershipTarget_e69db619-df84-4cfb-bce8-801e21f2635a" xlink:href="ino-20200930.xsd#ino_MilestoneBasedOwnershipTarget"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_MilestoneBasedOwnershipTarget_e69db619-df84-4cfb-bce8-801e21f2635a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b43df9b-d13c-43b2-856a-3c95dfde2a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b43df9b-d13c-43b2-856a-3c95dfde2a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_e7300718-971f-4b0e-9bb5-ef130b2ac023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_e7300718-971f-4b0e-9bb5-ef130b2ac023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_2af10790-ba18-4de3-aa1d-aa2ceb888dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_2af10790-ba18-4de3-aa1d-aa2ceb888dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InvestmentOwnedAdditionalSharesAcquired_d6ae1732-6ced-486f-9bcc-9fe624b5012a" xlink:href="ino-20200930.xsd#ino_InvestmentOwnedAdditionalSharesAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_InvestmentOwnedAdditionalSharesAcquired_d6ae1732-6ced-486f-9bcc-9fe624b5012a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_93b517e9-0d76-4c7c-a061-51406cdecab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_93b517e9-0d76-4c7c-a061-51406cdecab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_f2908dab-b67c-4168-bb6c-60a0b15a5210" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_f2908dab-b67c-4168-bb6c-60a0b15a5210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_73b68394-7004-45f0-b2e1-9b5b2f38b2e5" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_73b68394-7004-45f0-b2e1-9b5b2f38b2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_27c53ab0-f0ab-4c32-9a27-7b4a8f8afcc8" xlink:href="ino-20200930.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_GrantProceedsReceived_27c53ab0-f0ab-4c32-9a27-7b4a8f8afcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_5696d988-90d3-42a0-9f6f-1a23836ebe71" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_c823088e-8190-4789-8edb-4e9533ddefd6" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_5696d988-90d3-42a0-9f6f-1a23836ebe71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:type="simple" xlink:href="ino-20200930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9f8b7fbe-709c-4f2f-a697-88679aac5d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_0feb5195-c4f6-47e6-aba7-21f125db0f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9f8b7fbe-709c-4f2f-a697-88679aac5d4a" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_0feb5195-c4f6-47e6-aba7-21f125db0f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:type="simple" xlink:href="ino-20200930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8eb4877d-9d8a-4bae-81bb-989c57273342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_37268c11-e575-4e3b-8e2e-8f48e8cf9683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8eb4877d-9d8a-4bae-81bb-989c57273342" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_37268c11-e575-4e3b-8e2e-8f48e8cf9683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_56392d10-e218-4443-befc-759b2c52ebf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_807b9a6b-3c97-4ab9-a20e-ac4238fd6a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56392d10-e218-4443-befc-759b2c52ebf4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_807b9a6b-3c97-4ab9-a20e-ac4238fd6a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0976cac8-b0e4-4a85-957b-24b6a9570d6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_807b9a6b-3c97-4ab9-a20e-ac4238fd6a34" xlink:to="loc_srt_RangeAxis_0976cac8-b0e4-4a85-957b-24b6a9570d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad61f0d4-ef7b-4fc5-96eb-b666f3d61fe2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0976cac8-b0e4-4a85-957b-24b6a9570d6f" xlink:to="loc_srt_RangeMember_ad61f0d4-ef7b-4fc5-96eb-b666f3d61fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_146e584b-42b7-455c-91ed-40999c600bb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ad61f0d4-ef7b-4fc5-96eb-b666f3d61fe2" xlink:to="loc_srt_MinimumMember_146e584b-42b7-455c-91ed-40999c600bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0669935c-866b-4558-a438-689c4a5bd007" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ad61f0d4-ef7b-4fc5-96eb-b666f3d61fe2" xlink:to="loc_srt_MaximumMember_0669935c-866b-4558-a438-689c4a5bd007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5962c4c4-aa2a-4e48-a1fd-438c6ffb8754" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_807b9a6b-3c97-4ab9-a20e-ac4238fd6a34" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5962c4c4-aa2a-4e48-a1fd-438c6ffb8754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_302366c4-5cdd-45fe-ad48-e20ef308df24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5962c4c4-aa2a-4e48-a1fd-438c6ffb8754" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_302366c4-5cdd-45fe-ad48-e20ef308df24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_53f8b242-5e0a-452a-894c-ab43ad8a0bfc" xlink:href="ino-20200930.xsd#ino_SanDiegoOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_302366c4-5cdd-45fe-ad48-e20ef308df24" xlink:to="loc_ino_SanDiegoOfficeMember_53f8b242-5e0a-452a-894c-ab43ad8a0bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_24872629-ed30-497b-a8ee-06144494fe09" xlink:href="ino-20200930.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_302366c4-5cdd-45fe-ad48-e20ef308df24" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_24872629-ed30-497b-a8ee-06144494fe09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb8aa28a-d825-4ab6-9aac-5dd9ea6a7acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_807b9a6b-3c97-4ab9-a20e-ac4238fd6a34" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb8aa28a-d825-4ab6-9aac-5dd9ea6a7acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_4c16c77c-5e83-4165-9cae-e0c4bc6ab17a" xlink:href="ino-20200930.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb8aa28a-d825-4ab6-9aac-5dd9ea6a7acd" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_4c16c77c-5e83-4165-9cae-e0c4bc6ab17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ad5a4f76-9cd0-43ac-995b-7c6d8e053a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb8aa28a-d825-4ab6-9aac-5dd9ea6a7acd" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ad5a4f76-9cd0-43ac-995b-7c6d8e053a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c9b2abdd-b5c4-4d15-b3ff-bede1586357f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fb8aa28a-d825-4ab6-9aac-5dd9ea6a7acd" xlink:to="loc_us-gaap_LeaseCost_c9b2abdd-b5c4-4d15-b3ff-bede1586357f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#LeasesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c71f1522-05e1-4a47-8e32-5ccfdf8f5267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c71f1522-05e1-4a47-8e32-5ccfdf8f5267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_db074f6a-8252-43b0-9c80-aa78bd73ea2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_db074f6a-8252-43b0-9c80-aa78bd73ea2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3da9ecf0-6e31-4192-abaa-9e06188323dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3da9ecf0-6e31-4192-abaa-9e06188323dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1e80db7c-0f42-46b2-84f3-80fc7150efb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1e80db7c-0f42-46b2-84f3-80fc7150efb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c70c4c87-75bc-4f3a-a74a-693520e64235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c70c4c87-75bc-4f3a-a74a-693520e64235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9f90a46a-5925-4140-b745-abf96646dee3" xlink:href="ino-20200930.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9f90a46a-5925-4140-b745-abf96646dee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0dc72365-c179-4fb6-93b4-f903a31e7e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0dc72365-c179-4fb6-93b4-f903a31e7e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7aab9876-0dfa-4a91-9108-8755b24de225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7aab9876-0dfa-4a91-9108-8755b24de225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_220d2973-1ebc-4316-9647-aab9d303d796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_us-gaap_OperatingLeaseLiability_220d2973-1ebc-4316-9647-aab9d303d796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_42bccf87-8567-4100-8ed7-9858e21a33a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_42bccf87-8567-4100-8ed7-9858e21a33a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83b7de9d-f0b9-4709-b316-549f68ca0ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83b7de9d-f0b9-4709-b316-549f68ca0ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7e5b74b2-d730-41a3-903b-9b374b0df714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7e5b74b2-d730-41a3-903b-9b374b0df714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_cc404558-5a16-4d24-a94b-91fc722f3fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a0ff044-3bba-44a3-9702-dd4a6d831da1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_cc404558-5a16-4d24-a94b-91fc722f3fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20200930.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4bcf73a6-9863-4858-97ee-ab93ee71eff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4bb4568f-4298-4a1f-be69-c1a23df2d7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4bcf73a6-9863-4858-97ee-ab93ee71eff8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4bb4568f-4298-4a1f-be69-c1a23df2d7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4934b293-de59-4c5c-8b94-ae5bcc1b6366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4934b293-de59-4c5c-8b94-ae5bcc1b6366" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b7206c68-51ab-4145-a0f1-b0f927b82377" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:to="loc_srt_CounterpartyNameAxis_b7206c68-51ab-4145-a0f1-b0f927b82377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b7206c68-51ab-4145-a0f1-b0f927b82377" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_9b2b7f7e-4a5f-4d4f-8b4f-af0059216fc4" xlink:href="ino-20200930.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:to="loc_ino_ApolloBioMember_9b2b7f7e-4a5f-4d4f-8b4f-af0059216fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_b3fdcc84-a078-4d8b-8232-7c0fe74e43b5" xlink:href="ino-20200930.xsd#ino_AstraZenecaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:to="loc_ino_AstraZenecaMember_b3fdcc84-a078-4d8b-8232-7c0fe74e43b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_b46f20bd-534c-43c7-af5d-fbc68d4e8ed1" xlink:href="ino-20200930.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_b46f20bd-534c-43c7-af5d-fbc68d4e8ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_a4110739-a8ae-4a20-b53e-e6901401f0de" xlink:href="ino-20200930.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_a4110739-a8ae-4a20-b53e-e6901401f0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_9a02a0f7-baa1-439e-9552-6b72d03422b5" xlink:href="ino-20200930.xsd#ino_DepartmentOfDefenceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77fbba92-70ab-4702-9c6d-d9f976bde561" xlink:to="loc_ino_DepartmentOfDefenceMember_9a02a0f7-baa1-439e-9552-6b72d03422b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a84b7649-7d14-42b4-b3e5-ada391048b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a84b7649-7d14-42b4-b3e5-ada391048b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86a0fcb1-1f71-4116-977b-b1302d5a2587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a84b7649-7d14-42b4-b3e5-ada391048b00" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86a0fcb1-1f71-4116-977b-b1302d5a2587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_07d4599b-1b2d-4253-803a-26d33adebbd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86a0fcb1-1f71-4116-977b-b1302d5a2587" xlink:to="loc_us-gaap_CollaborativeArrangementMember_07d4599b-1b2d-4253-803a-26d33adebbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e6ec984b-56b8-4177-9dc5-e812c8074852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e6ec984b-56b8-4177-9dc5-e812c8074852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_61531691-c4af-4f20-ad96-d800a4d2414f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e6ec984b-56b8-4177-9dc5-e812c8074852" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_61531691-c4af-4f20-ad96-d800a4d2414f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_51311681-9bef-4ee3-8651-37cd2672c509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_61531691-c4af-4f20-ad96-d800a4d2414f" xlink:to="loc_us-gaap_ForeignCountryMember_51311681-9bef-4ee3-8651-37cd2672c509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0484c4f2-0d35-4db1-b588-dec82cfb26c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:to="loc_srt_ProductOrServiceAxis_0484c4f2-0d35-4db1-b588-dec82cfb26c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0484c4f2-0d35-4db1-b588-dec82cfb26c7" xlink:to="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_1cc75be2-844e-4888-bbc3-d8a07ab58361" xlink:href="ino-20200930.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_1cc75be2-844e-4888-bbc3-d8a07ab58361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_cc61647c-d8e4-4d8d-ae5b-30c0839577b8" xlink:href="ino-20200930.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_cc61647c-d8e4-4d8d-ae5b-30c0839577b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_89cf797c-7447-4f51-b5b4-a39768c45f10" xlink:href="ino-20200930.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_89cf797c-7447-4f51-b5b4-a39768c45f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_77a1f1ba-d246-47b2-8823-4898fd559a50" xlink:href="ino-20200930.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_77a1f1ba-d246-47b2-8823-4898fd559a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_65b3e611-95d3-42a9-8d95-365ce00abb6c" xlink:href="ino-20200930.xsd#ino_INO4800Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:to="loc_ino_INO4800Member_65b3e611-95d3-42a9-8d95-365ce00abb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember_07ab3f92-ac0a-450a-812e-c28d3ae224f6" xlink:href="ino-20200930.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_600f8e19-2efe-4dd7-87c3-89e21b177e1f" xlink:to="loc_ino_CELLECTRA2000DeviceMember_07ab3f92-ac0a-450a-812e-c28d3ae224f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c3246a1-6a8e-4721-a574-efd1d21663ab" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_20adc0bb-9916-4ca0-8602-ab7fc1f78ee0" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_20adc0bb-9916-4ca0-8602-ab7fc1f78ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_ee0fcf4e-824c-497c-85d1-c7c98fa2b716" xlink:href="ino-20200930.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_ee0fcf4e-824c-497c-85d1-c7c98fa2b716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_544db971-d886-44dd-97b2-6fca0e2b9531" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_544db971-d886-44dd-97b2-6fca0e2b9531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_9ea8027d-09ba-4a07-8d00-1874ba46da77" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_9ea8027d-09ba-4a07-8d00-1874ba46da77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_51dbbaf8-71fe-4359-aedf-e4b1c2736aa2" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_51dbbaf8-71fe-4359-aedf-e4b1c2736aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_3b55eb3f-063e-4665-903b-6fedb3135c6c" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_3b55eb3f-063e-4665-903b-6fedb3135c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_f8937e84-52d3-40e0-8de7-1b8b53d2d7fd" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_f8937e84-52d3-40e0-8de7-1b8b53d2d7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_193c236c-45c9-4471-a654-e791af770562" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_193c236c-45c9-4471-a654-e791af770562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_61446b50-e245-4a43-a774-62027d7553a2" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_61446b50-e245-4a43-a774-62027d7553a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_09cccec7-62fa-4c4b-a147-c3fad9890bf3" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_09cccec7-62fa-4c4b-a147-c3fad9890bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_8e859b54-9fbd-4031-bc38-e66217ac6705" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_8e859b54-9fbd-4031-bc38-e66217ac6705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_746a04ce-0c1e-4a10-b480-4c0354502717" xlink:href="ino-20200930.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_746a04ce-0c1e-4a10-b480-4c0354502717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfAdditionalProducts_5a70da81-71e3-4607-b2a0-4d022c819d69" xlink:href="ino-20200930.xsd#ino_NumberOfAdditionalProducts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_NumberOfAdditionalProducts_5a70da81-71e3-4607-b2a0-4d022c819d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a1313f5f-cce2-430c-be74-461d5ea784ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a1313f5f-cce2-430c-be74-461d5ea784ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_f31705e6-0ad9-4182-b4ed-2dbed35e30dd" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_f31705e6-0ad9-4182-b4ed-2dbed35e30dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_96b133db-8133-4d66-8b5d-0c78140a29da" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_96b133db-8133-4d66-8b5d-0c78140a29da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_2ac1cd51-2179-4f0e-8936-9ca838fe61b4" xlink:href="ino-20200930.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_DeferredGrantFundingCurrent_2ac1cd51-2179-4f0e-8936-9ca838fe61b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_f9c0a1c0-faea-4d7e-8314-5bf60209868f" xlink:href="ino-20200930.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_f9c0a1c0-faea-4d7e-8314-5bf60209868f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_6667faa0-da78-49c1-8a5d-c32e9a498953" xlink:href="ino-20200930.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_6667faa0-da78-49c1-8a5d-c32e9a498953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_b9408c92-c3a7-491b-a83a-b68c79927cd2" xlink:href="ino-20200930.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_ino_GrantProceedsReceived_b9408c92-c3a7-491b-a83a-b68c79927cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_4521a82d-7a9f-4025-ae75-2ff2c0d107b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_42f57569-301b-48cd-b3af-c7589d88d93a" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_4521a82d-7a9f-4025-ae75-2ff2c0d107b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20200930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bbf96cf8-163a-4f29-8e81-22e6b5d62bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e2ee4518-e77a-4800-a8e7-e909fe3ad44c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bbf96cf8-163a-4f29-8e81-22e6b5d62bca" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e2ee4518-e77a-4800-a8e7-e909fe3ad44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsInc"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_6f0c5346-5234-48a8-9ce2-2ed49c16dc6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b61c3603-10d5-4870-a884-b597791775a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_6f0c5346-5234-48a8-9ce2-2ed49c16dc6e" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b61c3603-10d5-4870-a884-b597791775a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_3d3fcc37-96dd-4ee8-a7b5-0694ec845937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_86964f20-8fe7-4ede-9fbc-3d45b3d811b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3d3fcc37-96dd-4ee8-a7b5-0694ec845937" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_86964f20-8fe7-4ede-9fbc-3d45b3d811b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_dceb1f20-6dff-4f9b-bf4a-2d35d32c9782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3d3fcc37-96dd-4ee8-a7b5-0694ec845937" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_dceb1f20-6dff-4f9b-bf4a-2d35d32c9782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_0f11efe4-b3c4-4a7c-9daf-dc3b66f92f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_2185d9a6-8f7e-4f83-a3dc-47f45f8581a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_0f11efe4-b3c4-4a7c-9daf-dc3b66f92f1e" xlink:to="loc_us-gaap_MinorityInterestTable_2185d9a6-8f7e-4f83-a3dc-47f45f8581a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d0a52bfa-7865-470e-8294-a6027d334487" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_2185d9a6-8f7e-4f83-a3dc-47f45f8581a1" xlink:to="loc_srt_CounterpartyNameAxis_d0a52bfa-7865-470e-8294-a6027d334487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5cd9612-55f4-4906-9c59-b0fe366e7fc6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d0a52bfa-7865-470e-8294-a6027d334487" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5cd9612-55f4-4906-9c59-b0fe366e7fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_8df4da20-dec2-4525-bd9f-9a2be0ae689c" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5cd9612-55f4-4906-9c59-b0fe366e7fc6" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_8df4da20-dec2-4525-bd9f-9a2be0ae689c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_9df40370-63aa-46c0-b1d9-3dfe6c6492ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_2185d9a6-8f7e-4f83-a3dc-47f45f8581a1" xlink:to="loc_srt_OwnershipAxis_9df40370-63aa-46c0-b1d9-3dfe6c6492ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7f1ea7c8-bc51-45b5-94a2-420e67abcea6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_9df40370-63aa-46c0-b1d9-3dfe6c6492ea" xlink:to="loc_srt_OwnershipDomain_7f1ea7c8-bc51-45b5-94a2-420e67abcea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_c5603cdc-93eb-46c3-994d-7c08f162ba2a" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_7f1ea7c8-bc51-45b5-94a2-420e67abcea6" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_c5603cdc-93eb-46c3-994d-7c08f162ba2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dc28704e-24e4-466d-a61c-4bfec61664c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_2185d9a6-8f7e-4f83-a3dc-47f45f8581a1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dc28704e-24e4-466d-a61c-4bfec61664c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c46bfe37-19ee-4ca0-a64e-5483228755a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dc28704e-24e4-466d-a61c-4bfec61664c9" xlink:to="loc_us-gaap_ClassOfStockDomain_c46bfe37-19ee-4ca0-a64e-5483228755a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cd2ef110-0b4c-4105-b0b7-c8ccc9f202ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c46bfe37-19ee-4ca0-a64e-5483228755a2" xlink:to="loc_us-gaap_CommonStockMember_cd2ef110-0b4c-4105-b0b7-c8ccc9f202ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_31af79c5-77c3-4e7e-a0ab-d7330be76837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c46bfe37-19ee-4ca0-a64e-5483228755a2" xlink:to="loc_us-gaap_PreferredStockMember_31af79c5-77c3-4e7e-a0ab-d7330be76837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_2185d9a6-8f7e-4f83-a3dc-47f45f8581a1" xlink:to="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ff152401-bd31-4176-a82e-bbfd4eda905f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ff152401-bd31-4176-a82e-bbfd4eda905f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_c0c3f476-1203-420b-8ee3-b8a96f6b2608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_c0c3f476-1203-420b-8ee3-b8a96f6b2608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_89f7a009-2356-43fd-b29f-ed938ca94ec6" xlink:href="ino-20200930.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_89f7a009-2356-43fd-b29f-ed938ca94ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_83d34e9e-a312-45d7-b079-dc9bd6f40d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_83d34e9e-a312-45d7-b079-dc9bd6f40d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_3413d83a-d340-45ea-bea1-34bbd947dfc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_3413d83a-d340-45ea-bea1-34bbd947dfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_399cf48f-7b84-4e2f-a49e-03c58d889283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_399cf48f-7b84-4e2f-a49e-03c58d889283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_298ccefe-6f99-4cbb-96dd-2e8023a260ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_298ccefe-6f99-4cbb-96dd-2e8023a260ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c02257b3-d4ae-4efc-ae71-56b295e09425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a05d06e7-857a-4321-9bc6-fa0f0dd6791c" xlink:to="loc_us-gaap_EquityMethodInvestments_c02257b3-d4ae-4efc-ae71-56b295e09425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_fcd8a76b-ee87-4675-889e-ac820907bad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_f1b98eab-b433-4c72-a589-9657d9890db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_fcd8a76b-ee87-4675-889e-ac820907bad1" xlink:to="loc_us-gaap_MinorityInterestTable_f1b98eab-b433-4c72-a589-9657d9890db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d2f512b6-ef01-4d6f-9592-a30dda7f2a6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_f1b98eab-b433-4c72-a589-9657d9890db7" xlink:to="loc_srt_CounterpartyNameAxis_d2f512b6-ef01-4d6f-9592-a30dda7f2a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1de92262-3c51-4233-81bc-23c10dcaec92" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d2f512b6-ef01-4d6f-9592-a30dda7f2a6e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1de92262-3c51-4233-81bc-23c10dcaec92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_2f1b3cad-e2ee-4f85-9751-28954a567e36" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1de92262-3c51-4233-81bc-23c10dcaec92" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_2f1b3cad-e2ee-4f85-9751-28954a567e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_f1b98eab-b433-4c72-a589-9657d9890db7" xlink:to="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash_0a719684-90c3-4f6b-86a5-d5eb3f7174a5" xlink:href="ino-20200930.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_ino_WorkingCapitalExcludingCash_0a719684-90c3-4f6b-86a5-d5eb3f7174a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_de2030c1-0d65-4305-a819-8b161018abf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_NotesPayable_de2030c1-0d65-4305-a819-8b161018abf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4368c86a-762c-4a7e-8309-1d4c65c3b40e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4368c86a-762c-4a7e-8309-1d4c65c3b40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_1af56b05-03fc-4ad3-8469-26ce6f89602c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_MinorityInterest_1af56b05-03fc-4ad3-8469-26ce6f89602c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_9740fc50-7594-4a36-b714-97232a4f3d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_RetainedInterestFairValueDisclosure_9740fc50-7594-4a36-b714-97232a4f3d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_824c4eb0-c7ff-441b-a70e-f6a295a38599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_824c4eb0-c7ff-441b-a70e-f6a295a38599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_6780e57f-5a7d-40eb-91a8-779674fc7fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1893f42c-1c70-4204-9619-a88029e68f1e" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_6780e57f-5a7d-40eb-91a8-779674fc7fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncInvestmentInGeneosDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_96970907-9038-49bb-90e1-d6917de873f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_de8f4c6a-fb01-423b-9e61-9bf58afd41c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_96970907-9038-49bb-90e1-d6917de873f2" xlink:to="loc_us-gaap_MinorityInterestTable_de8f4c6a-fb01-423b-9e61-9bf58afd41c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7c2aea13-fb55-435e-8e26-9e72e2de9386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_de8f4c6a-fb01-423b-9e61-9bf58afd41c3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7c2aea13-fb55-435e-8e26-9e72e2de9386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5704b635-b9df-4165-ad01-f6114312ba9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7c2aea13-fb55-435e-8e26-9e72e2de9386" xlink:to="loc_us-gaap_ClassOfStockDomain_5704b635-b9df-4165-ad01-f6114312ba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_759bbde2-d6c4-45a0-9021-56d9f87029ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5704b635-b9df-4165-ad01-f6114312ba9b" xlink:to="loc_us-gaap_CommonStockMember_759bbde2-d6c4-45a0-9021-56d9f87029ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_092aeb95-13cd-4b6a-aa15-850c224127c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5704b635-b9df-4165-ad01-f6114312ba9b" xlink:to="loc_us-gaap_PreferredStockMember_092aeb95-13cd-4b6a-aa15-850c224127c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b670e600-fc15-47be-81b3-a9ab674eff77" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_de8f4c6a-fb01-423b-9e61-9bf58afd41c3" xlink:to="loc_srt_CounterpartyNameAxis_b670e600-fc15-47be-81b3-a9ab674eff77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aee78f3e-0e2b-4979-b90e-9d786f47101c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b670e600-fc15-47be-81b3-a9ab674eff77" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aee78f3e-0e2b-4979-b90e-9d786f47101c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_5bf93f7c-1bc2-419e-94b0-6b65447b2ba4" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aee78f3e-0e2b-4979-b90e-9d786f47101c" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_5bf93f7c-1bc2-419e-94b0-6b65447b2ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_69274274-4667-428a-9f16-6debb253eb80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_de8f4c6a-fb01-423b-9e61-9bf58afd41c3" xlink:to="loc_us-gaap_MinorityInterestLineItems_69274274-4667-428a-9f16-6debb253eb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_bf468404-d60f-4fe4-9f5c-3b6c3ef1a694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_69274274-4667-428a-9f16-6debb253eb80" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_bf468404-d60f-4fe4-9f5c-3b6c3ef1a694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_3ed61c49-5340-47c2-bbff-b65f386576a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_69274274-4667-428a-9f16-6debb253eb80" xlink:to="loc_us-gaap_SharePrice_3ed61c49-5340-47c2-bbff-b65f386576a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_527c1ca2-acc7-450c-b7bc-20ea8e379a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_69274274-4667-428a-9f16-6debb253eb80" xlink:to="loc_us-gaap_EquityMethodInvestments_527c1ca2-acc7-450c-b7bc-20ea8e379a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_4c6d8d94-b2cd-4331-8f85-0bd4ff294547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_3a8ad1e9-725b-43f5-bffd-3c35d2472ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_4c6d8d94-b2cd-4331-8f85-0bd4ff294547" xlink:to="loc_us-gaap_MinorityInterestTable_3a8ad1e9-725b-43f5-bffd-3c35d2472ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3aba1439-476e-4710-8f6e-a3b291f6688c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_3a8ad1e9-725b-43f5-bffd-3c35d2472ae6" xlink:to="loc_srt_CounterpartyNameAxis_3aba1439-476e-4710-8f6e-a3b291f6688c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45acc914-eeaf-4822-a331-698c5f5cf302" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3aba1439-476e-4710-8f6e-a3b291f6688c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45acc914-eeaf-4822-a331-698c5f5cf302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_a427955b-8a3f-4602-b744-0fcaba3089c3" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45acc914-eeaf-4822-a331-698c5f5cf302" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_a427955b-8a3f-4602-b744-0fcaba3089c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_350128a2-0d1a-434e-aca2-8d60d093bde8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_3a8ad1e9-725b-43f5-bffd-3c35d2472ae6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_350128a2-0d1a-434e-aca2-8d60d093bde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f22b0ae0-1e80-4126-afb8-11e3f0172016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_350128a2-0d1a-434e-aca2-8d60d093bde8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f22b0ae0-1e80-4126-afb8-11e3f0172016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_78bc1099-101e-4f99-b6d7-39a9685cdc50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f22b0ae0-1e80-4126-afb8-11e3f0172016" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_78bc1099-101e-4f99-b6d7-39a9685cdc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_861b9ffb-4f74-4305-beae-a16378094ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f22b0ae0-1e80-4126-afb8-11e3f0172016" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_861b9ffb-4f74-4305-beae-a16378094ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_362b9193-4efc-4221-89e0-d38510048df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f22b0ae0-1e80-4126-afb8-11e3f0172016" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_362b9193-4efc-4221-89e0-d38510048df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_1c6030d9-c386-41c6-8b56-fb071c452c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_3a8ad1e9-725b-43f5-bffd-3c35d2472ae6" xlink:to="loc_us-gaap_MinorityInterestLineItems_1c6030d9-c386-41c6-8b56-fb071c452c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_e3f2e167-7148-46e3-9bff-8c44b2f12849" xlink:href="ino-20200930.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c6030d9-c386-41c6-8b56-fb071c452c7a" xlink:to="loc_ino_AlternativeInvestmentMeasurementInputTerm_e3f2e167-7148-46e3-9bff-8c44b2f12849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_712ddc96-74a6-4879-85f3-0685f7eee022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c6030d9-c386-41c6-8b56-fb071c452c7a" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_712ddc96-74a6-4879-85f3-0685f7eee022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_1f6a7600-c0e0-4391-ac85-313446197529" xlink:href="ino-20200930.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c6030d9-c386-41c6-8b56-fb071c452c7a" xlink:to="loc_ino_EquityMethodInvestmentEnterpriseValue_1f6a7600-c0e0-4391-ac85-313446197529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#GeneosTherapeuticsIncPreferredstockInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_82dbbde2-aa73-46a2-b4e0-26477631a18a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_babb1456-45bc-40c8-904b-fbeb12a47bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_82dbbde2-aa73-46a2-b4e0-26477631a18a" xlink:to="loc_us-gaap_MinorityInterestTable_babb1456-45bc-40c8-904b-fbeb12a47bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0e8c28b3-29ff-4531-8237-00d1bf896399" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_babb1456-45bc-40c8-904b-fbeb12a47bdd" xlink:to="loc_srt_CounterpartyNameAxis_0e8c28b3-29ff-4531-8237-00d1bf896399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90a02ea5-e308-4f09-b19a-35d454355f93" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0e8c28b3-29ff-4531-8237-00d1bf896399" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90a02ea5-e308-4f09-b19a-35d454355f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_81925496-90ad-4cbd-9c07-41463a5774f4" xlink:href="ino-20200930.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90a02ea5-e308-4f09-b19a-35d454355f93" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_81925496-90ad-4cbd-9c07-41463a5774f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_1c6c9f09-77ff-461b-9e17-83df089a65c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_babb1456-45bc-40c8-904b-fbeb12a47bdd" xlink:to="loc_us-gaap_MinorityInterestLineItems_1c6c9f09-77ff-461b-9e17-83df089a65c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_344c1c7f-573b-4ecd-839b-630e2a15c6ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c6c9f09-77ff-461b-9e17-83df089a65c5" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_344c1c7f-573b-4ecd-839b-630e2a15c6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_54a4627c-2917-43fe-a9ca-f55c3ab98b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_344c1c7f-573b-4ecd-839b-630e2a15c6ec" xlink:to="loc_us-gaap_EquityMethodInvestments_54a4627c-2917-43fe-a9ca-f55c3ab98b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c4184fd5-1927-4036-8ea0-4c6aba97d41b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_344c1c7f-573b-4ecd-839b-630e2a15c6ec" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c4184fd5-1927-4036-8ea0-4c6aba97d41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2b4616e5-b9bb-4e01-84a7-12ecea85beba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_344c1c7f-573b-4ecd-839b-630e2a15c6ec" xlink:to="loc_us-gaap_EquityMethodInvestments_2b4616e5-b9bb-4e01-84a7-12ecea85beba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ino-20200930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f7699033-f3aa-48ea-9ada-97aa541ab829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_dd20b54d-3f05-4a19-9926-1e9ed7c11481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f7699033-f3aa-48ea-9ada-97aa541ab829" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_dd20b54d-3f05-4a19-9926-1e9ed7c11481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20200930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3f94929b-ac57-4ddd-ba41-311b704a4d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_7cb65c05-cd6c-43f4-ae79-5bada40572ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3f94929b-ac57-4ddd-ba41-311b704a4d62" xlink:to="loc_us-gaap_SubsequentEventTable_7cb65c05-cd6c-43f4-ae79-5bada40572ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f5835208-45ff-440c-98e2-696530c4abf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7cb65c05-cd6c-43f4-ae79-5bada40572ea" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f5835208-45ff-440c-98e2-696530c4abf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3ad23261-1b0c-4f70-ab48-b1c46b28ed52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f5835208-45ff-440c-98e2-696530c4abf8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3ad23261-1b0c-4f70-ab48-b1c46b28ed52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_58a7aad8-9b67-4ebd-a58d-a465d6c85a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3ad23261-1b0c-4f70-ab48-b1c46b28ed52" xlink:to="loc_us-gaap_ConvertibleDebtMember_58a7aad8-9b67-4ebd-a58d-a465d6c85a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_db91e23c-d727-4c46-8f90-39bc7f1fcc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7cb65c05-cd6c-43f4-ae79-5bada40572ea" xlink:to="loc_us-gaap_StatementClassOfStockAxis_db91e23c-d727-4c46-8f90-39bc7f1fcc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_275fc9d4-0e8b-4a51-84d6-67101a73193a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_db91e23c-d727-4c46-8f90-39bc7f1fcc4e" xlink:to="loc_us-gaap_ClassOfStockDomain_275fc9d4-0e8b-4a51-84d6-67101a73193a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a5745123-cb1f-4db9-ad14-20fcd1a2d3e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_275fc9d4-0e8b-4a51-84d6-67101a73193a" xlink:to="loc_us-gaap_CommonStockMember_a5745123-cb1f-4db9-ad14-20fcd1a2d3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b919b49e-03a4-4638-959e-76daef7156f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7cb65c05-cd6c-43f4-ae79-5bada40572ea" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b919b49e-03a4-4638-959e-76daef7156f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_93e7cea9-5155-491e-aed3-932ed2ae700a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b919b49e-03a4-4638-959e-76daef7156f4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_93e7cea9-5155-491e-aed3-932ed2ae700a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_67247a37-ed1a-43f0-8ea4-ef99aa6e0e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_93e7cea9-5155-491e-aed3-932ed2ae700a" xlink:to="loc_us-gaap_SubsequentEventMember_67247a37-ed1a-43f0-8ea4-ef99aa6e0e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_67d7f388-e336-4d93-a32d-a563e670cb31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7cb65c05-cd6c-43f4-ae79-5bada40572ea" xlink:to="loc_us-gaap_SubsequentEventLineItems_67d7f388-e336-4d93-a32d-a563e670cb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_fa45bce6-3cb3-4aa1-a14c-46bf23cc9e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_67d7f388-e336-4d93-a32d-a563e670cb31" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_fa45bce6-3cb3-4aa1-a14c-46bf23cc9e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_88275ea3-af6c-4986-8ee5-0954975f929d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_67d7f388-e336-4d93-a32d-a563e670cb31" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_88275ea3-af6c-4986-8ee5-0954975f929d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ino-20200930_g1.jpg
<TEXT>
begin 644 ino-20200930_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( BQKW7[8FU^B/$'4^N-/8R>/J8J3Y"*UD&(?>'P?3>Q<\3R?@/!ZGX?AO
M)1K;F]^]M;BREATU@M5ZKE!_G=KU6K@<5*WFW(S9*=\J+_+[6$87'W%SY(";
MWE%4ZW*[^/<C(>)'IC36F-.1%R(SW1N9VZ(O[C%SFH4PE9_=XE6S']4'Y\L!
M-P.\3WOU/UCEMR=0M%(W25?%/1T_7Z?D!X<!3QH&S>7!2^)(_')&1>T@+SVH
M=7XG$0G9RV4QV,KQ-S)8R%VM2AC9_<YRV98@!OKD3,L1=:=Y!L9@G,;>YNEK
M4@<\QX2^VH"<F9WZ.K!CD(Q/V7%QD,.DN!-Q=V9Z,6?U!?RTWK.5OW<I9Y=_
M6,C;L7I^2][M+:DED9W^7VO-?(0%P'6/?B;,8[J;'QZKSYCSY8_"A5$G9W;@
M),M;H"_/#.SN[#P3-SSRS8JZM](*J YC@-K;=D7Y:.?-:K@QY#Y>1'3H8/*B
M?G[P&_'Y>;2?(JU"("<G4O?U;FV6(<;I71N*%_H2D'+9&8?/Y3DNUH3X;R_.
MP>?+_49NA-1=\MOQ?ZFBS^'Q@OU=/P=IZ@)"S]7'!7/7>7'GR=V=N1%W;W\Q
M8H@,W\_WD^^^2ZFL;G:BC8ODQ[8W$]+>UY"6+H4Y/+K?AW-R\A=R=P!QZ>RW
M:QW5O.7KFY^XM@2YYCDUQJ?P?,>A^F <HT(\B[L73&W4SOU<\OST"B YODMS
M=37>?7=2:AN=72Q>MYS*6>IA^AY\>U)ST_H>>>/D7&YLW=DY\2[<DZOHNNU.
M?/'NYZI'YXX;W_47S$0'ZR3R'QUR&?'/'49%QS[^.7?CGAN?UE^!@Q-P3,3?
M4+VF_7X?E?TB _#U6+_X8?\ R#_Y+^PB$?H18>??TLP\_K\<+]$0']A(0OR)
M$+M[G$B9VY]_FS\KW(\K;#Z"U9#_ +EB8?/ZOLFR]!$!RW'Z_P _4+JJ9[-U
M2Z@/JJY?(5RZP?D#9XK .Q _F!>\7X=G9=A8OM.[FT>&H[D[A4F'W#4UOJ>N
M/#GUD/1#E0!Q(_:('9Q,O,F=W==((@,RL#WA^^6-<7K;HZM+I]WK]V++M[^?
M:;+U[PGY_P!.Q-QY<=+,R[LT[WP._F/Z>O5M+)\-Y_">G\1)U?0_1>J5Z3_H
M?T+C]$7U6Z8R40$V.F^_<W9J,S9#!Z,RS>74YTLG1-_/E^EZN3Z!=VX9G>,V
M;CGI=9#:5](*M,X!G-K(#'_K+.(U<8$W]KH7=/$Q<^_VLF/'N\_>JY"("V_H
M[OV]I;SB.5P^LL"[_1'/CJ61A$O+Z$L9D;$Q!S[B> "X;EP;W++'17>C[#YO
MPQBW$P^-DDX^=YX;>#8.>G^B6,E7KTPX=^'YL\,[.[\-YJC>B V*&C-V=*ZD
MA:SIW4VG\]7+IXGPN9QV4A?JY8>):-F<'ZG9^G@O/A^/<NP%K=J-J6K,%FK+
M+6L1NSA8KR'!.#L[/[$T1!(/FS/R),_+,_O9EE!M_P!N#=_2W0V#W&U55"-^
MH8+.1?+5>?-N3IYD,A4D]_DTL)M]9 7Z450/;/OQMX<.T<6?KZ9U?"''7+;Q
MKX;(R_5ZK&&.#'CRW])B!9G\_-O)2$[:=_EHFWX4.K-&:DPDA,PG;PTN/SE(
M"Y;F22.:?%78XF;E^(8+DO+,S 74_2!/FBPPVJ[PS9G67AAA=?X,;,OT-++3
M28*[R[,_2];,QTI.7^A;AGZB;@7)^.<RH)PE )(C&2.01..0"8P,#9B P,7<
M2 A=B$A=V=G9V?A ?JB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"J']OGMX;PZ7WCU]I_3VO\UBL+B\O7@Q^.K1XPH*D)XG'3E'&\]"65Q>::63
MVY"?DW9G8>&:W@J+7>;?'WN;]G*OX#Q* ]?\DMWZ_LGZ@_P6'_W6GY);OU_9
M/U!_@L/_ +K6#B(#./\ )+=^O[)^H/\ !8?_ '6GY);OU_9/U!_@L/\ [K6#
MB(#./\DMWZ_LGZ@_P6'_ -UK-_NV^W-N[J_?#06F]3:\S.9P64FU*.0QEJ/&
MC7M#3T5J7(U6D>"A#,W@WJ=6R'1*'SR$&+J#J$H/5(KW2OTQ>V?]OU=_![JY
M 7>T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$=7>H[L:DT3LSG=0Z3R]K!YNME=-
MPU\C3: IXHKF<HUK48M9AGBZ9J\AQ'U1N_23N+B7#M5G_)+=^O[)^H/\%A_]
MUJRMWT7Q ZD^S.DOQDQRIC(#./\ )+=^O[)^H/\ !8?_ '6GY);OU_9/U!_@
ML/\ [K6#B(#./\DMWZ_LGZ@_P6'_ -UI^26[]?V3]0?X+#_[K6#B(#./\DMW
MZ_LGZ@_P6'_W6GY);OU_9/U!_@L/_NM8.(@,XV[R[?IG9VW/U!Y>?G#AW;R^
MJWP9YM]5OE;R5J?N\NW/C=Z=)^/.]>CK+"#%7U/AXG<!ZR;B#+X\#<B/&9!Q
M+I9B,J=D9:DSMQ!)/1U7=_9V[0&H=L=6XO6&FK#Q7L=*[3U3D,:F5Q\K=%S%
MY",>1EJVHO)NH"*M8&"[!TV:T,@ ;"%%CYV8>TCI[=71^,U=IV7YS<C&/(8^
M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
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M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
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M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
M2$6>EF[M)VX+E^1>MP;^XC8B'@79FSB[EK&^L;_M/PS^HZ/U%,[]#D[>+)CJ
MOD3>4?/C<<OY%ST^\F4;6I,F^0UKK?).[N60UAJR^Y.3&Y/<SN1LNY&WE(3O
M*[O(S,QO[3-PZEE[B*@\V\>KK+B[C5V_MCU<\<2V=0X$0Y']$Q1PS>?N%V9W
M\W%=$N/5]'X0S8]N32X4_P!*%=/]NQ1[@[Z_C6,__O+G^Z5EG]A;/=8)=K[L
MDU]8U9<]A(0AU54@?D!<(H\W#$S.U:=RX ;H"+C2LD0,3NU>R?A>%)7SN7CA
M<L/$OPUTCBW1\O0]:QED865#NMHWXUR3\K+Q+6I.G)HD^:NQ)I^]79&=4[*Y
M6YXQX.P->T^_3=1I5N/?'HULK:;$GY=]$VGY=U3>\))-/K"<95RG"5-W?W8L
M-4T):,T7JF;QDDS4I9A>(X+4;D$U&TSCU##*8N$H$W,4H#*W#@[%#?D<#/4G
MFJVH#@LUY#AGAE'IDBEC?I,";ZK.WR.[$WF+N+L[VW^]$R>E]*ZNT291#1R>
MMQS$5NP,D4=8[&+^# HRV(?(FFN-<EKE:Y$3D@KQD)F;F$)O:TV7:U"^J:$7
MYIJQA'EH8Q_HU828([O2WF\M;JZ+!,W+UF8S\J[NN(VM\"ZYX7<1QX5X@C9/
M2-5\S+X9U>4''&SL=Y%E"E5)[QA*5T'1EXW,Y8F:E)<U&37?;QC\8O#S*X8U
M7*P+I*WR'YE5\%M#)Q9I2KMVW]RR,6E=6V^2:E%2G'RYSC"*EQ\BR.[)W:7U
M'L_K3':QTX?64/YER^*E)QJ9S#2F!6\;:9N6%SZ!EJ6&%SJ6XX9QY82 ^GWI
M,_R-_+^7_LOR>E]9E)^FZW?AWTY6-;*C(HLC;3;!\LX60>\6FEZ/NGNFMXR3
M3:(KTCBO)P<FC,P[IX^5BVPNHNKDXSKLKDI1DGU[-;.+WC);QDG%M&Q V-WI
MP&X>EL/K#3-IK>(S50+$+DS#/6E;V;-&Y&SOX-RE.TE:S%R3#+&3@1QN,A]M
M*G1W0G;6/;;6'S&YZUX>B]:7H(GDG/BO@M12"U>GDAZG88:V1=H,?D3]D&XI
MVI'8*QNKBS.NJOA%XDT\3:37EKEAF4M4:A1'_%9"COSP3;?DWQ^MJ;;VWE4Y
M2G5,[8>!/B]C\8Z'5GQY*\_':QM4Q8O^1RHQ3\R$6W)8^3'ZZAMO9.=+E*RF
MP\HB*4B: B\+'S>'M7[;: #G6.MM.X*9Q<@HVLC">5F%BZ"*OAZSSY6R(%Y&
M]>G(P/\ 1.R\>=J&/BURNR;Z<>F'VK;[(55Q_G3LE&,?S:/QOR*ZHN=DX5P7
M>4Y1A%?C*327[S(1%"/N=W[&UN+>2+36'U)JV8>M@E&"'!X\C%WZ>JSD'*VT
M1MPXR1XZ4N'\X_)8-ZR[^'7U\C;3^C=,8*$OZ&]ZUD<_;!N/?XP-A:Q<OY\/
M1\O=Y^;O"O$7M)\&Z:Y1LU>&59'_ !>!3=E[[+?I=7#Z-OZ;>>NORW:U#4/$
M/2<=M/*\V2^[1"=O;X3C'RO^N6F^5Y5-+4?>W[WY)R?YK:.)9V?@<7A\3 P\
M\\</;AMD[M[F(G)W9OEX==39'O%MV;1=5K=7. 3]3NT&4J4!]OEW=HZ4=8!_
M[/2+=#>0=+<**M0]MKANMRCCZ9K>3MVDJ,6J$OZ67*:_.M&J9'C-I\7M7B9U
MGSY*8K_?-_\ 5+PO*<JC-6[<&XI.P_S6-6$[MY-\V>2=WX;E_P#[?=W\F796
M![>6[-?PRK;F:BEZ1  >?)Q9!G$.GI<FN#9:0G<6ZCD8CDY)C(F(N=<C[>&C
M1DO/T#6*X_K0GBV/^C.=*?\ 31C)>.F''[>GYJ7R=+?[G./]9=/9UY52C2W>
M?[SX]Q>34T&3;RY;)X?&RL3<<>^M7J/Y^_EG;S\_=Y+*G0W?.ZOKE&.?TC@<
MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
MB(@"(B (B( B(@(J.^B^('4GV9TE^,F.5,97.>^B^('4GV9TE^,F.5,9 $1$
M 1$0!$1 $1$ 7AVY_P!"\H@+,G<]=XB5X*6T6M[_ %78A\'0^8MR,Q6Z\0-T
MZ9MS&[==NN .6(D)W.Q7YH/U2P5FFL6+6[T[DU>:*Q7ED@L5Y8YX)X3*.:&:
M$QDBFBD%V()(I!$XS%V(#829^65R/NN>\$@W8T^VF]1V8H]PM.U ]>9V>/YH
ML9&XPQ9VLS^P5IG\.+,P1$_A6S&V,4-:Y#%$!+*B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B B>[ZKXA,Y]GM*
M?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$ 1$0!7ANZG^E^VX^Q^7_&3,JCRKPW
M=3_2_;<?8_+_ (R9E 2%(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (O'*A*[>'?2Z0VUDR&EMOZ<>XNX%4GK3UZTAAI3 6G!W_
M .6\V!107)ZY=+38G$V9+0'S!;LXZ5O+ \1<3X&DXTLO4<JG$HA]^V:CS2V;
MY(1?O3F]ND8IOU[)LP^MZ]B:=2[\NY506ZBMG.RR26_)35!2LML:6ZA7&4MN
MNVR;)A]=Z_P>E\5<SNH\OCL%AL?%XMW)Y6Y!1HUH^69GEL6#CC8C)V"(.KKE
MD(8XQ(R$7KK=K7TCK1&GY+6'VFP%G7.1B*2%]195Y,/I6.07<.NE&[/F,P(D
MQ/XGJN.J2CX9UK=J,W,*[/:)W/W2WKS YK<_6,F0\$G>AAJ0E%@L.+N;].+Q
M(&%&O*S2F!W#:Q?E#@)KDPB+-UUAMAL%%QXWKEM_E\6=HPY;Z@5XX29O+W%(
M?U.75+./O:^H3G3H^]5:W7TCRE=D3[]8*>V/6G_.MEV?-%]"M7%OC#K65S5:
M1C1TZA[I964ZYY<UV356UM>/O^K*%T^S4H/='+.T9WFV^>ZIV U1KW*U\5._
MLZ<TX[:<P,,?O&%ZN,\*U=%GZG:3+7<C9X,@>?PNF-L%JU(!;@6$?E\N&\_J
M_K^7F_O=2&8S;'3\/3TXJH_'Z*0'D+Y/>YN7/^?]?S7-J>DL3&S,.-H,W#-Y
MU('\F_[P/YJJ&O>-\\NR5N1'-RY]??R+TWU]%O*SE7R6R2V26Q7G5]$U'-L=
MV;GO(MZ_673NODD_12LDFH_LK9)=EZ$:D-9OK/[E]F"HWE[E)?7T[B_Z@QW^
M*5?J_P!K7T&T;AY?HL90-G][M5A;SXX_0BWR?M+4K?%VKUP[DOE;!O\ [B7\
M34LG@JY[[95>_7HX27]4I?U$;,%3ZC?R_E_+Y5]>&I]92#R;3:=FYZL56#GY
M8>N%WX^O&8O[N/VOE^I\.WV?<%)R\!WJC_)X=@9@_;&Q%,;M^M(/ZZ^D/%?3
MY])UY-7S<(2C_P!2QR_ZIJ.H<#Z@DW"=%G?ISRA)_E."C^^:,*8*GUE]B"G[
MO+^7"R7O=G:<>7IY"*3CW!9B*)W^HW7&\C-Q\K]#_6%<)R&U>;I<O+0.0!_Z
MVL06 X^KQ&3RBW_?C!W^1O<LKC<9Z?D]*LNGF?:-DO*F_DHVJ#?^RF1SK.B:
MEC[NW$OY5WG7'S8)?%RJ<TE\Y<IUM!47UHJ3/Y.W+/\ )QS_ "_T+Z45)Q=Q
M(7$A?@A)G8A?ZCL_#L_Z_'"^O!3^LO7;D_Q_C_Q_PR-LS4NZWZ]4_P NZ_%=
MODSN+9GM(;AZ!ECDT;K'/:?&,F(:M2\<F-+VVD=I<5;:SC)P(V8CCFJ212/]
M&!,IJNS[W\&IZ'@4]R-,U=0UF=AES.G/"Q>68.D6\0\78-L9:EY8R<8;.,C)
MR9A&-FX4!4-1?7@J?6_S+:.&O%?7M%E']':GDTUQ:_O><_/Q6EZ?1KO,I6ZZ
M<T(1FEVDC9.$O'7B7AV<7I.L9=%46O[TG/Z1A-)]GB9"LHCNNG-7"$TOLSCW
M+X79W[:NVVZ,(/I+4=:>^\;238.]_P GYVO[+N8R8VP[2R>&XFQRU'LUGZ'.
M.<XW$RRLY6NOQPR030V())(+$$D<T%B$SBG@EB,9(I890<9(I8S%CCDC(3 V
M8A=B9E,3V7.]YW T>57&ZQ_^SC3T;-&4MHFBU/5 680*OE'-H;P@W/7#DH))
MI?98;T/!^);'@#VP<.YPQ^(L7Z%-[1^GX:G;BM]G*[&?/D4)>LJI9*?5N-:1
M=WPM_N@.G9$J\3BS#_1UCY8_I3 5EV$V^CED8CY\G&BN[E3/+3W;<*HK<MCJ
MCGVKMPY-WNT-KG7ED_6-,Z-NEH;0T+\O"X8!RJY')1^;"7K&6?)W(Y.GK=KE
M>&3AZ ,K+^Y?>#:-S.SNNM7Z$S<%K-X_3UFK0Q%V,ZN5H:BS ?!>!'(8V5PG
M>JV6N5GGMUGFIE7ALG%:,89'&KCI#34.&QE/&0$4@5(6 II'ZI;$Y$\EFU,;
M^9SVK!RV)C?S*20G=W6K>V7XK46Z+IVDZ3F59$=84\JW(Q;H6UO"K<J8I3KE
M)/S;/-K:?;RY]IPZ3AXZ>,>!'1L.&D9V-FQU>,[*\K#OKOJ>'!N$Y1MJE*.]
MD^:C;?=.-J?+.OI\?=H)#TYEVC=V(:K2D[<^<<,L<TP\_P#;AC,7^JQ.S^3K
M''$GXN+)OE$1?S_[K_R]RRQS]5K%&Y7?S::K/$[?58XR'C_.L/\ 0IN=*2,G
M\_#XX^N+>;?^?^973_N->K0CPMQCHZ45/%U_$U)]%S.&IZ;7BQW^\U&6D3VW
MZ)R>W=[U1T35?I6%<_O8V738WZ[6Q27^Z?3YF878DVSOZZR6+T=CG(;-[-RU
MBG8>IJ=(A&Y=N$#-]#5K>LSLS\"1B .0L?4UXC1FD,?@,3CL)BJX5<;BJ<%&
ME #-Q'7KQM&'+\-U2$S=4LA>U)(Y2$[D3N]9GT?[%XV35>YDTH"65H8K!M1(
MF;YS2R5J\.0*)G;GKDEQM$)3;Z & /)IC8[1BS.O>#6-PWQWQYJRC!Y7$>M?
MI%32ZU8N3CTYDJOE*S.R,N^UQ?UB='/[U2VN]X#\'UXF+F:M)QGD:M>Y1:ZN
MK&I]Q5?*4\CSK9\KVE'R4UO#H57?T@;$.&K=JLD+<-+AM3T92]KS\&]B+$ M
M[/2W'CV'?D^I^IN!X9W5HA5T?2#<-_R1M=DV%^8L[G:!%P_ C8QU>P+.7/#=
M15GX;CJ?CR?AG937X(9'E\3Z;^W]*K_IX=ZZ_GM^>QO?BG1YF@Z@OA77+^C=
M6_ZEM^!7-U19\#U*T_EZO)7GY?I_ZF2.3Y79O+H_1/Q]7AN5L/='W_6L3B[7
MO]9QU&?GR\_&K12<^R[C^B^1W;ZCNRUW&MH_$QS>7/-<A_7Y%V_T?^2O_P#9
MLU!\*[>:%R;$Q>OZ1T[:ZF<28O&Q-0^IG%F%^>>>19F^HID]J"C>K1[=NUF9
M6W_.CCR7[^67[B'O9JO^IU&IOLZ6E_-G?%_NWBCNM$15$+1&!7>A?2_[I_:Q
M/^^:RI+XG_FL_P#NA_H=7:.]"^E_W3^U>?\ ?-94E\3_ ,V'^L'^AU=/V9O\
M%:A_^(/_ /34%2?:0_Y5IO\ HX_[^9:V[B&P9;,7P<G<(]<9YHQ?C@6.OC3+
MCRY\R=W\_E=33J%'N'?B:R?V\9S]ZXQ37*M/BC_[0ZQ_KUS_ 'O<L7P-_@?3
M?]3I_P"X@OQL3C%&<IOTQQ@4AEP[\  N1/P+.3\,W/#,[O[F9W7[+KS=S*^H
M:4U/>9^EZ>GLU;8NOP^GU?&V9N?$;Z#CHYZ_T/T7R+1Z:^><(+O.48_TFE_:
M;19+EC)_!-_N6YKS=O[1SQSVI.GQ+#S6).AN!\2=RD/I9W=V'J-^EN7X;AN7
M=3Q=P#C/%UQNE>X_.FG--U.?#Y=OA#*96;AI>?88O@SEX^/GO2Q?]3YP.;=#
MTX]W_P#N+?YQ96*?1[L3TR;PY#S_ #1/H>CSUMQ^8H]56..CWB[?"/+ESP7+
M"W#@[OT(\;+?+X6U-+IO'%K2_G9V-%K^CS%(_"6'F<6J7?E=S;_#%N:_ZS7_
M  BR:B(N>1=\JK=_[G/'W VWQ;%RU33.7NR!U<])7,I7AC+I8N6Z@J&W+B+O
MQ[)%P[#CQL+NA'G:1X3)DTN2JUN":7A_A&@XL!2$S^921<^%99^>H2CEYY(V
M'DG?>9WUO?VE2%^H<7H7 1E[_8GN9'-VI!9G;C^@%5/EO?U\>3CYX);(XBQD
MMSM XJK-+7ER>J<+B_$@X:48;]J.G:$6<#9^NM-,#B0$Q"3L[<.[J3O:0]DC
M2_%3P?IT;)56+K>F861K/#.K3BE+3]4VMR%59:D[(Z?J,.3%U"$>9*ORLN-=
MF1AX_+SS\>>'OT[K]^%#E60Y>7C3?:-T8U51C+X5V2CR3[[)\VS<8H^/O3M<
M6F\Y8J +^H6.JUC3?G\ZR$_SAW]SG5+F$O?U"T<COR?#=1O2_EQ_]2FL[:O9
MVN4/A;#682+):?EFNXV9F;\VT"9S8X7X]H+M01D\-N7&S$,)-XL3BH@O5/E^
M3Y/Y.R_FGX,UO+G1?@ZG79CZOI&3;INJ8]JY;:\K&DZY2G'NG/E]Y_9=BL4?
M=2.8/&>F9&D:AD8>17.BRNVR$JK%M*JRN;A;3)>DJK$X^ON\KW>YPLZ//EQ_
MY_6_;_6\_J*Y'W4/:Z/<K;^/#YFT\^K=%A6Q64DE(?'R6-(2'#Y=V<WDD.6"
M$J=V4F8CNU99B\[ \U"WH_6_E_?62G9+[2N7V?UA#K#%4_A/IQ]['Y##E:]3
MCR]*S&,H4Y+/AS-!Q>KTK 3E#-X10]7ADK+>!OBD^&M<IONFUIV7MBZC%<TD
MJ92]S(Y(IMSQ;&K%RQ<W5YU<.MA,'LS>.'_HEQ-BWY%KAI6H.&!JT7)\D<>R
M:\K,:Z^_A6M6[[.7D/(KCMYK+T61R5>G7GMV[$-6K6BDGLV;,H05Z\$0N<LT
M\TA!'%%& D<DAD( +.1.S,[J$SM4=^OM7HD[&)T8%G<?/@TT?BXJ6.KI>E8#
MD!&YG)NJ2V_B>8QX>G?B,(Y!EN5"*$I*P7:X[?&Z^]MF0-;9D<?@!F8ZNBL"
MTU+3]7PI7D@>W <TTN5N0%TN]O)36B&8&DK1U!$(@PP&L$8\"W#<?KOY?7_E
M]967\0/:GLD[,;A^I5QZKZ?D14['^U30]ZX+]65OFMI]:X-'8O7/$R"WAA)/
MX7=);_.&^\-GZ/ZS=>D62B=H7O>-Z=P#L0S:HDTIA)2)@P>D ^"@\(N18;65
M#KS5QW%^F03R$50W;K&G$7'$<-W6DLLLMB3Q;-F8G.:S;F.6:8W_ $<LAD<D
MIO\ *1F[O\O*XF7N7(M,83UN<.1ZAY]S^Y_U_P"7U_?P[1+X:^'7$?B=Q)C:
M+5EW9F7>K,B[)S[[I8N!B4[.[)M4%/RZH<T:ZZZH>_=953!)S6T4ZMKEEJG?
ME62FHIR]^3EM\H[O9)^BBE'Y(]"?6=]VX"08?+W1QAS_ /,;&_[;.R^#;SEV
M5OGEJP7UGE/CCZS,_#-^MQ^LLM<I7JT:#1/##R0<FSQ _P GDWF/\O+]=8AY
M<HRGE>)F&-S]EA\A9N/D^HW/N;ZGN4T>TM[&4O#/ TO/LUW3]5>HY4\18U>#
M+"RX2KI=T[JXRORO/QZ]HUW6.53KLNQUR2\WW=?X9UZ&?YDHXWE1A+:$VXR5
MB3VW^S';?NEU6W7<^+-(1\]1$7_>=W_T\KT#;W^7U/\ 0NV]J]E=7Z[R38C1
MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
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M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
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MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!5W._?[2HU<9I_:O'3\V,J4>IM2"#O\[QM2<XL)4EX\G>YD(;-UXW=RC;&
MUY#C9IH#>P=G,W4QE*YD;\X5:-"K8NW+,KNT5>K5B*>Q/([,[L$40&9<,[\"
M_#/Y*@#VHM^KFYNOM2ZVMM+&&9R$AXZK,3$='#U^*^)HD[$0L=>C'$TW03@]
M@IB#V29F Z"1$0!$1 $1$!W?V;=C[VY&N=-Z*H/($F=R,5>S8B9G.EC8F>QD
M[S<LXL]2A%8F!R9Q>00%V?JX6P#TMIFCA<9C\/C*X5,=BJ57'4*T;<!7ITX0
MKUX1^7B.*,!9WY=^.7=W=W5>3N'NS6,=;4.ZV0KB4EIYM*Z;.0.>BM#+#/G;
ML'5Y,\UF.MCAF%NH6J78!-ADG K'* (B( B(@"(B (B( L"N] ^(/<S[!P_A
M7'K/58%=Z!\0>YGV#A_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN
M,?B4L?;OJ#]Z8=3)( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (O7M6HH(I)YY(X888SEFFE,8XHHHQ<Y)))#=@", 9R,R=A$6<B=
MF9U6=[Q;O?Y;SW]#;1WI*],2DJ9G7-8Q&6Z/'3+4TQ(/)PUW=RCES7L33<.V
M,\.+HNR@9M=X%WL6"VT:[I71)4M1Z\%O!LR.7CX33,AMYED)(28;V3B'Z'$P
MS#X,CB^0EB8?5IJFVX^Y6>U?FKVH=396YF<SD97EM7KLKR2%R[N,,0^4=>K"
MS]%>I7"*O7CXCAB 6X7"Y)",B,R(S,B,S(G(C,W<C,B)W(B,G<B(G<B)W<G=
MW=?P@"(B (B( B(@"(N6:&T'F]3Y6I@].XF_F\O>D:.KCL;6EM6I7=^'+PXA
M?PX8V]N:Q*\=>"-BEGECB C8#B:[>V;V#UGN%DAQ.C-.9+/W',0E]3A9JE1B
MX^>9#(SE%0Q\3,[.\ERS /FS"Y$0B\\'9'[C0Y&KYK=[(] D+2!H[!V7:1O/
MR',YN)VZ7=F]JIB?H6=G?)]77$%A7;?:W3FC\5!A-+83&X#%5F9HJ.+J15(>
M>/.61HA8IYS?VI;$Y23S&[G+(9DY.! UV6NXJQM3U;+;KY@LI8%AD^97 3'7
MQ@'RS^'DLPXC<O WN*"@&/C=V]JS8B)XU/+MQM=IS1^+APNE\)C<#BX/,*6,
MJ1587/AF>67PQ8IYS9F\2Q.4D\G')R$_FN>H@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( OEYO!TLE4
ML4,C3JWZ-N-X;5*[7BMU+,)?116*TX20S1E^B"0"%_E9?41 0I=J'N3= :L>
MSE-"VI="9N3KD:E$'KFEK4I<OP>.+BSC7(N&:3&V1KQ"Y/\ !\I.+C7*[2G8
MGW(VGLF&KM/SQ8QY.BKJ+'OZ_@+G/T'1?A;\R2EP[>JY&.G:Y9W&$HW"0[\2
M^=E\/4R%::G?JUKM.P#Q6*EN"*S6GC+Z*.:"83BE OE Q(7^5D!K@$5KOM:]
MR/I+48V<OMC8AT9FG8Y?@*=IYM+7I'Y)XXF%Y;6"<R^A*F%JC$W$88X Z2CK
M7;Z=G?6>VN8+":TP-S#6^3]6FE#Q,?D8P=N9\9D8NJI?B9G'K>"4I(7(0GCB
M-W!@.E41$ 1$0!$1 %[%2Y-7FBL5YIJ]BO+'/7L5Y9(+%>>(F.*>":(@EAFB
M,1.*6,QDC,6("8F9V]=$!9/[OOODO%*EHW>&W&!DX5L7KLV\.,O98(JVJ %G
M$)"-ND<Y$T<+]8-D88NB;(26.:EN*Q%%/!+'-!-&$L,T1C)%+%(+''+%(#N$
MD<@.Q 8.XD+L0N[.SK6[<*6_N^.]+SVU4U33.JCN:AV^.2*".!R\;)Z5C.3@
M[.'(WZK&/C8_$GPTDG2(@Y8UX)7."R!<B1<*V\W%PFK,-0U#IS)5,OALG"T]
M*_3E:6&4.7$A?CVHYH9!**>"00FKS <,P!(!"W-4 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5%KO-OC[W-^SE
M7\!XE7I51:[S;X^]S?LY5_ >)0&"B(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*
M]TK],7MG_;]7?P>ZN0%WM$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^
MS.DOQDQRIC*YSWT7Q ZD^S.DOQDQRIC( B(@"(B *[3W1_Q!Z*_NQ^&;RI+*
M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
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M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
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MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
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M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
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M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
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MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
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MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
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M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
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MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
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M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
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M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
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M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
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MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
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M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
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MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
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M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
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M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
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M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
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M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
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MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
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M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
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M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
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M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
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M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
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M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
M*JGW\^\/PGK?2FBX)>8-+X:QE;D8OY?".H)8AC:1F\B.&AC8BBY]J,;DWDPR
M\O:IDD$!(B)A$6<B(G81$6;ER=WX9F9O-W?R9O>J ':^W:DUSNAKK5)&1PY/
M4>0&AU/STXFA+\&8<&;GAN,93J.?3[+RN9,W).Z QQ1$0!$1 %[5+'V;<\%2
MG =FY;FBJU*T3,\MFU8D&&M7B9W9GDFF,(@9W9G(F;EEZJD8[J;9IM:;W:6A
MFA\:CIP;6K\@S@Q@,6%> :+FS^3,68N8P&?EG8B8F^AX0%P[LY[05] Z%TKH
M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
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MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
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MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
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M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
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M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
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M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
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M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
M&<W*3_>2;CXM5,%757"J"[0KA&$5^$8I)?N"Z?W[WQT]MMI#/:VU3<&EA-/T
M);MH^1\:<Q;IKT:D9$/CWK]@HZE.!G9Y;$L8<LSN[=O&[,SN_#,WF[OY,S-\
MKO\ (S?*_P C*C-WY7>.?S4M4EMQI.X9Z T3D3];M0&WJ^J=4U@.":\#@_,V
M+PI2V:&.ZW\*S;];R #)%\'V&W;PWX%NU[4:\:*E'&JVMS;E_BJ$^L8M]/-M
M?U=2ZO=N;3A7-K&ZYJ\<.AS>SLE[M4']Z?Q?[,>\GT7:.^\D0S]K'M(Z@W<U
MWJ'<#4KL&2S]MI0HA/)9K8?'0CX6.PU.:4(R.KC:K! $C0P-8E\6T\$)SD#8
MEW_<_P"NN:WOE_7_ /-<)R#LS.[^3-R[O]1ET8Q,6NBJNBF$:ZJ80JJKBMHP
MKA%1A"*^$8I);[OIU;9%&/;*<G*3<I2>\I/NVWNV_P 66G?18-C7GU9NEN7/
M W1C,'CM#8NP\;._B9F]!G\Y$,CMY<1X73Y=,;OU=;^)QTAS=+4.7<0=FV3;
MGLX:.>_ T.<UL=[7>79Q<9 #/3N6"K2,7MC)5TU!AX[$3OP%Y[CBS=;\S&KG
M=XM:ZM0X@U&Z,N:JJ[Z+2T]XNO%2HYH?LV3A.Q?'GW]27M(H\O'J36S<>=_'
M>?O;/YI-+\@B(HX,D$1$ 1$0!$1 $1$ 1$0!$1 $1$ 5-WODNS8^B-U)=0T*
MWAX'7U<LW"<<3!!!GH3\#/4O9;H8Y#>KEF?@'D^$91$2>O+*5R)1R=Z9V:GW
M)VES<-&!IM0Z9XU-@>/HY)<>+EDJ(?5+(8E[E>$7<1]<]4,R8 +D"D4B\,_+
M<_R_O+R@"(B (B("5_N=NTE\PNZ];"W[/A8'7E<=/VADD8((<T,C3:?NOU.P
M-(]AY\5[QZQRCD_6<,(*YBM;K7LRPR1SUY9*]B"2.:"Q"91S03Q&TD,T,@.Q
MQRQ2",D<@.Q 8B0NQ,SJ^]V*.T3%NEMKIK5_6#W[-1J6=C!@%H,]CN*N4#PP
M81B&6P#VH8V%A:M8A<.0(2<#*Q$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 >'5/COH>TL^L=S
MGTE0G\3";?POCG>.5SALZANQPV,Q.PMP#%2;U?$/Y.8V*=QNIQ(6:SOVNM_*
MVV6W6J=93>&5C%XR8<57D^AMYNTWJV'JDW+.\<M^6#QW'D@KC-(S.X<*@CF,
MQ:R%NUD+TYVKUZS/<N69./$L6K,I36)SX9F8I93(W8686=^!9F\D!\Y$1 $1
M$ 1%X=^/-_)F][O\C?50$HO=&]FIMP=V<??NU_&P6A&KZHR77&YP2Y"&QQIZ
MG*_T',N1A*^,1OQ-%B[ N$D33"KIBBZ[H[LV-H#:7%Y"Y6\'/:Y:#5.4<QXG
MCIVH&?!4I>KVP]6QAQSE7+I\"U=MB0#*4KE**@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( L"N] ^(/<S[!P_A7'K/58%=Z!\0>YGV#A_"N/0%&1
M$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)( B(@"(B (
MB( B(@"(B +K#>S7PZ5T?JG4CN(O@M/Y;*1]?'2\U*C// #]3.+^),$8,SL[
M.Y>;<+L]1L][=KU\#L-K0@-AFS#8O3\3?HC^%LG5@L"'FWF-)K,K^?T$9<<O
MPS@4D86)@'K(C/I;J,R<C,N/:(B)W(B)^7(G=W)W=W=W=?HB( B(@"(B LN>
MC][=N%'<G5LL;.UJY@=-TI7'@@?'07<IDQ!_E";X5Q/5PW#'69N>6=FL:*+'
MN;M!MA=BM/62 1EU#D<UG#)FX*0)K\M*NY?7:O1C$>?T#,[>7"E.0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$6_?%[<MJ#8K44XAU3Z:R&
M(U+7?IZ^CU*R].X?#-R/_)F0O!UL[='7R7(,0O2W6PL[0^@/FJT'K'3C1M+)
MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
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MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
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M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
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MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
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MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( JKO?]ZI:;7>@<(Q>>-TE?RA!RW+-F\P=02<6;EN
MI]/FPN3NS]),#,['S:B5-'OJ=4?".^^3K]74.$TSIO#AYL["SQ6\R0#Q[F:7
M,R<L_FQN?R<(")U$1 $1$ 7.-L,$>4U/IO%QL[R9+4.$QX,P]3N=W)U:PLP\
MMU.Y2LS#RW+OPN#K+OL!:3^&][=K:''5TZRQ.4<?JAI^0M02,[</R/AXLNMG
M;AQY9_)W0%]"&(8P&,&Z0 1 !;W,(LS"S?K,W"_5$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!46N\V^/O<W[.5?P'B5>E5%KO-OC[W-^SE7\!XE 8*(B(
M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
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M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
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M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
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MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
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M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
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M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
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M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
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MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
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MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
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M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
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MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
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MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
MNIF<@]KB/S7'?'[DY1S;!8K3VFJ[];"9039FZ(<^R_BVSAJ>*+>]WI&#OY]#
M*&W$X_W>7\OY<+[>0M#$'2/U//\ 7XY_E]56 T?P4X=P(IRPWFV+O9FS=V_X
MU+DQ]OA]3\FWL5CXF\<.(<V;KIS/H=<ON84%2XKY7/GR$^W:U=>R2Z&3^ONW
MWO!EB(K6XFHXN>6Z,9/7P<?3P3=/AX2OC@<>"=G8A=RX;J<G9G6(NI]]=872
M(K>K-36'Y=^9L]E#=WXXY\[?GY<M^MY+AF8R/OX?]?S_ )>Y=;Y&YSS\JSEN
MG8-"Y:,/$HBNBC3CTU))?*$(K;^HU[#SLZ_:61FYE\GUYK\F^Z3?S=DY-_FS
M[-[<+..__/>8^K_SI?\ _4+Y@;AZ@C+KCS^<C-N68X\QD0)F=N'X(+(OYL[L
M_N\G=GY;R7%9#Y=UZ<AK'/'A)]80Z_LQ?]ALE$YK[\^G[4O_ #.W,5VAM?X]
MP*CKC5]0@Z>AZ^I,Q'T=!,8<<7/+I+@F?WL_FNU,'W@6]^+=O4]U-:\#PPC<
MS4^3C%FXX9HLHUV)F9F;V>CCWL[<._.(AEY+U#)?2S1L2SI9BXUG^DHJFOSY
MHLS>-J.57]C)R(?S+K8?]V2)!=1=ZAOCFM/YG2^HM75]183/8RYB,E4RNG--
MB<M"]7*M/&-G%XO&6@D:,B*.P\Q3A*_6TCN(],7UK1]<_H9)0^LSB_#?MC\G
MU%S$B^5>J1>_ZJ]NEZ7C8:FL3'IQHSDI3C15"F,YI;<SC7&,7+;IOMN9.>K9
M=KB[LF^YP6T976SME&.^^RE8Y/;UVWV.L+NW[NS^';X^L<7/]]Q-N/\ Y77$
MK>W-UW=AFKDWU>HV?]MNCR_ONN\#->E(:V&J^?Q3_%+^S;<R.-JE\?O)_C&/
M]B1GGW3';LN=G'/:LDS&-N:CTMJK&4PGQ.+M5X+-;/8RTST,I&5[PZXPEC[.
M2IW1$ADG=\>7)#485,)JCTCJ)HR;#[4GXGET29/5T3CSY<]5:GA'?R^JUKW>
M?#>Y5>9#_E]1>C(?_P!2T[6?#31=2RYYN9AJW(L5:G)79%<9>7!0BW"JV$7+
MDBH[M=5%;FUX?&^I55*FJY0@M]DJZY-<S;>SG&3[O=$NW:I[WG.;KX\\;G-M
MMM/5G$PKV;V+R&8R^/ZV<?'QF7]=Q]S'6F%^&FJD#>]B @=Q>*LM5FW/$LS#
M_2QN0BS?(WF3/TLS<-R1/\KN[^:X?(:]&0__ '6UZ)PYB8%/T?#K>/3OOY4+
M+''?U:YY2>[]>N[]3#ZC.>=/S<N7G6=N:48)[?#W8+MZ'V;V>\1W=@=W?Y3+
MDO\ -S_K.N,6;3E[^&20U\BU/PW"V*G#K77E73X]?Z]S]<;#A';:/[^O]9ZE
MN=FY7%;ECW^:]RY9]_G_ "_E_)UQ2Y9]_G_+^7O^M^VO:EMVZ&P8U/;I_P ?
M\?\ '0].W8]_[?\ H7$[UIF9W=V9O=Y^7'U/_)OKK.3LE=WUNUOG=&';_2\]
MK%#-X5W564/X+TKCN)'BD*?+3 7K<L)B8G2Q$&2R'4!MZHS!(07*.[W[B/;+
M9R:GJ?4Y!N+K^OT3093*50#3^!L, LY8#!GXD?K(EU=.4R<ER\ NWJC46*49
M8WXV\5-*T.,H76K(S$GRX6/*,KN;T\Z76./'MN[/?<>M==FVQN>D:%=?LXQY
M*_\ *234=OV?UW^'3?HW$K\]V+W"&K-U2QNM=U8\AHO;J5J]VEB"&2GJS5U<
MW:0&B@D 9<!A[$3,[Y"R(Y&S#+&6.K!&;7H[R>U&TNF="Z?QNE='X3'Z=T]B
M(!K8[$XNN->I6B'S?@1Y*260G>2>Q,4EBQ*133RR2F1OV'PO*I)QSXBZCK]_
M/E3Y,>$FZ,.IM44KLGL^MENW25L]Y/JHJ$-H*2L#3:\>.T%O)_:F_M/_ ,E\
M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
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M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
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M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
MW.67 6S)G-H1!GDQ%B4S*Q6&2O*96*IR319K8D[N;3X'7.G,MI74M&/(8;,U
MGK6ZY\,3<$,D%FO)P[P6ZE@(K52P'MP688I0]H&5&OMG]D?.[-ZSMZ;RC26L
M78>6WIK-O&X0YG$];,$GER 7ZG6%?)5A)_ GZ3'FO/ 9@8E(B( B(@"(B Y3
MH?6V5TUF,9J#!79L=F,/<BOXV] 73+6LPN_23?(0&+G#/$3/'/!)+!*)12&+
MW>.P'VVL3O1I".^)04]5X@(*NJ\*#NWJMPQ)HK]02?JDQ>2\.26J?M/#(,U2
M5WEKN1T7EW]V9^T?J+:K5^.U?IN;\T5'\"_CY)) IYK%R&!V\5>8/HH)VC H
MSX(JMF."W$+R0CR!L$D71W9T[0>G=S])8S5^F;+3T;X.%BN1"]O%Y")A]<Q>
M0C%^8;E0R9B$F9I83AM0]5>Q#(?>* (B( B(@"(B (B(")[OJOB$SGV>TI^'
M*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1 %>&[J?Z7[;C['Y?\9,RJ/*O#=U/
M]+]MQ]C\O^,F90$A2(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M*JW>Z99I-Z)X7D<O5M*:?KN+L_$?5)DK70/+-[/YI:7D>6ZI';GJ8F:*O,X]
MG9W9N6?E_+^7\G4D7>]D4&^.1ZN&:?3>FY@X?]!X-F#S;Y':2"3R^IP_RJ/6
MM(,T?2_OX\OU_P"7"Z0^'=,9</:0E_\ 9^,_S=46_P".YS4\3U*OB'5K.NSU
M#);[]O-EM_ Z0RU#AW\OJ_R_66/^-J-;U"$3LW!7#'W/PS0B;O\ M-X;N[^7
MU5EWF<:_+^2QAVJTGF-1:JQF(T_0L93-9?(24\;1JAUSV;-H9@%AX\@ !(II
MYCXB@@CEFF((HS)L]BUQIG;98XPA".\Y2:C&,%[TI2;Z))1W;;226[-BX*E.
M^C.\K>5OT5UU)+=NRV-B@DEU;<HI)+K\%N9(Z)T+G-69O&:.T=C9LMG<M.->
MI5@X9G?WR6+,Q<1U:54.9K5J8@A@B$I#+W,]S3L%]A/ [):9>E 464U7E6"?
M4^I'CXDN3LS.%"@QBTE;#47;IJ5_(II/$N66>>8A#A?=T]WWB=EL ]N]ZMD]
M?YRL#:BS@#U!6A(QG;!8@S;KBQE:08GL2-T%D[<(VYQ$8ZD%:254Z\8O%J6L
M6RT_ FX:73/WIK>+SK(/I.79_1X-;TUO[3VMFN95QKM%X4>%U>C4K*RHJS4;
MH[R<MI?1U)=8Q?\ E6GM9)=E]7#W>9S\LB+!KMY]N' ;(:1/,76BR.H\GXM3
M2NG&D<9LKD!'EY['0_B08G'L039*W[+,+QU83>W:K@4*Z5I>1FY%.)BU2NOO
MFJZZXKK*3^/I&,5O*<I-1A%.4FHILEW-S:L>JR^Z:KJJBY3G+LDOXMOLDMVV
MTDFVD=-=YKWB%'9?3S8K"E6O[CZ@JF^ QLHO-#BJA&\$NH<K&! [5:Y#(%"L
M1@>1NQO$/%>"W+%3RJ-;RES(Y[.W9KV4R=NQE,CD;LAR6;UZU(<UN:4F!V*>
MS*;&Y/T +"PCT@PBWT]4ZOU!KC464UAJ[(2Y/-Y>R5N]<F]D1;W0U:T7+A6I
M5(V&O3K1\1P0@(-U%U$7=?9K[-^H]Y-85-&:7!X*L;!9SV:.-SIX'$-(P37;
M'#BTEB7VHJ%-B$[EEV!NF$)Y8K^\"<%8/"FEVW9-E:N\OSL_,ETC[BW\NMM<
MRIKWVKCMSVS?,X\TXPC2GCSC+,XFU&&GX$9NKG\NJN/HI/9SEL^7S)KJVWRU
MQ2Z[)R?9_8B[%^;WUU8-")YL=HG#R!)JK/0N G!%Y%'B,=U,;%E\BSOX/5&\
M52LTUV;GH@@LW5]O-OL-I3"8S3FGL?!B\+AZD5''4*S.T5>O"/2+<DY222&_
M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
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M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
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M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
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M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
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MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
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MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
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MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
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MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"C0[U[LT?S1MILH=*#Q<
M_H^0M585P9O$E:E7FCRU#GWE'<Q<E@ABY82NUJ4K\O"(O)>OY(6=G9V9V=G9
MV?S9V?R=G9_)V?W.@-;@)<LSM[G;EOUG]R\K-7O!^S9_,LW3U!IRM \.%N&.
M?TVS1N$383*RS%#7@_0E%CK45O%CTN_#4VYX=85( B(@"(B ^AB,O9Q]RID*
M4I5[M"W6O4[ .['!;ISQV:LX.SLXG#/%'(),[.)"SL[.W*OY=DG?VIN=MWI?
M6E5P:3+8]AR, \,]3,4I#HY>J0-] T.0KV&BY9F.!X90YCD GU_JL&=Q)VEF
MQ^<SVUN1GZ*N<BEU'IWQ)'86RU*.*++4(@?R\6[CABO PLWLXNTY.1$#,!:$
M1$0!$1 =&]I3>ZCMQH;4NM,AT%%@\9-8@A-W9K>0DX@QM+R<2=[EZ6O7]A^I
MFD=Q\V6OZU'J.]F,C?R^4L';R>5NVLCD+1\==F[=G.S:F)FX9O$FD,ND6819
MV$6869FL,=_%VDQGLZ=VJQUEG"F46J=2A%(S_F@X9ZV"H6&'S;H@FM9(Z\C\
M.\F-LE'R->15SD 1$0!$1 %X=^/-_)F][_47E9;]AKLZ3;I;GZ8TJ\9%BWNQ
MY34<@MRT>G\7)'9R,;E[@DO@(XRN;]7ASW8Y7CE&(@<"T%W0'9K+0>T]'*Y&
ML\&?US*VHKXF/$M?&FQ18"F?/M"[8WP[\L9"!0V<A- ;.\/4\JZ]>I4B@BC@
MAC"*&&,(HHHQ8(XHHQ8(XXP%F$  !81$69A%F9FX9>P@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"P*[T#X@]S/L'#^%<>L]5@5WH'Q![F?8.'\*X] 49$1$ 1$0!$1 6_NXQ^)
M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B("LQWPW=X-1.]N]HJD(4CZK&NL17%V:O,1LSZGIQ +L,$G5QFXQX&(V'),
MS 5TQKK+9#VZD5B*6">,)H)XSAFAE!I(Y8I!<)(Y )G$P,'(3$F<2%W9V=GX
M5-OO1N[[FVFU 6I--U9I-O=0VS>FXLQCIK)S]4IX*<Q9B:D;M))A9I!Y>L+T
M999K-;QK $3B(B (B( B(@/Z W%V(7<2%V(2%W$A)GY$A)N'$A=F<79^6=F?
MGE6W>Z6[P[^:#BHMO=872DUQ@J3ECLE9*-BU1AJWLB9$W3XF9QD/1'>9P\2[
M5&/(]4T[7RCJ0+D.DM69+ Y3'YK#79\=EL5;AO8Z_6/HGJVZYL<4T9>Y^';@
M@)BCDC<HI!*,R%P-C>BC^[O;MR8S>G23697@I:PPHPUM48>-^EFE<>(LM0 G
M<CQ>1=B*/AR*I8&6G,_(1232 H")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4
M_#E54T$ 1$0!$1 %>&[J?Z7[;C['Y?\ &3,JCRKPW=3_ $OVW'V/R_XR9E 2
M%(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(#\+5:.>.2&:,
M)890.*6*4!DCEBD%QDCDC)G$P,7<2$F<2%W9V=G=E1:[V#N]K&R>LWS>GJ9?
MS-]66YIL$4;G)'I[)'USVM,V"+DHH8VZIL*<AFTU%BK]93TY>J]8NI=\=D].
M;BZ6S&C=5T!R.#S=4JUJ+R":$^6.O=IS=)%6OTIQCLT[(-U0SQ@?!"Q"4B^&
MG']V@9ZN]ZS#OY:\VA/[=:;Y;()M+SJ6W*MO;=.=;<58Y+7.)^'H:CCNM[1M
MAO*FQ_=EZQ?KR3V2EMVZ26[BD:YK2]]I0>)W\Q]L?KB_'+?M.[?WW4[/<J=J
MCYD->3Z#RMAX\%KMQ&D4CBT-/5-2)_4B?GZ <K5C/'$XN[E<#&@X]#E)'%[V
MU.Q;JC8/6IX3+-+>P-TY;&E=1M&PU\UC1)NJ*?H$8X,O3$ABR5-F%F-PM0"]
M6>-QZEQ.1.,Z]NG-)#+#)%9K6(3<)H)XC&2&:(QX*.:&4!.,Q\P,6)GY9E=S
M7=/PN(-)LA7;"W$U"CFIOC[W)/[55B71J=5J3E"7+)2C*N:3YD5YP[\C2LV$
MG&4+<:SWX/IS0[3A\.6<&TFMULU*/HS9 LHH.]8[?#;0Z2#":>G%]PM6PS5\
M*(/&98+'<%'<U)9 ^6^<.SU<7&XEX^1D&3I>"G:<>+[#]ZWI:QLA?UYJVY$V
MI]'5*^+S^%@<8KN:STT)QX9\9"3\.&I9(2,)!=Z]*4,AXQ1P4I#&J[N;NAGM
MS-8YO7>JIFDRN;L-.8 1O5Q].$&AHXNB,CN\5+'U@""$&X>0FDLR,5BQ,95C
M\*_![(RM5O>J4.&)I=_);"47RY>1':4*H[[<U'(XWSGU4ZY5P2:M;C(OB1XG
M4:?IL9XMJED9E7-4TUS4UO=2FUZ6<R=<8]'&:D^\-GP33N+\()+MLSEED,YI
M99I"DFL3RN\DLLLDCN<LLLA%)+(;N9D1$3N3NI:>ZF[#9;JZI?7&J:7B:!TG
M>C>M7G8FAU+J*N8S0TF!F89L7B7$+&58R\&Q,=7'N$\,EX8,*>S%V;<WO+KC
M&Z*P;35L>SM;U%F@ "AP.#B+\TW3>3F,[=AV:EC:_1(4]Z>)Y(_5(K4\%Y#:
MC:[":*TYAM*:=IC0PN"HPT*%87ZG:*)N2EFD?VIK5F5SLV[!\R6+,LL\CO)(
M3O+WCCXE+2\7]%X5FV?E5_63@]I8F-+>+ENNL;KNL*ET<*^:WW6ZFXA\&/#^
M>I9+UK4(-T5S^HKL6ZML6S2V?>NM[2GZ2GRPZI32[ $6;W>3,W#,WDS-]1OK
M-\C+^D14<+A!$6,W:\[36'VBT#G-;Y=VE^#X0KXK'\\2Y?-W"\#%XR$6X)_'
ML$)V9!\JM&*U<D<8:\ACZL'"MR;JL>B$K+K[(555Q6\IV6248Q7XMI?!>I^.
M3DPIKG;9)0KKC*<Y/HHQBMY-_@D0W]^1VTCQ^/K;,:;L\9'/5PO:WL0FW53P
M)D/J.#Y9^?&S9B<]T2Z?#QE>.)QD')<PUS:,,>,I/*3,)./ \_(WN=_\W#/_
M .7G[60U+EM6ZAS6K]1V2N9C/Y*WF,G:-WX>S;E*5XX1?GPJU8.BK3KC[%:I
M#!7B$8H@$<X^[R[)$F].Y$%3(5I"T1I=HLKJF?CB"R(2-\':>$G^BFR\PD\X
M,W 8RM>,B&0JXR]#N&M'PN$= ;OE%+'JEDYMR6SNR))<W(GLY-RY,?'B]FTJ
MT_>;;HUQ9JF5Q7KL,/'3=;LC7"/>,*HOHI-;[+;FMM?HN;[NR)GNY:[&1Z7T
MU+NCJ.JPZDUI6!L!%*#^+B=(GX<T$G!M\[M9Z46O2$/NQH8Z-B$CL"4Y[-PO
MRKP1Q1A%$ 1Q1@,<<<8L$<<8,P@  +,(  LPB(LS"S,S,S,OV5">+.)<C5]0
MR,_(?OWSWC#?>-54?=JIA^S7!*.^R<GO.7O2;=T>'M"ITW#HPZ%M73!1WVV<
MYOK.R7SG+=_);171(*LAWZ_:Y.W:QFR^ M?.HWK9S71PESR3O'-I_!F[-Y#Y
M%E[T?//+8L?)GE%YWNUMVD,3M-H#4.N,LXF.*K#'CJ3N_B93,W#&KB<9"(?/
M"*U=DB:4AX:O5&Q;E..O7FECH>-GLGJ/-YC5>?L%=R^=R-S,9:U*[OX]N_,=
MB9A;GD(0(VBK1"XC7@CBAB8(X@$9I]GS@7Z;FRU;(AOC8$N7'4E[MN8X[IK?
MH_HT)*SY6SIDG[K1%OC5QK'3L!XM<]K\J+YN5^]&G?;;X[VR3@OC%37JC\#,
M,;0^I(8^7'O8?J<?5?ZRYWJ3MYZ T)M1DMJ=-8J'5FK]PKF*R6XFM)#Z</IJ
MG4O06,9IC39QRA8RF2QE> Y,E=Z8<5#=RER*.QEQ!ZE'!_M0;J_!]%ZE>3BW
M><H(F%^"BKL+M/-];AG&*/W.YR,3>0DHX8KGEQ\GN_:^I_>5P-8TBK-5,+G/
MRJ;H9"KA-PC9;3)3H=CCM*4*[$K57NHRLA!S4HQY7%'A/PM*./D9^1%.W,A9
M5!R2;C59%PM<=_UHMU)[;J/F;?:)779G;EO<[<L_'O9_<[?M+\G!<,VIU!\*
M8#'6'+JEC@:K._R^-5XA)W^O((A([MY<GY-PNP2C^LM0G%PE*+[Q;37X/8U/
M*A*FVRF?254Y5R_&$G%_U;KXH^8\?\O?_H70F\%5XY*MIO<XO";_ +;D'_Y7
MG]5V;Y5D2\:XSGM-XW)2XVMF;=C'8B7*4(,MD:E<;5O'8N>U"%^_5JFXA9LT
MZWB3UZY$(SR ,3DS$[M[,"[:Q;[M-271-M]'LE%;MMO9))-OLC+:!E*&55N]
MHR;@]WLMI+;O^.WR.C=H.9LE(3,[M%"W4[-RP^*;,/5Q]#U>&7#/QU=+\>Y9
MZW'\/$\_5%W_ &A'_0W*EZ[U?LY: V<T#L[M_MU0CK8BSDLYJ&SD#DCN9'45
MF'%XZBV:RV2CAC"_:GAN@X21^%7BB)HZ56&NP@$0>IS8,4(Q@W649\,3N0]3
MLS"PB[-PSO[/MO([B_OY;J61X+XBAJN!#.IJG53=9?&I6-<\H573I4Y)=(N;
MK;Y=Y<N^W,WN8SQ9PW3JN-BN2E*#I<N7MO*M6;+X[;KKTW[[(O,=WEIWX*V.
MVKI.'08Z)P=B8.''BQ>J!>LOPXB_M3V)'Y(6)^>2Y=W=9E+J;8; AB]$:/QL
M;=(4M,8&LP\>[P<96!V][_*S_*_'U77;*YM:WD^=FYEW^5RLBW_I+9R_M+OZ
M;1Y6/CU?Y.FJ']"$8_V&$O>0Y3U/8C=2?EF_^P[*P>9.'YZC&K]$WROXW#-[
MB=V%_)U1RT@/30E?CW1?^2ND][;E_5.SWN-YN+VL=1HMP+%R]K+4(^E^?<Q-
MRSDW+BWFS<JEY@&Z<;*_/Z%F5P?9FJVTK/G^MJ#CO_,QZ'_XBK'M(V[W8->_
M^+@]OQOE_P"1:;[@_%^!M/JBSQY7]Q,K89^IGZO!P6G:7+"WF#,]7IZ7][LY
MMY$RG&4/_<>8UH=B:<[,S%>U7JJP7 =+OX>1]3%R?]'R-5G$OD'I!O(5, JS
M>*-WF<0ZP_AG7U_]%+RO_ 6(X$JY-&TR/QPZ9?TX*?\ X@H3._J^)?&_;U@/
MWME%-FH3._J^)?&_;U@/WME%\^%W_M#H_P#KM7];/OQO_@C4?]5M_P"Z54S_
M .:/VW_T.KO_ ':_Q#[6_:G1_P!:54@#_P":/VW_ -#J[_W:_P 0^UOVIT?]
M:564]IG_  7IW^O?_+W%<_9R_P"6ZI_,?^^@9P(B*EQ;4K:>D.X-BK[/Y7I\
MZF1UGC6+YYY-DZVF[;CY/X7M? S/[;/)['SK@/&YKOZL!I,0S?5BD;S^N+_^
M?]Y6>O2"L/XNVVAKS-[5'<& 2+V_*&WIW.QD/#>SYS!7?J+CCIZ1?DG9ZQV2
M;Q,2S_)P[?\ XO\ +_2N@'@'D\_#.)'_ "-N97^&^5;;M_VN_P"92GQVIY-?
MJLV^V\>3^?U"K_\ !M^1L!.S[F'R.@M$9!_-[VD--7'?I<>7LX6E,[]+N3C]
M'[G=W;W.[\<KMY8D]@O,_"&R^U]KW]6BL!%[G'\[48JWN=R?_J?J^?O;AGX;
M+942UJCRLS+J_P GDWP_H6SC_87*T^WGQZ)_KTU2_I0B_P"TB-[[S13Y7L_Y
MVZ$?B2Z;S^E<Y&+,[D(EF:^#LR!PSLWA4LU9ED=W%FA"5^>>!*HSB;!OCW,'
M]J/I)N?/Y..';SY9_E;^]P[*]-V[M#/J39K<S"B'B27-&YQX1;CEK%6G)<KF
M/5Y=44]>.0>?<0,J(NB9VFHF+>XHF)OK^SS_ */\RN)[-6<K-(S<:75T9\I[
M?"N^BGE7X<]5K7S;*K>T7B.O*P<N.\7Y<$I+H^:JZ6[W77?ELC^XYQJ/L^Z@
MN:+Q^XU7&N6"OY*]AI;M<GE@@RM"3H.E?9A;U*S8C**>D<O$%P)&B"9[ G&.
M*YDXN[.SBXN[.SMP[.S\.SL_FSL[.SL_#L_D[,[*V9W$MZCG=N]Q]&9:M6R%
M"MJ<)9\;<B"Q6GHYO%0";2PR=0$$LU&879P9N08F?J;V</.]$[I2'1.-RVY&
MA;0-I>@(6<UB<E<ACL8:*6:.!I:UNR<;7: 32Q11!(9Y&!I& RN0@TL/OJ\0
ML>&MYFB9J6/?7E>7B6_XK(A:HV45R;_D[N6R$8MMPM?9PFU"7M?!=MNF8FJ8
MF]T+<>,\BM)>97..\;9QV^W7S1DVDN:"[J23:KX/)_+W+\GD^NOQFZ@)P-G$
MQ?@A=N';_P!OJ/Y\MYL[LO6*5E)4:O\ AFH*D]HS9V=G9G9_)V?S9V]W#_5Y
M;ZJ[/[%^.T7IK>O;G5NL;,E'2> U/3S64>.I-=&"S0:2SB;#PP=4X5J^9"C:
ML'$$SPQPD;1=(OQU 4J_)Y/VTR,3SJ;J'*<(WTV4SE6U&<8VPE!RKDU)1G%2
M;A+EERRV>S[&7TO.LQ;86U[/EE&3A/K"?*TTI+INOPV:WZ,V7]>YIK76FB.O
M/C=2:6U+C9H?&JSQ7L9E<;=B.O.(30$4<L<@%)$?03'&;$+]$@.PT8.U=V<<
MALON5F]%VW.7%>,63TQ=+E_7]-79IGQI2$3-UVZ8 6.R#BW2]VK,8,T4D3+H
M7LI]M_<?93(G>T)F!CH6K#6<IIC*!)=TWEI.D8RFLX\)ZQPVBB$8WO4+-.XX
MQQ"<YQQ #2N=JCMU[7]IO;VKZ_#\P.\>BX;.3P6/R<\98?4<9Q1%G--XK4!Q
MPP22Y$*T<^(H90<;;L92M2K5&L26)HRAC@CA'4^%-4?(Y9^B9SC7?;5%^;B3
M3?D9%^.FW&,')PNNK<ZE3*5MC@X1@M\XUOPN)-+E!Q5&?CQE.J$VMK%_C*ZY
M[+FYDE*$6E+G2C'?=LP#V-WRRVT^N\#N#@A.8\;*X9&A&0A\+82UT#E<3(1>
MPWK,0,4)&[!#=@JV.6* 7:^/MWN!BM58+$:DP=H+N'SF/K9/'6@\FEJVXAEC
M<A\WCD%BZ)8B]J*43C/@A=EKT-.WH\A3\$G9W<>H'?ZOU/V_D]RGV[CKM=_!
MEZ]LMJ"TPQ7);F:T+).3-Q98"LYO3\9$_FT@129JC#Y$Q#EN'(7C"/(>T%P'
M]-PHZOC0WR<"#60HK=VX>^[D]O7&DW9_HIVMO:$4:9X$<9RQ<FS1,N349R_O
M=S>R5O5)+?\ RT4H>OUD8)+>399M7R\WAZN0IVJ%ZO%;I7:\U2W5G 9(+-:Q
M&44\$T9<B<<L9$!B[.SB3L[+ZB*D\9----II[IKHTUV:?HT6V:WZ/L41NW#V
M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
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M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
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MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
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M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N] ^(/<S[!P_A7'H
M"C(B(@"(B (B("W]W&/Q*6/MWU!^],.IDE#;W&/Q*6/MWU!^],.IDD 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %C+VINR7H[=[3Q
M8'5='JDA:63$YFJT<>7PEN0.E[./LF!\"7 >L5)1DJ6Q &GB)XXBCR:1 4/.
MV-V&=:;,9AZF<K%D,!:D<<-JNE ;8O(B[ETP3><CX[)B(\RX^S(Y.WSRK+:@
M^>MADMB[N!MY@]5XB]@-1XNGF<-D87@NX^]",U>>-_-N1?V@D N#BFB()H9!
M&2*0)!$FJG=O?NA\]H)[^J]O8[6I-%QC/;N8L6.SG]-P [R'R L4F7Q<$7)>
MN1,]VM%&;W(9  K9@0IHO#.S\.WFS^[CY5Y0!$1 $1$ 1$0';6S.^^K]O<N&
M<T;GK^"R#,PRO4E?U6[$SL_J^1I'UU,A7=V9_"MPRB!,,D?1*(F-B[LH=^7A
M,HU?$;KXT-/7OG<0ZGP\5BUA;1<,+RY#&L,U[%&[MS(=8\A5)W<V:H'$0U=T
M0&QFT7KG#:CQU;+X#*X[-8NY&,E7(8NY!>IS@3<L\=BL<D9?4<>KJ%^1)F)G
M9N5+7O[(]I+76W%_X1T5J;)8*4C$K%>O($V-NL+L[A>Q=L)\?;$N.ERFK%*#
M/U121FPF-@'LS]^YBK;U\9NG@),3.7$;ZETY&=O%N72+-)?Q$DA9"F!$Q<R4
M9,DPD0,\$43'*P%A]%UKM;O'I;6V-#+Z3S^+U!CR8'*?&6XK'@E(SD$=J("\
M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"J?=[CW=CZ+OV=S=%T6'2&4LB6H\;6 1#3>6MS= W((8Q%H
M\+DYY #I$>FAD)/#Y:O:@""V"OB:ETUC\SC[N)RM.MD<9DJL]*_1N1!/5MU+
M,913UYXI&()(I8R(#$F=G9T!KBD4B_>-]A&_LQJISI#8MZ'U!8LS::R1 1>I
M$S^-+I_(3-U"UVB!OZI+(X%DJ,;V8P>6"Z$$=" (B( B(@"(B (B( B(@"O#
M=U/]+]MQ]C\O^,F95'E7ANZG^E^VX^Q^7_&3,H"0I$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %XX7E$!Q/6&@\)J&J]'/8
MC&YFF_5^9LG1K7H6<FZ2(0L1R"!N/DQ@PDWR/Y,L"]P^Z=V0U YR#I>; 63Y
MXL:<R=W&L#EYNXT3DLXMWY\VZZ!\>YO)W9Y($67TSB#.PGOB9F3C>K5-UE<7
M_.C&2C+YJ2:9C\W2<7)6V1CTW?.RN$VOP;3:_)H@NU'W%.BY2+X(UQJFD+_0
MAD*N'RCM_P!XJ];$\_K]#?K?5ZMM]Q ?)^K[CMT\>QXVGO:YX_1]&2XXZOZ7
MSX^NK$:+<J/%WB*M;+49R7[=&--_OE2W^]FOV< Z1+OAQ6_ZMET?X*Q)?DBN
MI3[B*SP'C[C0\\MXG@Z?)VZ6+SZ.O)<N_3[NKRZOK+LG!=Q-ID'%\GK_ #]D
M?T04<7C:+\<OY#).>0X\N/-XWX?E^'\E/#PO*^UWB_Q%-;?I&4?YF/BQ?[U1
MO^YGUK\/](CVQ$_YUM\OX.S8BLT/W..R^)(3NT]1:DD!^IGS>=ECCYX;R>#!
MP8:"0&X?@)HY6?GVNK@>G.#;?LR[?:0\,M-:.T]B)8G9X[-7&5O7!)F^C:Y(
M$EKK?WD?B]1/YD[OYKO-%JNI\6:GF;K*S\NZ+^Y.^QU_E6I*M?E$SF%H.%C[
M.C%HK:^]&J'/^<]N=_FSQPO*(M>,L$1$ 7CA>40$'7>Y=DX[U%MTL!6<K>)K
MC7U;6B%G>QBHW9JV98&9G>7&<E#>)NIRH%%,[ %&0CKP-8AEX9V\W]W\O_+A
M7V;]""U!-6LPQV*]B*2"Q!, R1303 \<L4L9LXG'(!$!@3.)"[B[.SNJ?'>,
M=CBWM%JHKN,ADDT-J.S-+@; @7AXJR[/-/IZU)YB,E=FDDQI$XO:QP/TL<M.
MV36_\ _$2-]4=#S9KSJ8R>GSF_Y6E;REC-OO.E;RJ7K3O!)>4N:GWCWX7<MT
MM<PH;5W-+/A!;>7<_=CD[+[ESVC;\+MIO=VR<<(Y\2!M[+M_XLNN];:";(4Y
M(F9AGCYDKG\@RLWDSOQY ?F!/\C.Q-R[<+D-;-_7_P ZY!!F&+R?AV_O_P"G
M]966EB1?5=&5HQKLK$LA;7)\U<E*+^:_@T^S7JMT>UW<W;FRNP^N?6K36K&D
M<N84-8X0&>23P8SZ8LO1AZF;X5Q1.1 (OQ=J%8I%R4E>6&^#HW66+U#BL?G,
M)>KY/$9:I!?QV0J'XE>W4L TD,T1>3\$)-R),)@3.$@B8D+:\G=O1(61?+T@
M^?@S-=B!O.6,6X:P+-[SB%F&1N.2CX+SZ/:DD[I?O,I-K,G%H76ER67;S-77
M*M?L3F8Z,R%CABM@)L?3@;DK,61KPO''2L2290 )Y+S2U]\:O"UZC7+4\"O?
M/IA]?3!=<RF"Z.*^]D517NKK*VM>6MYQJB[H>%7B-5=3"NU\M4Y<LDWN\7(?
MVHM_Y&Q^]&79;J;VWGRY=^D*93KSNTM#G^@T=6W.GK=^/6;&!AY\/]#SZIQU
MMYEQT_H&4!NMXI#Q30PMU2RPF$8\B/5)(SA&W).(MR3LW)$PMSR[LWFTU7?V
M:@KW]PMM6J6(;-9]%V[T$\!#-!-%?R_,$T-B-RCFAFAA$XSC(@('8Q=V-1"U
ML>US*Z;H.PNUS-86HXD'B"36LG6A=BC]YL[2>8>\VY'WOPM]\&UY'"VG2:VY
M:LBQI[^N5D3>_J1/XO-W<41K3WWMICT_U>J/\-S81Z9H!4QV/JQ]7AUJ-2N'
M6[$;A#!'&/43,S.72+<NS,SOY\-[E]Q?C7#I !]W2 CQQQ[A9O=\G\OJ+]ES
MQG+=MOU;?[V7?BMDE\%L%"9W]7Q+XW[>L!^]LHILU"9W]7Q+XW[>L!^]LHM[
M\+O_ &AT?_7:OZV:OQO_ ((U'_5;?^Z54S_YH_;?_0ZN_P#=K_$/M;]J='_6
ME5( _P#FC]M_]#J[_P!VO\0^UOVIT?\ 6E5E/:9_P7IW^O?_ "]Q7/V<O^6Z
MI_,?^^@9P(B*EQ;4ZSWIP+Y71NK<6P];Y+3.>H,# ,CD]S%6J_2T9<#)U>)Q
MT$["7/2_DZUZ>VD_B40?W]=9G_O@SM^O^WY_Z%L9\Q#XE2U'_3UIP]SO]%$0
M^YO-_?[F\UKI](8YJ5FY0XX:E9MT^GI<>EJL\D'3TE[0\='#"3N0\</Y\JV_
MLOW^[K-7PE@S2_&.7&7]42LGM)T;XF#9\/I"?Y>1*/\ XBQ!Z/OE6$]V<>[^
M93Z2N@'4_DPQYV"0F#CCVN8F(^6?V1'A^&Z;)*JX=P;E?#UUN51<N&GTYA;0
M@\C-UE7R=J)W&/Z(W ;#<F+^PQ,SM[;*T>HD\<Z.3B?4/VXXD_WX="_\)*?A
M'=S\/:>_U8W1_=?:%7R](3?%MH?;LY[E>#,#K2S\&5#D9K=RD^$MCEGKQ,[D
M4-8WQLMF7IZ8B>L#DQ3@)SL[C;AX326!R^I]29*IA\#@<?:RF6REZ8(*E*C3
MB*:>>:4W$680%V$>>J0W&,&(R$7UL?;4[Q#,]H'?0=7V@FH:7H27].Z%PDLQ
MG\&:;>64H;ED'&,(LQJ"2"KDLP  7@2O6Q;6+<.+KVI,IX#\*9.;K-6?#>O%
MTUNRZW;[=EE<X5X\/C*:DY3?:%2>_O3K4LOQVXRTO,H:WE;19RQ_F+GYG^#B
MMOB]OF=Y6V:;%B_OXY_:Y9^%#%NACO5=09:+CR]=ED;Y.6FXFYX^NYO_ "]\
MS>#+Q<;(/U!9_P#2WZ_R^]12;TX:7(:UL4,;"=JW8*I $$ N9G9>$6(69F\N
M@68I7]P,)D3L(N[7RGZ/TV[_  *J>#.1Y>9J-#Z1496/=](I3@]V^R6TGU9P
M#;3;Z]J;+U<51'AY28[,[MS'4J 0^/9D^KT"7$8?]9*4<?+=?+7T.XU[$%33
MN)#<6W1>& :MC#:+AF%F(JQ2/'F=0NWES->G"6E7G(6(HOA"0.8;41E"AW5O
M=TSZNU!5P ,0U8VJ9/7F>AB=VK8\)"<,34F=N FN.TU+&]9<D?K63> PKRP-
M>^TYIRCB*%+%XRK#2Q^.JPTZ52N#1PUJU>,8H88P;R80 6%OE?CEW=_-5>\?
M/$)54?H?%G];D14LIQ?6O'?50?PED?#_ ""ES1VNBRQ'#&(]0REF27]YXDFL
M5/M?DKI*_;UC2MU7NOMM--2C**^VB(J?$J!$1 >.%T_NWV?-#:]J^I:TTCI[
M5%;P_"$,WBJ=\XX^KKZ(9IXCG@'J=R=H9 Y=W=_>Z[A1?M1D653C95.=<XO>
M,ZY.$XOXQE%II_-,^LX*2:DDT^Z:33_%/H06[S^CR=GG5!S6,-3U1H.W)UGS
MI?.E+CWD+Z'JQ>H:V<JPP _'SC'?!S./DQB[]2C8W)]%TO=1EI'=Z$@XY"'4
MNF2\0G9G]A[&*R0"W+\-XOJQ<-R[Q.ZM\HI#TOQ>XCQ$HUZI?9&/1+)5>5T^
M'-D0LGLNR][HNQB+N'\.>^]$%O\ J;U_P@XK^!0JUEZ-?VB:)&6+R6VN=A%G
M<&BU'E\=<D=A)^/5[VFVJ#SPPBY9'CK)NKI!GD;H?(>C]]JJ*4XX]#86R(]/
M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
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M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
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M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B +P[<KRB ZPW8V6TGKO$R8+66G<1J3$R%XGJ67I0VXXI6 HQL5BD%Y
M:EL ,QCMU3ALQL9-'(/4_-?#M.>CR8>X=G)[3:KFP4I,YCIC4XR9+%N?!.\=
M#-P.V2H@3LS#%>K99NLG=K->(1C:R\BVWACCK5='EO@9EE,&]Y4RVLQY_'FI
ML4J^9]N>*C8EVFC$ZGH6)F+;(IC-^D_LV+\)QVEM^RVX_%,UWN^_8#WIVREF
M^:G0>;^#X7?C/86 L_@) 9^&D+)8H; TA-_H(\I%0LFPD30=+<K$VAJ(@)^D
MN'$G$P?]"3/P0F+^XF=G9V=F)N';R6SR(6)G9V9V=G9V=N6=G\G9V?R=G;R=
MEB/O-V"MF]P'.35FW.F<G:DX8LE#1^"<OPS<=+9G#'C\J _+TC<87=F=V<F9
MVG_0O:6>T8:IIW-Z2NPI[;_/Z/?+;=_ZPEOV2711MJ?A5"3<L7(Y7Z0NCV_Y
MR"W7_1M_,H!X[4\$G R.T;\>_EW#]?GY/V_+ZZY?$XFW+=)"[<<MP[.WD_O;
MEG;_ -O)6L-P/1^=F<DYG@<GK'2YERXA6RL.6K1\^Y@CR]6S.XM\OB6C(F_1
M,_FL3=1^CL96N1GIK=R%AY+PZV9TH;D3<NX-);HYL09_)F-VQQ,[NY"(\,!2
M+B>-W#5Z3>9=B-_=R,6_I^=$+XK^GM\S4<KPZU2OI&JN]?&NVOM^%CK;_=^!
M N]@RA>N[_.B^3AN6Y^H_'^9=GV>UEVBJ6$H:8TGO;F=+Z:Q=,<?C\1C,'A*
M\E6F#/T1-F0JGEG(>HG::.>&9O+VWX;B4ZUW#6\4),U;5FVU\.IV8[-W4V,-
MP9O(NB'363'K=_)P8NEFX)C?GI7KW^XTWE@A\0,IM[<D9_SO4SN>:1_KB5W2
MM*'^_(+_ "<+VY?B!PSEJN.3G:;E1A+FKCE5PMC">W+S*.14^26S:YMHM?$\
M&E<+ZMIUEMN'A6X\[5M:Z:X>^MT^JCO&3W2;:ZLKD;F[7[IZTG*?6&ZFH=7$
M9D?5J?4FJ,XT;GSU#7@R=VW!7B9G<0@KC#!&'SN...-NE=>8[L43^0SY^M$#
M<>S6QTDO#?4%CM5Q]W][R]_RV.['<X;[1ETC@L',W2S]<6IL8P\_*/$Q1'U-
M\K]/3YMP7OXY?@^Y4WKMDPSMH_&-Y>W>U!8D%O+SY;&8K('Y<\/T@_G[N6X=
M\I'Q)T2FO:&JZ=""72-=U&R7RA#?;\HF4D^()=/HV1O\7BQ7\90V_P#WE>/!
M=CG3D#B5VYD\B7DY!UQ4X'X]_ 0 4[,_RL]DO+AOJN_?^D]K-.X3I+&XBE7E
M%G_-+PC+:^O^:9NN9N?E83%G\O)62-NNX:O.4<FK=P:L0<MXM/3>)EF/CY?#
MR64FA;S^A;JQ/E]%R_T*DBV;[J?9C2)Q63TX6I\C#PXW-4V9,I$Q>7)!BOG6
M&Y8A8HSDH2S1/_0YAY?G3=<\=]$H3\J_(SI_JX]4HP;_ &IW^3#;]J"G\4F>
MBG@O7,S_ )1/R:WW5URV:^55'.M_E)1^>Q5CV*[*.X6Y%@(=(Z8R.0KD;!+E
MI8GI8.HS^?58R]IHJ;.P^UX$,DUJ06=X:\GN5@+LK=S+IC3A5\QN-<BU=E1Z
M) P=>,X--TY&]IQL,;M:S1B_3_1VJ4WX(2I3-Q(\UM#'UZL,=>K!#6KQ#TQ0
M5X@AAC'^ECBC$0 ?K"+,O<4"<5^-FJ:@I58VVG8\MTU3)RR)KX2R&HN/_,PJ
M>VZDY(WW0_#?"Q6K+M\NU;->9%*J+7PJ3:E_SDIKLTDST<;C*].O#5IP0U:M
M>,(:]:M%'!7@AC9ACBAAB$(XHP%F$  1$69F9F9F7O(BAMMM[OJWU;?=LD)+
M;HNB01$7P?(1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 74._NSV-W T9J/1
MN6 2I:@Q<]$C(6+U:QY34;T;.Q<38^]%6O5S9NJ.>O&8<$+.W;R(#7+ZXT=?
MT[FLQI_*Q/!D\%E+^'R$1-T]%S&VI:=AF]_(/+"11D+D!QN)@1 0D_%U=ZWT
M[K3:/</4^1U?J#&Y8,SE6K/?DQF8GH5[,M:O'5"P=>,"#QR@AB"61G;Q/#%R
M;JY=^H_R$K8O^H=3_?):_P#HD!3A17'OR$K8O^H=3_?):_\ HD_(2MB_ZAU/
M]\EK_P"B0%.%%<>_(2MB_P"H=3_?):_^B3\A*V+_ *AU/]\EK_Z) 4X5]S3&
MFKV:R6/P^,@*UD<K=JXZA7!G<IK=R8*]>-N&=V8I9!9WX]D>2?R9U<"_(2MB
M_P"H=3_?):_^B79NS7=1[/Z%U/B-787&YB3+X*>2UCOA+,SWJD5DZT]4;!U)
M &.66N,Y2UB/GP+(1609I88R$#*[LR;(4=N-!:7T71Z2'!XJM6M6&$1*]DS'
MQLI?D8?+KN9"2Q8X\VC&08A?H 6;O=$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!8%=Z!\0>YGV#A_"N/6>JZPWEVDP^O-,9C2.H L28;.5AJ7PJ3E5L%",\5AF
MBL SE$7B0AR3-SQRWR^0&N^17'OR$K8O^H=3_?):_P#HD_(2MB_ZAU/]\EK_
M .B0%.%%<>_(2MB_ZAU/]\EK_P"B3\A*V+_J'4_WR6O_ *) 4X45Q[\A*V+_
M *AU/]\EK_Z)/R$K8O\ J'4_WR6O_HD!Q_N,?B4L?;OJ#]Z8=3)+'_LV=FK2
M^U.G3TOI&*[#BCR-K*D%^X=Z?UNX$$<SM/((ET.-:+ICXX%^>/>L@$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 70>]'9=V^W#@>'6.DL+FS8/#BO6*<892L/F[-5RL#19"N+$_
M5X<5D8R)F>0#X9=^(@*]N^?<)8"X4MO;O5UW"2/UD.&U)#\+XYR=VZ(Z^3K/
M6R-.,6Y8GM19>0W<>#C87ZH>=[>[(WIT*\TM[1MW-XV+S^%M*_\ +]7H\W<Y
M:M,7RU8 %N99;..BKQ^YYW]ZO,(@-;M:K2P2G!8BE@GC=VD@GC.*:-V]XR12
M,,@$S_(0LOP6P8W<[+^WFO(2AU?H[ 9UR8F:S;H1#?B<OHBKY*!H<A6D?E_G
ME>U%)YO[7FHM-W.XEVTRS2RZ2S>?TA8+K**"24=08P"?Z 7AOE'D7B'ZGPH\
MA?+*@*F2*9'=/N/=X,&4LF"LZ:UA4#EX_4;TN)R9@S>;RX_*1!5C)W\ACKY6
MX[_59_)1N[I=FC<+1+R/JS1FH\'#%SUW;F+LOC6X?C_G2 )L:_/D[,UKGAV?
MCS9 =((OY$Q+W.S_ *SL_P#H7]( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"+PY,WO=F_7\EV%MYM-JG5T[UM+:;SFHIA?I-L-B[F0"%
M_+\\35H9(:[>8^U/)&/M#Y^;(#KY%*MM9W-.]^H_#DNXK#Z2K&[=4NI<J(3"
M/D[\4<3!E;3R</[ RA"!%[)2Q\$0R;[1=P=I:FT4VM]9Y?.S<,\M+!58<'1Z
MN&=X_6)RR5Z41?V/%$JKRC[?A0N3" %7+GS9OE=V86^5W?R9F;Y7=_)F;S=_
M)98;+]AG=G7YQ?,UH;-RTY7'_E?)5BPN% 7]YMDLIZK!88/)SCHO;L")"7@N
MQ#S<IV:[".T>@O#DTUH3!UK@-Q\*7H3S.6=WXZG;)YB2]<B$R;J>*":* 2_H
M<0,PBV6HBS,S,S,S,S,S-PS,WDS,S>3,S>YD!6AV1[@RY*\%K<36H58_9*7#
M:3JC-.7GRX'F\F#PQ-Y=)M%B)W,2Y">$AY>9O8CL#;3;<O#/IO1^-;)P>U'F
M\K'\,9D#XZ7DAR&0\>6J3L[L_J?J[.Q./'2_"S%1 >&9>41 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
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MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
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M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
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M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
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M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
MB(@"(B (B( B(@"(B (B( B(@"K^>E#_ $DF[/V3VO\ X6-$JP&J_GI0_P!)
M)NS]D]K_ .%C1* U22(O3R,Y15YY!XZHXI#'EO+D <FY^MRWGYH#W%_)@)"X
MDS$),XD+MRSL[<.SL_D[.S\.WU%++WP_=]%V?]Q]/U\54GBT+N-H33&NM%3R
M%-,$7K6)H0:GP969BD*6WA\XY6#8YCD^#LQBI7$&E8 B<0&TA]&#[Q+^;-L#
M2T5J#*M>W V=]7TIE_6)WDR.2TL[3?,7G;'B&4\Y'BX"PERZ75ZSD,-9GDD>
M>>01LGK3S]RUW@;]FSM Z3U[>GEBT?E1/1FX,<?60/I+.VJCRY*2(&=Y?F=R
M5:AG6Z6*5J]*Y'"!G.\4FX-H7X+4$-FK-%9K68HYZ]B"0)H)X)@&2*:&6-RC
MEBEC(3CD B P)B%W%V= >VB(@"(B (B( B(@"(B (B( B(@"P,[S/MNXGL\;
M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
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M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
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MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
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M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
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M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
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M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
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M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
M'$[%:KD)0R-Z(3A8Z%*RQ6*P\SQZ<:]D+-NQ8N7;,]V[<L3V[MVU*4]J[<M2
MG8MW+,QNYS6+5B22>>4W<Y)9#,G<B=W ]53Z^C<]@X=[^TM@+F6HE:T;M/%6
MW%U$\@2/4GR="]&.C,3.0N($5W.Q?"?JI2<6:>"O#+%/6:>$X"#-A%R)V$19
MR(G?AF9FY=W=_)F9O-W^1EM3/1E.P6>S/9NPV>S- Z.L]WI8=?Y^.Q&T=RIB
M;<'AZ.Q<X.WBP'5T\]:[/3D=CJW\G=CEBBL>.* L2LO*(@"U%??Z]A2'8'M+
MZQP&*IA2TAK4!W'T9!!&05*F*U'>O!D\37\F 1Q.H*>4A"M'PU2C/CXV 82@
M<]NHJO'I7'86_FF=GHMR<11*UJK9&W+J9G@&/UB;1.1*I4UQ"1$/457'4(:N
MJ)XQDC?HT^1BTT@!7F UBRGS]&[[>!;(]I;3M')W'KZ,W8"';W4T<AL-:'(W
M;+2Z.S!]3LS34<Z38SJ;EWIYV\/29^%T0&,Z_DQ=V=A(HR_0R1DXR1DWF,D9
M-YC(!,Q 3>8DS$WFS(#>Y(HCNX_[>P=HCLZZ)UE=N0VM7X:L.C-?C'P)QZPT
M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
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M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
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M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
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M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
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M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
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MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
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M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
M$1$ 4/O?C=XM!V;-@M2ZKI6XHM<:CYT?MW4<N9Y=49>M8Z<D,0DQ^JZ=Q\5O
M.6YWZ8@]3@K]3V+=6">8):J[TEKO%2WR[061TS@KS6-OMG3MZ0T^\$_B5<MJ
M,FKOK+/N -X74&5A+3M$F*9_4L,=H90^$Y*M<"N[&+L+,1'(7Z*20NJ20W\S
MDD)_,I)"=SD)^7(W<G?EUYD-A%R)V$19R(G?AA%FY=W?ZC-YO]1E_2EW[C_N
M[Y>TEV@-,:4NQ$6BM+R5];;A2L)N$NG,-?K%'@7,';PY-47_  <.YN0O'1DR
M,\;O+  D!>?]%_[N0MF-AH-=:BQ\E/<#>7U35&4AM0-%<P^DXQF;1F"E8XQL
M12OCISSU^M,3/6R&:FJ%%')5D*2RTO7J5(J\44$$4<$$$80PPP@,<4,48L$<
M448,(1QQ@+   S"(LPBS,S,O80!$1 :.??[XP-P/M]UK^,^574Z[8W^^,#<#
M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
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MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
MF=W8P^&ZF082%WY F9B!V%Q=ND7$#3P:-TWD]1W0QFG,7D]19*5N8\=I_'7<
MWD#;EAZAI8N"W9<>HA'J:+IZB$>>29GF)[,OH]O:XW2GK/CMJ;FC\19%C?4>
MX^0J:2Q4$9?02%1,KVJ+#%_2T-.6R!V=IFB=;9#0FU6E]+5 H:9TW@-.48WY
MCI8+#X[$5(W^J%?'UZ\(OYOYB#>]<^0%/SL$>B(;5Z+GQ^H-\-27-V,Y5DKV
MFTM1B/3^WT=B,O%\.]4$Y<YJ*$#:,'AO9*IC+@A*UW$SP6/5H+;NCM&8C3N+
MHX/ 8RAA<-C*X5<=B\74@HX^E6#GIAJU*P1P0QL[N73& LY$1/R1.[\F1 $1
M$ 70_:FT>^HML=QM/C&TQ9S0>K\.,+L;M*^3T_D:31NT?SQV-Y^EVC]MV?@?
M:X7?"]6]6::":%WX:6*2)W^HT@.'/^= :(G$/S4K?5>O"[_KO&/F_P!=U]!=
MK[];;EHW7FN=($#QMI76>J=.QBX/'Q7PV=OX^J[ _/ '6KQ&'R.!"[<L[._5
M" OO^A5:P\3 ]H73SD[O1S^@,]T=(,PAFL5J#&B?6S>([F6G)&Z2=P%HV<."
M.17D5K?/0WMV@Q6_FY.CYIPC#6.V,60K1._MV,CH_450HP!N'YZ<=J+)RD_(
ML+1<<$Y-T[(- $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!5P?2M-9CB^QIK&B\C
M ^H]8;;X81=HW>8H-98O4+QMUMU,[#@2EYBXDXC=G^=/(SV/E3;],SW7"ELY
MM1HH)(GEU%N7)G9H.IO&:MIG367A"9AZ7+PFLYL(R?J$?$(.>IQ%F UV:(O7
MMSM%%)([<M'&<CM]5@%R_P#! ;:#T:C2YXKL6;,12!T/=J:KS0L_6SO'GM;:
MCS$9/U^?)1W1)^GYWR_SKYWTJ=A1_P#=4;5R:)[-FQNEYA89L3MCI"*;@8Q<
MI9\/6MR&;1NX>(93N<KL[N\CDY>T[J0! $1$!X=:>SOO^R>VS/:BW7TE6JO5
MPN3S?S;Z;!F=HGPFM&+,B,#M'%'X57+29;'C'"/A5_4GKB_SKAMPHJ,GIF'9
M(";&;5;Z4*K>L8VU8VSU-9CB%G/&Y%[F>TN5J;JZR"EE(\W7J1]#B$F:L.YL
M4@BX%"I61/17.U.6WG:JQFF[=QX,)NUIG*Z*M5S(_ ESU(HM1:8M= NP-:A/
M'9;'02R/T#!F;@,Q2R0\5NUS';K<O-:+U#@-9:<L>JZ@TEFL7J7"6.DB:/*X
M.[!DJ/B !QE) <]8(K$3&/C5SEA<F&1W0&\_1=3;#;Q8G<+16D]=8*09</J_
M3V)U%CB"49F&MEJ4-P(GE!F$Y(/%>"5Q9F\2,FX;W+ME $1<?U7J>EA,7DLS
MDYXZN-Q%"YD\A9E,(XJU*A7DM6IY#D((P"*"*20SD, $1=R(69W8#79^F&]K
MJ/4N[^AMG,=9:6IME@)-0Y^,"!QAU/K6*O+1JR]+];6:NF:M2X44K=(5LW5E
MA)WGE$:?:R:[:/:1M;P[N;D;I6SD(M<ZOR^=J#*YN<&(DF:K@:G3([G&%/!U
M<;4CA=_G 0#"W+ RQE0$NO<4=CTMZ^U'M=IRS"\NG]-9F#<757(@4<F&T1:J
MYB''2C()1G%FLW'B<1:B?HD+'6[\D!C/"#K;]JDYZ&OV0Y,5HW<[?#)5^F36
M>3HZ%TJ9Q.)CA-)RV[.H+D,KOP<63U!?AH&'2WAR:9ZF=VF\KL: (B( B(@/
MY(6)G9V9V=G9V=N6=G\G9V?R=G;R=G6F?[U_L>-L/VA=SMM:U9ZN$QN>ER^D
MXN2<0TCJ/G+X&")R<B>+'UK)8D"(G,FQ_47M/PMS$J&OIE/8T8;.V._^,K2<
ME"6UVL)(XY'@:$)LCG]'7IS%O!AE"S:U#C#DD^?W6N8Z'K:/'Q X%%E6)O1>
M>UM_,Q[56!P=ZYZMI_=G!Y+0.0CD(F@?-,\><TI:<>1C:>+(8ZSBXII"88X,
MW<%F(Y 9J[*^_I/6&4T[EL3J+!V"IYS3V5QN?PML69RJ9C"W8,EB[(L_(N]>
M]5@EX=G8NGI=N'= ;U%%CQV2NT/C-VML=![EX9A''ZWTMA]10P@;R-5ER-..
M:W1>1Q#Q#H7'GI&?2/4<!$S,RR'0!$7X6;,<,<DTIC'%$!R2&3\"$8"Y&1/\
MC"+.[O\ (S(#7S>F3]J\<KKC:_96C88H-*8FSN%J"$'9V#*Z@>UA-/Q2.).W
MBPXNIF+!1&(R117ZTK?.[3.=*]9T=YMVH?YM':"W;W-"89Z.IM87 PLH3#/$
M6G<!7JZ8TZ4$P,(2UY<+A:,T$@"PG'*Q^TY.98+H"2#NA^R26]_:0VHV_EKG
M8PTVIJ>H]5L+.XCI+2<L>=S<4KB0D 9(*D.$:07<H9,K'-T$$1\;D]F9O)FX
M9O)F;R;ZW]Y4*/0S^R2\V0W9WRR55O"JPX[;;24LL0NY3R$V=UA<@,X^1$ ;
M3>.BGKR.QG\+59>EX7$K[" (B( B(@"TK?>/?3&=H3[N^\?\(^I5NI%I6^\>
M^F,[0GW=]X_X1]2H##-7W_0[MG=(:HVUWIGU+I73>HIZFXF%@JS9S!XO+35H
M"TK4D*&"6_5L'#$4A%(\<9"#F1'T]1.[T(%L)O0M?BPWQ^Z3@_Q2I("V3_.F
M;5_V,]O_ +S-.?[M3^=,VK_L9[?_ 'F:<_W:L@40&/W\Z9M7_8SV_P#O,TY_
MNU/YTS:O^QGM_P#>9IS_ ':L@40&/W\Z9M7_ &,]O_O,TY_NU/YTS:O^QGM_
M]YFG/]VK(%$!C]_.F;5_V,]O_O,TY_NU/YTS:O\ L9[?_>9IS_=JR!1 8_?S
MIFU?]C/;_P"\S3G^[4_G3-J_[&>W_P!YFG/]VK(%$!C]_.F;5_V,]O\ [S-.
M?[M3^=,VK_L9[?\ WF:<_P!VK(%$!C]_.F;5_P!C/;_[S-.?[M3^=,VK_L9[
M?_>9IS_=JR!1 <+T3MOIW3->6IIO X73]2>7QYJN$Q='%5YIW$0\:6&A!!')
M+T"(>(8N?2(CU<,S+FB(@"(B IV>F=?$;M']V,/Q#UDM=$MB[Z9U\1NT?W8P
M_$/62UT2 ^]I72^1SF4QN$P].;(Y?,Y"GBL5CZ["]B]DLA8CJ4:<#&0 \UFS
M-%#$QF N9CU$+<NTGK]Q=VP_U/&X'_R8+_?2Q'[#?QV[-_=5V\_&W$+=FH#3
MT_D%W;#_ %/&X'_R8+_?2?D%W;#_ %/&X'_R8+_?2W"R(#3T_D%W;#_4\;@?
M_)@O]])^07=L/]3QN!_\F"_WTMPLB T]/Y!=VP_U/&X'_P F"_WTGY!=VP_U
M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
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MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
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MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
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MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
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M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
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M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
MI57=W?S*M\(MU\!4>'1N]9V,A;",6]6Q6X&-JU@S]8.!9XPU%5&/4<8&YN60
M+.E&8P-#7@ JWJ_-Z(#WBI9#%:I[-NI[[/9P R:RVT*Q/U2V,+<L2MJS3T('
MP71A<@=/,41C*1GK9F_%T5HL=#ZQ0960790[2>H-G=R]$;H:7E./-:(U%C\Y
M#$+\!D:<$OAY?"V&<@8JF=P\M[#VQ<P=H+IG')#*,<P ;NY%TAV:^T%IK=;0
M.DMQ]'W0R&F]98.CG,58'J8F@MQ,\E:<"$#BMT; S4KL$@!+7MUYH)0"2,A;
MNJ><(@.20QCCC$CDD,F   &<C,R)V$1$6<B)W9F9G=WX9 5__2/N\:;83L_9
M;&X/(/5W#W5&]HG1[5Y6CNX^I9J.VI]31$W)Q!@L5.T<%@&8PR^2Q,<9Q'*T
MT6J0BB$!$!;@0%A%OJ"+,S-^TS,RFD[^OO#B[1?:&U+F<7;>QH/0QV=#;?B+
M$,5C&8RST9C/LQ/R1:CS<-BY7-QC_P"2(<2!1!,,Y20OH#^2+AG?AWX^01<B
M=_D$1%G(B=_(1%G(G=F%G=V9;9#T=KN[S[/_ &=\ V>Q\=/<'<5PUQK;D&:S
M2DR43/I_3T\GFY%@,$].M: 7\(<K+DCB<P,9"HL>CJ=W2/:![0N(L9NKZSH'
M:@L;KO6,1AS#D;D%J4M'Z?E+J$?"RF<HO=N1NTGK.*PV1IE'T6BFAVQ LS,S
M,W#,WDWNX;ZG" \HB( B(@"(B T<^_WQ@;@?;[K7\9\JNIUVQO\ ?&!N!]ON
MM?QGRJZG0&R5]#5^EHW&^[_J3^#/:96VU4D]#5^EHW&^[_J3^#/:96VT 1$0
M&+_;>^);=[[E^O\ \5,LM(]A_P Z5?V/!^Y"MW#VWOB6W>^Y?K_\5,LM(]A_
MSI5_8\'[D* ^BMM#Z-7])+L=^P];_P )FLUJ7EMH?1J_I)=COV'K?^$S6: G
M/1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!H?,+^<ZO\ :(O]05]-?,POYSJ_
MVB+_ %!7TT!LX_1"_I2IONL:]_U<(K1JJY>B%_2E3?=8U[_JX16C4 1$0!$1
M $1$ 1$0!$1 $1$ 6MB]+<[>E?7^\>#V8P-QK.#V<@ELZA."1RKS:]U'2JS3
MU>1%HYI-/X&2K5F)CF&O?R>1HN\%JI=B5U+O?^\IP79?V;SFN+<E6SJW)1SX
M/;O 3&W7G-6VJY^IO)")-*6*Q+/\*9J6-OG5"N4;$,UB!BT_VL]9Y?4>8RVH
ML_D)\MG<]D[V9S64LNSV,CE<G9DN7[DO'D)3V9I).@.(XQ=HXQ&,!%@.-KM?
M8?9?+;D:YT;M[@8I9LSKG5.!TICQ@9W.*;.Y*OCSMN["7APX^":6_:L&S0U:
MM6>S.4<$4D@]4*Y'Z(5W?\VI]P]3]H'4&,+X V_K%IG0MJP#>#?UEF8)X]0W
MJ+/U.;Z<P1149;+-'&UC41UX))I:U^*L!?\ =D]I<1H+1VEM$8&O%5PND=/X
MC3F+@AB&"*.CAZ,%"NP0@[A$SQP"7AB[B+OPSNS+M!$0!$1 5%/3)?I>=O/N
MPXO\4=7+6]+9"^F2_2\[>?=AQ?XHZN6MZ0'?G9/^-?:K[I^WGXXX5;O1:0OL
MG_&OM5]T_;S\<<*MWH@"(B +7W>F+]A^3&:NT%V@\14=L?J3'P;=ZU.&$^B+
M.8E[N0TIE;4H@0,>2Q4U_"2'-)'_ ,S8>" )#DF(=@BL(^\9[%6#[0NS.N-I
M\YTPAJ7&"6(R/)A)AM2XNQ#E=.9B*2-GD'U#,4ZDMB,6(+=+UJC8BGJVIX)0
M-+6G5(+B<4LD$T9#)#8A,HYJ\\9,<-B&078XYH)1"6&0'8XY $Q=B%G7-MS-
MM<YHO4NHM&ZGI%C=2Z3SF4TWGZ!<\U,OAKLU"_$+EPY0^/ 4E>5V9IZQPSCR
M$@NN$H#<(=RWWAM3M*;"Z5UO+9A/5^*!M*;A4@<!EIZPPU>N-VP<(<>'7S=:
M6IG:),$<9U<B @ /&<4<L"U)7<.=ZK8[+N\,-O-V9GVKUX5/![C4Q%Y&QX1E
M,.%U?5C9^!LZ>LV3]?Z6YLX*SD(_:F@I]&V>T_GZ.5H4LIC+=>_C<E4K9#'W
MJDH3U;M&Y"%FI;K3QN4<U>S!)'-#+&1!)&8F+N+LZ ^NB(@"(B (B( B(@"(
MB (B( B+$KMR]LK2.P6U^JMT]:V'CQ&FZ77!2B(?7<WF+)-7P^!QD9.WBY#+
M7SAJPBS.T0%):FZ:]>8P IV^F*=O,93T+V<\#=YZ"#<'<0(I&X9HR>MHG"S,
M)<\G,V3S]H#%NCU7"D!$,TP-167=_:5[1&IMV]P-7[EZRLM9U+K7.7,YDGC=
M_5ZGCDP4L72%_H,?A\?'5Q6/#WM4IPN;E(YF72" Y_M/M=F=<ZITWHK3L)6,
M]J[.XO3F'A",Y7?(9>W%2@D*.,3D*&L\KVK'2!.->&4^EV%UNO>S#L1B=KMN
M-"[<8,.C$Z&TG@-+47=A8YHL)C*U![<[BS-):N' =NW,[=<]F:68W<Y"=]?I
MZ)#W>A:YW3RV_F=I^+IK:<[6$TL\K.\%O<3,8D!LS]+NP2OIO3.7>P(&,HQ7
M\[C;H^#9I59%L?T 1$0!:@7O[_IQ^T!]N53\6, MOTM0+W]_TX_: ^W*I^+&
M 0$1*O!^A3?](^TA]A=I?W]N2J/BO!^A3?\ 2/M(?87:7]_;DH"_:B(@"X;N
M+_T>SOV&RG[QG7,EPW<7_H]G?L-E/WC.@-%AA_SI5_8\'[D*^BOG8?\ .E7]
MCP?N0KZ* VH7HK7TFNB/MGU_^->15BY5T?16OI-=$?;/K_\ &O(JQ<@"(B (
MB( B(@"(B Q-[;O8QT3O]MKJ/;'7M%K6%SU5V@N1!'\(X++0,YXS/X><Q)ZN
M4Q=GIGKRCPT@M)6G8ZUB:,]0AV_>PCKCLX;FYO;#7<+27,<3VL'GZ\$L.*U=
MIV8R;':BQ/B=73'8!O"OTGDEEQ62CLX^<Y/"CGFW4*B$[Y3NG=-=JW;*73TQ
M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
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MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
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M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
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M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
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M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
MC+J#%P'//INU.3%.X_ <L\5:Q!)5UD<\$D4DD,T4L$T,DD$\$\9PSP3PF44T
M$\,HA+#/#*!Q30R ,D4H'&8B8NS;VM4&_2>^X]#%'F.TWM'A8X\?,=O)[SZ9
MQT9 U:>0@EEW%Q=.,'B:*4GL2:VCC*)VE>+4 12R2YF9@*.:LB>CS=]19[-V
MM0V_UW?<MD=<Y4"RDUF24PV^U%9!J\6JZ0,QM'B+YC6K:KKBP@$$<.;#Y[3M
MA<K=L_\ >7AVY\G]R N:^F:Y.O=W$V N4YX;52WM]J^S5M5Y FKV:\^;P4L$
M\$T;E'+#-$0212 1 8$)"[B[.J9:[[W5[36LM;Z6VYTAJ?)_"N)VJP^6T]HH
MYP(LAC\!EKU>^6'GME*3VJ6.EK108B,HP*A1$:8F<,<3#T(@)L?1R?IV=A?L
MKKC^"K7BVWZU('HY/T[.POV5UQ_!5KQ;;] $1$ 6K0]*Z^G'U!]SS;[][91;
M2]:M#TKKZ<?4'W/-OOWME$!6^5KST._Z9S6/W&,_^-^BE5#5KST._P"F<UC]
MQC/_ (WZ*0&RT1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %7$]*#[#=G=[LUY+4.
M"IR7-6;0Y$-?8RM!&<EF_A(8):&KL=!'&SG+-\!V)LK7A$2*>UB8*X,QSL36
M.UZ>0Q\%NO/5M0Q6:MF&6O9KSQC+!/!,!1S0S1&Q!)%+&1!)&8N)@3B3.SNR
M T3(&Q"Q"[$),SB0OR+L[<L[.WD[.WFS_*WN0Q8F<29B$F=B%VY9V?R=G9_>
MSMY.WU'=3-]^AW8=KLP;UY#"XZO(VV^N),GJC;2X[D<<&+*X)932AS.S=5O2
M5FY7J").\AX>UB+$A'++*;PS(#9">BU][C5W)T)7[/\ KO+!_-%V]HO'H^Q=
MG?UG6&@:<4?JP!),9'<S>E&ZZ%^,'*63#!C,@XD37I MU\K1C[:;F:AT9J'#
M:LTEFLAIW4VG<A!E,'G,5.];(8V_7=_#GKR,Q"3$!'#8KS!+6MU99ZEN&>K/
M-">RR[F3TD70F^M/$[?[KVL?H'>.*O2HQS7)J]'2>X5QV>#UK3-N69AQ^:M2
M1C-;TQ>\(QFM1QX.SE86E&J!:'1$0!$1 $1$ 1$0!$1 %3V]+:[QS':2VNK]
MGG 9$#UAN<6-R6K(:E@PLX/;_%Y2.^PVWA<2B^:S+8L,2%:20?7</!FXI89J
MDAL4D'?!]_3MKV7L58P6/DJ:[W@NQE%BM"8R]7<,$4M>26#,ZXM1R$6$Q,;M
M%X=( FS>3.: :=$:96<E2U;7: W_ -7[IZSU!N!KW-6,_JS4]TKV6R4[, N7
M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
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MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
M8!:7*:=OQSXRQ*0111RVHX8+TD,80E:\( !L4=5:4RV!R-K#9[$Y3!9FD;QW
M<1F\==Q&5IFSN+A;QN1@K7*Q=0DS--"#NXOQ[E\! 7D^R'Z9=E( KX[?;:NK
M<,7$)-5;8V)*C&'7QXMO26HKULHY B]J:2AJ*<+,SF4&/HQ]$+6#=@_21>QS
MKYHXHMW:.CL@8/(>/W&Q68T3X(LWT)9G,4XM,2R>]O"J9VS(W#.0,Q Y:E]$
M!O ]#=I7;O4]>&UIW7>C\Y7L</!+BM28>\,O+<MT>KW)'+EO-N&\UW1%,$@B
M<9"8$W(F!,0DWU6(7=G;Z[.M$E0#U25IZCO4G;W3U2>M,W/F[M- \<C/SY\L
M2[%QN\&LJ;L]/6>LJCL+@WJNK-0U^ )V=P'P<D' N[,[BW#.[,_'D@-Y9RNM
MM3[S:/P@229G56G,2$0]<I9'-XRDT8,+'U%ZS9CX;H=B;ZHNSMY.RTDM_>S7
M%IA:UKG6]EAZF%I]8:DF8>MF8^EI,F3-U,S,7'T3,W//#+KK+6YL@3'D+%C(
MFWN/(6)KQMPS"W!VCF)N!9A;S\A9A;R9F0&WGW[[_/LA[<L89S>_2F3O TC-
MBM&?".N\GXT?5S7FKZ0I9D<?*3CTL64EHPLY YR@)@3P+=JOTRW1U&*S3V4V
MNS6I;KB0UL]K^<-.82,W'@9GPN-FNYNX(2=3O6.?$^-'TNUR$B=AU_  (LPB
M(B+,S,(LS,S-[F9FX9F^LWDOZ0$H?;H[Y7M$=HF.QC]Q->3PZ6L2,9Z&TE >
MF=(&(F4D4-S'U[-B]F88G=NF+/9/*@11PRR"<\,<HQ=  BS"(L(BS,PBS,+,
MWN9F;R9F^1F]R_I>8Q(Y(88P.6>Q+'!7@B Y9[$\I,$4%>&,2EGGE-V"*&(3
MED-V$ (G9G \+LO9[9K5FX6IL5HW0VGLKJK56<G]7Q>#PU9[-VT?EUF_+A!5
MJP,3':OW)J]&I'\\M6(H_:4[W=O>C1[];Z^I9_5=2QLQM]8?Q/AK6&&MCJW*
M5F,6Z\#HFV6-O#!8!R.GE<Y-C:<T;1W*E?)4Y83FV%G=Z]U7LQV9L$>+VSTQ
M##EKL,4>>UIE_"R.L=1%$W+?">:.&.4*@R.<D&*H!3Q-4C)Z]*,G)W AS[CC
MT<; ["GBMT]W1H:JWE&".QB<9&45W3.VTLHN1/BBZ.C+:I #:O9U";G6I.,D
M6!"$))KURU,R\H@"(B (B( B(@"(B *-GO>NR*V^/9RW3V\A@]8R]_3=C*Z:
M%@ZY!U1ITPSNGWA%A(BDDR5""NT8N'C#,4!R!'*;J29$!HB*MAI8HY69V:2,
M)&9_>S&+$S/[_-N?JK]U*/WTO9)CV3[3>ZNB:58*>"L9Q]7Z7KQ1-!!!IW6#
M%FJM2M&/SH*N-N39#%U8XB(8JU&*,^F49(PBX0!<_P!I]K\KKC56F-%8&,I,
MWJ_4.%TQB1"-YB^$,[D:^,K2-$SL\C0R66F,&<7((RX=O>N *S9Z*3V/@W$[
M2X:YR-7Q\)LU@I]3#XD325I-59V*Y@=-B;G&<3R4HI,OEX!8@L17:%"U"_$!
MNP&R<[.6R&(VTT!HO;W 0M!A=%:7PFF,;'U/(_JN%QU>A&<DI")S33-!XLT\
MC-)/*9RR?/#)W[H1$ 1$0!$1 $1$ 1$0!=$]I_87%;I;=:VVYS8B6*UKIG,:
M<N.3.31ADZ4M8)^&X=WK2G'8'I=BZHVZ79^';O9$!HN=>:!RVE,]G=*9^N=7
M.Z7S66TWFZTC"TE?+X+(6,5DH28"(.8[E28>0(@=F9Q(A=G?BJLJ>E3]D-MM
M^T]:U=0I/7P6\6!KZOAE"-QKGJ;%/%@]5P@3 $36/G>%R5F./DN<L%B9RELF
M95JT 7\EU<?.XY)9'X:.*(7.660GX"*(&Y(Y)#=@C 6=R,A%FY=E_2E)[E?L
MD'O7VG=IM&RP//A:&HZFM]5L43S0_,SHFQ7SUVM8%G%Q@S%ROCM/%)U<Q/F&
ME%GZ'0&SW[G?LBCL=V;=J=O98Q#+TM.AFM3&WAD4VJ=4V9]29]WDC$?%CK9'
M*34*9%R88^I4@=^(F9I,$1 $1$ 1$0!$1 %I6^\>^F,[0GW=]X_X1]2K=2+2
MM]X]],9VA/N[[Q_PCZE0&&:L!]S/W[EGLA:8UOIR#;.'7K:SU)1U"]R751:>
M?'>I8F'%>J-"."R_K/B>$T[3>)!T=3Q^&7'6J_B("\W^75<C^IVJ_P"4N3^)
M:?EU7(_J=JO^4N3^):HR(@+S?Y=5R/ZG:K_E+D_B6GY=5R/ZG:K_ )2Y/XEJ
MC(B O-_EU7(_J=JO^4N3^):?EU7(_J=JO^4N3^):HR(@+S?Y=5R/ZG:K_E+D
M_B6GY=5R/ZG:K_E+D_B6J,B("\W^75<C^IVJ_P"4N3^):?EU7(_J=JO^4N3^
M):HR(@+S?Y=5R/ZG:K_E+D_B6GY=5R/ZG:K_ )2Y/XEJC(B O-_EU7(_J=JO
M^4N3^):?EU7(_J=JO^4N3^):HR(@+S?Y=5R/ZG:K_E+D_B6K@_=Z=K*3?39C
M;_=J7!AIJ37&##,E@X\@^4#'=<\\+5QR!5*!6F%H>KQ7J5^7)_G;<+2NK;P^
MC[_2;;!?:17_ '[=0$QZ(B IV>F=?$;M']V,/Q#UDM=$MB[Z9U\1NT?W8P_$
M/62UT2 RC[#?QV[-_=5V\_&W$+=FK29=AOX[=F_NJ[>?C;B%NS4 1$0!$1 $
M1$ 1$0!$1 $1$ 6O&]-!TF,&Z6R&;$&ZLAH35F-E-@X=WQF>Q-B("/J]KV<C
M*X#PW3P;\ESPVPY5*#TT?;%YMO\ 9#6H1/TXW7F:TI:L</PWP]IJYF*4#O[F
MZRTU=D9O>7A^7D+H#7W+.'NR-QOF1[2&PFHWF:O#CMW]OX[DQ.3#%C<KJ2AA
M<J;]+L[L.,R5PNGG@G9F+D7=E@\O:H9F;&V*V2K];6<9:K9*L\;N)M8Q\\=R
M!P(?,3:6$'$F\V)F=O<@-[,BZDV#W5IZZT/I#6=":&>GJK36$S\$M<F. @RN
M.KW>(C;R(!*9P9V_I5VV@"K+^EK_ $H&3^Z-M[^%I59H59?TM?Z4#)_=&V]_
M"TJ U>Z^=F/SI:_8\_[D2^BOG9C\Z6OV//\ N1(#>]U_Z''_ -P?]5E^R_&O
M_0X_^X/^JR_9 $1$!KXO33/C"V"^TW7WX;TPJ5BNI^FF?&%L%]INOOPWIA4K
M$!-AZ.A].?LA]D]4?B/J5;<!:C_T=#Z<_9#[)ZH_$?4JVX" (B( B(@"(B (
MB( B(@"(B @S[]'N>L1VJMN'+$#5QF[FC(+-W;_/2O'!%=<F>2WH_.V"C,GP
M6<Z>(Y.H"Q66&IDP/P([M:WJA-<Z'S6F,WE]-:DQ=S":AP&1MXC-X?(1>#>Q
MF3H2E!;IV8N79I(I!=F(".*8'":"22&2.0MZ.JA'I,'<B#NE@;^_NU>&(]S=
M*8J2766GL54\2QN%IG'1/+ZS5JUP>:SJ[ 5@F*B,(2V,[C^O$O'+;BQ;Q@:X
M9%X9_P!?WNSL[.SL[.[.Q,_FQ"[.Q"[,[.SL[,[<+R@"VP?HQ/TC^RW[(W3_
M (9MPUJ?%M@_1B?I']EOV1NG_#-N&@)[41$ 1$0!?"U/IC'9K'7\/EZ-3)XK
M*4[&/R6.O01VJ5ZC;B."U4MUYA.*>O8@D.*6*02 P,A)G9^%]U$!K;N_,]&V
MS^TUK,;J["XC(:DVLFFMY+/Z+I\W,]MS&;O/++BJW#6\YHV GD&((&MYK P>
M#'8BOX^.;(U*CP2"0L0NQ"3,XD+L[.S^;.SMY.SM[G9;W Q8F<29G%V=G9V9
MV=G;AV=G\G9V\G9_)V557O8_1>-N=YK&0UQL[8Q>TVX]F:6[DL?#C6^8/5]F
M5Y9)SR&+H%7+3^9M3R-/+G<3%-'9E$_A'$VYK#W:X&L[7;NQ6_\ KC;#4<&K
MMNM69W16IJP/$&8T]>.E9EKD0F=2[&S'5R-(R #.CD:]JH4@1RO#XL49CW%V
MP^P/N_L'G9L!NOH3-Z6D:Q+#0S4E:2YI3.A'+X0V<#J>L!XC(Q3>Q(%?UB')
MP!+$-_'TYS\%L0$!<=[&OIAVY^G!KXO>[0F&W#QT0B#ZET?TZ6U9TLS^U=Q=
MN>QIO*RN73\\J'IQA!G<HK$GM/9"[/GI0'8_UTU>OD-?W]O<I.T0O1U_IO-8
M>H$ILWBB^HJM3(:8CCAD?H\6WF*CRB[2QQN#2/'JH$0&[?VS[8^TFLZD=_26
MYN@M24Y79HK.&U;@LA#)U,SCX9UKTC'U,[.SCRSL[<+(6CD:]J-I:T\-B)^.
M)()0FC?D1-N#C(A?D"$FX?S$A+W.SK1*1U8PE:<(PCG%^H9XQ8)A+CCJ&4&8
MQ+CRY8F?A<_QVZ&JJ?1ZGJO55-HR$XVIZFSE48S!A8" 8+\8@0L L)"S.+"+
M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
MGWZU]*!1RZ^UW)&;<&$FM-3F!-]0A+*N)-Y-Y.SMY+B&3UOG;S.-[/9Z^+MP
MXW\WE;HNS,[,SC:MS,[,Q$S-QPS$3-]$7(&Z(W;[PC8K0413:RW@VWTV @1\
M976."K2$P-RXQPE=>:65_(0AB Y9#<0C C(6>'C?[TJ_LC:/CGCT]J74NY>2
MB&1@JZ.TEFX:)SASTQOG=35,#B9(Y&;V;5"?(5^29G/ECZ-6?%2AC)S"&(#?
MWD,8B3_+RY,W+OSY\N_O\U[* MW=LCTO[>;5K6L7L]H_3VUV'E:2(<[FO_LO
MUI)&3NS25A(JFFL*;QNX$!4-02L;!/7O5C;PVJR;U;XZRW(U#;U;N!JC.:RU
M+=<O'S.H+\V0ML!2'+ZO6\5_!H4ADD,HJ&/BJT8'(O!K1L[LNK%^<LH@+F9"
M CYN1.PBS?7=_)D!^BRS[%?8BW'[0.N\;M]MG@ILOEKDE>3)Y V>/"Z7P\DX
MPV=0:BODXQ4\=3#Q)1A8BO9*2)Z6+KVKAC$I1NZT]'AWH[1MBCG\S3O;6;6'
M+&<VL-1XF>/+YVJQ,\H:-T[<*G9R#2#UQQYR\T&$BE;JA?*/%-6;93=A?L ;
M7=G71E?1.U^G:^(I/X4^8RTK!9U!J;)1Q-$65U%ER ;.2N$+.,3&XUJ<3^KT
M:]:N(Q,!T!W3?=1Z%[*.WS:6TX3YK56:>"]KK6]NO%#D=2Y6,9/#CCCC;BC@
M\6TTM;"XP3D>O7=YK4UJ_/:M32F21"8D!LQ"3.)"3,XD)-P0NS^3L[<L[.WF
MSNWN7Z+P@-'!OE@BQ6NM=XLQ<"QNN-8X\@=F%P>EJ7*5G!Q$B$>GPNGI$B%N
M.&=V9G73V8_.EK]CS_N1+-_O(-.CB.T7V@<6 >'%0WQW:KP"PQBS5AU]J JK
ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
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MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
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MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
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MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
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M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
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MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
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M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>ino-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:ino="http://www.inovio.com/20200930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20200930.xsd" xlink:type="simple"/>
    <context id="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9d03834c753f4461bc91e302fe02118e_I20201105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-11-05</instant>
        </period>
    </context>
    <context id="id34815f9d2a14071b19c7de18cdedc2e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i91e7c0f132e34c59bf93da3effb57556_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iad00cc94b7054dba89db6de62bd2743e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i33802a693628436e990fd03d1c367654_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id37b739c3d7a4609833f69db4559a05d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib74217d38db64ce1adfc9b45c3791fb5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i99922d4c4991454fadefaf71d1e588f4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i37266a62557f4575b10ba5822c0a691e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifbb8d0d9ac154379833cab4cface6fed_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9a3e1abbbaad4bd7a9c51a4266035110_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i529cf22cf7c34b5cbc581544727e180b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb8e36088aad444883e60bc40d755771_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1d20b99727a54a1bb1084d53338a7ac5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6a191e57427341858f4afa549fa9f378_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibff05cfee55444728cba8c5821c8cd39_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5255fbfad51c4e9289a4ebb454a733a0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i82519fba8e3943dfbc56b64921e0755f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i12c41f3268694c0eb68fec4dba426315_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idd26d40a3bcd4f41a7939cead908de3a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1d09d690018a45498dd313c617375257_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic5b3fb71885d4741bbd44d4710aafc27_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b80e1cd70cf4455b48eaa840dc9db78_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4baefa69f3a64b9a86686d55294e5ee9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i241bac219d9b4d2cab239b4a93aa2809_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7b045061c7ab428582b10f52d98361c4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6edc82bc7b334d5aa607c4be90c9906f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7fd398adc34c49a398e8c5047ce7dca2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a3177da420f419793a90426cdb10103_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i490a2b67f81945fb92911af08177c0d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie245dae4bee84b58843b01eab260ebbe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i164d36cfc1194bdfa7a02c7620d6c38f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7da7e536da1348a49003199c51350098_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i08deaaf52352444fb06992fafb59e795_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i98b336c669ff4c388e47c257d1834054_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia07dddec9a874e3db329127b98b02609_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie23871a5e018407e8d1d917d80671cdf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib8eda4ce49e3408f9d4f5308a4037533_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4411f044a3a14ba18265a15b7226653c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i770162b78bb54f1fa1711d54652a4751_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6eaf13aa46744705aa06fb61cbe8aa82_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if9f754f0888148c498ed9fff863d50dd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i47296c4f224f4821b9b5398dff066172_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic38a8356669f4b94a31d4fe6a18ea3c3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id5dcbbe8e1f748d0aa61b641b73d3fc4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ief04ee355ac748d99c0d4127735597c1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i83f9c138d29b443f9ed4bc98e732da37_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ice079a38e1e1455b9775b3e80821be68_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if181d6b7610d46769fd6e637cc5073f1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib0244b4520d04e4e8f59d89ddd1fad54_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie69799d5ae944511ba30c40042a5b329_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib7569d7245f540de94c34ea74b24ab62_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ieb3f93f3c4c744d585e8ee4ebe462d9b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3cc6179ba6344761bb813a2e5b312a60_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0bf2f09d68754bb1971d7930890683f9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1b9c539a1838477abaf6bfa915ee886c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9cbfe1fda7da45e895ad0f7797870e3e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i510e75df51764aeab124f1f96a2ce60c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7ee3e0978a8246caaaca0810f4cdd6ea_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iff71970e3ccb4c1ba1e28e003e256dbb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i647bfa57e2c94d82bfe6d0586215e925_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie6259481f55947f8a81ad5e6bdf162e0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i59f9640746a545989d1bbdb6a45e5c57_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idd29250290ea4170b0c3e4f90e4306a9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaae34ec028bf4c5093d8f8caad4165ca_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6465f1fd3deb40cb9065e34705e46564_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i978b9d86842c4f2bb0684bfacb1d2f7d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i79c71d22c8084831b9423ab29cd4f183_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iabe71ccc813949e295ac419f3bf11133_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i25f2b47e634f4835ae39efe3509d84cd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6e2c3f19273a42778f051025844a72e2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9a012f253e8c4f838461bd187a090df3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i101ba48e80cc4d48b6199ad88e5a774a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iad543da68a144f83a4d3805ac1f6d89e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id389379a953b4eac99e35c98ee5f565b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ica8a6426b215442eb3caef7cecc4c115_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i56e81b2a6acf4575b6a2fd1a15aa3a3a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i912f365b06294ab497683dd0247e0307_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1e0f2db7f9c1466d884a3ed9d245869e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2fca9614850f4094a30e35df9ad3f90d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7c34cc69f8ff4a9e9279090d85e2ed1a_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i11dd26adaa634c719948d1c87ffa3cb9_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i6e69cbad70b5452e8efff3fcfbccf5a5_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ied96fbdb97a849e49bf60586fe4cae49_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i11229e332bfe44958cd20245c914ab26_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia760ea1651944cdda9f87141b2c3b22c_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ie93f9f62a04d495caf7d3e9ad734702b_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id8d984df17864fe6b064ed160b10dbab_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if2376931e94a479ab3da18397c83700e_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ie6ba01cda73b483185d19910f47e556b_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8d38c9c361a3445fa534a5a54efca8ce_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i68ff5039256e484d8748c537f9e688d9_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i62bb952cc15b4e1dbdd165eb7c3dcfbd_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4b38bc463ae342a1bc3326ab42796c09_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibb02416827ad434aacea7535d3776742_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3c7f59d7bc8740db8cb1ae6cde690f43_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i971bb2028af54bd38e7112fbc6dabd8a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idac672ec0b2e49d48f658a67d9cf0a81_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i01241b5b4e1d44b28b5be3eab2189cf6_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i5c40c2619a6e4f689eb5e72a7788b8af_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i71d44e1083ea450d84f392f8d18c62e9_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i78220f5c2a8e4adebfb1017126a472b2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i44b65c8171f84184a933954da0d120ac_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8c14c362804a4c57ba8b3135c378097c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6ecc7fb3c1d845e3a86bafa86c697ef4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if02c1be59ab240e5bf65dec5515fa519_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0fe6086a20184ba5bede380b65b2eea4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i00852cf554364a3aae33ca5c9a00c901_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie69970bd582c4a249c8df8217f771954_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4b6031a5c53b40dfbdf167f3ecc7127d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4db23d3c84734d66b66635aa8030bee5_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i679e13f56b134421b5679976e76aa618_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i65eb5d78647b4483b008e23b402ec513_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4d60de4ea362438a8dce34b8e79c0472_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i362cebf18fb64bc0aeb2df72a45e870e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7ea46918d69244b0b92fa827e8689f35_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib64ca090f73d4dd6afb773407d8d39de_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idbeadf22b0a640818c2ed7013bf0c883_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i31939003de4d4a3094a1ef0d323e91fb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:VGXAnimalHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic34da769042c4f00941ee0248f92939e_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i40baaae65a1744768b1b1675f3ad79d0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0bda1f1acb9e424588e758c721d6202d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic8936c9a775e4048b38647b7b881147d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9481fe2b9b0f4c18b552f08cc3c7e40d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i75ad5d40a88941e3a7a873faf3f7eb60_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74f44125bc13416a9aeb599f2cb231e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c753a8fdf0f4e7394bef90ba65bc0d2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i66d118519dea4ae7bc213714ffeb97a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifb2dc9cc60144c2ca1da77bc87b7812e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6b8bbe68292646fc920d02bc015f8116_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4058122d38c74b2495974de7f507740b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i19efa68d746c41c38d72557926a2c83a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i10bdaf5e033f4b6cb32118002bd714d4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1fe60d4ed164b4ba68d097b07daea40_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i59afc9c747d34b8c8a09631dec66eae4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0cb681e91bc24c64b846b49185fe2187_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i71790af5924c4ddab339efc7f993a154_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ice5ad4689ec9487e82f66dfbdc7bcff2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id6e18e4080084b71847f96b5e9a0e699_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i96a526030817474ca6bde92e79a78309_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie860f23b62fe487f8c985dd5b2c5316a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf4033cfc12e48aca490d914c0d2e740_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i02f68c7b48d744a6a9173080f6c38f09_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i918e4025371f42b5b7b58df82fc10039_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4dbb0afb9ddd4315b01e6f4ccb7ca2c6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if795f05efa0445c98031f36131b16eb8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i78c105aeef2c41549d702f116ad4f464_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie03669a396f4494cb8682e7da1ca04b4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4b71d42002e544b4a463361f34d11920_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9e85feb515594f70b6395ddc1f835acc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i151a4fa9e7064eb0913b049b54c5c026_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5a11d9344d464d08a2c4860a29929ef9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i038eb61ac20847bb81aa8ef1c87cefbc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8ea8a9e591f0496d8673b145a17803fb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id488e43085014ecdb6ffe6983f1f85b9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4cb90dd8056f43a3ada1c1be4856323f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i88d54f6841f54932bc303d237a8609b6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7212a769f73745f29da1c66276126ff3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i52399d29eb084b1fba8917f89379b49c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic787e50b63d34253bbe8d56456eb3701_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie0dcb790ab6d41bcb0c822ec87057c02_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i99efe129ba7f47c493d7948e3488435d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic0393158ad254b10ac5bbdca3fffa1c2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i692de2cba0aa4e9bbf5aee0bbed07c99_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0e17ec22317c4268b177ef3d384f59b6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic97b736b29264d8aa6220ac0e12c35fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b7d48f9d1074982822fddd2b379a517_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie48be730bf58424b80b0e60560d8fb7e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if6f88938286e46c5852675631383c455_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i915d187dcbcc4f6abe0cc0d82477a4dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibea476b8d6cf4060b5668a0a25d5da59_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i58ed83b261a747f18822c09954cbbc28_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia54a86390af04834af68005465847e66_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifa448e74007b43949527573adaece377_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8de60a0d0457444486d03b56271564bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61b22b095121487092da2a8e6fb84adf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifa2966e31f5c4d178bace1c18c46ea63_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5536482a9a094c779a9961b697daaf39_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i94285e36aedc4ac6936417abdd4e690c_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ie34b833b31b34228ad5580d790df4e4b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5f8340ca06974cc4af47f666f30b4427_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i35a4423ca3fd4a44b5437b54d8107c3f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i993e6fb6374f485f825fc460f02fba85_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icaf790af2a9c4f65a9e9b79b785a3c9f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i595e1f2af87d47f9825e175e8cdbe831_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i629f451db0a646ff9a5db84aee063ff4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i929847a653e343629b9e00d8a43f72a9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i55a6a7fc219f409290b994a921f5de9f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9158ca8f497c4770861d6068bf7925f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if2914df82e244dcb9b995f1185e3447e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibdf052a2e7144cdbbe989052584b4ca0_I20050131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:InovioAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2005-01-31</instant>
        </period>
    </context>
    <context id="i4afa819554cd473a95b7517d32ce72f6_I20090630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:VgxPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-06-30</instant>
        </period>
    </context>
    <context id="i2eca76820add42a0a986a746497d97dd_I20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="if070ef767938497492f880730056fd65_I20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-03-01</endDate>
        </period>
    </context>
    <context id="ib3abdef29e774d82a089595d8b564e0f_I20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="i172d0673a3194c5580d4987b79a2a44c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if59eceeb9abf42459b9e0b88dc6346ce_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i45d4d90e086a49749993964ed0753833_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i590d515cf6de40edb611587951823c62_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9d466a48e9e141aa8102e78c3a89cb07_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i864892cede774f3eb42a10f60eaf5a21_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib0c7c8a510c14ce3ba010b700fac6047_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2393a62fa5e34d739b1a36b6e8df6f31_I20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="i5cec051d961f4164be10ec4cd03c6eb8_D20190801-20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-01</endDate>
        </period>
    </context>
    <context id="i8a37a98039ba414db800ad308eb2b02c_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="i93454515f2814d1aa32809ed291c931a_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="i930a152e7e8f41e89ca66ed7945686b3_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="if776c09c12d048a8a03158014bdd629b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i069c085bd0884569a0c363b84262b982_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i666980e930ca4263a11fb9d67a8ff7a5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i438e7b59c3d54e9e998a30ddc65e87a3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8958471a957c4db3b44209f556886dc5_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ib8a6a5f3412b4170b586cb0a191c2b65_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i30b055a2515244df98c8096ff545da5c_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="ib669b19a336e48c890a2feda647d2035_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="i47a612180eaa425693bc6df2815b34a8_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="idecb5c7b97f44096ab202e14ea4c5a5c_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="ic5922a465abf4cc1be657156439079c7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i34550c65c6944e8290ed1e7c3cc2387d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i321babdbed2a41498f88f960499c9240_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2cca53a6bf0849c3a1f4c545316eb5ca_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2b79363a4154026a899e339e36624d9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iff76d992bdba46d5be0328b7a9a8d64c_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="ie4c32c65608040b68dea715a2abffbcd_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="i1abaadc504944f67824cef5b490c4d51_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="ib12d03d2fe7e453ea4f8ccb997e9f525_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie09a126e34b741aa9a646f361a9bfa0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie2d0bbde4d3e40a9883106a66764b89b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id6b8d7c533b04e2981466489c552e6c1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i14a978d9496a43e7aede0fcbc572e14b_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i9c298cf37a4848da8778eeafecf73788_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i97fe994b743146a2b11f82e54b658475_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id24bddea654742c4b5eecc7be2d6d449_D20200403-20200512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-03</startDate>
            <endDate>2020-05-12</endDate>
        </period>
    </context>
    <context id="ib23297044af5421488bf606a07fcad5a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4c022db15d174f8db8fb571a3e4db2f7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic3afac984f9d4d59bbd2907c5bbd7278_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i074731de2992483e840b846807d642f7_I20160513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-13</instant>
        </period>
    </context>
    <context id="ia9835623d0cf40b4861f5c838d46c1a2_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i4b4928fc44ae4021b15f75edc4b2c760_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibc202bd5f1fd4725bdbf57b6065610c3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i186812e80eed40f0bbab169954854146_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ice5f528ac7ca4891a83906dfc20c1df3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6db1b3c721d04b66b6aa18b2614af73a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia93b688d453949bda8f80084a4f8c0cf_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i44a63daa0269434b8f8645084440149c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if5353e9eb3d34cb7a882d3194dc9492f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i51b9fb3e5b5e4a31a8873ab12cfb64d0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1d0b8128b742495c90250bc5b8849172_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i02e3ca1e82c047479a0c74b2718566f0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i06030a312f124dce90532593ecc94dd9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9e44945591f04d5da4354f7f7bdd35cd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9bdb6a99776a4c4d800ab8e40b952f8d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0194a559551a40c8b27e764106336195_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c5944ef521743b3b9e876883e54f1e5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic5a0629abda644218979a5b63841e116_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i860fb08bf8184b179cac33e4192e1816_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ide8b04bd4c5e49acb95ba740445e35f4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1d3155aacbf84e0b8ce936aae7adf3b9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib68e05e899ac4508aa008ee16595c00c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iba702d59c1624ad78cddd0ba1ffc4322_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1a56a2b1e29242588c663774b4b5aa76_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i554f1ca12a6049099aa8584a524a2161_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7a898fb72f1a49f5bd77c57ed253bd16_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2b05350e1bfd4d9ab4452aefb8f891fb_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5d59312f204e4b97ab0b449aceeddccb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2861cdc8f69f41d5b5875d02a30fb6a8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia51339b229ef4a62b912b1d36f13eb7a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i65d7691f080348dea281680ef992b0a6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2e404e614cda487ba8a65c024ef8d309_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0f1be49da4d049788cefaa0996012c18_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i31d99600c91541e08b13dbd22f740ac6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id952f10e76044800b212f242883b868c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i39f1040f585a4f308338f4f88079b910_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i289251eaf4234243bc0156afcbc6016e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i06c12a6f77d0492195c95821a8e4b7b6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie3d462cb47b640bf897ca00c25614f47_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7a618cdb93274c3cb270ff6bda022556_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7af7c35ef173431fb3279d39c0f1d502_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i147548485ecd4491b08aef970e8b6c24_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5a5bf1e66b6a422a87b55518b074a975_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib6722d5596bb495cb02bbd3e009bb98a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ice161059e07d46408a923dd86909c6c9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ief5502197e4f432eb1f99435f0610ad2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic129651914c14c8c8f24304e6cea8cf4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia9c0eec23a36476e8fa9dc64d2143d2b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4fb2a364d2a84d27a0a8bb72b4a5d947_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icbfbede0bdee4bf2a1144f18c7e235cf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7053c11a98db4096a9e40bd43a3c419b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i195f8d33da5c49f1ad16bb63dfd92fc5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib27721d879d24dc09f0b0eaff7993400_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3b70f956f6ba4badbe26e9b1a4182687_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5850434bfd7f47e6aecdd16aac2a9c5e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie4b0c15ae5ac4a8e8c3949f8c677e46d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i847658eadc124bf3bfa5c9301c21bb42_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="iffcbbe5f4f454868b69c0a199c847e26_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i67d9bde506f34a86a79e76444931a225_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="id846dd9c3ed6491e8bd1b652cf0299d3_D20200827-20200827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-27</startDate>
            <endDate>2020-08-27</endDate>
        </period>
    </context>
    <context id="ie03bd2679d2e4a7d9318989067e22958_I20200827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-27</instant>
        </period>
    </context>
    <context id="ia3c081d7909a418589d0447afe757e8c_D20100101-20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="i85f7dcb7a22e4903ad067fbb0557bacb_D20140101-20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="i1d860bed7f3c477c927663b8fe0f5eee_D20150501-20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="i3bef37dba0d9484fa9ec9f1316d39f3b_D20160101-20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="i3975abdb45c8440abeef92728a3f628e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iecf61220d18043d899fc9e4751d53309_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i790052b1d4424f2eaa1cf12c5cc544e1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i40c874fb1aab45f6a0c7ba48d937c1c7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ief6a9b5c09ee4b90af8663890af888fa_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i49f5bd8f2ce54ea9aac77e18fa6578c7_I20200220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="iae58b01d628f4694912a6815b3ea0645_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i29248800a6f9460c9570869254c619d7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie258d44d8f7c42a788923cec12040ba5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib9f446d994234ef9aa5a5bc12c0b9dcb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i92e675b7850f48a7bd3444a4732e7d6a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i57c38a9d213944289a8cdaf81d35f929_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i8c3f9ed79a4848cab5edbb332f829d5d_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i652ec1b835ac4951b1455fa93ec2220c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0046f92427f94b59992479e7afc4aeab_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3c90a066b83c4b8380cb3cd37bc3a09a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if7fbaa1c34944d488dabcf367f55d769_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if8599ce44e474e488237d3872fc61db9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib51d61f346d74c80bcc530d2cf49fc35_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd1bef4535014b23bd76467b4f46b98d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i52fd1f860b3e47b3b28f24815064d334_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if8e016753b6d49ffa2bed4a3be3bc0ff_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i15135c10f2b84613a0bdfc1f99cfb3f9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic81bd389069e417a984bce2bcd1d1063_D20171229-20171229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-29</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="i47d345bee3e7411d98a3ba44f79db554_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i0a9ae846802141b899c438da3a7cd430_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i0d907bd30e814bf1997a9fd3ed4a165b_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="idcb1a6014bfb4665a8e53fda2328b9fa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2d344de8bac24153b97039f4a5da33f7_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i364410dac22d46849150dbb76bf79ea3_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="ie4b9ecc1c92b4eb3b546f10e1fd321ae_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic3ff9e9dd0e5478f9b9bee7abc6546ca_D20150807-20150807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-07</startDate>
            <endDate>2015-08-07</endDate>
        </period>
    </context>
    <context id="i790eb33d2aab4bbb89117717eaf49e43_D20171231-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i1dc0a0736a3a41e3a718ffe92978cc2d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i94a9e28f27b340909b69217c93f1e240_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i11fb2d121358429bbb5330755fc13578_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="iae268d9545fc40279bac5472d53ddf72_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5188afbca0524352a1d0626a807e0bc4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia0128722f91943efb7a4bdfdc5335c37_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i006215dec0fa4ecdac01b405a91894bb_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3a5d7fe092264c2db4c3072992ccce84_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i08d25cd3db624f0fa8d5198cf2a38bc6_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i99c40f03c0b148739b61b7e80708fc06_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i3b66be9eec75416f98e7e0628e15662f_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ia2db5556827143cdafe4b46ce571915b_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i18456a29ef3c4982b6471ce35dc6e525_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i312dea0c2ff240da9167e27ee1e8868d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id557bc0e9dca48c98443ad742ea2b548_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifa238803cd83463bbeb7a595eaa9463c_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i7e0e25538df447b9b57d8cdb39c3731d_D20190801-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="i04dd7aeed28047949952a8193bc3f3a4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idac8dcab713949bd94df184fbba19e22_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ida003d1fc52d461c9d2031cf761e1268_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i01999719b8694f2cb9344f65f0b9b3fc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie814bccba6fe456b84bc2d64be454d97_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8695b2243216498fbd1123097efeb201_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id80ffa0c4fd840e08766b83da4af802f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i59cb3488176045c9af0c67101f651fd0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i31f8cf75d3184c5385ae2d3930c43939_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icddc6a2b71ac4679b73a1761b7335361_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i42731760dc864386b6cc234953ed8db8_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i925dbb99e22c47109cfd6499f718d23f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if5310f1c21874dcba016f8044259901b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ied249d236e834e95ad34273624d104c1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic7a90a05adcc4f638f0b47beed718798_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i869d8bf326be4abfbb1e18a89a00961a_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="iec2d5f6527c24125972f2622cef53837_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="iedf6a38f277949399861daef313a0f5d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib53c870fb97b4899bbb5a65108c6bd6d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaeddbb99315448e8b2869ef6ad5da9ab_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if383b813ea7a4745bfc01e54b08f32d4_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i0362d182781f4ee797f88622a5c045cf_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i27451cafe1f2419998b0684fe0a1a45f_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i2874a1f41d394187a5752e0fa6598078_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i1f18198c2b4e4bd8b89b62558865184c_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i4859da00a9c04ed2b413734cd6ae17e4_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i79ae502b32684fdf8f98b1c19fcf0397_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i9c98da30e4704069839ed075f3b5a328_D20200601-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i10ff0a553ff04929a035481611ba22dc_D20200601-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i70b1c5c8e2f24fff8299e8b17608bb18_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i022bb72c504942ac878d6769a4a1b696_D20200601-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i05d2269442c846edb144f98b63b06aae_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i98c79c39dba34165aa075b540f1c274a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i135db666eca94e468d89995d1fdb8e21_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i0df0aeb02416451db34b6235410d3492_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="investment">
        <measure>ino:investment</measure>
    </unit>
    <unit id="day">
        <measure>ino:day</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="product">
        <measure>ino:product</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80L2ZyYWc6YjE4Yjg1YmIwYTExNGRlNGExNWE5Yjg1OWQ0ODlmMTAvdGFibGU6YTAwZjRhYWU5OGYxNGQ2OWIxN2UxNTBhZjc4ODk1YzIvdGFibGVyYW5nZTphMDBmNGFhZTk4ZjE0ZDY5YjE3ZTE1MGFmNzg4OTVjMl80LTEtMS0xLTA_d16689c2-9168-44f1-b55a-1e6a003cc6e4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80L2ZyYWc6YjE4Yjg1YmIwYTExNGRlNGExNWE5Yjg1OWQ0ODlmMTAvdGFibGU6YTAwZjRhYWU5OGYxNGQ2OWIxN2UxNTBhZjc4ODk1YzIvdGFibGVyYW5nZTphMDBmNGFhZTk4ZjE0ZDY5YjE3ZTE1MGFmNzg4OTVjMl82LTEtMS0xLTA_200b209d-1d6d-4545-b303-52c2b4f2e577">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80L2ZyYWc6YjE4Yjg1YmIwYTExNGRlNGExNWE5Yjg1OWQ0ODlmMTAvdGFibGU6YTAwZjRhYWU5OGYxNGQ2OWIxN2UxNTBhZjc4ODk1YzIvdGFibGVyYW5nZTphMDBmNGFhZTk4ZjE0ZDY5YjE3ZTE1MGFmNzg4OTVjMl83LTEtMS0xLTA_22d995a2-3265-4f04-bd2c-9b3bf60b875a">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80L2ZyYWc6YjE4Yjg1YmIwYTExNGRlNGExNWE5Yjg1OWQ0ODlmMTAvdGFibGU6YTAwZjRhYWU5OGYxNGQ2OWIxN2UxNTBhZjc4ODk1YzIvdGFibGVyYW5nZTphMDBmNGFhZTk4ZjE0ZDY5YjE3ZTE1MGFmNzg4OTVjMl85LTEtMS0xLTA_58bfb64f-738c-4762-8b0c-c64defd5dc6b">0001055726</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80L2ZyYWc6YjE4Yjg1YmIwYTExNGRlNGExNWE5Yjg1OWQ0ODlmMTAvdGFibGU6YTAwZjRhYWU5OGYxNGQ2OWIxN2UxNTBhZjc4ODk1YzIvdGFibGVyYW5nZTphMDBmNGFhZTk4ZjE0ZDY5YjE3ZTE1MGFmNzg4OTVjMl8xMC0xLTEtMS0w_b34f13a7-66ce-4f7d-9936-41857fce60d0">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ifb2dc9cc60144c2ca1da77bc87b7812e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfOTk4OQ_0932b4d7-3f73-4fbf-a0c8-940a3372135a">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="idf4033cfc12e48aca490d914c0d2e740_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81Mi9mcmFnOmIwNzAzYTQ1M2Y1NTQyNDlhZGI4NDg5ZDc1ZTM5NTk3L3RhYmxlOjM2ZjBlMjg5MDhhMjRhNDg5NDM2NjdiZjA5NDJhNmZlL3RhYmxlcmFuZ2U6MzZmMGUyODkwOGEyNGE0ODk0MzY2N2JmMDk0MmE2ZmVfMS0yLTEtMS0w_7961a5c4-2f68-469d-95bf-ec2551f75e40">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82NC9mcmFnOjQ4OGVjNmM3ZjM4NzRhZDM4NWNhZmQ2MzhmYTMzNDFlL3RhYmxlOjk5ZTlmZDljZjZiNjQ2NWY5MjU1YjI4NzVhYTFjNmIyL3RhYmxlcmFuZ2U6OTllOWZkOWNmNmI2NDY1ZjkyNTViMjg3NWFhMWM2YjJfMi0xLTEtMS0w_ad36144c-c69c-4ef1-995e-5f6792a7120e"
      unitRef="number">0.1858045</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="iff76d992bdba46d5be0328b7a9a8d64c_D20200803-20200803"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82NC9mcmFnOjQ4OGVjNmM3ZjM4NzRhZDM4NWNhZmQ2MzhmYTMzNDFlL3RhYmxlOjk5ZTlmZDljZjZiNjQ2NWY5MjU1YjI4NzVhYTFjNmIyL3RhYmxlcmFuZ2U6OTllOWZkOWNmNmI2NDY1ZjkyNTViMjg3NWFhMWM2YjJfNS0yLTEtMS0w_6f29341b-aff6-41fd-b0e3-30a02d1643ea"
      unitRef="number">0.0002110595</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i8a37a98039ba414db800ad308eb2b02c_D20200803-20200803"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82NC9mcmFnOjQ4OGVjNmM3ZjM4NzRhZDM4NWNhZmQ2MzhmYTMzNDFlL3RhYmxlOjk5ZTlmZDljZjZiNjQ2NWY5MjU1YjI4NzVhYTFjNmIyL3RhYmxlcmFuZ2U6OTllOWZkOWNmNmI2NDY1ZjkyNTViMjg3NWFhMWM2YjJfNy0yLTEtMS0w_aa9852d2-c322-437d-a346-c5a7b4360e16"
      unitRef="number">0.0002756873</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ie4c32c65608040b68dea715a2abffbcd_D20191226-20191226"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82NC9mcmFnOjQ4OGVjNmM3ZjM4NzRhZDM4NWNhZmQ2MzhmYTMzNDFlL3RhYmxlOjk5ZTlmZDljZjZiNjQ2NWY5MjU1YjI4NzVhYTFjNmIyL3RhYmxlcmFuZ2U6OTllOWZkOWNmNmI2NDY1ZjkyNTViMjg3NWFhMWM2YjJfOC0yLTEtMS0w_7bfc3422-899d-4191-981e-1aa042522f96"
      unitRef="number">0.0002147766</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i1abaadc504944f67824cef5b490c4d51_D20191226-20191226"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82NC9mcmFnOjQ4OGVjNmM3ZjM4NzRhZDM4NWNhZmQ2MzhmYTMzNDFlL3RhYmxlOjk5ZTlmZDljZjZiNjQ2NWY5MjU1YjI4NzVhYTFjNmIyL3RhYmxlcmFuZ2U6OTllOWZkOWNmNmI2NDY1ZjkyNTViMjg3NWFhMWM2YjJfOS0yLTEtMS0w_3e1c20cf-d9a7-4052-8331-987df99f27ca"
      unitRef="number">0.0003579611</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTEx_c50d95ff-2e34-491c-b22d-05858becb83f">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6ODJjMDRmMmI2NDE5NDZmYWJkMTRlNzUxN2Y4ZjJkMGYvdGFibGVyYW5nZTo4MmMwNGYyYjY0MTk0NmZhYmQxNGU3NTE3ZjhmMmQwZl8wLTAtMS0xLTA_9f932e4d-efdb-4c19-905b-beffe7deb4ae">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8xMzA_8d0fddd4-9a10-4a4c-822b-7fe4dc663b8b">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6MzkwM2U4ZTE5ODFlNDU5NDhjNzRjMjNiNTIyOTUxZGMvdGFibGVyYW5nZTozOTAzZThlMTk4MWU0NTk0OGM3NGMyM2I1MjI5NTFkY18wLTAtMS0xLTA_c506faba-d0dd-4ce1-87ec-2a253fd2c197">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTA0_7fd01f4f-b54a-417d-9652-ed3caf77337e">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTE1_0c9b6423-536e-4a8a-8c80-73e8eb8d5436">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6MmY3OGRlMzllNWUwNDY4ODllOTIxZTExMTYyOTA0NzMvdGFibGVyYW5nZToyZjc4ZGUzOWU1ZTA0Njg4OWU5MjFlMTExNjI5MDQ3M18wLTAtMS0xLTA_836bc44f-f09f-40cc-bd77-415dee76c6b4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6MmY3OGRlMzllNWUwNDY4ODllOTIxZTExMTYyOTA0NzMvdGFibGVyYW5nZToyZjc4ZGUzOWU1ZTA0Njg4OWU5MjFlMTExNjI5MDQ3M18wLTItMS0xLTA_1a2fef97-049f-4e61-93ce-35bbe2c9148c">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTA1_612341ff-ab76-4b56-abd6-a0718551e7c0">660 W. GERMANTOWN PIKE, SUITE 110</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTA2_abd4581b-761e-4f49-b2e2-9b514fc708c1">PLYMOUTH MEETING</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTA3_5ec4ffed-20a7-4d73-8eb9-14f257155b38">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTA4_91f8aa0f-150c-4014-8df8-d7c70f249f5e">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTEy_2c0b5ece-001f-49b2-8f74-a315cf718627">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTEz_ff07b98d-fac0-4ead-9584-5bb8db4beef6">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6YTg4MzY1YjlkZWQ1NDVkMTlhNjgyNTRlYjNhNTNhN2UvdGFibGVyYW5nZTphODgzNjViOWRlZDU0NWQxOWE2ODI1NGViM2E1M2E3ZV8xLTAtMS0xLTA_cacb8a9d-9e2b-4c08-b2a5-83945dab9954">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6YTg4MzY1YjlkZWQ1NDVkMTlhNjgyNTRlYjNhNTNhN2UvdGFibGVyYW5nZTphODgzNjViOWRlZDU0NWQxOWE2ODI1NGViM2E1M2E3ZV8xLTEtMS0xLTA_e135143e-e3ba-4663-bc92-509573e40270">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6YTg4MzY1YjlkZWQ1NDVkMTlhNjgyNTRlYjNhNTNhN2UvdGFibGVyYW5nZTphODgzNjViOWRlZDU0NWQxOWE2ODI1NGViM2E1M2E3ZV8xLTItMS0xLTA_e822ed82-8faf-400e-a0de-08bc3c4031f2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTA5_57524359-8a57-4ced-bcfa-5212e83b4759">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTE0_163c87ff-65af-40b8-a430-276b1a3d643b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6NTdlZDY0YjQ1NzIwNDk3OTljYTNjNTQzZDRkYmNiN2IvdGFibGVyYW5nZTo1N2VkNjRiNDU3MjA0OTc5OWNhM2M1NDNkNGRiY2I3Yl8wLTMtMS0xLTA_931a8e3f-f15f-4746-af68-87789a684d6f">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6NTdlZDY0YjQ1NzIwNDk3OTljYTNjNTQzZDRkYmNiN2IvdGFibGVyYW5nZTo1N2VkNjRiNDU3MjA0OTc5OWNhM2M1NDNkNGRiY2I3Yl8yLTQtMS0xLTA_4493b166-f7dc-41e8-8f85-024f87143580">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGFibGU6NTdlZDY0YjQ1NzIwNDk3OTljYTNjNTQzZDRkYmNiN2IvdGFibGVyYW5nZTo1N2VkNjRiNDU3MjA0OTc5OWNhM2M1NDNkNGRiY2I3Yl80LTQtMS0xLTA_1f634d3f-b05c-4d0e-b96e-8c1fd610fd2d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMTEw_085b60e2-e06a-4f58-9fb1-1c223f9acbc6">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i9d03834c753f4461bc91e302fe02118e_I20201105"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xL2ZyYWc6NjgyYjhkODdiMmQ3NDZmODljMDUwN2YxNmQ2NDMxZDQvdGV4dHJlZ2lvbjo2ODJiOGQ4N2IyZDc0NmY4OWMwNTA3ZjE2ZDY0MzFkNF8yMDkw_4aecf71b-7204-427f-815c-4cebba8e57c9"
      unitRef="shares">169408979</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNC0xLTEtMS0w_35e10cd0-34c6-48bd-b31f-172338fa3e45"
      unitRef="usd">178700434</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNC0zLTEtMS0w_3c3c2692-9685-4191-bd54-c8d1bcd9c992"
      unitRef="usd">22196097</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNS0xLTEtMS0w_1b11a39a-e615-4ffa-bae3-a625bd1615d6"
      unitRef="usd">158535744</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNS0zLTEtMS0w_371ba72c-4c15-4e3f-8939-4db6aa898feb"
      unitRef="usd">67338017</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNi0xLTEtMS0w_b8a9775f-4d53-4d58-96e3-1895b7bc1548"
      unitRef="usd">7692944</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNi0zLTEtMS0w_497c94f0-db3e-4c53-a8d7-85185de1a0c5"
      unitRef="usd">700073</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNy0xLTEtMS0w_7dd1c589-71d6-4e35-a52c-ea943b569cb1"
      unitRef="usd">501311</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNy0zLTEtMS0w_d5ea0d6c-0a9f-46a5-aae2-488f8a3a2502"
      unitRef="usd">1332044</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfOC0xLTEtMS0w_2347429e-9c2a-470e-b226-cd0df83ff37e"
      unitRef="usd">31563697</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfOC0zLTEtMS0w_3a19dbf1-c524-484e-8389-5e108d901d80"
      unitRef="usd">1584598</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfOS0xLTEtMS0w_483ea264-cd83-406f-a9c1-6454492b7569"
      unitRef="usd">70543</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfOS0zLTEtMS0w_62a13621-2552-42f0-be0b-7167f116ea99"
      unitRef="usd">1050140</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:AssetsCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTEtMS0xLTEtMA_3579c4fb-6428-461a-96f0-1f0785d2b45f"
      unitRef="usd">377064673</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTEtMy0xLTEtMA_8e4e0cfe-72e1-4d3d-9abb-729584b9332f"
      unitRef="usd">94200969</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTItMS0xLTEtMA_7ac09947-089e-4611-85ce-bfe8399c4ec1"
      unitRef="usd">11190521</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTItMy0xLTEtMA_81edfc23-dc55-4067-9360-094b27bee2da"
      unitRef="usd">12773017</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTMtMS0xLTEtMA_3a02bda9-980f-4273-b561-e601828c778b"
      unitRef="usd">4154049</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTMtMy0xLTEtMA_a375a65d-a63e-4b39-8519-cecf99102e24"
      unitRef="usd">6315356</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquityMethodInvestments
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTQtMS0xLTEtMA_c1088788-3433-4a79-a5c4-3ca2fec8dc61"
      unitRef="usd">957567</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTQtMy0xLTEtMA_a32d421a-3edf-4377-91e6-6d123d54c9c0"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTUtMS0xLTEtMA_6a4644fc-6ba3-444b-be65-da42160037ea"
      unitRef="usd">3283540</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTUtMy0xLTEtMA_95da6a22-7f73-4bb7-b935-8586107e50d2"
      unitRef="usd">3693851</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTYtMS0xLTEtMA_b2311d6f-d2e4-4b3e-91b9-cbf97b4bcb66"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTYtMy0xLTEtMA_6c80df62-33de-4319-beeb-e2ad9a14a5ac"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTctMS0xLTEtMA_42b952fe-b70e-426f-9dac-95e33e1e06bc"
      unitRef="usd">13008571</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTctMy0xLTEtMA_bf179865-efec-49e2-86c6-2fc12505eb30"
      unitRef="usd">13783009</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTgtMS0xLTEtMA_5bf8ac1b-45d7-436e-b018-16ea48a67cb3"
      unitRef="usd">17641755</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTgtMy0xLTEtMA_f690e406-4181-40b5-a999-0a2963c8cc98"
      unitRef="usd">2672024</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTktMS0xLTEtMA_2c464ccf-d311-4666-ba63-a77d3fd890ae"
      unitRef="usd">437814047</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMTktMy0xLTEtMA_8f665c1b-e108-4b98-88e7-3ed557f07437"
      unitRef="usd">143951597</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjItMS0xLTEtMA_7d123366-da07-46b4-b4b9-dcbdd555ed31"
      unitRef="usd">23533298</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjItMy0xLTEtMA_3cceb575-f4f1-49d4-a549-b7d4086dad21"
      unitRef="usd">18237258</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjMtMS0xLTEtMA_8511d8e0-8e4c-47ca-accd-f5e656c8c10b"
      unitRef="usd">794928</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjMtMy0xLTEtMA_796a7268-4d51-4653-9170-2a96b8e36b74"
      unitRef="usd">729729</us-gaap:DueToRelatedPartiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjQtMS0xLTEtMA_13149a51-09ed-4175-9bd0-74fe092be75e"
      unitRef="usd">5841180</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjQtMy0xLTEtMA_4514e086-1715-4d09-bc43-5a152741b30e"
      unitRef="usd">4049727</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjYtMS0xLTEtMA_7d3bae54-7d02-4cd2-b5a0-4c7c17678fa7"
      unitRef="usd">77878</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjYtMy0xLTEtMA_9da7239e-9c38-418a-9b95-01e0d7d9489b"
      unitRef="usd">92353</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjctMS0xLTEtMA_c25ba335-3eea-456a-9620-5e0d378d33c3"
      unitRef="usd">0</ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent>
    <ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjctMy0xLTEtMA_7adcfa95-b474-47fe-ad95-aab14c330abe"
      unitRef="usd">31775</ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjktMS0xLTEtMA_8deacc81-ae9d-4257-bd6a-3971b1a4c4e5"
      unitRef="usd">2264261</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMjktMy0xLTEtMA_d56e7dcb-2606-4829-bd0f-56bfb6de5e63"
      unitRef="usd">2074842</us-gaap:OperatingLeaseLiabilityCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzAtMS0xLTEtMA_da9e8821-9af8-4dc5-861a-fca84f8fb66a"
      unitRef="usd">8616622</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzAtMy0xLTEtMA_b0497d67-9162-4bbd-8f40-8d62e8ca72f2"
      unitRef="usd">6065212</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzEtMS0xLTEtMA_ef4e30a6-939d-4f1f-ba9b-a9e07a11b76f"
      unitRef="usd">135000</ino:DeferredGrantFundingFromAffiliateCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzEtMy0xLTEtMA_9635ba95-2f1a-40bd-8898-fe4b1bc6e6c5"
      unitRef="usd">708425</ino:DeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzMtMS0xLTEtMA_1d829d41-4e47-4850-ba0d-3e5e2d676648"
      unitRef="usd">41263167</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzMtMy0xLTEtMA_da5564e2-1671-4eb6-974b-0ed83ce9fd6b"
      unitRef="usd">31989321</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzQtMS0xLTEtMA_18399424-b851-42cf-9abe-6d881db858ef"
      unitRef="usd">82927</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzQtMy0xLTEtMA_43b3fc13-fb83-4178-b8ce-3783e5dc393c"
      unitRef="usd">101567</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleDebt
      contextRef="iad00cc94b7054dba89db6de62bd2743e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzYtMS0xLTEtMA_7a30f8cc-08af-4a8c-9c1c-e307ee743a73"
      unitRef="usd">49537210</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i33802a693628436e990fd03d1c367654_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzYtMy0xLTEtMA_83070327-f1b4-4eab-ac4a-d45275021c45"
      unitRef="usd">64180325</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="id37b739c3d7a4609833f69db4559a05d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzctMS0xLTEtMA_108eea79-91c9-4d08-a514-2b266db350d9"
      unitRef="usd">4151663</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="ib74217d38db64ce1adfc9b45c3791fb5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzctMy0xLTEtMA_fdeb0bf1-2248-4c51-822c-3bb8bae29037"
      unitRef="usd">12842592</us-gaap:ConvertibleDebt>
    <us-gaap:DerivativeLiabilities
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzgtMS0xLTEtMA_a2b3202a-a2e0-4dd5-bdd5-fe0fe9b364d4"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfMzgtMy0xLTEtMA_2f6549ac-49b2-4709-959b-536c79342df4"
      unitRef="usd">8819023</us-gaap:DerivativeLiabilities>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDAtMS0xLTEtMA_942e3ae5-2d2f-423a-ae1a-e855a703d298"
      unitRef="usd">18669643</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDAtMy0xLTEtMA_10036957-16ba-48e7-bc74-bc6d0490a3e3"
      unitRef="usd">20409922</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDEtMS0xLTEtMA_d8c8dd22-aa7b-4362-a2be-5629bf95dd3b"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDEtMy0xLTEtMA_2b4b7cc5-25d9-4bb0-9a7d-e9c644c14038"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <ino:DeferredGrantFundingFromAffiliateNoncurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDItMS0xLTEtMA_283a3d6b-a177-4be0-bc49-02332e28c6e4"
      unitRef="usd">37500</ino:DeferredGrantFundingFromAffiliateNoncurrent>
    <ino:DeferredGrantFundingFromAffiliateNoncurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDItMy0xLTEtMA_871241fd-03fc-4764-9376-81ccfed359e1"
      unitRef="usd">135000</ino:DeferredGrantFundingFromAffiliateNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDMtMS0xLTEtMA_a2e178d0-ca8f-46d0-99cf-11fa34275944"
      unitRef="usd">39776</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDMtMy0xLTEtMA_09423ad2-33c8-4f0a-8d4a-f6737eb62fdb"
      unitRef="usd">36943</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDQtMS0xLTEtMA_fc0214f4-baeb-46a7-b398-8b47e753a2b9"
      unitRef="usd">113813932</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDQtMy0xLTEtMA_58782ff8-33d5-4e2c-a7f6-00708f587187"
      unitRef="usd">138546739</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDYtMS0xLTEtMA_e0f0eaec-c10b-466c-8bc4-589f092ff21a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDYtMy0xLTEtMA_d1669de3-da32-431b-878c-097045366fb7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDctMS0xLTEtMA_9d2807fd-bc05-4a0c-9129-c12a746b382b"
      unitRef="usd">167527</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDctMy0xLTEtMA_14e51009-1630-4251-a907-2d14ea2548eb"
      unitRef="usd">101361</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDgtMS0xLTEtMA_f17e3371-3909-4f97-aa0f-45a4d4740dfb"
      unitRef="usd">1205842585</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDgtMy0xLTEtMA_f4a0f09f-73b8-40d8-b14c-69e823d32bac"
      unitRef="usd">742646785</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDktMS0xLTEtMA_64909960-6e45-4e0f-bab3-bb46a4548140"
      unitRef="usd">-881858432</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNDktMy0xLTEtMA_edc023aa-e2f1-42dd-b32a-d319a97e91dd"
      unitRef="usd">-739785655</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTAtMS0xLTEtMA_2835768b-95a8-454b-88fe-22bb63805e56"
      unitRef="usd">-247834</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTAtMy0xLTEtMA_33bbc52d-8d8a-4d8a-ad28-fd4fda76dfc9"
      unitRef="usd">472608</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTEtMS0xLTEtMA_95d59588-900f-4956-90eb-3d7a8259c07e"
      unitRef="usd">323903846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTEtMy0xLTEtMA_e878abc5-5bef-439d-9b75-67fd622d01c0"
      unitRef="usd">3435099</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTItMS0xLTEtMA_87c9c7c5-0055-4b98-9d76-7c35b7b0a3dd"
      unitRef="usd">96269</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTItMy0xLTEtMA_5fa8bf68-fb63-4497-9955-88cdc6e193aa"
      unitRef="usd">1969759</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTMtMS0xLTEtMA_90d7d56a-480c-4326-b9ce-4d173103273a"
      unitRef="usd">324000115</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTMtMy0xLTEtMA_24f562ab-6349-4ba4-a142-b688ed174a2c"
      unitRef="usd">5404858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTQtMS0xLTEtMA_63200217-8e6d-4414-9bee-6015bf79907b"
      unitRef="usd">437814047</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMy9mcmFnOjZhNTdjMTcyYzY1MzQ3YWM5ODg2ODI5Y2UyNThmZDVlL3RhYmxlOjBlZmI1MjFlNDE2YjQ5NTc4ZWM0MGJjZDg2ZjYxZDFjL3RhYmxlcmFuZ2U6MGVmYjUyMWU0MTZiNDk1NzhlYzQwYmNkODZmNjFkMWNfNTQtMy0xLTEtMA_102a3814-aade-4c41-903c-569425e90267"
      unitRef="usd">143951597</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99922d4c4991454fadefaf71d1e588f4_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMy0xLTEtMS0w_d61579db-1bd9-4941-aec8-03c033a47f2e"
      unitRef="usd">21490</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37266a62557f4575b10ba5822c0a691e_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMy0zLTEtMS0w_fc0ce290-a3eb-4b31-ba0d-b4f3e15d17b1"
      unitRef="usd">617427</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbb8d0d9ac154379833cab4cface6fed_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMy01LTEtMS0w_23c8bed7-54ff-4e90-bc2f-fa3bb82b0162"
      unitRef="usd">167092</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a3e1abbbaad4bd7a9c51a4266035110_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMy03LTEtMS0w_1845b0b6-3965-4ebf-bc71-bb9f6081b8f8"
      unitRef="usd">3452422</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i529cf22cf7c34b5cbc581544727e180b_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNC0xLTEtMS0w_74136e0b-ea47-4c72-9dc7-950bb5d8a1c7"
      unitRef="usd">103684</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb8e36088aad444883e60bc40d755771_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNC0zLTEtMS0w_eca16bd8-59d5-4d2b-aba3-e304f1b7d9eb"
      unitRef="usd">53014</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d20b99727a54a1bb1084d53338a7ac5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNC01LTEtMS0w_f5a5c465-14c6-4953-90f2-eeb899508601"
      unitRef="usd">1370956</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a191e57427341858f4afa549fa9f378_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNC03LTEtMS0w_e63cacab-9b33-4e19-beea-2db6a4132a0a"
      unitRef="usd">179984</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibff05cfee55444728cba8c5821c8cd39_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNS0xLTEtMS0w_8328238b-30f8-4e6c-bf7f-7d767c1d07ab"
      unitRef="usd">111004</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5255fbfad51c4e9289a4ebb454a733a0_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNS0zLTEtMS0w_aa531051-3f31-4c6e-b005-e4cfb03fcea8"
      unitRef="usd">196422</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82519fba8e3943dfbc56b64921e0755f_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNS01LTEtMS0w_179ca4ed-5000-4780-ac9c-a1aa01860775"
      unitRef="usd">292591</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12c41f3268694c0eb68fec4dba426315_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfNS03LTEtMS0w_2e628ac2-47d1-44bf-9f05-42352fc02b01"
      unitRef="usd">200036</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfOC0xLTEtMS0w_1195e48a-553c-4a81-8df6-ae230ff99daf"
      unitRef="usd">236178</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfOC0zLTEtMS0w_583ef0be-10c5-4e78-8aa2-7658cfafccd8"
      unitRef="usd">866863</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfOC01LTEtMS0w_2cf21f1b-285f-4440-8b97-1c7bbd18b4c7"
      unitRef="usd">1830639</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfOC03LTEtMS0w_d6e07fd3-52c0-478b-944f-92cf1c75bac1"
      unitRef="usd">3832442</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTAtMS0xLTEtMA_cfb5aa4e-2319-4bd8-93bf-38e56fb34540"
      unitRef="usd">26455112</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTAtMy0xLTEtMA_317f4ada-913d-45c8-9a5a-3e20799183d0"
      unitRef="usd">19137209</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTAtNS0xLTEtMA_210d5d4c-d536-49ff-8d10-8a046dfa298b"
      unitRef="usd">67942875</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTAtNy0xLTEtMA_baddb769-3757-4260-93b4-264d30f49e56"
      unitRef="usd">66013364</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTEtMS0xLTEtMA_737f2651-2bf6-4b80-a352-5e7c34b1298c"
      unitRef="usd">10110506</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTEtMy0xLTEtMA_811d1f6a-c85b-467f-8c22-8ec4e607fb86"
      unitRef="usd">5681441</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTEtNS0xLTEtMA_3ac3f093-a097-423e-a70e-a815a6a0019b"
      unitRef="usd">28630370</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTEtNy0xLTEtMA_9407b909-a49f-4fef-8d3e-95c61ffb2713"
      unitRef="usd">18506570</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTMtMS0xLTEtMA_3b2e0432-7e1c-4c1c-b8a5-d66f6b028378"
      unitRef="usd">36565618</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTMtMy0xLTEtMA_246b4dbf-5c0d-4fb9-b688-18715a68ff8b"
      unitRef="usd">24818650</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTMtNS0xLTEtMA_6e0fb4c2-8a9a-4114-a703-a87e986dee49"
      unitRef="usd">96573245</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTMtNy0xLTEtMA_240cf126-bed7-4b3e-9712-d49108fef794"
      unitRef="usd">84519934</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTQtMS0xLTEtMA_42bb1ccf-03ef-4500-8264-666575b7edad"
      unitRef="usd">-36329440</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTQtMy0xLTEtMA_1b63f0bc-c883-4215-acbb-1fd61cebc876"
      unitRef="usd">-23951787</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTQtNS0xLTEtMA_50db5b05-9266-4e42-84bc-c770b391f87d"
      unitRef="usd">-94742606</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTQtNy0xLTEtMA_6fffe6aa-a601-40c7-b85f-ec04d63552e6"
      unitRef="usd">-80687492</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTYtMS0xLTEtMA_7c898fde-52b3-4f0f-b3c6-8c650670f555"
      unitRef="usd">896710</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTYtMy0xLTEtMA_930b578f-83d1-40ee-ad06-0298e09b72e2"
      unitRef="usd">637438</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTYtNS0xLTEtMA_bf4e4a7f-4df3-4d28-a95b-4f36070262af"
      unitRef="usd">2380678</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTYtNy0xLTEtMA_3ee85f8f-9ac1-42f6-9c5b-814fc106f9de"
      unitRef="usd">2018302</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTctMS0xLTEtMA_568428b3-0a2a-441d-8309-0da8f1181a55"
      unitRef="usd">1984046</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTctMy0xLTEtMA_40dd7930-809a-4f4a-989d-8803a08d6033"
      unitRef="usd">2428671</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTctNS0xLTEtMA_5322c604-cb6b-4252-a90e-772583982caf"
      unitRef="usd">7634442</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTctNy0xLTEtMA_53fb4c6a-f758-48eb-a15a-319096bd1332"
      unitRef="usd">5279702</us-gaap:InterestExpense>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTktMS0xLTEtMA_9e5a025c-90cb-4cda-89ca-b4fa4e6b0338"
      unitRef="usd">35306000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTktMy0xLTEtMA_ef3bdf4e-85a7-4792-b714-87024639f969"
      unitRef="usd">2551453</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTktNS0xLTEtMA_db554d67-974d-4391-a079-9b37a95a5605"
      unitRef="usd">-75670977</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMTktNy0xLTEtMA_456e7464-c127-4daf-ba9f-e4a190b0af8b"
      unitRef="usd">2551453</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjAtMS0xLTEtMA_b188cdae-c196-4e11-8264-ecd4db7cd042"
      unitRef="usd">26951898</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjAtMy0xLTEtMA_7c2bfa49-df60-4742-92b4-067d1af419e1"
      unitRef="usd">-485841</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjAtNS0xLTEtMA_6cc3eea9-b955-4b3d-b990-d191613e1a05"
      unitRef="usd">36250341</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjAtNy0xLTEtMA_d2374299-204d-4b51-98a3-b61d532b7322"
      unitRef="usd">-1409156</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjEtMS0xLTEtMA_4d648c39-f7ad-4b26-af73-5f118f758e30"
      unitRef="usd">1315980</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjEtMy0xLTEtMA_b28223f9-fdd3-455e-b1db-1a67c562d0ed"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjEtNS0xLTEtMA_bc2a38ed-91de-49e0-84e6-2fa9c7b395c6"
      unitRef="usd">624522</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjEtNy0xLTEtMA_8bc7e2a7-7810-44d0-ba30-c9d00905fea3"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjItMS0xLTEtMA_06fc5956-93d5-4d3e-acde-3cdad2c02970"
      unitRef="usd">-136644</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjItMy0xLTEtMA_699f2da6-40c9-4dc0-80fe-1d95a9138f5e"
      unitRef="usd">140956</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjItNS0xLTEtMA_b6abacdd-09c3-418f-b94a-006e175373b2"
      unitRef="usd">-714246</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjItNy0xLTEtMA_9cdde910-7ea6-44d1-9f52-d0582389eabd"
      unitRef="usd">232629</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjMtMS0xLTEtMA_c741ee06-d15d-499b-9b64-2a10966ec4a4"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjMtMy0xLTEtMA_c377f49e-8ef7-4ef5-86b0-c707eee6b93f"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjMtNS0xLTEtMA_21aed3f8-4eba-43d9-aaff-a8cbd0635ec3"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjMtNy0xLTEtMA_4dd7244f-47ad-4edb-aeac-3dd8259e92e4"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="idd26d40a3bcd4f41a7939cead908de3a_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtMS0xLTEtMzQxNA_240fc44c-53a2-461a-8a42-afe98c200106"
      unitRef="usd">-8177043</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i1d09d690018a45498dd313c617375257_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtMy0xLTEtMzQxNA_a51a8add-a37d-4484-88c1-c051756f73b4"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic5b3fb71885d4741bbd44d4710aafc27_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtNS0xLTEtMzQxNA_dee2e69e-c288-4c3a-979c-628a7ed263bf"
      unitRef="usd">-8177043</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i1b80e1cd70cf4455b48eaa840dc9db78_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtNy0xLTEtMzQxNA_5cff0ddf-3816-4e1a-b986-521ae42906e3"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4baefa69f3a64b9a86686d55294e5ee9_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtMS0xLTEtMjY1Ng_1b4ee213-1173-484a-b531-f8c39bdd85d6"
      unitRef="usd">3087595</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i241bac219d9b4d2cab239b4a93aa2809_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtMy0xLTEtMjY1Ng_97ec855f-0e36-42a5-bc44-98932b61558c"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7b045061c7ab428582b10f52d98361c4_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtNS0xLTEtMjY2MA_dcdd53d9-0f9d-482a-bef3-16cb2c555fd7"
      unitRef="usd">3087595</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6edc82bc7b334d5aa607c4be90c9906f_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjQtNy0xLTEtMjY2MA_b64bdb8d-b555-45b3-841f-1d57d70d4fba"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjUtMS0xLTEtMA_a96ecd5e-64ef-4048-abd1-b52b3d4b4fd6"
      unitRef="usd">20931010</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjUtMy0xLTEtMA_419163f0-8953-4445-a261-b748c7d12f9c"
      unitRef="usd">-23536452</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjUtNS0xLTEtMA_014a1631-9429-40c0-8d68-6ba66d878fd3"
      unitRef="usd">-140475103</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjUtNy0xLTEtMA_a0a62e14-fe67-4f65-8099-5c69ba85d9e1"
      unitRef="usd">-82573966</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjYtMS0xLTEtMA_91efe0cb-21a0-48e6-af1e-95c154e41b05"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjYtMy0xLTEtMA_d0964e29-c351-4234-b806-826a116eb8dd"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjYtNS0xLTEtMA_93617016-0a7d-448b-95ab-e8b012d61c0a"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjYtNy0xLTEtMA_e75f8d2e-7a22-48f0-a89f-2cb993c449d4"
      unitRef="usd">-169571</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjctMS0xLTEtMA_0aa4faa4-7d98-42e3-aed7-fd9236a2c55f"
      unitRef="usd">-1759674</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjctMy0xLTEtMA_22ec30b1-f513-4e7b-a2c3-5b5e05ceb634"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjctNS0xLTEtMA_c49cffc2-5f5c-4939-aecf-56812416bbda"
      unitRef="usd">-2661431</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjctNy0xLTEtMA_5a441648-5734-4e8c-826f-729897d1b7de"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjgtMS0xLTEtMA_2007f201-22b9-4170-a80d-1f9f66bd817d"
      unitRef="usd">19171336</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjgtMy0xLTEtMA_f215d454-94cf-4d87-a470-437958597bfa"
      unitRef="usd">-23536452</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjgtNS0xLTEtMA_63f59cfd-fe8b-43c7-ad3f-269bdeb37083"
      unitRef="usd">-143136534</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjgtNy0xLTEtMA_bb3987f6-cb88-433d-8663-750280404b4f"
      unitRef="usd">-82404395</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjktMS0xLTEtMA_f22b6d1d-908c-495b-99e9-780dff37c75c"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjktMy0xLTEtMA_92844d51-559c-4dda-aecf-d480729954df"
      unitRef="usd">-445759</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjktNS0xLTEtMA_2bee6905-42bc-4e78-aaaf-e57f599a4da0"
      unitRef="usd">-1063757</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMjktNy0xLTEtMA_08d08761-cf57-4945-80f0-6e206df52866"
      unitRef="usd">-707214</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzAtMS0xLTEtMA_0bfa0ac8-8cb1-43c7-b734-f71986d7d3e3"
      unitRef="usd">19171336</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzAtMy0xLTEtMA_9b9c316e-7dfc-419d-ae8b-0ba03bec5f40"
      unitRef="usd">-23090693</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzAtNS0xLTEtMA_2e0bd7c1-1ac6-4793-99f8-3e2980ee2a22"
      unitRef="usd">-142072777</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzAtNy0xLTEtMA_082153ca-a9a5-4286-a31b-d713f89ecf58"
      unitRef="usd">-81697181</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzItMS0xLTEtMA_c2698ebe-acb2-407a-8caa-45f42acad8bb"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzItMy0xLTEtMA_bd8edfdb-172f-433d-b319-b8d742c6d28d"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzItNS0xLTEtMA_b1897623-eade-42bd-a66e-e12308943de4"
      unitRef="usdPerShare">-0.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzItNy0xLTEtMA_ab06bbd1-b29c-4d73-8449-37dc8cbf4d2c"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzMtMS0xLTEtMA_7caf4cc4-ade2-4cfe-9b19-d59587d4424d"
      unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzMtMy0xLTEtMA_6c659dc8-0420-4bc9-8a7b-0fd1e9c2f9d7"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzMtNS0xLTEtMA_f9a1bfe0-d5e9-4824-91f6-4e195c7ca550"
      unitRef="usdPerShare">-0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzMtNy0xLTEtMA_28626379-1eb2-43b2-836a-37c529cf765b"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzUtMS0xLTEtMA_c6304a22-f3b8-461d-b403-4f4ec744a0f9"
      unitRef="shares">165355540</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzUtMy0xLTEtMA_8d91140c-c799-4348-ac3c-8602148f1b68"
      unitRef="shares">99007985</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzUtNS0xLTEtMA_bc0cef19-c5b4-481d-a97e-f6b3cab199fa"
      unitRef="shares">148656454</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzUtNy0xLTEtMA_4d48c5e8-dbf5-4ef2-ab2c-db30658f5d46"
      unitRef="shares">98204375</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzYtMS0xLTEtMA_a724ef56-ce85-4089-aa3e-4e109e6b5d77"
      unitRef="shares">174376402</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzYtMy0xLTEtMA_8ee36f70-c834-4d99-9ca5-7e6d8d35f7f5"
      unitRef="shares">102807056</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzYtNS0xLTEtMA_01e48dec-de47-4388-9ded-038874cdc737"
      unitRef="shares">148656454</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xNi9mcmFnOjRiYzYxYWI5YjI4ZjRhNDZiMzE2YjM5YjQxMjBhODEwL3RhYmxlOjRkNTgwOWNhNmY3ODQzZjk5MzE5ZTE3YTNiNjJlNDU0L3RhYmxlcmFuZ2U6NGQ1ODA5Y2E2Zjc4NDNmOTkzMTllMTdhM2I2MmU0NTRfMzYtNy0xLTEtMA_112916ee-0743-4470-af65-461a3798db6e"
      unitRef="shares">98204375</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMi0xLTEtMS0w_6459d7bd-da41-4a07-97e0-4a0328e02899"
      unitRef="usd">19171336</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMi0zLTEtMS0w_351b4c46-8413-4220-a97e-3e128a9abdb9"
      unitRef="usd">-23536452</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMi01LTEtMS0w_8ddc5759-4292-410c-b537-8d57c78a4c71"
      unitRef="usd">-143136534</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMi03LTEtMS0w_c549c4ff-e3cc-4b58-8916-85d7d532a47c"
      unitRef="usd">-82404395</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNS0xLTEtMS0w_bc3e861c-7265-4e1b-b77f-f15555ac0b3a"
      unitRef="usd">6184</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNS0zLTEtMS0w_03acff56-f3df-4e0f-a2e0-33dd8801c0f7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNS01LTEtMS0w_c566f498-a415-4888-9d10-f1ed1f444827"
      unitRef="usd">6184</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNS03LTEtMS0w_f407e2ca-7af1-4db9-baa7-b5961e9fc77f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNi0xLTEtMS0w_d55a156b-1550-4da4-b46a-f15d0ed6ca7e"
      unitRef="usd">356012</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNi0zLTEtMS0w_cb33104e-1d18-4840-8f9a-32f61a4d74cc"
      unitRef="usd">-31457</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNi01LTEtMS0w_08975d55-a579-4dc6-b405-c69b070f4ac2"
      unitRef="usd">-726626</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfNi03LTEtMS0w_211e8bda-2ff2-4091-8774-99a64120fe3b"
      unitRef="usd">1229265</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfOS0xLTEtMS0w_94f0b15e-1d11-40c2-ab9b-767273a92826"
      unitRef="usd">19533532</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfOS0zLTEtMS0w_5710eac8-7f5a-40b1-b5af-9a442084b33c"
      unitRef="usd">-23567909</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfOS01LTEtMS0w_058f18eb-e6b9-4461-b903-cc6341f60890"
      unitRef="usd">-143856976</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfOS03LTEtMS0w_6de75e5c-1533-4f3b-a6a1-0ab18ac20079"
      unitRef="usd">-81175130</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTAtMS0xLTEtMA_ee0e2b81-9ed4-4618-a26a-f742d4c5b5d0"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTAtMy0xLTEtMA_cf97f880-cb27-4167-bde9-ec9fe9c239ec"
      unitRef="usd">-445759</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTAtNS0xLTEtMA_f0979cc4-6a1b-4252-9af5-43a4afdeff6c"
      unitRef="usd">-1063757</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTAtNy0xLTEtMA_b226f088-3580-4bda-8fae-176ed5133af2"
      unitRef="usd">-707214</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTEtMS0xLTEtMA_25ea5889-e0a6-443d-8f96-3a2b9ed85afd"
      unitRef="usd">19533532</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTEtMy0xLTEtMA_ef49ceda-1922-41d8-a1fe-4dc082b03eb5"
      unitRef="usd">-23122150</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTEtNS0xLTEtMA_45385dc7-aee7-406a-a51b-85d7609f1ee1"
      unitRef="usd">-142793219</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xOS9mcmFnOmI4YmNmMDcwZGJlNjRjYjJiZGVmYjc5NTYzN2U0MmI4L3RhYmxlOmI2MmZiMjhhMTgxMjQ5YzViZjVhZjZjMDAyZDMzMzY0L3RhYmxlcmFuZ2U6YjYyZmIyOGExODEyNDljNWJmNWFmNmMwMDJkMzMzNjRfMTEtNy0xLTEtMA_4f584f39-9071-4f77-a68f-62df382ce58d"
      unitRef="usd">-80467916</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i7fd398adc34c49a398e8c5047ce7dca2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtMS0xLTEtMA_611bae79-4a2f-45ee-8b86-ba65db48296d"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7fd398adc34c49a398e8c5047ce7dca2_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtMy0xLTEtMA_2ccd9bdb-b7fb-4903-9a59-eed4809d318c"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i0a3177da420f419793a90426cdb10103_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtNS0xLTEtMA_3c82bfe9-9fd0-49a9-92c7-91e96ede8a0b"
      unitRef="shares">101361034</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a3177da420f419793a90426cdb10103_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtNy0xLTEtMA_adec0aad-b607-4f04-b9c0-9d0cd9c67825"
      unitRef="usd">101361</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i490a2b67f81945fb92911af08177c0d3_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtOS0xLTEtMA_3c841a92-5d88-480f-842d-b6d6d7c53ca1"
      unitRef="usd">742646785</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie245dae4bee84b58843b01eab260ebbe_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtMTEtMS0xLTA_ddd454ee-2b7c-4978-b1fc-f2031b40e6da"
      unitRef="usd">-739785655</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i164d36cfc1194bdfa7a02c7620d6c38f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtMTMtMS0xLTA_ac43d301-7c93-4231-86b7-25a3aaa5cfc8"
      unitRef="usd">472608</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7da7e536da1348a49003199c51350098_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtMTUtMS0xLTA_9e9ef60e-d5fe-49ee-bf32-b232280ff56a"
      unitRef="usd">1969759</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzMtMTctMS0xLTA_99e3b9a1-c1f2-48b4-a25f-6e77c3e47650"
      unitRef="usd">5404858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i08deaaf52352444fb06992fafb59e795_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzQtNS0xLTEtMA_89d4a965-74f5-4505-9c83-241bdfbb350d"
      unitRef="shares">43148952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i08deaaf52352444fb06992fafb59e795_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzQtNy0xLTEtMA_f7af7cc8-a82b-4fc0-af71-5ea2754e25bd"
      unitRef="usd">43149</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i98b336c669ff4c388e47c257d1834054_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzQtOS0xLTEtMA_048a0d46-f0c9-41da-8d76-5271ce0ca65a"
      unitRef="usd">208198784</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia07dddec9a874e3db329127b98b02609_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzQtMTctMS0xLTA_b4662f88-d6e3-4d7f-9040-d1d16e16ded3"
      unitRef="usd">208241933</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i08deaaf52352444fb06992fafb59e795_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzUtNS0xLTEtMA_7c89e730-04fc-40dc-8558-a67ec6d71f58"
      unitRef="shares">1405114</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i08deaaf52352444fb06992fafb59e795_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzUtNy0xLTEtMA_41d6ab6b-49f4-458a-bdd2-02e45a5ca126"
      unitRef="usd">1405</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i98b336c669ff4c388e47c257d1834054_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzUtOS0xLTEtMA_482206a2-65af-4d12-a9ba-4108e2fa6491"
      unitRef="usd">3099298</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia07dddec9a874e3db329127b98b02609_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzUtMTctMS0xLTA_4dad75e3-773e-4b8c-9a24-406b3c1ab1e1"
      unitRef="usd">3100703</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i98b336c669ff4c388e47c257d1834054_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzYtOS0xLTEtMA_063757b4-bf13-4110-bf1a-044ff9d25b6c"
      unitRef="usd">4017761</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie23871a5e018407e8d1d917d80671cdf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzYtMTUtMS0xLTA_7ea46483-7207-414e-84b3-b442da30d7cd"
      unitRef="usd">-16208</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia07dddec9a874e3db329127b98b02609_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzYtMTctMS0xLTA_f7b64f15-acb9-4a74-962e-efc6799bfb67"
      unitRef="usd">4001553</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ie23871a5e018407e8d1d917d80671cdf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzctMTUtMS0xLTA_8d6214b1-2417-49bf-91f5-824aa5160a68"
      unitRef="usd">2169998</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ia07dddec9a874e3db329127b98b02609_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzctMTctMS0xLTA_4099b5ff-7517-4d9c-9d63-006ffc1af040"
      unitRef="usd">2169998</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:ProfitLoss
      contextRef="ib8eda4ce49e3408f9d4f5308a4037533_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzgtMTEtMS0xLTA_1893e972-cd7d-4e8f-9acd-e76cc1a21838"
      unitRef="usd">-32541054</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie23871a5e018407e8d1d917d80671cdf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzgtMTUtMS0xLTA_69dfd6c6-54dc-4e70-96e2-fa2386cc5912"
      unitRef="usd">-594350</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia07dddec9a874e3db329127b98b02609_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzgtMTctMS0xLTA_a3f73f6d-6902-4389-9fec-f4a0057cec2c"
      unitRef="usd">-33135404</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4411f044a3a14ba18265a15b7226653c_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzktMTMtMS0xLTA_640a6f51-d816-48b3-9138-3b376cdc613d"
      unitRef="usd">-1929538</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia07dddec9a874e3db329127b98b02609_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfMzktMTctMS0xLTA_23f64f82-ec95-4b3a-9b57-f9093ce9d8f2"
      unitRef="usd">-1929538</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i770162b78bb54f1fa1711d54652a4751_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtMS0xLTEtMA_d675fea4-3a13-4ee3-9ca1-febec176c9b7"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i770162b78bb54f1fa1711d54652a4751_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtMy0xLTEtMA_74657b7f-83b2-4e84-9e0d-54e2e61558c7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i6eaf13aa46744705aa06fb61cbe8aa82_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtNS0xLTEtMA_978283a3-fe5a-4fc9-a079-38096b71d598"
      unitRef="shares">145915100</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6eaf13aa46744705aa06fb61cbe8aa82_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtNy0xLTEtMA_e058e5a7-351c-44ae-8745-7525fc8d1fb1"
      unitRef="usd">145915</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9f754f0888148c498ed9fff863d50dd_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtOS0xLTEtMA_270e6d01-be67-4159-8e98-899f34c02305"
      unitRef="usd">957962628</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47296c4f224f4821b9b5398dff066172_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtMTEtMS0xLTA_ef953f46-6fbf-440d-bee8-a1d4aab243e1"
      unitRef="usd">-772326709</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic38a8356669f4b94a31d4fe6a18ea3c3_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtMTMtMS0xLTA_a6a69ccb-c4a3-4efd-8188-ef3bf2acc458"
      unitRef="usd">-1456930</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5dcbbe8e1f748d0aa61b641b73d3fc4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtMTUtMS0xLTA_aac4d2c2-8983-4e61-957c-62ca55eda645"
      unitRef="usd">3529199</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief04ee355ac748d99c0d4127735597c1_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDAtMTctMS0xLTA_616618a6-ab1f-42d0-8ed7-69041f750eff"
      unitRef="usd">187854103</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDEtNS0xLTEtMA_b39f204b-863f-4880-8e68-ca7dda0795ff"
      unitRef="shares">12041178</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDEtNy0xLTEtMA_7f77bdf9-2d3a-4be2-9be4-449e4d052b16"
      unitRef="usd">12041</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i83f9c138d29b443f9ed4bc98e732da37_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDEtOS0xLTEtMA_33623aeb-e48b-468e-950e-5659955fca00"
      unitRef="usd">121706881</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDEtMTctMS0xLTA_f5a1de24-b2d1-4bd7-ad60-3464b72ca1bf"
      unitRef="usd">121718922</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ice079a38e1e1455b9775b3e80821be68_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDItMS0xLTEtMA_b8415b24-67d3-406a-9f7a-ca58d6f37799"
      unitRef="shares">14</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDItNS0xLTEtMA_3041a4c3-19e4-4274-ba78-1cc8ac0c1672"
      unitRef="shares">5147</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDItNy0xLTEtMA_96d33978-67eb-4fc5-a916-5229820009f4"
      unitRef="usd">5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i83f9c138d29b443f9ed4bc98e732da37_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDItOS0xLTEtMA_13583b53-90f9-4c3d-823e-6e4bcf2b4d97"
      unitRef="usd">-5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDItMTctMS0xLTA_fca98f45-1fd1-490b-b926-8ce43e9a553e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDMtNS0xLTEtMA_40a2a5ca-e8d6-4833-af43-64873a211ba4"
      unitRef="shares">794986</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1a4571cc82e743b5a21368e3b3f599c9_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDMtNy0xLTEtMA_0cb453c0-c562-4b19-a43f-a58d8153080d"
      unitRef="usd">795</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i83f9c138d29b443f9ed4bc98e732da37_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDMtOS0xLTEtMA_daf945fd-8d2d-44e4-8077-698186046aad"
      unitRef="usd">4421449</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDMtMTctMS0xLTA_30784aca-7c4f-4b50-90a0-c0cf8a015385"
      unitRef="usd">4422244</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i83f9c138d29b443f9ed4bc98e732da37_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDQtOS0xLTEtMA_321135a4-314c-4105-9423-ed0be5a8c322"
      unitRef="usd">3654289</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if181d6b7610d46769fd6e637cc5073f1_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDQtMTUtMS0xLTA_f091bd26-a849-4c22-b14e-826861c68325"
      unitRef="usd">8146</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDQtMTctMS0xLTA_90a72e74-c810-455a-a03d-eba0b681231b"
      unitRef="usd">3662435</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="if181d6b7610d46769fd6e637cc5073f1_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDUtMTUtMS0xLTA_2d1a95c9-8f1f-41f0-9525-e85d4adc8cfc"
      unitRef="usd">209971</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDUtMTctMS0xLTA_842818de-74ad-4cbe-a7aa-d0d4b4da9e0f"
      unitRef="usd">209971</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="if181d6b7610d46769fd6e637cc5073f1_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDYtMTUtMS0xLTA_449a2e94-3567-4279-807f-dac5f63611e1"
      unitRef="usd">3181640</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDYtMTctMS0xLTA_fd6da11f-4938-426e-8ea5-e803ce3001af"
      unitRef="usd">3181640</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:ProfitLoss
      contextRef="ib0244b4520d04e4e8f59d89ddd1fad54_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDctMTEtMS0xLTA_ad113136-ec92-4fed-86e4-83876a4c38d5"
      unitRef="usd">-128703059</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if181d6b7610d46769fd6e637cc5073f1_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDctMTUtMS0xLTA_32443370-e4c6-4df1-be54-5405fb8185f2"
      unitRef="usd">-469407</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDctMTctMS0xLTA_5b22a93c-003b-4fcf-b70f-a7c6146e3352"
      unitRef="usd">-129172466</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie69799d5ae944511ba30c40042a5b329_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDgtMTMtMS0xLTA_3e70fb16-8b2b-49be-9a22-240abf8a31e0"
      unitRef="usd">846900</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia362228c119c4fbc9a1ff2547c75a249_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDgtMTctMS0xLTA_3a62be3e-4b06-4d18-b69f-f78e99cdae9e"
      unitRef="usd">846900</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ib7569d7245f540de94c34ea74b24ab62_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktMS0xLTEtMA_b34f036a-99d6-4754-8612-ffd70c664d01"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7569d7245f540de94c34ea74b24ab62_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktMy0xLTEtMA_fd0d35f9-ff18-4d1e-900f-86667569fc2f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ieb3f93f3c4c744d585e8ee4ebe462d9b_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktNS0xLTEtMA_6acdee8a-6ba5-45f4-973e-b31939219ea1"
      unitRef="shares">158756411</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb3f93f3c4c744d585e8ee4ebe462d9b_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktNy0xLTEtMA_077e3f13-539c-4c5f-8aaf-a21705fd13fb"
      unitRef="usd">158756</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cc6179ba6344761bb813a2e5b312a60_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktOS0xLTEtMA_21164d70-a567-46f6-a5fb-6ef94fb3d20e"
      unitRef="usd">1087745242</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0bf2f09d68754bb1971d7930890683f9_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktMTEtMS0xLTA_99fdbc6a-680b-424d-a02d-e39ffc96a0fd"
      unitRef="usd">-901029768</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b9c539a1838477abaf6bfa915ee886c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktMTMtMS0xLTA_d1278ff1-6ab3-494b-9582-5b92b8ca6c43"
      unitRef="usd">-610030</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cbfe1fda7da45e895ad0f7797870e3e_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktMTUtMS0xLTA_3f3a10f1-ff30-4420-a7f8-9d53834f71ec"
      unitRef="usd">96269</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i510e75df51764aeab124f1f96a2ce60c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNDktMTctMS0xLTA_dbee7f88-b29b-47f6-8d34-c3765fbed183"
      unitRef="usd">186360469</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i7ee3e0978a8246caaaca0810f4cdd6ea_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTEtNS0xLTEtMTQ2_36292741-e99a-4bed-9e5d-4d749fa581eb"
      unitRef="shares">3546074</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7ee3e0978a8246caaaca0810f4cdd6ea_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTEtNy0xLTEtMTQ2_2adaf028-b5a0-4d43-b508-c84dcec47ccc"
      unitRef="usd">3546</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iff71970e3ccb4c1ba1e28e003e256dbb_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTEtOS0xLTEtMTQ2_cb940532-3118-476d-aa93-0d0b153f7055"
      unitRef="usd">12967814</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4baefa69f3a64b9a86686d55294e5ee9_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTEtMTctMS0xLTE0Ng_2cebe323-5bf8-4ed4-8ade-80b9905fdb2c"
      unitRef="usd">12971360</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i647bfa57e2c94d82bfe6d0586215e925_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItNS0xLTEtMjYyNA_0f95684d-f9bb-4709-bf09-8391a8a0996b"
      unitRef="shares">4962364</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i647bfa57e2c94d82bfe6d0586215e925_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItNy0xLTEtMjYyNA_fd418145-9cea-4101-a515-f2f9a2234b46"
      unitRef="usd">4961</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie6259481f55947f8a81ad5e6bdf162e0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItOS0xLTEtMjYyNA_2abd5513-669b-41ca-b46a-d41514b63c6f"
      unitRef="usd">102666349</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i59f9640746a545989d1bbdb6a45e5c57_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItMTctMS0xLTI2MjQ_19f1eb86-7614-49e0-9c40-4b89312884ec"
      unitRef="usd">102671310</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="idd29250290ea4170b0c3e4f90e4306a9_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItNS0xLTEtMTQ2_fd3d1797-0cca-4f05-a035-b80393f9294b"
      unitRef="shares">263586</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idd29250290ea4170b0c3e4f90e4306a9_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItNy0xLTEtMTQ2_dba317a9-4900-4161-beaa-1392594133ee"
      unitRef="usd">264</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaae34ec028bf4c5093d8f8caad4165ca_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItOS0xLTEtMTQ2_e0228477-69a2-47bc-b295-54e824e78469"
      unitRef="usd">-1695315</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTItMTctMS0xLTE0Ng_4bcc7d53-b8bf-43af-b6aa-c9179756834a"
      unitRef="usd">-1695051</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaae34ec028bf4c5093d8f8caad4165ca_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTMtOS0xLTEtMTQ2_3da95b84-7b72-4ca9-902a-d2faef06535a"
      unitRef="usd">4158495</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTMtMTctMS0xLTE0Ng_202b1c7b-ef32-4337-ac02-ab4b06798ade"
      unitRef="usd">4158495</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="i6465f1fd3deb40cb9065e34705e46564_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTYtMTEtMS0xLTE0Ng_7878a616-8308-4812-8545-2fc1f04abce5"
      unitRef="usd">19171336</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTYtMTctMS0xLTE0Ng_648c5814-a9ef-4e80-881f-f0adc60d4a51"
      unitRef="usd">19171336</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i978b9d86842c4f2bb0684bfacb1d2f7d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTctMTMtMS0xLTE0Ng_f4a51971-8acb-4c10-b149-4e28fe7f05db"
      unitRef="usd">356012</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTctMTctMS0xLTE0Ng_07baffba-c316-4cbb-a710-f5e103ae7f7f"
      unitRef="usd">356012</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i978b9d86842c4f2bb0684bfacb1d2f7d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMTMtMS0xLTIyNzM_ea428d49-bfdb-4418-8f89-fc228706cc7f"
      unitRef="usd">6184</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMTctMS0xLTIyNzM_2046380b-a104-42a4-81b3-ba0f5d4a7561"
      unitRef="usd">6184</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i79c71d22c8084831b9423ab29cd4f183_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMS0xLTEtMTQ2_fa274ee8-f185-4e67-a2af-b07cca1c05db"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79c71d22c8084831b9423ab29cd4f183_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMy0xLTEtMTQ2_24c00caa-3c21-4ae4-a9ac-0ed7a5a74629"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="iabe71ccc813949e295ac419f3bf11133_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtNS0xLTEtMTQ2_aa181eff-984d-4e3f-8d17-82c95a0361f0"
      unitRef="shares">167528435</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabe71ccc813949e295ac419f3bf11133_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtNy0xLTEtMTQ2_1f59b338-7100-49a5-a2c9-a2ffc6e2623f"
      unitRef="usd">167527</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25f2b47e634f4835ae39efe3509d84cd_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtOS0xLTEtMTQ2_98cae067-dd4b-43c2-9f54-68efca3a5ff8"
      unitRef="usd">1205842585</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e2c3f19273a42778f051025844a72e2_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMTEtMS0xLTE0Ng_8cd47788-b4b5-4169-b021-0e48ccfd25fb"
      unitRef="usd">-881858432</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a012f253e8c4f838461bd187a090df3_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMTMtMS0xLTE0Ng_ef34db95-26ac-429a-bf12-9e422d060572"
      unitRef="usd">-247834</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i101ba48e80cc4d48b6199ad88e5a774a_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMTUtMS0xLTE0Ng_6bcb8e42-b3dc-466d-bd83-4e1c8d083bc1"
      unitRef="usd">96269</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOmI3ZTI4OTJmOTk2MTRjMTQ5NWE2Y2YyNTk4ZmJhMjMwL3RhYmxlcmFuZ2U6YjdlMjg5MmY5OTYxNGMxNDk1YTZjZjI1OThmYmEyMzBfNTgtMTctMS0xLTE0Ng_3b60804f-630a-4b38-9a9b-a3378eb967e2"
      unitRef="usd">324000115</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="iad543da68a144f83a4d3805ac1f6d89e_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtMS0xLTEtMA_bbe56e19-0837-40ce-a4e1-e33e5548b735"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad543da68a144f83a4d3805ac1f6d89e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtMy0xLTEtMA_1a0b96a0-a8a2-4c85-9062-5914cc69a12a"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="id389379a953b4eac99e35c98ee5f565b_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtNS0xLTEtMA_16724202-7a14-4a8e-93e4-94f24b236fbc"
      unitRef="shares">97225810</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id389379a953b4eac99e35c98ee5f565b_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtNy0xLTEtMA_be4fd13e-399b-4801-b6b2-99264cc81cbe"
      unitRef="usd">97226</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica8a6426b215442eb3caef7cecc4c115_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtOS0xLTEtMA_80aec2ef-a049-413a-a262-b9d8fe8655e2"
      unitRef="usd">707794215</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56e81b2a6acf4575b6a2fd1a15aa3a3a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtMTEtMS0xLTA_bebeb908-5fcc-4b9a-9488-430e2754c6d0"
      unitRef="usd">-620426436</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i912f365b06294ab497683dd0247e0307_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtMTMtMS0xLTA_24546fc1-cae3-49dc-98ea-f0d3b7d70d89"
      unitRef="usd">-528867</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e0f2db7f9c1466d884a3ed9d245869e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtMTUtMS0xLTA_9a2e330a-6d25-4ca4-9bd5-231fe8d66c0f"
      unitRef="usd">96269</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2fca9614850f4094a30e35df9ad3f90d_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzEtMTctMS0xLTA_06dcb3a3-a767-446a-a2b8-da6866c7825c"
      unitRef="usd">87032407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7c34cc69f8ff4a9e9279090d85e2ed1a_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzItNS0xLTEtMA_135ec7c1-9eca-4338-9611-40fafc0906c4"
      unitRef="shares">183200</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7c34cc69f8ff4a9e9279090d85e2ed1a_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzItNy0xLTEtMA_25360122-0931-4485-aef1-a45a9e451785"
      unitRef="usd">183</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i11dd26adaa634c719948d1c87ffa3cb9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzItOS0xLTEtMA_ac20c111-f986-4dc1-a54a-869af12a1ca6"
      unitRef="usd">907147</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzItMTctMS0xLTA_0cffe1fd-129f-4ad8-8937-80070bace3d1"
      unitRef="usd">907330</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7c34cc69f8ff4a9e9279090d85e2ed1a_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzMtNS0xLTEtMA_18843091-07ca-4382-81db-c02c7d61db39"
      unitRef="shares">525000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7c34cc69f8ff4a9e9279090d85e2ed1a_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzMtNy0xLTEtMA_618232ce-d391-44d4-b98f-baaf8edcef34"
      unitRef="usd">525</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i11dd26adaa634c719948d1c87ffa3cb9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzMtOS0xLTEtMA_a2614a1b-1af1-4191-9097-a17eb79e8b93"
      unitRef="usd">-719922</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzMtMTctMS0xLTA_1e14a02a-5128-4ea8-86bd-3c8643f9e1a6"
      unitRef="usd">-719397</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i11dd26adaa634c719948d1c87ffa3cb9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzQtOS0xLTEtMA_03206657-3cb6-43ef-874e-5fd73985ca4b"
      unitRef="usd">15752698</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzQtMTctMS0xLTA_7ab5ec07-ead9-44d6-acf4-ea63345daf70"
      unitRef="usd">15752698</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i11dd26adaa634c719948d1c87ffa3cb9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzUtOS0xLTEtMA_b314ff7e-6038-41ee-9c81-7d818e350dd4"
      unitRef="usd">3432796</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzUtMTctMS0xLTA_dd2011bd-066e-4b2d-986c-2e41db1440bc"
      unitRef="usd">3432796</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i6e69cbad70b5452e8efff3fcfbccf5a5_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzYtMTUtMS0xLTA_2e3441ff-e045-4cd7-bcf4-ecb4f29bd50c"
      unitRef="usd">3030107</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzYtMTctMS0xLTA_ea307189-d8c5-4352-a308-71e4cc743572"
      unitRef="usd">3030107</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:ProfitLoss
      contextRef="ied96fbdb97a849e49bf60586fe4cae49_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzctMTEtMS0xLTA_dc4a8a80-00c4-4d23-92fc-2e14f52ab86a"
      unitRef="usd">-29219262</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6e69cbad70b5452e8efff3fcfbccf5a5_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzctMTUtMS0xLTA_b2dd0503-9e40-49e5-a769-ae9be2f3424e"
      unitRef="usd">-69605</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzctMTctMS0xLTA_a161f2de-0907-4413-b79c-cfe0e8528800"
      unitRef="usd">-29288867</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i11229e332bfe44958cd20245c914ab26_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzgtMTMtMS0xLTA_3dee6946-d829-4390-86b7-62d6b279bfbf"
      unitRef="usd">819177</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i30e7acb9ca994982a44622aa630b7c1f_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzgtMTctMS0xLTA_5f230253-b347-4cd1-8de8-708ad0b5e6dc"
      unitRef="usd">819177</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ia760ea1651944cdda9f87141b2c3b22c_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktMS0xLTEtMA_e61b60de-a863-4732-8e9a-164df201b720"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia760ea1651944cdda9f87141b2c3b22c_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktMy0xLTEtMA_e5871f9e-b9d6-41a8-b62a-59a53df68533"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ie93f9f62a04d495caf7d3e9ad734702b_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktNS0xLTEtMA_352b6223-3699-43a3-963c-fe3a0dec3c22"
      unitRef="shares">97934010</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie93f9f62a04d495caf7d3e9ad734702b_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktNy0xLTEtMA_66d9eaee-2fd6-448c-822f-f9497e47629e"
      unitRef="usd">97934</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8d984df17864fe6b064ed160b10dbab_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktOS0xLTEtMA_78beebfe-fe8e-4c43-96b7-524fd2d4eef9"
      unitRef="usd">727166934</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2376931e94a479ab3da18397c83700e_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktMTEtMS0xLTA_fc0bbafc-3c75-4973-b4bf-58dc3ac92ed3"
      unitRef="usd">-649645698</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie6ba01cda73b483185d19910f47e556b_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktMTMtMS0xLTA_05550e41-efe1-456f-a5fb-11f552879556"
      unitRef="usd">290310</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d38c9c361a3445fa534a5a54efca8ce_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktMTUtMS0xLTA_1434fa15-fb1d-4748-81e5-19242adc64e3"
      unitRef="usd">3056771</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68ff5039256e484d8748c537f9e688d9_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfMzktMTctMS0xLTA_384fb060-326a-45dd-9d7b-15351bf5455b"
      unitRef="usd">80966251</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i62bb952cc15b4e1dbdd165eb7c3dcfbd_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDAtNS0xLTEtMA_bd75b4a7-9786-45c5-84a5-26b6e0f08b5c"
      unitRef="shares">476600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i62bb952cc15b4e1dbdd165eb7c3dcfbd_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDAtNy0xLTEtMA_6ac74f53-4579-450a-a50c-05f46229adcb"
      unitRef="usd">476</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4b38bc463ae342a1bc3326ab42796c09_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDAtOS0xLTEtMA_671122cd-278f-481b-a990-2209b7154453"
      unitRef="usd">1388510</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDAtMTctMS0xLTA_e1e4efd6-6569-4504-a3d3-413e0ebdc42a"
      unitRef="usd">1388986</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i62bb952cc15b4e1dbdd165eb7c3dcfbd_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDEtNS0xLTEtMA_3b7c4d11-457d-4bc7-a084-3068e0ddfe69"
      unitRef="shares">173761</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i62bb952cc15b4e1dbdd165eb7c3dcfbd_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDEtNy0xLTEtMA_e37b5fd5-0d5f-4d9f-b6d7-e0915e3c5841"
      unitRef="usd">174</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4b38bc463ae342a1bc3326ab42796c09_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDEtOS0xLTEtMA_afe18ddb-86f2-4de7-af92-0a23adbb6e69"
      unitRef="usd">-81433</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDEtMTctMS0xLTA_b8b449b0-4bb3-4abe-819f-f78b03d4506c"
      unitRef="usd">-81259</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4b38bc463ae342a1bc3326ab42796c09_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDMtOS0xLTEtMA_33ad5b0d-051c-42c2-a7fa-ce853d159a2b"
      unitRef="usd">3345378</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibb02416827ad434aacea7535d3776742_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDMtMTUtMS0xLTA_e37c9f69-0fd7-4aac-8b91-72d76a8999c1"
      unitRef="usd">9817</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDMtMTctMS0xLTA_618374a2-06b7-4201-994d-b0b99d3a69f9"
      unitRef="usd">3355195</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ibb02416827ad434aacea7535d3776742_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDQtMTUtMS0xLTA_755bb20a-fe77-42af-bf0c-e5fd75a1942e"
      unitRef="usd">13569</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDQtMTctMS0xLTA_44166f28-cbb6-4afc-a134-413a2dbcfd20"
      unitRef="usd">13569</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:ProfitLoss
      contextRef="i3c7f59d7bc8740db8cb1ae6cde690f43_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDUtMTEtMS0xLTA_33c92f20-0047-46c3-8f31-5c192f9966d3"
      unitRef="usd">-29387226</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibb02416827ad434aacea7535d3776742_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDUtMTUtMS0xLTA_f65078b1-43fa-428c-b698-19f1d6b43f2d"
      unitRef="usd">-191850</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDUtMTctMS0xLTA_9fbd27b4-676d-4101-9658-f8d5c6bc782d"
      unitRef="usd">-29579076</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i971bb2028af54bd38e7112fbc6dabd8a_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDYtMTMtMS0xLTA_f4c881c1-0de4-4954-a9e0-b485181c1039"
      unitRef="usd">441545</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibdc00906e98245b3a9aaae2397a9bccc_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDYtMTctMS0xLTA_d9b2cf88-8dcd-4a28-bf37-1e37ca9fc112"
      unitRef="usd">441545</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="idac672ec0b2e49d48f658a67d9cf0a81_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctMS0xLTEtMA_87bdd3a2-6202-4c46-8ae4-817d584e58ff"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idac672ec0b2e49d48f658a67d9cf0a81_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctMy0xLTEtMA_45f35091-961f-434b-955f-b42d0a6bbd86"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i01241b5b4e1d44b28b5be3eab2189cf6_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctNS0xLTEtMA_0520af0c-7e23-476d-8651-eb77ae205f66"
      unitRef="shares">98584371</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01241b5b4e1d44b28b5be3eab2189cf6_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctNy0xLTEtMA_dd2a844d-e4eb-421e-ad66-f59d3b32b09b"
      unitRef="usd">98584</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c40c2619a6e4f689eb5e72a7788b8af_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctOS0xLTEtMA_6cbb590c-194a-495f-a304-f548eb75e37a"
      unitRef="usd">731819389</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71d44e1083ea450d84f392f8d18c62e9_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctMTEtMS0xLTA_19444b39-16bd-4c6f-94b7-fdd7615fa73b"
      unitRef="usd">-679032924</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78220f5c2a8e4adebfb1017126a472b2_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctMTMtMS0xLTA_e1bae20f-9b64-4358-b948-6f2065bd0bc5"
      unitRef="usd">731855</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44b65c8171f84184a933954da0d120ac_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctMTUtMS0xLTA_a1174d8a-0a09-4832-a9ce-2ccc8e202f6f"
      unitRef="usd">2861169</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c14c362804a4c57ba8b3135c378097c_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDctMTctMS0xLTA_6f9a7c63-1086-4283-a3f9-3dd54d4bcaf9"
      unitRef="usd">56478073</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6ecc7fb3c1d845e3a86bafa86c697ef4_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDgtNS0xLTEtMTEy_79c93631-2108-4cab-87fc-39d93c1cbd61"
      unitRef="shares">382800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6ecc7fb3c1d845e3a86bafa86c697ef4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDgtNy0xLTEtMTEy_5ec84261-edd8-41f8-ae7b-355e1539872f"
      unitRef="usd">383</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if02c1be59ab240e5bf65dec5515fa519_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDgtOS0xLTEtMTEy_d0058f92-4a9f-4922-80f9-bbd2ceb5f0d3"
      unitRef="usd">1128366</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDgtMTctMS0xLTExMg_0e06a1d7-9ad7-490e-a77b-0371eae47e66"
      unitRef="usd">1128749</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6ecc7fb3c1d845e3a86bafa86c697ef4_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDktNS0xLTEtMTEy_3e7cdb20-1cc1-498f-978c-9df9220180d4"
      unitRef="shares">78987</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6ecc7fb3c1d845e3a86bafa86c697ef4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDktNy0xLTEtMTEy_bec1dd2f-bbae-4bd8-8858-7d725e45c559"
      unitRef="usd">79</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if02c1be59ab240e5bf65dec5515fa519_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDktOS0xLTEtMTEy_8abc793c-39f6-47f7-88ce-16e9e1d92783"
      unitRef="usd">-79</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNDktMTctMS0xLTExMg_a22339c2-0ec0-4d65-915d-ea1221b4efa0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if02c1be59ab240e5bf65dec5515fa519_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTAtOS0xLTEtMTEy_a666c7bc-2ae7-4098-92e5-ab379afabe77"
      unitRef="usd">2070067</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0fe6086a20184ba5bede380b65b2eea4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTAtMTUtMS0xLTExMg_4a077310-87a2-43ca-a584-e61990491951"
      unitRef="usd">9752</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTAtMTctMS0xLTExMg_a7475523-6e64-459c-8932-ff664f8f2782"
      unitRef="usd">2079819</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="i00852cf554364a3aae33ca5c9a00c901_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTEtMTEtMS0xLTExMg_13e8a7fc-e2b4-4510-bb49-484883cd0665"
      unitRef="usd">-23090693</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0fe6086a20184ba5bede380b65b2eea4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTEtMTUtMS0xLTExMg_742eec73-3836-4a17-b430-0e1a17bd34a5"
      unitRef="usd">-445759</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTEtMTctMS0xLTExMg_c74a9ed0-7d56-4b93-a3c5-836bc31c4f0b"
      unitRef="usd">-23536452</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie69970bd582c4a249c8df8217f771954_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTItMTMtMS0xLTExMg_fb3d8d4c-201d-4166-b244-80de0dd222ab"
      unitRef="usd">-31457</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTItMTctMS0xLTExMg_9ce7deb1-6f9f-4660-9252-74ffce6f9fdb"
      unitRef="usd">-31457</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i4b6031a5c53b40dfbdf167f3ecc7127d_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtMS0xLTEtMTEy_8e86b551-0b5f-4829-a684-d9976d28b0fa"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b6031a5c53b40dfbdf167f3ecc7127d_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtMy0xLTEtMTEy_71682749-03e2-4a22-b225-968a70901130"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i4db23d3c84734d66b66635aa8030bee5_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtNS0xLTEtMTEy_cf987c82-4618-4455-956b-f24dfe0ee91c"
      unitRef="shares">99046158</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4db23d3c84734d66b66635aa8030bee5_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtNy0xLTEtMTEy_0073346b-6317-4f92-9f25-49d35e6e49c7"
      unitRef="usd">99046</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i679e13f56b134421b5679976e76aa618_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtOS0xLTEtMTEy_d43f9593-0100-4ec1-b950-7846a09add74"
      unitRef="usd">735017743</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65eb5d78647b4483b008e23b402ec513_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtMTEtMS0xLTExMg_ff2b507b-b7c3-467d-8f02-8b6089d23046"
      unitRef="usd">-702123617</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d60de4ea362438a8dce34b8e79c0472_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtMTMtMS0xLTExMg_b06b21ca-63d5-435f-b122-854d99bc4fc1"
      unitRef="usd">700398</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i362cebf18fb64bc0aeb2df72a45e870e_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtMTUtMS0xLTExMg_c696b98c-eee2-47f9-a50f-f90134047ef3"
      unitRef="usd">2425162</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ea46918d69244b0b92fa827e8689f35_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yMi9mcmFnOmMwNTYzMDU3MzBlNzQ5MDQ4MzkwYzk2OWFhMTNkNzFiL3RhYmxlOjgwM2ZjMDQzZjdkOTQxZGRhNDZiM2YyNTI2OWQ0M2QzL3RhYmxlcmFuZ2U6ODAzZmMwNDNmN2Q5NDFkZGE0NmIzZjI1MjY5ZDQzZDNfNTMtMTctMS0xLTExMg_c582ea9e-b51e-46b3-812f-c89c999341b6"
      unitRef="usd">36118732</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMy0xLTEtMS0w_9e528b2f-fe92-4c6a-8c2e-90f3faa80a8b"
      unitRef="usd">-143136534</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMy0zLTEtMS0w_e00d8a54-533d-467c-9f0b-d83967d06e56"
      unitRef="usd">-82404395</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNS0xLTEtMS0w_a78d4cf9-da0f-4b51-bbbd-af6585976d7b"
      unitRef="usd">2323505</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNS0zLTEtMS0w_0b783d6a-ddc0-499e-9922-8155782d42ad"
      unitRef="usd">2746463</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNi0xLTEtMS0w_00ab7c93-ffb7-406c-b199-a70b253b8b3d"
      unitRef="usd">410311</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNi0zLTEtMS0w_6414555f-1685-4e93-bfef-294d3976d03b"
      unitRef="usd">799688</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfOC0xLTEtMS0w_0500edea-cd55-4c38-be6e-e359db9aac68"
      unitRef="usd">75670977</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfOC0zLTEtMS0w_9433be2a-73d5-4fe8-8580-d93f4f57370e"
      unitRef="usd">-2551453</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:ShareBasedCompensation
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfOS0xLTEtMS0w_ecb74dba-b18f-45f2-b26a-25da9e52e939"
      unitRef="usd">11822483</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfOS0zLTEtMS0w_e8656bde-1e06-449f-814f-6bef771c2bf4"
      unitRef="usd">8867810</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestExpense
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTItMS0xLTEtMA_cf024bc0-fa05-4532-8d3d-142f5f1adfa2"
      unitRef="usd">3019780</ino:NonCashInterestExpense>
    <ino:NonCashInterestExpense
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTItMy0xLTEtMA_9330cfd1-2183-4e0f-ab90-17b094503928"
      unitRef="usd">2587619</ino:NonCashInterestExpense>
    <ino:InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTMtMS0xLTEtMA_bdfe295c-5f92-4175-b53c-a230639e275e"
      unitRef="usd">0</ino:InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit>
    <ino:InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTMtMy0xLTEtMA_85c30e56-6307-4eb8-a1f9-54259b309db4"
      unitRef="usd">1962</ino:InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit>
    <us-gaap:GainLossOnInvestments
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTQtMS0xLTEtMA_32dedae4-fb84-4381-8ae4-49d2cebd8b98"
      unitRef="usd">-571778</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTQtMy0xLTEtMA_f571b222-6ac4-47bb-83b1-e8ba92c35200"
      unitRef="usd">238083</us-gaap:GainLossOnInvestments>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTYtMS0xLTEtMA_a2c78872-a6e6-461d-800b-a29a6f966825"
      unitRef="usd">1713770</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTYtMy0xLTEtMA_02023f82-22ff-4a06-b4a8-5008e0c55659"
      unitRef="usd">0</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTctMS0xLTEtMA_85b62ca0-138b-41a1-aea1-e09c700b72e8"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTctMy0xLTEtMA_4c52949d-546e-4144-b3ac-2f383e9177a1"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTgtMS0xLTEtMA_441b9801-f251-4f7d-9820-1f75573848e3"
      unitRef="usd">36250341</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTgtMy0xLTEtMA_94d3c59c-cfae-409d-b678-8ae56bbd7074"
      unitRef="usd">-1409156</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTktMS0xLTEtMA_09526c1c-9945-4362-95c5-1f312e42704b"
      unitRef="usd">-2661431</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMTktMy0xLTEtMA_9b65a8ca-daaa-4aec-bdb2-f0aaac235347"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib64ca090f73d4dd6afb773407d8d39de_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjAtMS0xLTEtMjYzNg_2effc3b3-6c64-4bff-a5a6-5087c3550c4f"
      unitRef="usd">-8177043</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="idbeadf22b0a640818c2ed7013bf0c883_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjAtMy0xLTEtMjYzNg_9cdd47a0-d5a3-4b0c-8009-484ed0be4e4a"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7b045061c7ab428582b10f52d98361c4_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjEtMS0xLTEtMjYzNg_3d910385-292e-4440-92d1-5903e4202791"
      unitRef="usd">3087595</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6edc82bc7b334d5aa607c4be90c9906f_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjEtMy0xLTEtMjYzNg_d8f65a4c-3507-41a2-ae35-5666ae38ba56"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjAtMS0xLTEtMA_f412913f-38e7-4710-b128-66f0a9e18186"
      unitRef="usd">624522</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjAtMy0xLTEtMA_13cddefe-c44c-4ff8-9537-e033599b53ef"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <ino:OperatingLeaseNonCashLeaseExpense
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjEtMS0xLTEtMA_69c7be3d-3627-464e-b6c3-349ab9f5f915"
      unitRef="usd">774438</ino:OperatingLeaseNonCashLeaseExpense>
    <ino:OperatingLeaseNonCashLeaseExpense
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjEtMy0xLTEtMA_b86f7ee2-8a2e-4282-9010-86322d78c292"
      unitRef="usd">0</ino:OperatingLeaseNonCashLeaseExpense>
    <ino:TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjItMS0xLTEtMA_cd4ada8a-9a20-46f2-b02d-542049c0a1bc"
      unitRef="usd">0</ino:TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments>
    <ino:TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjItMy0xLTEtMA_f33b954c-78f3-4aa9-8e24-1311ffcdba32"
      unitRef="usd">-335228</ino:TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjMtMS0xLTEtMA_23acf12a-343f-4e33-b347-6d097d0ff620"
      unitRef="usd">290602</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjMtMy0xLTEtMA_81d7056d-4cfe-4aca-8fb2-17004ebfdc08"
      unitRef="usd">-183756</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjUtMS0xLTEtMA_dc817550-a53c-4a06-9c0b-6ab6b04651a1"
      unitRef="usd">6992871</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjUtMy0xLTEtMA_de960711-8a06-4d89-a037-fefd722e3202"
      unitRef="usd">-2540066</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjYtMS0xLTEtMA_1715930e-029f-4a3a-b3d2-63a762e79b31"
      unitRef="usd">-846894</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjYtMy0xLTEtMA_892e4c9d-d0b1-4adb-8d19-194e44d774bb"
      unitRef="usd">239961</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjctMS0xLTEtMA_22c2f9fc-dba7-4616-a7c3-0b38712ac5c8"
      unitRef="usd">30055813</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjctMy0xLTEtMA_6a635f73-3193-4651-a252-af1172ba16b0"
      unitRef="usd">271012</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjgtMS0xLTEtMA_3b5fa024-f519-42a9-ac6b-f8ccac69e9a3"
      unitRef="usd">-409996</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMjgtMy0xLTEtMA_372497c5-d0ee-4ef3-adc8-3688a9a96f04"
      unitRef="usd">460306</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzAtMS0xLTEtMA_78cc2ec7-8f63-4989-a18b-ceb4835f2ada"
      unitRef="usd">14969731</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzAtMy0xLTEtMA_f1c24c05-387f-41b4-88f0-179a1498c123"
      unitRef="usd">61057</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzEtMS0xLTEtMA_47e64a57-b39a-4aa8-a346-dc5f1067d4b6"
      unitRef="usd">5383268</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzEtMy0xLTEtMA_9790e97d-19f7-40c3-a2d3-158740eb37c9"
      unitRef="usd">-12791123</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzItMS0xLTEtMA_7bffd068-0a5e-4ecc-8bf0-7a9e453f71ea"
      unitRef="usd">1853216</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzItMy0xLTEtMA_5d36794c-50d5-4719-ae30-9e8dcf257563"
      unitRef="usd">-1170866</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzMtMS0xLTEtMA_9546451e-662a-46ba-8caa-35a5e115ec87"
      unitRef="usd">287609</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzMtMy0xLTEtMA_8c8a6c5d-daed-4ef4-8406-525ca00b38c4"
      unitRef="usd">-515196</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzQtMS0xLTEtMA_73ec5136-e0c0-40ff-b347-7d5354573b28"
      unitRef="usd">-33115</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzQtMy0xLTEtMA_9770a7bd-1c35-48cb-b691-7f89bebd04c6"
      unitRef="usd">-144154</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzUtMS0xLTEtMA_91f8ad02-0724-467f-8333-9a54d2c29f5e"
      unitRef="usd">-31775</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzUtMy0xLTEtMA_adb21b26-2d7f-43d9-8037-6190f1ba7173"
      unitRef="usd">31250</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzctMS0xLTEtMA_133d2a27-f112-4796-ac27-fa39a180bff3"
      unitRef="usd">-1550860</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzctMy0xLTEtMA_18e98cb0-7d35-42f3-9b8f-1cc9b142b0eb"
      unitRef="usd">-622138</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzgtMS0xLTEtMA_243c7898-8274-4016-a45d-b513a31c7c1f"
      unitRef="usd">2551410</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzgtMy0xLTEtMA_d570b079-19d7-4ad0-a53f-a0660b5e06e6"
      unitRef="usd">-2269322</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzktMS0xLTEtMA_2dd2ba75-fce3-4ded-a1f2-e8915c8fbe2b"
      unitRef="usd">-670925</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfMzktMy0xLTEtMA_56723891-7225-4c21-a349-fc1a8f184c6a"
      unitRef="usd">828842</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDEtMS0xLTEtMA_6095dfca-7ed5-4514-97b8-66fb6ea3d965"
      unitRef="usd">2833</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDEtMy0xLTEtMA_fa60c99a-8032-41e1-9caa-c1f5c605bf08"
      unitRef="usd">-35107</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDItMS0xLTEtMA_e863e58d-c75b-4146-ba63-2eebb887deb4"
      unitRef="usd">-126762557</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDItMy0xLTEtMA_5b8e06f7-d7fa-443a-9685-4823263c6bc5"
      unitRef="usd">-84112789</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDQtMS0xLTEtMA_2ea27b38-3eb7-4638-9460-b23949b425af"
      unitRef="usd">153135274</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDQtMy0xLTEtMA_7d027afd-9c4e-470d-b835-ca5563130cc4"
      unitRef="usd">86950301</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDUtMS0xLTEtMA_562b9431-b5cd-4ba1-82c9-610084cea909"
      unitRef="usd">61263665</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDUtMy0xLTEtMA_a985933e-54b9-440e-b213-e1bba9358a09"
      unitRef="usd">68344014</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDYtMS0xLTEtMA_09ef56c0-b561-4708-a699-23d5fbeda84a"
      unitRef="usd">558588</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDYtMy0xLTEtMA_7eb2f652-8c38-4ff1-898f-aa1ca524bb7e"
      unitRef="usd">873484</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDktMS0xLTEtMA_94cfbfff-23b5-43b0-9fae-c4ddcbc2e2d5"
      unitRef="usd">-40125418</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNDktMy0xLTEtMA_76a16ae9-3390-479a-aee7-81da9eb057ce"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTEtMS0xLTEtMA_ec981302-c083-47a2-a21c-55f1ad993be4"
      unitRef="usd">2774851</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTEtMy0xLTEtMA_535553eb-b0c0-4e38-adbb-80afc172023a"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTItMS0xLTEtMA_197b28ad-cc5b-40cd-adf4-0aa7bf49971f"
      unitRef="usd">-55079630</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTItMy0xLTEtMA_1a825ff3-0e80-46a4-a408-a944e0d28d8d"
      unitRef="usd">-19479771</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTQtMS0xLTEtMA_099f2ec6-0468-4a05-8df5-89444a8ce91e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTQtMy0xLTEtMA_90298c24-442d-42ab-a6a5-093528cdeae3"
      unitRef="usd">93425973</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTUtMS0xLTEtMA_cd555f84-edf6-4ea1-93a8-1f0075a2710a"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTUtMy0xLTEtMA_f40e9929-6bdd-41c5-9b5d-c49142ba64c4"
      unitRef="usd">3314757</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTYtMS0xLTEtMA_8433c268-f774-47ba-ace7-267862f9d2a6"
      unitRef="usd">329960855</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTYtMy0xLTEtMA_7144311b-6835-4f58-b0d8-c5d487b93376"
      unitRef="usd">3425065</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTctMS0xLTEtMA_3c051403-e390-42e5-8231-2ef18d0ab996"
      unitRef="usd">9856073</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTctMy0xLTEtMA_9148fa2c-8a2c-4ec0-8472-860b8b2700a4"
      unitRef="usd">92272</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTgtMS0xLTEtMA_b860cae4-b098-43e1-9868-69335417e5ea"
      unitRef="usd">4028177</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTgtMy0xLTEtMA_d9fa8490-e919-43b0-b26c-bcd2fa359ed8"
      unitRef="usd">892928</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTktMS0xLTEtMA_87928cfc-408f-4455-be6e-e438a2e167f5"
      unitRef="usd">2379969</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNTktMy0xLTEtMA_5676c1cc-1c4e-49a8-80d4-6919a0632004"
      unitRef="usd">3016538</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjAtMS0xLTEtMA_12432ffb-4001-4b39-9cfb-cd98e8f9e7e3"
      unitRef="usd">171620</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjAtMy0xLTEtMA_6d7dac48-e75c-4ba0-bfab-3d4c5f896dcd"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjEtMS0xLTEtMA_5a9608c3-acbb-449e-916b-387022c2ca8c"
      unitRef="usd">338340340</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjEtMy0xLTEtMA_53d1ed76-bc4e-44be-9d69-31db5121ad0b"
      unitRef="usd">95752163</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjItMS0xLTEtMA_81734494-bd2e-4e0c-9c23-55baba6afeec"
      unitRef="usd">6184</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjItMy0xLTEtMA_4549b8e0-c029-4f63-8223-0f2ed78b6ae5"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjMtMS0xLTEtMA_fab51f60-63d7-4934-96f7-df0e9c13c8c7"
      unitRef="usd">156504337</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjMtMy0xLTEtMA_b0995f82-8218-4f42-9b75-c8575dc62acf"
      unitRef="usd">-7840397</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjQtMS0xLTEtMA_bc9029ec-bcb1-4056-b480-2d03d8245efd"
      unitRef="usd">22196097</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2fca9614850f4094a30e35df9ad3f90d_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjQtMy0xLTEtMA_641c324c-1a1a-4f2d-988e-4e2f66f02417"
      unitRef="usd">23693633</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjUtMS0xLTEtMA_96bd059c-26b4-4b5a-ac3d-3ee6fb1c8284"
      unitRef="usd">178700434</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7ea46918d69244b0b92fa827e8689f35_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjUtMy0xLTEtMA_df539d59-7789-4390-9989-9de5fbba3e7d"
      unitRef="usd">15853236</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjgtMS0xLTEtMA_bcc7f536-f022-46b6-8276-2368e001fb6c"
      unitRef="usd">198761</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjgtMy0xLTEtMA_974e1732-8fc5-45d4-9451-4cf1cf6559ad"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:InterestPaidNet
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjktMS0xLTEtMA_2abcf3ba-bd58-4c8c-a55a-a17fd6020a80"
      unitRef="usd">4614662</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNjktMy0xLTEtMA_92d62166-8049-4bc4-9247-c575cfc6e0ff"
      unitRef="usd">2692083</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNzEtMS0xLTEtMA_61da154c-8067-41a0-aed8-1045b1d801d1"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8yNS9mcmFnOjE3ZDI5MTg0NTM4NDQ3MjZhYjgxZDZlNmY3ZjQzMzQ4L3RhYmxlOjczZjEwMDVlMTg3YjRkZjU5ZDdkNTFjOWMwYzBkNjdiL3RhYmxlcmFuZ2U6NzNmMTAwNWUxODdiNGRmNTlkN2Q1MWM5YzBjMGQ2N2JfNzEtMy0xLTEtMA_e6fa7604-e6b1-40a2-83a2-88cc02a16e66"
      unitRef="usd">14634769</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zMS9mcmFnOjRlMTk4MzViZTE5NjQ1YTRhOWE2YjEwOWU1Yzc0YmI5L3RleHRyZWdpb246NGUxOTgzNWJlMTk2NDVhNGE5YTZiMTA5ZTVjNzRiYjlfMzMxNw_a45fcb53-51c7-4448-8769-89b8e3bac1c0">Organization and Operations&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;Inovio&#x201d;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The Company's DNA medicine pipeline is comprised of three types of candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, Inovio has demonstrated that a DNA medicine can be delivered directly into cells in the body via its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's novel DNA medicines are made using its proprietary SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person's immune system recognize and destroy cancerous or virally infected cells. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inovio's hand-held CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Human data to date have shown a favorable safety profile of Inovio&#x2019;s DNA medicines delivered directly into cells in the body using the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; smart delivery device in more than 6,000 administrations across more than 2,000 patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inovio's corporate strategy is to advance, protect, and provide its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill &amp;amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), The U.S. Department of Defense (DoD), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#x2019;s Medical CBRN Defense Consortium (MCDC), International Vaccine Institute (IVI), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Thermo Fisher Scientific, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp;amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inovio was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNzE0NjgyNTU5ODI2MQ_965a4228-cb50-49a1-b6f2-605a896a4a73">Basis of Presentation, Liquidity and Risks and Uncertainties&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of September&#160;30, 2020, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2020 and 2019 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three and nine months ended September 30, 2020 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2019, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;12, 2020. The balance sheet at December&#160;31, 2019 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc., VGX Pharmaceuticals, Inc. ("VGX") and Inovio Asia LLC, and records a 15% non-controlling interest for its subsidiary VGX Animal Health, Inc., a subsidiary of VGX.  All intercompany accounts and transactions have been eliminated upon consolidation.  As of June 1, 2020, the Company deconsolidated its subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest, retaining 47% of the outstanding equity on an as-converted to common stock basis. Refer to Footnote 17 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inovio incurred a net income (loss) attributable to common stockholders of $19.2 million and $(142.1) million for the three and nine months ended September 30, 2020, respectively. Inovio had working capital of $335.8 million and an accumulated deficit of $881.9 million as of September&#160;30, 2020. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $337.2 million as of September&#160;30, 2020, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of its current or potential future At-the-Market Equity Offering Sales Agreements (each, a &#x201c;Sales Agreement&#x201d; and collectively, the &#x201c;Sales Agreements&#x201d;). The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has a history of conducting debt and equity financings, including the receipt of net proceeds under the Sales Agreements of $330.0 million d&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uring the nine months ended September 30, 2020, and net proceeds of $9.1 million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $75.7 million from a private placement of 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;), net proceeds of $14.5 million from the private placement of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $4.0 million from the private placement of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#x201c;Bonds&#x201d;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#x2019;s condensed consolidated financial statements as of and for the three and nine months ended September 30, 2020 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will impact the Company's business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, that are highly uncertain.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNzE0NjgyNTU5ODI2MA_2af6bab3-2409-4188-b9a0-bd88448c1ae8">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of September&#160;30, 2020, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2020 and 2019 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three and nine months ended September 30, 2020 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2019, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and &lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;12, 2020. The balance sheet at December&#160;31, 2019 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc., VGX Pharmaceuticals, Inc. ("VGX") and Inovio Asia LLC, and records a 15% non-controlling interest for its subsidiary VGX Animal Health, Inc., a subsidiary of VGX.  All intercompany accounts and transactions have been eliminated upon consolidation.  As of June 1, 2020, the Company deconsolidated its subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest, retaining 47% of the outstanding equity on an as-converted to common stock basis. Refer to Footnote 17 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inovio incurred a net income (loss) attributable to common stockholders of $19.2 million and $(142.1) million for the three and nine months ended September 30, 2020, respectively. Inovio had working capital of $335.8 million and an accumulated deficit of $881.9 million as of September&#160;30, 2020. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $337.2 million as of September&#160;30, 2020, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of its current or potential future At-the-Market Equity Offering Sales Agreements (each, a &#x201c;Sales Agreement&#x201d; and collectively, the &#x201c;Sales Agreements&#x201d;). The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has a history of conducting debt and equity financings, including the receipt of net proceeds under the Sales Agreements of $330.0 million d&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uring the nine months ended September 30, 2020, and net proceeds of $9.1 million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $75.7 million from a private placement of 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;), net proceeds of $14.5 million from the private placement of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $4.0 million from the private placement of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#x201c;Bonds&#x201d;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#x2019;s condensed consolidated financial statements as of and for the three and nine months ended September 30, 2020 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will impact the Company's business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, that are highly uncertain.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i31939003de4d4a3094a1ef0d323e91fb_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMjM4Mw_d5f25ab7-a301-4190-b140-ac3757ce5ffe"
      unitRef="number">0.15</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ic34da769042c4f00941ee0248f92939e_I20200601"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMjczNg_7f4097b0-ea92-4079-ac2a-7b120d4641b7"
      unitRef="number">0.47</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:NetIncomeLoss
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMjkxOA_7595789f-b2c5-468b-a34c-818c48a7a242"
      unitRef="usd">19200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMjkyNQ_c2777f4e-d1b5-4504-ae5d-702a7f51356f"
      unitRef="usd">-142100000</us-gaap:NetIncomeLoss>
    <us-gaap:Capital
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMjk4NA_57349dbb-f1a6-4996-8752-9bc31389ce49"
      unitRef="usd">335800000</us-gaap:Capital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMzAxOA_146f8e7d-270f-42c5-9a28-34b58735b5c8"
      unitRef="usd">-881900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfMzM2NQ_62306840-4a82-4e92-8692-20b28500456b"
      unitRef="usd">337200000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i40baaae65a1744768b1b1675f3ad79d0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDA5OA_837de2b1-5272-4465-b511-ea83a14ef95a"
      unitRef="usd">330000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0bda1f1acb9e424588e758c721d6202d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDE1MA_489f0601-ce39-4f49-a8cf-7a4e6d7675f1"
      unitRef="usd">9100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ic8936c9a775e4048b38647b7b881147d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDI2MA_3a4888a9-d5de-4ff0-9f1f-9823162da776"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9481fe2b9b0f4c18b552f08cc3c7e40d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDI5MQ_1e1ca9d5-1eee-4b7d-9d1f-e84d05a78cff"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i75ad5d40a88941e3a7a873faf3f7eb60_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDM1OQ_bcb4a7a0-f121-4706-a809-f3aaca099fac"
      unitRef="usd">14500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i74f44125bc13416a9aeb599f2cb231e1_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDM5Mg_a86efe4a-4da1-4e45-8acb-bbfc5cea35da"
      unitRef="krw">18000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i74f44125bc13416a9aeb599f2cb231e1_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDQzMQ_b6d4c9b3-0cbd-44ad-baec-157fcf1ba028"
      unitRef="usd">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i74f44125bc13416a9aeb599f2cb231e1_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDUyMA_49b74752-0308-4569-8136-0daab1a0aa68"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i2c753a8fdf0f4e7394bef90ba65bc0d2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDYwNA_856ced4f-c7d2-4968-95ef-cdd613b82739"
      unitRef="usd">4000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i66d118519dea4ae7bc213714ffeb97a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDYzNw_4cd638dd-1ea0-4cf3-b6df-2d118391b4ae"
      unitRef="krw">4700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i66d118519dea4ae7bc213714ffeb97a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDY2Mw_ff65595d-a5a8-4b47-a3ec-c1c0f6d3e25e"
      unitRef="usd">4100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i66d118519dea4ae7bc213714ffeb97a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNC9mcmFnOjZjNmNhZTAyOTc0MjRhMTU5MmYxMTRjNjUxYzNhZmRlL3RleHRyZWdpb246NmM2Y2FlMDI5NzQyNGExNTkyZjExNGM2NTFjM2FmZGVfNDc1Mg_e0d13221-3ac9-45fc-b27f-3a91bc26f740"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMTk_74a101c1-50fd-442a-bf80-57da07e8aae6">Critical Accounting Policies&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;Topic 606&#x201d;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfOTk4OQ_0932b4d7-3f73-4fbf-a0c8-940a3372135a"&gt;two&lt;/span&gt; to 18&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#x2019;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $3.3 million and $3.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any.  The Company performed its annual assessment for goodwill impairment as of November 30, 2019, identifying no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations. See Note&#160;8 for further discussion of the Company&#x2019;s goodwill and intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company&#x2019;s financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the condensed consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMTA_6cb64307-f8ff-4273-93a1-1e6f5694b35a">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;Topic 606&#x201d;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgxOTY_83257ff9-4229-46f2-bb4c-41b8d7c451cf">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ino:GrantPolicyPolicyTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMjg_ebb55d54-efb8-41d1-89ed-09ea62f64895">Grants&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations.</ino:GrantPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMTM_61770758-aa29-4c67-bead-4b3a70415dad">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMjc_3796dda7-d8b6-4381-bd4d-e50e94287c7f">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMDc_e2ffc7ee-d4d0-40d0-96bc-8612d3a3aa4f">Valuation of Intangible Assets and Goodwill&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfOTk4OQ_0932b4d7-3f73-4fbf-a0c8-940a3372135a"&gt;two&lt;/span&gt; to 18&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#x2019;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $3.3 million and $3.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any.  The Company performed its annual assessment for goodwill impairment as of November 30, 2019, identifying no impairment.&lt;/span&gt;&lt;/div&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6b8bbe68292646fc920d02bc015f8116_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfOTk5NQ_7e4441ee-66dc-496e-af7d-d1e82c30a943">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTA4Njk_218245e9-f4fb-4cf3-9415-d8190b075625"
      unitRef="usd">3300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTA4Nzc_6b3db6ed-8319-4b21-a8ea-1af1b623c4a0"
      unitRef="usd">3700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgxOTk_34d17d06-1444-4150-9c28-226d6cdb94e9">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company&#x2019;s financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the condensed consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMTY_ffb665e5-5031-4d0c-a88b-c3d514044631">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included &lt;/span&gt;&lt;/div&gt;in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgxOTQ_f90101a3-7750-42bf-a38c-5a93ef6699bb">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfMTgyMjU_63f3cf16-1e67-4b8f-8466-77ab1b89258d">Equity Investments&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80My9mcmFnOmM4NzJjODg0MGFjODQzYTg5Mzg2OWUzZWM0ZWViZTY0L3RleHRyZWdpb246Yzg3MmM4ODQwYWM4NDNhODkzODY5ZTNlYzRlZWJlNjRfNTE3Mg_13b44aa7-8876-460a-ae42-13307f66cfaf">Impact of Recently Issued Accounting Standards &lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2019-12. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;adoption. As of September 30, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2016-13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its condensed consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#x201c;COVID-19&#x201d;) outbreak on expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2018-13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends certain disclosure requirements over fair value measurements.  Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (see Note 7 for more information about the Company&#x2019;s fair value classifications).&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2018-18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which clarified the interaction between Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2017-04.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In January 2017, the FASB issued ASU 2017-04,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;&lt;/span&gt;("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80My9mcmFnOmM4NzJjODg0MGFjODQzYTg5Mzg2OWUzZWM0ZWViZTY0L3RleHRyZWdpb246Yzg3MmM4ODQwYWM4NDNhODkzODY5ZTNlYzRlZWJlNjRfNTE3Nw_d39b97e4-07bb-48b3-a486-628db5b511e3">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2019-12. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;adoption. As of September 30, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2016-13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its condensed consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#x201c;COVID-19&#x201d;) outbreak on expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2018-13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends certain disclosure requirements over fair value measurements.  Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (see Note 7 for more information about the Company&#x2019;s fair value classifications).&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2018-18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which clarified the interaction between Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2017-04.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In January 2017, the FASB issued ASU 2017-04,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;&lt;/span&gt;("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfNTYw_9e0ca8b6-40fc-4f39-83e7-17afff946704">Revenue Recognition  During the three and nine months ended September 30, 2020, the Company recognized total revenue under collaborative research and development and other agreements of $83,000 and $1.3 million, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS"), $21,000 and $167,000, respectively, from AstraZeneca and $132,000 and $364,000, respectively, from various other contracts. Of the total revenue recognized during the three and nine months ended September 30, 2020, $4,000 and $127,000, respectively, were in deferred revenue as of December 31, 2019. Performance obligations are generally satisfied within 12 months of the initial contract date.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4058122d38c74b2495974de7f507740b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMTUx_018d0911-06c7-4a1f-a698-883dcc9760cd"
      unitRef="usd">83000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19efa68d746c41c38d72557926a2c83a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMTU4_64d2308f-1930-4502-a1c5-fcedf0a3ecb1"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10bdaf5e033f4b6cb32118002bd714d4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMjQy_a454fc94-daaf-4332-9b19-f94bd826ec91"
      unitRef="usd">21000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1fe60d4ed164b4ba68d097b07daea40_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMjQ5_832d0a8f-fd65-4b68-a63f-3854539f5b07"
      unitRef="usd">167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59afc9c747d34b8c8a09631dec66eae4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMjg4_7fd975b6-41a2-40a5-bb64-d1d55469d8fb"
      unitRef="usd">132000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cb681e91bc24c64b846b49185fe2187_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMjk1_50e5df11-7f82-4ea2-b765-e8f9b1e95e92"
      unitRef="usd">364000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMzkw_36d82f7e-ab7c-4bde-b10e-bb5ef3726e31"
      unitRef="usd">4000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80Ni9mcmFnOjllNjdjNTQwNjRkYzQyY2Y4NzcyYmM2ZTY4OTUzMTNkL3RleHRyZWdpb246OWU2N2M1NDA2NGRjNDJjZjg3NzJiYzZlNjg5NTMxM2RfMzk3_6354fcaf-ab5c-479e-b927-44472208524a"
      unitRef="usd">127000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMzMzNQ_90633b10-80cf-4fb4-8e1e-a22453e61965">Short-term Investments&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments at September&#160;30, 2020 consisted of mutual funds, U.S. treasury securities, corporate debt securities, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments at December&#160;31, 2019 consisted of mutual funds. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the condensed consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. During the three and nine months ended September 30, 2020, the Company recorded gross realized gain on investments of $105,000 and $741,000, respectively, and gross realized loss on investments of $101,000 and $1.3 million, respectively. During the three and nine months ended September 30, 2019, the Company recorded gross realized gain on investments of $155,000 and $330,000, respectively, and gross realized loss on investments of $11,000 and $93,000, respectively. During the three and nine months ended September 30, 2020, the Company recorded net unrealized gain on available-for-sale equity securities of $1.3 million and $625,000, respectively. There was no material unrealized gain or loss on available-for-sale equity securities recorded during the three and nine months ended September 30, 2019. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of September&#160;30, 2020, the Company had&#160;11 available-for-sale securities in an unrealized loss position, of which none were in such position for longer than 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,177,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,752,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,128,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,802,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,032,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,529,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,907,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,785,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,157,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,535,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,599,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,338,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;September&#160;30, 2020&#160;were primarily due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the COVID-19 global pandemic, and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at September&#160;30, 2020, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfODUy_2a72af3d-54b1-4898-97e7-619dea1d2cad"
      unitRef="usd">105000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfODU5_424bd361-ade4-431d-86bc-af6a2ba6bceb"
      unitRef="usd">741000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfOTE5_18ef944d-3281-4bbf-9c35-7339ce74de07"
      unitRef="usd">101000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfOTI2_5a5698bb-106a-464e-9f9d-4ce1e48a77b6"
      unitRef="usd">1300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTAyNg_701853a8-31ed-4eee-a4be-1c7ae1bbfb00"
      unitRef="usd">155000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTAzMw_6e700ea2-f773-49b4-a3cc-cf2bbda98a50"
      unitRef="usd">330000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTA5Mw_a6236517-f93a-4679-800a-343720b86679"
      unitRef="usd">11000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTEwMA_abe52c67-c988-46bc-8b12-33d408c6ff84"
      unitRef="usd">93000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTIyNA_348f9baa-ec62-4a1d-9c41-23acaca4333e"
      unitRef="usd">1300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTIzMQ_60cde111-3a25-424c-a24b-2f898b0387f4"
      unitRef="usd">625000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTI1OQ_5735ebcd-f8b8-4e2a-a6b4-2af04a917840"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTI1OQ_98a10ffb-c516-4d71-a468-ae54e0ca9d9c"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTY1NQ_0c7b54a0-bca9-4491-9fda-fd7e75c9f36d"
      unitRef="investment">11</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfMTcyOQ_65e90730-6b91-4543-a2c6-90d83615c829"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RleHRyZWdpb246MjYzYTE1NTIxY2FhNGUxNGI3OGU0NzIzNjY1NzNmNjdfNzE0NjgyNTU4NTc4NA_177e55b7-6444-4c32-ba5a-455b46f61620">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,177,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,752,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,128,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,802,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,032,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,529,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,907,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,785,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,157,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,535,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,599,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,338,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i71790af5924c4ddab339efc7f993a154_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMi0zLTEtMS0w_b6c0ae83-06bf-49f1-8143-26ac8cdbd12d"
      unitRef="usd">152177676</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i71790af5924c4ddab339efc7f993a154_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMi01LTEtMS0w_263ead61-9048-46e7-9273-26e0c01d92cc"
      unitRef="usd">1752552</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i71790af5924c4ddab339efc7f993a154_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMi03LTEtMS0w_d8aa8e97-23af-453e-a0b2-ba6af003ee91"
      unitRef="usd">1128029</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i71790af5924c4ddab339efc7f993a154_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMi05LTEtMS0w_9e46f92f-8dee-4d21-9b7c-21f196792b61"
      unitRef="usd">152802199</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ice5ad4689ec9487e82f66dfbdc7bcff2_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMy0zLTEtMS0w_daea4fd2-b53f-444c-a17d-00718947b80a"
      unitRef="usd">1200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ice5ad4689ec9487e82f66dfbdc7bcff2_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMy01LTEtMS0w_ae8b5d6d-30ee-42a6-abff-a85bd9c70cf4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ice5ad4689ec9487e82f66dfbdc7bcff2_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMy03LTEtMS0w_5063211f-ee23-480f-97d1-8619dc876f74"
      unitRef="usd">27840</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ice5ad4689ec9487e82f66dfbdc7bcff2_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfMy05LTEtMS0w_b0cfde96-a8c9-4ddb-9f82-cb7ebb652974"
      unitRef="usd">1172160</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id6e18e4080084b71847f96b5e9a0e699_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNC0zLTEtMS0w_8325a305-741b-4542-b30b-ae435a5c9bba"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id6e18e4080084b71847f96b5e9a0e699_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNC01LTEtMS0w_a728f95c-8b1d-4ffd-9da8-0c668b2321b2"
      unitRef="usd">32980</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id6e18e4080084b71847f96b5e9a0e699_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNC03LTEtMS0w_9a1970d0-2076-4a89-af1d-8b617b150ad8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6e18e4080084b71847f96b5e9a0e699_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNC05LTEtMS0w_438c84e2-328e-49c5-9fb0-9069ec15e0c5"
      unitRef="usd">3032980</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i96a526030817474ca6bde92e79a78309_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS0zLTEtMS0xNDcx_28721a6d-2f7f-405b-ad12-97c1bb31eb14"
      unitRef="usd">1529750</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i96a526030817474ca6bde92e79a78309_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS01LTEtMS0xNDcx_8cb210ae-007b-46df-a9d5-c65cce1bebac"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i96a526030817474ca6bde92e79a78309_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS03LTEtMS0xNDcx_2cb7267a-1b7e-4f36-87b2-b9862813ffb5"
      unitRef="usd">1345</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i96a526030817474ca6bde92e79a78309_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS05LTEtMS0xNDcx_f33101d7-9b65-432a-8673-17f7ad41e612"
      unitRef="usd">1528405</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS0zLTEtMS0w_64066398-8e55-489e-b7f2-d7c115e4049a"
      unitRef="usd">157907426</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS01LTEtMS0w_21f1a912-f1a7-4029-9896-d8a0354b126f"
      unitRef="usd">1785532</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS03LTEtMS0w_6ba3b879-2ae0-4e7b-9b38-95520727614d"
      unitRef="usd">1157214</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmE4ZGM5NDNkZmNjOTRkYjA5NTY2ZjVhMmFkZjYyNDQ1L3RhYmxlcmFuZ2U6YThkYzk0M2RmY2M5NGRiMDk1NjZmNWEyYWRmNjI0NDVfNS05LTEtMS0w_d77d26de-35ba-43a3-ac46-3f632667c271"
      unitRef="usd">158535744</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie860f23b62fe487f8c985dd5b2c5316a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmY5N2MwMzBhOTNjYzRmOTJiY2FkYjUyOWMwYzYxYjMxL3RhYmxlcmFuZ2U6Zjk3YzAzMGE5M2NjNGY5MmJjYWRiNTI5YzBjNjFiMzFfMi0zLTEtMS0w_d7e71d1e-7ee6-420e-9dae-ffa3e748b98d"
      unitRef="usd">66599219</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie860f23b62fe487f8c985dd5b2c5316a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmY5N2MwMzBhOTNjYzRmOTJiY2FkYjUyOWMwYzYxYjMxL3RhYmxlcmFuZ2U6Zjk3YzAzMGE5M2NjNGY5MmJjYWRiNTI5YzBjNjFiMzFfMi01LTEtMS0w_56e618ce-e17c-4f6d-a30f-3f4fb932b2d3"
      unitRef="usd">754709</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie860f23b62fe487f8c985dd5b2c5316a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmY5N2MwMzBhOTNjYzRmOTJiY2FkYjUyOWMwYzYxYjMxL3RhYmxlcmFuZ2U6Zjk3YzAzMGE5M2NjNGY5MmJjYWRiNTI5YzBjNjFiMzFfMi03LTEtMS0w_bc9b3c35-1d9b-42d3-b2df-dd1af082327f"
      unitRef="usd">15911</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie860f23b62fe487f8c985dd5b2c5316a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV80OS9mcmFnOjI2M2ExNTUyMWNhYTRlMTRiNzhlNDcyMzY2NTczZjY3L3RhYmxlOmY5N2MwMzBhOTNjYzRmOTJiY2FkYjUyOWMwYzYxYjMxL3RhYmxlcmFuZ2U6Zjk3YzAzMGE5M2NjNGY5MmJjYWRiNTI5YzBjNjFiMzFfMi05LTEtMS0w_188a410a-3b9d-4045-a2d6-dc53c99fa914"
      unitRef="usd">67338017</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RleHRyZWdpb246YTZmMzEwMGY0ZGE0NDM1MWI5MGY1NGJmNTNlOTM1MWJfNTMxOA_481b624e-5cfd-4dc1-ae34-24b5b3313c74">Fair Value Measurements&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets are, and prior to September 30, 2020 liabilities were, classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the nine months ended September 30, 2020 or 2019. All liabilities in the fair value hierarchy were extinguished as of September 30, 2020 as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,985,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,985,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,802,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,802,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,032,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,032,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,535,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,974,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,561,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,154,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,154,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,674,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,113,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,561,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,338,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,338,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,315,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,315,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,003,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,003,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability (Note 9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 assets at September&#160;30, 2020 consisted of mutual funds, corporate debt securities and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the condensed consolidated statement of operations as a gain (loss) on investment in affiliated entities. In August 2020, the Company sold its investment in 1,644,155 common shares of its affiliated entity GeneOne. Previously, the Company accounted for its investment in GeneOne based on the closing price of the shares on the KOSDAQ Market of the Korea Exchange (KOSDAQ) on the applicable balance sheet date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at September&#160;30, 2020 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets at September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 liabilities at September 30, 2020 due to the full conversion of the August 2019 Bonds into shares of the Company's common stock (see Note 9 below for more information). Level 3 liabilities held as of December 31, 2019 consisted of the embedded conversion option contained in the August 2019 Bonds that met the criteria to be bifurcated and accounted for separately from the August 2019 Bonds (the "derivative liability"). The derivative liability was recorded at fair value of $7.1 million upon the issuance of the August 2019 Bonds, and was subsequently remeasured to fair value at each reporting period until conversion. The derivative liability was initially valued and remeasured using a "with-and-without" method. The "with-and-without" methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the embedded conversion option. The difference between the entire instrument with the embedded conversion option compared to the instrument without the embedded conversion option is the fair value of the derivative, recorded as the derivative liability. There was no derivative liability associated with the issuance of the December 2019 Bonds.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the August 2019 Bonds with the conversion option was estimated using a Monte Carlo simulation approach. The key inputs to valuing the August 2019 Bonds with the conversion option on the date of issuance and as of the August 3, 2020 conversion date, include the Company&#x2019;s stock price on the valuation date; the expected annual volatility of the Company&#x2019;s common stock, and the discount yield, which was derived by making the fair value of the August 2019 Bonds equal to the face value on the issuance date. Fair value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the Company's derivative liability for the nine months ended September 30, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,670,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Derecognition of the derivative liability upon conversion &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,490,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RleHRyZWdpb246YTZmMzEwMGY0ZGE0NDM1MWI5MGY1NGJmNTNlOTM1MWJfNTMzNQ_bb6b5f42-3c76-40fa-b576-a6ee3caca95e">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,985,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,985,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,802,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,802,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,032,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,032,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,535,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,974,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,561,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,154,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,154,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,674,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,113,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,561,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,338,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,338,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,315,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,315,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,003,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,003,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability (Note 9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i02f68c7b48d744a6a9173080f6c38f09_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy0xLTEtMS00Nzcw_d7304245-0236-44ed-a873-77d0b1a086b8"
      unitRef="usd">99985000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i918e4025371f42b5b7b58df82fc10039_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy0zLTEtMS00Nzcw_b827ea44-1a2c-4234-94d7-824caf8ee43e"
      unitRef="usd">99985000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4dbb0afb9ddd4315b01e6f4ccb7ca2c6_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy01LTEtMS00Nzcw_b3c9a983-4876-4aa6-b46d-026bbba9b345"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if795f05efa0445c98031f36131b16eb8_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy03LTEtMS00Nzcw_e197b418-9244-412a-a7f8-8a75e7afe511"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78c105aeef2c41549d702f116ad4f464_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS0xLTEtMS00ODYx_41cf95d8-04ff-46a6-9fe1-6b0024ef6b59"
      unitRef="usd">152802199</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie03669a396f4494cb8682e7da1ca04b4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS0zLTEtMS00ODYx_936838a1-b1d5-485e-b7df-3a0c9eb67b7f"
      unitRef="usd">152802199</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b71d42002e544b4a463361f34d11920_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS01LTEtMS00ODYx_0b9777e1-88e5-4694-b380-cd8c0e7a70fa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e85feb515594f70b6395ddc1f835acc_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS03LTEtMS00ODYx_64b0799c-1d90-4831-a9d5-3f19cdc55535"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i151a4fa9e7064eb0913b049b54c5c026_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNi0xLTEtMS0w_89ed84d1-4a18-4955-81b2-eb585cbe4c26"
      unitRef="usd">1172160</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ice5ad4689ec9487e82f66dfbdc7bcff2_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNi0zLTEtMS0w_b0cfde96-a8c9-4ddb-9f82-cb7ebb652974"
      unitRef="usd">1172160</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a11d9344d464d08a2c4860a29929ef9_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNi01LTEtMS0w_396e0ae6-e05f-46f2-8104-f75a1072f0b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i038eb61ac20847bb81aa8ef1c87cefbc_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNi03LTEtMS0w_bdac37ba-6845-444d-88fc-85cde1ee1b3a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8ea8a9e591f0496d8673b145a17803fb_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy0xLTEtMS0w_a9ac5efa-067b-4917-8a71-afcc53489a1f"
      unitRef="usd">3032980</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id488e43085014ecdb6ffe6983f1f85b9_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy0zLTEtMS0w_c4c075c7-aef4-4bc3-81e6-582b2aa57b34"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4cb90dd8056f43a3ada1c1be4856323f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy01LTEtMS0w_e2a0e8aa-23f3-42b9-86e6-fa148d5580a1"
      unitRef="usd">3032980</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i88d54f6841f54932bc303d237a8609b6_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfNy03LTEtMS0w_a00d4cac-19a1-4483-899b-4cb792fff348"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7212a769f73745f29da1c66276126ff3_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOC0xLTEtMS0w_add1110a-9b0a-4484-ac2c-aff0e5b118f2"
      unitRef="usd">1528405</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i52399d29eb084b1fba8917f89379b49c_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOC0zLTEtMS0w_4d804762-0827-4ebe-af19-f0407c108582"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic787e50b63d34253bbe8d56456eb3701_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOC01LTEtMS0w_aa632023-45f9-4f57-b23f-9e3fe2fe3277"
      unitRef="usd">1528405</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie0dcb790ab6d41bcb0c822ec87057c02_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOC03LTEtMS0w_6b7e7c46-e597-45ad-8e2a-06925839e591"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99efe129ba7f47c493d7948e3488435d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTMtMS0xLTEtNDg4OA_afe47f26-6339-4bc8-aa14-4fb2a506f697"
      unitRef="usd">158535744</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic0393158ad254b10ac5bbdca3fffa1c2_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTMtMy0xLTEtNDg4OQ_5b60c7f5-6a0a-48f1-932c-750c5424768d"
      unitRef="usd">153974359</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i692de2cba0aa4e9bbf5aee0bbed07c99_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTMtNS0xLTEtNDg5Mg_c4b49d1b-6752-4402-a31c-f4924d961be1"
      unitRef="usd">4561385</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e17ec22317c4268b177ef3d384f59b6_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTMtNy0xLTEtNDg5Mw_c9057f42-3e23-4a61-a313-1159945d5041"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i99efe129ba7f47c493d7948e3488435d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS0xLTEtMS0w_1b20dd96-9927-48f2-a8c1-2728f6e8e1a5"
      unitRef="usd">4154049</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic0393158ad254b10ac5bbdca3fffa1c2_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS0zLTEtMS0w_0dbd8715-0a7e-4b94-ac3a-b9cee5e936d6"
      unitRef="usd">4154049</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i692de2cba0aa4e9bbf5aee0bbed07c99_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS01LTEtMS0w_6f7b07de-eeee-40c9-abb7-7af1a5a94327"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0e17ec22317c4268b177ef3d384f59b6_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfOS03LTEtMS0w_bdcbb0ea-56dc-436a-95f6-3c7844c67995"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i99efe129ba7f47c493d7948e3488435d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTEtMS0xLTEtMA_cd0b248e-939e-4963-99ee-8b63d35cc014"
      unitRef="usd">262674793</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic0393158ad254b10ac5bbdca3fffa1c2_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTEtMy0xLTEtMA_e2b504f7-cc19-456b-91d9-743e0173d33f"
      unitRef="usd">258113408</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i692de2cba0aa4e9bbf5aee0bbed07c99_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTEtNS0xLTEtMA_db4b95dd-0a33-402e-9e66-b4602817b630"
      unitRef="usd">4561385</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0e17ec22317c4268b177ef3d384f59b6_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOmMzMWI2MjE3ZDRjMjQ0MDk5MWIzY2U0MGFkZWVlMWU2L3RhYmxlcmFuZ2U6YzMxYjYyMTdkNGMyNDQwOTkxYjNjZTQwYWRlZWUxZTZfMTEtNy0xLTEtMA_34bbb189-c3f4-422a-9adc-bc950570659d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic97b736b29264d8aa6220ac0e12c35fe_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNC0xLTEtMS0w_b5c619e3-a83f-44a8-8673-db05c6560199"
      unitRef="usd">2349729</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5b7d48f9d1074982822fddd2b379a517_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNC0zLTEtMS0w_3da6716f-2d23-4591-976f-e4a758ef60e5"
      unitRef="usd">2349729</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie48be730bf58424b80b0e60560d8fb7e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNC01LTEtMS0w_8fb368c9-d8e8-46d8-afd5-8a3d461a02b7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if6f88938286e46c5852675631383c455_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNC03LTEtMS0w_961d64dc-6371-478d-9b15-f5a8b1575f41"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i915d187dcbcc4f6abe0cc0d82477a4dd_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNS0xLTEtMS0w_4977f9be-c6b9-47e4-937e-ee8b3e21a73d"
      unitRef="usd">67338017</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibea476b8d6cf4060b5668a0a25d5da59_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNS0zLTEtMS0w_136e220f-8874-4fcb-9e48-90680b027043"
      unitRef="usd">67338017</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i58ed83b261a747f18822c09954cbbc28_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNS01LTEtMS0w_d86fa28e-5883-4445-a6bb-3f6bb4ce08b4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia54a86390af04834af68005465847e66_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfNS03LTEtMS0w_69957494-8e48-4bd1-8d69-ebf6a410ea15"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifa448e74007b43949527573adaece377_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfOS0xLTEtMS0w_0aa90296-fad7-4042-a62e-e94ea6265ca2"
      unitRef="usd">6315356</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8de60a0d0457444486d03b56271564bc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfOS0zLTEtMS0w_ab2f602d-36ac-4555-aa37-5b74f50c442e"
      unitRef="usd">6315356</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i61b22b095121487092da2a8e6fb84adf_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfOS01LTEtMS0w_4178db82-faea-48ef-b5b7-cefd1a1cfeb2"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifa2966e31f5c4d178bace1c18c46ea63_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfOS03LTEtMS0w_120c47e4-8f9d-4c1e-9e76-efefc0f34afe"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifa448e74007b43949527573adaece377_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTEtMS0xLTEtMA_30613ce1-4766-4ca3-9989-cbeffb4ef957"
      unitRef="usd">76003102</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8de60a0d0457444486d03b56271564bc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTEtMy0xLTEtMA_3aa791a3-7031-4628-9243-dca2c049582b"
      unitRef="usd">76003102</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i61b22b095121487092da2a8e6fb84adf_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTEtNS0xLTEtMA_52d1580f-0014-4d25-bf35-984b11ec4a14"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifa2966e31f5c4d178bace1c18c46ea63_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTEtNy0xLTEtMA_aaafb57a-17a1-4da6-b0ac-9edf18ef1405"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ifa448e74007b43949527573adaece377_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTMtMS0xLTEtMA_5c6d02de-b4c2-4fb8-9e04-668bc0cc76e6"
      unitRef="usd">8819023</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8de60a0d0457444486d03b56271564bc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTMtMy0xLTEtMA_4ea15148-d679-415e-8765-ffaf6b38cf7e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i61b22b095121487092da2a8e6fb84adf_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTMtNS0xLTEtMA_8ed9996d-a535-4e28-a3ad-d8e9b240ac3c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ifa2966e31f5c4d178bace1c18c46ea63_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTMtNy0xLTEtMA_09bb77e8-c524-479d-90ae-c87c5f0c845d"
      unitRef="usd">8819023</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ifa448e74007b43949527573adaece377_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTQtMS0xLTEtMA_3e2d3630-30b2-4f0e-b27d-f4c24e8c9cb4"
      unitRef="usd">8819023</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i8de60a0d0457444486d03b56271564bc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTQtMy0xLTEtMA_d494a697-c79e-47a0-ba23-d66830c61146"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i61b22b095121487092da2a8e6fb84adf_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTQtNS0xLTEtMA_73b7fb9f-5ede-4111-b675-6fdc0804d8b4"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ifa2966e31f5c4d178bace1c18c46ea63_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBmMDMzY2M2MGU2ODRmZTY4NTBhYWRmNjA1ZWEzOWMxL3RhYmxlcmFuZ2U6MGYwMzNjYzYwZTY4NGZlNjg1MGFhZGY2MDVlYTM5YzFfMTQtNy0xLTEtMA_f530a838-5bb4-4b81-8de4-14e86f5fc946"
      unitRef="usd">8819023</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i5536482a9a094c779a9961b697daaf39_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RleHRyZWdpb246YTZmMzEwMGY0ZGE0NDM1MWI5MGY1NGJmNTNlOTM1MWJfMTkxMA_edf74d0f-7bc3-4835-b2e8-cebcc0366696"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares
      contextRef="i94285e36aedc4ac6936417abdd4e690c_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RleHRyZWdpb246YTZmMzEwMGY0ZGE0NDM1MWI5MGY1NGJmNTNlOTM1MWJfOTM0NTg0ODg0MzI4Mw_c399129b-513b-4d9c-9583-e90c39af87e0"
      unitRef="shares">1644155</us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares>
    <us-gaap:DerivativeLiabilities
      contextRef="ie34b833b31b34228ad5580d790df4e4b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RleHRyZWdpb246YTZmMzEwMGY0ZGE0NDM1MWI5MGY1NGJmNTNlOTM1MWJfMzg0Nw_51e6559f-4294-4a63-904c-c9c36da5ab92"
      unitRef="usd">7100000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RleHRyZWdpb246YTZmMzEwMGY0ZGE0NDM1MWI5MGY1NGJmNTNlOTM1MWJfNTM0Ng_8a7d08e5-d2cf-40d3-92b3-0ae34d5dd19f">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the Company's derivative liability for the nine months ended September 30, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,670,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Derecognition of the derivative liability upon conversion &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,490,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBiYjcxNDM5NTdmZjQ3MDE4MDdjY2FjNjkzMjEyNzViL3RhYmxlcmFuZ2U6MGJiNzE0Mzk1N2ZmNDcwMTgwN2NjYWM2OTMyMTI3NWJfMC0xLTEtMS0w_c4b19473-d45e-4620-bd61-69cc5a2d542c"
      unitRef="usd">8819023</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBiYjcxNDM5NTdmZjQ3MDE4MDdjY2FjNjkzMjEyNzViL3RhYmxlcmFuZ2U6MGJiNzE0Mzk1N2ZmNDcwMTgwN2NjYWM2OTMyMTI3NWJfMS0xLTEtMS0w_140baf10-f00c-413f-9030-edd4e34cd04a"
      unitRef="usd">-75670977</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBiYjcxNDM5NTdmZjQ3MDE4MDdjY2FjNjkzMjEyNzViL3RhYmxlcmFuZ2U6MGJiNzE0Mzk1N2ZmNDcwMTgwN2NjYWM2OTMyMTI3NWJfMi0xLTEtMS0xNzY3_6aaf060e-bb54-456a-971f-790280fab4e9"
      unitRef="usd">84490000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81NS9mcmFnOmE2ZjMxMDBmNGRhNDQzNTFiOTBmNTRiZjUzZTkzNTFiL3RhYmxlOjBiYjcxNDM5NTdmZjQ3MDE4MDdjY2FjNjkzMjEyNzViL3RhYmxlcmFuZ2U6MGJiNzE0Mzk1N2ZmNDcwMTgwN2NjYWM2OTMyMTI3NWJfMi0xLTEtMS0w_10fb9d44-8586-4736-9905-4b7c6a38770a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfOTg1_15b6c997-e90a-4046-b843-66bf3182675e">Goodwill and Intangible Assets&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth the goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.918%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,269,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,248,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,395,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,704,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,175,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,525,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,356,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,190,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,283,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,779,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,693,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,190,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,796,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,779,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,207,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for $3.9 million, $6.2 million and $400,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.&lt;/span&gt;&lt;/div&gt;Aggregate amortization expense on intangible assets for the three and nine months ended September 30, 2020 was $137,000 and $410,000, respectively. Aggregate amortization expense on intangible assets for the three and nine months ended September 30, 2019 was $267,000 and $800,000, respectively. Estimated aggregate amortization expense is $137,000 for the remainder of fiscal year 2020, $520,000 for 2021, $493,000 for 2022, $276,000 for 2023, $253,000 for 2024 and $1.6 million for 2025 and subsequent years combined.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfOTcx_3a0f882f-8790-4b61-b7d4-2cd7e3d27656">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth the goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.918%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,269,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,248,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,395,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,704,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,175,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,525,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,356,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,190,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,283,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,779,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,693,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,190,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,796,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,779,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,207,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for $3.9 million, $6.2 million and $400,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:GoodwillGross
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMy0zLTEtMS0w_b6e63e11-5062-4de6-aaff-dd04644c8bc4"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMy03LTEtMS0w_f3625c97-2ffd-473d-9d89-ca874b12740a"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:GoodwillGross
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMy05LTEtMS0w_4af353c1-1480-45ec-8fbc-6b04a06f70ab"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMy0xMy0xLTEtMA_cd711c7f-aac7-43c3-9657-50954515e081"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5f8340ca06974cc4af47f666f30b4427_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi0xLTEtMS0w_7d2ffa6f-0722-44db-97b8-ee6a8627d400">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i35a4423ca3fd4a44b5437b54d8107c3f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi0zLTEtMS0w_e35273f1-5822-430a-8404-80891e2730e0"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i35a4423ca3fd4a44b5437b54d8107c3f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi01LTEtMS0w_f4d6251d-f9a1-4fb1-a9c2-f375fc7a062b"
      unitRef="usd">1269665</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i35a4423ca3fd4a44b5437b54d8107c3f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi03LTEtMS0w_4f47d7f0-458a-469d-b1e2-52dc2cedcbe5"
      unitRef="usd">54096</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i993e6fb6374f485f825fc460f02fba85_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi05LTEtMS0w_e72ecf78-89b1-497e-bd20-8fb6bc2cc480"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i993e6fb6374f485f825fc460f02fba85_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi0xMS0xLTEtMA_19b68e28-6efa-4ded-b08c-8e9ec31cc1ee"
      unitRef="usd">1248104</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i993e6fb6374f485f825fc460f02fba85_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfNi0xMy0xLTEtMA_ba99df38-d4b9-4fa1-bff0-1fc973f21c54"
      unitRef="usd">75657</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icaf790af2a9c4f65a9e9b79b785a3c9f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS0xLTEtMS0w_8eb1b7f0-3771-4c30-82b0-038b0193df7c">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i595e1f2af87d47f9825e175e8cdbe831_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS0zLTEtMS0w_b4f66df4-6b36-4617-804d-a2ca1d688f3d"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i595e1f2af87d47f9825e175e8cdbe831_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS01LTEtMS0w_c0c92cd9-901a-4de7-9e53-978c3f91a39b"
      unitRef="usd">2395556</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i595e1f2af87d47f9825e175e8cdbe831_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS03LTEtMS0w_f70b99e7-7962-497c-ad8a-e4e8cf4c4ece"
      unitRef="usd">2704444</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i629f451db0a646ff9a5db84aee063ff4_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS05LTEtMS0w_f5ebed6a-8fc2-44aa-8c0e-d416094b1fe8"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i629f451db0a646ff9a5db84aee063ff4_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS0xMS0xLTEtMA_bc5ad8f4-9cb2-4249-b2f5-c503c2b8d3a1"
      unitRef="usd">2175556</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i629f451db0a646ff9a5db84aee063ff4_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfOS0xMy0xLTEtMA_ef01b9db-c3c7-43e7-9f05-a36438737168"
      unitRef="usd">2924444</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i929847a653e343629b9e00d8a43f72a9_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtMS0xLTEtMA_c14a1424-6c0b-4217-93e6-68eebde29db5">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i55a6a7fc219f409290b994a921f5de9f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtMy0xLTEtMA_be69e823-785e-4427-8035-c607e8f76fea"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i55a6a7fc219f409290b994a921f5de9f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtNS0xLTEtMA_8294af77-7bd5-4f75-ba7c-4fb3463eb6c9"
      unitRef="usd">3525000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i55a6a7fc219f409290b994a921f5de9f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtNy0xLTEtMA_ffefab38-b500-4307-8a4e-f3747ced3ac0"
      unitRef="usd">525000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9158ca8f497c4770861d6068bf7925f9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtOS0xLTEtMA_d263b217-2d56-4655-ab3f-5d415d98865a"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9158ca8f497c4770861d6068bf7925f9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtMTEtMS0xLTA_46a1f7d4-94c5-48f1-85f1-8598662f46c8"
      unitRef="usd">3356250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9158ca8f497c4770861d6068bf7925f9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTAtMTMtMS0xLTA_6126e5ef-e4b2-4e53-b5c2-39d61fc8a9c6"
      unitRef="usd">693750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if2914df82e244dcb9b995f1185e3447e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtMS0xLTEtMA_0d492c4a-fbb3-43fd-824f-9cb6a5f5f928">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtMy0xLTEtMA_5c8d322f-42dd-403f-a3ef-b7930f830b01"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtNS0xLTEtMA_e1e541a2-2d19-486e-bf45-5793a47815c1"
      unitRef="usd">7190221</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtNy0xLTEtMA_4531f82b-a283-428c-8b3d-dc19a19239cb"
      unitRef="usd">3283540</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtOS0xLTEtMA_c3ef73c4-b1b3-4455-bae8-df64457565ee"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtMTEtMS0xLTA_b855399e-7b00-4c70-99f5-245166790438"
      unitRef="usd">6779910</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTEtMTMtMS0xLTA_10a623b8-58d3-4778-93b2-0a8fedddcb91"
      unitRef="usd">3693851</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTItMy0xLTEtMA_45defaa5-ac60-45fa-81e3-c849da7b4ef9"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTItNS0xLTEtMA_923961f0-381d-4f56-aead-650279d2c9b5"
      unitRef="usd">7190221</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTItNy0xLTEtMA_f7753d4a-5213-48a3-9567-5bcc1fedd93c"
      unitRef="usd">13796911</ino:GoodwillAndIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTItOS0xLTEtMA_6239eb97-aa66-4919-b5b4-6f9d2662b2dd"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTItMTEtMS0xLTA_5f9f9aeb-ffb2-4304-8193-2dc377ec0e86"
      unitRef="usd">6779910</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RhYmxlOjk4ZTJmZTViMzlmYzQxODY4NTQyMmU5NjY0MmRkMzZiL3RhYmxlcmFuZ2U6OThlMmZlNWIzOWZjNDE4Njg1NDIyZTk2NjQyZGQzNmJfMTItMTMtMS0xLTA_0d638010-59f2-4514-9d01-5c7a74aba74a"
      unitRef="usd">14207222</ino:GoodwillAndIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="ibdf052a2e7144cdbbe989052584b4ca0_I20050131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfMjgz_41655890-0e30-4efe-8ffc-dbeb96ff9d8f"
      unitRef="usd">3900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4afa819554cd473a95b7517d32ce72f6_I20090630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfMjg3_8156bcae-d364-4c90-8b38-5ba50f926a7e"
      unitRef="usd">6200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2eca76820add42a0a986a746497d97dd_I20160430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfMjk0_0a7ccab1-8636-46d1-996e-c8567778b819"
      unitRef="usd">400000</us-gaap:Goodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfNjcx_36bc85da-47c7-43b1-882c-c25af9c6f167"
      unitRef="usd">137000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfNjc4_1738c169-cd9f-4071-9eae-643a20b1191d"
      unitRef="usd">410000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfNzYz_2eeea8e4-5375-4c16-9242-05a6f7d2f829"
      unitRef="usd">267000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfNzcw_bf9c4eb3-3058-46d7-abb7-5c68c3edc9f7"
      unitRef="usd">800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfODMz_0f422dfd-0170-409e-be10-680442b4df94"
      unitRef="usd">137000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfODcz_ee9ad503-2856-4aec-af5e-6e8d232428eb"
      unitRef="usd">520000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfODg1_7c6eea95-64d9-4316-ae11-4c4854967893"
      unitRef="usd">493000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfODk3_87d5fece-299a-40da-98ee-30753b6247f4"
      unitRef="usd">276000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfOTA5_1e47ef92-f45c-40ad-af98-cc06fd4418f4"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV81OC9mcmFnOjUxY2JmMTE2OGY4ZjRlZTZhNjAyMGZiOTFjY2U3NzJiL3RleHRyZWdpb246NTFjYmYxMTY4ZjhmNGVlNmE2MDIwZmI5MWNjZTc3MmJfOTI0_fd4b95c0-496b-41f7-a661-c40f0bc86325"
      unitRef="usd">1600000</ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNzY5NjU4MTQxMzcxOA_7b5ad682-c868-41b3-862f-13608d817163">Convertible Debt&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of the Notes to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately $75.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity in its condensed consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $78.5 million are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion featu&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;res. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $62.2 million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $2.8 million are allocated to the liability and equity component in the same proportion as the issuance proceeds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $18.6 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is 13.1%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2020, the Company received notices for the conversion of $19.1&#160;million of principal amount of the Notes, which were settled in July 2020 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;into an aggregate of 3,546,074 shares of the Company's common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The fair value of the Notes at the date of conversion was $13.0&#160;million compared to the carrying value of $16.1&#160;million, resulting in a $3.1 million gain on extinguishment of debt. This gain was recorded in the condensed consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at September&#160;30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount on the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,965,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,233,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,537,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2020,&#160;the Company recognized $1.7 million and $5.9 million, respectively, of interest expense related to the Notes, of which $996,000 and $3.5 million, respectively, related to the contractual interest coupon. For the three and nine months ended September 30, 2019,&#160;the Company recognized $2.1 million and $4.9 million, respectively, of interest expense related to the Notes, of which $1.3 million and $3.1 million, respectively, related to the contractual interest coupon. As descr&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ibed in Note 18 below, subsequent to September 30, 2020, certain holders converted an additional portion of the Notes into shares of the Company's common stock.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;August 2019 Convertible Bonds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2019, the Company closed a private placem&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ent of the August 2019 Bonds with an aggregate principal amount of 18 billion KRW (approximately USD $15.0 million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately $14.5 million. The Company also announced its intent to pursue a listing of its securities on the KOSDAQ in the form of Korean Depositary Receipts (KDRs) representing shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020 the August 2019 Bonds were converted in full into an aggregate of 4,962,364 shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.6873 shares per KRW 1,000,000 in principal amount (equivalent to a conversion price of approximately USD $3.04 per share based on the exchange rate as of August 3, 2020).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $7.1 million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the condensed consolidated&#160;statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $7.3 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022.&#160;The effective interest rate of the August 2019 Bonds was 29.4%. For the three and nine months ended September 30, 2020,&#160;the Company recognized $238,000 and $1.6 million, respectively, of interest expense related to the August 2019 Bonds, of which $13,000 and $87,000, respectively, related to the contractual interest coupon. For the nine months ended September 30, 2019, the Company recognized $374,000 of interest expense related to the August 2019 Bonds, of which $26,000 related to the contractual interest coupon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, all outstanding August 2019 Bonds were converted into common stock. Immediately prior to the conversion, the derivative liability was revalued at $84.5 million. The changes in fair value of the derivative liability were a decrease of $35.3 million and an increase of $75.7 million, which were recorded on the condensed consolidated statement of operations for the three and nine months ended September 30, 2020, respectively. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, a loss on extinguishment of $8.2&#160;million was recorded on the condensed consolidated statement of operations for the three months ended September 30, 2020. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the 4,692,364 shares of the Company's common stock issued upon conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2019 Convertible Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#x201c;December 2019 Bonds&#x201d;) with an aggregate principal amount of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately $4.0 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The December 2019 Bonds, which are unsecured obligations of the Company, were issued on December&#160;31, 2019 and will accrue interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds will mature on December&#160;31, 2024, unless earlier converted or repurchased. The outstanding December 2019 Bonds will be repaid at maturity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of 6.00%. Commencing on December&#160;31, 2020, the December 2019 Bonds will be convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver KDRs, if the Company has any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock of the Company. The initial conversion rate is 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. The conversion rate is subject to reset on July&#160;2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed 357.9611 shares per KRW1,000,000 (equivalent to a conversion price of approximately USD $2.40 per share based on the exchange rate as of December&#160;19, 2019). The conversion rate has not been reset as of September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The December 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including December&#160;31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the December 2019 Bonds to be repurchased plus a premium on the Bonds in order to ensure an internal rate of return with respect to the Bonds equal to 6.00%. In addition, upon the occurrence of a fundamental change (as defined in the Subscription Agreement) the Company will be required to offer to repurchase the Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon to but excluding the applicable repurchase date. If certain bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding December 2019 Bonds shall automatically become due and payable. If any other event of default occurs and is continuing, the holders of at least 25% of the in aggregate principal amount of the December 2019 Bonds by notice to the Company may declare the principal of, and accrued and unpaid interest on, all of the then-outstanding December 2019 Bonds to be due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity in its consolidated balance sheet. The December 2019 Bonds are denominated in a foreign currency other than the Company&#x2019;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#x2019;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario is fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency does not impact the settlement of the conversion option. Further, as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the December 2019 Bonds at September&#160;30, 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,030,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of premium associated with the December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,151,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represents the point at which the December 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is 6.2%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For the three and nine months ended September 30, 2020,&#160;the Company recognized $63,000 and $185,000, respectively, of interest expense related to the December 2019 Bonds, of which $10,000 and $30,000, respectively, related to the contractual interest coupon. As of September&#160;30, 2020, there had not been any conversions or redemptions of the December 2019 Bonds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, future minimum payments due under the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; convertible debt instruments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible Notes (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 2019 Bonds (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,862,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,862,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,862,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,346,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,189,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,535,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,932,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,319,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,251,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of 6.5% per year. &lt;/span&gt;&lt;/div&gt;(2) Amounts represent amounts due under the December 2019 Bonds, including interest based on the fixed rate of 1% per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of 6% at maturity.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if070ef767938497492f880730056fd65_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTM3_fdda763b-b704-4b55-a23a-f5ba2b7fc612"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzMy_0f9464f5-6996-48e4-8420-a33a59da856f"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if070ef767938497492f880730056fd65_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNTQx_2529f425-54d2-4c22-beb9-a5180b13939e"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ib3abdef29e774d82a089595d8b564e0f_I20190301"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTM1Mw_9edc2863-4776-444b-a774-de99a858e31c"
      unitRef="usdPerShare">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTY2NQ_ed28a8df-2730-4bd0-9ba6-f3841e26edb9"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTcxNg_d6c35feb-c021-48c2-b6e0-863a179a4894"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTc3Mg_5a9dd708-ee79-47e8-b9df-a513c4df813b"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i5d65975d1591494ab3f8835898c2ebd8_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMjA0Mw_8672a970-452f-4afb-96b9-a182dd6fc07d"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if070ef767938497492f880730056fd65_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMjU4Mg_9ffb28bd-885b-49e9-9686-e3db8a044586"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="if070ef767938497492f880730056fd65_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMjg5OA_a906bfcc-1bd3-42fd-9c27-0f0f879cf597"
      unitRef="usd">62200000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if070ef767938497492f880730056fd65_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzExMA_b0f2ba0e-2be3-4d4f-a77e-afc6e2c6ef4e"
      unitRef="usd">2800000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="if070ef767938497492f880730056fd65_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzg0ODI5MDczMDc4Mw_8c60b77c-b48b-4239-8b48-d6075c26abb5"
      unitRef="usd">18600000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzg0ODI5MDczMDc4Nw_15333902-0d35-4f1d-bb55-3b6572773dc5"
      unitRef="number">0.131</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="if59eceeb9abf42459b9e0b88dc6346ce_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzg0ODI5MDcyODg2NA_83985d19-3f26-48be-8a5a-f2bb2881bd55"
      unitRef="usd">19100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="if59eceeb9abf42459b9e0b88dc6346ce_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzg0ODI5MDcyODg3OQ_d251db2e-bc2a-44d3-aebd-f1a4740ae503"
      unitRef="shares">3546074</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i45d4d90e086a49749993964ed0753833_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkyNzY2Nw_6548f24a-61c3-4dd0-b48a-6a6fc9d91f31"
      unitRef="usd">13000000.0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i45d4d90e086a49749993964ed0753833_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkyNzY4Mg_85204c11-78ab-45d8-90c4-a26b606aa346"
      unitRef="usd">16100000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if59eceeb9abf42459b9e0b88dc6346ce_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzg0ODI5MDcyOTc0MA_af0f4d48-cfae-4b65-9636-9c41d6a30229"
      unitRef="usd">3100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ4MTU_63a9339f-8867-43dc-98ff-1f98d2630467">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at September&#160;30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount on the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,965,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,233,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,537,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the December 2019 Bonds at September&#160;30, 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,030,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of premium associated with the December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,151,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iad00cc94b7054dba89db6de62bd2743e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmEwOTIwZjIwYmZiYzQzY2U4M2M3MTgxOGZjOWJiZWRhL3RhYmxlcmFuZ2U6YTA5MjBmMjBiZmJjNDNjZTgzYzcxODE4ZmM5YmJlZGFfMC0xLTEtMS0w_decf31a6-6024-4fd1-ba8f-739dfb907726"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <ino:DebtInstrumentConvertibleDebtConvertedAmount
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmEwOTIwZjIwYmZiYzQzY2U4M2M3MTgxOGZjOWJiZWRhL3RhYmxlcmFuZ2U6YTA5MjBmMjBiZmJjNDNjZTgzYzcxODE4ZmM5YmJlZGFfMS0xLTEtMS0zMDYw_10ff3d59-799c-45e1-a761-e9aca177957a"
      unitRef="usd">19085000</ino:DebtInstrumentConvertibleDebtConvertedAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iad00cc94b7054dba89db6de62bd2743e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmEwOTIwZjIwYmZiYzQzY2U4M2M3MTgxOGZjOWJiZWRhL3RhYmxlcmFuZ2U6YTA5MjBmMjBiZmJjNDNjZTgzYzcxODE4ZmM5YmJlZGFfMS0xLTEtMS0w_088012aa-7fe6-4963-91cf-1b27a6f2e22f"
      unitRef="usd">8965643</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="iad00cc94b7054dba89db6de62bd2743e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmEwOTIwZjIwYmZiYzQzY2U4M2M3MTgxOGZjOWJiZWRhL3RhYmxlcmFuZ2U6YTA5MjBmMjBiZmJjNDNjZTgzYzcxODE4ZmM5YmJlZGFfMi0xLTEtMS0w_b5b2f8bf-e591-47e1-a359-076a9f6b3f0a"
      unitRef="usd">1233978</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtInstrumentAccruedInterest
      contextRef="iad00cc94b7054dba89db6de62bd2743e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmEwOTIwZjIwYmZiYzQzY2U4M2M3MTgxOGZjOWJiZWRhL3RhYmxlcmFuZ2U6YTA5MjBmMjBiZmJjNDNjZTgzYzcxODE4ZmM5YmJlZGFfMy0xLTEtMS0w_ca6dc4e6-b001-43a7-b75c-f670e3cc2a83"
      unitRef="usd">321831</ino:DebtInstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="iad00cc94b7054dba89db6de62bd2743e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmEwOTIwZjIwYmZiYzQzY2U4M2M3MTgxOGZjOWJiZWRhL3RhYmxlcmFuZ2U6YTA5MjBmMjBiZmJjNDNjZTgzYzcxODE4ZmM5YmJlZGFfNC0xLTEtMS0w_18c0f9d8-c4c9-4ca0-baec-0ad413c1bcb1"
      unitRef="usd">49537210</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense
      contextRef="i590d515cf6de40edb611587951823c62_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDA5Mw_c211056a-b409-4cff-983d-23c638c2fb72"
      unitRef="usd">1700000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9d466a48e9e141aa8102e78c3a89cb07_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDEwMA_e4c4495e-d8ff-4dc2-a2b3-0af9674cbc83"
      unitRef="usd">5900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i590d515cf6de40edb611587951823c62_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDE2OQ_131e4e3c-da28-4db5-9356-9ddae22d0fe5"
      unitRef="usd">996000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9d466a48e9e141aa8102e78c3a89cb07_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDE3Ng_5684095d-2377-4760-8b83-ac7bfe08e04a"
      unitRef="usd">3500000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpense
      contextRef="i864892cede774f3eb42a10f60eaf5a21_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDMxMQ_70745f3b-c67e-4c50-a29b-f12da0af895c"
      unitRef="usd">2100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib0c7c8a510c14ce3ba010b700fac6047_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDMxOA_f292f7b6-e360-4b4d-9ea9-bd1be6fa37e3"
      unitRef="usd">4900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i864892cede774f3eb42a10f60eaf5a21_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDM4Nw_fab485e9-fa21-43fc-9ce3-ea187e9b1b22"
      unitRef="usd">1300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ib0c7c8a510c14ce3ba010b700fac6047_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDM5NA_d8bff692-ab69-42b9-a86f-2f00198b2ad7"
      unitRef="usd">3100000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2393a62fa5e34d739b1a36b6e8df6f31_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDgzNQ_3cd280e5-ce1f-4dc1-b465-eeb9696671c0"
      unitRef="krw">18000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2393a62fa5e34d739b1a36b6e8df6f31_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNDg3NA_471b5361-e7a6-4f98-8778-89f40d8b5ea1"
      unitRef="usd">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i5cec051d961f4164be10ec4cd03c6eb8_D20190801-20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNTEyNQ_865cc452-d8e7-43d4-995f-d27c60fb3602"
      unitRef="usd">14500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2393a62fa5e34d739b1a36b6e8df6f31_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNTQ4Nw_89b782d9-00de-4e21-ba94-e44a45473124"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i8a37a98039ba414db800ad308eb2b02c_D20200803-20200803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkyNjg3MA_188bd3ea-a1ff-4f62-a59e-30c42ab9006d"
      unitRef="shares">4962364</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i93454515f2814d1aa32809ed291c931a_I20200803"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkyNjkwMg_3c352d3d-4acb-4c4e-bea3-8558dc7c1c05"
      unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i930a152e7e8f41e89ca66ed7945686b3_I20200803"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkyNjkxMQ_260bd875-6402-4f5a-b387-9be3a61d341e"
      unitRef="usdPerShare">3.04</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i2393a62fa5e34d739b1a36b6e8df6f31_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfNzAzNw_fcd7a1b7-d975-47b3-a28d-0eda5d619ddb"
      unitRef="usd">7100000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i2393a62fa5e34d739b1a36b6e8df6f31_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfODE1Nw_e2b45c4a-d9b4-4159-8f4c-c607cd1eb195"
      unitRef="usd">7300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if776c09c12d048a8a03158014bdd629b_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfODM5Mw_23e7b0ca-1289-4d47-af4d-57423b7112b6"
      unitRef="number">0.294</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpense
      contextRef="i069c085bd0884569a0c363b84262b982_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfODQzMg_6eb399a7-37ad-4169-b3c1-1aebd032ab3e"
      unitRef="usd">238000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i666980e930ca4263a11fb9d67a8ff7a5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfODQzOQ_4f9b2298-c6c6-4f36-92bf-e63204d7e989"
      unitRef="usd">1600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i069c085bd0884569a0c363b84262b982_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfODUyOA_b5968a3a-96b2-46c9-aa49-ce477af01acc"
      unitRef="usd">13000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i666980e930ca4263a11fb9d67a8ff7a5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfODUzNQ_8f85d13b-b6d3-45ac-8486-82061f634d5d"
      unitRef="usd">87000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpense
      contextRef="i438e7b59c3d54e9e998a30ddc65e87a3_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMjc0ODc3OTA5NjY4MQ_5f7adb45-2165-4bb1-bb96-6de038e9f432"
      unitRef="usd">374000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i438e7b59c3d54e9e998a30ddc65e87a3_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMjc0ODc3OTA5NjY5MQ_1193c0e4-eaa1-469a-a668-62fcc6dcc6da"
      unitRef="usd">26000</us-gaap:InterestExpenseDebt>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i8958471a957c4db3b44209f556886dc5_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkwNDY2NQ_9c9a7d7a-20b9-4e95-a19f-bad81d96da55"
      unitRef="usd">84500000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i069c085bd0884569a0c363b84262b982_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkwNDczNw_abda83a1-a6b8-48ff-ad2b-abe571f86fd3"
      unitRef="usd">35300000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i666980e930ca4263a11fb9d67a8ff7a5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkwNDc0NQ_650c7043-f179-4220-86d6-e8b2511a3b2d"
      unitRef="usd">75700000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i069c085bd0884569a0c363b84262b982_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfOTM0NTg0ODg1OTAxMA_ce3eeb60-bc88-4ef1-81b1-55921c3748c1"
      unitRef="usd">8200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ib8a6a5f3412b4170b586cb0a191c2b65_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMzI5ODUzNDkwNjAzMg_d88f73db-62c9-46c3-b4bb-3d6fc35cc3db"
      unitRef="shares">4692364</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i30b055a2515244df98c8096ff545da5c_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfOTE5MA_a37835fd-85d3-4ad6-bb9e-fec28f3348bc"
      unitRef="krw">4700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i30b055a2515244df98c8096ff545da5c_I20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfOTIxNg_f60251e3-4bc4-4057-ab99-bd74cc9509a6"
      unitRef="usd">4100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ib669b19a336e48c890a2feda647d2035_D20191226-20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfOTM2OQ_1c1943fb-9fe2-4dea-b686-ba1c75e38a27"
      unitRef="usd">4000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i30b055a2515244df98c8096ff545da5c_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfOTUyNg_3ff45a31-636b-41f0-8489-671254c52850"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ino:DebtInstrumentConvertibleInternalRateOfReturn
      contextRef="i30b055a2515244df98c8096ff545da5c_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfOTg5MA_6190cffc-dad7-4d2f-8745-47d3c7273d00"
      unitRef="number">0.0600</ino:DebtInstrumentConvertibleInternalRateOfReturn>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i47a612180eaa425693bc6df2815b34a8_I20191226"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTAzNDM_59b061b4-e6e1-4868-a0dc-02383e7afc17"
      unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="idecb5c7b97f44096ab202e14ea4c5a5c_I20191226"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTA4MzQ_9ec66c3d-f452-4149-8442-47ec6776dc61"
      unitRef="usdPerShare">2.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ino:DebtInstrumentConvertibleInternalRateOfReturn
      contextRef="i30b055a2515244df98c8096ff545da5c_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTEyOTg_9ef41fc3-7f87-4c2d-aae7-986b3716e846"
      unitRef="number">0.0600</ino:DebtInstrumentConvertibleInternalRateOfReturn>
    <ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage
      contextRef="ib669b19a336e48c890a2feda647d2035_D20191226-20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTE5MTA_98257092-3ce2-419c-bc9d-bb01902fa655"
      unitRef="number">0.25</ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic5922a465abf4cc1be657156439079c7_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmM5NWMxNzEzYjdhYTQzYzZhZGFiMmY4YzdjODQyZmJiL3RhYmxlcmFuZ2U6Yzk1YzE3MTNiN2FhNDNjNmFkYWIyZjhjN2M4NDJmYmJfMC0xLTEtMS0w_4fe42c9e-ceb8-4aca-93f3-83c79c513f97"
      unitRef="usd">4030978</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ic5922a465abf4cc1be657156439079c7_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmM5NWMxNzEzYjdhYTQzYzZhZGFiMmY4YzdjODQyZmJiL3RhYmxlcmFuZ2U6Yzk1YzE3MTNiN2FhNDNjNmFkYWIyZjhjN2M4NDJmYmJfMi0xLTEtMS0w_8a3f9cb2-20db-42d8-8a6e-8c71817f93d7"
      unitRef="usd">37985</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtInstrumentAccretionOfPremium
      contextRef="ic5922a465abf4cc1be657156439079c7_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmM5NWMxNzEzYjdhYTQzYzZhZGFiMmY4YzdjODQyZmJiL3RhYmxlcmFuZ2U6Yzk1YzE3MTNiN2FhNDNjNmFkYWIyZjhjN2M4NDJmYmJfMy0xLTEtMS0w_486fef24-55ac-4176-9a35-719cc86913d8"
      unitRef="usd">148593</ino:DebtInstrumentAccretionOfPremium>
    <ino:DebtInstrumentAccruedInterest
      contextRef="ic5922a465abf4cc1be657156439079c7_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmM5NWMxNzEzYjdhYTQzYzZhZGFiMmY4YzdjODQyZmJiL3RhYmxlcmFuZ2U6Yzk1YzE3MTNiN2FhNDNjNmFkYWIyZjhjN2M4NDJmYmJfNC0xLTEtMS0w_a5273bef-9d8e-4743-b69a-950c1fecfb3c"
      unitRef="usd">10077</ino:DebtInstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="ic5922a465abf4cc1be657156439079c7_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOmM5NWMxNzEzYjdhYTQzYzZhZGFiMmY4YzdjODQyZmJiL3RhYmxlcmFuZ2U6Yzk1YzE3MTNiN2FhNDNjNmFkYWIyZjhjN2M4NDJmYmJfNS0xLTEtMS0w_6de48090-7310-48ff-b458-61debca04fe3"
      unitRef="usd">4151663</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQwMzQ_240f4e3e-65c7-407a-8622-99b9086512e1"
      unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpense
      contextRef="i321babdbed2a41498f88f960499c9240_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQwNzM_092fe4f6-a93f-41ee-ba18-e8cb20dab5bf"
      unitRef="usd">63000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2cca53a6bf0849c3a1f4c545316eb5ca_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQwODA_09afc7ba-95d6-4ada-8344-06897e93c5d7"
      unitRef="usd">185000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i321babdbed2a41498f88f960499c9240_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQxNjM_f97ddd0d-a3e8-4c2a-874e-309ec8eb5d88"
      unitRef="usd">10000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i2cca53a6bf0849c3a1f4c545316eb5ca_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQxNzA_5df53fe6-bc30-492b-8706-3eb165095c82"
      unitRef="usd">30000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ4MjU_a196a25b-f3e7-4215-a8be-5435150c3ebb">&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, future minimum payments due under the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; convertible debt instruments are as follows:&lt;/span&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible Notes (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 2019 Bonds (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,862,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,862,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,862,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,346,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,189,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,535,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,932,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,319,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,251,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of 6.5% per year. &lt;/span&gt;&lt;/div&gt;(2) Amounts represent amounts due under the December 2019 Bonds, including interest based on the fixed rate of 1% per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of 6% at maturity.</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfMi0yLTEtMS0w_74f2e76f-0392-4352-9380-d39831cc5c52"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfMi02LTEtMS0w_4a425f96-877d-41e6-aa33-6243e69aa811"
      unitRef="usd">10000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="if2b79363a4154026a899e339e36624d9_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfMi04LTEtMS0w_67244b12-7b5b-4783-a2a0-f20eeb36887f"
      unitRef="usd">10000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfMy0yLTEtMS0w_8792ee92-6ad6-4812-9f6c-8642c8044834"
      unitRef="usd">3862000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfMy02LTEtMS0w_3c151d58-4b9c-4437-a416-66cd5469f958"
      unitRef="usd">40300</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="if2b79363a4154026a899e339e36624d9_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfMy04LTEtMS0w_4afe5a67-3442-4525-b101-218e226ab0a0"
      unitRef="usd">3902300</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNC0yLTEtMS0w_ce35c640-d662-481f-9632-a041c48dd098"
      unitRef="usd">3862000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNC02LTEtMS0w_2b0c9827-2c35-483f-8777-5057105fd613"
      unitRef="usd">40300</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="if2b79363a4154026a899e339e36624d9_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNC04LTEtMS0w_0f3afbd7-3eb6-42dd-8104-246105e1f506"
      unitRef="usd">3902300</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNS0yLTEtMS0w_f7ddab2d-69d9-46c1-8009-b8950baa6b27"
      unitRef="usd">3862000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNS02LTEtMS0w_f5abfc32-15ec-4f85-98c8-efc46181c061"
      unitRef="usd">40300</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="if2b79363a4154026a899e339e36624d9_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNS04LTEtMS0w_f9da9fa9-a002-481f-8072-9a80bb2b3e06"
      unitRef="usd">3902300</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNi0yLTEtMS0w_4b909771-ae04-46aa-a2eb-342b7e673f15"
      unitRef="usd">61346000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNi02LTEtMS0w_43f3effa-1372-4e9e-9eb9-56b035c93750"
      unitRef="usd">5189000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="if2b79363a4154026a899e339e36624d9_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNi04LTEtMS0w_da96dec0-9195-47b1-9adb-2511fede3f18"
      unitRef="usd">66535000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt
      contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNy0yLTEtMS0w_e1bbe110-8204-4c66-9cc0-d3af7f4487d4"
      unitRef="usd">72932000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNy02LTEtMS0w_e17277eb-4c91-4bdc-847e-86f1ee86cb6e"
      unitRef="usd">5319900</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if2b79363a4154026a899e339e36624d9_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RhYmxlOjRiMmI4OGJjYmQ5ZTQzZTZiNjQ4NWZkZjhiNjkxNmIxL3RhYmxlcmFuZ2U6NGIyYjg4YmNiZDllNDNlNmI2NDg1ZmRmOGI2OTE2YjFfNy04LTEtMS0w_f655b102-65cb-4fb2-b771-3b01139b9be9"
      unitRef="usd">78251900</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i172d0673a3194c5580d4987b79a2a44c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ1MzQ_969655d1-9a14-4b04-96c0-e6a7ed7e67d4"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if776c09c12d048a8a03158014bdd629b_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ2ODc_1d7b09c1-7787-4d0c-a2c7-b09a9832d460"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ2ODc_20feba89-2692-4a79-b39b-814a6f4a23fc"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ino:DebtInstrumentConvertibleInternalRateOfReturn
      contextRef="if776c09c12d048a8a03158014bdd629b_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ3OTY_a514010a-4f62-4647-9804-62d58778dada"
      unitRef="number">0.06</ino:DebtInstrumentConvertibleInternalRateOfReturn>
    <ino:DebtInstrumentConvertibleInternalRateOfReturn
      contextRef="i34550c65c6944e8290ed1e7c3cc2387d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82MS9mcmFnOmMxNzRkZDZlNzUxYTQ0ZjBhYzVmNThjMThkZGJlN2U4L3RleHRyZWdpb246YzE3NGRkNmU3NTFhNDRmMGFjNWY1OGMxOGRkYmU3ZThfMTQ3OTY_c10a9b78-e152-48e7-a3cf-5d9d94990b2d"
      unitRef="number">0.06</ino:DebtInstrumentConvertibleInternalRateOfReturn>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNTIwOA_a42bd28c-3bfb-4bc8-803f-b9ea9bea8925">Stockholders&#x2019; Equity&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of September&#160;30, 2020 and December&#160;31, 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,528,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,528,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,361,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, 14 shares of the Company&#x2019;s Series&#160;C preferred stock were converted into an aggregate of 5,147 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#x201c;Placement Agent&#x201d;) to sell shares of its common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#x201c;at-the-market&#x201d; equity offering program under which the Placement Agent would act as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from $100.0 million to $250.0 million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $250.0 million. Under the New Sales Agreement, the Company sets the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The New Sales Agreement provides that the Placement Agent is entitled to compensation for its services in an amount equal to up to 3.0% of the gross proceeds from the sales of shares sold through the Placement Agent under the New Sales Agreement. The Company has no obligation to sell any shares under the New Sales Agreement, and could at any time suspend solicitation and offers under the New Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2020, the Company sold 43,148,952 shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of $4.92 per share, resulting in aggregate net proceeds of $208.2 million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the three months ended June 30, 2020, the Company sold 12,041,178 shares of its common stock under the New Sales Agreement. The sales were made at a weighted average price of $10.26 per share, resulting in aggregate net proceeds of $121.7 million. There were no shares sold during the three months ended September 30, 2020 under the New Sales Agreement. As of September 30, 2020, the Company may sell up to $126.4 million in gross proceeds of shares of Common Stock under the New Sales Agreement before it would be required to file a new prospectus supplement with the SEC to sell additional shares pursuant to the New Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. The maximum number of shares of the Company&#x2019;s common stock available for issuance over the term of the 2016 Incentive Plan may not exceed 18,000,000 shares, provided that commencing with the first business day of each calendar year beginning January&#160;1, 2020, such maximum number of shares shall be increased by&#160;2,000,000 shares of common stock unless the Company's Board of Directors determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2020, the maximum number of shares to be issued increased by 2,000,000. At September&#160;30, 2020, there were 18,000,000 shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At September&#160;30, 2020, the Company had 6,785,707 shares of common stock available for future grant under the 2016 Incentive Plan, 2,586,915 shares underlying outstanding but unvested restricted stock units and options outstanding to purchase 5,878,252 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.&lt;/span&gt;&lt;/div&gt;The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At September&#160;30, 2020, the Company had options outstanding to purchase 3,412,095 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNTIxNQ_69215c6b-0653-48af-8d96-d11bc73067f9">&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of September&#160;30, 2020 and December&#160;31, 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,528,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,528,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,361,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfMi0wLTEtMS00NTc0L3RleHRyZWdpb246NGJkNDhlOTU1MDAzNDgxNDk2OThmZGI4ZmNmMDVhMGNfNDM5ODA0NjUxMTE1NA_93c9e4ad-047a-4713-9be8-ae8306030b2e"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfMi0wLTEtMS00NTc0L3RleHRyZWdpb246NGJkNDhlOTU1MDAzNDgxNDk2OThmZGI4ZmNmMDVhMGNfNDM5ODA0NjUxMTE1NA_c8f9c690-e463-4b30-858b-25f7d05dd9d1"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfMi0xLTEtMS0w_1754db3a-78c8-48f4-b2fc-10fdcff6e01e"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfMi0zLTEtMS0w_c58e6cad-7c67-466d-9e0d-acf74acfb375"
      unitRef="shares">167528435</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfMi01LTEtMS0w_917bd309-63b1-4299-af9b-c35ae988c7a9"
      unitRef="shares">167528435</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i91e7c0f132e34c59bf93da3effb57556_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfMi03LTEtMS0w_14c46c93-90f6-487a-aa19-bad3de420924"
      unitRef="shares">101361034</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib12d03d2fe7e453ea4f8ccb997e9f525_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfNS0wLTEtMS00NTc3L3RleHRyZWdpb246ZTM2YmM5NjFmNDY1NDI0ZjkwOWQ2ODZhNzgxMjZkYjlfNDM5ODA0NjUxMTE2Ng_68d440ea-2e98-452b-9628-6172e275217d"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie09a126e34b741aa9a646f361a9bfa0d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfNS0wLTEtMS00NTc3L3RleHRyZWdpb246ZTM2YmM5NjFmNDY1NDI0ZjkwOWQ2ODZhNzgxMjZkYjlfNDM5ODA0NjUxMTE2Ng_7b5dcd07-341a-4f92-ae20-62e70b6b0522"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib12d03d2fe7e453ea4f8ccb997e9f525_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfNS0xLTEtMS0w_a3f21f8d-3c0a-4f99-b8a6-b637b1ead955"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib12d03d2fe7e453ea4f8ccb997e9f525_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfNS0zLTEtMS0w_f2f88a63-8d6c-46e8-a694-f8f20bacc3d3"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib12d03d2fe7e453ea4f8ccb997e9f525_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfNS01LTEtMS0w_5ca67fb4-4926-468e-bbd7-10cd81c2bde8"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie09a126e34b741aa9a646f361a9bfa0d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RhYmxlOmE5MzAyMWExNzRmMjRmNzQ4YzVjMTk5OWU4MjE4OTBjL3RhYmxlcmFuZ2U6YTkzMDIxYTE3NGYyNGY3NDhjNWMxOTk5ZTgyMTg5MGNfNS03LTEtMS0w_89590134-8eab-4fcc-89f9-91e21a708aa3"
      unitRef="shares">23</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="ie2d0bbde4d3e40a9883106a66764b89b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjA0_433b31d8-1324-49dd-a261-6a97f7355097"
      unitRef="shares">14</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="id6b8d7c533b04e2981466489c552e6c1_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjky_99ba26f2-9976-475c-86d2-2a87df6e07bf"
      unitRef="shares">5147</us-gaap:ConversionOfStockSharesIssued1>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i14a978d9496a43e7aede0fcbc572e14b_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNTMy_329b1388-107b-4ef7-845b-950eecc61c57"
      unitRef="usd">100000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i14a978d9496a43e7aede0fcbc572e14b_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfOTE2_8bd912ac-5216-413c-8d8c-2259e3c03507"
      unitRef="usd">100000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i9c298cf37a4848da8778eeafecf73788_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfOTIy_17f67251-0e87-4faa-901a-68feca0c48ab"
      unitRef="usd">250000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i97fe994b743146a2b11f82e54b658475_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfOTU4_d6112818-4e58-49d9-bffa-911efacff313"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="id24bddea654742c4b5eecc7be2d6d449_D20200403-20200512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMTM3Ng_34e83f79-8a5d-4014-ace5-d1a07c8d1826"
      unitRef="usd">250000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementAgentFee
      contextRef="id24bddea654742c4b5eecc7be2d6d449_D20200403-20200512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMTgzNg_bb4e6e5b-25a8-45ea-af54-98b6a276b2b7"
      unitRef="number">0.030</ino:StockSalesAgreementAgentFee>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i9c298cf37a4848da8778eeafecf73788_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjE3OA_7ec4d0ce-3377-4aca-a2a5-f62243ec95ab"
      unitRef="shares">43148952</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="i9c298cf37a4848da8778eeafecf73788_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjI5Mg_35b8274a-02fa-4182-8e28-4d244ee56575"
      unitRef="usdPerShare">4.92</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="i9c298cf37a4848da8778eeafecf73788_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjM0NQ_a4ec63d9-742e-407f-b21f-d3a79f88dee7"
      unitRef="usd">208200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i97fe994b743146a2b11f82e54b658475_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjM4Mg_0c5ec82f-d159-4776-84f9-f1d80237e3b8"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="ib23297044af5421488bf606a07fcad5a_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjQ5OQ_41f62272-7d9b-4802-a19f-cd15e38ccb2f"
      unitRef="shares">12041178</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="ib23297044af5421488bf606a07fcad5a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjYxMQ_ef87229e-90dc-424f-83c6-6689dd517db4"
      unitRef="usdPerShare">10.26</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="ib23297044af5421488bf606a07fcad5a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjY2NA_07231815-b081-4f90-bfc9-72d792294de0"
      unitRef="usd">121700000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i4c022db15d174f8db8fb571a3e4db2f7_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMzI5ODUzNDg4ODc4NQ_47a1ef3f-6de8-4e34-a982-359a1f232124"
      unitRef="shares">0</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="ic3afac984f9d4d59bbd2907c5bbd7278_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMjcxNg_b2367db2-14aa-43df-a0b1-5aca645794e7"
      unitRef="usd">126400000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i074731de2992483e840b846807d642f7_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMzY3OQ_17c0ec24-ecf6-435e-b2fa-b516c2fc6480"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan
      contextRef="i074731de2992483e840b846807d642f7_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfMzg0NA_06ddbe98-8cac-40b1-b1ba-3f1b5187f7cd"
      unitRef="shares">2000000</ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized
      contextRef="ia9835623d0cf40b4861f5c838d46c1a2_I20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDE2NA_f7516159-a6f7-4873-975d-576e5b31b97a"
      unitRef="shares">2000000</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i4b4928fc44ae4021b15f75edc4b2c760_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDE4Ng_8c6cc182-22cf-44fd-9a93-8c53eb5a4c3a"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i4b4928fc44ae4021b15f75edc4b2c760_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDM2NA_93446c94-d6f1-4c49-aed9-767baa7ce36f"
      unitRef="shares">6785707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4b4928fc44ae4021b15f75edc4b2c760_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDQ0OA_93dcdec0-b09f-49c9-9640-3b6cefc910b0"
      unitRef="shares">2586915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i4b4928fc44ae4021b15f75edc4b2c760_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDU1Mw_0bc90871-3a97-4700-b2f5-04b65fb4405a"
      unitRef="shares">5878252</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ibc202bd5f1fd4725bdbf57b6065610c3_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDcxMA_fe648544-44cb-4e77-9dbd-8f132fd87054">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="ibc202bd5f1fd4725bdbf57b6065610c3_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNDc1Mg_1175a030-f12f-4c97-b772-077c158c318e">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i186812e80eed40f0bbab169954854146_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNTAzNQ_d03af92c-0b04-46bd-a2e5-ead0d262ee91"
      unitRef="shares">3412095</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ice5f528ac7ca4891a83906dfc20c1df3_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNTE2MQ_95574122-9672-4739-a640-e83c8fe2f470">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="ice5f528ac7ca4891a83906dfc20c1df3_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV82Ny9mcmFnOmQ3MmUwZDdkZmM4YzQ3OGZhZDFhZDNiNmE1NjQwNWQzL3RleHRyZWdpb246ZDcyZTBkN2RmYzhjNDc4ZmFkMWFkM2I2YTU2NDA1ZDNfNTIwMw_1f0d6817-1290-49fc-a441-1fbae85a1b54">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RleHRyZWdpb246MmIwMjQxODZjMzc5NDY3NzgzODBmYTU0YTJkZDBmOTJfMTA4Ng_acb9efe2-78a2-4a5a-9737-cd298ac0de61">Net Income (Loss) Per Share &lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and refle&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cts the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method.  The calculation of diluted net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;income (loss)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net income (loss) per share for the period, an adjustment to the net income (loss) used in the calculation is required to remove the change in fair value of such securities from the numerator for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the nine months ended September 30, 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options and restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables reconcile the components of the numerator and denominator included in the calculation of diluted net income (loss) per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net income (loss) per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,171,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,090,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment for decrease in fair value of derivative liability and interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,177,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator for use in diluted income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,171,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,267,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding (denominator for use in basic net income (loss) per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,355,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,007,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive potential common shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,020,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator for use in diluted net income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,376,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,807,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net loss per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142,072,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81,697,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment for decrease in fair value of derivative liability and interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator for use in diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142,072,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81,697,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding (denominator for use in basic net loss per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,656,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,204,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive potential common shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator for use in diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,656,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,204,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net income (loss) per share calculation because of their anti-dilutive effect for the three months ended September 30, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Common Stock Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,971,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,121,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,039,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,171,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,686,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the nine months ended September 30, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Common Stock Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,290,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,971,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,586,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,121,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,039,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,592,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,485,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RleHRyZWdpb246MmIwMjQxODZjMzc5NDY3NzgzODBmYTU0YTJkZDBmOTJfMTQyOTM2NTExNjMyMjk_d0560128-1fa0-49d6-8c0d-7aaf0f00c49d">The following tables reconcile the components of the numerator and denominator included in the calculation of diluted net income (loss) per share:&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net income (loss) per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,171,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,090,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment for decrease in fair value of derivative liability and interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,177,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator for use in diluted income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,171,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,267,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding (denominator for use in basic net income (loss) per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,355,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,007,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive potential common shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,020,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator for use in diluted net income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,376,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,807,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net loss per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142,072,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81,697,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment for decrease in fair value of derivative liability and interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator for use in diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142,072,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81,697,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding (denominator for use in basic net loss per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,656,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,204,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive potential common shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator for use in diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,656,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,204,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMy0yLTEtMS04MDA_1eda2347-eed7-4807-802b-d70d270168e7"
      unitRef="usd">19171336</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMy00LTEtMS02ODE_5e677090-9f8a-4c60-8b74-910ff7dd3f0f"
      unitRef="usd">-23090693</us-gaap:NetIncomeLoss>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfNC0yLTEtMS04MDA_5ef1e5ea-5ff3-4dcb-bd0f-aa96c18ed5b9"
      unitRef="usd">0</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfNC00LTEtMS02ODE_7503887a-7300-42a3-be81-66b36c398c98"
      unitRef="usd">-2177250</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfNS0yLTEtMS04MDA_29fca9f5-1145-4b6d-82ff-9b42d6b6e775"
      unitRef="usd">19171336</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfNS00LTEtMS02ODE_4db3270b-5fc2-4696-bc9e-f016cff144cc"
      unitRef="usd">-25267943</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfOC0yLTEtMS04MDQ_c65d8409-6338-4b15-9806-28d5d97d677c"
      unitRef="shares">165355540</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfOC00LTEtMS02ODY_3ba5f022-98ea-4069-9714-64af200e01ba"
      unitRef="shares">99007985</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfOS0yLTEtMS04MDQ_c62d271a-fd2c-4c6a-b02b-3e12274eb7b7"
      unitRef="shares">9020862</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfOS00LTEtMS02ODY_7c3d47fb-2e52-4398-a7da-397b3d304c7a"
      unitRef="shares">3799071</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMTAtMi0xLTEtODA0_f32d77ef-7f75-44c7-b077-2d94601bade6"
      unitRef="shares">174376402</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMTAtNC0xLTEtNjg2_818fc062-6567-4540-a1a3-c1b30a6d1f82"
      unitRef="shares">102807056</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMTItMi0xLTEtODA4_20d9a5d1-0e71-41f5-88fa-86bb5fc54256"
      unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMTItNC0xLTEtNjkw_98958ec6-6d05-44e4-a582-7f8dc902c900"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMTQtMi0xLTEtODA4_3373ed3b-482f-47d8-9337-ce8e16369ae3"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjBlOTgzZjkyM2RhZDRkNzA4ODdhMzIyZWM1NzUxZWNhL3RhYmxlcmFuZ2U6MGU5ODNmOTIzZGFkNGQ3MDg4N2EzMjJlYzU3NTFlY2FfMTQtNC0xLTEtNjk0_b8f4ebd6-9e20-44bf-95f8-47accaf657e8"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMy0yLTEtMS04MTY_2ddc94ed-4319-4c1a-80af-b0f6bedaefbe"
      unitRef="usd">-142072777</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMy00LTEtMS03MDI_6ec22dfa-34e0-4b70-b31a-a39aa82fcff3"
      unitRef="usd">-81697181</us-gaap:NetIncomeLoss>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfNC0yLTEtMS04MTY_3e6112f6-83c5-436d-9390-8ddb91d7b824"
      unitRef="usd">0</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfNC00LTEtMS03MDI_02f7e7e3-60ef-43ca-8bdf-0f2cbdaf0d96"
      unitRef="usd">0</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfNS0yLTEtMS04MTY_efe2c766-04dd-435a-b030-c0d55bb65c77"
      unitRef="usd">-142072777</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfNS00LTEtMS03MDI_c3c7df64-87ba-42a6-865c-b39f3d3fe4a2"
      unitRef="usd">-81697181</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfOC0yLTEtMS04MjA_9a407f15-ba88-471c-86e4-c4a2e579920e"
      unitRef="shares">148656454</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfOC00LTEtMS03MDY_93f9c7d3-ac8f-49c2-9d26-5b6e36eb8da4"
      unitRef="shares">98204375</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfOS0yLTEtMS04MjA_e66bab30-f02f-4ced-acf4-f7005a3f1bca"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfOS00LTEtMS03MDY_8ce40eb4-fc67-4de4-ab21-a9255d7d5a84"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMTAtMi0xLTEtODIw_f670bcbd-9dcd-4d52-a9cb-b94e92e3f7a4"
      unitRef="shares">148656454</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMTAtNC0xLTEtNzA2_8f34063f-476a-41c9-a936-f15d5cd9f113"
      unitRef="shares">98204375</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMTItMi0xLTEtODI5_4fc8e332-a33c-46b4-90e0-ced6523f82c4"
      unitRef="usdPerShare">-0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMTItNC0xLTEtNzA5_d16d351d-bad9-4fe6-8443-e932c22fb33f"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMTQtMi0xLTEtODI5_5018f8eb-50b8-4c97-b32f-8c82202836a1"
      unitRef="usdPerShare">-0.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmFhOTQxNzc3N2MyOTQ0Yjc5ZGY4MzQyZTExZDUwZmM0L3RhYmxlcmFuZ2U6YWE5NDE3Nzc3YzI5NDRiNzlkZjgzNDJlMTFkNTBmYzRfMTQtNC0xLTEtNzA5_9cf1c2bf-8393-4321-afca-caa027dc84bd"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RleHRyZWdpb246MmIwMjQxODZjMzc5NDY3NzgzODBmYTU0YTJkZDBmOTJfMTA5Ng_adc18d85-9603-41e4-9826-57271ad62e51">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net income (loss) per share calculation because of their anti-dilutive effect for the three months ended September 30, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Common Stock Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,971,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,121,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,039,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,171,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,686,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the nine months ended September 30, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Common Stock Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,290,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,971,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,586,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,121,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,039,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,592,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,485,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6db1b3c721d04b66b6aa18b2614af73a_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfMi0xLTEtMS03MzQ_af234fb8-e495-474a-a6d7-82ea641b9549"
      unitRef="shares">119438</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia93b688d453949bda8f80084a4f8c0cf_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfMi0zLTEtMS03MzQ_ad20ce8c-642d-4c49-9af4-e8016a9c7839"
      unitRef="shares">9971297</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i44a63daa0269434b8f8645084440149c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNC0xLTEtMS03MzQ_5642887c-08ca-4d6d-b2c1-f6dff924d9f0"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if5353e9eb3d34cb7a882d3194dc9492f_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNC0zLTEtMS03MzQ_2622ef0c-0fb7-4ecc-a96f-b1cad04465d1"
      unitRef="shares">2121359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i51b9fb3e5b5e4a31a8873ab12cfb64d0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNS0xLTEtMS03MzQ_520b3371-1224-4b59-99e8-5c26b187845d"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1d0b8128b742495c90250bc5b8849172_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNS0zLTEtMS03MzQ_22ba4e91-669a-4ac9-b35a-6c5b240a70d6"
      unitRef="shares">8456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i02e3ca1e82c047479a0c74b2718566f0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNi0xLTEtMS03MzQ_4fbc1fad-c278-4ece-b838-12b2d2d8905a"
      unitRef="shares">11039574</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i06030a312f124dce90532593ecc94dd9_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNi0zLTEtMS03MzQ_d0252535-85bd-42fd-9978-905993d76cab"
      unitRef="shares">14585653</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9e44945591f04d5da4354f7f7bdd35cd_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNy0xLTEtMS03MzQ_89dc742f-9bb6-48ff-aaee-55ba9851c271"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9bdb6a99776a4c4d800ab8e40b952f8d_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfNy0zLTEtMS03MzQ_4bd65025-4aad-41f2-b856-a6097787d5ae"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0194a559551a40c8b27e764106336195_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfOC0xLTEtMS03MzQ_0a9dc992-9a8d-4164-bd9c-918bba66b16b"
      unitRef="shares">1009450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6c5944ef521743b3b9e876883e54f1e5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfOC0zLTEtMS03MzQ_3382d926-5460-4bf2-9211-166d58b2e6b1"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfOS0xLTEtMS0xMDI2_ba3dc349-d95a-4aa4-9fd0-9808642dbc0a"
      unitRef="shares">12171771</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOmYxYmEzYzQzNjg0NjRiMzU5ZTEwZmZhOWI0MGI1NTgzL3RhYmxlcmFuZ2U6ZjFiYTNjNDM2ODQ2NGIzNTllMTBmZmE5YjQwYjU1ODNfOS0zLTEtMS0xMDI4_10163ca8-c1ad-47ae-9224-056797f8499e"
      unitRef="shares">26686765</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic5a0629abda644218979a5b63841e116_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfMi0xLTEtMS0w_88ac0bc0-1c88-4f7b-9b7b-358e1b1d6d34"
      unitRef="shares">9290347</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i860fb08bf8184b179cac33e4192e1816_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfMi0zLTEtMS0w_bc19c8f6-92b9-4408-b903-e94351963e94"
      unitRef="shares">9971297</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide8b04bd4c5e49acb95ba740445e35f4_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNC0xLTEtMS0w_bfbef89a-a15c-4c1d-bbcb-183286be997e"
      unitRef="shares">2586915</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1d3155aacbf84e0b8ce936aae7adf3b9_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNC0zLTEtMS0w_8a881066-8b5b-45d1-93ce-ed38f92bfa5f"
      unitRef="shares">2121359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib68e05e899ac4508aa008ee16595c00c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNS0xLTEtMS0zNTAz_343098d2-405b-4bcc-84ad-3ce0f1cedf3c"
      unitRef="shares">663353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iba702d59c1624ad78cddd0ba1ffc4322_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNS0zLTEtMS0zNTAz_092ef479-6d55-48ba-8654-2a03f0f831f8"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1a56a2b1e29242588c663774b4b5aa76_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNS0xLTEtMS0w_111ee040-69f8-472a-ab68-5e33b26db6d4"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i554f1ca12a6049099aa8584a524a2161_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNS0zLTEtMS0w_956a66c2-b19a-4668-b5f3-59c9c5d65cef"
      unitRef="shares">8456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7a898fb72f1a49f5bd77c57ed253bd16_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNi0xLTEtMS0w_17379152-1a8f-4f94-a297-b2898f447af3"
      unitRef="shares">11039574</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2b05350e1bfd4d9ab4452aefb8f891fb_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNi0zLTEtMS0w_6ef721fa-2f2f-4ad5-90f4-fdbeef8cd866"
      unitRef="shares">14585653</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5d59312f204e4b97ab0b449aceeddccb_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNy0xLTEtMS0w_7f61a5b2-de76-48b1-ae3c-dcf7ac0e6b59"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2861cdc8f69f41d5b5875d02a30fb6a8_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfNy0zLTEtMS0w_f5238f86-19ea-4f4b-90a9-edca9ec6c33e"
      unitRef="shares">3799071</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia51339b229ef4a62b912b1d36f13eb7a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfOC0xLTEtMS0w_180f55ce-cfd3-4643-bcab-242449147504"
      unitRef="shares">1009450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i65d7691f080348dea281680ef992b0a6_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfOC0zLTEtMS0w_8734b096-62d8-4078-b2cd-67165dbbee29"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfOS0xLTEtMS0w_461769bd-5991-4afd-a47c-dbe906c1ff4a"
      unitRef="shares">24592948</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83My9mcmFnOjJiMDI0MTg2YzM3OTQ2Nzc4MzgwZmE1NGEyZGQwZjkyL3RhYmxlOjNkYjRiNTkwMmEyYTRjZWY4YmNlZWI2MjA5ZmZhMjdkL3RhYmxlcmFuZ2U6M2RiNGI1OTAyYTJhNGNlZjhiY2VlYjYyMDlmZmEyN2RfOS0zLTEtMS0w_ceeb80c0-b2d8-4450-a597-828010216074"
      unitRef="shares">30485836</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfNzE0NjgyNTU4NzQzNA_23af9e96-f547-4cb2-9f34-e01e393cd40b">Stock-Based Compensation&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.43%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 was $3.9 million and $11.0 million, respectively, of which $2.1 million and $6.2 million, respectively, was included in research and development expenses, and $1.8 million and $4.8 million, respectively, was included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2019 was $1.8 million and $8.1 million, respectively, of which $922,000 and $5.1 million, respectively, was included in research and development expenses, and $885,000 and $3.0 million, respectively, was included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, there was $9.7 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $12.09 and $6.78 for employee and director stock options granted during the three and nine months ended September 30, 2020, respectively, and $1.65 and $2.20 for employee and director stock options granted during the three and nine months ended September 30, 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, there was $13.0 million of total unrecognized compensation expense related to unvested restricted stock units ("RSUs"), which is expected to be recognized over a weighted-average period of 2.1 years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share was $9.12 for RSUs granted during the nine months ended September 30, 2020. There were no RSUs granted during the three months ended September 30, 2020. The weighted average grant date fair value per share was $2.68 and $3.09 for RSUs granted during the three and nine months ended September 30, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and nine months ended September 30, 2020 was $278,000 and $884,000, respectively. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and nine months ended September 30, 2019 was $264,000 and $744,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 28, 2020, the Company granted 663,353 performance-based RSUs to key employees under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: 50% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining 50% of the shares in each tranche will vest upon subsequent completion of a one-year service period. The grant date fair value of the performance-based RSUs was $8.0&#160;million based on the grant date closing price per share of $12.06. As of September 30, 2020, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSU's for the three and nine months then ended.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzMzNw_9a3761c2-5dfa-4440-b916-bb3e92ddc4bf">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.43%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2e404e614cda487ba8a65c024ef8d309_D20200701-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMi0xLTEtMS0w_a09bea8f-2039-49fe-b96d-a78e58caf232"
      unitRef="number">0.0035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0f1be49da4d049788cefaa0996012c18_D20190701-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMi0zLTEtMS0w_46d473f0-0e2d-4823-b07c-b76e0e92156c"
      unitRef="number">0.0175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i31d99600c91541e08b13dbd22f740ac6_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMi0xMC0xLTEtMA_28912d7f-a29e-47d6-866f-43c4627c9759"
      unitRef="number">0.0064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id952f10e76044800b212f242883b868c_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMi0xMi0xLTEtMA_ac2ea61e-bcef-4768-ab22-41821121e2b7"
      unitRef="number">0.0243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2e404e614cda487ba8a65c024ef8d309_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMy0xLTEtMS0w_64f1d9f9-d413-4c32-b805-6d09158f0b7b"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0f1be49da4d049788cefaa0996012c18_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMy0zLTEtMS0w_f8eace4f-4709-491c-bdde-9eb7c68b1918"
      unitRef="number">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i31d99600c91541e08b13dbd22f740ac6_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMy0xMC0xLTEtMA_3351d335-4efc-4b0a-8240-f7d5f59a1a80"
      unitRef="number">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id952f10e76044800b212f242883b868c_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfMy0xMi0xLTEtMA_e24efdbc-a0b7-4e99-b4ec-80e217d6df82"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2e404e614cda487ba8a65c024ef8d309_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNC0xLTEtMS0w_b4fcd1ea-73b8-4737-bec0-d6ab1a4f26d1">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0f1be49da4d049788cefaa0996012c18_D20190701-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNC0zLTEtMS0w_43949fed-8a5c-4f10-8fe4-133ac79aee2f">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i31d99600c91541e08b13dbd22f740ac6_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNC0xMC0xLTEtMA_42bd8892-da45-405b-b00b-9e0fab7b646b">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id952f10e76044800b212f242883b868c_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNC0xMi0xLTEtMA_bf99bc2e-e7fc-4fb6-aa34-844e2269f226">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2e404e614cda487ba8a65c024ef8d309_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNS0xLTEtMS0w_395728ed-ff90-4267-9dbd-1bc5acefa60d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0f1be49da4d049788cefaa0996012c18_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNS0zLTEtMS0w_9ac6b908-5303-4f13-bceb-28d4eaffe26e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i31d99600c91541e08b13dbd22f740ac6_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNS0xMC0xLTEtMA_5c9ca40d-2aa7-4bca-a842-ad1ee7324c06"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id952f10e76044800b212f242883b868c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RhYmxlOmRmYWVlODUzMTczNTQ3NzNhYWMwOTM2MzM0MTMzYjc1L3RhYmxlcmFuZ2U6ZGZhZWU4NTMxNzM1NDc3M2FhYzA5MzYzMzQxMzNiNzVfNS0xMi0xLTEtMA_2d634a41-341e-4f97-9b14-a627297c2402"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensation
      contextRef="i39f1040f585a4f308338f4f88079b910_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTUyOA_a9ab7ff3-80aa-4c46-8d97-60d7711235b7"
      unitRef="usd">3900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i289251eaf4234243bc0156afcbc6016e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTUzNQ_6d9d7e30-fb51-4a69-ae8b-5ad088ad821b"
      unitRef="usd">11000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i06c12a6f77d0492195c95821a8e4b7b6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTU2Mw_f83721d1-5332-4647-a0cf-006c1b6035da"
      unitRef="usd">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie3d462cb47b640bf897ca00c25614f47_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTU3MA_f448946f-26ef-43ee-af1e-28eba9080143"
      unitRef="usd">6200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7a618cdb93274c3cb270ff6bda022556_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTY0NA_de6f0462-b9cc-4af9-b85b-b3db618c8c9d"
      unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7af7c35ef173431fb3279d39c0f1d502_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTY1MQ_80a0dd04-7766-40e1-ba06-576a134c50c1"
      unitRef="usd">4800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i147548485ecd4491b08aef970e8b6c24_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTg2NA_42db9746-c3f7-4b24-8807-4fd5d0c1ac80"
      unitRef="usd">1800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5a5bf1e66b6a422a87b55518b074a975_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTg3MQ_768a93d6-ede4-48ce-8c6d-5a2ab563352e"
      unitRef="usd">8100000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib6722d5596bb495cb02bbd3e009bb98a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTg5OA_b47c277f-276f-435b-8a68-e74309d33091"
      unitRef="usd">922000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice161059e07d46408a923dd86909c6c9_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTkwNQ_6a818d93-d724-492f-a613-8517a09b32d2"
      unitRef="usd">5100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ief5502197e4f432eb1f99435f0610ad2_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTk3OA_ecc8614d-4e82-4fc6-90d6-4b3fb159dcc4"
      unitRef="usd">885000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic129651914c14c8c8f24304e6cea8cf4_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMTk4NQ_18d9e2e0-e637-4254-b605-0a0eba75dc4b"
      unitRef="usd">3000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjA3Mw_3ce17db0-8caa-49ca-b3de-b720c5d39c64"
      unitRef="usd">9700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjIyMw_edd92fe5-af76-489a-b4b1-20e912285869">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjM0Mg_96f07396-9a79-4cbe-aba5-4276b2ec0161"
      unitRef="usdPerShare">12.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjM0OQ_083313de-63c9-46ec-b59b-1cdb1ff8b27d"
      unitRef="usdPerShare">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjQzMw_2e87b0ad-4754-4ce4-9ec9-5dcea6d63233"
      unitRef="usdPerShare">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjQ0MA_92433fc1-cb9d-4da4-9753-f8d03aa3ac25"
      unitRef="usdPerShare">2.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia9c0eec23a36476e8fa9dc64d2143d2b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjUzOA_043e4561-8a5a-4e73-9976-f4f87e3ea4a1"
      unitRef="usd">13000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4fb2a364d2a84d27a0a8bb72b4a5d947_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjY5Nw_48e30711-b319-407e-9d01-2e0f7a4af678">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4fb2a364d2a84d27a0a8bb72b4a5d947_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjc3Mw_ff29532c-ecb0-40aa-a775-b2e06b4e0cd1"
      unitRef="usdPerShare">9.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icbfbede0bdee4bf2a1144f18c7e235cf_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjc0ODc3OTA3NjIyMQ_1bcab3eb-1429-4237-b8f3-381696f5680a"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7053c11a98db4096a9e40bd43a3c419b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjg0NA_3e3cc25c-bbc3-41d5-9e96-ec499dbc37da"
      unitRef="usdPerShare">2.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i195f8d33da5c49f1ad16bb63dfd92fc5_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMjg1MQ_765d3f39-a206-46f7-a34d-a6b76b9e4a8f"
      unitRef="usdPerShare">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="ib27721d879d24dc09f0b0eaff7993400_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzE1Mg_4b425a34-b021-4a90-87c5-ba7afb495d78"
      unitRef="usd">278000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3b70f956f6ba4badbe26e9b1a4182687_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzE1OQ_279d2754-7407-40e7-ac4c-e6d1fac0875d"
      unitRef="usd">884000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5850434bfd7f47e6aecdd16aac2a9c5e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzMwMQ_986cedf7-34a0-4b63-8f67-a9d1d115e476"
      unitRef="usd">264000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie4b0c15ae5ac4a8e8c3949f8c677e46d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzMwOA_67928e24-ed81-46b6-a77b-40a7c09e2186"
      unitRef="usd">744000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i847658eadc124bf3bfa5c9301c21bb42_D20200828-20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzI5ODUzNDg4OTYxMw_48e33903-45c0-453d-b5fe-3967bb05bed2"
      unitRef="shares">663353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iffcbbe5f4f454868b69c0a199c847e26_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzI5ODUzNDg4OTYyMg_c9614bf6-82d2-42df-ac21-829e61a7880f"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i67d9bde506f34a86a79e76444931a225_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzI5ODUzNDg4OTY1NA_282698d6-8a38-4a87-96ab-1a1b558fb048"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i67d9bde506f34a86a79e76444931a225_D20200828-20200828"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfNDM5ODA0NjUxNzk4NA_8e06cece-57b1-4ccd-8723-fb3bf06821c1">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue
      contextRef="i847658eadc124bf3bfa5c9301c21bb42_D20200828-20200828"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfMzI5ODUzNDg4OTY2MA_2acc1614-021d-4c93-ba2a-bad84d7760a9"
      unitRef="usd">8000000.0</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i847658eadc124bf3bfa5c9301c21bb42_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV83OS9mcmFnOjM4YjdiYjMxNTRjNjQ5NDNiZmY3MmRkNWU0NWNkYTQ0L3RleHRyZWdpb246MzhiN2JiMzE1NGM2NDk0M2JmZjcyZGQ1ZTQ1Y2RhNDRfNDM5ODA0NjUxNzk4Nw_b1aad977-94b8-467c-91a3-f982cfa8a6f2"
      unitRef="usdPerShare">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzg1MQ_6a14241d-e0ca-422b-b46e-26f47053f0ae">Related Party Transactions&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GeneOne Life Sciences &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 27, 2020, the Company so&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ld 1,644,155 sh&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ares of common stock in GeneOne for net proceeds of approximately 47.4&#160;billion KRW (approximately USD $40.1&#160;million based on the exchange rate on the date of sale). The Company no longer holds an investment in GeneOne shares and GeneOne is no longer considered a related party to the Company under ASC 850. T&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;he Company's condensed consolidated balance sheet as of September 30, 2020 no longer reflects GeneOne&#x2019;s portion in accounts receivable and accounts payable and accrued expenses with affiliated entities whereas the Company&#x2019;s balance sheet as of December 31, 2019 reflects $128,000 and $511,000 in a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ccounts receivable and accounts payable and accrued expenses with affiliated entities, respectively, related to GeneOne. Revenues recognized from GeneOne will no longer be presented as revenue with affiliated entity on the consolidated statement of operations after the change in related party designation in August 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2010, the Company entered into a collaboration and license agreement (the &#x201c;GeneOne Agreement&#x201d;) with GeneOne. Under the GeneOne Agreement, the Company granted GeneOne an exclusive license to the Company's SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; universal influenza vaccine delivered with electroporation to be developed in certain countries in Asia (the &#x201c;Product&#x201d;). As consideration for the license granted to GeneOne, the Company received an upfront payment of $3.0 million, and is entitled to receive research support, annual license maintenance fees and royalties on net Product sales. The GeneOne Agreement also provides the Company with exclusive rights to supply devices for clinical and commercial purposes (including single use components) to GeneOne for use in the Product. The term of the GeneOne Agreement commenced upon execution and will extend on a country by country basis until the last to expire of all Royalty Periods for the territory (as such term is defined in the GeneOne Agreement) for any Product in that country, unless the GeneOne Agreement is terminated earlier in accordance with its provisions as a result of breach, by mutual agreement, or by GeneOne's right to terminate without cause upon prior written notice. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2011, the Company entered into a collaborative development and license agreement (the &#x201c;Hep Agreement&#x201d;) with GeneOne. Under the Hep Agreement, as originally executed, the Company and GeneOne agreed to co-develop the Company&#x2019;s SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; therapeutic vaccines for hepatitis B and C infections (the &#x201c;Hep Products&#x201d;). Under the terms of the Hep Agreement, GeneOne will receive marketing rights for the Products in Asia, excluding Japan, and in return will fully fund IND-enabling and initial Phase 1 and 2 clinical studies with respect to the Hep Products. The Company will receive from GeneOne payments based on the achievement of clinical milestones and royalties based on sales of the Hep Products in the licensed territories, retaining all commercial rights to the Hep Products in all other territories. In 2013, the Company amended the Hep Agreement to grant back to the Company the SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; therapeutic vaccines targeting hepatitis B, along with all associated rights, from the collaboration in return for certain remuneration including a percentage of license fees. In 2013, the Company further amended the Hep Agreement to in part provide exclusive patent rights to IL-28 technology for use with the Hep Products in Asia, excluding Japan. The Hep Agreement shall terminate upon the later of the expiration or abandonment of the last patent that is a component of the rights or 20 years after the effective date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2015, the Company entered into a Collaborative Development Agreement with GeneOne to co-develop a DNA vaccine for MERS through Phase 1 clinical trials.&#160;Under the terms of the agreement, GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a 35% milestone-based ownership interest in the MERS immunotherapy upon achievement of the last milestone event of completion of the Phase 1 safety and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immunogenicity study.&#160;The collaborative research program shall terminate upon the completion of activities under the development plan, unless sooner terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2016, the Company and GeneOne amended the Collaborative Development Agreement for MERS to expand the agreement to test and advance the Company's DNA-based vaccine for preventing and treating Zika virus.&#160;GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a 35% milestone-based ownership interest in the Zika immunotherapy upon achievement of the last milestone event of the completion of the Phase 1 safety and immunogenicity study. All other agreement terms remain the same.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from GeneOne consisted of patent and device maintenance fees. For both the three and nine months ended September 30, 2020 and 2019, the Company recognized revenue from GeneOne of $31,000 and $94,000, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses recorded from transactions with GeneOne related primarily to biologics manufacturing were $1.6 million and $4.4 million for the three and nine months ended September 30, 2020, respectively, and $232,000 and $2.1 million for the three and nine months ended September 30, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owns 597,808 shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of September&#160;30, 2020 and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On February 20, 2020, the Company entered into a Debt and Share Subscription Agreement with PLS under which the Company received 202,050 shares of PLS common stock in exchange for a portion of the outstanding accounts receivable balance due from PLS. Following the issuance of these shares and as of September&#160;30, 2020, the Company held a 19.9% ownership interest in PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from PLS consists of milestone, license and patent fees. For the three and nine months ended September 30, 2020, the Company recognized revenue from PLS of $83,000 and $1.3 million, respectively, and $22,000 and $86,000 for the three and nine months ended September 30, 2019, respectively. At September&#160;30, 2020 and December&#160;31, 2019, the Company had an accounts receivable balance of $40,000 and $589,000, respectively, related to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement.  The Company will have the exclusive right to in-license new intellectual property developed under the agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company received a&#160;$6.1 million&#160;sub-grant through Wistar to develop a DNA-based monoclonal antibody against the Zika infection, with funding through December 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three and nine months ended September 30, 2020, the Company recorded $1.0 million and $1.7 million, respectively, and for the three and nine months ended September 30, 2019 the Company recorded $482,000 and $1.7 million, respectively, as contra-research and development expense from Wistar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill and Melinda Gates Foundation and CEPI (see Note 15). Research and development expenses recorded from Wistar for the three and nine months ended September 30, 2020 were $411,000 and $1.2 million, respectively. Research and development expenses recorded from Wistar for the three and nine months ended September 30, 2019 were $313,000 and $1.1 million, respectively. At September&#160;30, 2020 and December&#160;31, 2019, the Company had an accounts receivable balance of $443,000 and $616,000, respectively, and an accounts payable and accrued liability balance of $795,000 and $219,000, respectively, related to Wistar. As of September&#160;30, 2020, the Company had $173,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to Wistar.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id846dd9c3ed6491e8bd1b652cf0299d3_D20200827-20200827"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzc_3fb37fea-e865-4018-836c-628b95a01add"
      unitRef="shares">1644155</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id846dd9c3ed6491e8bd1b652cf0299d3_D20200827-20200827"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfOTM0NTg0ODg0NTQ5OA_cb0ebc9c-8941-4fc8-9e34-0ae9b5d20b91"
      unitRef="krw">47400000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id846dd9c3ed6491e8bd1b652cf0299d3_D20200827-20200827"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfOTM0NTg0ODg0NTUxMg_ae17b3f8-c090-469b-99e0-aadb31c53699"
      unitRef="usd">40100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="ie03bd2679d2e4a7d9318989067e22958_I20200827"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfMzg0ODI5MDcwODk3NQ_4f7dea93-51f7-4951-8156-6e686d5780f1"
      unitRef="usd">128000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ie03bd2679d2e4a7d9318989067e22958_I20200827"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfOTg5NTYwNDY2MjAyNA_4eb1a53a-f353-41c6-bb00-efd4ed35de8c"
      unitRef="usd">511000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="ia3c081d7909a418589d0447afe757e8c_D20100101-20101231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNjQ2_a99e774a-1c01-4d30-9c01-26915281ee7a"
      unitRef="usd">3000000.0</us-gaap:ProceedsFromLicenseFeesReceived>
    <ino:CollaborativeArrangementTerm
      contextRef="i85f7dcb7a22e4903ad067fbb0557bacb_D20140101-20140331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfMjc5Ng_5d5c2627-c9a5-4221-b41a-708f6fb2f2c1">P20Y</ino:CollaborativeArrangementTerm>
    <ino:MilestoneBasedOwnershipTarget
      contextRef="i1d860bed7f3c477c927663b8fe0f5eee_D20150501-20150531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfMzE1OA_4ec64452-6968-4069-8b38-592de780ce2d"
      unitRef="number">0.35</ino:MilestoneBasedOwnershipTarget>
    <ino:MilestoneBasedOwnershipTarget
      contextRef="i3bef37dba0d9484fa9ec9f1316d39f3b_D20160101-20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfMzgxNg_1ad89c00-e144-4e40-902b-9c0f29f80539"
      unitRef="number">0.35</ino:MilestoneBasedOwnershipTarget>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3975abdb45c8440abeef92728a3f628e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDE4OA_1fde7c39-c830-4f2f-88c0-2a2f6a0c02c4"
      unitRef="usd">31000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecf61220d18043d899fc9e4751d53309_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDE4OA_fb109133-a963-40d9-bd90-64c5524d42e7"
      unitRef="usd">31000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i790052b1d4424f2eaa1cf12c5cc544e1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfMjc0ODc3OTA4MjQ1MQ_84fde5f2-3514-4250-baf2-1466d2c5d8e6"
      unitRef="usd">94000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40c874fb1aab45f6a0c7ba48d937c1c7_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfMjc0ODc3OTA4MjQ1MQ_a3f2767d-c057-4e5f-8ca3-9b73d83a64bd"
      unitRef="usd">94000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i790052b1d4424f2eaa1cf12c5cc544e1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDMyMg_5c29509e-b6a2-480b-a4dc-a145ac805060"
      unitRef="usd">1600000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="iecf61220d18043d899fc9e4751d53309_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDMyOQ_b1263ed9-4baf-4359-a374-0eb41c193027"
      unitRef="usd">4400000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i40c874fb1aab45f6a0c7ba48d937c1c7_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDM2Mg_44d7c3e2-fe38-4cdf-823f-3baf56aa6b0d"
      unitRef="usd">232000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i3975abdb45c8440abeef92728a3f628e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDM2OQ_f35966fb-21f1-414b-bb77-7d224f2727ef"
      unitRef="usd">2100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="ief6a9b5c09ee4b90af8663890af888fa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDgyNQ_5077866f-3fd5-406e-a9eb-17ee36cc2795"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <ino:InvestmentOwnedAdditionalSharesAcquired
      contextRef="i49f5bd8f2ce54ea9aac77e18fa6578c7_I20200220"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTExNw_a701bc85-21ce-4a09-b3e9-a02a01b8e255"
      unitRef="shares">202050</ino:InvestmentOwnedAdditionalSharesAcquired>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iae58b01d628f4694912a6815b3ea0645_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTMwNg_99a6f0a2-bd7c-49cf-9d5e-c7fbb7c5d714"
      unitRef="number">0.199</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4058122d38c74b2495974de7f507740b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTQ2Nw_018d0911-06c7-4a1f-a698-883dcc9760cd"
      unitRef="usd">83000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19efa68d746c41c38d72557926a2c83a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTQ3NA_64d2308f-1930-4502-a1c5-fcedf0a3ecb1"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29248800a6f9460c9570869254c619d7_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTQ5Ng_48bbbae7-79e4-48ec-9b71-ffc50346a4eb"
      unitRef="usd">22000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie258d44d8f7c42a788923cec12040ba5_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTUwMw_4c13ab36-ccff-4514-ba8e-3f700f951540"
      unitRef="usd">86000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="ib9f446d994234ef9aa5a5bc12c0b9dcb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTU5Ng_85e602c7-2848-4d4a-b86c-79faee3988b2"
      unitRef="usd">40000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i92e675b7850f48a7bd3444a4732e7d6a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNTYwMw_b03576c1-f5d6-4508-9544-b669ff0b51b3"
      unitRef="usd">589000</us-gaap:AccountsReceivableRelatedParties>
    <ino:CollaborativeAgreementExpensesToReimburse
      contextRef="i57c38a9d213944289a8cdaf81d35f929_D20160301-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNjI1OQ_66173599-1ff3-4454-9f03-a94e1317cb60"
      unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm
      contextRef="i57c38a9d213944289a8cdaf81d35f929_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNDM5ODA0NjUyNDM3Nw_85d33986-b946-450d-90a4-ea0081585d76">P5Y</ino:CollaborativeArrangementTerm>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="i8c3f9ed79a4848cab5edbb332f829d5d_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNjQ2MQ_f702d8e9-fb71-449b-af90-694c13aae2db"
      unitRef="usd">6100000</ino:CollaborativeAgreementAwardedAmount>
    <ino:GrantProceedsReceived
      contextRef="i652ec1b835ac4951b1455fa93ec2220c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNjk4NQ_a412fa6a-bbe1-4c1e-871b-9172db5ccd04"
      unitRef="usd">1000000.0</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="i0046f92427f94b59992479e7afc4aeab_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNjk5Mg_a7003baf-fdfb-4678-bb05-7c30619780c7"
      unitRef="usd">1700000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="i3c90a066b83c4b8380cb3cd37bc3a09a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzA0Ng_f2b14089-4552-40b2-80d2-93fe306d10a1"
      unitRef="usd">482000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="if7fbaa1c34944d488dabcf367f55d769_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzA1Mw_901092d6-0792-4d9b-8faf-ba0c97fd17a0"
      unitRef="usd">1700000</ino:GrantProceedsReceived>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i652ec1b835ac4951b1455fa93ec2220c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzQxMw_925c9fa4-8460-4de3-a59c-0ec4cbde6c5e"
      unitRef="usd">411000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i0046f92427f94b59992479e7afc4aeab_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzQyMA_82ace16d-ab99-4601-bfe9-6063d2b13a1b"
      unitRef="usd">1200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i3c90a066b83c4b8380cb3cd37bc3a09a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzUwOQ_e1ad97c8-165c-4167-a813-47c5e376b1b4"
      unitRef="usd">313000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="if7fbaa1c34944d488dabcf367f55d769_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzUxNg_4920905c-dacc-4cea-ab02-15905d8e7aba"
      unitRef="usd">1100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="if8599ce44e474e488237d3872fc61db9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzU5OA_f42439bf-f85a-4553-8cfb-a11bdda61879"
      unitRef="usd">443000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="ib51d61f346d74c80bcc530d2cf49fc35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzYwNQ_eae58b52-d3b0-4bf0-b27e-12d7798427dd"
      unitRef="usd">616000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="if8599ce44e474e488237d3872fc61db9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzY4MA_d00d294d-9441-40c0-8f76-5986ec8d0c24"
      unitRef="usd">795000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ib51d61f346d74c80bcc530d2cf49fc35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzY4Nw_e035ca85-9dad-47c0-bf31-ec9399793ae9"
      unitRef="usd">219000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <ino:DeferredGrantFundingFromAffiliate
      contextRef="if8599ce44e474e488237d3872fc61db9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84Mi9mcmFnOmE5NGViYmMwMDdlMzRlZjhiMzM2NzUzOTM5ZTBhZWNlL3RleHRyZWdpb246YTk0ZWJiYzAwN2UzNGVmOGIzMzY3NTM5MzllMGFlY2VfNzc1MA_ff97ba5b-de18-4781-be18-75d422c7d0ce"
      unitRef="usd">173000</ino:DeferredGrantFundingFromAffiliate>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMzAwOQ_4bce9322-92d9-4929-8655-faae0241ca22">Leases                                                  The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating &lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lease agreements with remaining lease terms as of September&#160;30, 2020 of 3.2 to 9.3 years, which represent the non-cancellable periods of the leases.  The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of September&#160;30, 2020, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,968,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,023,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,951,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,973,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,039,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,934,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,264,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,670,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 were $836,000 and $2.5 million, respectively. Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and nine months ended September 30, 2019 were $820,000 and $2.5 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="ifd1bef4535014b23bd76467b4f46b98d_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMTAw_f93a961b-223d-4f14-9c40-ed4dc7816ade"
      unitRef="sqft">82200</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i52fd1f860b3e47b3b28f24815064d334_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMTkx_e47e9064-c172-4d1e-84bf-79e3612d8829"
      unitRef="sqft">57360</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="if8e016753b6d49ffa2bed4a3be3bc0ff_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMzYz_b7732709-88d6-466f-ae8b-3a230de11f3a">P3Y2M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i15135c10f2b84613a0bdfc1f99cfb3f9_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMzY5_0e0bff23-2829-4789-b7ab-854b3b2cede7">P9Y3M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMzAxMQ_17bfe4eb-6995-4979-a247-33882ad1a29b">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of September&#160;30, 2020, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,968,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,023,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,951,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,973,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,039,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,934,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,264,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,670,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMC0xLTEtMS0w_93d4a890-cdc5-4aa7-9cab-84e5fa2e01b4"
      unitRef="usd">985000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMS0xLTEtMS0w_24b2889e-5d05-42f4-bbb3-8f511b8051af"
      unitRef="usd">3968000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMi0xLTEtMS0w_c18788f7-b47a-4471-88a9-6d9e69d26899"
      unitRef="usd">4045000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMy0xLTEtMS0w_3b45d750-9df2-453f-82f7-d0d4b28015e4"
      unitRef="usd">4023000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfNC0xLTEtMS0w_27f65f2b-d662-4bd3-8bf2-c2744c9c81ef"
      unitRef="usd">3001000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfNS0xLTEtMS0w_32ebce35-5da5-4720-aac3-92a1c02448bf"
      unitRef="usd">12951000</ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfNi0xLTEtMS0w_f9896d16-72e5-453b-8069-fe40fa74cfaf"
      unitRef="usd">28973000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfNy0xLTEtMS0w_e4c6cee7-e1d7-40e8-8b18-03bf12755a67"
      unitRef="usd">8039000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfOC0xLTEtMS0w_2aa672e8-66e5-453a-9c90-d788550f6962"
      unitRef="usd">20934000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfOS0xLTEtMS0w_704ac43c-43be-4b9a-ba93-69e1c57a71aa"
      unitRef="usd">2264000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMTAtMS0xLTEtMA_cff6d480-bf5c-4ee5-9ba4-f5e74fd1e843"
      unitRef="usd">18670000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMTItMS0xLTEtMA_a774b2b1-3d4b-4e04-b982-d8009bc16b32">P7Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id34815f9d2a14071b19c7de18cdedc2e_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RhYmxlOjU2YjFhNjg3YzFiYzQxYzk4ZTc1NzliNDRmZDcyNzk4L3RhYmxlcmFuZ2U6NTZiMWE2ODdjMWJjNDFjOThlNzU3OWI0NGZkNzI3OThfMTMtMS0xLTEtMA_c3e1ae19-b669-41d2-b34f-bf718f09618c"
      unitRef="number">0.084</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost
      contextRef="i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMjAzMw_8246740a-aa1d-4bd6-9936-64c46ed29ad1"
      unitRef="usd">836000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMjA0MA_47ee721d-9e29-4e92-802c-7b5b6fe33c22"
      unitRef="usd">2500000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="idcd3916d0ef344f48b117f5895d6017a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMjE4MA_e784ec41-dcf1-4ae3-b307-9e8f56b00f18"
      unitRef="usd">820000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ia83d932e08d9496d9afae4b066e98886_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV84OC9mcmFnOjQxMGRiNzhlYjliZTQ4ZjY4YTcxZmEwZmQyNzI2OTg4L3RleHRyZWdpb246NDEwZGI3OGViOWJlNDhmNjhhNzFmYTBmZDI3MjY5ODhfMjE4Nw_9e5cea95-1b73-4e93-8397-a7ae8101d5f6"
      unitRef="usd">2500000</us-gaap:LeaseCost>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNzY5NjU4MTQwNzExNw_af284cb9-6b5d-4991-96ec-b6ec3d7c8462">Collaborative Agreements&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and potentially Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the three years following the effective date of the ApolloBio Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ApolloBio Agreement, the Company received proceeds of $19.4 million in March 2018 which comprised the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the condensed consolidated statement of operations. The Company also incurred advisory fees of $960,000 in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement.  The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $23.0 million upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the entire transaction price of $23.0 million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. The Company has recorded the gross upfront payment received from ApolloBio of $23.0 million as revenue under collaborative research and development arrangements on the condensed consolidated statement of operations during the three months ended June 30, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AstraZeneca &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $27.5 million to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to $125 million and potential future commercial event-based payments totaling up to $115 million, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within the broader collaboration, AstraZeneca had rights to co-develop up to two additional DNA-based cancer vaccine product candidates not included in the Company's current product pipeline. The Company has received notice that AstraZeneca intends to discontinue activities with respect to the research collaboration programs, other than MEDI0457, that were covered by the collaboration agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2017, the Company had recognized all of the $27.5 million upfront payment as revenue, as all identified material performance obligations had been met with respect to that payment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2020, the Company recognized revenues of $21,000 and $167,000, respectively, from AstraZeneca primarily for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;manufacturing services. During the three and nine months ended September 30, 2019, the Company recognized revenues of $255,000 and $3.0 million, respectively, from AstraZeneca primarily from a milestone achieved in the first quarter of 2019 triggered by the initiation of a Phase 2 portion of an ongoing clinical trial in the third major indication, as well as for manufacturing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three and nine months ended September 30, 2020, the Company received funding of $1.6 million and $4.6 million, respectively, related to the CEPI Lassa fever and MERS grants and recorded such amounts as contra-research and development expense. During the three and nine months ended September 30, 2019, the Company received funding of $1.5 million and $4.6 million, respectively, related to these grants and recorded such amounts as contra-research and development expense. As of September&#160;30, 2020, the Company had $3.7 million recorded as deferred grant funding on the condensed consolidated balance sheet related to these CEPI grants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, CEPI awarded the Company a grant of up to $9.0 million to develop a vaccine against COVID-19. This initial CEPI funding is intended to support preclinical and clinical development through Phase 1 human testing in the United States of INO-4800, the Company's COVID-19 vaccine candidate against COVID-19. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During the three and nine months ended September 30, 2020, the Company received funding of $1.3 million and $9.5 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of September&#160;30, 2020, the Company had $1.1 million recorded as deferred grant funding on the condensed consolidated balance sheet related to the CEPI grants related to INO-4800.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Bill &amp;amp; Melinda Gates Foundation (&#x201c;Gates&#x201d;) awarded and funded the Company a grant of $2.2 million to advance the development of DNA-encoded monoclonal antibody technology (&#x201c;dMAb&#x201d;) to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the three and nine months ended September 30, 2020, the Company recorded $164,000 and $334,000, respectively, and during the three and nine months ended September 30, 2019 recorded $1.5 million and $4.6 million, respectively, as contra-research and development expense related to the Gates dMAb grant. As of September&#160;30, 2020, the Company had $703,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device for the intradermal delivery of INO-4800. During the three and nine months ended September 30, 2020, the Company recorded $943,000 and $1.9 million, respectively, as contra-research and development expense and had $3.1 million recorded as deferred grant funding on the condensed consolidated balance sheet related to this Gates grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Defense (DoD) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#x201c;OTA Agreement&#x201d;)&#160;with the U.S. Department of Defense (the "DoD"), to fund the Company&#x2019;s efforts in developing the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately $54.5 million. The Company has determined that the OTA Agreement does not represent revenue under ASC 606, therefore will record contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses are incurred. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#x201c;Procurement Contract&#x201d;) from the DoD for the purchase of the Company&#x2019;s intradermal CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 device and accessories. The CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#x2019;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $16.6 million. The Company has determined that the Procurement Contract does not currently fall under the scope of ASC 606 as contingencies remain regarding INO-4800 which does not give the Company the ability to satisfy its obligations under the arrangement.&lt;/span&gt;During the three and nine months ended September 30, 2020, the Company recorded $7.7&#160;million as contra-research and development expense related to these agreements with the DoD.  As of September&#160;30, 2020, the Company had an accounts receivable balance of $7.7&#160;million on the condensed consolidated balance sheet</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborationAgreementTerritoryExpansionOptionPeriod
      contextRef="ic81bd389069e417a984bce2bcd1d1063_D20171229-20171229"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjU5_27890fac-3cc6-4e75-ab90-895d94284000">P3Y</ino:CollaborationAgreementTerritoryExpansionOptionPeriod>
    <ino:ProceedsFromCollaborativeAgreement
      contextRef="i47d345bee3e7411d98a3ba44f79db554_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNzgz_fc37106c-fc7d-4591-88d4-47616d73239f"
      unitRef="usd">19400000</ino:ProceedsFromCollaborativeAgreement>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i47d345bee3e7411d98a3ba44f79db554_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODM5_22a0df79-385f-45b8-9cf0-6839fb5c70d9"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementCorporateIncomeTax
      contextRef="i0a9ae846802141b899c438da3a7cd430_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODQ3_142819e0-bba0-474b-a0e1-553b383a5739"
      unitRef="usd">2200000</ino:CollaborativeAgreementCorporateIncomeTax>
    <ino:CollaborativeAgreementForeignNonIncomeTaxes
      contextRef="i0a9ae846802141b899c438da3a7cd430_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODc4_aeee2f90-e69c-4f58-9c45-d758487f705e"
      unitRef="usd">1400000</ino:CollaborativeAgreementForeignNonIncomeTaxes>
    <ino:CollaborativeAgreementAdvisoryFees
      contextRef="i0d907bd30e814bf1997a9fd3ed4a165b_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTE3NQ_6da11376-81a3-41b6-b677-db95df4ca025"
      unitRef="usd">960000</ino:CollaborativeAgreementAdvisoryFees>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="idcb1a6014bfb4665a8e53fda2328b9fa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTc2Mw_9474c272-f5ba-413a-8db7-e0e848ca1b5e"
      unitRef="usd">20000000.0</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="idcb1a6014bfb4665a8e53fda2328b9fa_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMjMwNA_0afaf9f6-1930-4d34-b613-9bf924bb4857">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="idcb1a6014bfb4665a8e53fda2328b9fa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMjkzOQ_d786bcfc-2f56-4a80-a3db-48298d5a9915"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination
      contextRef="idcb1a6014bfb4665a8e53fda2328b9fa_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNDE3MA_11cf6018-8c24-4409-958b-4416745e251e">P1Y</ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination>
    <ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
      contextRef="idcb1a6014bfb4665a8e53fda2328b9fa_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNDIxOA_04a3da0d-4621-49bc-9b7f-da0ca8facca2">P90D</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i2d344de8bac24153b97039f4a5da33f7_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNDMwNg_1f729642-2f75-4bdb-8d89-c7a8f2fb76e2"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i2d344de8bac24153b97039f4a5da33f7_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNDYwOQ_3656aa40-64c4-4b0c-88cf-ccf7cc690d11"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i364410dac22d46849150dbb76bf79ea3_D20150901-20150930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNTI2Mg_378dba6f-1d6f-4afa-8d77-d48cfb5a961c"
      unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones
      contextRef="ie4b9ecc1c92b4eb3b546f10e1fd321ae_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNTQzMQ_e86b0140-7434-4593-b51d-bf5dd1aee1d3"
      unitRef="usd">125000000</ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones>
    <ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones
      contextRef="ie4b9ecc1c92b4eb3b546f10e1fd321ae_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNTUwMg_30a09309-ea67-4622-a8fe-29efcd2ba24b"
      unitRef="usd">115000000</ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones>
    <ino:NumberOfAdditionalProducts
      contextRef="ic3ff9e9dd0e5478f9b9bee7abc6546ca_D20150807-20150807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjE0OA_90f05673-94cd-4e1e-ac2a-4588cd031089"
      unitRef="product">2</ino:NumberOfAdditionalProducts>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i790eb33d2aab4bbb89117717eaf49e43_D20171231-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjUzMw_396532d3-f7b1-43d9-8e7d-af04324881f6"
      unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10bdaf5e033f4b6cb32118002bd714d4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjcwOA_a454fc94-daaf-4332-9b19-f94bd826ec91"
      unitRef="usd">21000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1fe60d4ed164b4ba68d097b07daea40_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjcxNQ_832d0a8f-fd65-4b68-a63f-3854539f5b07"
      unitRef="usd">167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dc0a0736a3a41e3a718ffe92978cc2d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjgzOA_10072395-e770-456d-9a2e-e5ec574f8b33"
      unitRef="usd">255000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94a9e28f27b340909b69217c93f1e240_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNjg0NQ_172b7702-5f32-4d6e-bd49-f1ebe6342e61"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i11fb2d121358429bbb5330755fc13578_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNzc1Mg_bf1c64b6-406d-4b90-ad6b-543096bb593b"
      unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment
      contextRef="i11fb2d121358429bbb5330755fc13578_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfNDM5ODA0NjUyNDUzOQ_87c02297-baa7-4189-bfdb-91af0faf8bb3">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="iae268d9545fc40279bac5472d53ddf72_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODAzOA_43bfc394-c75c-40ad-a5fd-848276b80bbd"
      unitRef="usd">1600000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i5188afbca0524352a1d0626a807e0bc4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODA0NQ_22767ae3-4c95-44ff-bc50-d9974b1d4cbb"
      unitRef="usd">4600000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="ia0128722f91943efb7a4bdfdc5335c37_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODIyOA_263fe420-fa5e-4de4-9f52-e4bde1dde2c8"
      unitRef="usd">1500000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i006215dec0fa4ecdac01b405a91894bb_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODIzNQ_c6fc8d55-26bf-4c1d-a716-4ed06e2605a2"
      unitRef="usd">4600000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="i3a5d7fe092264c2db4c3072992ccce84_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODM4MQ_f521235a-1c86-4920-a320-a1f59d879af7"
      unitRef="usd">3700000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i08d25cd3db624f0fa8d5198cf2a38bc6_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODU2MQ_0ce009fc-1ac9-4e2e-943c-386c43a1effd"
      unitRef="usd">9000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i99c40f03c0b148739b61b7e80708fc06_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODg2Mw_016e86cd-ee71-4a21-8b42-a9b5af088897"
      unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i3b66be9eec75416f98e7e0628e15662f_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfOTA0MQ_5e042dfe-0b0e-4e56-90ae-234cc1666f94"
      unitRef="usd">5000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ia2db5556827143cdafe4b46ce571915b_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfOTIyMw_703b390d-0d6d-413a-b503-59e0829d1454"
      unitRef="usd">1300000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i18456a29ef3c4982b6471ce35dc6e525_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfOTMyMw_8938f0bd-e16a-4cdc-aef1-18a1a765bc4a"
      unitRef="usd">1300000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i312dea0c2ff240da9167e27ee1e8868d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfOTMzMA_a8df7d33-4558-4526-8c9e-086d2d2d5e0d"
      unitRef="usd">9500000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="id557bc0e9dca48c98443ad742ea2b548_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfOTUzMg_5821b3a7-55fe-4cac-b058-7f30c1813183"
      unitRef="usd">1100000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="ifa238803cd83463bbeb7a595eaa9463c_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfOTc5Ng_fd2273a2-3bc5-4f9a-ad13-fc4740054d94"
      unitRef="usd">2200000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i7e0e25538df447b9b57d8cdb39c3731d_D20190801-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTAyMDU_fadade22-1532-467f-ba86-25eb4ff1301e"
      unitRef="usd">1100000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i04dd7aeed28047949952a8193bc3f3a4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTAyNjE_b5ec8ba6-b20b-4ff8-95c9-dd25974086db"
      unitRef="usd">164000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="idac8dcab713949bd94df184fbba19e22_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTAyNjg_92c9b23a-2c4c-4e23-abe7-437977aee382"
      unitRef="usd">334000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="ida003d1fc52d461c9d2031cf761e1268_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTAzMTM_ffb1f029-4c6a-4b6c-b0b1-1b922a4145c4"
      unitRef="usd">1500000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i01999719b8694f2cb9344f65f0b9b3fc_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTAzMjA_35900bd5-f57c-4272-a59e-4fcd747f08b3"
      unitRef="usd">4600000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="ie814bccba6fe456b84bc2d64be454d97_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTA0NDA_eb8f1f6a-f519-4d13-8b61-2f60c927c813"
      unitRef="usd">703000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i8695b2243216498fbd1123097efeb201_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTA2MDc_bad0eee0-0c37-4541-900b-59cc250f9870"
      unitRef="usd">5000000.0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="id80ffa0c4fd840e08766b83da4af802f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTA3NDg_364d1a87-563f-487a-8a67-bb55f74816f6"
      unitRef="usd">943000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i59cb3488176045c9af0c67101f651fd0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTA3NTU_35ca45c0-6a3b-4b2e-a46e-eceb93c3f7b6"
      unitRef="usd">1900000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="i31f8cf75d3184c5385ae2d3930c43939_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTA4MjQ_a0e02e1a-7b27-456c-9aec-c6950dc190e1"
      unitRef="usd">3100000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="icddc6a2b71ac4679b73a1761b7335361_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTE5MDE_568784e2-807b-4ec3-a967-8561d4dd70f2"
      unitRef="usd">54500000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded
      contextRef="i42731760dc864386b6cc234953ed8db8_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMTIyOTU_ad879b5d-1cdb-448d-8c3c-82aa6efe72f8"
      unitRef="usd">16600000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:GrantProceedsReceived
      contextRef="i925dbb99e22c47109cfd6499f718d23f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODc5NjA5MzAzNTEwMw_38bc52af-bc98-40fe-af29-8d35a575c57f"
      unitRef="usd">7700000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="if5310f1c21874dcba016f8044259901b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfODc5NjA5MzAzNTEwMw_ee3746c4-a742-4a9c-b568-4f3683e137f8"
      unitRef="usd">7700000</ino:GrantProceedsReceived>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="ied249d236e834e95ad34273624d104c1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85MS9mcmFnOjFmYWJhNWUwZjEyZDQ1OTViYWUyZmZmM2U3M2QxNzZlL3RleHRyZWdpb246MWZhYmE1ZTBmMTJkNDU5NWJhZTJmZmYzZTczZDE3NmVfMjc0ODc3OTA4MjExMg_f92f1532-ced3-4f78-b381-3d57fe829bc2"
      unitRef="usd">7700000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV85Ny9mcmFnOjdlODY2ZGYxZGNjYjQ3OGM5NjAwMDQzN2ZiYzJhZGMwL3RleHRyZWdpb246N2U4NjZkZjFkY2NiNDc4Yzk2MDAwNDM3ZmJjMmFkYzBfMTg1MA_b4f22249-4fc5-45c2-8323-bad4569c06f0">Income Taxes &lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act).&#160; The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19.&#160;The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic; some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act.&#160;At September&#160;30, 2020, the Company has not recorded any income tax provision/(benefit) for the impact for the CARES Act due to the Company&#x2019;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets. The Company will continue to analyze the impact that the CARES Act will have, if any, on its financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzc3NDU_78231bb0-d6e8-460d-b4ae-1eb388eec482">Geneos Therapeutics, Inc. &lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2016, the Company formed Geneos, to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;preferred stock financing. The Company invested&#160;$1.2 million&#160;in the preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, Geneos completed the second closing of the&#160;preferred stock financing, in which the Company invested $800,000. Following this transaction, as of March 31, 2020, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Geneos closed an additional&#160;preferred stock financing round, in which the Company invested $800,000.  Following this transaction, the Company no longer held a controlling financial interest as the Company, owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration. Based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support.  However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's condensed consolidated statement of operations.  The following table shows the amounts related to the deconsolidation accounting: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Working capital (excluding cash) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets, net of accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of noncontrolling interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,181,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of investment in Geneos retained&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on deconsolidation of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,121,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in cash resulting from the deconsolidation of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,774,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The details of the Company&#x2019;s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Geneos Share Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for Geneos&#x2019; common stock.  Geneos&#x2019; enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving Geneos&#x2019; own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#x2019;s exercise price was based on Geneos&#x2019; total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of Geneos&#x2019; estimated time to their next financing and successful exit timing assumption.  The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#x2019;s common stock is classified as a Level 3 financial instrument. The assumptions used in the fair value calculation as of June 1, 2020 are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Geneos enterprise value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,966,531&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock.  Since the Company&#x2019;s preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#x2019;s common stock investment and will therefore be recorded as an equity security under ASC 321.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#x2019;s investment and the amount of underlying equity in Geneos&#x2019; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon deconsolidation, the Company recorded its preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company has determined that its preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#x2019;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s share of net losses of Geneos for the period from June 1, 2020 through September 30, 2020 was $2.7 million. Of this amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of September 30, 2020. The remaining $1.8 million loss has been allocated to the Company&#x2019;s preferred stock investment in Geneos, thereby reducing the balance to $958,000 as of September 30, 2020 as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos upon deconsolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,661,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to exclusively license its SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immunotherapy and CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="ic7a90a05adcc4f638f0b47beed718798_D20190201-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzM3MQ_8122acb9-cfa0-4619-9132-b64812335c07"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i869d8bf326be4abfbb1e18a89a00961a_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzQ5Mg_0fe756f0-913b-4bae-a529-d9a641478e86"
      unitRef="number">0.61</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="iec2d5f6527c24125972f2622cef53837_I20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzc3Nw_d936af2f-41bf-4b84-a7e4-1c07c40b86a6"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="iedf6a38f277949399861daef313a0f5d_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzg0OA_49826704-3904-424c-ab28-95e09094c8d9"
      unitRef="number">0.52</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="ib53c870fb97b4899bbb5a65108c6bd6d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzEwOTA_daefe267-ddd9-48d1-8f36-82e96d78b0aa"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iaeddbb99315448e8b2869ef6ad5da9ab_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzEyMDk_e4fefa44-9cee-45ca-b646-d6bc4b15bc0c"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="if383b813ea7a4745bfc01e54b08f32d4_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzE4MDM_8d453e34-8b96-4fe9-ae46-fc39e77bab15"
      unitRef="usd">4100000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="if383b813ea7a4745bfc01e54b08f32d4_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzE4MTY_034ae0c5-6800-48ea-b3a6-37a2876627c9"
      unitRef="usd">2400000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzc3NDY_58577b96-156d-4bf7-a9c5-914d2f8eb6ed">The following table shows the amounts related to the deconsolidation accounting: &lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Working capital (excluding cash) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets, net of accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of noncontrolling interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,181,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of investment in Geneos retained&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on deconsolidation of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,121,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in cash resulting from the deconsolidation of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,774,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The details of the Company&#x2019;s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Geneos Share Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The remaining $1.8 million loss has been allocated to the Company&#x2019;s preferred stock investment in Geneos, thereby reducing the balance to $958,000 as of September 30, 2020 as shown in the table below:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos upon deconsolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,661,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <ino:WorkingCapitalExcludingCash
      contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzAtMS0xLTEtMA_68707ad0-a8e0-4581-a731-5d2512480292"
      unitRef="usd">59992</ino:WorkingCapitalExcludingCash>
    <us-gaap:NotesPayable
      contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzEtMS0xLTEtMA_bb88c313-1612-4f5e-9eae-8b26c9c7e282"
      unitRef="usd">171620</us-gaap:NotesPayable>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzItMS0xLTEtMA_fd058aa3-243f-4bf0-9b9e-2201254421b7"
      unitRef="usd">16340</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MinorityInterest
      contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzMtMS0xLTEtMA_c715b2a7-2374-480e-86fb-f88791fe2aa3"
      unitRef="usd">3181640</us-gaap:MinorityInterest>
    <us-gaap:RetainedInterestFairValueDisclosure
      contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzQtMS0xLTEtMA_49c01f12-86ee-4ad5-af66-351ae69373cb"
      unitRef="usd">3618998</us-gaap:RetainedInterestFairValueDisclosure>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="if383b813ea7a4745bfc01e54b08f32d4_D20200601-20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzUtMS0xLTEtMA_2ce83779-2dc4-4f83-99cb-cc8f3b220e7e"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="if383b813ea7a4745bfc01e54b08f32d4_D20200601-20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo4MzdmMzJiNWUwYjI0MWM5YWQ3OTZkZTJiNTgyNTRkYy90YWJsZXJhbmdlOjgzN2YzMmI1ZTBiMjQxYzlhZDc5NmRlMmI1ODI1NGRjXzYtMS0xLTEtMA_cfe9293a-1fc0-4bce-be5f-21af0f19f676"
      unitRef="usd">2774851</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iaeddbb99315448e8b2869ef6ad5da9ab_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzIxNTc_58a0e4e4-04c3-4662-b164-c078ef112c55"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i27451cafe1f2419998b0684fe0a1a45f_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzEtMS0xLTEtMA_402c45ec-ba45-45a7-962e-f30ef8eb52c1"
      unitRef="shares">3000000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="i27451cafe1f2419998b0684fe0a1a45f_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzEtMy0xLTEtMA_5edb0ed6-2e66-41b5-b30b-7555566fc990"
      unitRef="usdPerShare">0.273</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="i27451cafe1f2419998b0684fe0a1a45f_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzEtNS0xLTEtMA_bb58541f-b48d-43ac-bb6d-5705777e7c55"
      unitRef="usd">819000</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i2874a1f41d394187a5752e0fa6598078_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzItMS0xLTEtMA_001db53a-6411-4476-80d5-e8f0116b757d"
      unitRef="shares">2113206</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="i2874a1f41d394187a5752e0fa6598078_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzItMy0xLTEtMA_b7b3234f-befe-470f-8da8-fb11b7bea8c3"
      unitRef="usdPerShare">1.325</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="i2874a1f41d394187a5752e0fa6598078_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzItNS0xLTEtMA_f02fc8c2-56ca-4555-9a2d-92b1453f8bd2"
      unitRef="usd">2799998</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzMtMS0xLTEtMA_c584883c-ccd8-434f-b2b7-155198b28a80"
      unitRef="shares">5113206</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestments
      contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTplYWI2NTQ2ZThjYzY0NzA5YTc2Mjg4YjkwNmViOTRmZC90YWJsZXJhbmdlOmVhYjY1NDZlOGNjNjQ3MDlhNzYyODhiOTA2ZWI5NGZkXzMtNS0xLTEtMA_feb02bb8-930f-42d4-ac5f-0205e9f5726c"
      unitRef="usd">3618998</us-gaap:EquityMethodInvestments>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzc3NDg_d87cc92e-3a00-4e7c-949a-a5dcd89ea143">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Geneos enterprise value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,966,531&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <ino:AlternativeInvestmentMeasurementInputTerm
      contextRef="i1f18198c2b4e4bd8b89b62558865184c_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo5ZjgzNWZmMTFkMTY0YjBlODI4MWYxMjUyZjU0YjhmZC90YWJsZXJhbmdlOjlmODM1ZmYxMWQxNjRiMGU4MjgxZjEyNTJmNTRiOGZkXzAtMS0xLTEtMA_559ebc62-ae9f-45d3-94df-aeafbbaaaf50">P2Y11M1D</ino:AlternativeInvestmentMeasurementInputTerm>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i4859da00a9c04ed2b413734cd6ae17e4_I20200601"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo5ZjgzNWZmMTFkMTY0YjBlODI4MWYxMjUyZjU0YjhmZC90YWJsZXJhbmdlOjlmODM1ZmYxMWQxNjRiMGU4MjgxZjEyNTJmNTRiOGZkXzEtMS0xLTEtMA_4bdf7f0e-29af-41ad-b26c-8a9af94e56a5"
      unitRef="number">0.70</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i79ae502b32684fdf8f98b1c19fcf0397_I20200601"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo5ZjgzNWZmMTFkMTY0YjBlODI4MWYxMjUyZjU0YjhmZC90YWJsZXJhbmdlOjlmODM1ZmYxMWQxNjRiMGU4MjgxZjEyNTJmNTRiOGZkXzItMS0xLTEtMA_e7350ef8-667d-44b0-897d-54b0c597e235"
      unitRef="number">0.0246</us-gaap:AlternativeInvestmentMeasurementInput>
    <ino:EquityMethodInvestmentEnterpriseValue
      contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTo5ZjgzNWZmMTFkMTY0YjBlODI4MWYxMjUyZjU0YjhmZC90YWJsZXJhbmdlOjlmODM1ZmYxMWQxNjRiMGU4MjgxZjEyNTJmNTRiOGZkXzMtMS0xLTEtMA_ee39a5ba-df03-428a-bc70-9df42ca59232"
      unitRef="usd">4966531000</ino:EquityMethodInvestmentEnterpriseValue>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9c98da30e4704069839ed075f3b5a328_D20200601-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzY5ODM_f89b6864-ecd2-4e8b-8c6e-ecfc4c86b6fb"
      unitRef="usd">-2700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i10ff0a553ff04929a035481611ba22dc_D20200601-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzcwMDQ_f61e4df3-6846-4b2d-ae30-355883127859"
      unitRef="usd">-819000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i70b1c5c8e2f24fff8299e8b17608bb18_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzcwOTE_55e21efd-9e92-4aa3-8858-2f5973298bed"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i022bb72c504942ac878d6769a4a1b696_D20200601-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzcxMzA_32170909-857c-4727-9d65-e63cd1679b5d"
      unitRef="usd">-1800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i05d2269442c846edb144f98b63b06aae_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90ZXh0cmVnaW9uOmFhNDA1NzA3NDllNjQ0MjNhMTIzMmViMzRkYTlmNDUwXzQzOTgwNDY1MjA0MDc_d1a8ea7a-1bfa-4fa7-97ef-5519c25151af"
      unitRef="usd">958000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i0362d182781f4ee797f88622a5c045cf_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTpiNGFkYTY4Y2ZkMmU0MzFmYjZhOWRmZTUxZjcyOWIxZS90YWJsZXJhbmdlOmI0YWRhNjhjZmQyZTQzMWZiNmE5ZGZlNTFmNzI5YjFlXzEtMi0xLTEtNDY5Ng_3f656931-f788-42a0-881e-4d02f460bebd"
      unitRef="usd">3618998</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9c98da30e4704069839ed075f3b5a328_D20200601-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTpiNGFkYTY4Y2ZkMmU0MzFmYjZhOWRmZTUxZjcyOWIxZS90YWJsZXJhbmdlOmI0YWRhNjhjZmQyZTQzMWZiNmE5ZGZlNTFmNzI5YjFlXzItMi0xLTEtNDY5Ng_bb57dd07-ea12-4e0c-bf3f-5e4c40e3dd7f"
      unitRef="usd">-2661431</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i98c79c39dba34165aa075b540f1c274a_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDAvZnJhZzphYTQwNTcwNzQ5ZTY0NDIzYTEyMzJlYjM0ZGE5ZjQ1MC90YWJsZTpiNGFkYTY4Y2ZkMmU0MzFmYjZhOWRmZTUxZjcyOWIxZS90YWJsZXJhbmdlOmI0YWRhNjhjZmQyZTQzMWZiNmE5ZGZlNTFmNzI5YjFlXzMtMi0xLTEtNDY5Ng_cfb82fbf-c8ee-4ded-9d2e-56a60e437f79"
      unitRef="usd">957567</us-gaap:EquityMethodInvestments>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDMvZnJhZzo2ZWQ3YmFkZjQ4NDM0OTM2YmQwYTMxYzEwOGE3ZTc0MS90ZXh0cmVnaW9uOjZlZDdiYWRmNDg0MzQ5MzZiZDBhMzFjMTA4YTdlNzQxXzU4NQ_4a14a22b-33f0-4d47-a017-40bd2f404ff6">Subsequent EventsIn October 2020, certain holders converted an aggregate principal amount of $10.0 million of Notes into an aggregate of 1,858,044 shares of the Company's common stock.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i135db666eca94e468d89995d1fdb8e21_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDMvZnJhZzo2ZWQ3YmFkZjQ4NDM0OTM2YmQwYTMxYzEwOGE3ZTc0MS90ZXh0cmVnaW9uOjZlZDdiYWRmNDg0MzQ5MzZiZDBhMzFjMTA4YTdlNzQxXzEwMA_bea0819f-b029-4c52-b1b2-9087e83622ea"
      unitRef="usd">10000000.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i0df0aeb02416451db34b6235410d3492_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8xMDMvZnJhZzo2ZWQ3YmFkZjQ4NDM0OTM2YmQwYTMxYzEwOGE3ZTc0MS90ZXh0cmVnaW9uOjZlZDdiYWRmNDg0MzQ5MzZiZDBhMzFjMTA4YTdlNzQxXzEzMw_659273bd-fbc0-4a0d-b219-c574f0ecc884"
      unitRef="shares">1858044</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117259264024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. GERMANTOWN PIKE, SUITE 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">PLYMOUTH MEETING<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,408,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117258625256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 178,700,434<span></span>
</td>
<td class="nump">$ 22,196,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">158,535,744<span></span>
</td>
<td class="nump">67,338,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">7,692,944<span></span>
</td>
<td class="nump">700,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">501,311<span></span>
</td>
<td class="nump">1,332,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">31,563,697<span></span>
</td>
<td class="nump">1,584,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">70,543<span></span>
</td>
<td class="nump">1,050,140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">377,064,673<span></span>
</td>
<td class="nump">94,200,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">11,190,521<span></span>
</td>
<td class="nump">12,773,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">4,154,049<span></span>
</td>
<td class="nump">6,315,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">957,567<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,283,540<span></span>
</td>
<td class="nump">3,693,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">13,008,571<span></span>
</td>
<td class="nump">13,783,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">17,641,755<span></span>
</td>
<td class="nump">2,672,024<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">437,814,047<span></span>
</td>
<td class="nump">143,951,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">23,533,298<span></span>
</td>
<td class="nump">18,237,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">794,928<span></span>
</td>
<td class="nump">729,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">5,841,180<span></span>
</td>
<td class="nump">4,049,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">77,878<span></span>
</td>
<td class="nump">92,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent', window );">Deferred revenue from affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,264,261<span></span>
</td>
<td class="nump">2,074,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">8,616,622<span></span>
</td>
<td class="nump">6,065,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="nump">135,000<span></span>
</td>
<td class="nump">708,425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">41,263,167<span></span>
</td>
<td class="nump">31,989,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">82,927<span></span>
</td>
<td class="nump">101,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">18,669,643<span></span>
</td>
<td class="nump">20,409,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="nump">32,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateNoncurrent', window );">Grant funding liability from affiliated entity, net of current portion</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">39,776<span></span>
</td>
<td class="nump">36,943<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">113,813,932<span></span>
</td>
<td class="nump">138,546,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">167,527<span></span>
</td>
<td class="nump">101,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,205,842,585<span></span>
</td>
<td class="nump">742,646,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(881,858,432)<span></span>
</td>
<td class="num">(739,785,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(247,834)<span></span>
</td>
<td class="nump">472,608<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">323,903,846<span></span>
</td>
<td class="nump">3,435,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">96,269<span></span>
</td>
<td class="nump">1,969,759<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">324,000,115<span></span>
</td>
<td class="nump">5,404,858<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">437,814,047<span></span>
</td>
<td class="nump">143,951,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">49,537,210<span></span>
</td>
<td class="nump">64,180,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember', window );">Convertible bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">$ 4,151,663<span></span>
</td>
<td class="nump">$ 12,842,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117256900488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 236,178<span></span>
</td>
<td class="nump">$ 866,863<span></span>
</td>
<td class="nump">$ 1,830,639<span></span>
</td>
<td class="nump">$ 3,832,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">26,455,112<span></span>
</td>
<td class="nump">19,137,209<span></span>
</td>
<td class="nump">67,942,875<span></span>
</td>
<td class="nump">66,013,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,110,506<span></span>
</td>
<td class="nump">5,681,441<span></span>
</td>
<td class="nump">28,630,370<span></span>
</td>
<td class="nump">18,506,570<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">36,565,618<span></span>
</td>
<td class="nump">24,818,650<span></span>
</td>
<td class="nump">96,573,245<span></span>
</td>
<td class="nump">84,519,934<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(36,329,440)<span></span>
</td>
<td class="num">(23,951,787)<span></span>
</td>
<td class="num">(94,742,606)<span></span>
</td>
<td class="num">(80,687,492)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">896,710<span></span>
</td>
<td class="nump">637,438<span></span>
</td>
<td class="nump">2,380,678<span></span>
</td>
<td class="nump">2,018,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,984,046)<span></span>
</td>
<td class="num">(2,428,671)<span></span>
</td>
<td class="num">(7,634,442)<span></span>
</td>
<td class="num">(5,279,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">35,306,000<span></span>
</td>
<td class="nump">2,551,453<span></span>
</td>
<td class="num">(75,670,977)<span></span>
</td>
<td class="nump">2,551,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entities</a></td>
<td class="nump">26,951,898<span></span>
</td>
<td class="num">(485,841)<span></span>
</td>
<td class="nump">36,250,341<span></span>
</td>
<td class="num">(1,409,156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="nump">1,315,980<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">624,522<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(136,644)<span></span>
</td>
<td class="nump">140,956<span></span>
</td>
<td class="num">(714,246)<span></span>
</td>
<td class="nump">232,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,121,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net income (loss) before income tax benefit and share in net loss of Geneos</a></td>
<td class="nump">20,931,010<span></span>
</td>
<td class="num">(23,536,452)<span></span>
</td>
<td class="num">(140,475,103)<span></span>
</td>
<td class="num">(82,573,966)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="num">(1,759,674)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,661,431)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">19,171,336<span></span>
</td>
<td class="num">(23,536,452)<span></span>
</td>
<td class="num">(143,136,534)<span></span>
</td>
<td class="num">(82,404,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">445,759<span></span>
</td>
<td class="nump">1,063,757<span></span>
</td>
<td class="nump">707,214<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="nump">$ 19,171,336<span></span>
</td>
<td class="num">$ (23,090,693)<span></span>
</td>
<td class="num">$ (142,072,777)<span></span>
</td>
<td class="num">$ (81,697,181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income (loss) per share attributable to Inovio Pharmaceuticals, Inc. stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">165,355,540<span></span>
</td>
<td class="nump">99,007,985<span></span>
</td>
<td class="nump">148,656,454<span></span>
</td>
<td class="nump">98,204,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">174,376,402<span></span>
</td>
<td class="nump">102,807,056<span></span>
</td>
<td class="nump">148,656,454<span></span>
</td>
<td class="nump">98,204,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember', window );">Convertible bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (8,177,043)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,177,043)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">3,087,595<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,087,595<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">21,490<span></span>
</td>
<td class="nump">617,427<span></span>
</td>
<td class="nump">167,092<span></span>
</td>
<td class="nump">3,452,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements with affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">103,684<span></span>
</td>
<td class="nump">53,014<span></span>
</td>
<td class="nump">1,370,956<span></span>
</td>
<td class="nump">179,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Miscellaneous revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 111,004<span></span>
</td>
<td class="nump">$ 196,422<span></span>
</td>
<td class="nump">$ 292,591<span></span>
</td>
<td class="nump">$ 200,036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117258210904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 19,171,336<span></span>
</td>
<td class="num">$ (23,536,452)<span></span>
</td>
<td class="num">$ (143,136,534)<span></span>
</td>
<td class="num">$ (82,404,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">6,184<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">356,012<span></span>
</td>
<td class="num">(31,457)<span></span>
</td>
<td class="num">(726,626)<span></span>
</td>
<td class="nump">1,229,265<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="nump">19,533,532<span></span>
</td>
<td class="num">(23,567,909)<span></span>
</td>
<td class="num">(143,856,976)<span></span>
</td>
<td class="num">(81,175,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">445,759<span></span>
</td>
<td class="nump">1,063,757<span></span>
</td>
<td class="nump">707,214<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="nump">$ 19,533,532<span></span>
</td>
<td class="num">$ (23,122,150)<span></span>
</td>
<td class="num">$ (142,793,219)<span></span>
</td>
<td class="num">$ (80,467,916)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117247685656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>6.50% Convertible Senior Notes Due 2024</div></th>
<th class="th"><div>August 2019 Bonds</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th">
<div>Common stock </div>
<div>6.50% Convertible Senior Notes Due 2024</div>
</th>
<th class="th">
<div>Common stock </div>
<div>August 2019 Bonds</div>
</th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>6.50% Convertible Senior Notes Due 2024</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>August 2019 Bonds</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Non- controlling interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">97,225,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 87,032,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 707,794,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (620,426,436)<span></span>
</td>
<td class="num">$ (528,867)<span></span>
</td>
<td class="nump">$ 96,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">907,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(719,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(719,922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of issuance of convertible notes</a></td>
<td class="nump">15,752,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,752,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,432,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,432,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos</a></td>
<td class="nump">3,030,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,030,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(29,288,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,219,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">819,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">97,934,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">80,966,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">727,166,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(649,645,698)<span></span>
</td>
<td class="nump">290,310<span></span>
</td>
<td class="nump">3,056,771<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">97,225,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">87,032,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707,794,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(620,426,436)<span></span>
</td>
<td class="num">(528,867)<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(82,404,395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">1,229,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">99,046,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">36,118,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 99,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735,017,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(702,123,617)<span></span>
</td>
<td class="nump">700,398<span></span>
</td>
<td class="nump">2,425,162<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">97,934,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">80,966,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">727,166,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(649,645,698)<span></span>
</td>
<td class="nump">290,310<span></span>
</td>
<td class="nump">3,056,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">1,388,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(81,259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,355,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,345,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Cost of acquisition of non-controlling interest in Geneos</a></td>
<td class="num">(13,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(29,579,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,387,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(191,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">441,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">98,584,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">56,478,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 98,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">731,819,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(679,032,924)<span></span>
</td>
<td class="nump">731,855<span></span>
</td>
<td class="nump">2,861,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">1,128,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,079,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,070,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(23,536,452)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,090,693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(445,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(31,457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">99,046,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">36,118,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 99,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735,017,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(702,123,617)<span></span>
</td>
<td class="nump">700,398<span></span>
</td>
<td class="nump">2,425,162<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">5,404,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,646,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(739,785,655)<span></span>
</td>
<td class="nump">472,608<span></span>
</td>
<td class="nump">1,969,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">208,241,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,198,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">3,100,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,099,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,001,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,017,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos</a></td>
<td class="nump">2,169,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,169,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(33,135,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,541,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(594,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(1,929,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,929,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">145,915,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">187,854,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 145,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,962,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(772,326,709)<span></span>
</td>
<td class="num">(1,456,930)<span></span>
</td>
<td class="nump">3,529,199<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">5,404,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,646,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(739,785,655)<span></span>
</td>
<td class="nump">472,608<span></span>
</td>
<td class="nump">1,969,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(143,136,534)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(726,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">6,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">167,528,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">324,000,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 167,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,205,842,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(881,858,432)<span></span>
</td>
<td class="num">(247,834)<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">145,915,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">187,854,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 145,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,962,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(772,326,709)<span></span>
</td>
<td class="num">(1,456,930)<span></span>
</td>
<td class="nump">3,529,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,041,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">121,718,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,706,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(5,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">4,422,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,421,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,662,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,654,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos</a></td>
<td class="nump">209,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of Geneos</a></td>
<td class="num">(3,181,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,181,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(129,172,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128,703,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(469,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">846,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">158,756,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">186,360,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 158,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,087,745,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(901,029,768)<span></span>
</td>
<td class="num">(610,030)<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,546,074)<span></span>
</td>
<td class="num">(4,962,364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,971,360<span></span>
</td>
<td class="nump">$ 102,671,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,546<span></span>
</td>
<td class="nump">$ 4,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,967,814<span></span>
</td>
<td class="nump">$ 102,666,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(1,695,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,695,315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,158,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,158,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="nump">19,171,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,171,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">356,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">6,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">167,528,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 324,000,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 167,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,205,842,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (881,858,432)<span></span>
</td>
<td class="num">$ (247,834)<span></span>
</td>
<td class="nump">$ 96,269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117256282456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 19,171,336<span></span>
</td>
<td class="num">$ (33,135,404)<span></span>
</td>
<td class="num">$ (23,536,452)<span></span>
</td>
<td class="num">$ (29,288,867)<span></span>
</td>
<td class="num">$ (143,136,534)<span></span>
</td>
<td class="num">$ (82,404,395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,323,505<span></span>
</td>
<td class="nump">2,746,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">137,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,311<span></span>
</td>
<td class="nump">799,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,670,977<span></span>
</td>
<td class="num">(2,551,453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,822,483<span></span>
</td>
<td class="nump">8,867,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,019,780<span></span>
</td>
<td class="nump">2,587,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit', window );">Amortization of premiums on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss (gain) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,778<span></span>
</td>
<td class="num">(238,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity', window );">Settlement of receivable with shares of common stock from affiliated entity (PLS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,713,770)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">(Gain) loss on equity investment in affiliated entities</a></td>
<td class="num">(26,951,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,250,341)<span></span>
</td>
<td class="nump">1,409,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="nump">1,759,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,661,431<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(624,522)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLeaseNonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774,438<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments', window );">Tax benefit from other unrealized gains on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(335,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized transaction loss on foreign-currency denominated debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(290,602)<span></span>
</td>
<td class="nump">183,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,992,871)<span></span>
</td>
<td class="nump">2,540,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846,894<span></span>
</td>
<td class="num">(239,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,055,813)<span></span>
</td>
<td class="num">(271,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,996<span></span>
</td>
<td class="num">(460,306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,969,731)<span></span>
</td>
<td class="num">(61,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,383,268<span></span>
</td>
<td class="num">(12,791,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,853,216<span></span>
</td>
<td class="num">(1,170,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,609<span></span>
</td>
<td class="num">(515,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,115)<span></span>
</td>
<td class="num">(144,154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties', window );">Deferred revenue from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,775)<span></span>
</td>
<td class="nump">31,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,550,860)<span></span>
</td>
<td class="num">(622,138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,551,410<span></span>
</td>
<td class="num">(2,269,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(670,925)<span></span>
</td>
<td class="nump">828,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,833<span></span>
</td>
<td class="num">(35,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126,762,557)<span></span>
</td>
<td class="num">(84,112,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153,135,274)<span></span>
</td>
<td class="num">(86,950,301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale or maturity of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,263,665<span></span>
</td>
<td class="nump">68,344,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(558,588)<span></span>
</td>
<td class="num">(873,484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Proceeds from the sale of investment in GeneOne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,125,418<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,774,851)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,079,630)<span></span>
</td>
<td class="num">(19,479,771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of convertible senior notes and convertible bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">93,425,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Costs related to issuance of convertible senior notes and convertible bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,314,757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,960,855<span></span>
</td>
<td class="nump">3,425,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,856,073<span></span>
</td>
<td class="nump">92,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,028,177)<span></span>
</td>
<td class="num">(892,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Acquisition of non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,379,969<span></span>
</td>
<td class="nump">3,016,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Geneos issuance of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,340,340<span></span>
</td>
<td class="nump">95,752,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (Decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,504,337<span></span>
</td>
<td class="num">(7,840,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,196,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,693,633<span></span>
</td>
<td class="nump">22,196,097<span></span>
</td>
<td class="nump">23,693,633<span></span>
</td>
<td class="nump">$ 23,693,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">178,700,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,853,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,700,434<span></span>
</td>
<td class="nump">15,853,236<span></span>
</td>
<td class="nump">$ 22,196,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Amounts accrued for purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,761<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,614,662<span></span>
</td>
<td class="nump">2,692,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,634,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,177,043<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (3,087,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,087,595)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Income Accrued On Short Term Investments Certificates Of Deposit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLeaseNonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLeaseNonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Receivable With Shares Of Common Stock From Equity Security</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Benefit From Unrealized Gains (Losses) On Short-Term Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252915272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Operations</a></td>
<td class="text">Organization and Operations<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Inovio&#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The Company's DNA medicine pipeline is comprised of three types of candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, Inovio has demonstrated that a DNA medicine can be delivered directly into cells in the body via its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's novel DNA medicines are made using its proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person's immune system recognize and destroy cancerous or virally infected cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio's hand-held CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human data to date have shown a favorable safety profile of Inovio&#8217;s DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery device in more than 6,000 administrations across more than 2,000 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio's corporate strategy is to advance, protect, and provide its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), The U.S. Department of Defense (DoD), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), International Vaccine Institute (IVI), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Thermo Fisher Scientific, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254106504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation, Liquidity and Risks and Uncertainties</a></td>
<td class="text">Basis of Presentation, Liquidity and Risks and Uncertainties<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of September&#160;30, 2020, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2020 and 2019 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three and nine months ended September 30, 2020 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2019, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange Commission (&#8220;SEC&#8221;) on March&#160;12, 2020. The balance sheet at December&#160;31, 2019 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc., VGX Pharmaceuticals, Inc. ("VGX") and Inovio Asia LLC, and records a 15% non-controlling interest for its subsidiary VGX Animal Health, Inc., a subsidiary of VGX.  All intercompany accounts and transactions have been eliminated upon consolidation.  As of June 1, 2020, the Company deconsolidated its subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest, retaining 47% of the outstanding equity on an as-converted to common stock basis. Refer to Footnote 17 for further discussion.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio incurred a net income (loss) attributable to common stockholders of $19.2 million and $(142.1) million for the three and nine months ended September 30, 2020, respectively. Inovio had working capital of $335.8 million and an accumulated deficit of $881.9 million as of September&#160;30, 2020. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $337.2 million as of September&#160;30, 2020, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of its current or potential future At-the-Market Equity Offering Sales Agreements (each, a &#8220;Sales Agreement&#8221; and collectively, the &#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds under the Sales Agreements of $330.0 million d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uring the nine months ended September 30, 2020, and net proceeds of $9.1 million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $75.7 million from a private placement of 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of $14.5 million from the private placement of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $4.0 million from the private placement of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#8220;Bonds&#8221;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#8217;s condensed consolidated financial statements as of and for the three and nine months ended September 30, 2020 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div>The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will impact the Company's business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, that are highly uncertain.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252926424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Critical Accounting Policies</a></td>
<td class="text">Critical Accounting Policies<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfOTk4OQ_0932b4d7-3f73-4fbf-a0c8-940a3372135a">two</span> to 18&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $3.3 million and $3.7 million, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through September&#160;30, 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any.  The Company performed its annual assessment for goodwill impairment as of November 30, 2019, identifying no impairment.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations. See Note&#160;8 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company&#8217;s financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the condensed consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254984552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impact of Recently Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Impact of Recently Issued Accounting Standards</a></td>
<td class="text">Impact of Recently Issued Accounting Standards <div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Recently Adopted</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2019-12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adoption. As of September 30, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended September 30, 2020. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2016-13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its condensed consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#8220;COVID-19&#8221;) outbreak on expected credit losses.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2018-13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends certain disclosure requirements over fair value measurements.  Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (see Note 7 for more information about the Company&#8217;s fair value classifications).</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2018-18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarified the interaction between Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2017-04.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2017, the FASB issued ASU 2017-04,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;</span>("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=SL108384541-122693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31137-122693<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254423224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition  During the three and nine months ended September 30, 2020, the Company recognized total revenue under collaborative research and development and other agreements of $83,000 and $1.3 million, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS"), $21,000 and $167,000, respectively, from AstraZeneca and $132,000 and $364,000, respectively, from various other contracts. Of the total revenue recognized during the three and nine months ended September 30, 2020, $4,000 and $127,000, respectively, were in deferred revenue as of December 31, 2019. Performance obligations are generally satisfied within 12 months of the initial contract date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252999016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments</a></td>
<td class="text">Short-term Investments<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments at September&#160;30, 2020 consisted of mutual funds, U.S. treasury securities, corporate debt securities, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments at December&#160;31, 2019 consisted of mutual funds. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the condensed consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. During the three and nine months ended September 30, 2020, the Company recorded gross realized gain on investments of $105,000 and $741,000, respectively, and gross realized loss on investments of $101,000 and $1.3 million, respectively. During the three and nine months ended September 30, 2019, the Company recorded gross realized gain on investments of $155,000 and $330,000, respectively, and gross realized loss on investments of $11,000 and $93,000, respectively. During the three and nine months ended September 30, 2020, the Company recorded net unrealized gain on available-for-sale equity securities of $1.3 million and $625,000, respectively. There was no material unrealized gain or loss on available-for-sale equity securities recorded during the three and nine months ended September 30, 2019. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of September&#160;30, 2020, the Company had&#160;11 available-for-sale securities in an unrealized loss position, of which none were in such position for longer than 12 months.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,177,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,128,029)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,802,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,840)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,032,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,529,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,907,426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785,532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157,214)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,535,744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,599,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,911)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;September&#160;30, 2020&#160;were primarily due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the COVID-19 global pandemic, and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at September&#160;30, 2020, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252836760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets are, and prior to September 30, 2020 liabilities were, classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the nine months ended September 30, 2020 or 2019. All liabilities in the fair value hierarchy were extinguished as of September 30, 2020 as described below.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of September&#160;30, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,985,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,985,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,802,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,802,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,032,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,032,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,535,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,974,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,561,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,674,793&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,113,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,561,385&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2019:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,315,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,315,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,003,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,003,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability (Note 9)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at September&#160;30, 2020 consisted of mutual funds, corporate debt securities and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the condensed consolidated statement of operations as a gain (loss) on investment in affiliated entities. In August 2020, the Company sold its investment in 1,644,155 common shares of its affiliated entity GeneOne. Previously, the Company accounted for its investment in GeneOne based on the closing price of the shares on the KOSDAQ Market of the Korea Exchange (KOSDAQ) on the applicable balance sheet date. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at September&#160;30, 2020 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets at September&#160;30, 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 liabilities at September 30, 2020 due to the full conversion of the August 2019 Bonds into shares of the Company's common stock (see Note 9 below for more information). Level 3 liabilities held as of December 31, 2019 consisted of the embedded conversion option contained in the August 2019 Bonds that met the criteria to be bifurcated and accounted for separately from the August 2019 Bonds (the "derivative liability"). The derivative liability was recorded at fair value of $7.1 million upon the issuance of the August 2019 Bonds, and was subsequently remeasured to fair value at each reporting period until conversion. The derivative liability was initially valued and remeasured using a "with-and-without" method. The "with-and-without" methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the embedded conversion option. The difference between the entire instrument with the embedded conversion option compared to the instrument without the embedded conversion option is the fair value of the derivative, recorded as the derivative liability. There was no derivative liability associated with the issuance of the December 2019 Bonds.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the August 2019 Bonds with the conversion option was estimated using a Monte Carlo simulation approach. The key inputs to valuing the August 2019 Bonds with the conversion option on the date of issuance and as of the August 3, 2020 conversion date, include the Company&#8217;s stock price on the valuation date; the expected annual volatility of the Company&#8217;s common stock, and the discount yield, which was derived by making the fair value of the August 2019 Bonds equal to the face value on the issuance date. Fair value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company's derivative liability for the nine months ended September 30, 2020: </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:79.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,670,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Derecognition of the derivative liability upon conversion </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,490,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252676056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.918%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,269,665)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,248,104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,395,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,704,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,175,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,525,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,356,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,190,221)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,283,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,779,910)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,693,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,190,221)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,796,911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,779,910)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,207,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for $3.9 million, $6.2 million and $400,000, respectively.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.</span></div>Aggregate amortization expense on intangible assets for the three and nine months ended September 30, 2020 was $137,000 and $410,000, respectively. Aggregate amortization expense on intangible assets for the three and nine months ended September 30, 2019 was $267,000 and $800,000, respectively. Estimated aggregate amortization expense is $137,000 for the remainder of fiscal year 2020, $520,000 for 2021, $493,000 for 2022, $276,000 for 2023, $253,000 for 2024 and $1.6 million for 2025 and subsequent years combined.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252911976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of the Notes to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately $75.7 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its condensed consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $78.5 million are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion featu</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">res. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $62.2 million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $2.8 million are allocated to the liability and equity component in the same proportion as the issuance proceeds. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $18.6 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is 13.1%. </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, the Company received notices for the conversion of $19.1&#160;million of principal amount of the Notes, which were settled in July 2020 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">into an aggregate of 3,546,074 shares of the Company's common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The fair value of the Notes at the date of conversion was $13.0&#160;million compared to the carrying value of $16.1&#160;million, resulting in a $3.1 million gain on extinguishment of debt. This gain was recorded in the condensed consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,965,643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,233,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,537,210&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2020,&#160;the Company recognized $1.7 million and $5.9 million, respectively, of interest expense related to the Notes, of which $996,000 and $3.5 million, respectively, related to the contractual interest coupon. For the three and nine months ended September 30, 2019,&#160;the Company recognized $2.1 million and $4.9 million, respectively, of interest expense related to the Notes, of which $1.3 million and $3.1 million, respectively, related to the contractual interest coupon. As descr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ibed in Note 18 below, subsequent to September 30, 2020, certain holders converted an additional portion of the Notes into shares of the Company's common stock.  </span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2019 Convertible Bonds</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2019, the Company closed a private placem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent of the August 2019 Bonds with an aggregate principal amount of 18 billion KRW (approximately USD $15.0 million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately $14.5 million. The Company also announced its intent to pursue a listing of its securities on the KOSDAQ in the form of Korean Depositary Receipts (KDRs) representing shares of common stock. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020 the August 2019 Bonds were converted in full into an aggregate of 4,962,364 shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.6873 shares per KRW 1,000,000 in principal amount (equivalent to a conversion price of approximately USD $3.04 per share based on the exchange rate as of August 3, 2020).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $7.1 million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the condensed consolidated&#160;statements of operations.  </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $7.3 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022.&#160;The effective interest rate of the August 2019 Bonds was 29.4%. For the three and nine months ended September 30, 2020,&#160;the Company recognized $238,000 and $1.6 million, respectively, of interest expense related to the August 2019 Bonds, of which $13,000 and $87,000, respectively, related to the contractual interest coupon. For the nine months ended September 30, 2019, the Company recognized $374,000 of interest expense related to the August 2019 Bonds, of which $26,000 related to the contractual interest coupon.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, all outstanding August 2019 Bonds were converted into common stock. Immediately prior to the conversion, the derivative liability was revalued at $84.5 million. The changes in fair value of the derivative liability were a decrease of $35.3 million and an increase of $75.7 million, which were recorded on the condensed consolidated statement of operations for the three and nine months ended September 30, 2020, respectively. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, a loss on extinguishment of $8.2&#160;million was recorded on the condensed consolidated statement of operations for the three months ended September 30, 2020. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the 4,692,364 shares of the Company's common stock issued upon conversion.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately $4.0 million.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which are unsecured obligations of the Company, were issued on December&#160;31, 2019 and will accrue interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds will mature on December&#160;31, 2024, unless earlier converted or repurchased. The outstanding December 2019 Bonds will be repaid at maturity </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of 6.00%. Commencing on December&#160;31, 2020, the December 2019 Bonds will be convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver KDRs, if the Company has any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock of the Company. The initial conversion rate is 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. The conversion rate is subject to reset on July&#160;2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed 357.9611 shares per KRW1,000,000 (equivalent to a conversion price of approximately USD $2.40 per share based on the exchange rate as of December&#160;19, 2019). The conversion rate has not been reset as of September 30, 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including December&#160;31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the December 2019 Bonds to be repurchased plus a premium on the Bonds in order to ensure an internal rate of return with respect to the Bonds equal to 6.00%. In addition, upon the occurrence of a fundamental change (as defined in the Subscription Agreement) the Company will be required to offer to repurchase the Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon to but excluding the applicable repurchase date. If certain bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding December 2019 Bonds shall automatically become due and payable. If any other event of default occurs and is continuing, the holders of at least 25% of the in aggregate principal amount of the December 2019 Bonds by notice to the Company may declare the principal of, and accrued and unpaid interest on, all of the then-outstanding December 2019 Bonds to be due and payable.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds are denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario is fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency does not impact the settlement of the conversion option. Further, as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the December 2019 Bonds at September&#160;30, 2020 was as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,030,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of premium associated with the December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,151,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represents the point at which the December 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is 6.2%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the three and nine months ended September 30, 2020,&#160;the Company recognized $63,000 and $185,000, respectively, of interest expense related to the December 2019 Bonds, of which $10,000 and $30,000, respectively, related to the contractual interest coupon. As of September&#160;30, 2020, there had not been any conversions or redemptions of the December 2019 Bonds.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, future minimum payments due under the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> convertible debt instruments are as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:58.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible Notes (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 2019 Bonds (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,862,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,862,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,862,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,346,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,189,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,535,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,932,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,319,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,251,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:22.5pt"><span><br/></span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of 6.5% per year. </span></div>(2) Amounts represent amounts due under the December 2019 Bonds, including interest based on the fixed rate of 1% per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of 6% at maturity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254263896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of September&#160;30, 2020 and December&#160;31, 2019: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,528,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,528,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,361,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, 14 shares of the Company&#8217;s Series&#160;C preferred stock were converted into an aggregate of 5,147 shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#8220;Placement Agent&#8221;) to sell shares of its common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent would act as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from $100.0 million to $250.0 million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $250.0 million. Under the New Sales Agreement, the Company sets the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The New Sales Agreement provides that the Placement Agent is entitled to compensation for its services in an amount equal to up to 3.0% of the gross proceeds from the sales of shares sold through the Placement Agent under the New Sales Agreement. The Company has no obligation to sell any shares under the New Sales Agreement, and could at any time suspend solicitation and offers under the New Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, the Company sold 43,148,952 shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of $4.92 per share, resulting in aggregate net proceeds of $208.2 million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended June 30, 2020, the Company sold 12,041,178 shares of its common stock under the New Sales Agreement. The sales were made at a weighted average price of $10.26 per share, resulting in aggregate net proceeds of $121.7 million. There were no shares sold during the three months ended September 30, 2020 under the New Sales Agreement. As of September 30, 2020, the Company may sell up to $126.4 million in gross proceeds of shares of Common Stock under the New Sales Agreement before it would be required to file a new prospectus supplement with the SEC to sell additional shares pursuant to the New Sales Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. The maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan may not exceed 18,000,000 shares, provided that commencing with the first business day of each calendar year beginning January&#160;1, 2020, such maximum number of shares shall be increased by&#160;2,000,000 shares of common stock unless the Company's Board of Directors determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2020, the maximum number of shares to be issued increased by 2,000,000. At September&#160;30, 2020, there were 18,000,000 shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At September&#160;30, 2020, the Company had 6,785,707 shares of common stock available for future grant under the 2016 Incentive Plan, 2,586,915 shares underlying outstanding but unvested restricted stock units and options outstanding to purchase 5,878,252 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div>The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At September&#160;30, 2020, the Company had options outstanding to purchase 3,412,095 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252842552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text">Net Income (Loss) Per Share <div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method.  The calculation of diluted net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net income (loss) per share for the period, an adjustment to the net income (loss) used in the calculation is required to remove the change in fair value of such securities from the numerator for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the nine months ended September 30, 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options and restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are anti-dilutive.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reconcile the components of the numerator and denominator included in the calculation of diluted net income (loss) per share:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net income (loss) per share)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,171,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,090,693)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment for decrease in fair value of derivative liability and interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,177,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for use in diluted income (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,171,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,267,943)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding (denominator for use in basic net income (loss) per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,355,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,007,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive potential common shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,020,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for use in diluted net income (loss) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,376,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,807,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net loss per share)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,072,777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,697,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment for decrease in fair value of derivative liability and interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for use in diluted loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,072,777)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,697,181)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding (denominator for use in basic net loss per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,656,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,204,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive potential common shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for use in diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,656,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,204,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net income (loss) per share calculation because of their anti-dilutive effect for the three months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,971,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,039,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,171,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,686,765&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the nine months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,290,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,971,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,039,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,592,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,485,836&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254972584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"><tr><td style="width:1.0%"/><td style="width:57.878%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.652%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.652%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.276%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.728%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 was $3.9 million and $11.0 million, respectively, of which $2.1 million and $6.2 million, respectively, was included in research and development expenses, and $1.8 million and $4.8 million, respectively, was included in general and administrative expenses.</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and nine months ended September 30, 2019 was $1.8 million and $8.1 million, respectively, of which $922,000 and $5.1 million, respectively, was included in research and development expenses, and $885,000 and $3.0 million, respectively, was included in general and administrative expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, there was $9.7 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.2 years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $12.09 and $6.78 for employee and director stock options granted during the three and nine months ended September 30, 2020, respectively, and $1.65 and $2.20 for employee and director stock options granted during the three and nine months ended September 30, 2019, respectively. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, there was $13.0 million of total unrecognized compensation expense related to unvested restricted stock units ("RSUs"), which is expected to be recognized over a weighted-average period of 2.1 years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $9.12 for RSUs granted during the nine months ended September 30, 2020. There were no RSUs granted during the three months ended September 30, 2020. The weighted average grant date fair value per share was $2.68 and $3.09 for RSUs granted during the three and nine months ended September 30, 2019, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and nine months ended September 30, 2020 was $278,000 and $884,000, respectively. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and nine months ended September 30, 2019 was $264,000 and $744,000, respectively.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, the Company granted 663,353 performance-based RSUs to key employees under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: 50% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining 50% of the shares in each tranche will vest upon subsequent completion of a one-year service period. The grant date fair value of the performance-based RSUs was $8.0&#160;million based on the grant date closing price per share of $12.06. As of September 30, 2020, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSU's for the three and nine months then ended.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252876664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction, Due from (to) Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Life Sciences </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 27, 2020, the Company so</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ld 1,644,155 sh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ares of common stock in GeneOne for net proceeds of approximately 47.4&#160;billion KRW (approximately USD $40.1&#160;million based on the exchange rate on the date of sale). The Company no longer holds an investment in GeneOne shares and GeneOne is no longer considered a related party to the Company under ASC 850. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he Company's condensed consolidated balance sheet as of September 30, 2020 no longer reflects GeneOne&#8217;s portion in accounts receivable and accounts payable and accrued expenses with affiliated entities whereas the Company&#8217;s balance sheet as of December 31, 2019 reflects $128,000 and $511,000 in a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ccounts receivable and accounts payable and accrued expenses with affiliated entities, respectively, related to GeneOne. Revenues recognized from GeneOne will no longer be presented as revenue with affiliated entity on the consolidated statement of operations after the change in related party designation in August 2020. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, the Company entered into a collaboration and license agreement (the &#8220;GeneOne Agreement&#8221;) with GeneOne. Under the GeneOne Agreement, the Company granted GeneOne an exclusive license to the Company's SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> universal influenza vaccine delivered with electroporation to be developed in certain countries in Asia (the &#8220;Product&#8221;). As consideration for the license granted to GeneOne, the Company received an upfront payment of $3.0 million, and is entitled to receive research support, annual license maintenance fees and royalties on net Product sales. The GeneOne Agreement also provides the Company with exclusive rights to supply devices for clinical and commercial purposes (including single use components) to GeneOne for use in the Product. The term of the GeneOne Agreement commenced upon execution and will extend on a country by country basis until the last to expire of all Royalty Periods for the territory (as such term is defined in the GeneOne Agreement) for any Product in that country, unless the GeneOne Agreement is terminated earlier in accordance with its provisions as a result of breach, by mutual agreement, or by GeneOne's right to terminate without cause upon prior written notice. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, the Company entered into a collaborative development and license agreement (the &#8220;Hep Agreement&#8221;) with GeneOne. Under the Hep Agreement, as originally executed, the Company and GeneOne agreed to co-develop the Company&#8217;s SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapeutic vaccines for hepatitis B and C infections (the &#8220;Hep Products&#8221;). Under the terms of the Hep Agreement, GeneOne will receive marketing rights for the Products in Asia, excluding Japan, and in return will fully fund IND-enabling and initial Phase 1 and 2 clinical studies with respect to the Hep Products. The Company will receive from GeneOne payments based on the achievement of clinical milestones and royalties based on sales of the Hep Products in the licensed territories, retaining all commercial rights to the Hep Products in all other territories. In 2013, the Company amended the Hep Agreement to grant back to the Company the SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapeutic vaccines targeting hepatitis B, along with all associated rights, from the collaboration in return for certain remuneration including a percentage of license fees. In 2013, the Company further amended the Hep Agreement to in part provide exclusive patent rights to IL-28 technology for use with the Hep Products in Asia, excluding Japan. The Hep Agreement shall terminate upon the later of the expiration or abandonment of the last patent that is a component of the rights or 20 years after the effective date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2015, the Company entered into a Collaborative Development Agreement with GeneOne to co-develop a DNA vaccine for MERS through Phase 1 clinical trials.&#160;Under the terms of the agreement, GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a 35% milestone-based ownership interest in the MERS immunotherapy upon achievement of the last milestone event of completion of the Phase 1 safety and </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunogenicity study.&#160;The collaborative research program shall terminate upon the completion of activities under the development plan, unless sooner terminated.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the Company and GeneOne amended the Collaborative Development Agreement for MERS to expand the agreement to test and advance the Company's DNA-based vaccine for preventing and treating Zika virus.&#160;GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a 35% milestone-based ownership interest in the Zika immunotherapy upon achievement of the last milestone event of the completion of the Phase 1 safety and immunogenicity study. All other agreement terms remain the same.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from GeneOne consisted of patent and device maintenance fees. For both the three and nine months ended September 30, 2020 and 2019, the Company recognized revenue from GeneOne of $31,000 and $94,000, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses recorded from transactions with GeneOne related primarily to biologics manufacturing were $1.6 million and $4.4 million for the three and nine months ended September 30, 2020, respectively, and $232,000 and $2.1 million for the three and nine months ended September 30, 2019, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns 597,808 shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of September&#160;30, 2020 and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February 20, 2020, the Company entered into a Debt and Share Subscription Agreement with PLS under which the Company received 202,050 shares of PLS common stock in exchange for a portion of the outstanding accounts receivable balance due from PLS. Following the issuance of these shares and as of September&#160;30, 2020, the Company held a 19.9% ownership interest in PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the three and nine months ended September 30, 2020, the Company recognized revenue from PLS of $83,000 and $1.3 million, respectively, and $22,000 and $86,000 for the three and nine months ended September 30, 2019, respectively. At September&#160;30, 2020 and December&#160;31, 2019, the Company had an accounts receivable balance of $40,000 and $589,000, respectively, related to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement.  The Company will have the exclusive right to in-license new intellectual property developed under the agreement.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company received a&#160;$6.1 million&#160;sub-grant through Wistar to develop a DNA-based monoclonal antibody against the Zika infection, with funding through December 2020. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three and nine months ended September 30, 2020, the Company recorded $1.0 million and $1.7 million, respectively, and for the three and nine months ended September 30, 2019 the Company recorded $482,000 and $1.7 million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill and Melinda Gates Foundation and CEPI (see Note 15). Research and development expenses recorded from Wistar for the three and nine months ended September 30, 2020 were $411,000 and $1.2 million, respectively. Research and development expenses recorded from Wistar for the three and nine months ended September 30, 2019 were $313,000 and $1.1 million, respectively. At September&#160;30, 2020 and December&#160;31, 2019, the Company had an accounts receivable balance of $443,000 and $616,000, respectively, and an accounts payable and accrued liability balance of $795,000 and $219,000, respectively, related to Wistar. As of September&#160;30, 2020, the Company had $173,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to Wistar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254059736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases                                                  The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating <div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lease agreements with remaining lease terms as of September&#160;30, 2020 of 3.2 to 9.3 years, which represent the non-cancellable periods of the leases.  The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of September&#160;30, 2020, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,968,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,023,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,951,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,973,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,039,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,934,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,264,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,670,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4%</span></td></tr></table></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 were $836,000 and $2.5 million, respectively. Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and nine months ended September 30, 2019 were $820,000 and $2.5 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252876664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and potentially Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the three years following the effective date of the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ApolloBio Agreement, the Company received proceeds of $19.4 million in March 2018 which comprised the </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the condensed consolidated statement of operations. The Company also incurred advisory fees of $960,000 in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement.  The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $23.0 million upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $23.0 million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. The Company has recorded the gross upfront payment received from ApolloBio of $23.0 million as revenue under collaborative research and development arrangements on the condensed consolidated statement of operations during the three months ended June 30, 2018.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $27.5 million to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to $125 million and potential future commercial event-based payments totaling up to $115 million, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement.  </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the broader collaboration, AstraZeneca had rights to co-develop up to two additional DNA-based cancer vaccine product candidates not included in the Company's current product pipeline. The Company has received notice that AstraZeneca intends to discontinue activities with respect to the research collaboration programs, other than MEDI0457, that were covered by the collaboration agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2017, the Company had recognized all of the $27.5 million upfront payment as revenue, as all identified material performance obligations had been met with respect to that payment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020, the Company recognized revenues of $21,000 and $167,000, respectively, from AstraZeneca primarily for </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing services. During the three and nine months ended September 30, 2019, the Company recognized revenues of $255,000 and $3.0 million, respectively, from AstraZeneca primarily from a milestone achieved in the first quarter of 2019 triggered by the initiation of a Phase 2 portion of an ongoing clinical trial in the third major indication, as well as for manufacturing services.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three and nine months ended September 30, 2020, the Company received funding of $1.6 million and $4.6 million, respectively, related to the CEPI Lassa fever and MERS grants and recorded such amounts as contra-research and development expense. During the three and nine months ended September 30, 2019, the Company received funding of $1.5 million and $4.6 million, respectively, related to these grants and recorded such amounts as contra-research and development expense. As of September&#160;30, 2020, the Company had $3.7 million recorded as deferred grant funding on the condensed consolidated balance sheet related to these CEPI grants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $9.0 million to develop a vaccine against COVID-19. This initial CEPI funding is intended to support preclinical and clinical development through Phase 1 human testing in the United States of INO-4800, the Company's COVID-19 vaccine candidate against COVID-19. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During the three and nine months ended September 30, 2020, the Company received funding of $1.3 million and $9.5 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of September&#160;30, 2020, the Company had $1.1 million recorded as deferred grant funding on the condensed consolidated balance sheet related to the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Bill &amp; Melinda Gates Foundation (&#8220;Gates&#8221;) awarded and funded the Company a grant of $2.2 million to advance the development of DNA-encoded monoclonal antibody technology (&#8220;dMAb&#8221;) to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the three and nine months ended September 30, 2020, the Company recorded $164,000 and $334,000, respectively, and during the three and nine months ended September 30, 2019 recorded $1.5 million and $4.6 million, respectively, as contra-research and development expense related to the Gates dMAb grant. As of September&#160;30, 2020, the Company had $703,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the three and nine months ended September 30, 2020, the Company recorded $943,000 and $1.9 million, respectively, as contra-research and development expense and had $3.1 million recorded as deferred grant funding on the condensed consolidated balance sheet related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the U.S. Department of Defense (the "DoD"), to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately $54.5 million. The Company has determined that the OTA Agreement does not represent revenue under ASC 606, therefore will record contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses are incurred. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $16.6 million. The Company has determined that the Procurement Contract does not currently fall under the scope of ASC 606 as contingencies remain regarding INO-4800 which does not give the Company the ability to satisfy its obligations under the arrangement.</span>During the three and nine months ended September 30, 2020, the Company recorded $7.7&#160;million as contra-research and development expense related to these agreements with the DoD.  As of September&#160;30, 2020, the Company had an accounts receivable balance of $7.7&#160;million on the condensed consolidated balance sheet<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254155320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act).&#160; The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19.&#160;The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic; some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act.&#160;At September&#160;30, 2020, the Company has not recorded any income tax provision/(benefit) for the impact for the CARES Act due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets. The Company will continue to analyze the impact that the CARES Act will have, if any, on its financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252876664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company formed Geneos, to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;preferred stock financing. The Company invested&#160;$1.2 million&#160;in the preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;preferred stock financing, in which the Company invested $800,000. Following this transaction, as of March 31, 2020, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;preferred stock financing round, in which the Company invested $800,000.  Following this transaction, the Company no longer held a controlling financial interest as the Company, owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support.  However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's condensed consolidated statement of operations.  The following table shows the amounts related to the deconsolidation accounting: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,121,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for Geneos&#8217; common stock.  Geneos&#8217; enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving Geneos&#8217; own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#8217;s exercise price was based on Geneos&#8217; total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of Geneos&#8217; estimated time to their next financing and successful exit timing assumption.  The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#8217;s common stock is classified as a Level 3 financial instrument. The assumptions used in the fair value calculation as of June 1, 2020 are presented below:</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,966,531</span></td></tr></table></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock.  Since the Company&#8217;s preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company has determined that its preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the period from June 1, 2020 through September 30, 2020 was $2.7 million. Of this amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of September 30, 2020. The remaining $1.8 million loss has been allocated to the Company&#8217;s preferred stock investment in Geneos, thereby reducing the balance to $958,000 as of September 30, 2020 as shown in the table below:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,661,431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span>&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254155320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsIn October 2020, certain holders converted an aggregate principal amount of $10.0 million of Notes into an aggregate of 1,858,044 shares of the Company's common stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117258573992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of September&#160;30, 2020, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2020 and 2019 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three and nine months ended September 30, 2020 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2019, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange Commission (&#8220;SEC&#8221;) on March&#160;12, 2020. The balance sheet at December&#160;31, 2019 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc., VGX Pharmaceuticals, Inc. ("VGX") and Inovio Asia LLC, and records a 15% non-controlling interest for its subsidiary VGX Animal Health, Inc., a subsidiary of VGX.  All intercompany accounts and transactions have been eliminated upon consolidation.  As of June 1, 2020, the Company deconsolidated its subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest, retaining 47% of the outstanding equity on an as-converted to common stock basis. Refer to Footnote 17 for further discussion.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio incurred a net income (loss) attributable to common stockholders of $19.2 million and $(142.1) million for the three and nine months ended September 30, 2020, respectively. Inovio had working capital of $335.8 million and an accumulated deficit of $881.9 million as of September&#160;30, 2020. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $337.2 million as of September&#160;30, 2020, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of its current or potential future At-the-Market Equity Offering Sales Agreements (each, a &#8220;Sales Agreement&#8221; and collectively, the &#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds under the Sales Agreements of $330.0 million d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uring the nine months ended September 30, 2020, and net proceeds of $9.1 million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $75.7 million from a private placement of 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of $14.5 million from the private placement of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $4.0 million from the private placement of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#8220;Bonds&#8221;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#8217;s condensed consolidated financial statements as of and for the three and nine months ended September 30, 2020 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div>The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will impact the Company's business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, that are highly uncertain.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantPolicyPolicyTextBlock', window );">Grants</a></td>
<td class="text">Grants<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span>, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Valuation of Intangible Assets and Goodwill</a></td>
<td class="text">Valuation of Intangible Assets and Goodwill<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdiMzk0Y2JiZTE1ZTQwZjRiZmNlYmQ3NDI1YTY1NzI1L3NlYzo3YjM5NGNiYmUxNWU0MGY0YmZjZWJkNzQyNWE2NTcyNV8zNy9mcmFnOmUyNmY0NDM2YTE4ZTRhMmJhODNjMzNiN2Y2ZGI0NThjL3RleHRyZWdpb246ZTI2ZjQ0MzZhMThlNGEyYmE4M2MzM2I3ZjZkYjQ1OGNfOTk4OQ_0932b4d7-3f73-4fbf-a0c8-940a3372135a">two</span> to 18&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $3.3 million and $3.7 million, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through September&#160;30, 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any.  The Company performed its annual assessment for goodwill impairment as of November 30, 2019, identifying no impairment.</span></div>Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company&#8217;s financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the condensed consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included </span></div>in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities (VIE)</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock', window );">Equity Investments</a></td>
<td class="text">Equity Investments<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Recently Adopted</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2019-12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adoption. As of September 30, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended September 30, 2020. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2016-13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its condensed consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#8220;COVID-19&#8221;) outbreak on expected credit losses.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2018-13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends certain disclosure requirements over fair value measurements.  Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statement disclosures (see Note 7 for more information about the Company&#8217;s fair value classifications).</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2018-18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarified the interaction between Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2017-04.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2017, the FASB issued ASU 2017-04,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;</span>("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252999016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Summary of Investments</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,177,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,128,029)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,802,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,840)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,032,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,529,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,907,426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785,532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157,214)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,535,744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,599,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,911)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252899256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of September&#160;30, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,985,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,985,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,802,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,802,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,032,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,032,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,535,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,974,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,561,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,674,793&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,113,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,561,385&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2019:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,315,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,315,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,003,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,003,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability (Note 9)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Value of the Company's Derivative Liability</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company's derivative liability for the nine months ended September 30, 2020: </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:79.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,670,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Derecognition of the derivative liability upon conversion </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,490,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254972584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Summary of Intangible Assets by Major Asset Class</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.918%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,269,665)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,248,104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,395,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,704,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,175,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,525,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,356,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,190,221)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,283,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,779,910)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,693,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,190,221)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,796,911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,779,910)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,207,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for $3.9 million, $6.2 million and $400,000, respectively.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252919176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at September&#160;30, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,965,643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,233,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,537,210&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the December 2019 Bonds at September&#160;30, 2020 was as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,030,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of premium associated with the December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,151,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, future minimum payments due under the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> convertible debt instruments are as follows:</span><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:58.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible Notes (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 2019 Bonds (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,862,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,862,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,862,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,346,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,189,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,535,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,932,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,319,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,251,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:22.5pt"><span><br/></span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of 6.5% per year. </span></div>(2) Amounts represent amounts due under the December 2019 Bonds, including interest based on the fixed rate of 1% per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of 6% at maturity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254059736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of September&#160;30, 2020 and December&#160;31, 2019: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,528,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,528,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,361,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117356372152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">Schedule of Diluted Net Income (Loss) Per Share</a></td>
<td class="text">The following tables reconcile the components of the numerator and denominator included in the calculation of diluted net income (loss) per share:<div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net income (loss) per share)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,171,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,090,693)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment for decrease in fair value of derivative liability and interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,177,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for use in diluted income (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,171,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,267,943)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding (denominator for use in basic net income (loss) per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,355,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,007,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive potential common shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,020,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for use in diluted net income (loss) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,376,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,807,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net loss per share)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,072,777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,697,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment for decrease in fair value of derivative liability and interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for use in diluted loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,072,777)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,697,181)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding (denominator for use in basic net loss per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,656,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,204,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive potential common shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for use in diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,656,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,204,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net income (loss) per share calculation because of their anti-dilutive effect for the three months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,971,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,039,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,171,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,686,765&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the nine months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,290,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,971,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,039,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,592,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,485,836&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117252726168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"><tr><td style="width:1.0%"/><td style="width:57.878%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.652%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.652%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.276%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.728%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254375144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of September&#160;30, 2020, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,968,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,023,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,951,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,973,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,039,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,934,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,264,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,670,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254325064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments</a></td>
<td class="text">The following table shows the amounts related to the deconsolidation accounting: <div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,121,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The remaining $1.8 million loss has been allocated to the Company&#8217;s preferred stock investment in Geneos, thereby reducing the balance to $958,000 as of September 30, 2020 as shown in the table below:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,661,431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,966,531</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117255597560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,171,336)<span></span>
</td>
<td class="nump">$ 23,090,693<span></span>
</td>
<td class="nump">$ 142,072,777<span></span>
</td>
<td class="nump">$ 81,697,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Capital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(881,858,432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(881,858,432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (739,785,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,960,855<span></span>
</td>
<td class="nump">$ 3,425,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,030,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,030,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_VGXAnimalHealthIncMember', window );">VGX Animal Health, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Capital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of total capital as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958568-112826<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47080-110998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Capital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_VGXAnimalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_VGXAnimalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117254996728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 3,283,540<span></span>
</td>
<td class="nump">$ 3,693,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117258711304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 236,178<span></span>
</td>
<td class="nump">$ 866,863<span></span>
</td>
<td class="nump">$ 1,830,639<span></span>
</td>
<td class="nump">$ 3,832,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from deferred revenue beginning balance</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">$ 255,000<span></span>
</td>
<td class="nump">167,000<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember', window );">Other Counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_OtherCounterpartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117258725720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gain on investments</a></td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="nump">$ 741,000<span></span>
</td>
<td class="nump">$ 330,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized loss on investments</a></td>
<td class="nump">101,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="nump">$ 1,315,980<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 624,522<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | investment</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in a gross unrealized loss position for more than twelve months | investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117258654440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Summary of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 157,907,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">1,785,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(1,157,214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">158,535,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">152,177,676<span></span>
</td>
<td class="nump">$ 66,599,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">1,752,552<span></span>
</td>
<td class="nump">754,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(1,128,029)<span></span>
</td>
<td class="num">(15,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">152,802,199<span></span>
</td>
<td class="nump">$ 67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(27,840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 1,172,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual maturity (less than)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">32,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">3,032,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">1,529,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(1,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 1,528,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117258328136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">$ 158,535,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">4,154,049<span></span>
</td>
<td class="nump">$ 6,315,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 9)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 9)</a></td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">152,802,199<span></span>
</td>
<td class="nump">67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">1,172,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">3,032,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">1,528,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">158,535,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">4,154,049<span></span>
</td>
<td class="nump">6,315,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">262,674,793<span></span>
</td>
<td class="nump">76,003,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 9)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">153,974,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">4,154,049<span></span>
</td>
<td class="nump">6,315,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">258,113,408<span></span>
</td>
<td class="nump">76,003,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 9)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">4,561,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">4,561,385<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 9)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 9)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="nump">99,985,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="nump">99,985,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">152,802,199<span></span>
</td>
<td class="nump">67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">152,802,199<span></span>
</td>
<td class="nump">67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">1,172,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">3,032,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">3,032,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,349,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,349,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">1,528,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">1,528,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117259576248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract', window );"><strong>Marketable Securities and Fair Value Measurements (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,819,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract', window );"><strong>Marketable Securities and Fair Value Measurements (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares', window );">Number of shares held in an affiliated entity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,644,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract', window );"><strong>Marketable Securities and Fair Value Measurements (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract', window );"><strong>Marketable Securities and Fair Value Measurements (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of affiliates held for management investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611322-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117256312760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 8,819,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">75,670,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Derecognition of the derivative liability upon conversion</a></td>
<td class="num">(84,490,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117346018728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2009</div></th>
<th class="th"><div>Jan. 31, 2005</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">10,473,761<span></span>
</td>
<td class="nump">10,473,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(7,190,221)<span></span>
</td>
<td class="num">(6,779,910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">3,283,540<span></span>
</td>
<td class="nump">3,693,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsGross', window );">Total goodwill and intangible assets, gross</a></td>
<td class="nump">20,987,132<span></span>
</td>
<td class="nump">20,987,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsNet', window );">Total goodwill and intangible assets, net book value</a></td>
<td class="nump">13,796,911<span></span>
</td>
<td class="nump">14,207,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ino_InovioAsMember', window );">Inovio AS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ino_VgxPharmaceuticalsMember', window );">VGX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">1,323,761<span></span>
</td>
<td class="nump">1,323,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(1,269,665)<span></span>
</td>
<td class="num">(1,248,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">54,096<span></span>
</td>
<td class="nump">75,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(2,395,556)<span></span>
</td>
<td class="num">(2,175,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">2,704,444<span></span>
</td>
<td class="nump">2,924,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">4,050,000<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(3,525,000)<span></span>
</td>
<td class="num">(3,356,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 525,000<span></span>
</td>
<td class="nump">$ 693,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ino_InovioAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ino_InovioAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ino_VgxPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ino_VgxPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117259273032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense on intangible assets</a></td>
<td class="nump">$ 137,000<span></span>
</td>
<td class="nump">$ 267,000<span></span>
</td>
<td class="nump">$ 410,311<span></span>
</td>
<td class="nump">$ 799,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated aggregate amortization expense for remainder of 2020</a></td>
<td class="nump">137,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated aggregate amortization expense for 2021</a></td>
<td class="nump">520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated aggregate amortization expense for 2022</a></td>
<td class="nump">493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated aggregate amortization expense for 2023</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated aggregate amortization expense for 2024</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Estimated aggregate amortization expense for 2025</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117246509112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,984,046<span></span>
</td>
<td class="nump">$ 2,428,671<span></span>
</td>
<td class="nump">$ 7,634,442<span></span>
</td>
<td class="nump">$ 5,279,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,306,000<span></span>
</td>
<td class="nump">2,551,453<span></span>
</td>
<td class="num">$ (75,670,977)<span></span>
</td>
<td class="nump">2,551,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,692,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,233,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,233,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,965,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,965,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,087,595<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,087,595<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,177,043)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1858045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,200,000<span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,546,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of date conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 996,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002756873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="nump">4,962,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Bonds | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002110595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage', window );">Debt instrument, convertible, required bondholder approval, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0002147766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds | After July 2, 2020 Conversion Price | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0003579611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleInternalRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Internal Rate Of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleInternalRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Required Bondholder Approval, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJuly22020ConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJuly22020ConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117258291768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Balance of Convertible Bonds and Notes (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleDebtConvertedAmount', window );">Principal amount converted into common shares</a></td>
<td class="num">$ (19,085,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">78,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(8,965,643)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(1,233,978)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">321,831<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">49,537,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">4,030,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(37,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentAccretionOfPremium', window );">Accretion of premium associated with the December 2019 Bonds</a></td>
<td class="nump">148,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">10,077<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 4,151,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentAccretionOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accretion Of Premium</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentAccretionOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleDebtConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Converted Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleDebtConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117256750264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Maturities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 26, 2019</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 49,537,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">4,151,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">3,902,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">3,902,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">3,902,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">66,535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">78,251,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">3,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">3,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">3,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">61,346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 72,932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">5,189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 5,319,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleInternalRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Internal Rate Of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleInternalRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117258777128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares, authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">167,528,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">167,528,435<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117335162664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 12, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>May 13, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan', window );">Number of potential shares authorized for issuance under share based compensation plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,785,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,785,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,586,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,586,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,878,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,878,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,412,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,412,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Prior Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | New Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementAgentFee', window );">Agent fee</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,041,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of potential shares authorized for issuance under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Agent Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_PriorSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_PriorSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_NewSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_NewSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117255295800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Schedule of Diluted Net Loss Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net income (loss) per share)</a></td>
<td class="nump">$ 19,171,336<span></span>
</td>
<td class="num">$ (23,090,693)<span></span>
</td>
<td class="num">$ (142,072,777)<span></span>
</td>
<td class="num">$ (81,697,181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Adjustment for decrease in fair value of derivative liability and interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,177,250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Numerator for use in diluted income (loss) per share</a></td>
<td class="nump">$ 19,171,336<span></span>
</td>
<td class="num">$ (25,267,943)<span></span>
</td>
<td class="num">$ (142,072,777)<span></span>
</td>
<td class="num">$ (81,697,181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding (denominator for use in basic net income (loss per share) (in shares)</a></td>
<td class="nump">165,355,540<span></span>
</td>
<td class="nump">99,007,985<span></span>
</td>
<td class="nump">148,656,454<span></span>
</td>
<td class="nump">98,204,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive potential common shares (in shares)</a></td>
<td class="nump">9,020,862<span></span>
</td>
<td class="nump">3,799,071<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Denominator for use in diluted net income (loss) per share (in shares)</a></td>
<td class="nump">174,376,402<span></span>
</td>
<td class="nump">102,807,056<span></span>
</td>
<td class="nump">148,656,454<span></span>
</td>
<td class="nump">98,204,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToParentDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117256154872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Schedule of Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">12,171,771<span></span>
</td>
<td class="nump">26,686,765<span></span>
</td>
<td class="nump">24,592,948<span></span>
</td>
<td class="nump">30,485,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">119,438<span></span>
</td>
<td class="nump">9,971,297<span></span>
</td>
<td class="nump">9,290,347<span></span>
</td>
<td class="nump">9,971,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,121,359<span></span>
</td>
<td class="nump">2,586,915<span></span>
</td>
<td class="nump">2,121,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663,353<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">8,456<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">8,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">11,039,574<span></span>
</td>
<td class="nump">14,585,653<span></span>
</td>
<td class="nump">11,039,574<span></span>
</td>
<td class="nump">14,585,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,799,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">1,009,450<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117255079448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,822,483<span></span>
</td>
<td class="nump">$ 8,867,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.09<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="nump">$ 6.78<span></span>
</td>
<td class="nump">$ 2.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 922,000<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">885,000<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan | Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">663,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan | Performance-based restricted stock units | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan | Performance-based restricted stock units | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">0.64%<span></span>
</td>
<td class="nump">2.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,000<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="nump">$ 884,000<span></span>
</td>
<td class="nump">$ 744,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117341034328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Narrative (Details)<br> &#8361; in Billions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 27, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 27, 2020 </div>
<div>KRW (&#8361;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 31, 2015</div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 20, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,960,855<span></span>
</td>
<td class="nump">$ 3,425,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236,178<span></span>
</td>
<td class="nump">$ 866,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,830,639<span></span>
</td>
<td class="nump">3,832,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneOneLifeSciencesMember', window );">GeneOne Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">1,644,155<span></span>
</td>
<td class="nump">1,644,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="nump">$ 40,100,000<span></span>
</td>
<td class="nump">&#8361; 47.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable/accrued liabilities</a></td>
<td class="nump">$ 511,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Payment received for license granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MilestoneBasedOwnershipTarget', window );">Milestone-based ownership target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 589,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences | Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_InvestmentOwnedAdditionalSharesAcquired', window );">Investment owned, additional shares acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable/accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411,000<span></span>
</td>
<td class="nump">313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">$ 482,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding, from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_InvestmentOwnedAdditionalSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment Owned, Additional Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_InvestmentOwnedAdditionalSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_MilestoneBasedOwnershipTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone-Based Ownership Target</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_MilestoneBasedOwnershipTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_RelatedPartyTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_RelatedPartyTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneOneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneOneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117246474504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost | $</a></td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">$ 820<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117259548856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 985,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">3,968,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">4,045,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">4,023,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">3,001,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">12,951,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">28,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(8,039,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">20,934,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,264,261)<span></span>
</td>
<td class="num">$ (2,074,842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 18,669,643<span></span>
</td>
<td class="nump">$ 20,409,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117246156984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th">
<div>Aug. 07, 2015 </div>
<div>product</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236,178<span></span>
</td>
<td class="nump">$ 866,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,830,639<span></span>
</td>
<td class="nump">$ 3,832,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,616,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,616,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,065,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementTerritoryExpansionOptionPeriod', window );">Territory expansion option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromCollaborativeAgreement', window );">Proceeds received in upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="nump">23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAdvisoryFees', window );">Advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination', window );">Period from effective date for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement, Product | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementCorporateIncomeTax', window );">Foreign corporate income taxes reducing upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementForeignNonIncomeTaxes', window );">Foreign non-corporate income taxes reducing upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember', window );">AstraZeneca | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones', window );">Anticipated development and regulatory event based payment receivable milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones', window );">Anticipated commercial event based payment receivable milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfAdditionalProducts', window );">Number of additional products to be developed | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever And MERS Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill And Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334,000<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill And Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">943,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded', window );">Purchase price, procurement contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementTerritoryExpansionOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Territory Expansion Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementTerritoryExpansionOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Advisory Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementCorporateIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Corporate Income Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementCorporateIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementForeignNonIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Non-Income Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementForeignNonIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number of Days Written Notice Before Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period From Effective Date For Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementFixedPriceContractAmountAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfAdditionalProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Additional Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfAdditionalProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaborative Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_INO4800Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_INO4800Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117256690456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,121,075<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,759,674<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,661,431<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 957,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 957,567<span></span>
</td>
<td class="nump">$ 957,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment', window );">Stock purchase agreement, commitment of additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of investment</a></td>
<td class="nump">$ 4,121,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,661,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 957,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,567<span></span>
</td>
<td class="nump">$ 957,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">$ 2,799,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 958,000<span></span>
</td>
<td class="nump">$ 958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Commitment Of Additional Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117255326360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,190,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,190,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,773,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Carrying value of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,969,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,774,851<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_WorkingCapitalExcludingCash', window );">Working capital (excluding cash)</a></td>
<td class="num">$ (59,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable</a></td>
<td class="nump">171,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="num">(16,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Carrying value of noncontrolling interest</a></td>
<td class="nump">3,181,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedInterestFairValueDisclosure', window );">Fair value of investment in Geneos retained</a></td>
<td class="nump">3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="nump">$ 2,774,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapitalExcludingCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital, Excluding Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapitalExcludingCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedInterestFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of interest continued to be held by a transferor after transferring financial assets to a third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedInterestFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117257870024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Investment In Geneos (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">$ 957,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,113,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">957,567<span></span>
</td>
<td class="nump">$ 3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock | Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,113,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">$ 958,000<span></span>
</td>
<td class="nump">$ 2,799,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117259187224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Fair Value Assumptions (Details) - Geneos Therapeutics, Inc.<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EquityMethodInvestmentEnterpriseValue', window );">Geneos enterprise value</a></td>
<td class="nump">$ 4,966,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Measurement input, expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AlternativeInvestmentMeasurementInputTerm', window );">Equity method investment, measurement input, expected term</a></td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Measurement input, price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Equity method investment, measurement input</a></td>
<td class="nump">0.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Measurement input, risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Equity method investment, measurement input</a></td>
<td class="nump">0.0246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AlternativeInvestmentMeasurementInputTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative Investment, Measurement Input, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AlternativeInvestmentMeasurementInputTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EquityMethodInvestmentEnterpriseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Enterprise Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EquityMethodInvestmentEnterpriseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117258602760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Preferred stock Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos upon deconsolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="num">$ (1,759,674)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,661,431)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos as of September 30, 2020</a></td>
<td class="nump">957,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 957,567<span></span>
</td>
<td class="nump">957,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,661,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos as of September 30, 2020</a></td>
<td class="nump">$ 957,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 957,567<span></span>
</td>
<td class="nump">$ 957,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140117258697112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,692,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares)</a></td>
<td class="nump">1,858,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument principal amount</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M9P&7^@&XOQ%"G4_T#Q3;K./_ %!+ P04    " !M?FE1Y.QYPN@'  !D(P
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M:GU#@004C3&UCE(D3:F(VM."(]2-<6@FYU[X=A+!BL="Q&&,O 5CE4^)H-H
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M"X.LKY0*#H 0:)91FF1IH#@25*9:0>D)R@D2-.5039*Q:C(X)AYW3,?3+J8
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M#6K_P=9/W7L^\]K:>M/]NC8YK'@'@+^O:BB__0?7P>%EM-O_ U!+ P04
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M?4"^YWN6_<S?;(X36SK_+_KRAZ-?D4%:99#*'[GE[RR!FPKXXV&MM(2C_N=
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MMT4."TXG@+]_JJKVX4/WC9>;K\$]_3]02P,$%     @ ;7YI48[?V>8S#
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M<J67_V11-Y,VASPP1DVKBFWC"X\I<;G"1%+@M=2VQ17TV6((!0DSBCW$K12
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MB1S( A^%-&-/T=D@+ T(RS (RX\B_JM^T6%?EST.1=O/?=%VOU7Z-CL/><C
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M[)!O/EPT%]&5Z6/!PD5D*/WD&E*>#^#YTF&G:"_8P.[KT<6_ 5!+ P04
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M8#IXUL].K.4&("C4IP9TA4 SF;%1TI%6<OUKB(M:I[ERL(K="]=;+'?IK'Q
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MS>GQ6T*<5=E]:3.[9A+9=!?,?4GYF]!"RT==IOI5X$7&TGP+<JERJC0?55H
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M=G@#?+^V8*SR 3>(OU#TXE]02P,$%     @ ;7YI4>XE7E2="   'A8  !D
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M_O2(_#?BH[-Q'<0/-E?YX?D1;&T-GC8&WTY?%/B@RJ$X'??%=#P=OR#OM W
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M #+,62/L6NT^8!?/J>-+E3#^'W:M[?@\@+0Q5E4=F!147+9/]M#EX0AP$;T
MB#M ['6WCKS*:V;9;*+5#K2S)C;WXD/U:!+'I2O*QFHZY82SLS7>HVP0UIBJ
M0G*7J4EHB=@=AVE'LFA)XA=(+N%625L:>"<SS)[B0Q)T4!7WJA;QJX0;K(>0
M1 .(HSAZA2\Y1)EXON0/4>9:5; DK9IN V7:EK#T.48-W^=;X_=_O.)P?' X
M]@['_Y?6OR8!N&XTEP78$NFG$8')#"0AH6IK@*X&0!FT6&TIKCZ- X]9JJIF
M<D_]Y#E_D:E5E@G::)TU!-= UTJPK=+,]0R=&60Z+;VOC R%JJDQK5\KHM7
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MAIW]MA)L6<J$%[% H"RY3F2Q9"EM?W3;\^9V82Q?9!(^8QAG=J6%.+-2Z";
M"L]<QZMMQ#8K&:_86DNEI95_ ,B"GBS6)7"51B18!P)MJN?$F!&,<!MLBK,R
M$5?L@W@4&1M$%#N0.F'<,+4@$<%5C=B4((HO7TIEL0?D8T%(0A@C!/2#L,0+
MMXQK@??88"2AP!MBL2$T2[@5KP/I88MTH*< H0E;\7R20CJ@1&JDF&S+E,;N
MW5,MTVO&BR00'[6(E\6AY"#H59Y):_$:6 L5B),<G(FOTE@3D9!(84J3T;^4
MTJD?_$->:;?,*E "2;5FD@3<0!"#W+NF;&C.V5MC2!H($CG^G(4)"H%G1;Z
M9%7T@16^D.!'0B$;01!Q!F0RE9"#DF+"D&%)Z4CR\"^6.6%5ZH7R*I.PJEP6
M (HY3 )*!'#$2YWSL#N5KWFQA7R/E([W 6HOK=F)N<OUE.YA1ZZMT# %.)3
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M5:-1D0W ]).^WSB]"=-UJ1W.ZK!L\..(&P] ^4IKM]]X X?/K=F_4$L#!!0
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M(7A]P16*-7*)2,>U"QF(B=&FL*E:GFD 52!%92?P8F3KR[R$:Z"2^$HL</3
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MF=GUD58R<'%V(Y.V^[0_(5#'4F.QN_IUP5,1ZM0ZJ\J6/3"-+=P(]9ZM4J@
M;'\@H!,[NF]T^:4-O]+DN;L/?KN7B,/+7JNX&%V*SWRD_%'1;YK0PN"8@\@Y
M ]KAZ"4^.?$W'S @%%$PGX[XS_$PB/!?%"R&(_[$CG/Z^^B>[\=B&@;1V)XG
M3H)PON!/TVDPB=C('./G8C8*%M'(,3@)HG !.D-[&7^$^$%_D "N.:QXCMPQ
M$NF^[6K 7:!N6_[&EKJO#W)=X?U*@<64Z1<.!J+O=S>NO-\PV:IBS;_40FH&
M#_;G3)JGS8_!7-O?0&F'VU^2^5D6:U@#VJ(5I@X'L\F9*.ROL]@_RGS'OXB"
MPA>-&G_<*(D=T@!\O\JQ2?<'+=#\1,Z;?P%02P,$%     @ ;7YI4;4PW0B>
M"   ;1D  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULM5E;;]LX%OXK
MA+>[,P.HMB1?TR8!DK2#[0"=!DT[^[#8!UJB;:*2J))4+OOKYSND)%NV[&2Z
MV(?8,LESSG?NA\KY@]+?S$8(RQ[SK# 7@XVUY9O1R"0;D7,S5*4HL+-2.N<6
M/_5Z9$HM>.J(\FP4A^%LE'-9#"[/W=JMOCQ7E<UD(6XU,U6><_UT+3+U<#&(
M!LW"9[G>6%H879Z7?"WNA/U:WFK\&K5<4IF+PDA5,"U6%X.KZ,WUA,Z[ W](
M\6!VGAEILE3J&_WXD%X,0@(D,I%8XL#Q=2]N1)81(\#X7O,<M"*)</>YX?ZK
MTQVZ++D1-RK[ETSMYF*P&+!4K'B5V<_JX9^BUF=*_!*5&??)'OS9\7S DLI8
ME=?$0)#+PG_SQ]H..P2+\ A!7!/$#K<7Y%"^XY9?GFOUP#2=!C=Z<*HZ:H"3
M!3GESFKL2M#9RSNKDF\;E:5"FY_8^^^5M$_G(PO.M#]*:B[7GDM\A,L9^Z@*
MNS'L?9&*M$L_ J(65MS NHY/,KP3Y9"-PX#%81R>X#=NU1P[?N._H";[75G!
M_GVU-%8C./YS0LRD%3-Q8B;_HS5?SN4??UO$T?QM _G+1K"5RI!*LE@S:1AO
MTHFI%;/8O5%YR8NGG[!5V8W2\K\B9;Q(<=A4>$Q4GE,V8 59O!):8]&01,8-
M,8'IK<B70K?V=X??B:1>C6@U.GO#/E766.P1%$][M17YP8OKX7; B3 3)J=W
MP$JNV3W/*L%>A<,PC%B)LV;#M6"S, Q"_\>BV3R8QHM@,IYVG\,H&,^B(!Q/
M(%U+8=@-NVU5?5X(2,^B^O.,Q>-]8O:A8+]5A7#:!"R:>#JSYX':<V8+8M_>
M#P+2$E7<"VVQ* NK8&K&UVLMUARQ"8;3()K,GQ%0N]0Q'7:,25 _\B>R\B+8
MI66BL$*W0MD=S\#_"H(%*JY%$;(;PH(R;F0J6)GQQ.^@4N/S9^)% .+P[6V[
M=T5[;C5Z^PL#8U3?; >\M%VPM9A6W[56QL!,*A$B=11526Q>12&<A/*79:CD
M 5MIE3.+WD";]$VZ:56M'>8:%K>O ?(U<N.;:$ QX=-(K> ("EO(6FN>LPIU
M2[.'C4PVSDQ[.J&U5%E*+80"W3AC.4,,V;O*,2*BE=3&LN\5ASLUH?<!LFMV
MRJ0^_GON\)SHL!$($$C&V=2=)XW!8-]ASB&#6RV5WM\;.%?((D'3-L)1\UQ5
M( +$CCOLAELTER>V%,R@_M1FZ9/G7-#UB_-4/-U9&;(KY\6/7,.N/MUKBR#R
M'V#*0J&ST^Q -DQXR1-RSU9LKT)#]JE@5Z66&1L'/V[D B-#OQE_/]P9O"B>
M#Y$Y,)2"4=P'=24S0858F1)C2H78JLHR<Q*1")4V%=_ZO <6FH$WE(MH'S$X
MT8#KU (Z^GRN[1>@?8]^;7W3 Z>KG!& 0 LHM@A@&-^T>!N4WI@!A6=6I4TF
M%95K$.T^ 4-,^A;FA;CT1]&6*F6IST&?OG5V(L TLET8*JV>/.<I*D4F<VFY
M&PDI9GNE[>>!I(:)LH&BCUG!P4RY#S1:QUPF\RJ'-64B0(3VW %#K IE&PQ#
MU\;[O EWW*/<U@CZ8A@M'U_29EXK1!_&<^/5(=N2UXW0]P!B/.PFV6$,GA&-
M]_-X&/Z]:2A[L>#+:^TDLV,79XNFTO:AJTX%AU>["8Z-SWZUS.3:PV_RRX6.
M%WB27^#LG_C*;!V9"PI3(9DH$50FD\;5=-3ER#-,.P4=J@JXS(^V@D;;OE*V
MC7<RSV2,CKT(SJ;QJ4+Q;(7[TIK?30D4-DY)_*1[!LUT&!O0@^J@HTR=#,_B
M[1P3(/X-[B9N4-Q-ZD+83MZ_BL/%,/Z_U^S3=G4#53,B]I@5Y3.<1$$T7[S,
MK$?C[Z\:-0J'\>Q'K!K%T7"^M>H7;S_Z@ %W$RH]:9B> ?H9+:^.C/%=JU)-
M<NG6C%CQ;#AI6SE4.VP06\-W^LI).*AY*$LHW<T,M?1U66I?P*@!UKVXMPOZ
M$=%-(.]OMB4B326E-6^[\0MZY;#&^ZDD4N-*PF?T![C:MK/]UX*":K]0<1]?
MK^G^3]T@H1I\[\;BPIL5$_:,?<H+N03\#^T!%,B"_4P<<N].P$L1+IYHX*BZ
MIP>_!!UEMC/IKN<PM&+;![WR^KC(;)2I+W0/7*=]&Y73TM5$RNN.=IZ(*0IX
MI3%$"YTCS<UF1^_Z#.")O,S4DZ 6GL*GB57:U'6YH#P!3.,3KT=75TYP7UQ+
M>#)#/RVI 0+#\FGO+FMVKL34MMU$Y4:L:!;4??AP2";W',R^!]V>WW.9\64F
M? ,U9/K$E[I]0'TP%OX2ZY7,^:.;! Z$O.#J=@P( /CT<IZH&?59LQDSQ".E
M+,.5K[DK-U-6/5^D?KX@X:)(W.C49)F_>2"(92&0_C3E0*+@B,$$Z52DN#<_
M"7PL!;SF6L!OO*CH!43;*DR%TT<M@2]D,$USM5><=>,]K =WDZK("% W+*X5
MXI".OFMC+Z4Y,R?TI"YU(@1 "]$/P=14JGV-@DZD='2H)RC Q-5,H(;W^%<[
MT^\'VQX':C90GD X 237W1D.;&A/!=/N-'S$C&@#]E@/:/K008 <&!UKF"7!
MNA.058D#XE'H1!I_U=@O#*X\U>^=/-AV!5>6RE:03F5P=QCKB>A32NS4YY3-
M@OEB&LS#^3%%NJE5(_!%]"0"" RFBUEP%DT[,VGV1)&O=EZ +2MB=>_O&Z<*
M;MU]=FEA(I3\9$-1,PT6\T40=\;'(S-.K\6H"O5XX4<-P##78R2BZDRZ-<6(
MQA0*7J_3AI/KVWA%Z7=O5-U]HZE9HO $QYN!SUL7%8ADLA>MU'66AM$SY_[9
ML.]%[6CG%7@N]-J]Z*?ZBK3S;\/;U?9_"5?^%?KVN/]'!(2AM!F6B15(P^%\
M.F#:O]SW/ZPJW0OUI;)6Y>YQ(S!+:CJ _952MOE! MK_L%S^"5!+ P04
M" !M?FE11"R^"0L'  !L%0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6R]6&UOX[@1_BN$>R@20&OKQ9*M- F0[.[A%KA+@\NU]Z'H!UJB8S:2Z",I
M.^FO[S/42V3'3K*'[7Y(+%J<X3,SS[R8YUNE'\Q*",L>RZ(R%Z.5M>NSR<1D
M*U%R,U9K4>'-4NF26RSU_<2LM>"Y$RJ+2>C[R:3DLAI=GKOO;O7EN:IM(2MQ
MJYFIRY+KIVM1J.W%*!AU7_PJ[U>6OIA<GJ_YO;@3]A_K6XW5I->2RU)41JJ*
M:;&\&%T%9]=3VN\V_%.*K1D\,[)DH=0#+;[D%R.? (E"9)8T<'QLQ$=1%*0(
M,/YH=8[Z(TEP^-QI_]'9#EL6W(B/JOA=YG9U,9J/6"Z6O"[LKVK[DVCMB4E?
MI@KC_K-MLS?R1RRKC55E*PP$I:R:3_[8^F$@,#\F$+8"H</='.10?N*67YYK
MM66:=D,;/3A3G33 R8J"<F<UWDK(V<L;Q/U+E:E2L).?E3&G[%9H=K?B6IQ/
M+ Z@;9.L57;=* N/*$O9+ZJR*\,^5[G(=^4G -:C"SMTU^&K"N_$>LPBWV.A
M'_JOZ(MZ:R.G+SJB[S/7E:SNS;.1[%]7"V,UR/'O5_1/>_U3IW_Z;;SYJC)*
MQS.SYIFX&"'?C- ;,7KM!';-C<Q8A1VRW5&X'6OL,&Z'- POUK45.5L\L5QN
M9 Y_,+L2!^20\NX-Y*5R K3:.J)# =\(C;QE55TN<():-H<8>H*:$CD'^F8/
M#+7 6%ZYD_):=P<V:L?LDRP<H+> \R*K"TX[)65SIG3.JPR I%TYA195R=3Z
MJ3VV%'8%V)T50Q0MKC45!L/P)>H+6" STMZ\K"MINU?+0K ,*X=:65%9R0MX
M#[BILM@5MR@^=9$SE66U9A*N$'B05I([X!M(:CBE<DR#(@6+3"UV_;05L%0\
M"IU) QS*2<#)! H2P[UC]ANP- @V<$\)GEAR_+ZE-X#;F'&MJMPTQ_:Q_ @R
M\.J)G>32H-B8QK<DP])3MN*&+82H"(:1.=#EK#9=^$9R^:''-VJ]W>#J0D7.
M :;\'0'6XH]:$GG(F1Z92V>(1W*V>^S8AM;Q #UK!$MT!M<H-[IX<I%M*-@%
M78NUTI9>M"06CYD0N6FU-Z[>5=:QH@_;()3D1T<"G%&7(G]60>ROL]7.9CV(
M$ QZS?S=5/-P$./Y?U#^2V>_.I*A=1LQN^=TI$OK4,<<+4I%&&C7BE?P(F26
M7&JVX45]$/Q2J[(Y%'9J;H%O%^.8_2P?Q!:V'T&;BTJA83G1%WB6U)7;"#4Y
MW7NJB:!'201JCMF/[;$HW(A^TU\$]1>&[F"%JSU=B_"H0Z,&4IR&K"-O#;Q-
M?Z32\)+0-VS@9C^D%'IK"^&L(A]]3=78J17%T[Y]+A'Y H6E7JNJ3733)@S)
M[B>NPPUE'SI%3:HM58&YRN4D:2,_0U<FBS;<2'!5 83I]#['TSEI&*0J*^K\
M,*'>E\5G@*2%V)D"#D0)_X*4W?1 ;EYHY!9N7=1MX?M2J8U4[!9'E&B'L![0
MP!#TP3$[V24H,H+P+]YJA:?L!Q:D7C +O"A*L#@)(\]/?2])HU-V]<QF4IJ+
MC%K+@;1!W9$;[N):2+Z0A;1/SK&RLH+8 3IA?H;H7_\R#X/P;S@'A\Z\,/9/
M!RX80._\?*Q4O, =>V$R\](I<'\:A//WXWVZZR1MNQZTBY,A(;[.GT$2>U$<
M>_'49VGJ^3XPS6/V>;D436OJ,^"YA>X"@1!2>)Z$+/)FI&(6[%ATP$FOU=1@
M-O6B6>)-_9 %?NC-@<B/DP-TZV6\7O$/S!\' ?G7'X?QZ>M"C7><2-B*(!@W
M5+#^1"JX8O4-,V"W^!'Q3X)I".^&WFPV<^MY -[/O& >_%^YWWV^RON]6OT&
MVN_ ^'W_!=.YE\3@53QEZ=P+?:+95Q%]WQ_O(/F>5XY@N'FQ<\AH\#)-3IN'
M>71Z<'='Y?V]!WI-^T->_A<6/5MZY#= ,R,W V[;9OH1XSW)/&Q&"Y'QVG0#
MF]2[?9&))A#=N&)=2WIC<'"\I5P\HYF88-\YV)\QM(#PKH$^Y^O?VQ$ F;FN
M-48JLS?)!RC1TVB.BI:B4(?I#$?J#8;,#W2#<'1NZ/B %A&BOL<IP+@!6Y*[
M,70NA=:]3.1%?LKFX$"RLZ]RDT,0>'Z4>O%L"K)X\3P&7R)V5=\CN1LKFKGB
M)1>SQC6#/5#EPZ#8[W?]IBQB'82N$<U0I\/$2^:)-TOB[T:5O93X\PQYSV3Y
MC0F2@A2^%TUG7TN1$*%,O#2(!R2Y%=K=SE5O"2<). ,6=%'\?NP:-O3W\RN$
MZC3$:#.G.$QQRAPSSZ%[FLG@!@R]Y=[=\]%E1UW9YC*L_[:_2KQJ;M">MS?W
MD+]P?2\1NT(L(>J/9_&(Z>9NKUE8M7;W:0MEK2K=XTIP=$/:@/=+!1>U"SJ@
MOV"]_!]02P,$%     @ ;7YI47(;'&Y0!P  F1<  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&ULU5A;<]NX%?XK&#7IMC,R)5&R+*>V9^SL;G<?LO7$
MF_:ATP>(A"34(,$ H!7MK^]W#DB)LB4[EYU.^R#Q=B[?N0.X6%MW[U=*!?&I
M,*6_[*U"J-X,!CY;J4+ZQ%:JQ)>%=84,>'3+@:^<DCDS%6:0#H?302%UV;NZ
MX'>W[NK"UL'H4MTZX>NBD&YSHXQ=7_9&O?;%>[U<!7HQN+JHY%+=J?"ANG5X
M&FREY+I0I=>V%$XM+GO7HS<W$Z)G@K]KM?:=>T&6S*V]IX>?\\O>D  IH[)
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M*DDG(:.ISN:Q4.! ";$( 'GD"^8?W6&H'?F04+DI <\>*4Z:;K#CH+SO]ZZ
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MG1&NT:T&3H6YW<J+Q-\WUN[<M5:4&7L!SP'I/\0:AP_I=KD*46];9H^W8X>
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M'TM<D#G( >P7WJ=A(0[V5^[+?P!02P,$%     @ ;7YI4<9V@E#=#   *20
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M^GA!I"UF(N)4VD14IN HNGCV*GSPV=:2HB@>R#=\G4198'<4U"%G @-=S[Q
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MG&!HXQ^FA#?>5/QCD*7QWA3\<H/,K"PMP/.5,;YY0P>TOPYZ]0=02P,$%
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M#,W&[T\2<-V8=0;9)K;VSA(/2MS6_#*A"PD<WULNM3?" <-;M_H%4$L#!!0
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M&,(P]OTKTU!2GEB!FX7VFN3>H)'%<8" 10Y*I84,<L7T!> Y$F_*/BX3=PF
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M\1X D*CGJ 7;\V&ZM#N-;/0#6)+BS';O<>/#-O\!:H0DD[ PC-\O3&.65<0
M>7B*K7OZAPO.? $T^T8^818#W+'2>=^!9/\>F0AL'6-L05D:B@K55(''6-#>
M/$2*X]CUOA=C QDD&L5[1.A)'$%0_7.\+*JX@? A2-S U-S L#&YXW(4%48T
MO[3M6PSP'0<[+ +XD C!(17&>7A$K5#PD*3:+?54BAO _@DEU.<.)Y*HW!\H
M8@L;%7;K(UA_FKT3E'##*.%&<6,"<1AN:8I4)4 ZFVA/!60@3&C[E<<>9-XK
MVKGQ#I<$.,@@DO10,?9)3C2GK>&T$4P93ARH46+7:K<C>)/$4T21HVW,$XI[
M VIO*UJ9KTE0O6Y4P^!M9\7QTZ@+[W6E-QAH<)@7I>+J0\!P$(F0*"-E7\?5
M61QY941T4U,T3&66B>GC',+^@!K'2*-(@E 'O7722J<C),!R089<9]BW3QK=
M3;.?/.1\IV!MSGL=6K2P0HKR'Z>\8O%S8\#U=-P_G:4F:I_-I#@Z'&<@(UGR
M!3?,)QM6:"!-RFL!+44!"[N98</T/E;IG=:T-Q9<:%U]HGHQ#\+VAI)GXY6_
M)(GHE1JKSK"K=U10P+00M2>).7/.%A59@< ^9 <YB7OIC;?.,]W[")PK2JQ%
MK6!C&5\)>^+2!8I62%%%&(BL\"VUS*8:CU,>W2F)72#P!0=>2XCJAU/$3G$"
M*\\HGJ0H-?'/QV 7%4'(V'+^XQ#FE<H(FHK]INN1'%-.G/1HX/[0)<3VK4EB
M!58VTY1>S:)"Q]#C3 9TG:>>*RZH8Y1$#">PWU.I*V@5-7_NO!OR8+";J$$=
M\6DH.*IBOC?WEK9_3#ZQA,L"%!7ODKB,=D?Z3[EJV!7K\WZ;%JI8>Z1Q0^S^
M9"#!/N3T((_L0=XVTHVGVZ1MCYZD:?;>Q\*(M_*#3I9"Y'.N7_CX.2[&CUC!
MI VH1B]+1Z1PI(FO]P6)BU!EB348!<F\N::T6%!'=P/Q3TA 4I+%+X+W="@I
M^Q(L'AV]*]*$&0LOSRH7DA5@HP644A+C'JD/=#DK$"\<S& RH_:(H,G^HP 4
M,0BGB@X9&/_Y&2=,]U:)(Z 5BL-Z7+S,&<PREOXI'*?"!7<:#*SB(#UT+!_^
MW.?#GQ]-97^/W:6C=;V'O)=6\>)ZBG;U['6O#JP/MJJ355KU%1\5Y0=N^D5'
MA9 73Z_.GUT\G60_V^X<1CY_1YT&V6O,9X-HG=^;T4_X<N7Y<G5T?3\"3!Z6
M4IDO#WF/E!8W#P\:<#MUU!A.CQS0!>I_'SS+(//<+L\I.L,2N';*#Y\,O3[6
MMR+=>ZI34.9PA#0PSM6:<[&-,0'V:#"NYY>]B6'<DL=-3JVV%NIYE+V#AVQ3
M80PR,+;%+0L-ZM+MQN89=0*KAS6QC"RS-QY$"44+C;06X9KEO. ^)ZNA0?0,
M8'NL8)TK6=N\HFQWE+H;PNHH"17H(1D0"O=HPW-?BE*0;PH[86QSAXA^&SJ!
M>&QQ,/IYF_1I84:.FBVPB1!#)@K;J\]"K9;3?,O#7D^^%U)D3B2:Q'ORR<A%
M%'UA/0?%D@SU762T</+<*70,L_BC$]:72K[D /$T^ZAX?B!_43,:?3$RY3 9
MJSUQQZSJ"V\]7MQ3((PJF:^B./8USSYF5_ZY$=UX-UCH5*"&A#IO5T8#81+M
MHV77)4A(FNZ7KXF1F$EK[5;13FEJ<%  QBE3:6N[(B3RZN<Y&(NBX$PG_E5M
M-GU#P"C?:@]%^=/\)9V+.EX!=DHYR[9\YKL90;;$_7,0=F^A.I(30!5\-B_*
M?B'XSHNXI8CQ'(K[&D_6*@F3D+7H,"U 78R"K4.%+;POK6[Z^D,63C'G&O>/
M-B+N#W2ANN"%6#K<_.O2DNC3>4'GJR9T ]XK"C#7G:$,2?21#QFY!!QC8&UQ
M&SO:,AW4S&_Q^A1I*L3>5S=@JK=;H5O'MI]TQ_%,/",\$%>I(870&TV2[;2'
M-$B,'PJ;<VBA#9X$Y+2M'+Z5;(/K0%"2;>2.KW097&[#'<&S/YP0Y!-FD8%F
MAI/=2DDD$X@$0@0*3-.DK((IL(,K([6FL%7^>(AMAQR3;/XF+PW=,4$=Q<-G
M>,*T60=WPWGI(I'V>4>45O]M*I6Z0VEH4S513+#,"XUA5M1.4CD3BK(\+M!,
M1QH_-?:NF68_T#$?KGI.(M+(I#&V1N%F Q"ZA>5F 5K-<>WZ&JM%W&&39YOX
M&A!=2&L[BS?M<)DO92"R'<%478<V1<_;M!TX%V8-FIC^HOHY]&]'7-'L(ES7
M<W'4=7RD:%PH>]MTP!;J8Y^'7LKOK2TQ1SEZ)\^_;/3X:VWD;"DE!M'4[SX'
MOS95&^%&0&K+OL[0N3CJQO=!4G=G?<$G2+'WZ0FJHZLK/&A-JU.$Z;0'+U 3
M<F\IY-$TOV(>.C/)\2IE3?3Z!T_XTB<FXJ)MWC&@V0=.ZF\U\ X:W@W:_D)P
M3@?B,'*%@1H.%069]XC^Y@>.:PJ<V+O*H1L!$]7>[@V"5JXK V#G*T"B(_7S
M&YKH945G_[.?3$GZ\TN"%.3<MCRDQZ.B+O1 0 +P8@G@,V:49@I'B&5+Y40"
M^0'X]$^/IX_3 ]"/PTFXX2EF-/&*ZY.;3[Q(C7&'ZN!N4/S>Y)_,?27TZ$#0
MWN'=+^D03L)S[?\)QU8J^*9J?0/[_A(TJ])2]L=@\:/1KAKI=T;K%^YP*:H6
M^(XIS8(^H/M23 CU"@  )/ZA<8>.S&,@%IV]0AV^-8IC]GB@94/* >>M/\])
M1Z:(0MP0OSBEP[9RF((5([J))D*X^TR@\J;:$F^<Z0A)E&KB9 V)/P$+Z2M'
MP=[P\5E_<B.Y^P+<H95S73'%@7GE:/W8'^#R'/62R'62=!5TY-F;0.R>J>JH
MH@/DK+V3C3N=L8M>V:0GVJEW*\A0X&W"])3J!6*R6XF(]_G/"47?D$/6A$_D
M[TDD+M]\+@RWS.\_(4(RX,M$<65RR]9]2;IH0V3MVL _=NN =W.^)=F)5&+2
MFHU2,(YHKH(/2=T3U<#IMBU:L[Z9RE4T(47I")\E5Q'1[8_2YW0%#U=-?X9Y
M/?':+[9L.;^/G66DE:3@G&?UTJB:%IT43^:;9J^X[HV[M_+T!7J8SOTS@5)R
M_0?06'7BOU@UQNO[7/ BPJ4H!C:FH4WTQB9E:D7F0DL7?<,CU-QSD$NV+#5/
M<1Y=%\,6:8Q.27'P14!:[\+;3]BRH!TH6HOWF=A-543F *<I>P 9W%$?S$7
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MI=9L<^K)('GPMZ;BEN%1#<ZA.P\JY5YL)[XGG-<[Y/R2^?7PES]L$ @0$S)
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M&MJ\3JSIJ4-E'>A\+:79*S;!X?%<? =02P,$%     @ ;7YI4=FSO76H!
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M>%L!S^*N#5F4-TRSR4B*-9&&&[49PKIJI1$<+TQ2YEKB*4<Y/;EE7))O+*N
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M.5F'\H&]W- L("OA\UDHTM_@96/K."W@KX5D4096'D1!O/E+OF<;40(@N >
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MU[U7T2K]EB\:M[=$;&DF@>%&A_)N!WJ?HFB&BHGB._O:K[C2O8,=)KI_1&$
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M,9J,4 (KMLO45[[_'>H-^<9?S#-9_D?[>JT[0O%.*I[7QAI!GA;5+_M>)^+
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M 7Z%+0A".U+M-TS]]]5\T 0RZ$SINLA6H(A,B$Z9PAA2$#'A>(CA-TFP!LQ
M3# $+ ;IX49E=^A?,Z]<]5NRTT$8TG[_L.S#)L;A&V0/.K(=-4RC]Y5]W 0R
M_B^M/G[5R$/JV<]A1:GW?%1ZG0',99;A585G<O1 ?I-_=S9MG<+T?46FSR<;
M]3NS_))O01OKA,A=CGW<W< 7-5V[@_OCX<@;_26WV[JD["L%IKSFN28"$@1Z
MIT-D4-4M74V,W)3WUDH:O 7+88IO-J"L >XG4IK]Q%Z%S;O2[ ]02P,$%
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MU '!>UL(ZP#3=:?JNP$W(XI,)X(?D=!JR*8O#'T3#;Q8J8VR4 +>,HA3TW_
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M5NC,@B5."DXDP0)<A5C&)%.NUT!H1S$UI I-#V D51CW^S#0.V%8X NC<B-
M1%.<#OB'X_[!B+^A**EY06^\W*-1P"7>W@#+_!D@$YD#\2Q.=H?!T'1^;/3H
MPZ,?D&'5(K%*/.L=/)WZ="#ST6N2%8IOL.(L!PN6;PL9E^M?Z26*.25T+5J"
M^NNS @8/$N?B[Y&P[#HLNPS+/B4LT82%W\*Z(K12Y*<A2>[1G1)=;Z@O<XB@
M!ST/3HV7=J[[ALAU?==SG4/#<,#0=@(4V/ZA8=0WM$S;=WS+K0T/*'%J2IQ1
M2G[;:OH%D QL"YYLU!8*U.+.54K45I(\C[#NUD.XER0&KP[+.ZL8O+X88&!;
MG<0M^F9!X$$4>!TE#-BAP+3LCEUT'.^ #;]FPQ]E8XGY"TGPM:ZAJ2KH0G*2
M2/58J@ 4E$@Q0GI0#Q-<DA:@V50U\ZQJJ.#;>3$[2A@P06K_L)R@(X4A0\=W
M ]C9/:(3$ _I:!5Y.$J'8KK\IJ0?EP1$S6#HHD315#%HG5,4807?SH_K6I9C
M=?/8MS/?R6!3ZN!XK5LP^H*Y)$_J8TR="%:8\[?4C7'3U WH7%32FFH#W?.N
M9+=?:BTSZ"[FOI5O.VYW)9^"%1W#.B2BJ6]PO,"Y-X[Y$VCK8(DI81Q\95+Q
M$198?RW:X-\#&ZI?CB6BJ2C0ORB%-#4(!N=52#!0^DTK<#R[JY(!2]OQ';>[
M!80G8T:G8!Z>8)HBB(X4P6*M#I#E(0#<,YJ*_ZD-U-07!"])&ZBI10B=51L5
M_-AWP'&3\+A)-&!B>4%@MLXBAQ0T50^-5[T0)SA_4A1_7 =-E4+V1>F@*6]H
M_%STPSIP^JO4- /;Z:FA;]A3PXE8T2C6G@BC=?.38[XNK]R$.O(55.[/]W5O
M?:UW5UYF=?KOX>T"#O2'\#;:7]HU\/L[Q"\Q7Q-UU,SP2@UEWG@J3KZ_EMLW
M)-N6]TY/3$J6EX\;'*>8:P/U?L64[JJ&'J"^')W_!U!+ P04    " !M?FE1
M[B+HI'T&  #'(P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6S56EN/
MXC84_BL6ZDJ[4@=B.PEAQ2#-<-FNU'9',WMYJ/K@(0:L26*:&%BJ_OC:2<"!
M&(?9G;:4AQD"YSL^/I?O^(3T-SQ]RA:4"O UCI+LNK408OFVT\FF"QJ3K,V7
M-)'?S'@:$R$OTWDG6Z:4A#DHCCK(<?Q.3%C2&O3SS^[209^O1,02>I>";!7'
M)-W>THAOKENPM?O@GLT70GW0&?279$X?J/BTO$OE56>O)60Q33+&$Y#2V77K
M!KZ=N)X"Y!*?&=UDE?= ;>61\R=U\3Z\;CG*(AK1J5 JB/RWID,:14J3M../
M4FEKOZ8"5M_OM$_RS<O-/)*,#GGTA85B<=T*6B"D,[**Q#W?_$3+#>4&3GF4
MY7_!II1U6F"ZR@2/2["T(&9)\9]\+1U1 4#W! "5 '0$0/X) "X!^!B 3P#<
M$N">NX)7 KQC@'<"X)< /_=]X:S<TR,BR*"?\@U(E;34IM[DX<K1TL$L49GU
M(%+Y+9,X,7@0?/IT=2MC$X(ACV7"9B0/^>L1%81%V1MP!3X]C,#K'][T.T*N
MJ'"=::G]MM".3FB_6<W;  4_ N0@QP ?VN$/=-D&V#D)'YT-AST#?/Q]JT^^
M>?6.#-(^4F@?*93KPZ?T+4A*KQ[KD;I)4Y+,J2QW 1ZWH"IW1[;YQS<;DH;@
MMY^E2O!>T#C[W6(0WAN$<X-<:^H4"TTK!ID\76CR<TV*[-8#" .$W #W.^NJ
M3^N"0>!W ^CLY0YL=?>VNE9;/W)!(K!*4CKE\X3]>62RO,B$),J("/F-X%)R
M33/U/E.;!'RII#)3!KLU@WM=1[T.-S9NECO8F+??F&?=V!U-&0\!7],4;!9L
MNI#6O\16)0U%$7BDH*+F-4O EI(T,S'!V&XG*I  @9@G8I$!B$!(MIDE#_V]
M"WRKZB]Y]Y#V$>D$V0W!7-:#D-H%!3/"4K FT8KFUH<\BI052^FM3-6):2?#
M8KEN-5E1V^D=!G1DD&K[WE'4ZT)^NQL<Y7Q="+61.2VZ>Y]TF](B/W4DTQT5
MI#+(*9OJ0*\2)FSN#_9+!9?!2[V]0;W_J-9[=1;#CJG8SQ \V!IT=+MV_B?U
MWF#HKN!A4?# ;RIW6#FRP!<H^!]/I/SY1# J[3BL3/^H?,<&J5X;PE[U=53Q
M!@BN,LRA8_0) 2*K8]XI/Y2!RW=EC-RPU.)55C^5E_HL .V'@7N:R7#+="1)
M"$9T+4>695[BXZ\J%:DM\+J)0_<RJ ;J]@OM?>TFBO@T+ZVLLNA! 5*3!\I(
M>#6B0-! *".#8 ^A.O$8Y'QD4#@Q"'K0QE"Z&T-[.WY'$UF549X(-Z$<69BL
M0J+FQW-R03<XV+V07-"-$ ;_9"X$M:J$@3$7ZH)!X!ER(:B%V#4IG!@4VKN5
M[L30WHKEZ..#]_(0DN3QOXM(8IN$=!=$SF4$'^FFA.Q-J5"K6BM+YJJOJ#9M
M[Z -&G$!M5E7F1WMG<$0"/ 7>(%3(M(= N$+B9GN)\@^%?Y;!XG;TH[CD<(W
MUQ?2W0?9N\]Y#?^VU%(M<-_'V,,GUM=<CQJXWN0OHP5^?:ZW40S2?0#9)YWO
MRVPI^E'N8;J@X$-B:TQ(=P%T(?,0TC2,[#3\6;.2\I/,=&.,[$H\I^TXKVSW
MC31]XX;9X*5B]G'#;09I\L;P,F*&-6-C.V.?%[,&)<TQJ]SLLQ_PG]_?;ALT
MPAQJ,TX3.;83^3A>1GQ+:5:,'TP.L8);6R?6'(N]"\D-3;O83KO/N/,ZQ'7F
MQ3W3L=(@:#Q_CDV"T'0;9&*0#&Q#!M:LC^VL?R+@DAIRWX /IILXAVMI0L<7
M0NA8$SJV<_$]RYZN9BFE@,G^KV@2R!'+.%8T:'+:V'MEP(T:<+#=->+&C>OY
MK@DW:<"AMHMM1.;JYN/:FX\:0O.6LN:1C&/$Q-9X7]^N)?#JS%HXK@'HGP*.
M&X#=[@G@I G8U 1<W2==^TBR]UW$9BKW3!-*Z3Z[(F]W=]#9_1Z 7,,-PM*C
M=EW^&7<:2P^_G%&3,XUZQN\=KCX;N/:V/F)K%E))?%M&H]#H?KL"0T:4KOXV
MW/@;<9/GXPY=IH\OKOVP\:ODZUW3L"FL_*!X(?<B77U2<>W3X'..!:[ASF,W
MJ)\*3'*^:_AYLRX7!'6YB4&NZ[KU$T&G\DB#>L3E%Y+.69*!B,XDT)'=IP72
MXJF1XD+P9?Z4PR,7@L?YVP4E(4V5@/Q^QKG87:@')_;/[@S^!E!+ P04
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M+%T!)N4%GGR1]URN+[HD3.1X>.),?!H*/7[V2"/":0 >".,OX"LC24;RQLW
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M4I&N3%,(=HEKOU/I.>6)CM:3^T4\IBPOM;P+\^H3F11LR:OCP8%X7@L<@O]
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M#&_/:'1USPT3N7X#H(_K>W3UQYN%;\"*)?2WK>QM(TM'9->\ND8!_@M13/$
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MX01DDBI4Z@*ZUKEDC$[/",CS_=-.UF#H.X.3.IRVM)M=MML/AE7Y7*8_-7_
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M=202DB&E31E[:2(Q"E.SB5&OW^N-/(8(A_,9S]@=4RE8B8RK $X*%W##US"
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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MR*I19"U09"U09"W^4]9G:Y=_'#\\\];4W2&?#7\RFKT!4$L! A0#%     @
M;7YI40=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " !M?FE1>Y)QU>X    K @  $0
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M965T-"YX;6Q02P$"% ,4    " !M?FE1S>E[L>\-   25P  &
M    @('0(@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M;7YI48[?V>8S#   N#8  !@              ("!]3   'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &U^:5'5^2]26@@  $D2   8
M          " @5X]  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " !M?FE1O1:Z?YD,  #((@  &               @('N10  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ;7YI41HH"MUW%P  K4@
M !@              ("!O5(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( &U^:5'N)5Y4G0@  !X6   9              " @6IJ  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ ;7YI40VT[Q<2
M P   P<  !D              ("!/G,  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " !M?FE1%BFTW\$'  "%%0  &0
M@(&'=@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &U^
M:5%RRD<G"PL  &@A   9              " @7]^  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ ;7YI4?0 M24*!   >@D  !D
M         ("!P8D  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " !M?FE1<Z^S9FP3   N1P  &0              @($"C@  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( &U^:5&U,-T(G@@  &T9
M   9              " @:6A  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ ;7YI440LO@D+!P  ;!4  !D              ("!>JH
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !M?FE1<AL<
M;E '  "9%P  &0              @(&\L0  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( &U^:5'FS\:[\@P  /TG   9
M  " @4.Y  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M;7YI447W.L C!P  NQ$  !D              ("!;,8  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " !M?FE1WJFV %(2   $.@  &0
M            @('&S0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( &U^:5&DI1TC304  'X+   9              " @4_@  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ ;7YI4<9V@E#=#
M*20  !D              ("!T^4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " !M?FE1_XD 74 "  #W!   &0              @('G
M\@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &U^:5%X
MQYI/XR0  *%X   9              " @5[U  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ ;7YI43(87PEG P  2 <  !D
M     ("!>!H! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &U^:5$BT\;4; 4  #L0   9              "
M@8 N 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ ;7YI
M4<X9!<?. @  ]04  !D              ("!(S0! 'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " !M?FE15/&I#.D"  !?!@  &0
M        @($H-P$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( &U^:5&Y<;@_8@0  ) )   9              " @4@Z 0!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ;7YI46YY97TF!@  52$
M !D              ("!X3X! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " !M?FE130F.VY0"  "9!P  &0              @($^10$
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( &U^:5&Q=)HB
M8@,  !T,   9              " @0E( 0!X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ ;7YI49>A6OH^ P  G0H  !D
M ("!HDL! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !M
M?FE1?H)+!7H$  "B$P  &0              @($73P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &U^:5%2A0Q H0@  *1    9
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M970T-"YX;6Q02P$"% ,4    " !M?FE1^>"[)UL*   ?0   &0
M    @(&+:P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M &U^:5&_'6*53@,  )T*   9              " @1UV 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ ;7YI47"UU8A^!    Q<  !D
M             ("!HGD! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " !M?FE1ZU:PW?,"  !D"@  &0              @(%7?@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( &U^:5%;#^@=[ 4
M *X;   9              " @8&! 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ ;7YI4:@>0I-@!   >0\  !D              ("!
MI(<! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !M?FE1
M5I#?NW4$   H%0  &0              @($[C $ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( &U^:5'N(NBD?08  ,<C   9
M      " @>>0 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ ;7YI49'0;A>Y!@  !B   !D              ("!FY<! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !M?FE1GIY"S&0#  "P#
M&0              @(&+G@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    ( &U^:5$[[V%@9 ,  .$*   9              " @2:B 0!X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ ;7YI47_4V.;2
M"   9S0  !D              ("!P:4! 'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    " !M?FE1\Z/4F?,$  !/%P  &0
M@('*K@$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( &U^
M:5'#&_?ESP,  /4-   9              " @?2S 0!X;"]W;W)K<VAE971S
M+W-H965T-3@N>&UL4$L! A0#%     @ ;7YI4<R:@J<] P  4 P  !D
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M<R\N<F5L<U!+ 0(4 Q0    ( &U^:5%J;^NE"@4  "DI   /
M  "  6K( 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !M?FE1=TMQA08"
M  #Q)   &@              @ &AS0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " !M?FE1_R>G=>,!  !L)   $P
M@ '?SP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     1@!& "$3  #ST0$
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>396</ContextCount>
  <ElementCount>424</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/OrganizationandOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Critical Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CriticalAccountingPolicies</Role>
      <ShortName>Critical Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Impact of Recently Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards</Role>
      <ShortName>Impact of Recently Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108105 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110106 - Disclosure - Short-term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestments</Role>
      <ShortName>Short-term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114107 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119108 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123109 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128110 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2132111 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2139113 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2141114 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2145115 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2147116 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2148117 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2155118 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CriticalAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Short-term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsTables</Role>
      <ShortName>Short-term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2315302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2320303 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2324304 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2329305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2337307 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2342308 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2349309 - Disclosure - Geneos Therapeutics, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncTables</Role>
      <ShortName>Geneos Therapeutics, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GeneosTherapeuticsInc</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Critical Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CriticalAccountingPoliciesDetails</Role>
      <ShortName>Critical Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Short-term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails</Role>
      <ShortName>Short-term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - Convertible Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails</Role>
      <ShortName>Convertible Debt - Balance of Convertible Bonds and Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails</Role>
      <ShortName>Convertible Debt - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Net Income (Loss) Per Share - Schedule of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Schedule of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Net Income (Loss) Per Share - Schedule of Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Schedule of Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2438418 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2440419 - Disclosure - Related Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2443420 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2444421 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446422 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2450423 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2451424 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2452425 - Disclosure - Geneos Therapeutics, Inc. - Investment In Geneos (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Investment In Geneos (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2453426 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2454427 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ino-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2456428 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SubsequentEvents</ParentRole>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ino-20200930.htm">ino-20200930.htm</File>
    <File>ino-20200930.xsd</File>
    <File>ino-20200930_cal.xml</File>
    <File>ino-20200930_def.xml</File>
    <File>ino-20200930_lab.xml</File>
    <File>ino-20200930_pre.xml</File>
    <File>ino-93020x10qex311.htm</File>
    <File>ino-93020x10qex312.htm</File>
    <File>ino-93020x10qex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ino-20200930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ino-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 29,
   "contextCount": 396,
   "dts": {
    "calculationLink": {
     "local": [
      "ino-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ino-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 576,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 6,
    "http://www.inovio.com/20200930": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 12
   },
   "keyCustom": 68,
   "keyStandard": 356,
   "memberCustom": 37,
   "memberStandard": 40,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.inovio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Impact of Recently Issued Accounting Standards",
     "role": "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards",
     "shortName": "Impact of Recently Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108105 - Disclosure - Revenue Recognition",
     "role": "http://www.inovio.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110106 - Disclosure - Short-term Investments",
     "role": "http://www.inovio.com/role/ShorttermInvestments",
     "shortName": "Short-term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114107 - Disclosure - Fair Value Measurements",
     "role": "http://www.inovio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119108 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123109 - Disclosure - Convertible Debt",
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "shortName": "Convertible Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128110 - Disclosure - Stockholders' Equity",
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132111 - Disclosure - Net Income (Loss) Per Share",
     "role": "http://www.inovio.com/role/NetIncomeLossPerShare",
     "shortName": "Net Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136112 - Disclosure - Stock-Based Compensation",
     "role": "http://www.inovio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139113 - Disclosure - Related Party Transactions",
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141114 - Disclosure - Leases",
     "role": "http://www.inovio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145115 - Disclosure - Collaborative Agreements",
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147116 - Disclosure - Income Taxes",
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148117 - Disclosure - Geneos Therapeutics, Inc.",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "shortName": "Geneos Therapeutics, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155118 - Disclosure - Subsequent Events",
     "role": "http://www.inovio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Short-term Investments (Tables)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsTables",
     "shortName": "Short-term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320303 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324304 - Disclosure - Convertible Debt (Tables)",
     "role": "http://www.inovio.com/role/ConvertibleDebtTables",
     "shortName": "Convertible Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.inovio.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337307 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.inovio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342308 - Disclosure - Leases (Tables)",
     "role": "http://www.inovio.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349309 - Disclosure - Geneos Therapeutics, Inc. (Tables)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncTables",
     "shortName": "Geneos Therapeutics, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i40baaae65a1744768b1b1675f3ad79d0_D20200101-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Critical Accounting Policies (Details)",
     "role": "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
     "shortName": "Critical Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i6b8bbe68292646fc920d02bc015f8116_D20200101-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Revenue Recognition - Narrative (Details)",
     "role": "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Short-term Investments - Narrative (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails",
     "shortName": "Short-term Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails",
     "shortName": "Short-term Investments - Summary of Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i99efe129ba7f47c493d7948e3488435d_I20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i94285e36aedc4ac6936417abdd4e690c_I20200831",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i91e7c0f132e34c59bf93da3effb57556_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails",
     "shortName": "Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i91e7c0f132e34c59bf93da3effb57556_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - Convertible Debt - Narrative (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
     "shortName": "Convertible Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib3abdef29e774d82a089595d8b564e0f_I20190301",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:DebtInstrumentConvertibleDebtConvertedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
     "shortName": "Convertible Debt - Balance of Convertible Bonds and Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:DebtInstrumentConvertibleDebtConvertedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "iad00cc94b7054dba89db6de62bd2743e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Convertible Debt - Schedule of Maturities (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
     "shortName": "Convertible Debt - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "if2b79363a4154026a899e339e36624d9_I20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails",
     "shortName": "Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i4b4928fc44ae4021b15f75edc4b2c760_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i074731de2992483e840b846807d642f7_I20160513",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "iad543da68a144f83a4d3805ac1f6d89e_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i7c34cc69f8ff4a9e9279090d85e2ed1a_D20190101-20190331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Net Income (Loss) Per Share - Schedule of Diluted Net Loss Per Share (Details)",
     "role": "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails",
     "shortName": "Net Income (Loss) Per Share - Schedule of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Net Income (Loss) Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "role": "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
     "shortName": "Net Income (Loss) Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438418 - Disclosure - Stock-Based Compensation (Details)",
     "role": "http://www.inovio.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440419 - Disclosure - Related Party Transactions - Narrative (Details)",
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails",
     "shortName": "Related Party Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id846dd9c3ed6491e8bd1b652cf0299d3_D20200827-20200827",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443420 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.inovio.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444421 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)",
     "role": "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Summary of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446422 - Disclosure - Collaborative Agreements (Details)",
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ic81bd389069e417a984bce2bcd1d1063_D20171229-20171229",
      "decimals": null,
      "lang": "en-US",
      "name": "ino:CollaborationAgreementTerritoryExpansionOptionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450423 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
     "shortName": "Geneos Therapeutics, Inc. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i869d8bf326be4abfbb1e18a89a00961a_I20190228",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451424 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
     "shortName": "Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i0362d182781f4ee797f88622a5c045cf_I20200601",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:WorkingCapitalExcludingCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "id34815f9d2a14071b19c7de18cdedc2e_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452425 - Disclosure - Geneos Therapeutics, Inc. - Investment In Geneos (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
     "shortName": "Geneos Therapeutics, Inc. - Investment In Geneos (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i0362d182781f4ee797f88622a5c045cf_I20200601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i02a53eefc91548709afbca6ca797ff0d_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i0362d182781f4ee797f88622a5c045cf_I20200601",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ino:EquityMethodInvestmentEnterpriseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453426 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
     "shortName": "Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i0362d182781f4ee797f88622a5c045cf_I20200601",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ino:EquityMethodInvestmentEnterpriseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i91e7c0f132e34c59bf93da3effb57556_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454427 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
     "shortName": "Geneos Therapeutics, Inc. - Preferred stock Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib8a6a5f3412b4170b586cb0a191c2b65_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456428 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.inovio.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "i0df0aeb02416451db34b6235410d3492_D20201001-20201031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Operations",
     "role": "http://www.inovio.com/role/OrganizationandOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Critical Accounting Policies",
     "role": "http://www.inovio.com/role/CriticalAccountingPolicies",
     "shortName": "Critical Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20200930.htm",
      "contextRef": "ib63f54fb66ec4dd69dc581b5de38ecd5_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 84,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ino_A2007IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2007 Incentive Plan [Member]",
        "label": "2007 Incentive Plan [Member]",
        "terseLabel": "2007 Incentive Plan"
       }
      }
     },
     "localname": "A2007IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A2016IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2016 Incentive Plan [Member]",
        "label": "2016 Incentive Plan [Member]",
        "terseLabel": "2016 Incentive Plan"
       }
      }
     },
     "localname": "A2016IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "terseLabel": "6.50% Convertible Senior Notes Due 2024"
       }
      }
     },
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Clinical Trial Expense, Current",
        "label": "Accrued Clinical Trial Expense, Current",
        "verboseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_AfterJuly22020ConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "After July 2, 2020 Conversion Price [Member]",
        "label": "After July 2, 2020 Conversion Price [Member]",
        "terseLabel": "After July 2, 2020 Conversion Price"
       }
      }
     },
     "localname": "AfterJuly22020ConversionPriceMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AlternativeInvestmentMeasurementInputTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alternative Investment, Measurement Input, Term",
        "label": "Alternative Investment, Measurement Input, Term",
        "terseLabel": "Equity method investment, measurement input, expected term"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInputTerm",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ApolloBioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ApolloBio [Member]",
        "label": "ApolloBio [Member]",
        "terseLabel": "ApolloBio"
       }
      }
     },
     "localname": "ApolloBioMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_August2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "August 2019 Convertible Bonds [Member]",
        "label": "August 2019 Convertible Bonds [Member]",
        "terseLabel": "August 2019 Bonds"
       }
      }
     },
     "localname": "August2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bill And Melinda Gates Foundation [Member]",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill And Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BiojectMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bioject [Member]",
        "label": "Bioject [Member]",
        "terseLabel": "Bioject"
       }
      }
     },
     "localname": "BiojectMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA2000DeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CELLECTRA 2000 Device [Member]",
        "label": "CELLECTRA 2000 Device [Member]",
        "terseLabel": "CELLECTRA 2000 Device"
       }
      }
     },
     "localname": "CELLECTRA2000DeviceMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA3PSPProprietarySmartDeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "label": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "terseLabel": "CELLECTRA 3PSP Proprietary Smart Device"
       }
      }
     },
     "localname": "CELLECTRA3PSPProprietarySmartDeviceMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.",
        "label": "Change in Value of Investments in Affiliated Company",
        "negatedLabel": "(Gain) loss on equity investment in affiliated entities",
        "verboseLabel": "Gain (loss) on investment in affiliated entities"
       }
      }
     },
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "terseLabel": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "terseLabel": "Additional revenue to be achieved"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones",
        "label": "Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones",
        "terseLabel": "Anticipated commercial event based payment receivable milestones"
       }
      }
     },
     "localname": "CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones",
        "label": "Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones",
        "terseLabel": "Anticipated development and regulatory event based payment receivable milestones"
       }
      }
     },
     "localname": "CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Royalty Period",
        "label": "Collaboration Agreement, Royalty Period",
        "terseLabel": "Royalty period"
       }
      }
     },
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborationAgreementTerritoryExpansionOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Territory Expansion Option Period",
        "label": "Collaboration Agreement, Territory Expansion Option Period",
        "terseLabel": "Territory expansion option period"
       }
      }
     },
     "localname": "CollaborationAgreementTerritoryExpansionOptionPeriod",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementAdvisoryFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Advisory Fees",
        "label": "Collaborative Agreement, Advisory Fees",
        "terseLabel": "Advisory fees"
       }
      }
     },
     "localname": "CollaborativeAgreementAdvisoryFees",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "terseLabel": "Awarded amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedAmount",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementCorporateIncomeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Corporate Income Tax",
        "label": "Collaborative Agreement, Corporate Income Tax",
        "terseLabel": "Foreign corporate income taxes reducing upfront payment"
       }
      }
     },
     "localname": "CollaborativeAgreementCorporateIncomeTax",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Expenses To Reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "terseLabel": "Expenses to reimburse"
       }
      }
     },
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementForeignNonIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Non-Income Taxes",
        "label": "Collaborative Agreement, Foreign Non-Income Taxes",
        "terseLabel": "Foreign non-corporate income taxes reducing upfront payment"
       }
      }
     },
     "localname": "CollaborativeAgreementForeignNonIncomeTaxes",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received",
        "label": "Collaborative Agreement, Funding Received",
        "verboseLabel": "Funding received for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingReceived",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received for Research and Development",
        "label": "Collaborative Agreement, Funding To Be Received",
        "terseLabel": "Collaborative agreement, funding to be received"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "label": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "terseLabel": "Number of days written notice before termination"
       }
      }
     },
     "localname": "CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Period From Effective Date For Termination",
        "label": "Collaborative Agreement, Period From Effective Date For Termination",
        "terseLabel": "Period from effective date for termination"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodFromEffectiveDateForTermination",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "terseLabel": "Collaborative agreement, period to receive funding for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementsUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreements, Upfront Payment Received",
        "label": "Collaborative Agreements, Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementFixedPriceContractAmountAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "label": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "terseLabel": "Purchase price, procurement contract"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPriceContractAmountAwarded",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.",
        "label": "Contract With Customer, Liability, Affiliated Entity, Current",
        "verboseLabel": "Deferred revenue from affiliated entities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAffiliatedEntityCurrent",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible Bonds [Member]",
        "label": "Convertible Bonds [Member]",
        "terseLabel": "Convertible bonds"
       }
      }
     },
     "localname": "ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "label": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "terseLabel": "DNA-Encoded Monoclonal Antibody Technology"
       }
      }
     },
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DebtInstrumentAccretionOfPremium": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Accretion Of Premium",
        "label": "Debt Instrument, Accretion Of Premium",
        "terseLabel": "Accretion of premium associated with the December 2019 Bonds"
       }
      }
     },
     "localname": "DebtInstrumentAccretionOfPremium",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtInstrumentAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Accrued Interest",
        "label": "Debt Instrument, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtInstrumentAccruedInterest",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtInstrumentConvertibleDebtConvertedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Converted Amount",
        "label": "Debt Instrument, Convertible Debt, Converted Amount",
        "negatedTerseLabel": "Principal amount converted into common shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtConvertedAmount",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtInstrumentConvertibleInternalRateOfReturn": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Internal Rate Of Return",
        "label": "Debt Instrument, Convertible, Internal Rate Of Return",
        "terseLabel": "Debt instrument, convertible, internal rate of return"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleInternalRateOfReturn",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Required Bondholder Approval, Percentage",
        "label": "Debt Instrument, Convertible, Required Bondholder Approval, Percentage",
        "terseLabel": "Debt instrument, convertible, required bondholder approval, percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRequiredBondholderApprovalPercentage",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale contractual maturity.",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "terseLabel": "Contractual maturity (less than)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_December2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "December 2019 Convertible Bonds [Member]",
        "label": "December 2019 Convertible Bonds [Member]",
        "terseLabel": "December 2019 Bonds"
       }
      }
     },
     "localname": "December2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Grant Funding, Current",
        "label": "Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate",
        "label": "Deferred Grant Funding, From Affiliate",
        "terseLabel": "Deferred grant funding, from affiliate"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliate",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Current",
        "label": "Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Noncurrent",
        "label": "Deferred Grant Funding, From Affiliate, Noncurrent",
        "terseLabel": "Grant funding liability from affiliated entity, net of current portion"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateNoncurrent",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DepartmentOfDefenceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Department Of Defence [Member]",
        "label": "Department Of Defence [Member]",
        "terseLabel": "Department of Defence"
       }
      }
     },
     "localname": "DepartmentOfDefenceMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employees and Directors [Member]",
        "label": "Employees and Directors [Member]",
        "terseLabel": "Employees and Directors"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EquityMethodInvestmentEnterpriseValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Enterprise Value",
        "label": "Equity Method Investment, Enterprise Value",
        "verboseLabel": "Geneos enterprise value"
       }
      }
     },
     "localname": "EquityMethodInvestmentEnterpriseValue",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Estimated aggregate amortization expense for 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GeneOneLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "GeneOne Life Sciences [Member]",
        "label": "GeneOne Life Sciences [Member]",
        "terseLabel": "GeneOne Life Sciences"
       }
      }
     },
     "localname": "GeneOneLifeSciencesMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Geneos Therapeutics, Inc. [Member]",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "GeneosTherapeuticsInc.Member",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GoodwillAndIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Goodwill and intangible assets gross.",
        "label": "Goodwill and Intangible Assets Gross",
        "totalLabel": "Total goodwill and intangible assets, gross"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGross",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GoodwillAndIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Goodwill and intangible assets net.",
        "label": "Goodwill and Intangible Assets Net",
        "totalLabel": "Total goodwill and intangible assets, net book value"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsNet",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GrantPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant Policy [Policy Text Block]",
        "label": "Grant Policy [Policy Text Block]",
        "terseLabel": "Grants"
       }
      }
     },
     "localname": "GrantPolicyPolicyTextBlock",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_GrantProceedsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant Proceeds Received",
        "label": "Grant Proceeds Received",
        "terseLabel": "Contra-research and development expense"
       }
      }
     },
     "localname": "GrantProceedsReceived",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_INO4800Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "INO-4800 [Member]",
        "label": "INO-4800 [Member]",
        "terseLabel": "INO-4800"
       }
      }
     },
     "localname": "INO4800Member",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.",
        "label": "Increase Decrease in Deferred Revenue From Related Parties",
        "verboseLabel": "Deferred revenue from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenueFromRelatedParties",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "terseLabel": "Operating lease right-of-use assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.",
        "label": "Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "negatedLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_InitialConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial Conversion Price [Member]",
        "label": "Initial Conversion Price [Member]",
        "terseLabel": "Initial Conversion Price"
       }
      }
     },
     "localname": "InitialConversionPriceMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_InovioAsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inovio AS.",
        "label": "Inovio As [Member]",
        "verboseLabel": "Inovio AS"
       }
      }
     },
     "localname": "InovioAsMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest Income Accrued On Short Term Investments Certificates Of Deposit",
        "label": "Interest Income Accrued On Short Term Investments Certificates Of Deposit",
        "terseLabel": "Amortization of premiums on investments"
       }
      }
     },
     "localname": "InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_InvestmentOwnedAdditionalSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment Owned, Additional Shares Acquired",
        "label": "Investment Owned, Additional Shares Acquired",
        "terseLabel": "Investment owned, additional shares acquired (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedAdditionalSharesAcquired",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_LassaFeverAndMERSVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lassa Fever And MERS Vaccine [Member]",
        "label": "Lassa Fever And MERS Vaccine [Member]",
        "terseLabel": "Lassa Fever And MERS Vaccine"
       }
      }
     },
     "localname": "LassaFeverAndMERSVaccineMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "terseLabel": "Area leased (in square feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_LicensewithAffiliatedEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License with Affiliated Entities [Member]",
        "label": "License with Affiliated Entities [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements with affiliated entities"
       }
      }
     },
     "localname": "LicensewithAffiliatedEntitiesMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Marketable securities and fair value measurements.",
        "label": "Marketable Securities and Fair Value Measurements (Textual) [Abstract]",
        "verboseLabel": "Marketable Securities and Fair Value Measurements (Textual) [Abstract]"
       }
      }
     },
     "localname": "MarketableSecuritiesAndFairValueMeasurementsTextualAbstract",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_MilestoneBasedOwnershipTarget": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone-Based Ownership Target",
        "label": "Milestone-Based Ownership Target",
        "terseLabel": "Milestone-based ownership target"
       }
      }
     },
     "localname": "MilestoneBasedOwnershipTarget",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_MutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mutual funds.",
        "label": "Mutual Funds [Member]",
        "terseLabel": "Mutual funds",
        "verboseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundsMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NewSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New Sales Agreement [Member]",
        "label": "New Sales Agreement [Member]",
        "terseLabel": "New Sales Agreement"
       }
      }
     },
     "localname": "NewSalesAgreementMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-Cash Interest Expense",
        "label": "Non-Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_NonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non employee.",
        "label": "Non Employee [Member]",
        "terseLabel": "Non Employee"
       }
      }
     },
     "localname": "NonEmployeeMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NumberOfAdditionalProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Additional Products",
        "label": "Number Of Additional Products",
        "terseLabel": "Number of additional products to be developed"
       }
      }
     },
     "localname": "NumberOfAdditionalProducts",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of potential shares authorized for issuance under a share-based compensation plan.",
        "label": "Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan",
        "terseLabel": "Number of potential shares authorized for issuance under share based compensation plan (in shares)"
       }
      }
     },
     "localname": "NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_OperatingLeaseNonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Non-Cash Lease Expense",
        "label": "Operating Lease, Non-Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseNonCashLeaseExpense",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OtherCounterpartyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Counterparty [Member]",
        "label": "Other Counterparty [Member]",
        "terseLabel": "Other Counterparty"
       }
      }
     },
     "localname": "OtherCounterpartyMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlumblineLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plumbline Life Sciences [Member]",
        "label": "Plumbline Life Sciences [Member]",
        "terseLabel": "Plumbline Life Sciences"
       }
      }
     },
     "localname": "PlumblineLifeSciencesMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plymouth Meeting, Pennsylvania [Member]",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "terseLabel": "Plymouth Meeting, Pennsylvania"
       }
      }
     },
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.",
        "label": "Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "verboseLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_PriorSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prior Sales Agreement [Member]",
        "label": "Prior Sales Agreement [Member]",
        "verboseLabel": "Prior Sales Agreement"
       }
      }
     },
     "localname": "PriorSalesAgreementMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ProceedsFromCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Collaborative Agreement",
        "label": "Proceeds From Collaborative Agreement",
        "terseLabel": "Proceeds received in upfront payment"
       }
      }
     },
     "localname": "ProceedsFromCollaborativeAgreement",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_RelatedPartyTransactionsTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related party transactions.",
        "label": "Related Party Transactions (Textual) [Abstract]",
        "verboseLabel": "Related-Party Transactions (Textual) [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsTextualAbstract",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_SARSCoV2COVID19VaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SARS-CoV-2/COVID-19 Vaccine [Member]",
        "label": "SARS-CoV-2/COVID-19 Vaccine [Member]",
        "terseLabel": "SARS-CoV-2/COVID-19 Vaccine"
       }
      }
     },
     "localname": "SARSCoV2COVID19VaccineMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SalesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Agreements [Member]",
        "label": "Sales Agreements [Member]",
        "terseLabel": "Sales Agreements"
       }
      }
     },
     "localname": "SalesAgreementsMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SanDiegoOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "San Diego Office [Member]",
        "label": "San Diego Office [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "SanDiegoOfficeMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ServiceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service-Based Restricted Stock Units",
        "label": "Service-Based Restricted Stock Units [Member]",
        "verboseLabel": "Service-based restricted stock units"
       }
      }
     },
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "label": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "negatedLabel": "Settlement of receivable with shares of common stock from affiliated entity (PLS)"
       }
      }
     },
     "localname": "SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value",
        "terseLabel": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award maximum contractual term.",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "terseLabel": "Maximum contractual term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "terseLabel": "Increase in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "label": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "terseLabel": "Stock purchase agreement, commitment of additional investment"
       }
      }
     },
     "localname": "StockPurchaseAgreementCommitmentOfAdditionalInvestment",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "terseLabel": "Aggregate number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "terseLabel": "Aggregate proceeds"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Sale Agreement Weighted Average Price Per Share",
        "label": "Stock Sale Agreement, Weighted Average Price Per Share",
        "terseLabel": "Stock sale agreement weighted average price per share"
       }
      }
     },
     "localname": "StockSaleAgreementWeightedAveragePricePerShare",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ino_StockSalesAgreementAgentFee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Sales Agreement, Agent Fee",
        "label": "Stock Sales Agreement, Agent Fee",
        "terseLabel": "Agent fee"
       }
      }
     },
     "localname": "StockSalesAgreementAgentFee",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "terseLabel": "Maximum authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSalesAgreementRemainingAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Sales Agreement, Remaining Authorized Amount",
        "label": "Stock Sales Agreement, Remaining Authorized Amount",
        "terseLabel": "Remaining authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementRemainingAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Benefit From Unrealized Gains (Losses) On Short-Term Investments",
        "label": "Tax Benefit From Unrealized Gains (Losses) On Short-Term Investments",
        "terseLabel": "Tax benefit from other unrealized gains on short-term investments"
       }
      }
     },
     "localname": "TaxBenefitFromUnrealizedGainsLossesOnShortTermInvestments",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_VGXAnimalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VGX Animal Health, Inc [Member]",
        "label": "VGX Animal Health, Inc [Member]",
        "terseLabel": "VGX Animal Health, Inc"
       }
      }
     },
     "localname": "VGXAnimalHealthIncMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_VgxPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VGX pharmaceuticals.",
        "label": "VGX Pharmaceuticals [Member]",
        "verboseLabel": "VGX"
       }
      }
     },
     "localname": "VgxPharmaceuticalsMember",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_WorkingCapitalExcludingCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Working Capital, Excluding Cash",
        "label": "Working Capital, Excluding Cash",
        "negatedTerseLabel": "Working capital (excluding cash)"
       }
      }
     },
     "localname": "WorkingCapitalExcludingCash",
     "nsuri": "http://www.inovio.com/20200930",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r44",
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r311",
      "r313",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r500",
      "r567",
      "r569"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r311",
      "r313",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r500",
      "r567",
      "r569"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r173",
      "r284",
      "r288",
      "r501",
      "r566",
      "r568"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r173",
      "r284",
      "r288",
      "r501",
      "r566",
      "r568"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r300",
      "r311",
      "r313",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r500",
      "r567",
      "r569"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r300",
      "r311",
      "r313",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r500",
      "r567",
      "r569"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r176",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual with Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r476",
      "r478",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r16",
      "r177",
      "r178"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r15",
      "r101",
      "r461",
      "r464",
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r39",
      "r106",
      "r461",
      "r464"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r48",
      "r49",
      "r50",
      "r551",
      "r577",
      "r581"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r111",
      "r112",
      "r113",
      "r392",
      "r572",
      "r573"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r343"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r339",
      "r340",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of issuance of convertible notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r314",
      "r316",
      "r346",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r316",
      "r331",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Equity method investment, measurement input"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r87",
      "r224",
      "r231"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense on intangible assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r99",
      "r161",
      "r165",
      "r171",
      "r197",
      "r386",
      "r397",
      "r427",
      "r524",
      "r549"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r41",
      "r99",
      "r197",
      "r386",
      "r397",
      "r427"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "verboseLabel": "Gross\u00a0Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross\u00a0Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r182",
      "r212"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "verboseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r180",
      "r183",
      "r212",
      "r531"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair\u00a0Market\u00a0Value",
        "verboseLabel": "Debt securities, available for sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r318",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r310",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r310",
      "r312",
      "r371",
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r110",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Basis of Presentation, Liquidity and Risks and Uncertainties"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Capital": {
     "auth_ref": [
      "r546",
      "r587",
      "r588"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of total capital as defined by regulatory framework.",
        "label": "Banking Regulation, Total Capital, Actual",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "Capital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r25",
      "r89"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r82",
      "r89",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r82",
      "r432"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (Decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "negatedTerseLabel": "Decrease in cash resulting from the deconsolidation of Geneos",
        "terseLabel": "Decrease in cash resulting from the deconsolidation of Geneos"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r97",
      "r99",
      "r136",
      "r137",
      "r138",
      "r141",
      "r143",
      "r151",
      "r152",
      "r153",
      "r197",
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]",
        "verboseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r374",
      "r375",
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Product"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "terseLabel": "Common stock, other shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r62",
      "r537",
      "r562"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r55",
      "r61",
      "r382",
      "r383",
      "r403",
      "r536",
      "r561"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r55",
      "r60",
      "r381",
      "r403",
      "r535",
      "r560"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r95",
      "r396",
      "r399",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities (VIE)"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r265",
      "r266",
      "r285"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r265",
      "r266",
      "r285"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of stock, shares converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r11",
      "r526",
      "r550"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r301",
      "r309",
      "r582"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r91",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]",
        "terseLabel": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r91",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument principal amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r91",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion, converted instrument, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r91",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Name [Domain]",
        "terseLabel": "Debt Conversion, Name [Domain]"
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r8",
      "r10",
      "r11",
      "r525",
      "r526",
      "r547"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r33",
      "r255",
      "r258",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r443",
      "r445"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of date conversion"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r32",
      "r245",
      "r443"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r34",
      "r104",
      "r255",
      "r259",
      "r260",
      "r261",
      "r442",
      "r443",
      "r445",
      "r545"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r442",
      "r445"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized debt discount",
        "terseLabel": "Debt instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position for more than twelve months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gain on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Realized loss on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r188",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedTerseLabel": "Gain on deconsolidation of Geneos",
        "terseLabel": "Gain on deconsolidation of Geneos",
        "verboseLabel": "Gain on deconsolidation of investment"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "terseLabel": "Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value"
       }
      }
     },
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r27",
      "r444"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt issuance cost",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r350",
      "r351"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r87",
      "r235"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r42",
      "r43",
      "r424"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "netLabel": "Derivative liability",
        "terseLabel": "Derivative liability",
        "verboseLabel": "Derivative liability (Note 9)"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r107",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities",
        "terseLabel": "Adjustment for decrease in fair value of derivative liability and interest expense"
       }
      }
     },
     "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r284",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r28",
      "r106",
      "r461"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r106",
      "r461",
      "r532",
      "r557"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Accounts payable/accrued liabilities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r63",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r134",
      "r136",
      "r141",
      "r142",
      "r143",
      "r147",
      "r148",
      "r538",
      "r563"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income (loss) per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income (loss) per share attributable to Inovio Pharmaceuticals, Inc. stockholders"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r63",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r136",
      "r141",
      "r142",
      "r143",
      "r147",
      "r148",
      "r538",
      "r563"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income (loss) per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "terseLabel": "Fair value of derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r118",
      "r128",
      "r130",
      "r150",
      "r202",
      "r254",
      "r262",
      "r339",
      "r340",
      "r341",
      "r359",
      "r360",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r26",
      "r162",
      "r195"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Investment in Geneos as of September 30, 2020",
        "periodStartLabel": "Investment in Geneos upon deconsolidation",
        "terseLabel": "Investment in Geneos",
        "verboseLabel": "Investment in equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "verboseLabel": "Investment in affiliated entities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "negatedTerseLabel": "Net unrealized gain on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r194",
      "r564"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized gain on available-for-sale equity securities",
        "verboseLabel": "Net unrealized gain (loss) on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.",
        "label": "Equity Securities without Readily Determinable Fair Value [Policy Text Block]",
        "terseLabel": "Equity Investments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r412",
      "r425",
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r413",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r412",
      "r413",
      "r415",
      "r416",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r301",
      "r302",
      "r307",
      "r309",
      "r413",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r301",
      "r302",
      "r307",
      "r309",
      "r413",
      "r474"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r413",
      "r475"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r417",
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of the Company's Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Derecognition of the derivative liability upon conversion"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r420",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r186",
      "r187",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r215",
      "r216",
      "r217",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated aggregate amortization expense for 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated aggregate amortization expense for remainder of 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Estimated aggregate amortization expense for 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "Estimated aggregate amortization expense for 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Estimated aggregate amortization expense for 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r230",
      "r233",
      "r502",
      "r509"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r230",
      "r509"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r225",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r230",
      "r502"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net book value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Indefinite lived:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Unrealized transaction loss on foreign-currency denominated debt"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r68",
      "r87",
      "r181"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Loss (gain) on short-term investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r87",
      "r247",
      "r248"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Gain (loss) on extinguishment of debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt",
        "verboseLabel": "Gain (loss) on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r218",
      "r219",
      "r523"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "totalLabel": "Goodwill, net book value",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r222",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Goodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "verboseLabel": "Goodwill, gross"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r105",
      "r161",
      "r164",
      "r167",
      "r170",
      "r172"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net income (loss) before income tax benefit and share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r58",
      "r87",
      "r159",
      "r195",
      "r533",
      "r558"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Share of net loss in Geneos",
        "terseLabel": "Share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r353",
      "r355",
      "r356",
      "r364",
      "r366",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r129",
      "r130",
      "r160",
      "r352",
      "r365",
      "r367",
      "r565"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedTerseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Amounts accrued for purchases of property and equipment"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Definite lived:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r223",
      "r228"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Schedule of intangible assets by major asset class"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r57",
      "r158",
      "r441",
      "r444",
      "r539"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r69",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, contractual interest"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r80",
      "r84",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r583",
      "r584"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Investment owned (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of affiliates held for management investment companies.",
        "label": "Investments in and Advances to Affiliates, Balance, Shares",
        "verboseLabel": "Number of shares held in an affiliated entity (in shares)"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r192",
      "r522",
      "r542",
      "r586"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r454",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total remaining lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r99",
      "r166",
      "r197",
      "r387",
      "r397",
      "r398",
      "r427"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r99",
      "r197",
      "r427",
      "r528",
      "r554"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r99",
      "r197",
      "r387",
      "r397",
      "r398",
      "r427"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r11",
      "r243",
      "r526",
      "r550"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r109",
      "r238"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r109",
      "r238"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r109",
      "r238"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r109",
      "r238"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r34",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement input, expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Measurement input, price volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement input, risk free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r40",
      "r99",
      "r197",
      "r427",
      "r527",
      "r553"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Carrying value of noncontrolling interest",
        "verboseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r262",
      "r384",
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Cost of acquisition of non-controlling interest in Geneos"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r40",
      "r66",
      "r380",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac).",
        "label": "Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member]",
        "terseLabel": "U.S. agency mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/OrganizationandOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r82",
      "r85",
      "r88"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r52",
      "r54",
      "r59",
      "r88",
      "r99",
      "r117",
      "r123",
      "r124",
      "r125",
      "r126",
      "r129",
      "r130",
      "r139",
      "r161",
      "r164",
      "r167",
      "r170",
      "r172",
      "r197",
      "r427",
      "r534",
      "r559"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net income (loss) attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net income (loss) per share)",
        "totalLabel": "Net income (loss) attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r52",
      "r54",
      "r129",
      "r130",
      "r389",
      "r402"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToParentDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent, Diluted [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToParentDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r135",
      "r140",
      "r143"
     ],
     "calculation": {
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Numerator for use in diluted income (loss) per share"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r115",
      "r116",
      "r119",
      "r120",
      "r131",
      "r132",
      "r133",
      "r203",
      "r204",
      "r295",
      "r296",
      "r297",
      "r298",
      "r342",
      "r361",
      "r362",
      "r363",
      "r506",
      "r507",
      "r508",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Impact of Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r114",
      "r117",
      "r118",
      "r119",
      "r121",
      "r122",
      "r125",
      "r147",
      "r199",
      "r200",
      "r201",
      "r202",
      "r205",
      "r206",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r357",
      "r358",
      "r359",
      "r360",
      "r503",
      "r504",
      "r505",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r263",
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "negatedTerseLabel": "Deconsolidation of Geneos"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r263",
      "r384",
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Acquisition of non-controlling interest in Geneos"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r262",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r11",
      "r526",
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r161",
      "r164",
      "r167",
      "r170",
      "r172"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "netLabel": "Long-term operating lease liabilities",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r453",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r452",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r48"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on short-term investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.",
        "label": "Payments for (Proceeds from) Investments",
        "negatedTerseLabel": "Proceeds from the sale of investment in GeneOne"
       }
      }
     },
     "localname": "PaymentsForProceedsFromInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Costs related to issuance of convertible senior notes and convertible bonds"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "terseLabel": "Payments to acquire additional interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of capital assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r318",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of convertible senior notes and convertible bonds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "verboseLabel": "Payment received for license granted"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Acquisition of non-controlling interest"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from Geneos issuance of note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from sale or maturity of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r75",
      "r334"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Miscellaneous revenue"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r52",
      "r54",
      "r81",
      "r99",
      "r117",
      "r129",
      "r130",
      "r161",
      "r164",
      "r167",
      "r170",
      "r172",
      "r197",
      "r381",
      "r388",
      "r390",
      "r402",
      "r403",
      "r427",
      "r540"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "netLabel": "Net loss attributable to common stockholders",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r236",
      "r556"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "negatedTerseLabel": "Fixed assets, net of accumulated depreciation",
        "verboseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r308",
      "r460",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transaction, Due from (to) Related Party [Abstract]",
        "terseLabel": "Related Party Transaction, Due from (to) Related Party [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Operating expenses related to affiliated entity"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r308",
      "r460",
      "r464",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r458",
      "r459",
      "r461",
      "r465",
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r349",
      "r597"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r95",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Performance-based restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r262",
      "r343",
      "r552",
      "r576",
      "r581"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "netLabel": "Accumulated deficit",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r118",
      "r128",
      "r130",
      "r202",
      "r339",
      "r340",
      "r341",
      "r359",
      "r360",
      "r572",
      "r574"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedInterestFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of interest continued to be held by a transferor after transferring financial assets to a third party.",
        "label": "Retained Interest, Fair Value Disclosure",
        "terseLabel": "Fair value of investment in Geneos retained"
       }
      }
     },
     "localname": "RetainedInterestFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r156",
      "r157",
      "r163",
      "r168",
      "r169",
      "r173",
      "r174",
      "r175",
      "r283",
      "r284",
      "r501"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue from related parties",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.inovio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r287",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r451",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Summary of Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "auth_ref": [
      "r137",
      "r143",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]",
        "terseLabel": "Schedule of Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r225",
      "r229",
      "r502"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Summary of Intangible Assets by Major Asset Class"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r102",
      "r462",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r318",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r36",
      "r97",
      "r151",
      "r152",
      "r250",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "verboseLabel": "Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "verboseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, restricted stock units (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of shares of unvested restricted stock units and options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r315",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r326",
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r9",
      "r529",
      "r530",
      "r548"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Critical Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r97",
      "r99",
      "r136",
      "r137",
      "r138",
      "r141",
      "r143",
      "r151",
      "r152",
      "r153",
      "r197",
      "r254",
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r111",
      "r112",
      "r113",
      "r118",
      "r128",
      "r130",
      "r150",
      "r202",
      "r254",
      "r262",
      "r339",
      "r340",
      "r341",
      "r359",
      "r360",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r150",
      "r501"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r37",
      "r254",
      "r255",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "negatedTerseLabel": "Conversion of preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r254",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for cash (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r254",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r38",
      "r254",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r254",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r262",
      "r317",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r20",
      "r21",
      "r99",
      "r179",
      "r197",
      "r427"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r99",
      "r111",
      "r112",
      "r113",
      "r118",
      "r128",
      "r197",
      "r202",
      "r262",
      "r339",
      "r340",
      "r341",
      "r359",
      "r360",
      "r379",
      "r380",
      "r401",
      "r427",
      "r433",
      "r434",
      "r438",
      "r573",
      "r574"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r262",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r439",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r439",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r439",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r439",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r467",
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r186",
      "r187",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instrument [Domain]",
        "verboseLabel": "Financial Instrument [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Effect of dilutive potential common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r135",
      "r143"
     ],
     "calculation": {
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Denominator for use in diluted net income (loss) per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r134",
      "r143"
     ],
     "calculation": {
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding (denominator for use in basic net income (loss per share) (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetIncomeLossPerShareScheduleofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6284393-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759068-111685"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229187"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)(1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611322-123010"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r598": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r599": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r600": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r601": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r602": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r603": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001055726-20-000052-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-20-000052-xbrl.zip
M4$L#!!0    ( &Y^:5'GO;=J<"D# ([L'P 0    :6YO+3(P,C P.3,P+FAT
M;>R]:Y<3QY(V^GU^!<=GG?5^F39YB<R,9+S]+@S8PQ[3V(#M@2^S(C(C0;A;
M8DMJ3/O7GTAUBYMO>%!+54*^0$DJ597R>>*:F1%?_-]7IR?77LI\,9E-__&9
M_=Q\=NW_?OG%_W-T]-]?/?CVVNU9.3N5Z?+:K;G04NJU7R;+9]=^JK+X^5J;
MSTZO_32;_SQY24='J^_<FKTXGT^>/EM><\:9]SZ<W[ .:B&6(^^\'$$UYHA<
MKD?.UBH<+5;C_OWIC>"0(6 \BHW:$9"W1X28] N, 6M(@?._UQN)?8;"+#8(
MF ;<BG!-X +%D%SHMWVVU%^GOW"ZN'$RF?[\C\^>+9<O;ER__LLOOWS^BN<G
MG\_F3Z\[8_SU_C'30CZ[//UL.?_#L_-U_71]XN35\O=/G$SUFM*'\?IR3M-%
MF\U/::G#K)>PX<BX(Q??7.2/;F;]6Q=:G[Z8O[EGHP6OSM4WK_=A/S+VR-OU
MJ?U2=?+Z[+=_1KQ^\>%;O^1H(>6=)]'7GS^=O?S+'X-OW_(W0_V+7]W3YIRO
MKSY]^^DF?X+*9+I8TK2L4?GCBW:@7U]T,?F]$_6"]OI_W_OV87DFIW3TWJ5O
M5'EOE-8_73_H/S*_.ZZ3Z>R=F^CKEY/9YV5VN@+!9&]>4VEQ])3HQ6\1N_S@
M=U";+&;@;/JSD;DX8_6%&R<T??J/SV1Z],/#SY3T0O7++TYE2=?ZUX_D7V>3
ME__X[-9LNE11/GIT_D)_=+EX]8_/EO)J>7TU?->__+=_^[<OEI/EB7RI/^=H
M_3N^N'[QWA?7+Z[,LWK^Y1=U\O+:8GE^(O_XK$X6+T[H_,9T-A6]_^35C7ZB
MS"\.)RK<T]6A?GZLZF0^*1>W?[5\(.T?GTTX^A:@<8Q2H-:8:PEH.53Q**6&
M_[F]>A2K0_1F;*=TVF\MDQLW54/5KJ6^/J&GGUV;5+UD]3^>\^W9RV_=@Y>/
M_;VS^OS.RR??Y.?WG]?)O5]_-H_=/R=/'MVQ3QY]_\N3YP\F3TZ/3QZ??N^/
M;]^UCQ\]ML>_WK7?>GWOUYE__/Q>./[F>/+X](=7QS_]8.Y]\]@\/GWR_,E/
M__SY^-?OSX]_NN..'Y7SXQ_1?.N>G#_^J<3'S^_ X^=/[>/3N[\\?G3GU?$W
M#TZ.O]&_?[H3^OOW?_K>W+]]<GKOT<V7]9NO)_S-#_'QHYO]69X]_NF'</^;
MQ_J=[]W]G^Z^.G9ZWT=?/7ORO,#]VS_;Q[_>O?S.CWJO,'WRZ,6S>[>_.CW^
MYNMG3Q[]#$^>WS%/;C_6^]SQ_3?>^^;KT^-?G\+]1S\^OW>BS_CHSO+>0_/J
MVT<W_Z?:&#$7=Y1MQ". 9H\X!#JR$DEI5DH4^.S+1B<+^>+Z.Q!>):)KL_/U
M9%'HY+'0_&M]9W' ]J^P=6]CJ^/*SJA]M376(P@0CM@;?Q1<<0S-24CILR_[
M^.\,VN_T^K-Z />#P/7O@.MJSH&<^E(Q'$$S<,35E:/,GELTC"G09U]^[[<(
M[9VIVHGS6PKNG$[N3JN\^B\Y/\#Z5["&MV$-R#K^T(Z2QW($*;HC9%..2H0J
MK89:(G_VI>D@!'5RXY7#>^'HZ;=?+6]4#0%.]8K/*IV_#?RML_G\'6U]9UIO
MZ[D'[/\*^U?W;G7<5_C_\C_LU?YZ2D<Q%HV/6JI'.?MX!!9#TN@FFFH^^]*Z
MZ][^'=P;NUJRFG)C 8HK9"NEQ 43)[1._D2L+SW4&U]/II.E?#MY*?7N5-WF
MIQ,^D9N+A2Q_6$@[._EVTG:,]J_'Y_FTG'X]O7_ZP_GQZ6-S?/N>4[3AR:,'
MS^Z=_O/9_=O'S^_]>CPY=H_=DV_NFN-'SYY_ZQ^<R'\^.'_R4WW!#N*31W?=
MD^??FWN_/GEV[]&SSI+SQZ=WX)Z[]^L]=]?KG7]^_/Q[>_^;XW9?T;W__?_H
M:*DQK>G(M^05,VY'9 H>93#D?7+6=SW\G7O\=Q"K#8SWI15%!Y *038U6RBF
M.DE@_DI2>QAWHY[-SU46UU"J1W_CMO#RH92S^60YD<7-ES0Y(052O_F03J0'
M"',JRS,ZN4?+?M*.M;>]-UEC>O>7XU]O_OKXT?=64;7'C_2\VR?/%$<XOOTT
M/+E=]-YZW4<_>\7TV>/35R?WG]]3++\ZN??\:;AW^]FS>RK-_=S.BV-][B?/
M;^KQ/Y\=GSXY67]'[W7VQ/T0%?_3>]_\<*X2_LM]Y8#R0#7$S\J+Q^[8_?/T
M7C\^O>.>G/[85'+/7TMPRM%2*'#D6G>G5<4>Y:"4D.)"L"WU3(5*\!]PX>L^
M^AI37SM3:5LQ87IVRC+_[%UVA!I#3J':H)3(0.P;H@^8L3CABIT=-ANG(>OJ
MP!N-*ZN4R:FZ\?_X++TOW)T5=S4:GJ\<,V7!2YDONX!?'/;,T(,>Z^M5NH+7
M;YK=\L(=W[KDQ?/OX?XW/SX_/KVGLGD/CG]]\.S);?W[I^-G3TZ_5ZE]=OKX
MD4K][:]/WO#BY_#DT<GID]LGS_7JD^/GW[OCGQZ'>\]_L(^?*Y]^_?'9XT=?
MZS7OGK_/B_N/3D[N__3DY_L_'9_JY^[X]F/[Y/G/Y\>/?IPHS_SQ3U\_N_>3
M,O3Y/]N]R5N:G:J/7?FJ'<]JUD7#+/7>Y"BTF+*C9)W1R-E\KHH>#80U/]:$
M^)L$:2U%]0X=5R:(-; 8[Y 39<(:H5RJ#]188'WP-D'L;]3_@2%7P9#CMS5'
M;"Y[L'Q$K76+W^H1&_%'WI!Q&J6#%^H,4=?/677^\L>2!,DK(13ZK"2Q/;=J
MC-+4H+!CXPXD&0A)SM\B"2E@P55W5+QS1^#5020/\:@$2@P^&K%Q39(4(B;_
MD201T#N5&*+"#X8C5E%EI6$G<6M<ZH6IL<[%H_7!@23;)\G]6V_[(-R*!^4'
M9G4_0%$YRFCER!(9<,&YEE^3Q$)*,7XD22PQD<:21IT14(.&#HJTP.JT:IP9
M[($DPR#)V^;&BRW.E'94L\:;8(+2Q?O.E%1;SLVELC8W/G2OUOZ6)-??S>[/
MI<E<ID46OS,GT2=];BQ6,R]*FFNK2: ;R_,7BMUB<OKBI$_#K-Y[-E]QZJWI
MA\]?+:I>X?J[E[BX_9M[7C["8G8V7[U:S2S=N.3I!3G^-_F/]85DE=M:OYK4
M_KI-9'YM]4#RNW-FM^[^U[NIFO>__.7ZK7>O_F*5%%V_6BQIONS9E"_7TT3&
MKK_WYK/7CUG?.C4?]<F;=S]9OU[?Y/H[ [6^3A?XU: MGI$.ZNMA.!5:G,WE
MR\O;KSY<7V+]V?IUO\;OXI"K\>BAI. ;0+1<LA5O7)/NVJ#\S]W^^-W)&<#P
M7TP3+B]&U.K@A]<7NOSD;X[HV8K-[P[9Y63>C1\>WO[;HUD]H TM5T<63+)L
M<TE5+)8J50/"B]$<")G?&<UW^/GW1O-=/EE)Q33KG2BK0N:6?24OZJ&$%$+L
M(]#-CK>#&@$-SZT[\G8#(T#5F%(R<#)!/7G"7#E6B1H!NJ21P_8X<*D8Y&FW
MW!<OJ][LU8N329DL[TEW'Z[5B7YZL>#D]TW^S5<3U3D]8W4S?A[,6Q[ 0YE.
M9O/CV5(6M\]$?Q5<7/.+Z[][J]>C]_J)=D52[]$XBME'A^JI2\ZFJ1ZLMOB8
M8H#MD72_(-J@%%6?./E<?$T$T61UB)HZ"0PA9#*ACE>*WD+GJ]FT+D8B,YRZ
M5:P>59MI2&&IMI(5CN)3MJK<QRLSVP1D@Q*2<W:N0H&<+:@K354:M62KE8#8
MX-*#3EOTH/\N,HOY\L9W\UD]*\O[\X<R?SDI<H'+&K-O]9WI0C8/R?N>?-J&
M)_^N$=)!C!2=CF:#OH[2&J: SA6CILG*Y<S!!7YZ<,#OC_#KRP$_$+]^ZH;P
M:\Q8C8;LQ090):@6JA!#:50D-JD[B&!'BM_6(NEW]:=&)9:8>[X,6-V,7((E
M4*$T/FC >RE_]B!_'R)_'XC?!N4ON%R::LN6B@<.A7L"*0 DES3@-CQJ^]?]
MDDOL^BK_FZU-3B9]T?]J7==$KL!)V;U%%$;QT2!VB01 ]!(-%S UZ9 G.VJ+
MN&-$=V,C;76&<U:1I !D67T<A!J\!N"4J.PBR[LWB.[&:D;2($^"!H/)]Z5P
M&FA04W!SH]Q\PE%;S0'(Z/;M*+=F0FDB08VG6D\L3*BVU-F"I?H\:CNZ]H,N
M/[TYK9<?WU\^D_D^&M&@ 67C1C78 I(=9@)A!M6_R7LRHS:BNX1S-Q847;"Y
MJ42*S^!K4R\W<H3LK!CUBMJH+>BNI7/[YM.Z K9Y%S%F*$8X8NL3X-P#3V_#
MJ,WGKJ5S^[;3. I>I)6LD2<FDTD%E&*AE).:U;H#VSD*(U6[8V%C-=(\0 -D
M:U,+F$.-QB;:@9$:A34@]#5[)P9KAARK\HT$V,0H&1'C#M3'*.2T5A=KWP3"
MI2K=K,JGST6H9AU)\30"'W?WLUB[5QNVFEQCUG%%4H<V8ZW>^A)M\DG]WC0"
MWW98,.Y&BY7 OG&RB*%" LM< ?3(&J)67!J!3SLL&'?DRS(:L:4F4QI " PH
M1 BFEEQY%*F@8<&X&]L(3-(HYN8I F?"J,%)#<%ED" RAOS/$%=%[=Y:.M6L
M5)S--3-45XB=UR/*GLBAR7M@+7<-[&[L9V(#P41;$C$X#.C8FA9<S>CU7=@#
M^[EK8'<TN2*U*)@EL?=0 U$TJ0!+-B5G$]L>6-1= [LU&_OV'H/O9/ZP;\]X
M#5:=O-1!?OO4U>YS6LY>#_G?W([PF^_W-V_+='8ZF?[>92]__5]N&GGG$M??
M??JW3OM]/=6JSTBU^+Y*D?18L.],2T52+>2&OV3TX;)76='OW/G762^G,SM]
M,9OJR\7["<^^]6DN]>%R5GX>R?I10]ZF5 F<:6!S4K<@&W"Q5+4FUOB]04??
M/YU-QP0-9$..8VIH,X3&V65KJ1E4P(JI^P/-S5HG??\BG7Q'DWIW>HM>3)9T
M,A*8Q$&H/?\J@L !$3P;*^IG1R/,LC<P/9 E3:92[]!\.ID^'<L*>1NA^M@K
M]Z@8<6V4R+B2HC,U%H]M;_"Y6<K9Z=E)7ZFRFFKKY\WE6;_:2[D[+;/3*U@!
M>B60J3U*$GRL9#U@+[5DO,U]9:X/&LC@WD!V/)OV'SZ?G9RH1-W5(5!';#D2
ME/JD"9%&G#XX &AL8LZN4>.0)>7?+.OSHX?K2GV(CP@\_5N ?LQ:>-2(,Y88
M<VN@JA%%G7074K7HP83?9!3&#^C6/(_=@TLFU5JE9,($XBM[=2==8@7=J*>2
M=P#N*,9-G,=D*8BQ""8)5ENS315-3+;4WRR]&K]0;,LH[1Y;1M'(MPAD406'
M+5=HP1OU.(Q/P?O]P_;J??C=HPI@;3, Y,D"DT47 ]G R;D8@R_[A^I.//_=
M YV2L=%Q0N8 S3:RR=H:( 9'D(*]K XP?GRWEUE\'YV/" ^B4"^=3! 30#*!
MR,3&T186)$*W-^AL*;.X06A:;DDEQB"B!2R0U0ZJS]\P^AI,K7L#S0XRBQN$
M"9++L4!SKB^.=98S!Y^QMF9BM&E_)&B;F<4-XJ,A,J$/L0?,P+FWQ5('4J*Z
M'$*^^+W!9\>9Q0U"UMLUL!H@L2T!5D,4+4>PG'SUK<#>0+;]S.(&41)UWT5\
M"%0Z2CD74\&ZE/2MG,H6';M=C8 E",F6@KVY@.= SOJ(XMFWH,.QSM; .H:)
MPUT#,@0OZOU8!3X\5HD;VL'G6R[68W69 ?2%5."BCE?RKI)/^P?HSG*KVP>7
M?'3.89]A5'=-827;F@N02E+)A5U(ZRC&K8A)F;Q:8[%]Z7A.*; 7--W9E8C[
M)Q17'<GO'M-FT=;(*5JUV3&I:URC1)]*"2;Y9O</TUWER[>/+1L'P!"<J>J@
M@: Z(Q5SK=7V4@.P?]AN/U^^?50EYI1S#209(%C+Y$T!A=%1Z+.$^X?J(/+E
M.Q#?%&*NR4%H 4Q5N(L'H03L@#BN\TGCQW>[^?*XF=*ZHK%=]LT7T* 7:L @
M**ID62"ZFGEOT-EBOGQ#T/2FRS9EIN@!U+-A1NO)B:I'ZRB:O8%F1_GR#<%D
MN+G6]X9C"L!L<[(U96\PF]CC[[V!:=OY\@WA8SF7X#4X1H^0$C&UR(VR#2*(
ML>P-/@/(EV\(LERXB6V5^A81-4@Y4#4MI9PP&7G=QF+\D.TF7[XAE((UDD)M
MP:8(),36]?40.9+K+8JW*%B[&H$D2D:CK"1T$ L1%3)H38-2:Y1]*.WRT7LF
M1^7'[7[C?&M)/0A5<J4P%(V*K3@48[RX$"N/H;+TZ"BULSF#[=,K0E+?)R1Q
M)4-%IW8V5A,P.G6'L@O[0*^SIV>+9=]S\C<KJ!PTU=],X+F0 6T+^E=J:@,M
MU2"1:[/1B1D1E:Y43^R.T*.D5<CJ08))$"E R)AKK]'%L0<"H80T(EH= +VL
M?ZB&Q;ALA, FPZ9X@:8OP9M(8ZKQ=%#\JW4')!ZD&(>L@4Y0P"HV++UQAHVA
MC"GJ.3B(OW408] @OOHJ#*9P-C$HW,D$T4_B&#J[#2ZMN7M4<T+.%2."ZRN[
MF8T>:B!0V%;7TBYJ15^UR YALG7[0*=<DD+J"AH$])8S.$_L<J\];-$/OW7I
M("=;-]3'E%CZ\MJ"UF?(XG*@ C8WS\U:Z_<'G2U.MFX(&A=4+4*2Z/NN%Q_4
MQ\G*,*_N344H(^CY.S1?YDI@BN**;S:[Y E<2MA,L,8%!*#DQ.T-3-N>;-T0
M/IF,=<T%+ZB.1I]QC9:KQ40FF]KV1\,-8+)U0Y!98YD !4TI4 $YVIRI(DJ@
ME(#V!K+=3+9NRG6H 7REB&2A"Q9!]6C4?[ M5LP7]=YP#XI3;;&>)6ZL*)5B
MD7W*E(-G$"HYJ^?0]]E(:"$&WAMTME7/<G/0%$**X"*[WJ#7"?M"TE(1U7;%
MVK WT.RBGN7F8 I1T+*C2.6B(WTDUZHE&XB\_KLW,&VUGN7F\,GJUGG59":Z
M#,204T1?JW$:,QEOTM[@L^MZEIN#S(IIKG+J6T AJI> 0%YJK@X"QCUR&790
MSW)S*+E6*$<+&$P#T\LY&/4=:E,7W#>-F;:'TJY&(/4:[27FAJT!9='@/O=H
M$8,X41/P?N>!\9=)V-H$X=_L.+"A"EG6]IYW5*GO7"A)PTG :@NFUL@7SOL'
MZ$XF"'<#KJJG1 JB:JT,&1T!1.<ZU(:31J,[ '<4XQ8EYL)4D^$ P0E*:\VW
MTKB4%N@WW7?'+Q2[V*&\&VS5J8J-*^=$"%D@<XM]4643T& 3]E#A;7?2?%=F
MS+DLWO=%L@ Y8*E]<7(HV4+OL[!_J.Y\TGPW0%.*1LC&8#/TG1NDKFBR8-D5
MS\Z5B\+_>X#O5GL%;:PL5]8XJ$5'!JI*8:&6JA<-CU)?EN1X;]#97J^@C=6U
MPYH1:K,)8R]!R":"1FS1L#65:7^@V4VOH(T57G4^Q>RM9"!(F=C7OALVIX(^
M&2-[ ].6>P5M3,-%)F-+I>2Y+]K"4#5F[ML(DX00]TB,=MXK:%.08?58<O'1
MD@<(C8('TB@.I!7"LC\BM9->01LK!HZM!>.S"U% #14FP!)\:EDBJNW:'DH[
M&P''G(,KQ08&L96KFN<@G(JO14/6RQ@&UC',^+?4;S6W^H'5E/JI&ZJF!.R1
M"T3?-V$XLEPT0(V]%W/*L;QNK+U'@.XLM[I]<+D68Q0SR>@@L*=,1.+44Z/,
MI90=@#N.<>LE FU$EZB"&F(J0BGX4'U*,8';/Z'856YU^]CZDGJ]Q\1%K;=&
ME5C8DL12)6;UD/W^8;O]W.KV4<W),COCD%H 5F=:DK6N<8F5N"+M'ZJ#R*UN
M'^A*)28GQ; 3R!6PQ8 44\VE&4)[Z8*/']_MYE8W5;O.JMWDB]  @!WJL?C>
M1=JB A3W!ITMYE8W55VK@"DNVDP:N[:(63A(<I02(JO:W!MH=I1;W50)L"XX
M8@VJU$ P%:'Y[!I6BR4ZR7L#T[9SJYO"!YTS+11'*$!5N+$U-EF-F2$Y=GN#
MSP!RJQN"3 U1# 45I(9@$2A[GP-4,M4Z0V5O(-M-;G5#*&&Q4'QT:("@A,2$
M[*T/Q2<T.6T1I5V-0)2BL2G[8E7K!_&$D:GIGR7F) TN8YBTCF'&OX-NJ[G5
M#RR>T$_=5.U%XXIE"5G]7S 26&.5*B4$VR=X;-X_0'>66]T^N*9)-!BI+UT'
M)HUSJG@T:FHT,E7?;?_ W56.< ?8&@RNM!# Q]Z F\3[0J%D,J9D8_</V^WG
M"+>/JL2<D^$:T!7H#<T*UH;.II:2S6$/)780.<+M ZW^OO%6Y;7OGC:UK2J(
MIN:[?V5=JI>NY/CQW6Z.<$.5!Z"R\]47A.2AQL@Q1A^(T'C#(F%OT-EBCG!3
MU7!2%NM;B&P]@+,<])V<HJ386PSCWD"SHQSAIF *PJ'V-;*) ="S^BOBNJYS
M&EU8OS<P;3M'N#$-%TT5D-Y0%7IW]5K$ Z.D7 PDMS?X#"!'N"'(%*DBW"PV
MCL#%D+"K+;E5NYCT>DGS^"';38YP0R@EC:MCMEAC[BT\#6?7"%T2C)B;WZ+K
ML*L14':67OJL)5^AUDB-D[I1)E6L/E>Y++QJ1U!X=8C5S#]PK]@FJYFS4&W.
ML:$(!BT6)U5#4,_-%$3__J;  Z!7M?GO?P_HV71R@>;TK#_X:WQ.A19G<_GR
M\AIZN+[ ^I/UZWZ%W[=+-OMLC%=WHO92'AG(2C/5.R_9-AYN,;W%?'GC_B]3
MF2^>35Z\(<./W_SWS>GDE$[^4^AD^4R=A)$4S"L:K%**V:Q*7NN0@Q4Q#K!E
MIQB][B%G!K=#XP^0^$:F,EL\4K>-7LC9<E(6"L;G5XU&?$L@/\;%-MR7,L=
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MJ5^=__#PF]E+F4_[-Q^^F$T7L[G4.ROC.)\L1B-H@M$TYSFZ)JH)&Y:,H=;
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MC'@[]QN?=BKG]VC^LRP_Q35^&]QJ'CC5WE&H6I,@H]-0K-5:'?N4*=AT(,L
MR+(_CM8&F2N +,D;=; 0'# :-A)-B*9BXW10<P</;Z#,;;$A9J_*-@K$$C"X
MF$+TUJ,O$,((F#LH#V\ 8O2),#?;4"VF6K@4:)%83"FJ;QVD1%!'T##HL&OD
MJCG"0I B8XVE@8F&0XQ(AERHH5+(!XX<',E!$3:@5/3LHJ4$J5G4&*B8G ,4
MYN)P!(0=E#^WM](S%,)2 ,+H>SE9 ^B!6D1C D0-A)+$^&D0]K"1=#2$;02
MO7"A20P^0PXNA=07:DL1G\:09/KD,,,JT9"I!D("_0=C-5Y].9=LB'"Q#^Z
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M)^;'K*;SAFQPD@352 KF0C%*[[H0(D;V!V)^6GQH*<5B<K&N&D!",KVW@['
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M^?V(?\!5$(>#U$<$X'$S 7CM?<]3"=ZS 7$9+<2^Q[R$X"06NU^P#G7US8;
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MW+AW+>8J MP<60O0+)8DSH>+\NDCR2,-#<P=9(Q,\,5:RE@93(Z4>X6R"JI
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M'P(5;[8/BK^W7[_;G>]&:OVH:8%W[YCU1J27;]T[W+J[E[>N1X0A2CSPQ&A
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M_'G6T1,N/P2M^9%S_W9R'@WODF[]X(_E\>C4?*;I'-/JD^/17?@1\=1K,@3
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M=6,RJ[3TK:7N[SQK\6.6@XQG[[KZS+6'WOTQWQOG3O-SG_QVH^WG3_U>=,[
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MJ/B;' \KVMVY[08]A1WLQ6N*41^U28>EEU\;[4Q#]Z*A_2N!#0VQ<5H!)6$
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M8<VCJ[M2Q&C/*! .8D"MP\ P#>-OPB+!A0Q:1#],E%+D,,KZ GGQ890,Y$4
M>:IJE=,"$^6!LD2F\R$Z.C&* 8@\=,(I*I79V%*X)&Q>[?QR/.7^4B+W9%^*
MQKA>DS>Y8[]DI.O-FC-#/82AKM2LL)@930@#Q'L-*..IZRB&@$6"(D(Z0BRI
M8['>'&19%:V14?U8J)[:R-'.!AV%AJ&" BJ"!]K%?VIM$+6$0&W\QA9!I1!U
M.DR>8RXU$TK7"WE=)+*?Y^!+3<IW96]M)M:\<KI4.J^ME0AHKQR@F E@7!1$
M1"4[:FJI9^D@/^8T_LGEN]87Q8]=OBNC>%843[2/8]P+9PW /-7DD%A%%,,
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MTNYT!$ 0$3!GT48F1(UA4EH^81@P7]5?0E%CV%26)WK_L&2P3IF[.3-_92,
M&=!S!O1$94B$' I< RN9 92+Z#18C$'T^JCG4 0CH\I@)9>HI#2?M%E?/#]B
M""#C>;YXG@H"$&U)B+8!&JKD-1 /M(#QAT1,<QWMI\S&%I8E)S!5W\F 7EM
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M QJ=/Z!U"$!+:QSDA'E+-K9HB3 JH6 9SVN+Y\?9_\]0GC.4I^H.."=PE%2
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M@R= >R= < H3KE.:;T@=/053)1>Y@<?J0+NF#G_&\IRQ/)$;&'M+H$$@,$0
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M#HV&Q'C+ H55>@Q4L.1JEB* F>@RT:TTT2T](I>)[IY$-QUM\] X81% VG)
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ML<B0$N@68.Q F\ZK%1P&)6(D8ER?^UZ %[/.*49T*(H%EWD(1D0#(EJ554E
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MU!U.OZS$_U/0Z+]%7&!S)KZ<E5TM?U#KO_0L[&6Y2FYR#:<4(%HM"(]U1"3
M&X+;:[1ACEFQ]8Q'8\K$F-.A5?7WR]SWBW,_N7)F574ZL//#LW,'VB:*)LI)
M$L<RPO*$BBCG4I)1JZ33D4@-G/K_Y__+&&4_;SPO#]!NL%-^OH5!2*9"^.;3
M04I7+28^6K$%>R"D9E,?P*>\$ 3<ATAO-E@R-\&2B>&FSPL4_\[B4?"\OUO#
M<7";X^"XE^SJC,QH'#%BHBR&XT QHA@U1(B<*BMEK!W'9-<TY>-,;'0DRF#
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MO:\8MW+9'WPX/W7E3J#+5X72Q61(U[@]O.M7#S0F!827D#QBC/!$)P1P>T(
MR64.]A%VV@"\DZ#J)G3C;9^WQBF#E/HNI=37"6$>!-2#":A._>>4.YK&C&2Y
M$80+RXGD@A)N<FKR1 BIAAS\QZ>BK&?QO;J^H:\!?9=J3]^9K%XWP^]%5G]5
M1!G(ZS50UX$;H@AO)Y9[%1J9TB:/M2+:B@R$<6:($N@GH6EN$]@GE458=3JA
M\"_9_,K\]^X#&:31YDQM,^L1#-+HCM*H Q*931A-0'>-N"1<&P")C*?$B%28
MW"0NRG.L%YM(-HZRS6_[\Z P\6X/?RQ7?O=VVC?X.YGE9%&YD:HJ-Z]&,SU7
M<*'%A+VVT (:<"<^HV^F8<R^%O^EK+W!$/)='F?W"ZZO,H1X4CS,?Z_<#M+A
M84V%>],F<^?EK#P\=R60WO3D%9)B8QRY&$Z]VYQZGWH5N!)J%17<P*F7I(13
M%1'E;$9HQ(6F-HNHI8_'-#+8;@>1]941^""WOJ+<6J)UE^0J32).7.(3:Q0C
M68P_,F,BIFCBDF3K&1H.8CY.[][>X3%8=?\UQV*]\+\M/CS[-_QH[NB,SSC4
M&,.(BZF%OWXBTHO$KXP_F0\G<0YC!&9G\.X+3!;$FNX5-NQ;3-7"%MB]#Q@;
MAEF%WWP,EV_J5U=551,8,WS@NTEMM]NYN@+U6V.Z+6!@Y[/0'N<GWR&P^.!^
M_EC8^6DC9SKWA9W[*5K>HC2,83&_^I9+B_V-UC;K+T;W)X[6"YQ4QY(;K1T5
MCD<YU[EQVJ:<"96(E(FW+-MJ;CIM8]+.U8DCNG3J/5$Y3/ G-?FH+JJM?_76
MX:R8-@/B;#O%=5]=LK PS_ZM2[AUS6B_Z:I>"H#RJ[IW</C'WN'H]7]VWNSO
M[+[X_7AO=^?5T7BT=[![-?6=J?($5@.CTT0?/GS3N1P<'K\X&AT?CG8/#YZ_
M.#AZ\1Q_.SI\M?=\YQC^>+EWL'.PN[?S:G1T#!_LOS@X/GIL<_SA]T:0_'AY
MZ#?C@9AN73W?6D#$7T&$7II@RF&"='M4 Z.#Q1D\PMR#\K92\U3-%Z4[S&L4
M T+XV\*53_LM7'D#D.,]W__T![Y''+S[#9[[YO00KOT+(,GAG[_3OSX9>,Z>
M .@Q<?]Y<_'WG_9<,YX<_ J0X_CDT\&?_XW/8 ?/_S@]^/6%^.OX[P(@B?C[
M^(]W!Y_>%'^]F^3[G_;_.?CX5G&1&RUB(J@!58GSC&2 +$B&1:]B@ S41 &'
M%M.%LSN('@%CI*E.,VFDX!K4*Y<Z+4U,N6&)C?76R $&/$<!5R[@-#\L3]2T
M^.27V<?&+1>]03#U-J\(3/BN?G.XUV_09]_^60ZN(0)C>&Y^HX-L;SK[4,Q&
MKT\50'+C%AY952!RIV9[],/\U(U0/671S[L!1_B_Z,^C6=E\$9Y0?_[C>%14
M(S72!6 -<SJ%69Q<C&H, KC?+!!KP!*6ZKRPDXN1+@&9(#@!6 )K]-[-1^>E
MPZ;<\*5U6.<$;GA^L#,Z<[8P,'Z/8.9P0,['(P.\,_9;>5[B"^%F-SN?N-#6
M!K"<\S&1JJIF@&80V7PLYJ>CTP6LV^@<AC"9P!)^*,I%-?KA/Z__@.$;[(!3
MAH<64ZQE4LS@V^99VZ-C6)-Z,?ZKZHUL=%Z<.UQB7 .<<UGXV>:C^6D)8&Q^
M<1X"-.$=UB,M6&A\P > :3BS\%=Q=K8 J';J<(UP]-.P &YJ9ECU_FPVG9G)
M; KH3 %1ZIG%JWZP^SN_5#]NP\Z-# P"]Q&6J:AWT^_RJ8*).+B_FI>A>?.I
MFL-N]28!@QMI!]=- +N5<)$M8$/FL!W%%%;>N,FD0O,ET@:\^V+TH5"C8E[Y
ML-.R<'-57HPJV,LY/.-#81SN%Z++HIH#N<-S?*5^+"Y;SO2BFOL)YHL)?),O
MIEZ!@*$?^S?Y[^I97HQ*5YW#@W!-3D 1A%OA92?. UF_;6&QSM7\='8"L'9[
M=*L3=1/XL4]=L&UNLD+]V&?[3%DW6E2^X^3*RA]=3'=GTV;>]SJ%Q./[S\UA
MC0* JTQB?_>J\@8\A0] *Q@<N3\_R+AON/2CCL3RC(%!8Z@QS<[GQ1D\""AK
MHJJSP@)'?3PMS*G?"U.49C%1".!+H#[/X+ACX1$H9\J970 ;(!DC58Z0SLZ=
M)S;/554!NZD"O0.OG+K)N><N.)VJV13(P$L$-ZHN@(/.@ O,[ 3.,>>)W6).
MU>RB9@ 452":0:*IB7\V"C!D#^3:1\@.07#!$IS"7.&KB1WMOGCUZL7N\9N=
M@<:_@,8;P>R%^T4MH:NFI4J'U!?G<_7>MX)#"=,707B(UB< $M9X!&*JA //
MMV$9O7<7HPD\9:Z:+KG^,,-G$%P+VV4T=0ZO5N;4/4;J_(_'$7"0*^1;/-"!
M3C\ HY[./@+"'.7JPZQ$L]&H4KF;7^ RY\7$K^H2-M'TY]4%OOGA&PX!_'/@
MBWOG"USILQG(>)#ETU$RAC&,E 4R+SR 0L4!P$PYJZK.9<Q?!ABDN-YJMJE$
MW8I<,RO/9[X)0("+P*V%!]_*?L##9MR [A:!>Q&"XF(=;D& [P#>+P"Q30/H
M<Z!L>?!_,IEIP'RG3DT GD^Q35H/:+>*7_?]_A$?5+!9PA]P&I?JHCE^NWBV
M!MOA2 Z0<01HGW@B]4P6P/WMT/](%6>]\0 75BOO@P/YY!1U 9@IVE.[VF<S
M)WS$Q '9J1-\1E%:<JXP?0O@[FQ1FMZ#)A.E9RWM>;!;SJ< %$Z+<QA_T91D
MK%'''"2Q00,O(&9008(A]U$)6BHNH>)FRO4J-DLR*ZMZ_FZT<PX?SWX!G6<7
MJ'A[/-I!&O[;39U1X]$OKGB':[1C:\UK[/?U%U '1_]'G9W_/-I'R635Z%>_
MCR_16>'7? S/4Y/0_AW#-EZ %NO."C-Z73H8EK- Z17(=F" >H]^V'WQ>N_'
M\(+?MX^V1\_QPCGNA"=5E_OM^>'Y[#E<U?RY$TC*CMX 2:D2H.;K<O8.R+$:
M[0#[F NX8>?-ZQVX!9NW'@*=ORIR-SHR('60-?^S]\?HCUJM'!VC&@A[,?\X
M*]^/_6E1#R6\[?@4D2Z\"RD&IQ;>T1Y.^\A+\(3=7]X<M#?MHL, !/KB;/3#
M_N[SW1]1S9R[<JIJ#:Y^/7Q:S8OY GCTA[T_<"D.FBMV/;<M+^A\U7[F\?1_
MO&!8]S5^NS.9@!P)Z8Y[2Z9]WG+UH8<:0 U ?A[OA#5XC?:&SNO]CC9CZBCA
M%^/1Z\GB3'O5OKO,\)PW#I8*</=TO0G%[WMY-AN]+"K$0/[&>9$7!FX%#0+6
MB_S'3<YP<*]F)X6IKKO#;]P43R@X9;VD>^VFT^IB L12J/#]G[!2<-L;D*&C
MG?+LHK]4#3D%"8<T^2><9:JS"(_OP.J)9)3;\VI%*G@U;5&60>%"GQ?2.9;/
M+%&E"Z4T6Z-)-5]XB\I:Z(LD@D='QZ2$]JI@?>C*7^-)30$X_K" _:G/%(7$
M:R_0QU@5ZN?51ZUY#IR)MA9*(+R >Y</QH?!(>RF "G[K_F@8*?4Y.<:>:^\
M!4XSG]$/[ZD6J,56J%.&]?$VEL*OV\720C8'6 >B[,V;US_^#(=U,=,P_CE\
M,3I;3( X9^49</>OO^S#UW#P>*=A/9F?413]/'JA9Q.8[WYA+>#?%W WTF+[
MIJ.+J2UG^)#]%V^.X"FO8+P H/%8_'GT=_%>C;R5[F<_/0]W#__8>TZH'-76
M.T K(!G\'S]NCQ[5$=<UQ'Y4_A!KH)</%'P.,.4CTC#\_M]H"$"?@E\(-.@%
M Q#<4YP#;;E_8"<1> /YYEZU@YM>3R[.9@M 5OL P("HQCVYL<+Q_UJQ=G_1
MZJUS.[8^R?M;VANM[$HPPFT=5'Q#'51^;NS!'52_H(8)H.:YJTQ9G"-%[$SM
M+R"^JL,<4$^%Y2KPTV-XZR^3F7G_C1U8![N- ^OO=P=G!Z=_'^]<'!Z;:/_=
MF]/]X]_%_ME?_^P?OWEW\.[W?_[Z!-^?O9E<<F"=[;._V,O)_O,]X9__ZXM_
M#H[?7_S]#O[_=9]A[,T^>WGV]Z]_8.Q,=/#NY.( GGWX?(_M__96)D)QQC)B
MM(@(EXH2G>2,))%0F4P45VF\ZLS*N#)QI*+<&L,3RK02L;(42#/)':7IJC/+
M[X"' )T]& ,\^9]%88NZ^,.;HGH?8/+O*(LQ>BHTR+VUM^OSPUOQS3GM-*>Q
MU5',<V>5M<*YC OI;": S*YGIY^O$S3I0[*;?^)/Q1Q0OKF!<%F[#3<Y?/CV
MUYW7M;-X:!D2I,6.,5BY! Z@US-8W8OP<Y ;M=S G+T\T4K'A/%($DZSC&B)
M/<UMEG&>&:I<MLIH6J<)5W&6&VDXRYS,8LE8K#)M=9X(MBHW$"WWHL*^*!AL
M:<$,%D_M'#HZ@@Z,D -?45IO%O$N5Z]O>E7).R;@:W>.#U<M330@9H+.S-JW
M[._Z=6?G=>->1JR*\V^3*! *OFP'N*2PT=$<Q)XJ;37Z90;_C7[8>KES],O6
MC^NOV9U95+&"P/MA:^=H%ZY$K%^@2EN<=1:AF(;PU<:,XZ>'SL@R*,_>)/02
M+@FX@T;D-W_=#AH_)Z[Y-&AC)XM)>-(1^7_;?F@EHO[)A5?F+D9VAE%[K5D#
MUBZXD]VE8>2SV3P$^)58\J<,[=';!?23P5V?.%1TU\7W>77P"AK0:N+W$E12
M-\=-@%$<X0Z>:5>&*<71>(0"(*BA5SRG3T&S-O[B%C=YQ[H[A>L0Y4[0^-KH
M!#>Z'_06\_YT-D$%Z+]\>:3YA5\=?$)PU./SIJCLGP&IG598=Q@>T\YWU$S5
M7X@QSK<;@2]LG$]F'ZOVO;=\&^@"+=N.1WK1IQ!EWRVJ>7C=#[7GO6X6,46:
MF=3JGG?7+*_]L;:/]LVNZ)P$%1IT3P"!Z&#&(:-KHRB1X=LSKZ'+)6DUOH Q
MZI2@)E[:\LXZ>$M>W6JVF%Z_1Z'\<]6\W=E N6M?\J4;&SPXH#L[E&6PW,B%
MS1H4WAUCO;CPBI9_0_-^OXAGZ@*#*-P_Y\'_V@SCPJD2WXI+_QP>UV$?VK /
M7.K7&-8_J.]APGZ656?CUW)QT/_K2%\<_WPVQMDL)A8'5*(U 9O%S:;OZEB+
M(,!P<)USX#/2?W4Z&**S9C94-I:,I;!>FG%WIH P)R $0=6=8TQ03VC^WQ%Z
MRNQR=%Z4'2'A^I(M?I[7 ]EK-=F5Z-DG$;4LKXY:?K  Y#5SS/,'FV, U-:9
MVD?RTP*(LPQ>QG^KC1G+"*018.O_[_/FAQ00F_<@@Y3915CN&SJJM1'=Z\,4
M/Z>(K>!)*V3N,NMR#B-CL9;4&<%HEH(6D&4JV[KB/9_'H?WWB)3*&,8$.G'$
MK=,R2E(%BG/B8L"Y*KTR?))_0R-=DW:$4NRLJ"J/%FNL>O1BMT6I\/$^FMEK
M:<:": _GU J4FE\A.;UMS\-J(!J01S;$-';E]%K1[$]P^('2.T #.W/55T21
M7V1Y_7:J[UYK4VV@ZVX;K5J>H88R^@A(9')! !$@E%MH@$0%(*$VK'*G*M3H
MU:O=\<ASN'_(1'T,(-G;7?_O#.3IN'7CAN"Q[KM0S<#8L8XW.;@Q&A>\=1_<
M9.8+>:*%/;@"<<<"1&@")SUZZKRS<PF.$@]^T'U*.#\_Z^>ISSGQ+8TQG_/[
M].#0;=37AA7FM3:\Z.NTZ\.A&^=22P+%:D1 Y\7!,+^>=!"^H-MV7LZFWN47
M7(5__/K_K@K$WH+O0",-'LX5HL,/,280]5@UNC*1<[I (;.2RQF#$)91%%O'
M+39-DEQ1ET<V9K&3--?K>V2P50//?@&*!6#TIF+*X<<Z).&U*Q'Q *3XY>)@
M-L5WE[ B '_#)6V6)F%/S/RS_VZ?[W]\:T4.9[U."2P^)9S*B&C*(VQGD8K4
M.)'G#JNW7TJQ_-\@TJ>DLZ#!5(&UV;S=HDNG%YZT=J:X?:TO/="<ZEX%#  7
M;H_0HQX>UT3NMSSB%=T2N%;5\F9I_G$8]#?U/+<XGTT[S  7XD,]AWEA2\=K
MY"TBI0[?KLP ^656>>>X.O?LL62.\-W6CV.T3'0?.9V-)C,XK\N1#QU5H^YZ
M=4TZ8>504T73$GY[.SXR,;<J363$F>$Y, RGSD6,9[EDP&%-KYDDH@,?W3<?
MF4\')V]3;/N6ZH@X)1GA42J!A9@BJ8;#PO*$4PV0DE_N ?B_&R@$AV:%]D#<
M_-KBX$$1T!2R&08O8NCJS$=SS6H;!:"YJH!# *@ #WXT_ 4 -:*IY\-\4?K3
M%\NY+SQ@_+( B\O'[)55C[Z=,V3I?'I$<[R)5Q[@ H9'H 2!4]L[Z#%6 8V/
M<"C/ 5 !T/9JV@I]U#8LI+'_=8L2"Q%3(G8.="DJ>)9&4N7:J,2H5*8Y',^U
MSR6]HBH,$;>HL7#@YGM^/J]@-JT<29Z<&'G_S^'.VU1(D68R)YIA,=LDTW P
M8P$7FAF>J50QSK#:]O;E@HDC(+])HT?]K]NT []C#2#<[;8?^+"W:_?VXN"W
MMX:E*1P3CEA86\)%Q(ERPI(4N"W-!8U%DF-5"[9]N8[ZC^WN?IE!V=O T18,
MFOSD8GOI.[,CC,GT 6/J' 7M;47%EW6YNY6$V TC>\KTPP]VWHHTYM)J37*J
M$L*E3$B6"FS.;F(:9](X+K>>Q;'8SJX7#LJ[1Q=GBSKZW.6%*>9?;^-;87'S
M.CPN>%Q?J!+!<;6S'/[S,/JG2QR?=O#@H#S),Y=:PM(H)QQ/#ZE81F*N19;&
M0@N3;3W+,KI]N5K.DCBN\ZOV+0VG(4XPH!+$(<%QYI0Y#5Z9JFB,2/C+>6OA
M"RZIJD[*;1,0_+,\97@_^'3N+PRYMFA":HHL->]JQ"#\[RKG//;)%UC+H'8O
M3=V*=ZEL(ME#LHAKXVV][Z_YHVOGJ@-PFTR&96)%;RG:*'5T)XXO=8WUCZ].
M9^6<@$YU!J/[X!KGZ":*VDM=]':F]@B'?PRCWUL._@DS'/S]V]N$Q5&2\8AP
ME8'"YT#KRQ+XP2+-,A%%7"0:I7%Z+52[/I !';_5 N-H,08?V:1:G'MO9=^3
MN>)O5K7'%I^MYKZTYWQ$68,16CN^SUL"P5\ CU;5HD[DJQ[8L+X!.M7(AY^O
MBJ!\X>L >!G2$Q9=F>!K!Q3S;YDK6#3Y(XTL_HAY0YBTYBG$N?<C+&169ZK4
ML Y%%NPSQ@7,#(K:QA=0Y]85!MTR19O7%M*V?(1&6:++J?;NGY0HFY?)7'CQ
MO[R=P:_;^4+#G3ZOH0PU%JS3<_R[":((I 5G>"?'  O4UL*V20/ )\S0VXA4
M6#]\!T3HJ2/[H4S'B_# PSQW/I+D2&'DULYR9#_@8806QL9!UK^@J232)'$U
MX#BL[?I[JL;#UCL!UA'#-Z=R?T*K$6RZ3W#P@4MMWHG?E*8[6V]7NJD?X=0T
MKCCW9^'4UT:9&<R.['B:+JW[+4\U'FFEE$N$HBGG*:B\<+ EJ<AC95-IHQMH
MGS<^WE[7PW\)(G /1!Z2^V&^ZPTF1W,? _I$3[6#YSL"8&06 Z!@FA+!4CC5
M>"*(%I02I[(80(?+I5!XJD7;T=6GFOV6TG%1-J1[,[W8:]!=RKZMJ4Q;14$C
M,UHZSKC( (6+S*2,V@3>8%>JD5(6TX%\'X!\7]#]G;<\DSDZ.8AQL20\YY*H
MS.0D5=PE-D6I0K>>R34&EI9X@V!3JV)M9)>$M2;J;-2$3:QD:$^J61"A&$!Q
M%S(SF8P3(U6:8J .SW2<)3S5J0:5CO+T*Y#9<S@SGC!]^0#Y6/$LRY0D5E@'
M])5'1.8T)S*#]4Z8A>U)MIZE8ONRGV=IP$/XK5I\=#Y1QC7JYNV<?A+4P1RD
MM=11S@W-M! LCS)C8I,"D=C05'V5%/8.7JYN.&[MGH\@QX$TSK\W,+PCQ/]V
MZ?U[NGZ^ RR=_-M;ZJA1T@I"G0,*T*DET@(%N(S;2*@4I$V^]2S9%I?/Q_\]
MJMUXA:_(XJ8%@-P0[&07/@"(]RK>'>!7R[IV=Y$>J5! L3Q268:>X5BE"@/J
M5![GJ=-)-$B/!Z:=?7KXVUMM-(>5CTA.&24\C1(XG2)) .DJHR(I<X6M5/GV
MY6B+OO3P4>BWDA_ORX^K) &G(Z=,:$-C3A,EE=,"AL",AMUW]!KA<6-2Z,N5
MES#0T#NZ)03Y] A![)^\55GB<L<5X8 ="7=<D P )-$Z-\(X%0L+*)NN,>/K
MF@Q\<-UT]"?&?_[?-W_^./K!%[+Z!W9ACI4K?S]Z?CL!L0G4\/3$PF^?X$C1
MB>5&ZIA$1EO0N90E6CE#J$ASDU.M(BS43<5U*E>H:S8+*0YM8Q\?N5E_Z(U]
M:&2I1?*/(W4"X/;$RY V?5_Y'6F,,;>#(W>@H0&.W)YV?K] A4?JE*,3,(JC
MC'"!%8MIG)#(*J6IBI1*D';6D$X?C>@91O\B#-E9G&!-U"4:V6H_H7+T"U[G
M ]WNJ#8SDXI89;G- ;NZ-)9<NUQ&6B5 /Y%E R)Y8/+YZ^/!SMM,),99GA.3
M6D:X3#(BA8,_K4UHK#,&&[/UC%\G>>X-D"2)I3035%JGN'*I-HS&*04ERVF9
M*C8 DH>A@T\'']]R8Y,XLQ:T&H"GW.0Q@5,I)PRW))84<*M#.EBCUK:(Y,V?
M=P4A&T$!3U 2L/V/;W/?*5U8HH2"@T1SC @'$()U[_/$QHX)3P'76,XV 8/<
M@80&#')[TC$4M!D761HST&AC923!/@I$LS2'/T%P&);D*8]NAT%:JVH'A70^
M:W$(HI#Q:#X[<3[&N0WUN(18>CX]_TF;*G=CN^Y_9A^Q&MBXZY%'ES'>C6Y5
MS'#3;J0^J&+BPU'JA./@O/1IU46^_'K<Y&@C;[CRK$[<[D3 8 ."8N(+YY4A
MA^IC@84T+=;?0_FJ<JPU&-QTZ 'Q(,S]4V?;=^-_MT=[\&KK_F>!K(:CKMJL
M\LZ(NDYE/Z7:IVS=1%U@"*&O(XY7569V[ED9_;0+GSV-KX+__6A]-=K&H]N)
ML_F7=PPO0V_@M#@IU=F])8-]RP)J+ST0@B?Z_A#P?V\]0VA'O>750K_S.S<;
M?5"E+Q8Y 2DX:="T=X^'L"1?XQ6N";7V T7Y&AV8DV)FBS*XSG5=)6O%_8"A
M4A@M%<(<L*AF$4K86H<TAPXR+Y<=NCGP.3  73>P"WE=7H;C%[.J\ESJ"U[D
M/?>\,J9<^#26.FGP<YV\1CO3$4A3CQ-"]%AGA+[*KW_D,FG_!@EU>1W)$F8P
M<4UOB4G3D&^9T+J,IJ^K9BQ/')\ZZ<<3NE"43E6S*3SO8CG@[=&KU<WJ>LVQ
M.NM)70WK! N33ST8#G%?37?=X'S'Y-<:*]?I3&/<TXFMBSGX^L\*"\!@(,>L
MP@ ,C-XXO^A%R@'IJA"@T2G9&UXP!]X>F>)#48>YE3Y%:H)%&]5D[B-)0*A-
M<?FZS(]%%6L0!^R* J+:#A2\,[UH*VT DY_,?.@P-L7XGX4O27II LA.2.&8
M6.A98TWH7$.^5Y3J"*G![;9C($,1DKH>6;+ONK#!ACR[T4C(1IWI%UB1O>[8
M$'+;\(+.C:&M\YJPG_XA%*)_S6D!>QYJP8>DD>6K^O+CBEC-$ND"*ZXLYKYU
M1$-RL&=M($E;;MM+A'HPOK#VLH)F[Z3Y@%[79FB^LL4'MZS0TA0?N4V.[6KM
M(A2(G<HT-2EB5#PR4BT$6KD+XJXIR.1G5C?0#K%18>D]^X1<ZC/<9!08RSHU
M==&3.M)>^TSA-D.G7DP?HM/RD %9L;U:F/\V,P[AA"&/_HO*SJRII851BOTA
MAIRS9N8>?I^=3^J"XUYDMF7&^^OFE]O-YY/6/-!9R3H.Z^RLF#<ITB&*(U0,
MNGS471,"?#E4&6389!%*(2UTD%5S+_EP:%AE)'0TZ)5&\-I*$R;7CY>L%KYY
MT2TI\KXR[[Y=@MV5]1RO+WLS%,)964<:#95P-F,L#U,)YT:M,_$H*O*+#< F
MOL?!^K(ZGRW'LUI6)U<68]^M2Q-N#54\%K&*+964,V7$5>_Y;#F>U??()%.:
M"Y-8PZ70DL<9=S9B.DJES9* M>J^'K":H4M"0)<^^1ZUM::&-V9M^,: ^@(S
M;'WS$(R++J8A;K:M[#T>'>V\.2*[LS\(&_N#I;ZQ;3J LK%^*Y83F.%;^^BU
M[C)HBZI<G'= 5P&GE:F5$-1CFC&W:DLH]CB9P*GYWDTN>I#,UWJ;US4)O=;@
MU;\ W[#HX PTO_E%<VB?^I+KN!9UM<SFT=UG^JGU%(W.F!OXU)OKA2^ \-'W
MS5N"^N9LKT%@F#\JM1@=[1_R<59.[/;H1B?'[5O4KN6S;]E-Y H.^%+.N1$G
MM(5^T" S\^8C (/%?-9:O[KTUREOW])AK74@UIM=.-^LIM_D /.<0G^+IA=/
M69.V)TUO[EA6'FJ?Z^FN?GD_K:5%>IT,,"0]?T=0B'!4M6[3R=*X%,5N%V6O
M2"1H+OY<'6,M$>1V-.Z6A5EJF[Y9P00I?EXK-#4>_7WJB_UX*W"W E);V&C<
M8EWG[7/ D7X2B(6; JWJO3=#W.R!C<:@:D;UO4?#M$*'D7%MZX!%. 4R@ZU=
M-.AL^R8\=;46??/3ZHJ"^S<M<I]N<I'[^,&+W!\MA>Q*D6K8_XTI4'U1NQ?.
M?K\X./LK.GB^S_XZ?L'_/GYSNG_VWZ>'SP_>[7\Z* [87^SO7_>B@^/3=ZON
MA;^/]]C?[WZ+]C_]?;I_?#HY^/7%Q5]G+_@^P[2ZO1C>_/ZO=[_1PU\/\OWC
MDXO]X_=O4ZY@[0PE(LHQ/H8IHO,L(B*U*DI=ALDCEZH(IM+!/4I;1[EF1LK,
M9G&*TC76B;I4S7X7BWJ:?@7G9OV_H%K]YU_?'RX0"G<LPGJ(BK-<*TU3DRAA
M529CD:</7B%]=]G8ZX/;669\K99,?Y(DN/,V,3KA<922/,LQNSJ-B8P5)=0E
MN4@DU[%0JR3U&/7[W6Y_MVY.U^99+F[>DJEQ@GP\#6["?G\FGX;;26<L>^Z9
MG:/=T?'L'#@NB[*?@@F\QRNC#K-4X?NF(&=[7^MK;#WDS5!\C?5B^F$V@2>]
MFQ5H%6LSW>M4T\8VUMP#Q^&I;T&'7WB#G;_0A<_0A1[D4$ 7G>S-8/TM?57H
M655GBW;0?=D:=TKW$:O2 WB;U<[\@-^:\MS=A^8*6X)V.K*VKL%V_GW'XJ7]
M"&CP(JR_=O./J.ST[FB+FW<WK>["M[IC 3QUROI/ %[!+=XLN)<OW]0&+JU_
M;-]3 4M2E_MN:Y*'R^ML#K/ =E3H'8:;5D;?E*X+]DI8^>48UBW;VOX OY][
MXV-#6CM'O[=$Q2+*200Z[ -GW=W65(C655 D@Z*-]>*4J6<\VJU7J_J6B8*C
M/I\F4;),[FU]_2M^,;2 HS.A=M9?EB0-]12AXNV2,$+EV@#*.YR][(#6_=[T
M),SG<M$OY8/7E%J%9[?$YIT-9=MC$4CMRB?7M3?6=.;JXJ"'A20U :%;O2&?
M/X%X&MK9L.8M7Q^8_'-X_-?;+&8BS7,)F(3!#VSRI#4WA%.=V=1P04V^"C8C
MIO,H2FC.N.-4YI*E5+ T%2*-\CSG-P RFU";]POET9O0O=ZSP/=0@KAS0OF)
M??*UL\-</^)95,Q#P=0<ZP"> S<5>/:?S+"%!<B<IB6IMS(T<CG8!)NX""_K
M2I=/@C.XCL=8GH&M7:>8=UW&:),$NIM/@HVQC0A<GH.7!N$1QS(VI9E'V=FS
M4 &\=YRTPUX1@Z[$L-"J=A).)K./H>PJ=DB?N_/JI]$/Q8\@-WQ_TXMF8O[)
M/U0_AF<O)?C/</7JY?4KO--PIB=M=,<R;,4_S=\*]_:C;CIE;#'ZT3B\[,./
M6(=C9H+O<<U%#3"Y\:M1MO\ CVWIHT\>/V#!&-][9;ER%3RKRHNZAO05;]H>
M[<S;URR+/%T!]KRM^!+->>!=E^NML9"O(-4^UD-6_XP6+OH+\%&=)_D("1_W
M5M_376FDM,9 MED8Z:$AV[4OOW);NT+%H]F.9%%+X7(Y<&H-K7J45+4D;1OJ
M758CO(*\+A/G%=?!TQMRM8_?P7ZU;KEY4[OQR>0][2B9O"&[.\%N;:$@;]O>
MZD'9O#A'JYSO=Q2B>&HTZ^/#^K&F/2D?1'O3>SYWKJK%=U/,#0MIP6,;2=1(
M:%@)!^)^VM'1?!S"DG+K&*5F$!W4C,V0R]!1;8;=&4*K"C@YO"?A9*8F=?M@
M+^7+V46(P$-[ &925;[@A ^*,2&@I!XKL.2?V$D)BP9@P_. W;'Z.IS)V!C>
MQ^XNSD'30GW<N:H-&.[.HBY"@>IRCQUK<.@[X%UQIBR+_81(971E7+V3=>LX
M5;JZ+0"^%2/8 (%@1%$C0)J^ 5ZTV*YHN<3[P5]_<?48^V+@"]LO?SMNV:D\
MX3=DW+%>U$%.E5NIP]4+H,-@]YH0VS#5JCD[%V>-QS; .-]69?1N84\:&N[$
MCUX*#>ZLO*].3M0$N:-RH89]$/,X2'\L7RG+$1VV#ZY&I[./5YP8O<,"CI?:
M@;?^P>&L\N-:-RP,+&SD1C%W9U57V79&5?,E-<*2=A5@C-_&;<*/B\KOAL]D
MJ>KJD4V4=-VG?>[,Z;*8Y%((X O-I;#L)ABMNG;1>EL1PIOKH.26T$<^POG<
MVPT1]V'P.;(^QE+B'QA,V :%CGVLN8]@Z<-W3SX(UML8N36O+D)<MP^*")'3
MG@9! LTPN0' ?>BRUEK5+FWMXS^<7]7'R4NW&O*V"9.YON9A[D/AP_A]N=6Y
M\R7O%B&0'6AP?A'BC.M]M[4*U\+J=F?;IH#K]8^@'Q7+X/W5HZ%?M_"26E);
M9J\]WR[AR69J'QOK:_,!3*G1?LM+E[O6M-Q^@/*GCM+%Z!?\7KNIRXO. M07
M;V/#P.:/:NF#US#FMG-@O5A![5Y7MW$Q!SGRJ2.0L053T'A\^*NW7#<' ^ )
M[??F)C*C:U__W(W=XW,I/U"8K!$QGOE!++37A6GYY$]@=51=S^#5H0#IF5-5
M2+'RR3Y-X.[YHD0G1!7,D($$\**:"*X2F/B>\,0F724\T@O2TG=RK$$"UC]M
M!MH&98_K"/#+#^HL2Q#A ?2ML4 \?CGVNL; 1P$#']48^'IC[Q##NQK#2X<8
MWLT8RU?L9OG90(T56SMEQF19#A-@.4^M4+F5C#&>,[A58U[L^O=\UD:_&8+G
M>J6FJ]P'2U"3BM,<B'6+(G_$U1HYZM3EXJ15U+UN482(N+5%VGM:=OV0VD_=
MG.IM,@UB^=(%GS^\<MD/OD'$00^=G:\QA?G3NCZ9@UL0\U%JW:H.>(29M?EZ
M/B5W+> H,!ZWUI+]4W6K\M6MFF$,%>;?^,3XF]CIEB?D,LK!8Y_3;F8]/OG$
MU2=Y'YFMILS8'A(,SL[+#VR,S771YIXY9Z456MTRK'E"SPJCO1;1O.$R7&M,
M\)N8[W?+LW>_-3"]KDTSFS>EZ[DZL-:RJ0/FG"/ZZ@:%=+F]6F=4^V&]+OIC
M'R!?IFH/VYK'A6B=#NNVN;^8)N8"G(2AU9F^2\M(QW0=E)S5)N&7[1*+JHDE
M/IN!NER'X-</"6C7AY>L3T+NA=FTD!+S^(&)/OH\00P7\)79:S!=^0AD% C+
MY</E\"K*9\>[/=J_O.BMAH+OZH2>=!H)K(N.JDVRW8Q$Y.1EZ$+'WN%U@ ^^
M<6A?P.(KK]VIVJYJ1VCXFM1NF_9QC371VS"#K%IK._+^BIYV>)V)Q><V-ACU
M&OM6G?"(DOERZ]PU?E?E5[+513]O5EWZNTK7M6/6S.8#W6LVZ^0OKNH[XY5Q
MD;[>U,WM]\'HN.#>L+?P&:Q+KO(]@BY:):@U_,S'S?FU1J/RR0$UB[5Q]A_\
M]J^C3TPD#P34R<GMV8S][M1]?D(R\-R<DL5Y/_\T<$]="J,^9L<K%-R:PUL3
M@Y<'=3.AAHDZ33/:(3U^9>]-XV?8O)E<7TX#P<J5"-([2TB(IVP]*=VLCS5G
M3J\^T00AI,^,PB>-VZ3I)7]W+$@6HT,;@UA@)6=G6$D!L=3<G?536Y:NG<!!
MJWQY65[4<!6A(XX)?5>M]&BXL/8/A2,"1NK=69^1,<MQ5;/:G+/LO1Z&V:F+
ML92;[4=+HQ"Z8WR$J1?G[><_AI"-2[/$)Z#,[SIX</+U.Y>'8"\A3X7J$BMG
MT(JC<$U4VI6&B<?"I0\42U=,9S_]BAU;0K3<DX^9N]A_=_+6:2V$%9RX7&>$
M4TM))ITED70J87G",RE6]7CI<B%3GN2"<LYHG%$1*25Y+A.)&2BK,7-^T3^3
M.7(K,EUK)?C\J/JS2'B<&BI5XI*,.YTJDZ:)@)NQ,V7JH@V(%>A%2S?%D2XU
M'5I!3MC]UB.JDT5AO0@,%QPM]-P']TJ1D202FQ8C?3"#5\U*\MJ78AF]P&@Y
M.#;(FEC%EG0N2;MOL6/KR?'SY-6 -CA3F^(Q:U(&DBAI.ZEW*BBIIGZ5)X=&
M'6L(IU_4+*@*00,T!59J D4KJ$^U1[TH^[2S[9O.]\FI#9KPAU-CY;C< FLE
MTJ%N\ZY('48=3$IMSD5S]LW:2+UU!43:LB']4DAK$CI'EQ+2'C J^Q6&\[E7
MF'9:#<?)_O'^VX2F:92"@%$*0[!-DA+ME"5<QRJ-.!56V>\A-RSL^2/4(A!-
M@E)_$OIO=CJ)^@E= <Y]E]R5:X-)E\QRXEW#6-BHZ:>[>N6RZMRL+8JWCLM[
M%8=JF^[J$_I>>=4H\R$;*<@TK+P5K.CAYE;G"68KU2VW5S9%6.N:ILNTKM;2
M[55J>(;7>&9E.?O8Z6A:2]J@G2-(Q_2JB5\RKYBWVHP?B;?-3^LB=SCG,,<U
M*UFL:FCM @1UO#&-AP27<U7X .!.5-FJ$;L3;[0<CZ>!>H27QH;U/QHC%:Y;
M8W6$9[N/:#\_7Q8(",^N[0O-YV6O8B &7_D26EB5$QT4&#/PV!BH^*=>W"8I
MJ*V[=:G_:,M3N)<=3O*DXBU(N.GXCII20@!!'5;8EE_T^^3M3'U#Y_(M;6O@
M&QZA*^4$MT=_--;G%7;I5''T7ZQYY>IAWQ23_,:Y4B&1:V=JGR]]8R_"F)]N
MYO8[\S9.96*M2HG-=$(XJ$A$6VZ)$Y&3G&6I2?/OX71^TTWEZ]# J":";YMJ
M>1.A)S='Z'5.D669SF4VMD^ZGL#(7>,Y]J?3M0F5.4C-?C!Y_;47+AB)5\[.
M&WNU=1-0.\J+$%<*DS[QULWG!SMPWAL3XE+QK^+L;#'UIFUUWN2)V_V=7T#$
MO?E,;F?5C#P<3_5G;6E<D+>U23$H49]-0>W(S@I 3=D,IXZ>0_>),MU:C\$B
MCT? *<#E=@CCI9M_CGYT7V>H]HXL\X:6]]=J9'/[32;NO8:GN']^([IU9JME
M['HKV.O2H^WM=6G;-AQP>0XBY39E6C]+"IU*6<N/6J=?2&SK>C&:VJ/K^C+W
M@0\HF(7[6/MQ?"'E:F51V[-\69%@5KYO=MS91D\'<JTS%);.4SRF9_.F(/&2
M8MI'80$"/]%I">,/89\ M<XGKO$75W,@E-XVAE*<_6F$9 [<$6Q<'0(**_0[
M=S%66'!_EO>'Z&$!#E"=G\.B-4&=C4FIPM+]=2;#<JO:;I^S<G7%ZMCK,V71
M>567IUZ])KRP7Y  =Z-JJ<N3=!NWB-3:?MNGRF:'^LZI8MKQ,^3*-'Z1$Y\H
M7E1NF6 5G@MC-FCZ?S^=?9QNC_[CVT&'G)IQ9VA>I 7#R;(JW++TM$_<K,)L
MKN>NGS&V/^3.J]'9S+9%=-N)E+/Y# B[3B+I+R N.^I#J%4T]6/;M>V7E5;U
M8JT4:OBOAC]7,=_U\.P1GO@/#"E_G<TL!B<!I-R;SF'_L?K[CB_F.]A]]I^;
MMX[EN4F=(P G(\(C^"$3;4B64&9C%2O%+Z7>V\QHH:(HYXGC+DITFG(CX]@R
MIBD7\2H2_</[[VM.6&[#:&=95+G9I^M]#4/T[FKT+ANB=S=C+%\Q>O>ST;BK
M7C]A)4UHYA1U/.$)L+2U.K>9BVQB9'9ET=S/LGG_/5I*FSB:I%A+3%DKC4SS
MF"5QQE64)W)#5-+K,XR6TJDI^5[Z*+MR'HQ M:VG*#NVR$7E\@46M/V N!KO
M;R(!>G. ,1E2_$-."PO3_.G)'#6'Q^_YX6]OX7AFFMN4Q'D:$SC6<Z(BDQ')
M(Q7'*:-8?>[9_..L9@2$1->A@T1GP&5)QB0#HLZ-9!&6BS41%7E&:;(6'70Z
MK.%V_&07)?9+6H4-+PLL9_H*O68KL.%WO]>OBMP],<  NR@.?GN;.LXY!;R0
M)-9@KT4'9TIJB:4N8R:.E.1QM^EO<Y"'HG*XUNBC-#Y]%^'Y.G:KQ0HH.#ZJ
M&KFIQNANV1.B]A2TY:D_M(;V3B\'VQC)0QX8A@O"FZMBF7;;K2@\F];.T6 0
M\26F?/3DLM535^=;T? [P;7J\OS"+;Z)@_=8V%!(H*,(+SVQS10751."6*U_
MY@;&]=TH]72I8;8VZ)[3)%=%N?0)]?-\O<NDJ0&X%,S+Q>^;Z)L4OL9&7YW"
M'2$^S<>D^D(_71F>MV&?W71]-0\&^,N&_L86U@3:+;7O^4K9P64P'I(!%B8"
M%;6<AM"PFIP7Z%S9\5I?V]@DL$[;W2281DWWJ[J[VTJKKMKD=YG'5L+56HH-
M?!% NF_WLG/DW_9+,?-F@'UG/;T?]^QY>U.S/?IAJ[ZHZ:K;:>+398)N@ZD.
M+8Q][0C/GW6H;,B;Q\VMFU!Y:PU\>IM6G#;F&9P&TC)%>9123:5)K:.9 9(S
MS&$?Q>9D^,*NO*M:Y8&;O_BGGF.CU&Q.5\ZOKF3N\(-W[]\RFC$NG"0Y'/NA
M,:OD5!";41GI"  C$UB@.KZZ+2?2U&VV7E*7FBBG,7,Q-T+J7,96Q2[/M4B%
M2-:WT!RV_EZW_I-YF^C8ZL19DL54$JX9)0HT$4)53G7"8@.Z 6[]FIZ\]=:/
M.V66)A>/[<A#C-&X\'O%^]OC;9U\]D=]M5+2Y$R]=Y\KC-)IIKEZ#MRFQ=/Z
M_HO+7HG8Z* HVPYDEZ?01'27/O+<85;AM*FD53>L0BMI;9'%8J%%"9+?MRGP
M'^!),W?+J ZCRM(?Q<MB77B"^IB+3M]2Q!,?7./ON+0&37D"G^VCRK:S@F\W
MZD>(&]).KAE'TQBB/J3;?FX]3]AZ+-OBFM:(Z_L6=L+<0Z!X"^^6_4;&39.5
MME-@U]> 9O-9W1.U.^+EXMFU=2K:YJ?MBK:4&#+B^K/ F2WA&-9P*B:=5$G$
MM*TQOEOUV;=*J9?)]Z*L/58=&EJN;6_1^Z/6Z+OY4 >_7%[_D,S0CW LYNM
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M5DONY/<0K+O<^-&K90?L[ZH;P;+T!,H3ZW202BCP?4I+M0CVBM52HZ'NQ[+
M/U9_ A1AK;>^G)W/IDT\_^J5'IGF%Z'4<,M8]1GCPU*;BDK==@+%>F%TM6VG
MCD!KVK1V2O7ZOHP-\+P"Y?J#NIG/<IBU;H97><>;K_2QIAMY4S)YF6G89LDL
MH?_R^.V\VR[:1I^7RB36V1IEDV=1'Q0^;O"'.J[OQTYC@=OE6NRMFJ@^>J33
M6PEX%!X1RUR:.L+/?SSW\KG &B2+9GF[R & A"[@ *AK!H=5J+&4FE1-2ZBU
MR]X^M-LX8=T[V]HY5[XYP(O.2*YXCQ_6:K4O+!$T/9FX$"GK&^.NO3W0H)G
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MY//A6]'ZU#[XO.-9ZS"G37TA>T0XZ8U1.3/*(HZY1$YSAJ1TB1%-I1*QTFT
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M&;J6@_6KAH@]SK9LUS NA!&1  \EK0)7R8!Q$8D24?O@HF:D/EC?-(Z:JR$
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MK^6!DK\UR$G\,3SC8.D\)["#MT>!"A(<C<AY:A'G@2$;74")6*XXME%@EH?
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M0*(C1F0QNSY+\=%F;ZV2LIL,WYKGFMN/WEK-GYL%&I)2TF/C"0V8:ZLM9D0
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MJV'S';XXXBERZDU$/N8B8>LM,BPQI)F'0Q.$)9-#D3L81(91RT,#*WER'PX
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M7K6[Z_[.=;"+[48VE0&U8[;V[3(XB] ;9<?M^.7J"XJK%[XMOO?)E\_ 7_>
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M"84(-1AL^^01R%N"2'(V:F&)*YKN6B5F6>&X;[+(JO2F_)!R.LHQ RJYBT2
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M8F 3,?!N7NNC)GEKDD"$<(&XDP%IFA(RCM,@G8PJ3P=[<(?=K>.23]F5MT7
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M%;(]!;)=!1O?S@\-K(N.7B)8L)R(B!Q9H2E220=O,(7_XHQL]/HF]<)'V*H
MHPHPJ@"CJ*Q\P?!B2/TZNUB5L7[LU*RV*5_!T*0J-%O<?'^8#DP84RP&YA#7
MN:6I"AH9EKLE11V)9-+8R(K 9,D;"(_2E/4(6RJ<?)4XN=(A3X68#T',B8 '
M'SJ=>'1!(A,IAH#')61$TH"=UGN;I%!1%P'/8\XGK@!8%G[VOPI:_NT;F[)4
M;0"J-@!5&X!E4JTW<E^HJ@M U05@%:>LZ@)0=0%XKD&^AH-$C5$SOR62_T\W
M!ZPX_RN.[05(=A[4N;#BV)Z-34_?'<-U/^ ZUJ#U"_@='YQX\?7W _C>APL8
M[X^ONY_A^W4\&YL>?'DK&KMO6?[NP>5[^/UCLW'9^O;UY.BRL?M'J[X/\>K^
M;Z<'EQ^GV?_W#PYI"-[P&!!GQ"#NB44:VX0<3M+%8&-R8+@(IYM8T4VEU&J0
M;%>H5*'2K:AD-0N&T8AU,-S(8&RRD3L,*&6TUG*8'B,5\_^*H-+H5!>#,1Z"
M*:$T)(L8CQAQIS!R#*#),F.MILFGQ#:V-=F41FT2?;T"JF+^KYC_7R'=QU-X
M9Q7S_PH Y!3S/[AM+$I":))(,R_ =Y,!&68PTB$X0X)RFO**^?\5Z/?C_9Q*
MOU=#OZ<<($R3BBHR)'%,H-\>PC(7$L*)>A=LPL'(5=3O5Y&!NXWM?SJ55I'\
M5Q37/WGV[?507#^7*?@T[>K%%*E74B(,ZPNF0&0Z(X:1QT$(YZ3P2BTY0[<:
M)745#E8XN#[YO@H'EX^#4RZQ9UZ%)#G2RMG<_0J"7P _Y)A)++ 4N:7+S0FN
MP=FABNJ_HOJOJ/Y?_!ZO(?/_1%3_RZ@]J;*%]V=P6NZ&0$7^_2*^T13#_\G.
MH;$<JT0$<E;G8P7$@V\4.?+@$T6AC*&XJ.+0FU+(32[X"J4,*R5?OI(O=U>@
M4O*74O*) .C@T+!D( 1BR'J=$#>>(A.H1,+)R&1T.EB^L6WT)L69PK%B^']>
M#:T8_E<'_YZGZN%5\WT_%PA^FO9THI3..H91POGPN8\!X#!QE""T%98EXKQ=
MVL;HZA6L5EK^[+4/E98_BY9/N3K:1XZC [7VF8XV9(8H1PFRA@H15!!6+Z^\
MJ:H 73:G_Q**("JZ[M7S@RJZ[I<JCY^B\G]_?IBDPLZ[  &@#X"/@@(T>H><
MX='0R)+*H>#R\SVK41A08</J>4\5-KP@-HS)9BYWZ*%.C&/ ?<25M(@3;P ;
MF$2)B"!\,(D0]@1IHC78+%^QG<2*:',M_=_&-0>W(O"O"*^?F?WMD8[]*R6\
M?C:3/$GE_UX<\N1U9 R<=,8\XM)Q9'#$R,<@!65)4\\S_YNYWE9GQ0BO*U"K
M0.W)0.V1$4D%:D\-:A-QAC@,1 8F2$#.!H-XBA)ISAF*L(2>TN082QG4]/)(
M+:O@H@HN7E]P\=+D_945?E56^-E"BZHB;'$;_&$ZL!"8Z*2C0P([C;@W"CE&
M$])>4U@<S:0E56!10=HKA[1G"RPJ2'L(I$V%%<8GXJD##&.&(<YRU4?R%GEK
M,57!:^["3QM6/#G]]B-B@2=\X)R^ 7EMLPXWVX/B5-IH<[,@WVCZ);@LTYK\
MR1_',&C%O;0##PW7^6Y^^-8@Q/"NVSE]TSD]&_2+8>VE60C8AU']UNKX;^NI
M_*WXGX\77[^$,T>YK)^^/Z^??/BQM_OUI'[I09$/0*F/+O=V07GW/^.#_3^^
M?87?]_;_R/N0HG%T:(,G.FB!C,2@OB1R9'0N4E=4$1LDC8*4Z PK&\-.WCXV
MS%M8)2R)8YQ+Z12AEON M;-)6$#S"(AZ!JO5[P[BQKRF$L,6$J6&-MLAMON_
M4E5(V#,;*9J-U/YQK*5.J]4YSX?@AETM!J<P6+A);Z(N?'1D[NH,73XU7NL?
MVW[M/'9C+0[EKI9 \.#S.%5H=4/#MQI DA^T"@FMN>AMKM&"9\#7F]V:A4>C
M<8UZ+,O6<R57OGO_N!MC#4:2FPG$Z\T$:EF!"AZ_;"E_O2IE7_]N'XIL$77S
MGQ_1ZD+PY3<1P5N"/$D3$2K9?6\[!_I'JP50'1>_\@:321]C,J\W];B'!5O*
M:]PUY+4^&EZ27-0*EHO:V_\.FM_!YVWW>X]ID#''\UKU]A;WZ@BRC+X?:S@W
M,ZT_7D#3EI43AN5XH7!W[RPK7B^W>#@;=/UQYMJ==!5NG.''%#^^BOI'&1SX
MFUY1$C"'T,%):XEV5!)NDV+VCDZCB]0_/C*DV#F%Q?M9#I0<_#@X?7MY</GA
MLG%RA!LPKOKE9P'CA.]\/=[[ O?[_3UI[!]=SJ85OIZ\:Q[L-TX:NW6ZMPO/
M^OW]96._U:KO_W8*SQ,')Q_.#TX^D[W=1AIE28L#)9<?#FVB# )$C2(W G'%
M+;(R**1IM)(39\!%V]@FQ&QRII^Z(G+%<J859-R[9-HP)[4.7###C0M6)XVQ
MYI8G[;%/=_3<K"!CQ2'C<@HR L4^:H\DIP%QSPTR-G$4-2;2&J\T \@PFT:1
M36JNLRZN%6@\J1?VN)NORY7/Q''P<J[HI]C]WO01.?!!0RVW<.@V?<Y$E3FK
M#)TW1W_5>>6-)N=6LI#W,:3AC#NP'I(+L!^<8\*-7\SCO.F\<F4YGMMRC/:O
M1I9#@,706GF$M;>(!QF0HYZ@)$-*AO)@$E[%T\L51\'R=3X))E@TT;' N'?*
M:DT#(X;GMFN&5B[CFBO^E,M():4Q85#\Y!3BT7MDC4S($6\#YER*0#:VZ2:A
M9),)L_*J7^7F;D6"-YUV,9:\BW76C2EVNR-OZ#%IN9\>$P5Q)CD6A1.16T8
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M'I.@1''FF#-1*ZDUBQ#ZD"@J_V=MM7[*_V%,TV#RH7<N,>(._!]#"4%$RB
M\"/H_?K4_ZU$VJ>$ [W*CM!^IV];2SB.-SPQ/T.<D<?^N@_?8&H%@XGRA@BN
M%38V.6^EM\JHE/""&:/*<5HM"+VJ&OH!8Z2'SK+@&3<H&)'K!RQ')@6,C,8Z
M'\AQ'N>=,[I)%-E4BBSW^,T2='"-$D\5\-P*/,$'9H@,.";&>>+:$:*2T$8$
MB8FRU:[=>@//Y03P\$."B63>:N1)3EXI&\%YHQQA(;.AT=P8<&ZHW)1:;BJY
MY/8I*P<\2_#^KA-[7?%XS2/ZNHU$: @8V__7=?^U?2/WT%#9.=U2F13JK--K
M%O0EW9@YD;['*ZZ@?TRS20T?A*^^8AW,]*!_\U>N<7"\$.44Y=/3,?GS>,RH
M<V:/(G+=:+\AFV"PO]K6N;WH;?QK>MIASF?F</;U;UZ'\N?,JI9 1+P*"8(B
M8G$^  ?1;V*1Y:JGZ*QE<>.&[]U)$+80\]1K(PF;YI-^!#<8V)J*&JRB!JNH
MP2IJL(H:K*(&JZC!*FJPGS/B]\)B28UUP4K.*=%&&2N<9)J32(A<8MOD*N(?
M1_PGC6\',);&_K?S^NG;BX/]C_", WX 8_OZY3VMG^R('/G73\*WV8B_3N%[
MO[\G>_L[\+T_CF&\K:\GQ\T#^G?KX.3@HK[;RI'_18-^G*0&.S_4VGKL/$;$
M:XUX4@X9!S^8T)$X$F1@/)/\4(,W&5]SDI^*&>S)$$-+G!R$HTD3S1U1!@)6
MQB(GAD:BR3*;*5>(\0*(<3E&#.>)\3I)9*@SB'.LD3,XMSWC3! C&?Q2T8)5
MM&"OI@"PH@5[[/Y2U YS%[@7D1OKG1'.*HXY%Y&)Q"MO<XUMQP0W&-B.Y&+2
MQB)+A$?<Y^:9SCM$-*-:NFB,RGM+FT++34,>O;54E0.NM-Z3P(@0%A0^:1ZQ
MTSX:)JV-RH;$G*E\QO76^RN?45NM"982:2<<XB(09!B8S!B83N!')BM2Q0OV
MTR3F0&T*S6P_A5?T6@Z+.:DC%E$;\(@R2:JU&.L8B11&>(Q]Y16M,SI>E?M=
M-O9W+@\99]CH0!''&2&=]TAS&Q"@)$[$1S"(?F-;2@;X^.B3\M4QT=76?*LP
M#<)X(BG(@-(^A("=)2EYSBA=S"^JCDFLD-)?3BD]-C0FK@R200C$M;-(2\$1
MM9@EG#0C25?G1'^2--&RR5)?391HA;34D4@-Y51H[<$**L4==Q [JFHO<LTA
M\2H[1 B)$7.,I$D:<44MLN %(Q$9<U0&)P-?$E-JE1E::9T7^3RHMX1:B3DX
M.,9:+< ?%N /42))E1E:;YV_R@P9 '<I/46.9)I4">KN1&((O%_C19#"Q[0D
MFM0J*[0Z#M##:5)?2Q"HK#8Z.443L=PDX8)27J@8J& N5"58ZPV!DR581#%E
MB*"(6)T03X8C2XU"CF8)X%S9Q);)D5IE?U9:\:G#@@D<B4N!!V,=YX+:F'*W
M+$.2JWR?]5;\*]]'QJ0H21;11$'Q;1#(X,11"@Y$7?N@I5PF06J5 ?H9"%)?
M30P8A,E,T13SR)U1UF& 0F-!B$/PWBWF %59\)6!P(L)WT<E2:QP%(6H,CNJ
M(\A&YE'P25F/HW3"K ]34)7T>93CHR7Q(9<6F\1)$$YH)0*FEN'DI-65X[/>
M6G_E^"1!6>[]BHB)%B(>[L#QL0;%X*V)7N:3 SG1JXS9Q(^GMJD2/S\'0^IK
MB0"M((P91ZF)B5M)G2'4D<!D(BRZDF^G2OVL*1#N3=9#$XV3$#XBGP)#7'*&
MG+<.44[!U25<"<R72(]:97Y66N^E"$KF?A :,ZY#M%03J7%,QE"'[8)GZ*J(
M9X54?J(46C'NL)%(TJ 1QTKGWN@!245@_9V+D2XOXGD=&9^?FAMU^,H51>$=
MQ=(L"0YAHHR>AR!-\$(3)T)D.OH@*I=IG?%SLDB(2P)&T@4DC"&(VQ20Y<JC
MX*+!TI,$+G,F@]L4AFX:KI<4/*XJ/>&3IIPJT+D]3M,L&$8CUL%P(X.QR48P
M[@!"1FM=<1ZL.>A<.6W@1CF-/097+3MM$(HA*XQ"FFI87@J HG)E(M[D6FQJ
MMJQ2I54%G2?A1)WF0%V,%74=^!,5YT]!24@>R'3X(OR))>_G*O$GLI^+/G'U
MZ#^J2:@FH9J$:A*J2:@FH9J$:A*>?1*F(XT<112QKW+,<.]<)")RG+A+/KJ@
M.!56"D7%H3(;VW=1M[-GX,Z_QB!<^-#@3-=J_W>JE<02,J+328?=9L^W.KU!
M-^ZEG%Z([5X1BWW,721B>-/I]7M%>N&WS/'QE[TXS237^S"$WUH=_^V%DPQ[
MGT9)ACH_@&?!=W\T]C^>-$X^B,9N YX#HSG]^"W?I_&E\>U@_P/^DWULQ?]\
MO/CZ)9PYRF7]\KC9@/'5+W,RHDX;N]]PG?X!3_0Y,9''3 [HQ^/&[L?4N'R+
M&R='%XW]S[R1F[;L'%)FDXE&(E@)A4#:*#*)<10QB<PP'SAV94X)PMP8=G(F
MR%B=,/PG4JVY94E3^(01$TA,-CJQ48L];\]@F?K= 4AZ03*.BA6H32[2]3XC
MP]S#S=TI[G[T]%"M$XY3'X7UDAMB'9-4:H>U8BD*$C:N]PE9C:83>9YL^Z+6
M;/M!MU<KSF /B6K\Q!36XH_\>ZQU2X'/1-/SB6R*I@_EOSLE*?56K>AN89O=
MVG?;&A0=)JY]M]FKA=B/W5,89:BYBZ+)1%:YW _C#"X=-:88C?A_>K6I#AC=
M>-;IYOO!)_FRANT%^]_:[ZV.LZW:I]C*W2OJMOLM]D>7!'B3?->CKFWWRU&.
MI@.&USR%/_>*"Z?'/O5RY9?AL8-BI/GJWUH6YO"3/^ZT<J>.XKKB%?(%IYT0
M6^6S[KZN=F[SM'R/K<Y9[NC1Z=9RAXYF>S2^T2.G!]COVMR08SC"S=KY<=,?
MUX[M]WS8K/8]?Q>^-UJ"XBWRHN6&(&G0:EWD&[1[*7:SM=BJO6_7<DB?+]P<
M#3,_JQ2,8J ]N-M_!TVX01Y-LWTVZ!<S-7 G,.VY?8CM]0:GHP&!L+4&833X
M+%H3DE N]O=.;DO2:O8OBK&-KQD^O]5,<7K%["DL?]$L9<Z$P"?VW'9#+R^]
MA0=U;=8#E'6B!M(.TM?Y'LO.)L6;])H@&J.9.@/UZH3I&VW5WHZ&-#%4N$^I
M._"8XR:\3S=GSR:N*,<\?IO\&OF^L\)TPWVFOE?>JMOL?4.I&_.L@_K B&O=
M+-:3=\BC_KSU";[0C19LV$7MHAE;H9"CLJN+[1<7@4S-*@2@5A-P*HR^,G/;
M9'V_;#X#DC6ZME?*FHL1Y-DVP\0KM,KES)Y)(6\ .EU 0?AX_&Z +"Z6WVL.
M']*!]XJQ2&.F01^,\%;M&H8_H?$'%8UAT +3?\W$[V1A*.S.D('_[Y%B[%P)
M_'X>^6OU!>J7]<O&^:&Q3$GB*1(A6<0YQ\@9(I%S+!H:@@>O<]:>SW$V5[!M
M4WD!""[(?-<>34%=ANNQ&$_C?0GP&=*'D%8H7='!(9Z>M3H7,9:P' !6/:A/
MKU"8LZP*!48XL KGOX[T8/+M;]Q$>:YIJ=VWWY.8WJ_(MW^B#0O#MWBYZ[#H
M?H506UHM?PM ;TE!GV*[0MV[+]/3C'4MPN&%KKSW'-(MJN329U]M"?DD&UM/
M("EJ2]'[C74=FU_-KY28OZ%]R\[8"_=E,O?JR[1_G)W*>MGA[^WU#G]/WK/I
ML5<^8,MR+1:FD6.6>Z[+PY7L9 "Q3[I8(SU;K^9H]UOK>S:.N]<+_R1=Y>X[
M<<_056X5KWREJUVIR7+4Y*<_@/EQ?K[L/M*SC'Y,+R4.CRWZ;0^R?S%[2CUR
MS*,DW ?+M7)66RD\ICPF'1@VP]2:NN&D ;^69QMGUR9W;W:Z7=L^BCG;]MO%
M_ 3<.]OLYL1;G$BZY85^!^O\?KC,'V&5QU6_B*YG%JXL^SW]>'KPY>_6WN[G
MR_J^OVSLPW@N&\<'7^KG>_MU6K^LX_I^_?+@Q)/9LM^OOW\]_OKE,V_LP_,N
MZZ2QZUF=OCL^N-P1\(W+^N6''_7+1K-Q^?=T<T2+C8N9E(MB9A W*2)G9$!6
MZ2BTMXDRNK&-M]CU3C7_>(QR+0++E8+.*"A.Q$5N0#L#YD9I[6.RL))&8D(]
M&=%(J!NJ\BL%77D%O9PX#!2X8@DC'&E 7%.&'%8>.24CCH82(?W&-ME2#U/0
M=?%_[W]E!3E/ 3F,A POV!LB.(E8.\*""Y0FQ;'U=W%U5I"S\I#SHSZB;=@Y
MI-H0&E3*+)T1<14DTE(FQ)GGDBIO5.:LPEOR.E-GY16\E(H&(V@B."J).=<8
M.YJIY3C5FCDMM;_CK%ZEHFN@HLVQBEI/HY4$W'5P_D!%I4;648HXT9002B)U
M:F.;;O'KG)K_>%QJ8-TX*><4]#P(H^Y^[[6'D$=&_O1)(62TCG^/E[$"D85!
M9)*94O($7ETR*'#"$/>,(J>Q0#)@\/)TPDZYC6W]L,#B4:;\%:C:(V/X2M76
M0-4FZ"!UM#[R;*AQ3K,1".!#B,A$I[R$8,H0O;$MJQC^GHA0H<J3A.D5JJP!
MJDP&ZHP)$N ' @_-(^ZP19IRC)(*(@ECB=5X8UNIRH2O7L!=*=M:*-M5R!US
M'!2<1Q8\8] X8Y#CT2.-(R4JR) T!66[SF'ZR(![W?;BWTX=@VFV:Q?1=F_F
M0W[<JZ\NBLP]MO*@"'N"0PO&Y'\-@VZ>TKGXX>[&#[<(?NS'[BFIL.).K&A,
MDAX[GGP@T2(%E@!\?J:0BQZC(*TCEB<J ]G8%EOFQB.L+Y0\_WD4[4'Q=:5H
M:Z%H$[OCS.2:E8"T%>#_@C>&=(H<$<:L5\;&2!/$U5OD 8JV+L'RBFR-_SS0
M\: @NH*.M8".R>"94Q>T-A2!D8 (&@N''$1QR$2<K%-.<NDJ*_VDJO:@$+I2
MM351M:O0V25CG*<1197S5,E)9"WC2',>*94FP8]LI^FMJO;3;U7O3K$R5+O4
M3[)+_;[Q[GYM1)XD'S=:XJELW$NS5:\%HDQ2Y#,C%-7@]Z=D,.)4*F3 14/$
M>6%SI"=QN+G%2)7[?NGMZTH'UU4'KV)O Z&0,U@CP3#+L7?N[!4=HCKP:%.*
M5,9'Z>"ZA-75OO:J[VM7<+.N<#,9KPMOO.4X(&JM0MQYBZSF%-E 8E2,<H]E
M9?17=\.[TL+UU<*K4)X&R;CE!#$ 8C#[!EQO1SBRDBIJE*<<TWMJ8<7@7%UY
MSRMOZ*@SF2DJ/BRERW7_M7U/JCJV0JR#N8/BF"5PBB2P=@\"7]\Y:L/3QKR$
M -TA_RE_H5T<@[(E&RO\3T%C73*4QJXM.0TS9V'!%EHP1!5TGIF2Z+2D)(K7
M*8EJV=4JN&S_SXUV9- +LZZ< 1/"<1):6)X8UHSIQ)/66!EG"+XC>X/$ CW%
MYAN2,?K+]43_AW-V[G^^V-LYM,8ZE1)#&EN+N.<2Z0 P+G%0BA#*1#XZQ*[V
M/<;H70.I;^7US=*QR*)3;:@@$!5RRCCES'E,A+3).R\QD?$._[U:]$<M^F7C
MPZ$,)JC(,$I.Y*:2TB ;M4/"!JRU#6"NW<8V(5O7R]=&J[Z9N:7/2N+GUL5F
MAH^2@GH12<@-+*F52:F<.*+$@%<OX.%61Y[WW):I_CNM5L=GT)LO$F]+Z'S-
MDD'K^6P"4Y0$@@1C-'=H5\ABGQ#.2^4D9B+D=J-7-12/AX/( I?4.YXW6;%+
M&OQ&"]$]%9+PQ-4RX: 2@KN$@(%7GR"@,UPF1&4^3LIB1#:!?T]U=-9@C0EG
M4QMT=Z)#]@M*0OC2)<D$Q[8+:%'X-27Y?79#1AY,;W-A,5)6$NV#,XPJ[IEW
M5.&4I L64RI$A27/*48'N+%S&*),&%0;.>-];EULD-.YKH(%E]=*>Q,R6\GU
MGL4/QA)ED_),Q$04XXPD!\)@ C,>)Q($IA66/*<0D/J'0W K<0#KCI22$G$<
M"00N6"*AI"6,>X$]V=CFMPC!75AR%-L0MK3*]A;AM-ENYM8/14.*$9IL5?'?
M,\1_Q"P<_Q&N!-=<B^@#YX8XK&U,1F'P1J6G_(Z=PRH4>(Q^'M%&KGL#DZD@
MZO,LY3PZY2A'WXBG( +HIO7YT-A205I8X<"=D-))RRFU6CDA!-$.*VZ-$G=D
MCJM%?]2B,P!E);4U+$@40^2(:Q^1]C) _$>M$Y(Q0>/&MK[%RU]*^.>DHC0(
M8:1S'&(_AZES@46PR\X9;>_2?O9TUGI-]P(>(QAB;^<0@C!/E0+/7Q4,3^"M
M:2LUBHHS#(X4_ !K;2C=!.MW73@610(?B218F(@5Q( <P-]0%H*6L-9>>K-,
M)*C<M3L$X-MYS@Q9370P# 4%EH ;FA#$50QI052F!V4TT%P&?7]D>(;0+R8!
MOCTQ*O+$&8V.)&- >!,&Z;*!5CCRG&+$ $>B]UH2'A"/FH(OX24R&.P-=RPY
M(DSPGH.!T6)).$*HD8(8PCW\/T26B0)>\2A]M-HG7N'(<PH !QS)(!)IQ"A*
M!LXD%1PYB06":# ZJT3N!9:W%>Z?8'Z*L&_%.HWM]*]BJK(1QFAC;3,'8]VX
M<'P5&-=$)!.H)1PKXHCQ*L2<*(O!TWCX_M%ID+?#$/53['X'@SY?*QJ==FZT
M&$-1F=$K@MO)O^?>NHU._R#"N$>AZ^M5H9,=5C\_9. =J> PN.9Y9\YXFS-G
M$3E%L1<YJ24!0\W6=3Z/<626NUD6>81!>R(E<%?/U\%PK6I335!'+4:;O=DV
MCA.W+AILVG&[/#1JEW?577/I;1SO>0#HR<3TK^+5WG6ZPX_R=6MZ*.@1$OO^
M B0VA@ .8Q3()@6V7AN06.[R8D5#*-4"'/N\>73M8$])"K%N<#VW,631X;'L
M.CS1GQ;DO];+(K=9 TSS@U+7%FDGO'DW]H,D%F(]N\E*K6 QIJ)<5BML;'+>
M2F^542GA\&P\CL/NJ;\7/3#?MTO%^3*<P)UR_HH_[L+LC*OW7J\K?5+']:-#
M(Q-6S( ##0N6FZI'9)T5X%,IZ6CT&$+HC6U"M_"<$HT['>D;9.9!2%S)S$K(
MS-Z'PUQ'1;*O()D'F8%%1$X8AX@/$!LG[:@*>0-7S<GJYLS_+=L.U]I8@[T=
MH=ABQ6*S#OY#935X\(6(##@FQGGBVA&BDM!&!(F)NBN+6,GJB\GJATMP&FC4
MRF$;4-X* GR+')D(4@LA8K0R2$89RQL0<_@P'RPR5K-@&(2G$*5R(P.81!NY
MPP!W1FLMGXVLK1*9144&UW<.#>6,)4^0=P;D)E@0&2482CI@9BVSGHK"SYR3
M77@F>"-F&MYFF]FOO'.[_%R$-1['Z"FS3'(EHTX6W K) R6<!>JJ7,1*:MSG
MR[V=0\Q9Y$*23*UD$8^*(6,@QLNUVBJR:+G-3NAM^;S')B-RHP@(B*[R$EG4
M>K5?-CY^^MS;^.<SI"? 'Z99=@.U&GXHBZUV3E''K0 [,K]0L4I/K((0'XC&
M^2'7D6%%"'*,@%>,540FY,6*."F0X"25GJIMG4E/U&8P/%^5!:39'MCR/-,$
MJ@_!E-,ME5']K-,KIO[70K3!)/Q[V&>]/'DW\<5A*1*^^HIUO4YKT+_Y*]>.
M%;Z0S:!B9H(F?AYWKPY6'D7DNM%^0S;!8'^UK7-[T=OXU[15!),X,X>SKW_S
M 9_RY\SRE#)OG7"<^B@LF!Y#K&.22NVP5BQ%0<+&&MCFAR2>'IP^>A#J/86O
M_/:_@V;_XGT;S,"@*%G;RW[(_K%M5U[T@G#H\_Y"2M0(1CV*WF& 0VN154H@
M!W@H'8_89UY2LT7FE'EG+SK;W7EN\GUB_ZW:?NE#YA\W"F4AN+W9O5Z77 P1
MNQ A9$O4$@)1/]%>1<J$3PL2_A1&&9S*\PY8U-A^*6E]S<*(]W8]V]O?88V\
MC?#AD#@/L!P=(IR"G::9,%<GAI@FTL@DI,9V8[O=N2Z6-XED&;G=1R:?#U<5
M%LP38HT.CF,CK8D<A)I#>.0Y,>[9TE85KBY-E(_RL0<6F?=4>.2<9XB3()")
M1@+,<F,"?*;*(U1R3O+UH0DM8D2F.V/!"GA*(C80Z9QD(>4=.7]726TE3*LH
M3*2HU!6!)6:0I5@B+I-"EG&(7*53T@%D6)V*.IHYFS^W&>E'Y;+N>9HB>\RK
MZT!/@#G$_?.3?_U.#684C?*%O0+L(0('M;EM_W9JXQ;,2I'UN//01KJ6@\S+
M,[6 U\;S3,?T'57Y5*A6)E >/#8).YQIO90Q#*;XKK-UBQ18WE&Q_^IP *ZI
M'QUR"%I%)DEUF.83VP8CK3PXZU;9E(OG0Y&[4'HY!97,*9R,D$DZRYT-+O.W
MF=RN@&@(E^\\DULM^*,6?._#83ZW2/..F.+Y- Z. /R>0[ F TG68ZU$R!6T
M?.Z"SVX^K!@$/>"DF- "<P8!7U")JRAM] &<'&L]M<:+N,P:[THB9R2R?@ZN
MB-'2QP .".,6(P[>)=))@EB:0 (A(G(E 8+D?(E<O*B?.^R)L#E3!UY.U+YH
M[Z"]5"IR&>ZJZ:X6_%$+OK=S*)6A.E*.8M!@<V3FZ5;*Y521 A\@4J)AP16_
M%P0MX#/>STFD)/_G:9Q$(L!)W&O7=@9'@UZ_1O7$SF<MBXAM7XP1<;'TE08M
M$3K:X D%-&,N0<@&LDL\)0Z,_-"R:JK1Z)=;:?,>(-=5]FJ)FO)>9,J]QNX1
MW]L_^%$O=YF8R22XP@-,"A:0$RDB9J1R#@L7\PDJ*=DF$]?;L>?$4K&\;1^'
MEKHPOV!VO\6+VI79'8!^E(87T$_6WK?SSD\^_/!7R[;+5%;QQ?-FJU7+NX;%
M2?#S3JT/*^>/X0XVV^Y6JW/>^_5F&9Y+_9B2=RZ*Q!,77$OMI/'8$F,\2#=X
MBG?(\/QLPT.:,Q0__LX!6?OH8U;='LACG@A[M/[=#9<EE!<0/G@C":"-1)H&
MBC@-";Q)""0T-5$2J[3&:6-;S.E66&S;@S"58):%*%I_/)*B"?$:G.6CX/ZX
M&;\7:S;ZXEDWAMB/W5, V# IWKDP +[8:<?2S<P7=^.I;;9S[+R81$H5C M1
M8)G .]'2*A.5Y)P;1BREHI+(59)(TM@YI!!'&AU (BW3$-!JA8RT#A%+G! Z
M.<SU,B2R-W"]^-]!%L@<\K1B?UB+8F^M]7B00,VI]5CVMM*D?)6V][45<S1V
MZR!+.[AQ F.[_,9!EG3$$)J P13*@:/J?4!:48:2 _<*2TU)YI@!H$&YD.-:
M=4>OK+D95@&5MG/^KL\(TN;;Z$5#VD>Z@O>JC&NV.\_F!=Z2O7]U97/3@$<S
M5;+UGH 51IB2 $)J&,@.M? C:!Z4DMB:S+EQ'?'*\LM1&5TI<)V2UF="3'VK
M4Z2C<_)Y<G\29/8A.TJ/%,YJ1VGE9/(:<)X?.F)M, I,+\^M::7RR! +P&DT
M]2FW4DJT/%LDKTGE5FVG((V:=[ CBV81H+0N"I&<[_0-T;3$SEP(TN[T07P[
M+A,[%R;ZRILLCX>T.W?G,#,*3Y1\CM*3<S'[?^Y*7\)?VF4.<VN!VK_[;7K=
MQ$Q="*5RS/ <9>6\&DZ@@3ZZH/(F@!0*_(_<7?P>=&9/OL&FYFZP$9:K)9=]
MU'<:43Z61<)_V6[_8A_4O%<*9F^WV<M8..C&?7C<;RV0EY?5=%YO#C7]]"U\
MYV_X3OV\OAM:]<N/K:\GQ_!LT-S+SY=[^W7Q=?^WXZ]?&JU933_8_X;AWLV#
MRYWS!@7+\OO?IWN_O[^L7QZP!GRO?MEJU7]_USJ@?Z?&9;%W+"WAE(.QB=A;
M"/JH0X[+B*A,/%>?)&R'J ]2#(B9_0BCI L",X#ZP+%B5N!@M!1PN=$^V(U:
M!/@\RT6G7<#2[>$BU(I5J$TNPXW-^VZNS;S[X3.#Y<)K:I6-5/,4M$G*<6L%
MI1B@*Z=95G1SNKCCK\V^;37]/;:K?X_MN >@]&<SQ=HGWXP 8KV;#Y2\_";[
M;/Y4S<N?]CJC-Y@<W8V]5)YKV*U%,[K@OLD0C&<QY(KBJ%T@3@HPH)@:$]C8
M4U(C3TD](J,+KLM>^I2-8*-(A, _BD&][_5 +=ZW)U1P53R=%\ _?\@@^%,I
M6A0!0!#'1"/-I$>2:F>$Q<2&3#Z["3'])A%SSA;VCN>)YW-)89': !<(7)S3
MG,4H-F6;[=H("K+;THZ%N^1C#,6U]@S^]:.H36E=W"S$W[KGRY5@I!<0X+^&
M W[7[9QFF<T.V5YZ4[QF(=9CJ36O3&KA/KBQ?X3W=H_@?S]D.C[O<'3>>*0-
M)YE&2R,3&820-AKPE2AVF8Z/JRU^0]#HAD'C_W[\4OME6CX^?]I=C$KHD4*R
MR#F^^PO)"R<67EA(/O^H'QW:2"!:2!IYG-N?2N.0,1$C".T<(UXP:0P("9[#
MV7=+9B'^\,<Y-*]U<W)A^&&1:,C5<C#W_RP392-K#J%9JP/7=VO'G5;(&7V
MJYR&+?8")I!KF+;-D=;HHV9OXNN9G[@)H6,NP1X?!#PKW,M^9\J!*+? =CZ]
MJ6F1J[=7TIVX&B\$FS>P,#O;*F+CWG$$2+<WA-43<]2-J15]OS>:P:+!EOIW
MKW;6Z9;N=-Z*\?#:_2(8CLWO14Q=<*6-/C^S%Y,?@CL?QLQIM?-F_[AF4VJV
MFL40\^9BOYG_D,]MV-[D0HR?/N\]=N'IY6N08>7/>/ +58-@Y@*5N2@J<JN"
M840;;;!4D5(C]/#P\"SH+,3L.)R8C^/YFH@PF]GM>Z7N5/TRX\U[4=_UYWN[
MWUCCPR%/*D1K&!(DLT8;09 F0B(9I99!*(U304JSI'+$9UC]W4'<[TPO^)M!
MMYNSD.W0Z+1]^8]7*P1[^T>BL7]PWM@]H/63G8M,'1X=L8)9E)C(!QV\1,YA
MC&(*/ 8F0M1^8UL0,E\(,D:]I(O])/@X2VHS<9)]B-5;M8_Q>VP/XG2:$CR=
ML3TLMC"OT-X5F^B]6%0;%=G-XOOSQW QLM7S>?YG:/Z+ [CEY:6U+PAZ)VUN
MB+WF4=N.K,HHHB_.2ZT9I<7[=C9 ,UF(XKQTP2@*2V1S!\*6=9UR?HJE;S5]
MD5>V1]U83N$O^?O9Z%'\[]&2[8S^6GQ._OW/<G7&:_YY7*YS[1OSJ\I&E]F<
MV?:M02_7]HS&,NT(@6/QZ:+]IM-^$FV26^(>LSOG@'M>?<2*;\]VN05',]\@
M=P8EBO_[A5"@$(IL=F!XX-&""*36(+8O;>T[Z'O>!0@PS.^%>!2K&;/?TNV<
MC<2CY)<8<EB7K+0>WM3F_\T8TFV6]0D[O::=DAJ(;\+ CV6EV$H9^;WEK4?;
M$J,5GRB_'DK&M-B4();Q 0SI&: )R.E9N8MVYP[@+$\+\UB3H PVN=Q?:!,P
MY\JFJ(2*P\:^H]0\_*2,+"70^[-\U7<Q#EVPU:%=>?X,ULD'>F@AC%.*6T0\
MS#4/#".3?Z/2$$%U[G-M[^)0S@B6*5&R:6B5\C,4E2LB]M[@+,<-^>+V /1@
M)'.Y%*L?VX5+G^(P9NMV+FRKB 1 BG(&:BC+14S8*V/":Q!7 \GHY%Q5[KH\
M%3L,%6N,<-VB9BH/,X^JE>U/KLTH]^D\J&^&D6(@.3,6N[X)_SP;= %^X*)?
M2H+HO.>8]\+!> ]ZL=@F[+3SUO$_)_2GN&/^\[!#SO ]RC?(]6JC_<GK;U,\
M&F8EE"5&\4?T@[&]*(PW*%-L%[&T'4+!1<U=7/UJ>\U<PMEOMDHMMV!386C@
M7C3++7L+-_E83/5%K=S8GMBJC-UNL]^!^_P"WD!OD(N?\GCAEB&FHLQN^$[7
MAO[/XB9YWD?+5EQI^Z.A;<*H8!U[-[PY/*(LY2L=#MMM-<&L#:/-;BA$I5C1
M3,U3K'>O]#-Z13#?&[0*.,KL'_YX,T_)Z:"?9<Y>64,8('P^?#;8MD(D"I,W
M>G+QB,X !FWS A:+< 9SU*V=P\3 S.>=9)":-?50R'T]E.]CXU,JV9W>RG_B
MV0*>RM35FT4\#VL!*] "O2R%/H;IL4YF=8HA%(CC.V@XSKEI@\IY>;#SDDMA
M[%D$]/$CIZ7$B>-X9G-$TJO]5BS*F^S=Q')G]II(#+&@=^6/7 E!5KIQJ<:,
M1$S%*R.S IKU+>;RQ!&6CV!K])211[19PGZ!UG]8F+VAM<H12'_0;9>W38,L
M;6D ?WG?V$5@CEPK?Z.\%-X0P..O8UB3&BD^HU=6HM>'FX]BM6%8-G*=)U][
M.I$Y]3)38=G0G^I-)TIG2I['3Y^I;KZRF^-O%Q9S<FHG9VC"^0MCQ!\&F/UA
MC70V$A-F\,IVSKMAOKB3Y67R;ENU$G+8C!J?EN?VKJUYOGE9<Y83J[,)V?Q[
MI<S+5>8^&*I2G294&C0EYP:&&0!86-OK=7R9!2BE8+,4W3(1,!G27JE7X5$-
MPY5N/!VTX_B2D5K:7#8UK%[/@CJR+MD;O$%TTJ!;"-FM(@1/S-F%D4<XX?_!
M*^9KKD3Y_9^(:A!9?]R&=3BZ&+MMQ;O/$_2YV%+J^/1 >L=YZJZ\BL*/*-VQ
MG!49*F;ADY43DUTG!\K<:4\><"B<M^&X"U>JV2O,]-#I'%TV?"6XQVUU45HD
M%;Q3EM+(#68V8*E2/C<D%*A<R0K#1\$7QRP'7W=P#.8:X#>37L-$U>4^O/TK
MBZWJ)UXTC@Y%$)Y*JI W!9LZ)<AQ8I'".LGD:**Y:/R*0G::#' B<Q93*O-]
MQ?;8NC4Q "6NVXNLR.)6MW-*@&J[$V[GE4)-.I(S?I^M[39VQGF5K,/UMQ\_
MY:K+SN#H>&S!Q]:SWP6+UMLJ-RAO\$;L#9Y(P?G9.\OYE)R_S0_+_L/(8IZ!
M<9\*)&?]A9E!#0?Q?@2<-_@]@[-:,5&+'5PB04OL8E")>:Z4-U1)R9Q.$2<1
M8WFL76!1ZGNNA"/7BH>NM+P^\CF**NJ]<X#TWG'S;+^P(2MS_.@%-K#>DKV\
M7^$EYX(B::1&'$N#M&,:"4-#5!K[2,/&-KM>"_2/*V=N6#O<&4UM5H_8'1VO
M!*$LQ+IY"N:T4]KSBQM/QA6&8WSG6L[J]X<U/Q/GE K7>:@>/9MBOXRR*BK2
MVZE(Y>I3D3ZH?'5H/EYH6DO!/HH F'FK*2/FQ1 ?]Z==S<D$([AY$#2<WNQP
MS9S,R]:TK#:X.N4\F>@X:^5@<9BHZG5 >;H3::DUM,!_6!",;F&%Y2T)E0F7
M^C[F^,K*%IG%T1E;.^F)]S-TE2WTOA?9N^E])3#:0\2;--UGQ0YD?Q2&]T&!
MBG]\;7ZSM>_-[F!DN-?6+#,7$U/!61P,!^6TN25%(HS(P$QBI1LN1VXX_%*9
MY0?5E?P 1YQ8@#Z?ZP8(YXA'CI'!U.6]CD1-TKGZ_]%FN1#-QYGEZT!U@VF>
M"Y*UG7'^94(!"W>V//1>GFD&F;DO58J</L$@5P?1A@4.-]8W%%N=!:D_3.(P
M<AYV \YG%V?WG;9J[_*>0&<8[R_(=5<D!0L.PYG]TM'01N444T-<<,^4&26L
M"RY;=,ZQ=3$F<.6IMBQ)JN,RR8J&LYNW3-_ &/+HOD#@]68 \@HAZMM1XF.G
MUP/[&,.^_?%JJY8:NV\Y>/XD@8/OF4%>,XQXH@EI[3&BEB9IL<<TMR->I"#-
M)TG 3PM$8\X OTSR)G(E2!"Y2?HR^?&J]5YXO9,CV!#&D#620:07#'+!8"2Y
M%X+RP&E48%+F%Z8]OEQ1&8P%=21P3D'8HK7$)T*]\%YP'LDRZ3(KZ5@H\S?B
M&N?UDP_YC&0.O*)(%#%!>.Y3C<&5@'\2+B$"\R+H*!="!HZ]5CSED]5@#0IT
M4<YR'0Q3GGBU3)[":NT?M?9@FZF2*B"/A0+'4Z3<:IDAXQ1 .K.2N["Q;>;3
MV]U)N;GV7MQ>628*X=FXZC5[3=TP<N?Z$Z=]IW._XQ+2+HAM%X96E,HU\P9.
MT_? P6L/$GRQI*,NCOX_)[PN4J!VPR'SM\,9R:HW>>@YJ]_D5UYO =MN/?..
M"4^-P ;B,VDIXAH[9'GPR!(NK(?0#DM<-'>\N6W8PF<%'NF:5=+Q/-*Q]^'0
M$2I9!.>,@\U%G F#+%,<X>@X\016AH*;QN><;AQ+Q\,(T!=N/?NB1GXY,O;:
M##[(&,W$Z3Q Y!<I2C'SS/D 1IZRA!B(G)#62H?!R%-&ET2<_LA$0(4^SR,9
M@#X)\$;*Y! EB2!.N$/.*854H-FM4%3%--4.<#GHLW WC96G)_FK-3C-17DS
M!"6;F93VY^@5,LH:=L[!TUV,'22"=3!.9+[LR)W!-FDIF2Y^T3K9^5UO%R,%
M>3\^:)WW%L)OY3'<3\/AO%K\/[IH?#@46"F8<0#\%#(/B(S(FMQ;3,7(I/=4
M&;&Q+8S:U'A.0Z;A:?4Y3!RW2GWMEXV__ORT\<_9P]S3G90+Q.BTQ[R25_MN
MHZ;4<+O=[G"G:]=^;X;:;UNU+Q&>VMW,^Z3#ROJ<4!^T^K;<TX,GKR"HW*ID
MY1M>_[G7KKV+KCO<')W'(C13IK0;7;F74$A_[=/ ]7RW61 %SA8JP30-]Y?+
MSL%SCU,MINS<).&"3KF_*(_66.N5B@347 JEP2\LE1VBD\65/6\DSBCZ3@A%
M689ME;J^X_\[ ,%9&3KVY]?Y_;<_&N>'%AQOY[4 R^XCXA8;Y%B$X )3"W_1
MD8K<'QZ#SS>'8'A"Y[.(S.K]F!BC.$DS9EP8JG!GT.^!'I:[VG-.&(\H$L)H
MPRDK:^U=P<,^:B;5'#*>#._9F^+,N!50IE7C.+;"PCO?-@KM, G@K"8N#3>$
M6JF)@ FT6'(QWUZQ:_VL"];.>NP?=\*TU!;[LRM(BOT"PEH_;QP=&F-EPI8B
M!X$*XL8G9(*(R.>R7^5%4(1O;!.S=;W#VS]NV/!>0P-PTY9QJ8'%=G$A^.-]
M^<VKHT[M,-I$OMHM?DA.X#[[PWD\"^X-<RPTH30P,  <A,2 L\%#5"F[)AR[
M:C?HI?3O P5C@8D.V!""L/0*C 5)R$JCD=8L>&^4Q#XWVF++R0\0$\$9T$%Q
MZ3GQ#'X#8Z0,E99ZS>QRLY,/%X97EQ/8AS'O'.8VYPSKA'+R$7&!*;+$"Y1R
MYRML6?0N\]ILS6G<,CYR_;C4(C64:XTQ& 7#0?:,4%A+0P7WDIA0[1^^G(#D
M4R-<.^=L5$B9R!'7T>?M0H)2\@(S+BV/#ES+)643P5'5@7.(*)3G-+=I,93Y
MZ,%F@N&P=[7UK83AR83A\WEN]>0)LXY)Y'U*@!:$(V=U1"PIG-MG$L$QF XY
M7QB6DCRL[?1OS2Z,Z->&?R*;<VKACFU!&W);N+*@R^-,XEP&8SAE/":(@X45
M#L368V>"=_.#B(JM;4FRF8%*BR@Q!8^&:JX1#]PBIZ4'W$HV1F:T=C2S0BX'
MJ R-4@FGM,"):ZM<8)QSRQ6C40599#F)N4854RWX4A;\((.1PTPHZ<$4B2"S
MZZ*1$1P024J3$G:".+:Q+;2Y1[?&*=ZRU8PF%]RCR%G\+Q!$VFXMMQ)I]@?]
M^#-M34SDC&_,&)<'D\>7#3-6?P\/=KPI,JGYTWES5?MEH_QHXY];^0&3M\S<
M/OE.;TL>G.]PSUS&_1=(5#,,B^?++Z__;E!Q7#:?:;I^5&<J$WW#2:AQZ?^P
M8*J<EG*U)D_6?(^CEGAC1H"KHSC3QQCLV1FHP(C/+^="1F?AKXC)W,50(*X6
M+E\Y7.2Q(Y+/\8QY+++=[_:&/!LE=<@@"QF\22]G6>X^E#M-\U2<R6F>ND&W
M%R>?G,_^E#(Y?-;P'[[3*\[S%\2;8T:CS*";:8O&YS'F3?-FT4FF./64V<46
MZS.M("BW)E#"#.=4&YL[3R1- A/)4#,\^<-&)W_8 ]C/KA_('TW::.\^4Y$.
MY^KUAN0G[W,C="F)8L(81%)BB'/!D4DXEW;S2!A1WN42,G;;-GTH"PVSP-S&
MO?"@I;^[YU]%OS!;?3%J0W4!O[/&.?BJ@8%'*I$SO'!= C+8<A0MQIH(^'/N
M+)Y@ZN8W\)MD:QOCSU;M.JW/L?T>1^SFDX1S)2<)&F64VV K<CZ]E?D>,SL9
M0.I9+-E01Y!Z=3)U\HFKYR?=9<T:G>]E@'G=H%UQ2I;68Z'>AIXE$X,RED/\
MX:T3,3C'&$V:FB#*[NV2C Y0$O* /.?-,%HTCHMAYS1'#*\80#_0^H?#I# -
M.AJ4<J**<^.03?DPC"GR%S;2X#:VY2T 6BY_;^!0R?TT.HD[M.*@/%,T'T,W
MY;33[OA6WIT&P]YONDX 9^7(-MN9ZW!\)'/$2K99.D2C$\&C1XSIX]>2<7@2
M@$:>\B2#7V8LO'(#"[K(-OC<_7C4+;MJ79V)_M>;T7GHG?>[G\9>^^3)[W)Q
MQKQ/C?=PY0W3.E%40<GZ>^6[,<7"2QQ.P?!M9S<3A]-<T+&-3C+8@GFWW[7H
MRDDOCZ*.YW746;#9FPR+P<I_&W45+%SL*>P<$AM,<*PZY(=IU8DH8'F;E<7+
M+(+04M#HB=-,6)\)_!WA0B1K6/244NR7<8HB(W31@7/$\UL1^YY\XXT/AY83
MFJRT*'=X1(##$6E%'#)$ 1H+[P/.F_ZW4/LNG*+#F$OP8CE5R7 '#C7\GIM:
MV^2YC=8M8^>Q6N\YZRURCQZ%<:XX1RDDEQNMZMPJ02"(.+ D)I,/J;S>:J%]
MQ8?M(#P>.I@']QQ+">#A.?R T3OF U/.,XN-7<8>Y=VB].KRO)<0-!T=)@I(
MC;6!.$E0Q+&C2.- D6$I@C %@FWN"::7M 695'+Y@!WC$!,'KG6PSB<F51(Y
M+#/+.-!0P<:<M2;U\\,\KX8&B; RL-8!7'>= $6<Q=ZH%(BR>$'8N+^[,^$R
MW?LTZ^JZB!_O>-W9PZU#7[%T^*8/LMZ<>)S,[^;GW.#U3;J1^6:_Y=Q$OKZ>
MR6B#K?T.?^V!:PA^[%4CDC=O_WI?^Z4'2-_HP)"(^&=N)?.@MWK8J;G%3^H^
MUL>LSLD]!]1\^)&AA@IODN5(<XD!:B)#5AB/</3<NQ"E%Q',RDW-G%;1&ZW.
MR3U:,B[J.X>:6A^)#,@Z UZ'A"5Q*1HDL60!G!%FB<M&B-[3"#TK:H&[NS!J
M/8=[6Z'68V7S\_G>A\-(;##*:T2D\(@3J9#5A"&N *Z8DHXXGHE^EE2]^QS.
M<(5:CY:,S"K(#<4&@U $ZT$R?+2 7Y@B(N#3H,'2.)M1Z^:L]UI4VB4-MM-'
MSB-7\%^M*5.!:463ER0X4U7:/:FDY2;=B5/.C$L(UL+FJ)PA[9-#EA 7@I5$
MJ]Q_F2\)@YP@09+$N R*>XV=]X+A0'WB)GDFJE*[IUSQ@_,&6)WBD)R@*# '
MOK)+&#FJ(B(T*&4T.+4A;&Q+,K_P=UXF;Q(4YO4=;36M:[8RF^CJXD350?=.
MX>'@3@<,RFIX0.!"$,2QQT@G)9$P6D:O _847!9EQ-K 1;7P=R]\X_PP8B:\
MU0*98$/V4 $U$B,H>L.,48;9"':"DH4+=$<YNIT%C@;;!1W?IX./G/P=[=\6
M2>!WY>YM=G!W1LV-7['L> *@D9)1S@J'0B0:9$=##)Y_4R)P2KT"U(C@S:H;
M?(S)W>XP?Z_\JFMT*'N.3?6/'EF=WG&,_3FRMT WBONEA^>U4L@W*19?.6:X
MSUNG(G*<P #[Z #>J,@\"U0<:KUQ9ZJ:/4,J6LU-11.>*\5N*41TDB7!DY-@
M$'@(T@0O-'$B1*:C#V)N<FP:D__,9[3BF,+QSZ)H=Q^>\%NKX[^]L!+MO1DJ
MT<F''_7?/S8;E\>M@Y,6/.L#_WIRP _V_8^OIV_/OY["]R[?T[W](SZK1(U=
M^/OO[]D>*.'>ES]:C=WCT\;)\7'C\MWIP?YOIU]WW[/ZR8'8VSU.=5"TO0^'
MW/EH&*7(T,PY9ZA!6@H!BVPCIIQX2VF)>R"X,>QDU)+&""IBXDHR[CV H%+:
MI90+0JG1$-!'0*:SW/D$'+6-[7*B:PO_WVQ-XYH5.LUO<'+WY$U/MG8.L^2(
M2,3R!%Z29$)Z;KTC,N)$I@NJ6N54V[.S;N<'6)0^V,5;^%K^F_JS1BT0!X,3
M3&#"'64 (9)+Y7CBTAD=[LA!XWL:MWFJN-.-MI/^!&>N**,O/EL9&_?LZKF_
M<WZ8P/\QDCA$*0/O*!&.C.<8Q<"#!WLG;0#UTG23SC-PO?\.,MU/RM8)?* .
M^ T^4T2,RNR&8=8T\2PHBB_:/W\"A=EMQJ/.9NV-;35A5=M-6W996D"<! 6!
M2KF=%P,OR3%'=:)<$X$E#XSQ2IR>2YR^_3B$%8@&)AYYHO+.>2ZP C\A']MF
M$N)T\&#!V19JD\G[BM.5O/S5NCCM#/K'M7HL6G-NUOZ*[7;OHO7=9L$I2\._
MVVYQ8@9NC(K#-'G#&,+ZSIA6>8Z?=!/JO\H67FKU6WC=;;%6KH5783:O'40K
M>]!DJ2S_7I[INIV]#OYTFQ>;=,1$*L&<#-RD9*D#,+?,1>8\3FDR9KRC@^EM
M7NW'T<B+?ZW @9KG]VX/+@^=4HPJ#!ZMSJ=_,^&AC=HA9BG#$#22Q&P^)46O
M'Y[IW+J*1! F/,&).LTE81:[D#Q)X,PEQY*I5G%IJR@.<<3@'E.&*)BG'.8;
MY)1U2 N>_0D?0^Y;8J[H9Z:;TFX.F0R[\2Q7)+7+<Q:S!@CFO=D)XP.;K>%Y
MSJG34L>@^64'Y6&_.9"'V.X51'=GY5'38F>^"?@Q"1BC4YJVY0<M.R+&2P/P
MN(9/NNJB;G-+MWA1RY8VG]<$#.]U<GOWBW%;ZMPU(#\[-SCOQ3#5J/U_>K,W
M'/*$311KY6<W?Q0<7NU^/L<UNG142C ^_94[2N</"MO=NA@#84Z9]&+F'OL^
M/.XU@X_GL6B_/7WK(6<@O)F=ZF95-MH#8P3#'):. 8KGIE<S3>CS_(^/7_F"
M@B6?UFBV?7DZ>'+ZX::M?.)PL]8;Y)J*WM4YVXF7S2/HUYJGN>7V1(5:M^B]
MY2!X*CLKEK(Q$J1Q:^-6KA0.@V%_P'XG3^;,['?.X[@BN3<6JS6+8R?7X.IL
M!XPC?K>MP5B@F_U1&:4?&5 _Y,D9%?[E4]GY7\UR9Z<;"@$H+MWY]*:VWSD#
MI-6<#FM@RO:5A;+9?M&]'(SNE9A&F._8Z^=2Q&'8&V(F-G5Y=*XS/"X^<CD]
MW!RDM;PR'X8N*6;SJ,L.=%=CS[]E3;.E*J!.0ED5"J'_":H^KWJ8E-)Z_27+
M]1KMK^4^DXME0H=(6V!9;02[65C&K+ZSKM65QHP@9:[SM57[:Q)2[)CKM2QX
M HW,;(=EF^W1C:Z@L6 ,+<[Q#Z$4PMYR W%<8S7"70"5$N>;[8G@Y-[S-0U<
M@WSG9GEPOUM@"@P8@O!N26^:C[450QX:B#A_VJ[,RFBR-H?F(B-8*_=5+&XU
M-CBC7-"5*0D9_T=ZE>W>#!0]?_KUS]$>;MWF!$3_8C\/ZQ7G9'_4/QP2Y5+D
MT:&<*T3<*(,LY0HQ!A&Z#<12XV9SK->"U1?%&<4!9^ZQ]79:KGHSCCVO*VV=
M5;M)."K*%VT&@<P1W/OU89BLBZGI%P[@.#70!5\'%97L9[WXZ^B7?X=F[ZQE
M+WYMMHL7+;[T;X"8?CY^.LP,P#VO(N@M7$;1_2[\-XSN/_SS5O&G?_7#];]I
ML<6YN?'/>(O<^+?;;DOH%A,W?W7RMO\JAEP.&]X_SVQ!9CR:(NN_'75S&3X:
M2I+W$9RB?Y]E.&X?_4K/?M3(R-R5,].*J3]GMIY?,'%Y["&;EE 2^V1A'(O/
M]-3<ZTUQ[9[O6\K@"[WR_WG4*TZ^6F']5NK=%MBR#RSGGI,)U!*.%7'$>)6W
MCSW8>D_C$BI^;K5R(^]E+(%[Z5TSIZ0/BI3 >B>GCP].?[3V3C[3@Y-WQXV3
M(W9P^:YY</GAQ\'E-_YUW\-X6LW&[D<P>? <^&ST'7C6X"O]+!O[7YMU&,?>
M;CBI?_GCI+'[[F1O_[C5N/S,]KZ\QXW?O\)8P93N@ZE\@W_\N?^V7_^$SP\-
M"]QJ@Y$'KP1Q:Q4R/J<(<O]"2R,N*IZ-GE\^5!JFQR@(:']M045Y&-*FXO_6
M!VDSD\+LQ(Y?E"[VHG.!MD*C):#1[B V8%#[Y['U/=:+DR,5%BV"19\FL(AR
M1[4V$8F  8MHXL@YQY!.@A"GL2 V;6RS32/U,M!H/B(\#QJMF]\'VD0?A$;W
M=?LJ-%H.&F5O:/^\4X'0(B#4G  A3[32.BGDN+*(<T60UM8@&4R4L,)2FWS\
M8A/SRB5Z?A!BE4NT+B"43]56,+0(#%U,P!!S7 0E,#(A4<0%RWUF 94"#ME+
MPKE4N8 A.K]&N_*%GA*&>.4+K0D,O>L,JNS0(BC4F,P.496D2-2A("6@D L0
MC#G (T\5Y]YX36(1D6$\G\>C<H:>3"7WCV,W%B6*E4OT EAT4^GT&(?V.[_%
MOVPS[.0EJI#H(4@TF1MB-#H?F4 B6(&XHAA9ZQDRL+0>##('7-K8)G33B*5
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MEU>O@PSOILK-U+;!NN98;*:-R7JF[T6[.*UK5N?S*>FRA6&^^FRF<)?&(IH
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M,"Q\#QT6"M])P-YS,BY9&*7"C7)W,4Z5A;[/P8M+\\AC>1ZG(HZS-$G<G(M
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M;4=.FRAQ0VMWIV>[\]F*9R#P^V.40 T#F+-N$V&'>^'BAW.I$>+FHXD>W+X
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MYZ ULI"YN2?\F/'5,;DGL_YG*X;!HF(0>9;X>98[(E%HS"OII-)73ACQ",R
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M?@P:F+7S[==1>D&K/**E\S8PYFH3;A79^ W9_$QMN,B0\59\%4,^/*?K4I)
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M1UHNOV&=O&1YH$/T@-\EY&]C33V;9$M&#&^/#*6Z)I359;%.F!I;)5 L38\
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MA$X?883^S_^5C:*&CGTY_\,@7?97KB@,"B2QF"*U_V&\:C/4X08CU\ EI+9
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M@TL"VS@RP%)RCMZ<ZCTEPJ&IMEHF7>1<TMHD&;VQ+:B=QL<6 +/FGSX\@!:
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M+PIX/7E]B+OU1RGOJFO6\)[DSSB:O@3?YL,0?[*4F_$>,NI<3A$92O*PADK
M#&&WGPEB$HXRCP'_!G6PG:5'%08,SW&)(XI$FAB1KTM%7,%9LL2+DH!LBC%-
M[(YZ(9K40S27 /_P0-%7&U_&4P@3HWW&'U>EGU'OD<V40@MY!AF23*4Z(XF3
M7YF7Q=I/0'O-=C$29*05,F6)DVQJ)L<+$#X6%R@ECQ0R%TLKFOC<HF2V]0#V
M3\L[+%<7XOMEY_SCEJUZ#B'@%=!VH8W$ JI/^]R#B@=/N,"F@(5L>E*H?L;R
MI0@,\T;G6R0#Q#2H<@2%S]'[E.ZB(EEBK$D\H/'.=.Y':M"X##E15]1GF!:>
MPKO2#99%TTH)DQ=X81M0S C0AW>,@H&"48; JMPEEOEQ<&T#=O4%8;M;)0B4
M3"7=^>?./[A):KPBE#:>\[Q$Q.-G_R=NW,OB[H W'C0SY=S9/E23,S]*#_Z[
MF'V @NA;,<":2P55G-^U];0RS2A=#;% 0(?]6ZLCK48A'1!&)?-8[#S%%]1P
MQ4RPTNXC5.(QL:N#.YC1< Z])C_WQ83J>_Z:(67#_,E4<H;@:V13%=O"9G"C
M'?C*M^P?N*H_V+BCZ7U=W>4F1MN-,[YEG!?%A-K>,RL,S)#Z?X9X5Q@(0DK3
M1(D*X1[=[O#4T#L@XJGJ;A?M$#Y)C,W(U?9PDW]%%T$B51Q>P,#,,=/8"(?(
M:O$N!7(E-,$NP91;WGNA7\YN6E,R_T+PL$CPIK*GF<3Z Z^7$(8.<:"\:/H4
M^T=>S5OG[FF()E7.BVN*AY:@,?%.^"(OZ@&\_<BN=.LS%'A? @,SPE3AFT'K
MKTB)*&:;"[?'F;H5/J4^G]\L1S!XI+2Z2RHR:O%;&JKS7G?#D34H148].0!D
MU.GC+RN!_NGD^]>D)E\L5?8"Y"TMR%'\)="YDK@]%T*H;O6DH49O!?)"#6&0
MB,TF1 UAO#$*+<H9*V&7['3+5<%)D7I6E+8\O-S0\S0NED[(S$>[JB2BS5=F
MI%'&,8U2FF_3WFI*F-5Y)]E>/[PL,Q)2)5F@R_AJ4M/#2-@,SIS91AG@=(Z%
MVRD*0Y$/;DI)>:(?94W5FH]UR?5^7IO0\:3XI,/Z4[,&FCSW'[HLI@66PDB@
MOW;5>BDL? W("EI)L!$)!H@>:LG><G_-JBME+V=2B26.*T8 \D\99Y@X5T55
M4=)CF[A"<Z441[FZYK.-U&="#0U8$8@VX1F(.$>0?_+)UJTR'PM6\XSLCS@N
MM89PF>'V462)]"FM\KEC=HP=XZAET9"_,/!+WAS4@LS,0N6<7BIBVSXYJ7,]
M[ BD:@TA,R=<W:/&(;T1'HWQU*(9)/ID- )!#:5T7 KG5G3FY?E05M=+1U5/
M":5#6K_6[I69OI?_ZE5106&J0)MU$-#"%:DUMF@9ML&?@\B&I,%#2Z+_W)Q[
M8F:4.O0&19^<)?)B^8'FLS$3J.EH0,)H19K[])&C>P]T*.JB&6.1+Y$U8D/:
M+9'HQF,AF\O)M)!VF/F%N9S\B.\\9S&_LUG[F>"TH\';V^#I)//X VE8%RM*
M2,H$BK(B'5:VGK5]SOKF<%OQ,L*8=7\ATT^+D782<RE0H86Y![@Q-V=*'$;N
MR!\I;RI/R20.;(]P)34PF>&U"Y(Y8V2!VD@QLGJ/B_$V3U^I")R'%.1KZJH6
MSPC-WS-DQ_574M8]_?;;KS'%/Y^_/CO;\VAV#(&B*M:DF5VZE:B;J0NXL390
M<^5J"UES$(84:P;N)Y=C+36HN<**N$NH0O+6[S0B&_G,<D5V[XZHSX.8'W?(
MWCM$5O56CH/SDA+G?(R_B^J)9!=_\,=SM1)2IN<*'9?O,7,"UU>*.B5]2:-2
M["=NJH_-N0GWBEWUC,)$3.0#,[_+ZD '3='4JFB4OBX>" 0J9B1\80)DZF@+
MKT91K-RZWU*C)\G16M^&M7X=:.=>*P;E;4< @5+8.!1^'/UWP&&U51++INGC
M,?IBG][RP ICS2P$Q725+SL)-\A85]!?XZ5%9< ^Z"9"]JIK$F8E# ,C<:Y<
MPW5HI3UJ_));SE,6]F1S*$Z/QWJR BY2,@ 45J#O'91_(#Q#2#'/VYS^^/SE
MVZ.5O(65^:,<IC\BAJ4>VTP W,W*$26L<57'? *.##&),'^$@38%?BM='+R+
M7H$>'FCD"4[Q 2B:+18/H,P$+CR3CG(,+.W+,W-3!8 O1_MV*ZL(4)4?)7_X
MO*KK;DTL1 H3BVMH2\XGK(QHTOR1UW'O* G16X8\K)>IGW!IU,)-*^@XY$*1
M;7!3 "/DRA/']]4$XW%Q?.G%(:B[_!K4[1#18PP%("C*'#'UTQ7<>@ZA-?5%
MN?P'']2C1YJZ'V^+=4)V>+UFKN6Q1$[@Y9VRB/<@KK6!NV%=4T9W)0^DA^"L
M.>[.I[,&^S4A911L,X10&KTE(4CRAQ_'Y\RZG5FP(EV>E[)>/B3.T9\F?F*
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M5R+*"->Q)X..B;MDE=0Y-^"!>!G31(IK_,**7 #2A953?%#M6IHWICI0Z$+
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MU!#*HA)6IM?(MK%\:5XUIMS@<R&!498@<D0B1I8EHK)%,I>!MA)<[-2"BPA
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MII ,0S*F3Q:(IYVFA0RKWV$-R4$_QU%EP\?6PJUA\M2N\JV;+KH&#LXQXJR
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MI7'; E49[A.[A?A6L>DCG=0 U%8J #GX,H[=7'@^(*XU. '6!#" S@RNY<;
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M+:;YW$>;7B;\SOW(8.,HML+VS1#I&HL.=A 0^QET@D-R'WG,[*,7H$=E!BR
MB$\K_#DA77-J[SP%VQB\4[D:7=CK>2+47J^)"+7'W)^+*5Z>'"#X]!=_G/EO
MNVL>U5USL+B[YC%M:0??_.7I>G(>P6"T_G%=T/36_K0_[4_[T_ZT/^U/^]/^
MM#_MS\;_G%]<_L_Y9>?#3R=7/Y^<GGV\.3\]>7_=M7]_^@#_2\.A8Q4FL0TX
MJUR?__7BY&95BI[C9Z/@T)!XHNQ"Z0D2'ULME]6M<WV!;CG+VTR!#!E)DTFQ
M$F[3-\CR#1+!&2+?^F84I4,A#<,,%7T KUR8*3#3X06=DF#\<,ZG.4?=.]Q
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M\#<!GWWBQ=[XG@L=Z9<A&'^7XEB'BP$IW_7S>&;_,ZK&Z5_^'U!+ P04
M" !N?FE10F/&/Y04  ")VP  $    &EN;RTR,#(P,#DS,"YX<V3M76USHSBV
M_CZ_@ILO.[=JG!B;I).N26\Y3M*;6WEQ)>GNV?VR)8-LZS:6/$(X\?[Z>R3
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M2TF&PK3:WF+!W#BU,!4(MDZK50;U#0GM(&[U^NGHMT"\C4-V4//=3$Z.K-[
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M*6HIE6BC_YM AK0Z5E9^+YE7T_Q)2N,R=C]Y[\?I]?2%_S)>^LF(&Q8@.B#
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M.0!!"T22S(.'1%VY_=TT1':)I7^]MZ\P74%A\[9$O(LX="$]_DFE(I1&2CM
MWRQ:2XDTH$E(7A&M J/@7/2A25#H *Q#<J'[,NEV2;BVJJL?;SY?4$<Z</#"
M"Y*=9^4I K3AJ= $UV6#"V:V,C>Y '<+R9X.-7E2!.DG]X;J-S9'YW&'5"*C
M-2X,#@K'B7^QH%W./K:I9O2 ^@]9/1> $BKQK)<X&R>S+JMCT_K(@X@J*T^4
M=^AO2-.%,!Q)2> <-%&FT.0:TKVH!KDB'L2,V^MA+674.S^%*8YP4B[/I;/Q
M=+Q8SKMJ0^>@%'.,&^Y(""P0R87!Y1@G)23%T61UU/DVQZKWXQI2F+$N1VHJ
MI&(^QOER?[Z7CZ<K'/&E9?LSY-D<+BK-P.+F564<T/56[DHX48P)Y5DD$$K^
MH7+HH6@!Y1&@K+(+Z/$VL=V..,9J^]65;3B %@R].$)5"3J:7.+2R M&$P>9
M)7=MSHD>M/@?=P$?*G/OM(0.5&G-U*MNU&L<%[!&45K%E-*$256"VJ&4+4 3
M32?+G>$2N&EB$-^!9T@;P%/A6 W55N?9^;X&TAE%729&\TQDA$P"C9DD]/D<
M.H54L":FZ T<>QY7M76WGAJQ#M%EO;3ALP IE6+SYQ4S?_7C:1GVN^GMGY6\
M=N$Y!]5E*/+RW""2WR==CEPB^JP>;:O4Q-+8&^F0#L6>"B?;TJ'.]>Y3/_V,
M@NKR2=[E*R-_/;T,W)?J]W[Z?>0$V)"#(X"CQE7:<A*8-T09RK7ED$*ZL0%O
MO]>]3Z=#.EL;.O'::K3IO9K?IW/PD_%_0SJ?(R.6HA21>Z*TM43*C)/!2D6B
M3" *,@I-S+W=X WI0&_HO&RH^+JIO6]GT]EU+^C<GDC10&892"HCEC$$XB58
M8M ]BJ6.$VWSTM/]L(:4\?U42%A1T14K5L>+@UN45)D)[^9%""=G)6EG9#@5
MB$*5&Q"F/"I37J46E#C0GCD?>%9-KD\_@&M(N>9/A7XU55TO!(\H%@4$%-/T
M6YD5J_'BM(SV7>X>?/".V62D)^B)^W(!5Y+@%"4F1@BX3COCV@3A'T*V"P?=
M_^=@0W578R%Z0%</=6V6BGM7^A2X$*-]:JTIYPT\NF"TR:Q)_>UK*"H4%<CC
M93<>B]TI6]XHE:4."XV*6,G*/#<"AQJUDDU2Y"\A#"DH?KBNM]0-.$3$;5B[
M4_E=3X$SJB3Q7JER=2T0JVTB*5OF)!4IY":VY-Y(!Y7X48\Q;356LR#).;&-
M NW0)R(^L/*H8%=A7Z12N@<7:F2VU$W*R=^U=@S[^!94M(()0ZR 4%+8T7HR
M49*L&7/4.B5,DTSQ1SN^?=RE_$">WH[@#Y,AE3,8$/C&U?P9IH""&]$DK'2X
MBB4A$8S!12U0!X3J9+V6!FX],U.3KK?P#&K1K\JM?J)OE,ER)T49 P'<$PT4
M_4!A([$T(6.]9 C1J<2:I$]76WZ.=:.NR?)30RN/>7?ACO>*6UQDN*NK(]QJ
MV&F4E:XX;.GKXO5G)[3E*GO"2NE4:7%B>>LM"0G=99&3<KQ)=;A[,/6O%'YG
MTX<].9*-<)XK$H5RZ)J5\WAE&(D>-UZ<.#K31F^S5AW'D.RN6HR\78C\\51?
ML=+]G8/8"73.+./*'DGV$05(*46/+UH2@Y<J)&>#;?*N2D_<@S+>'H&@U75[
M#$(>-*NX$<*'8 E7GI9;E*[4130DJYB2D3R!;E)HH>F"VBM(DDQ2B4LTYK-4
MY?)"($XR4PJ&Q>RIBE$TNB ^Q #K8_+MGA#M/DJJ>[:_12"7N0?_:S;I"@E>
MY&==)BF<S,<+_-%+_!(E!O/Q+%VL8H9[QXO#:/!_I;)50(?#X$JBI1#:6:]H
MN\I?#08TI)3F(1%X$ 1J/ATZYW<V1^5.U[?XX_=/<S]=^-@)>9JZKS:$2/^U
M6CO%%V,1/$NJ@B,YEB Y!%-N85*2!!B:1,BJT=,>388SI!#'4Y@*1R3/8P96
MMKPGVR"F<M>KM6W#*0^-[2*2\KQ5U,HO3E]-9G^VB5-=-'Z,R-3VD=2*16'K
M-TH#?L!Y/1_'DMJ[+AUX_1M7/KG>@7#2SDM9U9>P_O=B'?GE6^PRB#_@8'[)
M&>)R9"V+2K)$+$ BTI5JFR" >($KA6/21MTD$?>XPZR0!U @H*W[=8PJ_OG[
M[\B/U].+.TXGN!!^73^8[AE'6Y<)$F2)4[/R)$\*D3 AT265X#QOXJGL#G%0
MGLQPV;XELZ %!VKFJFS#MS[AN([/!006O21"EU+;.01B??<(> 0OA<NZS8/M
MNT,<E+/RY#G:EP.M.?IJ//73>!U?]%3'#)2 D))(JP6QVA5\#DU9KE)H<WMN
M=XB#\B*>/$?[<J#>#:9NB._RU6&_F_82\,@R2 J\)5K+3"0W$2=;ILB]"(EY
M2B-MDN_:8"Q#NBSZA%C_V*QZC"7<\N2T48X('S3*"V>N-3H3K9(/T23EVQ0Y
M.W0)/^B$(B(7NK22UXO%"MN'=_G-;/JY5//NLNV#L3I(BJIAH63;ESH]B5F2
MI4I1)Q1(:'+8^#"T(?D!C5BUY;"BIKYJI@-OP?5B=G8VFW:1FU'F3)@<!&'E
ML0VI57=US1 MJ+.120&ZR6M4#R(;DJ7^J"PZ5%M-2-3!>/>E2ZW]Y1O,XQ@E
M,7+49UYJ\D934F.C#,09%8GW0D;'K0#;ZJ7+^Y$-R91^!!+UUU8]$OGO9VLS
MI"L@_VGVR7\K155/UV=@KV;SCZ=^#C_[Q;K0 $P7G5!'7&JJ<U=CP#FTU24"
MU3P088W1-@DM0AMN'0AX3SNV^?V7HW#N&,IMLIZ=WP;H\&V.,4;,"^5$!L(A
M%7L< 04M$J'*X]0P'E2;,LP/ 1M269-'6,UZZZH)@][.EK# "5 .3T<V9%#>
MEJ?8W293)025"7?,XQKK4TA-CK/O C2D@B./P)B#=5-]VUM?D3XWZE[,%N5>
M@/566J>)8P$!.<&)C^ ($\%'&;UGM,D=GGLP[5D;Y(?:O/JJJ'4D9-N!$ ]:
M2YX#,5PP(B%;XEQT) J6HPN)&]8D"'#HH6"O7$T&F9<TW'*%!CUHB[!<B!EM
MA\0$#_A-WR1[=9BYFHU8<D\:YC[RKUCEYLL<XGAM+NKHG%(XS9/4Y0JFDZ7(
MDT=S43*7I0^4-0G\707Q!.(2M3EPL [JO1)W5C+5_KM#4.K377_6>^2 *1L-
M)9H%Q*08)0'W]')3ER:F:5"B21#K?EA/(/A0FRD5]53SZNR-DYC+^IEOQCZ,
M)^MQJXQ&@I:2<%X>AU;= 8P1Q+*8)$_&NC9!K!WQ#>E\[$AL:J&YBD_:;HUH
M!!JY,-(2X\I#94DZXDVT:#LFH(&Z)$63JAN'!Z,>.6)0FS05]%*E2N[;67<*
M>[/&=(X>1+G]+5B,:$EE1D)TM#Q%CBP.4>ET(T5J:SG<[:T_ 7>_EKHKB;B*
MJJ\7J#^)<;Z"]&ZZ[?7E%X#[8QYC:] YG%]FBU)20I02(A")8:*\144SDC-G
M@@./5E&A?; [D*(OCB%5!CT"?8ZJMJIE%]>WA:[6F# L)^J4(9'B&B=5*$]S
M,D\ ,N4N6= WJVS7*[5X"\V>)3X?)8I4>]OIKY8J2]%'6"XGL"[*>/EJ<SF+
MZ?;%Q;7CY,NB)9N+9]]'C''($MF,P$4)DB*E+>7$4P\94C+\YM''UI6H)XP]
MZW,^:0(=6VM'JS\<K0<9G"""VE0J<AOBJ$_$!83$>8Q9-TD&KU!_F-$?A%PM
M=/4(;TA$(93 !89H60HW.JN(16F0G*4+W.?$1-AA5:K^A@1C/PA/VJKDR%70
MHN LRD1)RB:5(@&*!%G.AI@.2&UKI6AR3E"O".,QZZ,>*9!366]'K&+.M1,L
M24-2H@B+HSOIG=>X0$;MI13<\281G2I5S-G1'OTZHIU=3U]'?)YF%%D*SO-$
M@($C,C%#@LB.F,P@*NY$;%.;_&%H.Q'IL7/6:A.ILL:J6$478WQ3PMV;\%;W
M__/8EF3 C$V<:%7(K4Q)V\3_I>0C$SP9X^@.EM"#'>U$B1\D<EQ?\E7(\,E_
MVY2<+9OF=6I>K(#;@E4C*9R4"E<"Y0W:9J543'D(#D%'%Z,3N)7N0I*# >Q$
MGA\H#GT<357;J^ZNN'(>Q%H7S>YJ#27E@M.")*9*P2T;2$F6(]EEFSR73I@F
M%87WP+@3VQX[::WV[M5*APU/W4]B++&&Q66 :V1=Y"EQ3QP$W&"]X\1Q:TGF
MUB5.C=>LR0-!NX#;B58_6A2[NM:.RJ?-]8/W?KX6A#2:,DH),R4IU$2*/H!-
MQ&L?8S9.:VB2QK\_U)VX]J,$O(^DT8;,>S^'+WZ<7D(&7'[3QD(\F::NSMEY
MKE/)C<0=G$C&(Y'6>!)\R9ODG@5FJ&#^2.S;!>Y.68T_6E3\")JME%]P!\X-
MOL4YP+4YL%SC++;H9=SVE^FRG!1QYK02U!*=?'F[EX:2&Y%(]%K'P#)HM5NF
M02U$.Q'O1PJS/Y(R&RZ''=I+$:TG27 H$FYQA1))E51/1ERY;LJB3M(S1C4[
MTO*W#=Y.K/L!H_"U-7<$\VYS?0MGQ29#YVKFIW?2"B$= 8;^C4S>$QNE)[F\
M=.F<T9PU>1_Q,+@[L>X'RP@_@F(;[;$;5"_PTV/4U:?YV$_.@X'.HCAT9*0\
M.HX2L1%=($>)=C3)P#C#;QVTC=[3Z4[L^4$RP-MJY'BKU@W_16LT%KF.1)A2
M0SGK1 (:B[BT,NE#]E:TN;^T)\Z=F/:#!/^/H<J&?"M/'LY]7)9<L1>KQ7)V
M!O/S=10-1)]8\$P3ZY$7TEI&K)6)R,@24&.I%DU2L/;$N1/??I#S@F.HLM&&
M>.X5?X"O,%U!<4EN3 IA*0/K%5% T1]&1YC8[#SQ67O+O5#\YOJVX[;X8-<[
M4>B'REUOJYU&%+I^S/JAZ.)=1NETKD?WO0O&HQ!'%H1+4EGB#77HBJ2,FSH'
M M%1JIU5*9J#^+0?CIW(97]D<C746Q.FC2^FPZ]S/UV^6DU+':)-1&64HZ%>
M24ZH<:)XN)F$!)EDRB,Z&=E+=\@R=6^G.W'(_;@<JJ>1(Q+F6M3M'*M30IK,
M)6&\.TX-&LD-GB0&+(,P"6"7&WR'(]CI7CG]?XU*O75UM CIU3@'$^B7&@7$
MB&+,"70H@K4ER<@EFE0Q]H[D$=Z)<2>Z_6!53UJI\#$>9=#""@-1DY29))(Q
MQ)=QE449"*%0+#HW*3-UZ*,,^POCO(+3I]E)_-=J/(>MN5;!1 :XM1 JB@?%
M2^6:B X5FK]4, O9T"9YW#NAV[.RT*.<1_0EUUV%M^JIK4W)6S^!=WDK-B=D
M1M,E$PH<S1:N,KKGR9"@>,JE5J]L\X;W;O">0*6BZI2JK[?JI0 OZ(Y@<3]9
M?G\_02OF9)I*1OJ7L\YLT<&E+#+AO)1%I5(11X5$.?!$ U51FS8%2'>&N&=M
MHQ]SO:JCP.H$>S6;7ZLD?H7XP$!'FREAWA9<J2RF41 N@K-,9<UCTY*3=T-[
M"F636Q&JDL+J/3N.8W\Y+B @%4 W;@^/6$I<2Y>(\"4+2G,@GB9!DE*<A6 H
M;U/CZ %<>Q8[^B$H5%-5#9](?3?_[*>;NG!^FC9^%"*]WO=.CW;>W5;_-SIW
MQ-GW4=.?_6*\F.7W<UC@+-^@Q,TCC9??L=L/X\4?"_SW]VG$[<6/IYV3M+^D
M#NJFOQ#[C^XQY/L>)TT\GIPONGL<>6\?[6/(_27@_R;'$OMY;X\C]:UC[?U"
M<KF_BH/8Y"MTSWH?3.5[&JOP O*.2-M)Y'"R/=QF2_DT(<[KLR\^+F==Q:'I
M<O*]E#Z'=-GYQR7RU\_3(>+:O>W^8CMP''W%MSEHQUYGGZ?CS@#=7TY;&NDO
MD(>0U1_Y6S\OAM)7.'R"[=!H"\G<C[ROI+KHT_)&6&Y_V6QMIK\T'D;78OR?
M2C9=+2EL&FLCBVU(6TBDPNS9J=DV4CK^#/I8?/#Y]UD^^8H=%B7EV7SA)W!9
MS:.N)/?HL(V,#QWQA?1[EM\_[[6\Y(6]ECH[ESUOBKZ7VF"+96<6CZ0QY5W"
M4-Z4*R5X929>N$Q BJ0S3X':)N^2[ NT][L$]_<7X^ILU>7@_3J?+1;7*T-<
M7M"G3FFG)9 LC";2@B/.JI)+K*F@*#?*FKP:507]H$XNFQ+UUF,'1U=^O?<T
M#H1^O;"$8)8GJ@PQGCLB==*E_C%'6<:L48+</LHLWPW]D$Y'GP1M#]=],]I>
MW?VN#F*4C*>:1UT.>,M[1>6QY?(L!%C*+ -G+&U2MF97@$-Z&N91R5=%@PT/
M+E[Y\;PKB/H;^,5J#H=Z<-O;Z6\L[H"OKP6^M8N#G;C[6FLDCA9NW-:.UA>H
M_?3J3=;-SY-?7OS*X;Y)C5X;";G/V&MY*>M*"1==C1=Q,BL 1MRI $XIXJ&\
M>&VY(4[BBF*D"S'8S+EO8ZC<A:C&"?W)-)5_2M+)5UQ)I]N'[KC*+.E$8I9=
M73E++/.!*&.]U-F@7)ID?.R,<$AO*M9AT+8S^OK*.KY1E2-8 2*1#*58H66"
MN 26F.0R!$:%<$V*+=0TJHYFT3=A4A-5-:V!/*(R2)J9(5H'I#0D3IQPEDAO
M.-IP$=V(HU4]'I35W80@O550K\CH^I5F/[EB#VP;K<%%C@.(XC@F'&U$MT(J
M(#%F#H%"RFU2J'?$U_^1E*T/%EK+ E6:0,:12XB&6(X*\LDG9[ATF3:Q1PY^
M6/)8&W +UMQ^"Z6O2H[M;U8X']JMW4:^0=L3HJU=7GQSEI>GL'FT9'%;]=\K
MBW3O?AN)O-_X^ZKDU]DL_3F>3- =O/4H\OZ"OJ^U_N+;&6M#H1P<37FXS:8"
M:A%9N:>[C_$4TFH"]WSD\.E<I]^FXCYT_#WC*^4.]GF7)[>[[(X)1LY$H2EZ
MK9;%4@H5%+$)35<&N41K@P&='M# +OWT?NYGT_X:-!=:=:8V%Y&A&:$\&MV:
M$<>4X<R9'%,3.^P:BB'87]55?.O9GH/E7M,CP<&_P<WOCO'19+12U!-*2SE5
MK3@)Q7.VR<50GJ:W;>[B/P1L"'&-Y@2IJIUC<*;4N7$<I$P,RC6_<DB%C XY
M<T*%#31G38-S1V;,K7)%#28*TRQK;C(QR>/T]5J3$% *X)RU-%IG=9- 8(V)
M<D1/MA9S]IXJ^^CG&%/E2D[!YCAY?3DMQ^RX9)98%VTI2*:)RXX2"-+8I%PT
MM$EL<'^H>R[!;9.<'H=:-918I733/=M0&;[Q8*GGD?AL'$%)(+)@<)_0GC'N
MO0/:TQ"ML,2>MS[*1D)D+N%>IB2145/B(#'<Y)Q/: [II)J\57H.8 A+9F6E
MWF5Z[B7K8UD0VBCMF/1$Z9+]QW0BOA1F%,KI8+/)D)H<S^YC00S2XNS+BHIZ
MJ?<6[3E3!1="*!Q8MBD023-NX" CB4(&J;5FIKR]>*Q5H:^7K;-@RI4+[1JW
M"9FM)C[X3)2RC)F<;>9-K.3!>=F]]'R_1[V/C!L>7]P3F:IPB+%/ZTT#<6T/
M-%[,IE\!#:RPSL4\0% W6ZAP-?4^3)4'?' T?'L[U0??(NI]HXL*D^6A%JN+
MY:B3XF>/\S+"+%_Y_L^S:2H9B&]GRUXWO0_LJ;I #QMCI63*-[/IYU(VK7M2
M7;),)6.BO#&%EC/%'2M =NCH:16$I"JUJ4=V%43_3(RP?#U=+.>K<D#ZRD=
M-W8U78ZHUSY+] B22>4YRVY<RA!-063E4P+>Y)&$NP -R5(YF 6WDRXJ2+^:
MH7T=S>]3?W[)H:28=+!,B"$# )$NE,+!RA-'I28T6T.39S&Q)B6N'D0VJ$A4
M(WKT54A%GJSK3*_3DJ!<@>F\0^$<"\HK0A7BD HH">49&,$<]<""]=*V8<=6
M/(,JQEB1$_V%7R7@>)V<Y1$J*')X5VK_G(U79Z-@,E-,"H((RG,'#G"4#(AU
M3"6.*UQR] &C8Y=^]BR1.&PM5Q=L(U6ONO@0S&&Q'"E9HD&:$Z9I.8)$_]JR
MF(EQ+O)LT(=GNU3^O[>3/8L8/D4E'RK2!AJ^87%OONQ..,JF UE2'W0FE(OR
M%*9AQ,=HB..X EGK#9=Z;X7?W^<N^M=/9BUO*O&&<:P;*,\3KV;Y-[_L76%D
MC\:K^Y0[CZ2%&\FY5(H;3Q1GJ10ZA:+<0(QQW&9+<])-ZES4=".OMG4IP@_P
M95/+MVQ>XVD<?_&3#W#FQRC#^;O\"LU8/_D_X.<CG#A,IPR$2UMN3R=);, )
MI9EPC'ENE6\2#>\+?+!NZ3ZLNFEC'E6;U=R2/5"_GK[%F?SI3YA\A=]FT^7I
M8N2TB=:6U  3<8G-2>"6FPS).BD07CK.FR0]]D(]A!/)QV1?3ST^#O7*#/GT
MYVR$(A(YT42X+R_Q*.1&2"F0X*/T45O<9IJXRX> '=(=P<<AVB%:>T1^(6%@
MQ !T8%&B-(1'VU0CS*!05CFIY(4%"LTMB]WA#M:1/R[']M;<X['LU6PU'VFG
MJ2FO6G+E<,&%\KXE:$LL.D0Z:,7%0$A6T XVCG!4CNVMMX8^Y<?E+/YQ.IN@
MZ!?K>]H'^(Y;&JE0<?(!9+UK>-YJ__ :L'<UU4(*3>J_WNKELK;G:GDZFY=3
MCY)RTA6Q?C$[.^M>HG@_WT3#N]_O4=VT9O<M9%Y+&O7U5*-*[\.-MI!IV\R,
MM[!\/<6OH!0(? _SCZ=^#@<(9WL[_>6Q [X*(KC:^,&KV_9VJHC@(7Q-6' 9
M;7PYGJR6D&X .7PF]>JN$:<.&FVE..LU0!=E@C[-UDOFU25A@VT45) I2T%,
M*/<V+"\%9QC^%96P1DMK69.<GKV1]C7VKW4XRI8Q:8TDRJ.K@>8G&H/46<*8
M0@]7Z*3;&/'74 PIEMJ6.3<M^,.542^IHPP#-\/+*DF_Y QQ^6Y:RIO&7_Q\
M.IY^OIBUW<//(T4SC89K$CQ0(@TZ$D&$2(*A04462V&F)AD?!X =4JSTN.QJ
MKMIJ)/QG)WQ()U]A[C_#V]59*"<+&R%TZ!;O5LM%>;H&(8^X<5D Y')C7A,9
M B/!64X22,H1/%C1)&B_)\Y&8KG53Z?.D>4Q*6HH44$8=.R9(2$+183B7G,G
M-- F]Y#W0CFDM;XEZV[.Q7:J;#L)[Q+&2?JOU?HUCI&/E&D&0'!!*K7"#*Y.
MPC("--O,LDFTS;WE _$.:3]X= 965F_#>.$#/L;)=#F^O=\U\ZCN[ZZY1[7'
M:*M$?G!5ZN)-7V"Z\ >^[79'0Y4B/ \@;".%?G';NYIK)9%F\=M;/?4,"=[9
M7BO)-)DX'Z"K#O'>SY??/\T]=A5+7X<]!GA'4S6> -P%92M95'DH<<>FV\FJ
M;4#Y#2!=#Y',YA?[CWL;@CJC.G@!O?;KM4;88H%<MUR!YW<T5&OLQ^#PQ6'6
MJ]5R-8??QM/QV>JL^]G[S9%U7_GLT44MR1TZJEHIQ;!8 +S[ D5]T\]=OQ?E
M;"\ K&"D8C0:(B,T2EL2U@7Q-*(K82Q+"F2T()KD:^P(L'<6RR[];$];A9R2
MY-X2*GU<Q[P\!1R)34[EK%363:XW'@YY2&&4)@R\E>MR'.W6RZG:42BW\EAU
M]HPF;XB)$MWMD@OD- N(6VC@7D67V^0C'PAX2.&4X3"QKV:/SL/S-->@2[@'
MY:%1!D0&SXD7*1,K08)W5C+3))BW)\Y!Y24/B76'Z/%QR-;EN^+*+'4.D;C@
MRVD36.*-H8C5:!N%!V$>;^>]BG102<J#(]S>NGP4RG7IKU&ZR%-P)&20I4!G
M05F>TV2,.1JL-="DF-R^0 >5L3PTPNVMR2J7I>]%^&GV,_I[XW22ES"_P @I
M*I8U@A+E0K>1I0:X]R2PF /C*2=QXTQVZY7I_7O>\^+TTZ7/$113;;&Z ^$H
M<&J,I9G0%#*1R6AB67E"V-O,0G(\M#E!O0-/HV&^6,WGY4 Q,1\]UXHHA9N%
MI#F0X H^5$4"YQS$)LE#]\,:DD==@R<WE]>*2FD]'][.IG$#RRH#3&B-B[K$
M$5M)B9-*D1Q4,LP;GG63@M /(AN2VWM$NARHFJ:U*2;(K-DZ>'WR&0W10Q\E
MOZNE&E4G=L#8OR3DUD[Z%.:XM\%F8FER K'.IOCDOQUTW'3UM_N/^TXLO1\+
M@RG,%I].<>I^@=5R'!?8U0'#W=Y.A1K"#^-K(H+#'Y2[I[5&XFCRB-RVCFI4
MH-ZIW4:":GMBN;7+EQ!GT\5L,D[KK3YVQ1AQDZPLP@?[:232_<;71,2OIU]A
MG7CX>KK^0&79WMU!(Z'N.*(FTKQX]_1D@<;DERY;I;(\[^NBD41W'E43F5[<
MMEV47+)+[5:6ZT/=-)+M7J/KG3VX"@OXUPJ;_^7K@4;[K28JY C>BZKVF'OD
M2M[14GT)/*C\C4-7_@KH+O[C+_\74$L#!!0    ( &Y^:5'Y@VH]T)(  ))'
M!@ 4    :6YO+3(P,C P.3,P7V1E9BYX;6SLO6MSF[>2-?I]?D5.WJ\'">Z7
M7;/G+<=V,JY*8I?MS)XZ7U@-H"%Q-D5Z\^+8\^M/@Q)UX47BY0$E4YG)3F1)
M?KC0:SU -]#H_O?_^^5B\-UG'$_ZH^'?OQ<_\.^_PV$:Y?[P[._?__'Q9^:_
M_[__\6__]N__#V/__=/[7[][-4JS"QQ.OWLY1IAB_N[/_O3\NW]DG/SSNS(>
M77SWC]'XG_W/P-A_S/_2R]&GK^/^V?GT.\DE7_[I^&]"ZIP@(E-2(=.9<P8R
M9"9%SABM\)G+__?L;T;ZJ(VWS!8H3(,2#+QW]!>B-SX;9V*8/W30'_[S;_5?
M$2;X'0UN.)G_\>_?GT^GG_[VXX]__OGG#U_B>/##:'SVH^1<_;CX[>^O?OW+
MRN__J>:_+4((/\Y_>OVKD_ZZ7Z3'BA__^[=?/Z1SO #6'TZF,$PW'T ?GZ?7
M?_$V&O/CY0_I5R?]OTWF?__748+IG)X'A_#=QM^H?V*+7V/U6TQ(IL0/7R;Y
M^__XM^^^N[0<C--X-,#W6+Z[^O*/]V]6D?:'TQ]S_^+'J]_Y$08#0CQ_PO3K
M)_S[]Y/^Q:<!+KYW/L:R$?UBR!64J7#^3WW:CP=C.B<@XS0C:=%W<5@%WB'&
M=4\_'//ULUC& K/!M$/$J\_N%._H OI=&GCET1V@G3^(7>!%Q'&74.\\]Q;.
M!<AEA/61_>'H<W_T0QI=_#@']W)$L_ [.,.'@=%?974VY4'Q.8";OWOKPXGE
M_K!?)XY?Z8]7#Z@?M0\,_#+%8<;\_7?]3 "XX;H4ARJ TM$F+[)0.0!$DZ7)
MNK<6T6[FH(\;3C#3%Y/1H)_K8O,3#.H\^N$<<3K9RTX//K0# ^X&?,FRHI0,
MEENOE--:<#!6!1\E=Z$$"+*WQ?/K$!:#&(S2G8\;U,5D=*W^ 2V]@_EW>[,)
M.P/XU/LPI2?6)9Y&C6_HRTD/I%;>YL224[3F:A685R&P4H13.=H@P:]]=^;O
M38%)G+\\5Y_P8^7D1QQ,)XOOS%EB7%RM1_]G,Y1+?O8?W(O)A"ST(DZF8TC3
MGC=):FX%(]TFII,'!BH1%,LA"BB^V-AB8'=AW!W4C>Q>C!?#NYK!]ISBJE_6
M*<?346=6O22.X'__W6B<<?SW[WDW'+^<C<<TP&M0)5K.4RKD06;R(+T7+ AR
M*$$4G4JDJ<OF=E0OH3D^XX=0M);M0^R[2KHXE/27,#E_,<SU/Z__-:,08T#@
M)B^F+V$\_DK!S'_!8(:][#,:'A4%#YHS;8QD,>3 8BID$:M(\+R%"+9"]UBB
M.(C)46L:&FCEP_EH//V(XXLWP\\XF=9Y<-*S -)+"TRYHIAV')C71K' N>8<
M3>:I-%GCUH Y!24<;.15XN7!*T-*HQGA>(\)29MQ@+_C]&K0/:YXT2 #$\8A
MB=)Z!EEH!D9F896PMLW<<!^H4Q!"9T9?%83J7A#O<5 =ZG<PGO9Q88>>,)"R
MUHX%"FZ8EB:RJ*UD(=D@$I##'MUQM+$6WVG*Y' J5A6C#U7,NS%^@GY^_>53
M#<)HJ7L[/<?Q'7/T2-%!"93,Y4"NM+><5K;DF? 2DK;<9==D*=D"VRDHI6L*
M5E5B]E5)?SA:@C=9X%M88 [S9S+3BU+Z@WY5^.OAM#_]VK/2V4!N.4LZD;(U
MEPP(*!-"2^>C1B/3 QL<AWS^MRR-H]E]52NVTW"U%Z*0/#G.0B8W24N;F4]H
M&*!#)[DP7*<F*\VIS1+[FW658W?XJC'ZA./IUW<#H.$-<XV-/E67F%PA\H&4
M=X[&5B32*!$H*G>"1&A=JH=C6*QLLUQL!O5-;U!T9NT&(4C%,OWZ =-LW*]N
MS<^??^_WDH]69UF8J6N4=L6Q&*UA/!21M/;9+\_\W2A@'9AOFOF#K=L@QKC$
M]!M.ST?Y=BR<5$G6:T)D@%P44V$E=,QH(907F$0.[4A?P7,"O!]FXP;!PIOA
M%(9G?8IE+L=*\\_K+VDPJ]D5OXQ&^<_^8- S@2<#UC):SVC<0(Y($#0A<6=U
M*2 4.&BA@VW ?=.BZ-SZ'08*"XS7.**BB 0#,HN0F>:*5B1%"Q24PBF6"4J&
M)L<3)\'T7E9LX,J_);<#IB2O7Q$F^+ZF/;TM?TPN]=?#XB(Z;IEPP)FVH!C,
M4YH2-S823IF;G*+>B^J;YKT[>S?P^6_M2OP^&J:K0(3FF\!! POD>M1E2;%@
M'#")6B9KA>.ZR8GS6C3?-OD'VW>5=-]-,-^S-FFN,VD-(TE/!&"^9C5:M%)K
MBXGBVG91_#=-ZQX67.4Q',KCKWV(_<$\AJ  \L-TE/YY/AK0LR>7KN;U4+4*
MEBN7&/<UG'2DO B9Y.>*+CI(YWV3]WE;@-]\;DD3)AH<*M_"N;R-Y4HI6GIR
M*H4CKX3^Q&))CF54)AF5G#2JL48>/?^D#8V;M7((!PW4L3C=>@=?Z]$6F8"^
M,YYA7H7<"P!*.QIR]!2OZF("HV$KFCT-)@=:"VPBEQTP/JI^#J)VPZECU[PT
MD-"K&7X<K3\3!5.<XX*\G.1K$!L=\QD*R]8ES"X3--U",9LAG8Q .K)ZASO)
M]:SK2J0OZ6?]!(./XSX,K@Z^%NBB4\$K;9DL03 =4F;!T[^23$$&JW6*2]N+
M:T\3'_ZD;Y[J!@9ML(W\<C2<#_$?_>GYR]ED.KK \<(07Q<8,9?L),4\M&PB
M#1_(:T[TZH:@%=@HE$JF27[C%N"^>9TT8Z+#G>>JY7OQ+9]^7R=BE5"BI\FL
M3EQU'Y3B9K2&V9B5SIXKA66+Z6*?S_[FA7$4HS?8?+Z[?;8B8:<\U.P\%F+@
M-8K7S/,B&,\\ZNAU%'+]C:E.]RM/=AKIT/H=;F57+;_"@@0B_S*&X?3GV; >
MF%RGWV7@G!P;1J,V3'N%-*5)9.B<T9[TG*3>8IZXYR.^>8*[-&&'^]*;8-W)
MB5I@M J2*3(QZ:RE*%PXP@B2Z>Q\T+2VZ>4-S*UI7O=Y)\OYP<9ML$>])K25
MR F2LJP(&K>6H3 0*)C5B*9PIU$VR5@]X9V% ZW<8$_[7A?EUA&*<X0O:<\*
MSS0_1>58U!3R%)NY=<5A+$T24[;$=Z)[ERW8:9"_1C _XWA:LRI>8:2H..@X
MSZR.A2NF1?0,C"%TMGCM1>!0FB0O+N$X75'L;>T&>Q"O<-S_3#[K9[PU^A[%
M*D9Z1RAHAF1:6\= &V3)2W)@;739-#D"6XOF1(5PN.4;I+=MB&!N358)B]98
M./-(4M6A(*UX/C&33;*6%)N6=Q6:AI GOXATRTB#+8>%C_QFF&B!^PA?;IFE
M9F<'8;3AI8[64]3K+$UU5@@&( 4W$5!@H[GD7EPG*I<NV3C"'L2=8.J6IDN1
MVEBK&'E$Y!+)3 BMKQ+W"I22W*BE#-K]@M63G3Y:&KQ59MUMJ=X@@Y!]*C77
M>^X=AWH[-%+$91(WVJ,5N;19<#9".C&I=,Q!V^V-GL_&HR:A2E'K#4"Y*CG!
M58&"04G?IG#1Z3ND^UJYP;[&Z@AI/;M,\W\W&L]M/9V.^W$VK2D>'T=5JC78
M'@WHB6=OAE,<X^1FTT<73,XF<HG U.3%F!APK9C/6N1<M,JI2>YFM\,X4=D]
M(M=K4GH.+E7U;GRUZL['=54<1XJ< KU-61(2[7-BD0O.4/%DK(Q6MLD=7H/E
M,9)''X_?U3(#!W'3HLC5Z.)B-+R%!X5P%.Q'6ELMO4HY6!:B#4SI1-^P68%N
M4I=D&<BS%LI!K+2H<I3SW/@P> =]BNU>PJ?^% :]XH(#SRF0P^JU9Z*5O#''
M%!)6+I)P1C3)*UV/YUEKI@N.&FSPOL<I&1+S:Q@/:<B3%RG-+F;SY$>*#_NI
M/^W98'5QTC+.BV4Z:LN\!:A[CDHES)8'VT)%#T-[UH+JF+D&N\6W$%T69AE=
M?!KC>2WR_!DO=Z!^'4WJOM/;\A&^]+Q&'Z!H)@O7U1J>!9$54[3V2L6U-J[-
M=+4;SF>MNI:<-MA]7K5<SXG$HZ3W(89"LZY"P4(2AA693#&^4&#;Y/QR%<JS
M%M*!S#2XR_U;?S@:STUR.<R>$"4*D)YA\;0T(_EW$+-DF9L$2<GB8Y/<ZF4@
MSUHG!['28"NZ&]/T<BP$-P!3IEY5=UB3.KQC@:=$*W.DD319Z[J!_ZP5^0@*
M:+MIOG;SKI<*@;/.LJSJN;&/@7G-#?F2UGG!K2^IB4(? G:B^YR=\K%F)^KP
M&MJ+6]X?JZQ[TOI@ @1FDJ*QQMK&20O'A)5"&)Z$]VVJ9]^!T:$8;G4T:G[%
M_0!;KMMD_.ZR/\W?TF TP?SW[Z?C&=Y\D^8>_#)]/9A_X-^_G^#9Q<HIY3YY
M'7'Z9DC"GS<'>_&E/^FE"$XI<MV40PHW,1@6/4J:X(26-*MR!TTDL0JE0UG<
MTU3J'IGLP>M*IL9!]FUQ'?D.HM_A E_-Y\^M</66VENUX_\&6)<KQ:8V7:L:
M.)2X>W5PH-6/J0IM,R@T)/[B,XF_EF(5%ECQ*EJDKY1H<JIU7#7<:8+V>&+8
MQ=@=BF!^D=K^8/BMM.4/..R/QK^/ICAY-4,B2?\V]Z_(YS:>O-K P-7 S7GR
MCERL5RV,<\;%M!+RK+^?ON7G'=]/[(:=46/3=MA_Z>H:[ +>3Z-AGEPARB8&
M;6-D2EDD[RA[\H[(*?:6NR10"O*4MR![_=-/@-H.S+;Q/?[W'Y?L0D[K/SML
MRG?MY4Q&Y2K_F'YZ%];^W?DV/+U-F[YMAK+4KT\*JS&#ILG:: \R"I<0O/+%
M@(+,U_?KV_!!G3?NXU9:%P0PEV,M>T[30<"8*514PGA5M MMP[)?NVK<]QX_
MXW"&-S7F+,CDZAN!I689>D\!%T^&YCR>9=1&I-)D0V(9R),HL+8+SZLGAP=8
MMD'[OBL\-?=XW9VXZQ*^M5 @_9/KN9* F'61-._R0A.E2,!"H!!<>&$-<&>+
M:[(WOP?6X^OE,(+7JZ49.PUBDNM+,=>M0:X-@=X5S+2^9K*!EDDR*$XR%%S9
M2*ML5FVO)RTC^N8GDVYLW4 $[W&"],#:G/ 527@PFC>$N$+9BU*KVLZ9!4?.
MFS8R5T>+P%GN@T8-)36IOGTOJN.+H2/V5J:,KDS?0!>_X)#&/*B%__(%&;B.
MMUZS7,#+D@,!3$S4#D$D?4$#1WHME";7G*)T&]O49;\?UZEHHTOS-TBE7!ET
M3T03T=:"TKXD&JQ4+$8:=M(2E:EJ%4WTL(+D5!1PF(D;Y$!> [K)7^HY!$EN
MBZW%_B+%]:74U1!8BA$(KA0>F^19K\%R.B["GO9M\)K_/AJ.[J):-!=<*)S[
M*(0QCI7 ?56X9U!K0:I8>Y:FZ)5M4F'U063?O!RZM7V#^6"1HG$)[EJ]/5*J
M@6PB,Z)F;'A(+ J:IHS/'I$7X5R3.6$#GN,+H6/F5KOW'&SV!O[B M;"02D1
MT1M-6G>F9NUGQV(Q@A8K'G@P21;9)!U^"<>ILK^/F5MT[2-;Y%Q3Z1=E6'XA
M&]6EZ^UP]6>U=$*6MECN(I. BMS5+)@7PC$94L@% EK=I(C[SDA/33EMJ>IP
M?9F?^YS#\ S?#.?WQMZ66ZWKW@QOBL;6K'H8?NTY%Q('C\Q%5<LN6,FB48J6
M62%X%)I+7-KE7'^*MLN'GHH\VEJ[P769=:TL_QB.$0;]_\6\T'0O9!4(9&1.
M^]K.M$Z1Q642KP#-=<F6-W%,MX-W*NII2$J+NL[U*LY&0_2*52G;4%-'49 !
MD+/ K6(49!55!/J8FQR6W _KU*32(0D-;K>\PG1]'$U&KLI].Z[:?7%1^Z'4
MRS<4N7G/'#?(=":,7B?%<G$J8X@UD;%-NM:]N$Y-)%W2T.!V2\4SJ7"P.D]?
MJ@UF_<EY73+?EGE!2L*5I+&1%9TH\@<E6,S1L\1]X&ALX&V*53R([-24TBT5
M#6Z0W.SF+<Z&^\,9H;Q);_D)RVB,U[7F<+)\F>O%,-]]RJ:VSK*D8BVG*5-*
M>BV0K!GKT;(UR4I5DD;7I#/!$<=X:OI]JO)H4(_J>@A7]OL)AT3?M*>P<&_J
M(6?B%%"89)A/2; BBW#9*A7:9!MLP'.:"CO,["UJ/&VG60PB\)PL*[GV(3<Q
ML "TYCL=99 $T[<Y5_QK,NJ$DA97[-Z-1Z3?>4 I?)*8BF80:B,"7WBMP<J9
MM EU%%Q*WR39\0;"J4E@3^.NX?GPTT><W@ARJ\O"(G(N@\D,8ZR-)#)G7JG(
M@E>9EVR\\4W\GYV1GIIJVE*U1EP'GU[>04R>D59):L?X?$\S)<ZB &32"6<L
M#US;)JO,'10G+8J=3+R&\,/WC:\*0+W#\8=S&.-/,.FGFGK7'\RFF&]&K+50
M@)D90Y&B+K7*MY"".9=LR5'E8%*3C>/M\'WS>0TM>&AQS+ .9B\!)!>T85(I
M7RL8:A:,X*P([:Q.,5O9I 706C3'ET(3[K;1QTZ&;Y#=L SJ:L ]4S#S[#QS
MGM.+$#$R;[,G?QA\2.AERD>9+*[P/ ]%[&/\!KD/_\#^V7D=XV=:0<_P]UFU
MU-LRASAY.YM.IC!O%G!IDNO6::) YJXPE9UFFOO (M0[)CF;2(&X3VV: NV%
M]IM?;-ISU."8<B?0O6Q)_<DA2U ORA>564C&L"QKSXG";7%-IJ"=4!Y?2$=@
M_A"M[41;@P5M ]BKJ74%<P]*2"71^^>SXO4V2NUL(A,#H25/+@67FIQ[[HCS
M&>NL$^H:+)-+Q7Y27:S1: H#+8W<(ZW7RGM6( JM HV^3?6C)U,0ZY#E[ !;
M/G9!K,EX6O<6\RQ-WXX_X/AS/^&\T$M)TBFC(N.J[B9+;FLA.,6\1!$SBJ+%
M-H*@Y]\2 _UI60B; #R1(E@[<3GJT*8=+BZW\,RK\UTBFES5 -D&U [UKW8A
M?!7-<8M>=4/4*NL=6?EH$@!O$"5DEH)0%,7GQ'QTB:$5"13F'/@V&79/D?H-
M%:Z.R/PNQFW@4?Y*4(83O*K0PP4WQJ%AKK:!T4)H!KQ$9L%$GT2R0C79*+N#
MXGC>8(?,K!0\W=>L'5>PN@+R9W]Z?I,3_GHXG>?[+NHR>>!2H&39UD5,U3)/
MUD?F2G#<):ZM6DJZ7IN(O\5'?<O4MK!F@Q?Z:M W8YYG[EYA"Q2CUHT[)DSM
MF5%\81&Y8_7*B'(!M(A-KG?=!^I;UD3G1F\0R:VITIAE<D[34,E!)42V)@OD
MQ)F52FOOK,_^"-4KOW$WOB/[-F?\5CV_;7 ]ZUJV.Q&W;?G2?:Q^S%JV-4\(
M<RUE-6^DE(5D8!"81X=%)>&#;))%\=1KV381PR[&[KB6[8:JG(7&Q#$J)FJC
M$8W@F#>T O(B75*@?(:TA??WY(N9[F3YAXN9[F*VCGWZK2OG)M1%1V]83E[5
M;C*D8",3(SU[;W01!;9Q[+_!HL3[DMW$M$^BENV&7F9W,793V';31[6O<KO5
M()=*WJ+,09N4BI5)SU-D97'(@R-Z2XGRX9*W6XRW4RK7M(UIP.*FYC1-"7QH
M:$O<Q:!I@78<:@L:[W(H1BIZ%PL*]$5O4:YXS0=V7K986NM!9U?+DA:F)6@6
M$B*#DKGQ"!K:E-OJOFSQY3'EF\EDAKG'!214(M>Z[(EI$22+3DN6=+!"0LB^
M437F6R">1*K++ORNG WN:]$&I8H[ZOWE!;V+PD?&P3BFBP4&%C537#NCK!09
MFZ2V?+O=W[I5U/%9;!"MSD=Q^5J\FHTK=ASW1U=Y$K_CG_,?37K:R"*SH)<%
M;.V7&#2+V7)6DC$HDDR^38++=O!.0TO=LM D5V4MRGE=G!N0]1:#<0)9J'D[
M6AG!@B 'WGF,D+E ;9N<;6V%[E25<@ '#6H?WBOGRZBO;A:]+7<BP$5UG![/
MMA3!-7.IJ$OTWIK ' ;/390>4Y-*,X?!/E5IM6"MP8V4^UZ,A\&C]UP!S:<.
MI65:DSX@6<UL5,K2M)IDFWJ,!Z$^5<4UX*Q55_A-K\OBML=E73B*C.?%*GH4
M4>MH=&0R)H*L:F(C /U1<*N"X"'Y=FWC=\-ZJN+JC)\&Y;7N>Q\V(.9@=8)Z
MR@U*UFH#A@7#.<LU4QY3\%XTN3"S.]13%517[#0HQ/4B_\_LJBS%Q]&+G.?V
MAL$[Z.<WPY?PJ3^%P67H6E&/AO.J4+<FVWF!*%%R<4X7EFW-UX@Q,F]DJ+<,
M;2@@-;=-MI^Z /_-:^[H##8H\;7-&.;O3UQ^?]XC#6W2G^)5ML_E"_<>T^CL
MDL?YN]?+SF2;DV.*?%!ZR\C]##7[Q_J,/'H!"IIL3K0>V+-0[]&8;U"R:_V6
MWIMA&B,-J!8)^C"+DW[NP_CKU18A+1\P3-@S/$5C(V<VZ<QT*()!K?H:O;>@
M-.C"V]1BV1OR-Z_&(['5HAC8>NBO\ ;Z4DG0GE4N>2T+DPD,TT!S/DA?J\C4
M],L@@)LV)5MV17JBLNJ*FQ85PI8K)-[&^AXS7GR:5U;LI42AD""(0#(GG,8R
MB!*92QF#1$2^G-;2C8:VQ/?-*Z<%#RTJC=TJ>A:\19628C:#8#HYSR"$S(#;
MY)#^/\@FX>9C5I3KF/4]K=FBRM<\>WY-5LU-;?K_' WJ@>9-+XR;_;<78W+0
MAF>W0^'?D:*/VKH5DM9""\^\+11GB)KC7Q2R8(OW-1L?39.9H]6 OGG1/0FF
M6]0MVS2P>97.T1C[9\.7L_$8A^GKQS%0=)'FO WS_$^#^8)\$Z9<#TL*8TH2
MNHY(,FT%L,"#9BED%"%H*]LL?6V&<[+R/2++:\1[^!'"[:0DL#+SJ#DC5Y 6
M U\7 P618>0VH$4*--JD\VQ,\WJTS"8M37 ^ [,NUZM]M1P6ILR4E,EPEZ/R
M3;I@M<AL.B"S\?+.%!;NI K(E$=Y>5\N<*'(^Y,V(U>ZM+DK_&1*@ARV9[^W
M+1^[),C*$);V>2?SRS.@3=1!NYK?H6C62)+%8!VK;B5(H;56C4X4[T'U1&X;
M[L3V)N$<;/46]1;O8EK<Q=@"5,M;AVM1/<Z5PP[96]O*JPO3'TT7W'(HM7@T
M>1>)7H-8-R]-8BI;6TK(H&63 [PCZN&!2X?'EL,N%F]2F@ +DC><Y_[,HC8&
MEN!HW60A2G(O%0\5DV5<:P..UE!=&I4D6 7S"(58#^=I91OG0",WN%A X[L8
M#6\#BH67[.==3")YTH$$[HM1C(?:24Z@<;E)!X@5)*= ^6'F;?"B;SA27=3#
MH/%H2WXS@4$*<2F6A) <<]8H+H*6MC0Y8KP7U2GHH#NS-TC2?X]3&A_F15GH
M*U2R<&T*H0)/#K%V2M3+3_-+]D5IZ;GS33:TUL,Y!15T8.@&J?<O4II=S ;U
M^N6F3;,%4.]\E+HP&RU-8 4IP [U;HE&7Z1"^F^3$^*M$9Z"2-K0T2!]?OU6
MUA4V'0I:GRQ3P52WQH6J;I(X!=A@7+0(1TPF.!UU=&;T!NGM:PJU "0=8D2&
MV:FZ$5?(VPF:&:^"*#IF%YHX%$^VG-4A&TP'VO>8Y:RVP?6LRUGM1-S6%8SV
ML/HQRUDI'SRO7>^2-+YVR81:MLDP:S#9K%VZU:W^VU7#[N6LFHAA%V-W7,YJ
MZU(]O%Z525$RRRUAA$P8=0JLMJ:7,1D+=BDWZ%2J(.W$SCY5D'8Q;==%L&9G
ML\E44N2ZH4"7MS9%4Y# V'H-SRL&-F?&>>TY%)3PRTU&U]/^P.>< MU=FO)I
M%+N"R?G/@]&?;<I;73_\" 6MU@]DJ0Q2\BBB=%PJS;4#]*A-]A(LRA2TV*:$
MU?7G=%[]2' ?509D5O):,EU(YB$)YGBTKFX\B-RH1$?7U8]^QVFUT[LQD4C&
M_^GK'V31-\.WBUZ<+]*T__DR,^VZ8XR3,BE16$[.U'KQD7F?-/.*!&=(=2*W
M:FV[(]0GD8NUBU;6]"UMR4Z#8Y%;&;?U4G@0"5B.6M<:T9[Y !2M.ZO 26V+
M\J>6O]R:L,WYS;M8N\GQR*WK9_7NV##U!WBG[^['T:ZFX1JD%(DS02-@&K5C
M$=&R@!B<"]:Z-DVT6PSFY+7XZ IHLDWS:8RI?WF5* AAE(/ HI;S/GG @J\E
MQ$ ;*,(*QYO,9[=!'%]%CT_K2MR^)R<M9KV+FJKZOW,L;\N;X12&9S70>#&9
MX'32DUDI5: PFSS4&*-V5BR960=<!QIV"DT4<S^LOS34)6\-9IW%-=G%';4W
MPU<X[G\FM)_QUS[$_N"J"I1($G2,-%L'1[$Q^9C@(=9,;F%U <YYDWS4+?']
MI;,F3+:H(;>^HHK )"CPS@Q3+=VJDF(AHV><&R<!<DJ^3;V;)U+3YLG)J0.>
M.CS.KMMLOX^&U0"+X]377RHJ[+F4N<RV7O'Q];*/-RS6;7IC"!&WO'#]T);5
MYJ<_8R%T9/(.C[ KHEOE'<@:+U(:SS"_'7XXIT7V(XXOW@P_XY7Y7M:=V-*G
MI^'D;2%7;C3I3WO2%V.E 59*-84)A46.@J6"IIA(XEZNNKU6+H?B>.;".BJ-
M#2JZW5RGO86TQX/-5H? K*D%(+(3+)2H2#TA<6XC39Q-KG2M1?.,%=8=2QT6
M;ZNR_X#3Z>4ULK>%#(3DGE$D\(_^]/RJ@7FYE8M<RT5<YB9=7=G^VDO<B1Q(
MYDYPSW0 RZ*2P- Y7Z)'X8+:8O(Z$,8S5M:Q26Q0MFVI:DU]1]Z.JP4I4)T-
MI[V<3'2U65?V-2 MU<.#7)@4GG-O>(FYR862!W ]8]&U8*[#JFGS)E_G,#RC
MD'->OJWN<EQ/MV^&-YU>:R0!PZ\]81,-7"$MV<#I#5"1A5!<G9"3TC[:L%5?
MK9T^]!GKIRU!+>JBW:H"<3U__H;3\U&^O9!GF84WF3,$LH#F,9$90- ?098@
MK>%MBGMOA>X9ZZT=BRVJIM5I=%)!TLH]?/VEVF'6GYQ?KN_S.JO2SH\U2?Z\
MUA1)6C.H1^O:1H,<8LR\2=^"!Y']I;&.V6M19>V.]T?#_OGS[_V;\DP5?T^2
M-^@%)":\0X*8"D4DLN[+JN(X*@]M!/8PM+\4UC5_7=9[JPO[];!_K9O^5QMV
M\Z\7NW7)YMH7AIQ!5#3!IJR8CQB8]"DY<A53,=OD[S[X0<]8*]T3T65-M8KN
M(WSY"8?$R;2NQ7?U>SU_KMM^(U\P\I1C3?'A9 _PAE#'S#+62_$)09IM-DSW
M!O#,974<XEI40=M<P&VQ+_<3%OJ=6K$-<S:!&\^"-(9>C7KA/M=*NEE:9=%F
MT$VR%W; ^(QUV)K1->H[>(=^]3C\VBI7]_JO39*]LL9EQZ30<GXQEP5.JWGV
M4BDG(4'FC>+(+2'^I;U6?*Z1WL'M65:AODBI[M!-;K:+>T6X($)TS$"]; )(
M8:_3GED$;8)RWI0F9T7;@#N^W%JQ^Z"(#F2F09[?-AC?X[STP#L8SU-ZH 3O
MZSE62H8<RZ@S@U@W[D0)//.()36I!+8[U&>MK -8.TKFW[LQ?H)^?G55 .LJ
M;'DQO"QQ<96OJ"/'S)-E65>OD@O.  $92F\E1;J)9O3C:&T;N,](;YVSUV'R
MWV7*QP;$5T@G"ZB7[N7T$G$->F[.)UX/I_4$52!F;XQC)9<Z0WO) B3)BE!H
M):)S<9NKJ=TA.CF9/2)A#8K@K#%6Q7WCJEZ^'-&!BM4R4=0)&2)YIM8[^DJK
M(C0%S:;)3<OMX)V<QAJRTZ!NSN8%_AU\K:L[O0U7>6RWLZT-JD+("],>2/F(
MD7FE%'/ N0O!>=&FY_5^<)^1QCIGK\,LP_6S[Q6^E_3;_02#C^,^#!9;RT8$
MU#(II@I$IEV<5QD#!BH95[S3!O=;$>_YT),32UNS-^@#^Z"JER(.)YWG(FG&
M>:EUK3C!K:TH1$C:.8IM<YM2 COB/#EA'8.O!IF"JW!?UJIV9(6:[/AR-IF.
M+G"\F"^_]H+)I>2HF [5--$*!MP95KB)W'KE>#C2/NJ].)^1O+KCJ^-\P767
MU2[CUO?X&8>SJUYY=]X&S7VD& *9$+62ILV*YEFRCR@<>0(CI=YOC7OPHT].
M,<>@H,N\P/5X[YZXO^^?G4_?EC\FES=KY]^[UOKO..W)$*6M92JL%01>Q<PB
M2,\LST)R 6*EQ^&6^MD-QS,14T-RNLP"7 >^?_TF_#*&X?3GV;!VBKK:Y>C5
M:_Y18F$9E6&UEQCS(AL&LFZMD844;'/?<*</?1::Z<[L7:;Q;8_TSL[7 K;A
M IT 2U-DA+I742O\ =G*66\]5]*'W)E:UB%XQM(YF) 6O5D?VNVZO?W@(&@1
M#/G_DN=ZV9HFQ5I\-.9@51"T%K>I2;0#QI.35VN>6C1+W;[Z4D]9B,X@9Z3U
M1--H[6GCG60^>&%$K4D?FU3WW1[BR1>O:L16@UH=&Y!>)AEN2/&QSD;E''-%
MT*M@:(X-5D=&[IO1/JH80I-NI[M#/=6"C5VQTZ*!&7R]RBA[D?XUZX]Q;=ZJ
M<VB*"H4!.79DDUQ!4K@I72R0O7=%M^EHM@VZ)S,[=4;S<IG'SCEJT@EOE!#S
M_+#Y PSP;5F/,CBKG<Y,^GK3GR9FFJ6QUJXQNF[=1]6F%<YV\$Y?2MVSU" /
M:D7P!)N6XNG7=P,*)5X,<[T ]*G^2D]:&G\VR"!P4KTQBO2OZOYI5LD*B/FF
M8W'3F6DCQ-/75!NV&CA/"Z0_C\:W7X0[-S2DE(;@L*#(!=!14,C@:TN)4&01
MZ 5-I"WUM!G:L]%11^PT2%JJUGC5KW P5VA+U1]Z.1A?0K0,=*SY,"&R"+42
M,XB8HI'2Z2:>]@.X3EXY7?+2($]I>VOT)#J()@H6B_9D!3N_L>K("@YLRE&0
MB_>XL=K)BZD16PTJGFU ^G-_",.TWC 4R7INE6%<UONNI?B:NP<,K27/+G $
MT>2*R^Y03W4OH"MV6KC=MU?=R61&."E ^'4T/*OQP;QR \')!81F0BA);AM9
MQ=>=^Y+!:/ ZYMP\?%L/[<G,2YT1?$_HU@$[#?>2+JM\+#"^'$W(<\."0H .
M3* BSQ\303/6,I&\I\G8.RN:%*N^!]/I*Z8C/HXVU=PJTM>+2H$D-"3>3 -'
M4G5 F\CS=\4*6S38)EG:#R([?=ETRDV+,/[V)E8%]/93)6#R^@N.4Y]LTPOH
M;4$ !@Z!Z9PXN6AH6-)1AIP+SZK-;/,0LF<EGL.Y:1##+R;%JS2ZCZ./\*7F
M8IZ/!O,$A=%X0YEU57-;M!9D!D,Q!3K+ MF&@8F)XH  Y/"W7,%V!7SZ4CL&
MDPVV VZ_(K_UAZ-:@7:.M +'\:1GP0-WP1.@0OBDB2S2M,JRS398*U-V;4[;
M'@!V^HKJDID& ?]M?//6M5=W%'I6:N52<<QD+^J<2KAH;::O@ ( Z8M+3=+\
M-P%Z5DK9FXD&UX^V-T,O"9&X)O%*<OB9=D:SR+5G*>0@ZOF,Q6-N-:Z!>/(J
M:L16@WM'KTO!-'U;7G])\ZK%[VG%?3LOIU?_5P_X/L/@<C$FN_13+5Q,/W@Q
MS'>_<>LW>Q:-2:HD9EUM69(L9P VU_(N.D2,I<@F>Y$-QO+-;U8^-K\-HL2#
MP+_#<;_61%Y..$V#6?4M;YOITG2]G$VL+@ +P>EZ.1EIXN><%2,T%[%VKFY2
M+N^XP_SFA?Z$5='HP'K_%Q@*U!["A3G+D>G@JK=+ZYN0VGMO8\JI21SRO*?B
MXW'6(+8]#+PKQ041!4NU989&%5ATX%D0+D?N7"C8I&A:AX+;W60?9I\^7?:N
M@4%]],^#T9]OAF4TOICO5MS<G(A(TBFA-K<E9NM(0JU2)KWV45H-SC1)+MD2
MWS?_WK7@X2@%)BZ+B:U62JD7:F*TP!*Y8>1_2<NB%HE)"E1$5,)HUV3#<FN$
MCR"9%AQO=TOI0(*:5+6\;/CW#OJYWO<%A5$K$5DI%&=JGRSSF)%6$J^$ ,Z-
M:'2U[0Z.4U7%_L9N</ZZ=/G[;9R2H>K>P\*'_7DTOGM=_*9&1<E2&)Z0@:S)
MX34=$V*HG=>+%UZA];E)BNP!F$]34\<BL47+Z<7:_7&^:^K E"#J5D%4M&X+
MZUF46C!P+F:P(CO1Y+#_+HP.50*#P?$<E_UMN6Y5^:X.*D__E@:C">:_?S^E
M9>OFFR.:Q[Y,7U]*^^_?3_!L]8[#[G*8YZ<,Z968U:>]^-(GBP0?8M*.F>1S
MO2@<&21E&0=K*)86M&XVB056H70HBW.RQSC-(C+Z+@XG]9CV89GLP>M*F\*#
M[-O ^;B+Z'>XP%?SB74K7#TB 6:#:7O^;X!UN80LN&=+XUC5P*'$W:N# ZU^
M3%487ZQPG-X;(\E5=D*Q*GF602K!C8TF-.J >DPU7#[ZT<6PB[$[%$&M(O)B
M=C:;3"47X>5H^+FV&:>I[Z?1,$]^FSM</9$Q"RMHH53DLFBA-0N@%>/1ZV)T
M$68Y+7!M\9:'/N?X#F,W;(P:F7*5YH,*A[VP/QA^"]8''/9'X_E!^JL9$EOZ
M"J,G!SAG#0QK33-M?&+!9!(Y%ATT=U!@FUH]VW[>*=#>PK0;W_)__W')4N32
M_G/^@_GWJR7>8_FN_O>/]V^NK?;GGW_^0& _]T<_I-'%CW.#O1V?P;#_O_/P
M"(;Y*G 9#2=W04SZ%Q18/<#YYF?]> /N+NBK!]XA]P"8Y"3C,-=;TGWRH?L&
MR:4WLL9Z4=,7H5YWS<"+D$2#2KVM$.]BSI]@TI^,RKLQ3FH0>CG,?\WZF:(_
M^H#W_<D_)_3?/X:)A$*"FV_([6[IO3[F8!(.']P2/\[9R 5B[3Q*07@*O.AB
M2S2@I2L2>H>.LS5U[T:#?CH>A=<?]RA4KA_L,J72*) RI%2*3IAB B]"@LB]
MM26GO2A=-^[6U+Y"^FIP+&87G_8HQ*X=ZA*O6D64#J4"CUJ@J0E0P8(,$9RV
MX/;B=?'!AV;?_7E5/;H_/'LW'@WIRX27=W#&BW;OMW^C/TQ]HO%F'\AG*TUQ
MM"CG3*N^",AB*.3/VV)2IJ&[-DT7#T9^:.2W2+==[).__7.(X\EY_],['*=*
MXQG^]/7WT;!N0)&\Z#%GE[_2DP9\*D)0S%,+OM=ZE-'P1'Y3,@$H E*Z21[C
MWH@?(ZWQF+I<CC./0VV'$<JM],R;UHH]A5;H7*^3\]KL1$C+@O/T577@"KGK
MC;ILW4'QW+2S/P4-=J>N:EGVG 0?'2\T(,V9CIS7UDF&Q1*XYE8*'QNEJ<P_
M_[EI8!^SMS@RQ<OCM=<P'M(@)S3>V<5L?O7H%7&0^M.>D#&D+$4M!DDA-7?T
ME8B969JY!/DGJ4"3U?MA:,]-,QV3=9STY!?#O+8:6U196I$#LX+HU\HA"9]F
M02Z2A*C1)G^LM+@-$)^;O!J1U^*ZZX.7N454SAI0M=$($D!(+$A5:C%NIV30
M6:HF>85/\J+]8XJJ6ZH:7UR] 3BO/"+!DJ"]8]ZFFN<>@8%)B1744&SBSLLF
M;:PV0_I+/7N1T^#6ZMTCCD446"])S#,<\DT8V./*1)]J\S9;"VH)91BD7,C9
M,]J8I)-KTS5[>XC/35:-R&N0&'T7Z<^0\,5%M4DO"%GK']$TZ<C;TR9S%A5J
MYIU'GI20I4W@O@G0\Y;0GL0TN-.ZKU46Z5@N>5UTS=2,-*G:Q'Q6F67O,L4.
M4D%LLN(=A/I8&8Z/O6ET+&(?.W]R,I[VKK=3YPE!T:NH"TW"KM2Z7I$FX: 5
M&<\X#KQP*=PV*R@]^)8DZ4_+<ESYY,?*DCPBV:,NC-[AON0=(%=I(]M V2%]
M<C<=/$:FY(%LK./T %,V9E=P[S,:8"Z7VN,F.08E298YQQQL5-YLX\H\'58W
M9#RV(W47"W:<V_A?O_SWBV'_ @;_B3"8GK\9ID4F%GG-*?$:QTN*S^JM(!]H
MP<.(G":H$+Q<2FY=F^2VZ?G'\S</-OBH8VMUG+;X"PYQ-/EXCF/XA+-I/TT(
MU@]7N(+$8(V)#&N33)T F(^2'!A:89(3'L-R)^^U+-[W&=\FDYU9K7G"^7RF
M432C2Z4\,]99TI>GJ,3%6#=/O.)@1.2BA6/_="Z>'-^EZHB.!J=^&_-SM\'U
MK.^I[$3<ME<3]K'Z,>^I<)Z$@4!S).C"M*WXH,#\>D8*$+PK3>[&/O5[*DW$
ML(NQN[ZGLFV6?3!.ZD2.B@JTR&F>H-[T+<S4#K?&.4W>ZVE>8-B)G7TN,.QB
MVJ[OKSQTMT87"5('P5)1M<0L1 :FUIG-#I* + GN:5U3VION+DW9\5O^"M,<
MPSWH0',A+?>U #KYK^ UB^C),[86N$:-QFX3NSW\22= =<?F;.#MU6X:TZMN
M&A_I[\S7+HM>AQ0+0Q\H[HFE-AW3GL525)$9; Y-SH_6@7E^(<'!E#3(W5K&
M=/5>;(.J94BP'M;C! 2'T_: #@ZP>8. 8 .Z9$$(GA4K*=5^A48P"!98<"8Y
MCY$FT2;MDHZIA >"@6,)81=3M\@-OUG/*K"%B^J+S2EKQJ6HU1AS8I';P(PI
MPKI:\*E-B>.U:([O071!U7+FY<%V;G!1Y+I2R\L!3"9ORSQ;;R[TD!Q/,FJ&
M*07R9WAA/B3%3%1!R*(=^"89X1L1/3\'HAMR6A3GO87GZLW8!E%+#V(5TN-X
M#QUQMCQW=&/P%JO'*K*(:+FA.0QBJ#><1*V%&VO8*THJD:8[T60G\5@2>,!M
M.)H"=K%S$[_A.KW[:BV3Z-!$D1FH>6>^0L&PEIZY6+BS8*5R;8A?1G)\?^%0
M>E9\A4-LV\)/F,5)/_=A_/4##/"VJ)7WIG#+&>KY920D7]B1/R-, 7!"*(Q-
M&M9M1/0,_81.R&EP[>(6G+H)][9\',-P JG2L3@6VP)A2[_A88B/Y$=TP^FR
M4MH0TF!UV0*I=ZAY(58%BGK''BATRK6E.;>J%DIQ =J47GTDR3SD=SR68G;A
MH>-CCHIN\N)LC)?S[-5:22LB&HN!E< =TZK43A+>,"%S3$ESLL<V1UAK'_X(
M]9@[9F#4I?DVNAH=EE=[.:8')!C<6COW+QEUS\,.KANT+="ELD#@38A<*!%"
MU)Q>T:!16$VD*9>"X[WM,'=CTOU+-CW\S(8&WJ;\DBW1ZXR"K"PTZ PEY^*4
MB25;57BXQ\[=%%GZN0X9?^U_KI7.I^00UKW >0'TR:_7UT="BD$)"TPA:%8K
M'3(O36$1(J?X$#"5)DE\VX [=%'?_!E_3+#,!K_V"_925#3[Y,2**!3IY")9
MD%;1' 0420GZIFA2,'<;<,>?_3O7S/("WSDG#:+/Y9'_CM/77ZY:E_TR&N4_
M^X-!K[:9Y"D:9@P T\8! Z15C)#+XJ7C0;9J O(@N!/43>><M @BTCGF676?
M[C''9?P=E<K*B\+*_!PF!\NBYX61'91P16=5FIQW;0_Q6#<@FRNG$2M/X4;C
M^[K+,X^YG'19VB 8U[7?M@=)WGAMDR0,^1[>!2S;K&);W7>Z_M1'Z_?0B-'1
MH9;M^%+;',15E+0-C*ZO*][Z_.-?5=R3@64.#S!?2S91<BM59L&&5#O^.N8U
M(BO%9B615JZMTAV>!HOW7$WLF,0=K-8Q>;^1I2YF%]>9MMP&JP(SMNYP66?(
M-:4U"34WV1BK_5;%9[>B[\XG'_=>V]ZV'W5AN X=^SD0^'(+2*'Q0/&U5D)U
M*#0:%C(YCA2Q2UN\B4)LT_)Q.P9O?_(WR.#>ACM&,X0W%Y\@34?E/=;J.H.O
MM:(3YILME0_D%608YWVVF+9_]L%;37L.8VG+B:;1 KG>\[:1G.04LLU"61^2
MD8:7W-MK1+O0\1X_XW!&OYY&9Y=6V,/N:QYRL($? K9<.YW>%!&BPYR-=B ]
M!T&.8U ^RY2EZMV/\3"3_0[CVM/B,^Z_.[K%0QN8]'[@R_NC1GB7$Q9?D@Y:
M^2BLL13?&5VK8\4U)EYY_H&7$_L3.#L;X]F\]/W;<O6!-V%GS,X[R0T#@9&B
M!\,9H(PL1E5D2%X ;Q*E/P3L\ J]\^?5"G@O:RUQFA/^T9^>OYQ-IJ,+'%]O
MK-1(BO[)'^%+3P3C/$T;K.@DF0ZUI(3R-:;RQ*!79)TF%>?VP/H(-X"Z5-)J
MB=ZV;#7805V'\[JEZMWW^G\Q]SS-MISKQ*2K!:M+3BP(#TS8[#7WQ2G-6VAK
M-Y@G)JN&'+6X2+[>%)>[/)AM-"8[II%36"$E,)\,$C;4.>ABG6YSF?P>4,?:
M/VVJD<ZL_A1V2U]6)Q?'GV \_5I3&R[W)3P:F:5A9MXIH=[3!,LM,>V4BDH4
MV*ID^%:!X#H C[6'VAVSHPXMW/66&WZ:C=,Y3/ ZZV09XE5*RS8@.]]>W1;=
M\3=?#R=R="P6'DTR,EIZ)[AFEF Q;8MC4?A8KVF9()S&M%5=TV]!*O?L\#Z2
M4G8Q?L=)@.\&LXM(/\":JO A]7&8<)'+Y@&MPF!8R<K5@0L6.!::.)V,QD8A
MTU*+K;6I@/=\Q)'W#]L0,NK>FEW7+9F0;_S_X1 3+&Y$R.)U+(%A<O.[F/8J
M3=% ,BF@<5EN0>W*@T^-T,,LU_&[^G9ZCN/; [R"I*P2$'1F-:^@MK0A=U@K
M"I0=SP%LHNC&;T'FAL>?&J5=6'%C#9(.SP+F;66F2PUW=M\[7?N8@W=+'P:W
MM#^:0A B>^Y0>*U5\44H7LN#\5)KP;O>0S@/-=T\%NC*@%</:V+&=4"7C"EX
MR"GJZ)RLAXQD05DDV.*YI&4EA;7&7,5\J$D[V-G?ZK%-S+S3[KXQ/CCN!7F"
MH+-V$*32PNB,4%PV?*W![QO'H:;_,+NX@/'747GQF1Y=F2VC\01JV;0TJYG8
MAR2C'_B!3>C:=\#+1.:,RDMM2HE:2^FMS]I(D()K4;"L)7*'S^XJY?+ZDWX>
MC3_<^:2;K3",RF@>'"NJ+E,U. E0K[9BLL;(8,)6-?\/R+K< N5A==CB].:1
MMXU?/VRQXSN#P6\PK;_TM;8\"MG4ZB+>DX]MO& 1O&6@-.<),#BYC2>T\P<_
MPL6F9E*Y6[JM)0,-CFHV&^-%G,S!]F1.2B1>DT: 8)J0&;B4&7+$HBD.$[E)
M<::'H9VBBAH1T^!,9AGADO8O:%VH1T<O1Y/IO-5\#W0H1I7"I$^Q%BU4S"-8
M9K0K]*<$L+P]TD9(#P$]OJRZ)OL!+77*U/&5==.C]I?Q:#+Y8SA&&-0!_$*V
M_JE.ME@/P3%IB++&IRE:BG=-K7O+D67M:\:)#E$UZ3S5"?KGIL$&G#:H>[KO
M(&I7]IM!<-0B&B^9B%$QG9UF003%K')1!^.*%$TN77:"_B]A'LQI@TJKFVUT
M=S@]X42B&#PP;P2GF1TX\S$&AK40.'+Z)S6YM[@MP).75R?,-*BRMR%RN4)]
M53:H! I20#'E:BX)8B)7UD?&,U?&6HI5VG4(?0#;L?)MCA< =$W(8^?@W+KQ
M"</4A\%2ZXO@T2CG'#,":"RI7E50J%APT0@CC<JZ52F"=7@>+3.G:]I7;^ ?
M;/X&+O^\S$S!\>3%,'_ \>=^Z@_/YC<\E]%.:H7<R?H?+:I5;C&6EF6^NAS,
MXQ0$ZT0EHR=&\5.7K9+&(Z>1^!P"T[7@8A39,>^24MH)%4J3@/7IR_6!8F1/
M7JV[,-MQ#L1OL[K=_//LIG=(4"E*:QSY(S6&SA%8X*DFUV19DH_2N6VRE%8>
M?'S7_?$X&G5EX":W+\:?1F.*6.^Z$HL[N *C!I684Y:&*<AW *<X2REDSV40
M&IH4/+H7U3.43O=LM:BZ7%L(E#[]6K7 *_PTFO2O>PD(D\$BC3+6*_U (P^
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M%RG-+F8#F&)^<3$:3_O_"Y6@GH9L75W^O0##M N9S"&1)8HL>31&1SBVHC9
M_4MC77#8(H7_7D>S1\Z?)T?2,:5E31 +AGD?(RN0C2@)"NAC*XQ@_:6F7;GI
ML%A<O05S/<S5[=G+N30JGI6PM2241Z8#&2 FJ1G!M4;0VJSB-I=@'_J<$W2I
M.S=OAY/& ]CFHA16%JT]4X[>:FU38EYQ(&1<ZJ+1$MC#B'^D]_]Q:=_5M V*
M0RZ.9MZ6A_>Y?_KZ&_S/:#S/.+Y,'?4R& @T6960.=.UYE+,)-LB:=ZR&I(O
M36Z!'83Z6-?#CG9P<#P.'_N.V&0\[;VGX> \_4]HH5SFR P%@A0:&DY!HE=,
M!:=!!"&]W.8:-#WTEO+H3\NJN_.ICY7*?4221X<:N\,X_!K$5?+4-C!V2,[>
MGOON<]8>3K<^@(%E#@\P7T,V(5FOM?$L>5KW-'## 'ADU@:=#'E#16RS?CP-
M%C?D-'=/XBY6ZYB\?V#_[+P&NY]Q#-> HC*&UBY"H!3-+E@DB]X XSP%$Y.7
M:+?)I-B*QK4(CN<Z'L3%J$M#'O=4__:2<EESLZ"D<6=F=&W$8HQA(2?.K%$@
M:^OS#&T2BK?'^'R6ZM8$'G=C] ;H[W"!B\J^6\!M>BMK-[R/UKJN#?_;ZZPS
M\HY[F+,>-DVWWCK+1/:2:1TM3>Y)L"@=MUQ@T+Y)G:4GH;6'^\X]3:GMP%D#
MB?W:3]6 P[,79V.\3.2_6MN=US%&<OHRU(T>L(J!"Q3P\P+@/02AFF17;D3T
MI/)?#N=RU(*(CEO(_=0?_0^F13<A:72L:?+,F^QI> H)B+7,"JTQ:\FAE+N*
M6+NK>N>AITGJ8;9K\)J_G9[C>&6X5]6_.6A/.)B"H&BV4\! 1<]DP9BLTU&6
M)E4>[\%TFJKHFHP&7NY/,YJ"D);!&@A,+FU>5\0B=8A6TSH(]>:RTK5"O,R,
M)XD@#$5ZN4GVT08\SR]2ZH*8!@?WZV!=6F;QHFP#L&4<]"#"QXE\.N%S"XT<
M3D:#U>AAH-Y'E7WM,!!J(U7R(!B@*"SJ9$ 5:;5JDO'Q2&IY('9Y'+'LPD&'
M(JF^TYOY=<$7BT51J)CG^2K.863:\<S YTR^E"?_5RDOC-S"\;S[U./[&!V;
M?-2)O3J.&/[K[,N[<QA?0,+9M)]@L,#DN<88560IYXJIYO=;=,R#<":51/^Q
M6W"XZ?FGQ&8G-NSXC;P;S2B=R5_1G*4Z*!TRLAB\8R8)BDJ=!Y!Z"S(?.1)L
MQ^#^UCI&2Y1[KC5WT!AEEZ>WO$>^4Y,4*;!((Z.)F'1M>\4CE,!%MMYQ(>ZM
MN'#?J':AY>5H^+GV<J8'UX[@>YA^^0D'F_=>2$LFS$9:IY2V-@@=B_8J@X!:
MQ0*"RR[V[D%W@)GV+DZQ_CE=FVR+(A0^Z036UQ4Z:\S"*P&..PY2A!)C7C;<
M884GEA[6P0O_T!.[-NE.+[:-0M%BF1WYRCHCS;4EZ @F:YK9A8=EXW;<]Z@^
M\J8[\J_7Z7/&%N'(86?ZLG>M0A;0<E8DV,2E<PJ;E ;?@.?P!@VW'_LS.2XO
M+D:SX;3'M0Y6BWJ-TRL:IU#LLC:KM"5DY9+%)G=F-P$ZOI/1A0)6VS!T8.X&
M^1COQJ.$F"<_DQ5JM^Y:P/5MJ6A[Y+5R"DISS4%&\J1*KA=]D27E%(]2TIK1
MI';D9DBG(86.3-Y@D^?N:-_4_NPXF;Z'*<[K?N=W.$[T SC#GD3MN2>08 W)
M%GE@/@G)L C.*80EQ$UV>[:'>!IB:41)DXX_MY'>6J,OOZR[9N_KS371XZ%>
ME.2>F9I]IGVR+/)"L9;FF*60+L<F59&V1GB*TNF*D 8G$EL ?3?N)Q2]1$ZV
M<C$Q6C)I?HR)YL>4(A/*(Y@".8@FYYY;(WPVRMF#D 97BS8"_4CL3\Y'@UOS
MXU4#@SGPC^/^V1F.>X$;FA1IRG0N$GQN2/A1&%90NN $+T7SH^II.]PGKK(&
MY*UJS[37WL<QU&M^K^#KI$?>?-%2<"9$3>).)K(H;&8@0?F2K<1R!'_I 93/
M15?[$K.J(MM>1?2]":99W>"XA5OT9) %E3/,U0E7.R?(W3.>%:,X.JX\Q$=2
MU ;$ST5=71"VJC37K=+>8\:+>;/ ^9QZ*XP 15-G?2&LR(6F525J APR'X!K
M7824Z@C[7!OQG:**NB%C53.^G6<.X_'7FODZW\1Z6SZ>X^M_S?K3K[6(^&A(
MO]R+HN0(PK)L8ZZ="A2#6ML^I5 ,N Q9E>/ZZ@]B/D5MM2-M56_A<+T5'%^F
MZ-5=L9>CR64% ^!<%UMWPTPAFU@I&4 T+$6N@BJ)_+U&<]):/*>BD\.-O683
M\N MZ;MC_6,(EU6/,+_J3])\S]QE'XPJ@F;%NM,E:O=B92D(+8"%<V6]/$+8
MM@;9J0BC2P+62*3A1O7K4C!5U^O6(AI :PLZLXB")C6!NC8K3"PJB*H4!5X=
M02X/H#Q%Z71)S!H9=;)E?;.E=;52UJSPQ0 N5TK1 P@^!.N9J'4AM544)'(3
M6. V)"6CBZE)$9IM 9Z.>#JG8XUN.MFPOA?HAW,@W=?#/<QU>SUK6TPF<1=+
M<($4+C)Y\H%[S(9<?/TXZKD#\YEH:']JUBBIXPWLZWY,/9.SR D5B]K5"X0!
M&$3RR'/PW!6I')8C!.'7>$Y'&X<:>XT(#MY)_H4,,OEU-)G@Y.WP]9<IA6BS
M_N2\@KS*"P@2U3PKQ(- DBD64FB(C,ND/=<*#&^2BO$@LM,01K<$K)'(P=O$
M"T_J]9=/.)Q@3SB,3@)GGF?RG$ 'Y@6WS,F2"5-THLV2LH3C-.@_Q+AKR#YX
MIW8)SUR $.ES-5AFM%3U,K)AX+EA' -F97A2OLEN_QHL)TGZSD9>0_S!VZVO
MR0PY4YQ]W8'Q>I%Z6U9_>-V>L>>MM J=8SF)"AP=Q5#UYGH$X%)!YK9)I:1]
M 9^&A(Y"UQJ=';S-NHJMKH!U :3E;^5G\SW! ,*6E%@P6,UD=8VX'+,"I+$:
M;2Y-*HOLC/14E=4E06N2_PZZ0+CQP&$^QPYA4/=_WI;W.)V-A[W$:?#&6"9%
MK3Y>3&$0LJ.O,#MK=$S+W2S67D3;Z4._;56TM?$:-1QT[7 CTO=X67_AI]$P
MUW-R'+_X]&D\^@R#6UN".<KLBP@L9U5]+Y0L4AS.+,@DBO;T[VW*@!\$XH35
MTCD':]33<2;Q92$.[96C^8U\L=H)03M.,;J/CG$?M/7R_V_OW9K;RG&VT?O]
M7_@6SX>;797N=$]E5[J32C(]]>T;%4B"B>IUI(QD9R;[UV]0MA-'EJRU)%*2
M[>[J<GQ<? A@D0 )/! >39<-: .68Y%[]S\"&2_:4[-SW\[C]7SVD=:]SZOB
M.OJ;%;<"S3VF0$Z[J.RWM,@I%JWU]6S/.2W);/MT^]L$YE1T-P<K>)WC[%!!
M]R# 6\-T4_D]!%5/VIK-L$[#57.XVG;8P0$R/Z)%& 11UT?CJN';K%D0@L+[
MB* #UP7"41:$$_+0',T01HBZ@P&LE03?LC@4BJ9%3,PFH.TR.631T8Q#0O)P
MA'*QSZ'91C3']RI;J&K>6LX=:EA_WO-6%IYD#M$JT@Q%0(2(:P;(/9.8.?<\
M!_JGO[OXE!R! X7<O>#P#M'C$%P]'8%MP$[C"ARJN ?MX$"I=Z]AOH//(>?6
M.<?0U?9'M,JQ$$P]=#6&&Z"8%H^0CWQB2NUC&<,883>FO7IA_\?P._O4>YQ-
MYXL_YY>X?'F%I"1]VPE#H]-" ),*:>+%D0-4\XF,SZ$6O4:=AQQ$#AWOU*=*
M^VIGWEFTC=GL7EQ]O%I>2B["':#UN.L[-[<)7F@>F4BT$Y*]%P:<H*(5.0;A
M4S1NB-IWC/,4U-U2E(W?\I>85A@>0!>CTTGKR&)VG&D?:FUR6/'O69"1"[E>
M(+?E*'G72$] U8W%V<G;^Y'8]\NW?\ZF_[ZB(&29%M,OW^E5HTNQ%)IZ0 IJ
M-<^%18..@;'&!Q H4I=$J4'HGE(HT%85G4@E?H"\\XH,P=4[.M@$['3106-=
M/F@M!RJB4\"P$9^TL:BH.<NZ]DJV'FJ]+K!B>=)6:,FQ&]G(\0QD0,!P(OL8
M(__F9-8D6;A8HSNY[<=G@)P>-.3<AMJ9'3.+0B(S/#HG I:4A] B/S3&:3R*
MP[4P[R#"UO%!N<3%_W-U\4U6C6R&I\&0PQ0-R\607RM#=:!H]I"MU$HE<F_%
MD!!A]U!/0-&M!=JC%^QJD4(HD$71S&1'02D9'(M 2)S+$$(.P:8A29*/HY=S
M*Y]O?Q$VI'M:[X@Z!,83[= \2@-;FOON([X>;^5M_R2E2PR%5AJ'A<S21 8R
MT6=)RP3.@<I##F;/0XN#.C2W4.(8J356WA_PW^GGJ\^WUL1C-#EZAE'7]L2N
MEH$[SUPENQ%)5AZN5NK[:>33=60>)?MY"\%UN#5=\8>NT@-KNZL;@K65>8*B
MO2#3UF]+(4] R$#F&2,C#RTX:43,' =H='3@LQ718]]$VXJ\ Y?=73PW[N 0
M1#V/2>Y#.LT!22.=K>=1M!%XCTR:^\AL\D'6;BK"6#+YJ SSJC@6G'%<R*QR
MZL+7>RP3V'$$<C0+&"/G+CE4GS_/9RM -SM4*@A6<L=JFR(*"85@ 32PD*SW
M6<;D>:?\J34DQP^3#U7/O;RI0V2[=?=OV&%H+;/K%[BHI%#SLGX;!+-\?>';
MJOG(X)%:-R79;XIKS4J<#AC1@\D"M3 <9#:^9"-E]BX5OYXQ-WC0/DU,'&@;
M3-84:AC/M"(_")(S+'"?$Q<N@.]&17+,)B:.AT130::* *:-1Q:,C,Q(+4I5
MDNO3NV(;H%-?$>]G 8.;F(P1=^/SW*VE3C\..B\QW^!<W45D@IA,J:FO-? V
MW)(OKXT1+DJ_SA\_KKILPYB/6_-=)=P]^V\3==VJ9U>VA8&MA;*^<GH8M#4!
M7EN;E.;R"+3)9\T=V&Z).%0!7?)(-K->>M0%G0D,G*V^? S,NU)8S.3B:R.4
MQB''6'O8Q9E3C!YF#8<+NV%NR/W5[$5*"ZQR?5/>+O#S].KS)"?M$TC)K(F<
ML"7%/"C.3*K9;A8-ZCAZC[@_SN-6<'-)-KPMVHSMJI+ 75.^3)S4W(%)]=26
M9HR29@Q>L@Q@O!(!K=I/Q7<&>8KZW5>&'4XL:VW3AYO:IDE4%&JEK)C@E4]%
MFLJLGP43F,CR2A)AT,WN7G5^MR >M[X/%FOWUAC7I^^N1%] ><;1TMPX>A:<
M\TREG&Q6W!C^7&@ VGEIXT5[+C0 &\I9G!?2H[>L&,ADM+4646G!+& T&E.4
M^0C,F>=V:S5*N;LK_\8(^:@U7@-P/>O*OU&*&USLM8?4CVD5*63OE"7?1+M
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M:E@UT^6!B:R3-4E%S;NL50^!>BI&T$SP'?+FUV<\(1_)V$BFR56I>+)B7MO
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M,F;LTTYV"Z#'[S\T%7F/Z&(#KMMM:P"RGME4VZ&=)JNJC0H'V,4!\N^08O,
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M"EFQH"1F26\%YT<Y73[M.<%QC6*,S/L;P\TV9IW4#I1C>%U57'C-%-8,2P@
M%CF*+KV1-J(Y^>W3OMIZV ;V$/78U)*;;]</$9;X?_]?_S]02P,$%     @
M;GYI4<$@5?$>*08 AP4' !,   !I;F\M,C R,# Y,S!?9S$N:G!G[+L%5-S-
MENC;C;L$=PV$8,$=$MS=-="X-*&1QDF"N[LEN!/<(;A#<'=W)SB/[WQSYYRY
M=][<F7//O6_>NK-9J]>/VE7UW[7WKO[OJ@7/L\^K "Q921E) ! (  !??@#/
MZVC:,F)B1LJJ2I(R\A)_4:!)RUN![6&P   [L!-$54J44EM'EQ)Q!  #0 8@
M -@  &.0XR<%-4EUP(O(2(A1.KYT OP+N9[^8W8 8()96IF2$O ?$VS0)XC3
MBX'*+\QA:N8(>F&_%[:%.GWZH_WTA7%-;/Y@&+@_&/)BX L3_L$6?S+37_K\
MR>__8%,[L.D+_V'S)U,[TS^XZX6#7)S-7AA6_H4#7*S,H"\\^<*TMLYV5B]\
M\\=8.S-C1P  #NV/=B<SD.4+OWMA-(BZJM@+"P( 2&@6?\,F?\-.9JY.?RQ*
MS/Z3&\3*PM*)\@V(@9*-CX^74MH,:FOFY,2L; RR,8:84HK9VWTR!KL! '^N
M^2_RZ@_?4KXXF9N-CYN;F9V%[6\<]6\J_YWR1VS_I N5O\0,B#_TU[9_K9]]
M%@# >_7BFZB_MIDD P!U_@  X?Q?VVB_ 0"8+W&K'?V;]>#_D2^63DZ?^%E9
MH5 HBY49B.4/A_ZS_$\[_#OD;Y['\L=T_^P>2G$S<V-G6R?*/_P&LK>U=X90
M.GXR!IE1,O_W2?QW#_S7[6!2-3,W@YB!7T9HOF29%=CB)=Q@4RLG*WLPI17X
M_RV(?^>P_T[^S.L7P<EY N :L0"P1G$!L$=# #@<5 "L?L:+!OC/<9-'U@3\
ML?.T*';^S/N_"/!_G!4F\H\/1RN+OXP34U6G!#E#7/[4_;$M ?  %  F !=
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M4(0H%;9 90FFC9%T)D],3 ^-^3L5XX*F.".N^:R"A<&!(:6+14WD7'=<_KG
M+/VJ3:5O87(4<"VO$*)[R*FM^$GYJLZS48F7":<>S15"QWH*6C8(JF1=>+4:
M;5(=B0KV+TUZ/2QF&OV\]MJNO0A&]%B3;8Z,2G_,>_O-R5]KD?CW:($M^LS
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M-S'UMER20H8')RR)>JJ)L?AT_7A(#70Q6_(M,]89E[Q!#1TN\A(\5E/G8HY
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M>468L?M[HB=040A_FUJS+5 AVET02];+!=*2@Z.EGB1AJA^A9?_@\7E,K?+
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MEE76:*1BM15&*H6?8?;AQN?Y NF"PGIG]>!=) =[$V^VKW.371M7OL-%5IH
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MD+_#,AX,E<L$#V:FUW^I<EZZDKZ$2H@* M;6V6\?1VNK6Z"MI6K-PY*&-.(
MJS?!X\2W9N<6Z\4G"A_.R="X$G+'YXV [PG>6_U#W7&A-WFY976-GQ*A@32M
MC@34KEO#Y?D?<!]_7MIS"N\Z;5>#_#2B7YV' (,T.[4#HV-N1Q+P3K9^XN%)
MTS",,(RFM#H !,))>:,)BSWV^=YN;S\C-_'4I(T3$_G,\9B&VD_"KT.=#,"
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M$UK;?N/7@"SN%K6%40?>_HR=X/;$-IV=%]]G!1K5GX_9W\2:[--L_*G.[J&
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M,F;MS#4I@-).$%[XN]P@-+0+H=2R$C&X&(&"+>Y($_2WY26Z9T&C3'RM 5X
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MV89(F*HSBW8"SH7KA9EZ29!%'XX^/\+)+V'&*$2XO'X2!I>XTSHS.VH[N2S
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M$\"4&\\<2[X8:?*XA8 P?XS_%)4SXER-CIOP_>*R?\<T^+^)/9H.L,7U _?
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MT:P=:>RS+)Y2!_:$E?!-M)TW,& JUR\G!AMDPMZ@A7L;YT-#+SWH.6FP\E3
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MQ8T:VXVLN>6Z;:)U^I4#+"*<?3K";60SZ70V8/_P<?Z11VR"[\9#H0>[@_&
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MG3H1F1)+!+#:+/=-ML3\K)/V*Y;=S.BP>>?&R[,1'"5<Z^C+0S:%&]0I6BY
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MJ= F D?_/Z@@3]<BJF(B<_2%]<,*]TG!]%B-XWDC?#S[V;DH)7N5"TAGU.Q
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MXU:0QEC4YGJ SCAVRJG_0(#-MX;F$Y%XO27P)U"$O'4I@LKONW<J/C9+,81
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M/N#W5MH(8#Q#]6Y:@8*>'@+XPY^EX&#E>A.8G/5R74/^?V7WB^N774ZOFSM
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M9LX YW/::+A3=PX9Y^#:_KG0P?(C!QF2QZOUJ+(%5=J[M^TFD'C?Z+ATN*5
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M7B;-W'=Q0?'^7\7W"X:PF/QY%R<_Q;W7\;UB6WTY(S<6='P*H6(4$8>!V"'
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MFV^.OP22:SD!KL/OK2F\,N+$8^RY(RJ-57 ^#0V(E7(;WM0WCVP;<6WI:)0
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MSE=F<21<+5Z'CGN?]5,C*B-9DKLVF/)#D+Z> V.'R6??\FH65X<!3M1>4H5
M?AO><Q5=FN"<2!K*R@;)^AT21QX/;SJ'/07&N-D KO09+): $DHDVMDP7;R*
MJ\M"X7Z_![F["(&6< ?&';$)(2CGNUQ*KYKIN?A[+&1685;^^[GL[JG5!BN]
M/SAR_'CI8,;O+HG:I[[%<&*Z /S,DNRER5R8!7-)@A(.M0>Y")L/"7&/##M)
M$(*=8WWIQN"WKY*UV_U<BW2&CU,O%'!E4M8R.R>D,N1@+0]0 ^D5Y<YOS"NY
M*#&U5Z0/=D04JX8]=8[FH6C''1J&'1\@NW@]FN]4!+039G'J_2S*ZHILV(IX
MYG*F&V4%.0ROD@;F"R)^C!^2+9J'Q\RQ8#?)#"] "#T[G*51?4_#WH]<@@8,
M,_7TA?17'JVM=SV@Z=@]H'UZO'QF=.M>/@0'BM%(]DQ!?J+V_MSB*L]=-L<W
MW2F>L%FC9H1(>\R-1<W[<E!:UU.\ZM^OKB9.F*N](K2:T'SM/%:3"T\\5ML8
M.XNP/V9(T/\R8J^D3K'*UHM]>L) -D)]#Z=?\&(^UZVMW3BZ._')V-S>U"?V
MS=FZG0H<>3^Q?PXK#H%2.&T8''B52^H?P-,7EAL;*HXX^FX:/PT.T6C[M#ZO
M=^6="7XZ&] "&@6Z@K>,#XSP/$P25>SKTW <S6'X3ZPNTSH-7HV_<:P5DU(=
M[N[H*M8T=$E$U)+U52ML+4Y4.UHWE00X50_(-$B/R F1M),X??$HT # FC_5
M^B(WVNXC#@%9[:W[J8]/RRHV---"ONSH]@#$,T*M%B&0ER,28#;;\NFO'%1
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M<SBR)RWD&E*;4<'17D0Y:D%-DSH?9F'"&!MITT94SN:LD+ACFR5=;:@5O<U
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M<-X]C.JMKLC,7M/M-&!EVTEGH(CT4-3JOQT@$JG$5*$>5S"E$/)X"W')\].
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M_OM_GL]?M)O7<KZO'=@;D7&-IBHS99^-)K@VC?YL4IPR0'"""ENO(I#'O8V
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MW5A5<F!:Z<%R&NVJ1J$2S5PSK;_574;VUEG3T 2I+3:\C.).&%)8 JBRL+X
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MOD9%]?)I[5KE*2P?>GJG7+9<5::=FL\V1SQ#J++PCL;*ECXAYV$03.#_OW(
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M[-0H6M/U6R#=*;A>)1[*^U3FDQ-%YB[;ZM'B<G5P?0.F<YGRM([\6BA7\J-
MYA'K]S%US$NJLSHOJ'UI')3'DVA2S?>L,/]A'K/5';[?7SY3;@)=S$C :3@D
MM+&^NF&VNML9EBA2.^.@T^1.FE;J[9QPABBX+)#%X;HA1-D/\(X9" QV,SQR
M!/O-Y[N\N%@^"7.!0A\@"/DBGDM3<G=OX9$23UQOH1@=GD>690/*8VH6=FT.
M[@A"S&P-P>4"U*-LF_]7RA[]J_B5H\, [MPU;X#3K+M-<63KBQ\VVFHV./)Y
M2&ZIU') #_V -^2!Z;;XE@),1,@G07^VVT2P<S *UMEI/4Q!]J]:N%^5SV5^
M1HM:X,]O82*)$XF?' M%_92?.*(:#XI:C'S#/Y.W99#;J$=-5W*680"@IN 2
M3VJ.:.X6C$K03,NW7;,^LZF0^6$.\+L3DLRA37%Z_D\FALYOHLN/?GT18P?W
M.RV'.U1?+%V5I =),=\>2C]KS#R1Y")I=(-!;&I)S!^9A4\=E[V%61TA#RY/
M;46"SKQTL]"?)Z[;O;?MO-LS+BK(.@I+K0QH'<8*D=.K->0GJRVM+?^+J6'_
MCP@R^WE9I-'F,JUOYJ5;]2\1!<RG_[8VY:H]JB?)&@(7+F#'ON5)GO^IS-'C
MH_]:H_3Y[9&KV.K^Z1,F46D;2E;N.?^"+_^39O(?$>1DIN1YW_QVNK<ZORV.
M1]:?)/[70/5?'U;;_;$HNCJ]VAWJ(8WEUR:8XV@;6HP]QEOW+3S]XJG-ZIE(
M\+-\R* ,,!Y=L%2WR:<A4*^S&>"W,-*V_P=#J[T,12,Q.CHZO'_0_7=\[Q:%
M^LNI;<W6A+7E([JO<]8W%KEHE;](;CI^W  >X\7,6_ YR4)<G9Y9=&VP"+RN
M6J=3.(]^IY>7D_;]9=&_O]7Q_E]&_A"Z,IT/_HKH>:"I5+7C;Y<L!ZNP1,I:
M'2I),T."O7P>,.&<6:WI2GY .8\"(>&JGUA?BF?8/?7*\V[(L^K+2/>,\R$^
M,%O=B&FP9P%KA1;<L$^7\STK^)5;]QN\C^;[JQ*C'U$8$=R^M;[^VDO4O%<5
M4]\(.B:U.+"@9.0K>"/&(N3U^.3=83<. P1"PL<?\7'[AH&RZM,L0A+_NWL"
MH>B_H,$ZW$=E5T&C_CD3N:'L93;_J*@:'ZUZWN'8/W?7L<9LI;;QKV#Q8XGX
M?QE7:_]H;&F&_&W,XDS\306AW5V/@\K(KW=0UR;!=9H8/*L&"D7,L[%L10EB
MUFM6Y0K&W4ATW>_>1EQW?F@I3H:2!XJ"S9S1^47^+T.YFQBQ#UX]TFLYST1=
MY!<JY_MYP:F HEA,P< =G_Z)0NK=R3V87^LMJ"KXJKJB@7M"BU[XA$_G1BQW
MO?< 8GC7D9M,76A_)]9#.S2FLODV1.9"Z TB2B#B@H/_8#KKZ^>!;O.*'^84
MS]M*BLK!>/&XK0)F&3@4+<P1<HO!&\N6MY<PXL?'FK,W!F05I2_D%!-Z%6Y\
M!3$6^8:/101.=-8)K:_[0R-LE5HB%B70'*_K4Z%8M^8N<VA5216M*?+A(@[:
M9#MRSM#8G#Y9:!)T*4>'.*!=#-)F4)%?0\.KE,7PQN/)N@K]U:.D(7F9\ZN*
M)>$9;C;--"Z+4RU(_SH'\35<M]B&+H>%^5=H3Y1/Z&<:Z85,:U&&4*^86,#R
M-SO>XFPA'3O86L-EPE:1:WMA2\Q./45=S@0'#:2Y)X- Z: L\^1D?WU=A6:C
M)F(91DF_5].VT;!T;GZY/>YV'WIDA>+RW+T(U?I1Z#9Y_G'5,S7T8U(1-_-G
MRDLK/]'T,'1^!"LO-N?F/D^?T_Z0;-E"A%>7#6.,30$IZT98G]PZV>^7Y.!P
MW+L8P/Z>D=+5:[*G=[RTMKDH,?'6A\O TJT'JT5?V7E*3X&ICW5B#:,K''VK
M:S$4^8-F8=(/'[^C;)Q7;ZBS,E$ES**6:FFT3\:QB7S?:G%M%6PI-*+5,IKW
M]K:KB]A=%2]+Z^\LY0S!!V2:&=7J?>NIUL+^@\X/$?U(Y@=@+<>ZR0&)\26X
M8Q8<>VQW" V+Y2#V5DX?KY55.5+%/QO[Q#L3DC3A#4X+,4\C3J7O[!Q/FG#
M]AH=<U+4B52UI_+W*SB@],/,#OQX]OYM%J@\6O&(W"#),A WRV^6+@ZUA%-(
MD,B*'2X"G'U;96MEJK\3^W B<2--&5!7K,-7*:XJP-\1+[3MYUJX^UQ<!EFF
MD7I5V@$8>7C.MY!>;2S+=,;WB2Q&)_EKIJF4%':H+G+^1<W,PF&T,[;^CJ&3
M^@!FOPF \";'+<W[F-^=7X0J2 W>H?/Q+-E-#&^%GA Z6&?<RGE[4A$]]]M
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M$851NG%GWB_=O/@^S ](FQS@2%+DT@R.BMD_<?AR.## ,K2\S-7\D=(7"1I
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M!!_R!!="C[5%'F1]4M?Z;T)L40-'*L/%U:+*J5UC&2T#:S4C(M"<Z0ZJ(!5
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M=%H'*6RS5D5/\8=%3[/Y%4UZNLG-1\__0HBG&P0$;!0S;W]\YX/1*^DA<%U
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M*EK!5O*D@'1JI@0BI6?^EC%I;XY V1 ^".3(5$#B=N'R\-J6*) O+?N:3(Q
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M[\BVH3KN\7^-FZ&"X5O3MLLY.]\>WS#Y\K.>31$;KV@L=R"G;;*'G=D\FDF
M ;W0V_'F@%2T[GB/U.%(;N0G[\[$/^*3K7V>[*(""]NRK-00CQ!?8_H!WDS
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M;*A'T6*W/=N/ )6.B7O!MUM]H 01'(/=A+$8#5ZQSZ XHH)K4*K 0Q>>;0Y
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M)46D>Y.X2H,[AYZ.EZ]9<K7JWJ1UR%YBR&[AI3"8G%*THW(+9&DNRIW L?R
MP::X/\P]Q6NJ<YLWILX].I,;G=MJ^\>^/-DX3SV^<+L80?&S:XU254D,]L8#
M%9K9=8">9L/VM1Z ^$XYS)Y\GB]1IM/X;T%L"7$1#(Y-O:)GWVHH%:=L* S:
ME)8^/6 T/F#0@_L1-]GH#<12-Q<"OE<HA,6-=S82^8"A"=V^\H!*6(4?>5?:
MKZWKE>JXIJO:>//-%:=INGJHG@!!$.$!3MAR70ORE'-@<WZGKKII=][YSY,
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M+W=^/IO9R@MV"%2:5K!IR;[%W25\*P6O=/_Y!+D9U<L;M_(U2U_B;,IB'G3
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M0&3!Z*J<B9JX(76.F] ?' HB;8.\&@:.KN,O B*!6G7*@_2#E**_([YX?&N
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M:M67Y0Q'=I:N9M?=H _+FZYFU4'B#&*;I@-&#^X'5H]_]AKV4T7<89@,+^]
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MY8CU0V)V0T[W#J/QBBYQ\I=8Z)S#F(MU?I;0D*AXFZZ^A\+H-[PMTKDAD<R
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MBFD"0XKTIZ@G*<;8^-5XH<8*##O4E3JXTIC=RFEP)4?(1".N08AX"_A;S]2
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M__-N^E/DDD[!GW)=WI.R_G6D?ZYEEE<B7_6Q:I*DP7_QU/V7=UD,B?=_S]E
M1/6G7!:VC/,_Q37];2;_,7*IA/T?,UUH&3/_9?7\+9YWE;O3L!LV(#NW&#*L
MPERB4%*=^'GIE/I5N6']PI$LYV9JKPS%U6]=Z:G2KRMMMAG"T@]_Y.2A1H;V
M]@_ _HF-* -&(DTHPKN%1F$9TJS/&>LS9&E?EU9$HL_]J^Y O8/[^J6Q4("Q
MJ+B*%8TN-6[Q>@']$69%/WWIPV=_#]UY5@Y9.D4P:@=%C=G9%8(_&7/@IM:9
M=D^O/2N<)+&B)V1[7HMORB004_A)E=SE28>D\*Y\N]=,P1?=HB\*=%E/&-*>
MY/"&Z0)#%N0+P]Z A9!A;PFCWH"Y><Q^[[&/F/T):DQP!P0N\>Y/"J4= YZ^
M1G*O<@>;X3EQ&YY8[FZRTBX8CR&6*4XWQO#*B*DMK34[=Q='\7\RHFA;?#Q]
M.7S1%[^$O^U#._?VM7W2-?-:)7P Y]6:M<P MN@\3L2IC21<:J@V.%V0$SY7
MQK5\LZ#<?9(U]3Y[1+=/=X?[_KGTI'[?]F4-0$*Q:1A3Y20F&8NF;#QUL= :
M?BZ!UVBT2]Y&_6QT,#,+J)2L8FB;G.INTHPD0G:T95FL+%=7@;3KZJYQ(A(A
MHJ:P=WX057A54:FZSX1)&=ESEE+^,U4M6YS>PF$5;9?YO<RA!DDS/Z]R>$8A
M-R;JPQ=BYB\M;[HH^=?"2+L9(AXU@;$0$K"=RNP.G^SZV\3%"XEXM*_6A.U.
M)"B CNCQ6TGN".WQ"+,F<](JF1=QBC7RF[,$NLB7@\J#ZBX)^9=-[XPL%D\=
M&A:%3TL>VN$3?@\)%29LQV$?AD'_*(<KR'F'P<!9,W;)(M:8ED>6_S&1H=\"
M=194+Z1WS<TI5E*IG_S%=NJ5=)_9T,:2#,:+ $8CVL;*ZNE:I+U48$] $KD!
MOO:'RD>,L_LPVAY<VY^4"1'J,7VD#PB'V:)5V;NFG1UW57X\M[]-HD1X-6:M
MV-K&9-G#NN)_DC,JBY*#,SY/+8N H^SKQE-QRS]Q/Z&R=5.0-68&(<FI:3+0
M]C!(&NE'P;,]!2>+B9V2@M<;,TO#O?5,+TM>DG1RX; /-IG$DSR:Z&N^E86<
M&2CS;RY"IGON,%A>;$S&@:)U'?! 6>-F6^,<QNAATZ3'##[!VDYT05T#3CE9
MVF4Z3S@%?LT\,;IFSKH.I'U\T=65X$0/M9Q;LSVQ#K>I:)](*7DH[0MD%U.H
MHL ;2YC=EQ.;7W>Z99QAC+^=&! G290]=128/FY*TLY+M6=<1&6>R09"E^&Y
MO)%J)JP=7C[8T5^[4DA'TR)$O39OU;2P[.8=9F8RHXMZ52^R,T"/'X=@/\;F
M#OG]#8'<IV<?ZAP:[N+S_/WAVD_UE"E+_1;2!C3@4P]@ IZ63I4%C\]!1+5R
M\%C\;?5"&&B8W8^9SR6F3'B46^,<V@;<G%#B%(M-)[,_ID4,R#+ZC+J!H).:
MN8Q$&YMUGB;R[_ \<'G7.(>WEOW#&%6<+P<LE-_>*!]:?C6H0"1^OQ0M"&9H
M3(F(G/,DZ=O^5E]2(9IW^&GYR:.%>N =1JW7L)H39ZZC0<H2W$2>1;5CM2L'
M?,67'INYP-8<=N-#).@HEBJFG^%I%SQQZ_2DWJ\09?-Y.0GQT03W]'KVB=EV
MJHU !D<-C4S5:@&%"]5[;W<57G\&_:D+V+MNU6VRN2.[%@9^^]F!SDI/KF%\
M7 1\ZVK]->WZ.879MCYL*X3>VW/XX01\P!:7EX-.+#S-2R&KIWP#DS4T/RO@
M.,N<B%)= 2?U7>!X=)DTQZI0G=]B-A4.[M3F*#0G.)G%/S9]V #F E@#O+6-
M)A#1$WT67<$2TU/H7+%[G_UPXM!;T(K'O&=M:Y#E"R]XA_1M:R))K34A-*8U
MJ8F2)79P,>M6]N=LA;%B,L>@QGPUFTX8*4*AD"].)8;8E=XOF]^S!= ]N]6%
MXI]?,['T*0W?;8#Q&@*$+ 75*P?Z"F=E!U1,UH21+4LLW<:<UG4#+986RT:K
M:+:@VXQ,*Z;KV8=M%&!Z &Y]ZM62J-!\M\D2F*PL^@[C%,1UAT&2>.Z&.6[+
MCG,O,8;!HRS#)3',)2-0J;MG-4Y6R RT+9YL<R\_PB0JUXF)L_XDDE7HB#&R
M$4TQ>H-SAX'F(EE\]DM9_X--;M9+VB3>M?S5!&/A1_/S\W,!F;^OMK*76(F7
M>W(N1Z7S!C0LN ;J<9MA$8L)@CL)BVKJB[6+#E>%S918EN[D2B,,)!D5/#/]
M'8RJC/7#:TF%ZA%?_$0Q'_;@1_P@+I,?Z<4Y@@)(VTE^'%SL&U'O[\-QAN/P
MIW1+*+!+:8'W[C 2V:3((B_6GI&56=I1ZIB!\".8 ?QOFTO3!1K%8?H9/,WQ
M/$4^LJ^2UFLTX;"DTS!"TFC%J^R^DNFI0UCL6QI*EYT!JDFJW&C)@P(<RZ8
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MBVP5J!L@NWK39F]C^$ E=BGCGKS[QQEIYGIU,I$'/,&U9)K#*\A=YR=T ^;
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MG0GJ$\-% D,'<P\82[3642ABMYWUK8WV*^, @L^YYU8"I8/^9 9J$XGLKRM
M*12.CE'.)B25(5>HSP9VJ)R17Q07U<<H-=N RJ$]/<D&)ST0UCD)+K^(N0QH
M^M,OX_<^EF?Q7!E?"?JL0K"'ZD<M)17LNUAT@3\GB57$4P?7(%]L^G9<6K"]
M*ZO%QD4\F2QM53V<9M--8E\3;W)NMR=96Q"ZTGLAZ(8*^0N7YKG)14M_WI^6
MV+9Y/YC8=V3/21D*AI$K&2?%XO(+@%QQNXD6&4 0<0B64?^XQ<:.5'GOMRO?
MS4'UQ OE#!@-T] (_:IB7>).MD+'^$ PD*6NE4E6>)G>P@/QGO%VPLBB+A<N
MFH0R_ROU7XO*8^U$8BQZ'L&/*5:/</04A=(#I&1Q)/!)OQI,MBA\)R]S&-SI
MDA8 $SA-VU%VO8K1UY2'<PF+4=* \ 6@_Z*Y?MH-^<M:Q6GN<P]8_,"AQBK\
M%LOOA6K*AYQ A\R'H)"Y76+>,UYYE3Y%I0*0BGBF7X&KM3 51NN)?A6CFOX(
MEVZ-B'3_NW%E=%J-/J<M"5I+^F<KTNSP880Z$\)G4<AI!#G5E"%\3G9;):A_
M%#XZR.0Q2#?*Y'@Z73G(D$360O9F@]M=&,"I]&5C<WY;27_["EHXAL[/\7)U
MFXN;O3_I(JEX4"K#WX+=V+9CE&=.4KYX1D#6H3Z_$,;;+"T3)?[I/T:?RIL"
MTZR+N_9'9'<LUEP**KI8^5Q^47:3RX!*>HFWQ+F(W03T.][$T<S.V]&:4?M$
M?NR"B3NIPG\"4Y?LC3Y($!LWJ!^9;B?,BQJ(QNW F;63L_2IA-%F;/CI"2O,
M7<0L '@_'C(A$JP_=:/D6258XW6#/S%N!WLK%Z026]";8YG'*PJB942\DE?(
M6 K!7/O[%;LPM.E>46P>V)$SK)>>WVEM':=B+^[4]:'/JB3L0SM_KE)_5-N,
M&YX' *H3W(WNT5SYUI@\GI3V6<9"=ML":F%I-+M#SKGR8"C6^$!ULJ9%6"$T
M$WG(_F-*9"_ZFN-PD$\ HW8NLF7[\4WO>\%M]F<!KE5].%/X3"3_Z53)U-F'
MTBYHQZA!$-%K@/O<BV.J^&+I.T1QP;\0\&@7-YJ=2RZ)W4(!&V]7M]X:>/:U
M(M>7PXX/4;4TLE!BMOMK[UL 2_#OI/*V!(M*53W24X _,NI150GWX"G\?+I&
MVA?.:+8AK'-.]#=6T2O6KM%+8G"8\Z+5PS^VK@2]^1IBL2_J%S]W^X+H5(B^
MHC/F@$+6227I^0M:3$]7^CX+4:"F,S4I(:,\[CG$ZH6KM!N1'-&[1'DI,M?O
M;F[REEUH.&<)23]!_H7(H>OEKW[\L;.'UIE3 %F:]$3T$7LF@< R=Q^;RPKU
M-!$W'AI&+I=[ZL<:609ZGY>2'P""_^FL\G]'A4%YX)43WPU\W"!XA)QS-4UM
M^\,?M'I^GD;\65S$Z&Z@<#3"#0$ P#3Q>5>T9/VNOH"GEA%B6M\+ 4( "G;D
MBH9*],#66OSMK4)>3KUS_^^/(BW7WUZ6_LNZ%A*V-JGS 8*N-MRHW]0&<<7P
M ;W%0WEF[4,^*,,1(+W:9UGB2418+D>L0V)I09X:,T[?$8<=PX*<#>06)874
M0>Y86P==JBC_;&Z8. /9^=;7>>KAH?\6DO'_VRP_#EHILVM8^=;%Y;/Y)065
MA\DVS.?,Z?$L2Z\%6#*UT[5U-#:I_ K>/UJ:PN.W[R'7)7R<5#,S+: "*#Y9
MWX%WC;UO&T0[/;). S"P/CH"@QA>O,C^^T; ^;J?^:BH%9^Z0MHRV*1"^K]S
M7@IG([+UNT9$FC1;%$>ZA]V.N]8.V.^?V(F'73<YV+K.3%76"LI1EI,$2D[C
M 9IP!VZ\ZPYL@&0^-F=>'TTDB<(XB3I;/S[[B-$^0CW2-7HW@N"8^0_,[/\V
M$O+?/,9J"53;0>AS\66>I>8]ZS)FZE4Z7$39;>,LD#0NG K@71+=,?+&T@'+
M]<,KS8CVJ(8! .\;DKUK!J=S7RGAI"G]V)#FD5GJB>EV5>MS+,Q@+&HQ(NLJ
M<VZL_?G7%CEM"4.XD\K-0BV8OB9>;<)5WP+4B^VE24-+]ET-?NCS3S>GRQ<E
M85DNA;&X7 [SD=@1M;*^G:2.Q0YG?;?3H*]+EXI5(& 3K$>52?SQK_"=SQVK
M:Q6=$25('2]/^]3Z Y<KO8V-Y3]B^%\6F!AX6+WBY>GPN<$P*W%^7#]LQ*QT
M#]<P-#;[EUGXI\T-"A^(5ACC<5?W*,);@)^/9=JE-0==5(E%-D>-U!Y['A6J
MRSX!U?Z4V=":FD]<L5## UQG!4B;T;IA-\?C"XN_;N@JVSP*/WX;P.1;/7N@
M=+1HPV1)/>DC+$M#D3NXF+!PJFT3'UZ FY#5NY\!4Q4[C6_!,3#)^-I@_]\C
MV_^4^/[F<GC]7LQR[UNRF[V1>C'GAXTC^ 8_+5PW;G ARZHDI):XU@W^7*5?
M1%@#]OSQ.&GY,3=I$':MW7$15P<7=FK2?30H#NB]O*8HWC_(*^+%4:>G$,I.
M=ZL#)(FC3U,CCRQZ5>P63\P$Q=2=;1[/3[I65X..6=:1MU'EZP,J7C  \UX@
METM>H,$GF.C0\496=@:<'&%7WERSZ\R+<GPL^+W+;<S3_096BPFYS%&;@$T'
MY@B1[KN@_);GK/9BGIYKQ?:&F9WJ%3Y)"K/&'2?$?0#XJ9R='&X/"]TNYS8*
M:P!5R_OL<)ADZ@3;\I0_==).S(9056#I-9B/EAD5U#QS?>*A&&BDBL8J]P$R
MS^!P'W:-3K,^6'D)SYE*60"?OWY:M2SATYD1FB],L(2CF =R0ZJ_5A4CDEL!
MGA[?_4$CLR-13IQVM\_OQQ#X?(ML57<JHE-1S\ZJZNU52I'[<G?A9RN(8*K8
MT=3F2Y+.\LELO1XFDDNAWQP3E!29=-M-7 U(7!"]^O#(^EP(RF_X]6B5!A!T
MB((9!9EE_.".?I_G1X"[$$O44Y0J=Y?02]06AN)OUINIYQMK/K<Z>7R7,3'M
M._1+G/[6<30Z0($\HWF_+/B&:SF]#?&Z\QO_4W.IZ5X:J,5"@?,70PN"Y E]
M"[2NKC%V?AS9]@PR__F=1LZ[Z;/S'8TQGL0$/VG@HSW#K&@13WF3KJZ/CYM1
MD4T:2/.&E_ZP:?=8D_ A9QFPL"2V4U1JSQD<8.C@WFC",ZDE=:W'@=K3:\Q.
M],K5_^(_XE1=G%F?8Q;X\';J9@XWN9LF1\1)+]U@M*L-HG+W-B*R1U'"<[6Y
M^\LYQ;O,&FV[*A:LYK:?D]B9L2A3E4$7M)M6JP\^M9C5%QX!KT+$)AO.& OT
MKF+F.);-YR*_4\J]7)$9/LT^TA)MY\NG!>??8.69(P]C%C3V8!F\AD+^%8I!
M';.2VK/7^$ZR#/E.*JDSOD-3 (_0BO'UV@"G_H;WK"*<2Z9!8A8-R<T<8[#!
MY(1#-8O1J@E<XCTGC&(N/G-/%Q@!?>4"E^?F<E(]_A;I:,9RYIB:3D,_Q] @
MK;HLI.^N(P\VQ4L&+6"_A!:1!#$[;)4%OGR15 \GG/J9J-NL>]&PJ%[./G:G
MP*3[!TV0<A@;X#+:S=\"1JPR)/FEY1 FZ]?FO(@<0@/UL^QNUUTR:N=L'VCM
M:581*UDOMQ14Z;=)(I(A:ES/U&79+F0MJ5=9ZFZCG J3G-H3C0R<ZY0V_/F;
M="9H?N>#1*^/(^<?WF[JA'_2G?61;Z'\_D7+NPXQL)HG4GG%9+I!$)A3XI^4
M*^$A0U;-SDQY70.+<X7$L!G!)F]B2 T7>KCUS)WDTI\'?4F0=-7JD6 1]N <
MU:%Y<RD0KS#9=Z:&ZRU3LV]85_'TBQ9;!PQPO]B>NZ)>ZS,5!R\O[G@.KO+^
M7FC*Y+/@,>1Z;,0QFO,'#6?S2 95(I"-L_?:2UDN.O78%J>Y3V :ZJCF[L*3
M3_#RJA**YB#TOKOHCFW>)5Q=)^)%N[7MN:B(0E)"GG#MLF&H(X%DT2)D]LG@
MW8RS[M/H:-;9$-H]]+6>9P>0ID]Q'%0"9V-#HSC#RP%]".(5>..L?KAZ$C3M
M>_R O,#-\JV7_4UYE0'A9T$OS]@& 0M"K[WGVW/XW6OYA3T?-K:,1)7%&=1F
M'IJ"W*#^5#_V23P3M"D*THRMFN]EH6;$U?J:4:$:6:N\'2:Z7?TO5],&,2F]
M,N;@-*=*F)KMYN::C!56(]M\6<D_LJZWPZ&O+3,#+^[;H;D.#M=W3F4K 2ES
MIT/JZOW[N[_LV9-<B.L;RWR]VPZ4N_NCI\O>;CM(6O[2*=5R<[VCG[=YUV5.
M_XS^^<A'2:3D1V4X+2VB%@L B02<(%&0*O/VGVL'ORPP1UN&3X>%:_EYV/FI
M#[M!3>W9[7#$_8))26M3/1<PSN:A=N9\<,/2>NHP9!3_I.=VE TXFSDLOWZA
M'@INSJC6L;B*K8J@VPKI&7IZ%37.7Z(R0T,)8>%D3UVM&DN(SCT:VK^[,FI4
MM#Z! ?S%Z3K@[E&W[@T<FXR)KR*B*A*__A>S/3!T CY4W;,(A<LX%2GHK?59
M;,\L_$"WV6])3/4'DK1%BW_T*)\:6&#<VA[@F$J6UDN/;?UK;U/D15Y0@@"0
M>^5'E_[^UTYGEVE@S.ESCH268=63P]W;^I7E@6D*)A75QKRFD!^JR,-]$J<E
M;&Q9E2UU)38FZ]"E@6"SH+24;REYF8<YU6F"-O'2$NTHZ,\0B[N_'!*Z/(RJ
M;E59AX?5+^.J]&YOYT[D.0W/C0W<W?MTL -J._W?:1CA,:?A"^SN9^CQU?\N
M[RN 7EN1>(6(&;;5GM/MS=4LV@@L/$"@%0U\69/>*S4A'GS.Y"'EDA14TC[8
M7)UT)3&K2R0)Q(M<NXM$V2U [2'REG&B=I9OW7N5=+I[YBZZB]YM ;:A(=15
MJD^"Q;RM]^/GA7;B6P2M *F2--P,<P\+Z"ZFBP&C4Z3?DG\-ESGL#;*/S$=4
M8^ +$[@VEG;;D^))F)(H<B]<#OS:M$[5E>1.Y HL;B+HN1YPC*T_<5@:79H0
M5!#".%T<JO?^C=(XVV!MUSLVLXHK _V(17%? ,C&/V[]RJ.T=:+4&8%@_Y[7
MXU^ST!)FK8L0UAAH]*\[9ZD:ZJDH;^85E) 4<TQ,/9(.72]Y:P?D%R_^5,>6
M94$$5\29PVC=3FX$[207'94!;S4=\NG4"0<Z;7Y;,4L$$7L6R\;$G[(8Y5F3
M>K!BLB^[+%2[23&ZP9<_6B(@32P'Y0F,]8MVQ3FCO! 5+Q6Q47P-NZJYS_>\
M\]34-V)J9.S1R\8C?C[5&$LZME6\N0G]>566KN]VVIYT\RL+/H]P_H@ \,,=
M,5LZ"M@O9'[W#3=&5C U#CD:E7S>-IQ;9^29VQH;VJ>R-&0-L2%< 40EFVP4
M9@8UAS[,'G$N('8C^7)KR^JUZO8_W##0"[[R,KC/5 ZT)X6/0X)FIIOD<\."
MWK97EVXBJM</AWI:A@L]4K.G3^+8WUA6+$VE18)'P4/*#?S<=P0V$*(6U^FU
MUT=\;3*TOU< KA0$0T(A9Q\Z=BS-DF"#"^;GD[>RT[9W36'Z]-9'(R1Y#->E
M*ZE-E]O?M9IN.I.%$8\#X*F\UB4-)WAA6!8[:HMK!O.3!9GW=I'PC2 W[_J!
M]7;8Q%P*>,$[M+>W-K*!38H[K(>-[-<#MZSYJ1(IK#V6VYHSJ%)R[#*U[WW<
M?<V"IE/#B!I!U?B=@Q#J30RH.;.C'5?S;-N YIVK23D0A3IKB"@\#W((#[1J
M)UP$]@Z3RRE'IZTTO9XC[[ 'W5ZCQ!(H'@9R]:Y<NVM;UJT6E*%]_')!G<+V
M6PZG9QF2Q%S-PZPH84QQFI\PV-:C<GN[L!S;]WK^BUEWEF HZ3DY@D#[BGK-
M#063B0Z(FHH34T7VC?Q!XQ!G*_-2:RZQ/7ND;36_*IYP3P*'?#F3R^S_#AO'
MK=@5!4[UT5THS\U'F(1Q>9JK-[62]T(AH31I"O9.7)7,V&=O]%CT;5@-SW\U
M^*$G])%B^[P+3?\VN)QE:NUEELJ32^IM(^JFEW1APPNI$$K[K'^CV+NSZ72S
M/!WKCB+?,!(]W] ]CC:1DXGJGVJ<"#1:;<5UCHP!FZVD+6++W;AV5.!HJ;*G
M7AKIQ8732S_9^G5]T,Z:Y^$7I<"NP.5^X7\/_8/FYX>H!4,;,Z&.33I.B@T!
M:J$02=:KE$&,^=_;>IG^JKHN&1$?4J$6;NI:32."%:GD^9Z@PLCL@C]H7^YY
M@"O!%J)Z/SQX7[K4OLL0J*VSXGI"!(4,\ZD1S#'IQ-P$IC7PO#[<Z3[2?3#0
M^03IU^WQ_X.FB!Q[M-%S?GBR7B6KM6-A809EJ2.822G1+7-IQ-,,F3YE("FB
MH\V=E74(/' ?U(DPU"D29Z$SX4G2J*$6.>QO1+2\=5>Z33)A#Q&W]K31^$11
M5CNIVL6Z2\?@0#-&EH8FHHI<"0PD).-G1[8.A(=[_JV&CXT-D#P[-]S&YEI8
MV 7YZ/BH=J19YXVT2CWSQ RJZ&XZ./^#5A>5,TVBW\B@O115(Q=NWV[0PW4?
M9M>SJ+.WGFXL&=<3M!<1L3JZ/!T_MWZ+A_GT)O[2,-+<*':OE6=H?E!6/3J9
M#H/V>MGYN#@S$.RHGSLANY*8F'-XB#A[=(=\G=6]B1Y. U&]CV97J>B_8'VC
M%-=/'@RDK$927 6QA%;YB,4\;TUZN^C&ZB?O]+ITJ<KBNX!NAQ?M3)4I+RM>
MNB! )+Z_!!FBX2+[Q-P%^%R/W)'O,W[_*)?%*87TYH35YJ:5TTE2> +_X_3O
MY#]HB_.UB^2QNJ=J1T/JJ*8=$RC8>8":.NS5K_\)K9G7;]./#]5]5'F[R-O&
M2M 1K'SI%DUD"A(DBR'X4;K,VC7Y;M> 66URV2DYD S.9%3]N<"]71-B!^2;
MM Z+\<S]9&?R.,09/3J2F"J"=99LL9GFWA[IY_H+IYO\5WG/AJCJU\)$CE=(
M)'QEU]K3^.^"!$_8R4>S"W-E@(7ZGI=A<>@U#HT$9O%WYM^%GXC<L#@>(VL5
M VM!]%>ZJU18">(5?<Q;V :CI%?,8QCE20KZRWKY$.T1VG5>/TYY[DX1V14S
M5NZO"L3\X^D@5!3J(08J*=%*ZEK,&V)%6;62SWO.V3_5Z[A-.=*BZXMY1]1>
M"K>5VJKAX=B!P]<L[_YS,,_)_H^'R^PB QW@9U_ND%%Z2N<\9O<WE)\U]T5"
M/JFET%M[$?K[L^D0J6V9 4E/WT#0W^I--5C?3R^I=,P(3<Y)Y% 2"FY6O'UQ
M=V7>[=M(#?)P1RX,*!G241%3,#_R/!)'JW)\K+SRW=&^1.3(NC7$#RS5^EXF
MW0D3'(ZXSZ=WR/K0QP\7M87F%NIE9,13TOV#L!SN>7ZW OR:M+)G/,K6[ >)
M:?&$CGX;?ZPI=W.4['W5Y##V!^V#1EK% E4N'6%5LMKT5&=<+?$WZ3/N5C!C
M[5$8<IX$VZYV0<ECD?6HS?XNE]I21%7@_@U@C4EAF.O%7+_2@1CVK8P-E1U"
M5H%V1W/\/Y\N_5-=3YOR7]47N!&B(_>8N.N&OD^C(_ZU($B0%Q%*4??>:YJR
MG7/?,IGO^M]VX_^=H0)%/QA1_CHL_O%F=S?S.S;5R<K8IT\P-$&_!]CK04#0
M-;>'I0=.P&TF\1F8PX01?= NV^+[D#P2OKT_]V-@[Q9]^ )7S+JRY&BS$\_+
MFO#C9YQ_&9;P6(>*5\&\R>C.42M5F'=X;"&G)7H<E@2YE7_ZJ#JVO85\=#B1
M?MZ'TSX];GU")#)J8<=B]?-F)-N'*#U]#::(K4[Z!EK+)<<(Q1>&0,[&NG:P
MG_LU>.1V0PD;&PWOX*G@BN])8VF84]OT)%P,=QT81$J##STK_I4[_ZU:II^Y
MCI_,JN2L9 \.8%WV+>9?B7&D%7*Q47"4C()_J^8U08</[E>N]49&_3U8,K#E
MUF?RM'N'N7W\WN]WN8\$ D>1?<^,@:/;.\AA0WB0NNZ("2R]Z?:8S7='8^I\
M;"<K)A*H>[[><GO1ASI!/,A^]$_^EW_5&$;4%CSBK[(Z=5%8=-JAKM0J8GWI
M4MMT!V &I<XCB-L'59%I%1;L._%,0-_8D6H>U5G_QI<K$CS/,[>AI4&CG[\>
MCTK[\4UJMJW321%'7R%#_X'/_E_'7?[[K#:\NKT\VS:#O"Y4**RC:1MJN-Y_
M).T+XS(75=?^8.:6^=;<?PV;>!3_M4QH+$LX6^S<ML@31C(WM$&RKQ*TUJRF
MILH;'_]6-T;RB)86W@-''G:A&^0SA1_K'EV(UHY2U$\F#^^@?S(R$_+XP8&M
M8&5#R- /[I_FVN!0Y%8 I?<Q5BC1F)LLDLA84_S#E.3N_O)D_6L9KXC&GWD&
MCKQ%1U5Z4>4J)=R>1O.7!-0_^'>8=ACVDGA!X<-C^<IA8GRYQ0;OG=5H#ZM<
MYG$D@O!]<]0(W>#"='$0G"'"O:%/BR7 ENAXW6#U<RP:+CR;<YO-PO10A/&!
M$4*TS?98+-7[#%<_M?F7W"LA$"GQ"YQ?GJ;AHG&ARZ!I8)*P&E$M+W:V5G0;
MH-+]"<WO__/X(\?KKU5JA;&XYRP-,MU0OM(Q[#2*X;=FZYZ$'.Z"G$D0<?#/
MI*;QUG+>0>\7!<X3PN"F WZ<RPZ3<Q:O.SEO-]&:)23(0V 645J:2_:EJ69/
M5$WX;9,:6_>FKW2+&; C<2M:H 35/]+F'TP]>F\(NS-Z&'KPQC7W!T3 M)$#
ML-ZM!8[]Q ^O1<,?&\!!988PY :L$F)2D%>G8L-5<XTWS7JZL6_Q)95$X[FG
MGQ?B+*,++\B6MD:#C-5Q\T)]-=WDM[=VHSHE M3TY"ORMICMQA&P[W?;+L7U
MY0O9=S%9>U[#6VLWZS))RA>K@QLNKEZ$[]E?%MU *MM6J*8K5[VU_'JJ?!G-
MZ:26MIFZ/,6S5M>4VIC"2J=."YKTND?3>J$!C[ 0_;BU>&D9,O";OX4C?Q6)
M,M?YS"1+[J8]"T;MZ"*(%Y7]2RV6'IS!05XPM\PK]>\^"0/FU"M 9,<$*$F1
MJ?%O]?R<KA38JW)Q"IL"\(Y6I>,:V]SR0?[0G2LI.>]Q"T@J[ZPL>RU))A_1
M&:^JA!<P-VPGM?'=M]5P.U.HJ3QE.DH.F!:NLGL\LVPDMZD](>2%G<=,^8%@
M-[Y!S"X\5D0B9T:1J-DR4*A//!C)8]@LTDB</IW1O8+K<!?'6M&9P\OA7#T:
M)!LV!OF4>;Y+N5B=49-1Y&!,;4>$=;N0 G= &5$:<'1[/QB:#&F"V/)RI[U1
M6GK.5AR?^S5"6XN;?$=X6:1'X*BL\RS7N"3AVR3W[I/\<[_[G49^^7>7C#:'
M#H;UKR4O>&*(CZ<MS+9;S\]C')_@:GI;SW#S(27]ZU/ZPS<*%_^@Z1]D>YB>
M"2UIV[.I""9<^/.F-MD7!=8=)#-MPK7[+=:VP%'3#EJ5R\!.?)^Z#1<[5(#$
MCE1<JK/+Z5E 8-"Y)NSU/<]&M]V^S^R64H&'>:^Z1F"YMFYEX\ ?-#X>I9T(
MI0C1?'-PC5J?JE%+Y<H"JC%$T (3M:<;&;RR\I ],8W!IH)1\C.3A<(_8K4#
ML[0!NTFDMD<CQ9&-P=4+/^*TA=NY(&K:N9M'&^BYYE#5_7.V 5X.WS?'$M'-
M&UI-U7^_M9O3VKSCTC]#[\S>S-P70,VZA63K'_K57EGTH]\.P2?''\]O%A5+
M2>[,YBOE>4:T-Q[L]UQU=(L*'WJ+RF(B7H#O&5W,%KS/BN5.#>D;^:7"5U8G
M$6\+&BMU27[>.[]EMGLN>IT'H)17Y'*3Y6[0=\8^&7EW^^5!M->O48]QF#E
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M@F,788K&7K>GG:4Z>)D,;;86G$("PT3I;'$^-"3=VO>N<GGL!GT]:$9O_D!
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MTMF<\O8MV)\2_0&G+^Z<?+*F\JO10<BHSS3SVO_PAM_7+'M4Y^$CC5'9_<-
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M!RL!(M(1]'R:5A#CA>2J'7P\4<DU@^/JPT;]@D<1.5FI$+:X0IHY=G+LW#B
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MKH6$$-_[=K@6T? L=]9LK\XOY2=D4 %N\D2B?BDAPK3/0;PLXH[$GCZDQ"C
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M_8:H@BQH=TVZ=)3]L;*.LJL;'-8"N>S)IU3&-7@/Y1ND#OP18TA03+S.)6H
M8O2*-2I@CU"W$*.S*/)VG BFKG/J>3%=:<&Q%/P42$ZY$DH9PAS)3V[U]*?"
M:^.,C(RTEL@FIQ;UO-+Y=3LL*D566]"O@^;2T&2N>7I[FK(Z0=9!DHT-/]"
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MT&2Z#XY6\('I=K7L'U\B\][HR(GMB"G'5<P9MK(QF!?W;CRQ#EL,,^[C*4+
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M ]<QZAV*S5 #J48IU\ R])XE1Y,N2L_"8'CQ4:!AHP>W?HNKYU>+YRW8'\%
M0J8M/:)I*KN9A!SI,.B,F#YL@@^J&C!':5KF/IWO6]EH$P/UO#@QZ!=]E-/;
M:O7XHZ3H,^$C>Y5\%_6\\O&UW]9ZGD,^DYW<X_Z5WXT,"&NLYGRL;H>+6A/
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M&%?BU+815(,CDD,QE18K6)B8U-/.\[8/9R515?JF/FL\WY;I1=F.O([8S$E
MF(&($+F,N9RL= .SXGVCG.+MQFSGG*W7S<8IS\T1,@#D&NK]H-A]?.3:L5(V
M=384A%GL22[N'A@DD'=)FM&9IF!OW$^R_=ZA+O8\KB+?<D69D'I\99JM77.@
MB4*I8RBM=QF]6'#FVY&U:V0#R0L(:^J2\#4*C@LW6)%;B5/-8=^V\"#7%("1
M%Q'#"=F8.!] 8FP(18J]IXL:^FWX:[UL B<RB=P_22!?9G]=_15N,JR69I=1
M&92%=[DF+'/PF2HGM%)NY0._YSZ6@:MQT+'&;EA8<Z4LG>A+37*#@RL)O:2M
MC[D+#>&P3L[BG/ W:>C&P< W7XB&@ATVC>READ PPK#?JBQ+0X4EKM;9("2G
M+8YZR3,P^-GO\/2H]VP/2.][>O/&^!.CW<A+HHE^034\<_AN3^JNV>(R8YZ5
M"!&V-\]W.^6GHUM6M-&@<F1,_:L[P)O;YO23BLZ:C',U5.#<3V%R@9I7S29)
ML*U*-/OKJTZS"5N/AYK;JA)DG#J,+B3;J*6RAG#7U\*NR2]#JR<>,U$FDW'V
M"$T[".6?C-!H+7^R<;_5"K,G2*ZAJPS4IK;C3 'K)4)Q/];=HP7Q[GI:K.)F
M$X3T39?'D^^;YA?.8D _5ZB%RSMH4/0[K3<F62S(9CWC%(>H;7;F7P(;F;<\
M^7I9L3;"BV"H0V75-1O!PB)K<TP'-F/P%XG==ZO_%Z!KB282*D+ $MF8,S;M
M'TA$I.I;N<JO:UEE*.FS20^E:\5(TA6&"8M:\8)>LQV:%>NH(^2)8TI$&ZED
M2%Q3BA8&^:+4FA9ED^8[X*-#3%10I=)^#JBR&GL?3U73)7.Z[J*L&UB/<L)P
M':_DDTHJRMKEW,%!4FL!,?<U5I,GB97H>5<_T<L(,C@Q#,%&^(/Y5KEMOA1V
MW#LXPO2)CXE3+%NMHI%.2492/+32PIE47""Y,Z.'QZ9[P_-9'@63J/Q/GQ:_
MFO*3!8VE +,\Q!9^.,\!,J%6"VX0'<:^J4/YO,'"D\0FKI(XTCU>6ZSYE?_O
M.X -4D-(?D?>7C4?.^X:GY'!<E3AW9]S%>!P/=!Q7/]L>8]&\)K0;O_WT:Z9
MC\I0?_0?0--0#)Z_K:9-,JF2*SX+ZE"QWV=A,0$^-C(RQ7&Q[.\5P0J0B4'J
M,*X2_%EBSK_=728_MV9D!\\L2PG!_0-7,;2SCZ+0,W:PD]H,:6'01KCDT'G3
MR/-<]N;VA<3@SKQW[(Z]*S<+9D,7SAT+,C][Z9A.Q.\ 9G%!Z>.Z#Q3VM<.=
M&;-K%QRCVS,@7D[G8U"^T_, #41SG?YY%ISP)3*K.AN5/\D+#7VD$G5A?'%(
MMC,S/EFODI]\>=6\L&\=$36Q;"<"Q;3R)4]VP=%=0(WPD)HX''K<Z:G0N19P
M"1O((Z(U+\ C=)2QN4)(*!RSF &9?N<5*+(^LIB7SGVYH!(&XI>\93CY\VM.
MAWITR*^+7U>(@G."93"%1*01U5&"*V@M)?_\)U6=I9.U1Y":&0-J:#KB9*V3
M]:IH$3DM"KR 8!?FN%8ZK\^^778>%=\!;F0NOK3X?N7?CI?*CIE-LXSG2[P/
M\EPZ?U'/NS:"O=UC\PPT0K@8$*5[; [8TQXLL4T0;U_Q!4TYI*C;[Z%*=E3N
M  +-?";YC;<2/TJW8\W>!Y?D;V^I]@;0/>RG=7$;*FIA#?*3RMQ19?"F/%N>
M;]?P$*IYT/-D#JF1'&/0LI3)56@2F9&1-;VQLC R)W84$6:J,L9OIB+HH/+&
M(#K6YE+Y5>;U1<'P@G!AJMD48B#\B*>)X<PJ\M&8R1;-2B;Z(H>WM-$C0"X$
M9<ECP:_#W^JF%CDD<^):)6YI\RRZWQ#W.3]C7,^P=DC-Q*A8Q''?216#\6V8
MTKMM@>C]Q28IMC'CWFB,:=FSSJT:<'KQBGE9I:JO2Z$HA[J@SE-+T>)F@5B7
M&..FS8[9#-&M:<\66+T3M,N1VL1A)\6RXXI#?_7T9#8@KA;6O(N]I>N0K.M#
MG<VIM=P!,!Z]53O(22_S3"AP?$LX:!8<S[O7NO= :%/1WKS\XEK[6NL6V<PO
M,E-\<(6XY8L_9;;)<X>#AW*RW6;J5?N%UPI'9RJH5=EZEW?TOB(=3OG1$OA%
MUGX]U:_3)$>4<WZ14K-YP=.9A:@^=-O%*VZQQF01-;(M^[@K)8__$CG"H'3L
MO!6">,LGVA?\@5"=M7>W9IJ^_ QW "UT8QZ!H(D*CP_TF]U<-(6=JYZ5'K6/
M\_MHY_(IN:&D5V*-XW)@1V]_IS(=K>\5*2^:IU]M)QLCFR'95E?MOWCFR_T6
MW+)JXL7!;HY-Z/%L5<[I]N@!$/_Y;9/+P4%&D E\#FYH'OC<KHA@S^(^CHMW
M!;>N(XITN.>&"RS#M<CDDRRE(N \ER@U^ <7M?B'M5,3W0$\&C>R12._:/S:
MW_8^WNM,Q>-R61RO]E':O?'=O5&5+!1=UT .I>?8@&WE<7?VSS["?!E IWZ]
M7IXX7D$I0TE_8A6I[3<KE(ZB?N=6"9,#C5($W5-E/54>&!-)B: :MY/^GA#/
M&:G.FI/<8N@TU%@7$Q^4><9C<'9Q!^#%7.>XJ*0%W 8-7?C=-N_4V!EY;CA0
MC9UNW@$8#NX =$3J\_%!.W> ?!>QB8R,^?F,]H5 XP"-ZZSMRE5LZOP)S&C=
MW7SVAE>B\CURR63<X-TYK_)*2^)R0LF0ZJ-MUVX+"_<Z8JMZNK>.6S%=+Q\-
MBK5?19P.V;"6E)V(/E[>OKPADTX9U &@SVGP[X_HXU.?)UX.I.NI:[.Q#/W@
M62@=TR^FM@P4/M!6_KG";F(W,*QTN&0YR _+0H^DZZ_ FW91 ? JC^FF_O6B
M3WIFD!@?SCL !_.8YTW>9%"XVB60M%-BJKW[.<1#A:;*2U<\+'JVS+!]1O\K
M-<<6TL1XONAQ%"[ ^H<Y5G9X+Z&>*1&"7Y?VIE;>T5<,L2,_NIF#5W+0JJ>P
MQ'?II6'QXOD45IVG9;+,\.51X$,?#I:$G-7<WCZ6:-)$-?%Z92NG*7_>5TDN
MJ(C6N,X@R0\7?$NL&SUEC7*<]7Z234;-2D82JY>EI>\^<7 ^4*NA%Y-V8CO]
M?HN^ R#\2:_/ F08N?$'_LD]70IWL7,QH;;CAK7-%7L(XFT'J%'@\Y6<%N)\
MBA/>X_/(R+19QI6-,<BLJ+N;.*OB6779(G<1W![)4'H<J-/)9T>K-NR0).#J
M49S+=F)4>X19^=7P<RZX+-O_TX-219]G#TQ?\9BUO"%C*3Z"QHI^"_\Q^+%>
M]\!K^6BI$OUMB9_0VRO*-"V-S=.&/89N.N?<6/KO#:.FGN8,Q.ZD+6\ZVMX;
M^&E1?Y]:T3((Y:WRXT/]N&+ J(=VII(YJ<7'9@*?ODQ%2\_.N&=\1B_5BR_=
M'D5Y54B[%D<@XD2W#2)8O^H/F/1^U8]1Q<WY%PF+M!869WI,X*ACQ2GB.':6
MGM7&R2J8\H?3$1K=-&/Y8W#NAEPG#$^_=NG6BXY*-D2VP.V^Y7_,O?1M!O<9
M4E=JO'CWR+LHT];*DVHYZH5;TCNV0V( *:/7H;F-UP?&G:J9YP&_YMHU*Y3?
M<;F?8?)+EH'7>R5U_1XN:J,C6%+#SX'$]?CR3.#595):"\+*.\ BS8S2L>28
M89<E]EQTQT?@]RN19V32$>#(QD?YH-.LZO#K;Z1 E3X>1=8'!XPDK^SK_X%^
MHG=M8P42D*MUYPYJEK"4(9.J6/B'^ VL">RU7A6>V 4>[2@@L;/^ 2*Y-AIV
MS_QV:039PY49[\%/,3WS(%G9%I)B@BCRWIX96?B2%V:^D?9=6+0O<BZ+R23B
M#0M9??FFY(@1QSMP@WS6KV^[2<$/8L(J(1&UE_.C:PZAH^!'E]6F:7WI6^#O
M!R)L7C9>N[W_/+F \I'77_[2NS93(D%/5R9\*Y_NO3T/GD/5.M]2P/]B'_A7
MC-=\YA+?6QS?'"!]A2;\KO3.Z=^]_D<5>WMHF5Y+CJ"^GQ'15=OJ?>S;+@<#
MK6+HODHHA,>Q.S04PQ5SKFU'Z_"@'L,>3ITJ@A)RCHU?VU<"LNX F9[H+55N
M?4/C-6&<L><N[6$"0\N6HMW?,IR[]G.<]/M/1)]\,<0EF+-T<6:OCQZ"0&!D
MQ,EB=;AXD7B0_669:Y%DJ>3H"\@A:M?T7S9,PL'^Z2EOC>'0.T##U?9-=548
MPN"@D3XTX370%Y%KKY]&V$8I/9O.N)8E^48[B!\2GR:S])W0.D S'!;<2+,C
MO[',?XH]?^XF= >8NBTC]=I7H/9\N\^;Y3;*$MDAM.M=/;+R =P[\N CHD:(
MO,""]2'K8ZZW%E@9&;6!!)CK"//(GX+%7M<_./[O)H<_!IZV[#S0L#\]TMI6
M"<#AX8E\S%-&#%E &K.617[G,I,=G4]CS.E56RZG9'-QCAA_U/C8=TWW!OM=
MQ@T2Q.8Z(7.2'*C>-P3)R1+(NH"E0 9 MX&'VE\6O\Q4K(7KKIQ.DEG'DQ1.
MU]B8 @.Y[/Q<DA]I_\%?O98Q4G< IY=6N-_*H]O(_Q$D0,1@9Q 8.'![,Q9H
M\;@NXJLKRH[XI6ODOK=EF)&FQ@^8(+ 2H4%E8HQ+L1\[8#P]BZ]3<Q4K!KQ^
MD%]O%!D(@R=.3#RMYBHBV280C:CC(AE@* 0,6'7/(<='T9-5RBX6$?G ^^X/
M#=HR_J5DA8&<W/@/_ZL YNF_RWRWORJ8]&F&+ZS=9%><$Y%^[I+]EX[\]\1P
M#)WRO]=E^0R;^8^W.4OW"LZ_C.6!W--76$6UJ8W7_UUB_!\G.2C^3>H;HV3M
MF;NQ%Z%&<3-U+>!SCWGC_R-IGGPQY5-W-*RDR-7PG=9;N.YO[Y3=S_>,>JU6
M'MCY&#YTQ!J6RYL:UVK@(G7!'W.E7_&<QF&/2IM@NJL-@<7!!3NDMJ_FXCB8
M2M+[!]?&^5L.$SM\M(;N14-(VOU(]$LXO$\PE%-O:G':F&IW!7P%(\<C[-$3
M(A_31M*&AP;PW=(?"?-<?$ZD%V!\\6M@A%F'2U#O);AT->XC^TQTXC8!4S+Z
MPB$-3T#=P=.(Q+-?BD7^1XN:[KRE-R9B=FYGB _^XHCV%[F;K +Y9VOX/^:V
M0?!45A.A$\@CQ^3=NWY86"-:0_NCH44<?M/KG.D!HQ&10\$GN2/"0]$MRFRF
MZO8&M8_"!SY/Y37Z%09/9/J1E0MB-NI%')"*U5H0FF8)4F#SPX.C<=-YVS?;
MLQ6<^.,.<"ZR)PAJ/,^GWVT\UKUIKU1*C=2WQ+15FF>BYEXZ*UU+HPU$8_/Q
M3SYZV3P%];[,"I,L>?-+ 4PUTN?TM&^P;"ZLET^_AME-6EQ:D$S6DEFKA[T.
MS@7B6789>-C_F&=9!HO='1D@LOY?5ZWL68!>+ZL;]C3E6E1'6]JXLZ-BF4ST
MU$\YD+:\[*]_#&H;T$-J]*:9P?+P#A"3D:J0Z@W>"BJ^ DO",7< :@%VW*?_
MJ6MP_WYXZO;S*EBM;)M.('+D,RZ!'^56L!7'B?/JL:NFMU<95"3>K&(JQLK<
M/#5&(G7^4SL5U/.7E>/W(8XF(F^##QCCY5N^%,.DZXP+$UFNZ-"$V(1T)1D7
MK6@S$83@'4!0;]'_*OI@@M >YE&.Z8>=$/]NY'KD6Y*7I: GH+,"-<:)H^+1
M0E GNNI:D&QZ>R_28[G'1HM?8@19-5Y^"+APY""QJ1 #=BA9]H5,OK@'?H)I
MEZ>:G3N4>M2W,AE'WISOO52YS-[#J&,ST>J82&C49(97CG%-WS&BL;I1P]'9
M1ZD/+.AP+"-/+LN<3.\ &^NM*ABCJN>3)_0HXPH.669I]D.4[C&;U@^8%"%/
M/W*HF5;JO4+/A7-K'E^1JX>/3YGZC[GK?28?BY6MMD2/B*.>&[+F;>[4RW70
M<5I)3.&8H<V#K =@W/IOY7HFLUNB^B&(642'66)'(9?@^/P8[%FZ0&J#K46)
M9*!?*'+=Y5>XU/4;OE45*EH?9Z1"?#*R+27O^Y7TYN'LIKZHN\KD0*H!W^)!
M=EU1^A*U5.)WJW.==)P3:I'3FM#R0>MS'OUYAN7TW_9[A4KKC::=1(C!^]B=
MM1X4"V9O*31G<=L5=MZ5-732:9LU5\FT8#^/;/+3*>"T,Q'C<8;HN1W7I?Q&
M&)> [X7I.^K#7B2L_*[?)?[Q*[AMY'H(<7)1?@>8K>EI36ZH9H6/'RQE1*Y=
MT!Y5^=0>8I!TT%8GEOIY;O06VC1$H'_*RWP-3GHK9^W>[Y3D?V!JF3;O:6)L
MD8MT@DC2!M]:;RKB;5'5)*;4_I3FJKD$>#E5F\D07%DM+S:OU8_[(>6\'%F.
M%NMJ5O;8J*H/;5F._)@[!>B:C3B7473F@3+T)9[KN1H;9E<CNU(WVP'6HYZ!
M.N[J7?,#6<#JIL)W]K%=_79<:07C(OI'39959?7?*OTT!V9R%U[^51.;5/D9
M;1X7.:PA2H+@JK^'P[BR<;J#-9@Z@^QFX^;/#'@\;D7*O_O^FEK-IL:U3H59
M_:U!3)_]3+T^ISE'NE[,STE2A#YQ(3YX3RBJ%2/)NUDCL2G2TIIF:LP+H9"/
MXKN&&GS(YLK+ )F A=BHU765<>5I!HV8];--*2!DCZF?&<6KBW/$UJ>L2UH5
M4_!"GN<>.6(+<G<UK#ME<M\P2",SZL7K'BD.^!N(>!XPY&WP=:9G-?]*=ON)
MNA&(2J@B*7Q1 I!Z*X<O,\S(V#V,W#5WX@VZN+EU&OJ>]*NV'R4F;5HIBQ'H
M,23YVL #6G7I CCSR?;N+?6+/\&Y+ZDV.+B+E,@\$3[<FA(,3*&L,B2F$9U;
M_46]LB\RTA'<;-T3EC:VVT?Y)EY?R;-'I$[AH;"#-*\U2#,\'J2KD_ ]\R.V
M"=%>^*1ZYWC^MEQ)5%E-G@-1M+U(O WU7; 2G)?D3TJY( T/[*A!9U3#.A+B
M=MH3OXI-MIV\]C#67_$94'SUX>"ALA:8>J!]EP^'ZU!QY^01E)&"\C)9$YG8
M+#'D^=Q@G:? 2_BW41Y(9'K^DNGQ[[<TB*QM&&SG]:SZ;FP&VIL6A.]YI@*2
M)*HD1J2@/AY C9MD JG7H;X[@T=JS!,L6PFA$>:1D?DUM.]#7.*!DCU9_*I8
M(YWFZC]@"E7DK#XR,B<FM<:0VKX%,]L1^%J9&9:1:D5>E _T>.\:%8B%BK(,
M#;>V'$G P%=IVE_;7H4EQU*531RR)K?V45Z>.4?[27ZXZHAS6@B,M .[V@2Q
MV=Q87^E6NWZ3HR)/4I0! .;E01H_(B ^,!A,0,#O9LA.W@C&"4EMF7)R *-1
MY.J' @8_,^T4NWK]49%\NTRCXH>FQL#!<ND%/#T+L+WW/@U34ZN8VO+Q>)90
MO2_D4:P=VN;PHPW^SQ53T0!=<6[& R8\%^GEU>+?2SEU!S(3P+C'!X$Y?APK
M%IO0VM5XB4GDZ,9W"1]_1%F9FP'+T!-Y_I3</;#^B.;9@<F)+54]8J"I>5[/
M<%X=<4UJCX6W8:9Y8[*UHQS#IT%P66&N8'J9'\U1QJX_'\#(]&)O"YUY.8!T
MH#F?B.@.BX7FQZQE?F]9NW=E=[M_B/L<:O0("+BN[F*15^J=I87!9#K#EX;J
MN?[GIT;Q!8&!$+=U#)RGV.NC7ZR 6%_S>JG0]ZKAG>.,T:C^W/Z54FTHV%_@
M\\ S@4130%*ME=JU<L/6$.V>4D&=!>BDH(+R#M [9_"E8 7.]+Y=$X^U(AS&
M,>(:F%#]5#LIZJQH.3-&=P_MV_C=MC7\V9:CG,K&SW2AY("75'+'%^PW4PH>
M(Y=.]0ZEN0<V+M/<[Q*@,3$R;?7^^UW?+.O,<V;\^*)]W(=-)_5N;#V4;UW%
M.E_/\/S,B.4R-QXXU(^K)F(0'^D#P&")FM^^+4!==S7((#^L]P",/H8]8HT;
MY;O%]T3=)3$;$JK#ZN^TM31'-B[Z6<'^KR%QP?IZ$/.;KN5W<2&1L]6*X:4I
MIGMZKC:V[?BDJ(19_#1P-M>JEZ!'JV\!3Y@3T_.I"S-V$].EQ_#SM@MRB]VY
MI>,]DI8@479T^9+:4$%HT\WS_MNG;:EJ69?N\7JG1MR"+;:3\?A&[#FI>L:<
MQG< _=.0#Y8\WLT-22;+:#.6GWL$CVH.?.,2%OL,J L/J0LQ8;[U^[W[T^'I
M[$4@3T^;4U63F">ATQ,R6#.[@.%IKH;69(>]]E9=9ML3^GF,@WZR\I;S,\8D
MI&$!6(1.5F9WD<!B.<YO42R>C6+_:YNYV8Y$A< EF12S',$PCT4&8+4VPRZ-
M[W2!S<NK*JEO/@KO?9T &=X0OIOL=;8LZUQ9\.R.#7T0A38;+>DX)_&7(2VP
MN#YSD#<L>O^MF0+)A6BOC.R+ ,TX%;U?91T9.HDZ/B+-?1QZ#A^61#HJ/*Z*
M\5Z,%9RFL% S#Z#%B)@4!\+DA6+E$*7"D\!^'0/Z;$2-2=,Y=G1A,V=Q?H/&
M?H:,=+T$?(U;R=XSF?M3-(L87EJG3GA/*.K ?^?P/"$E\^7@K^AN7%H+* 4G
M\_B,PD1=P#PZHXHCHQ!JR, 2I+&%+_&YR8=6%JZ[PRGI0JA>%RP&U*?I"B0E
MK;$@"]*/TH\;HJN %5\=NQB5>L_#YFTY?@.9^Y]^J]R((:]]L]9S0-Q':[%$
MR*:EKLJJW_5DPXHY<9%DB<R?@4+A@*E+S/FEQ#NE=<0/HT&LU][J4O&$FD-S
M)SW>WAV T]AWJIB"4ZDB3*2C<BL?U< 5N+TSN([V[@SIH$]2$VJZ+H<K1E0<
MM/X3<9SH6Q+_M@G7-.&<[#"9>5]!#FF6+"]N))UO8T4WH2M*_# !3JX9+$J=
M\21:  ;CKPCR9O/_KJ&9.L\ 27=8JC51T&.K#I/"X4Q_S(9KCN8;9&$%TG'Z
M,> K$Z\Z$&F^CRMRHH">WA+^CMEQ8QKHJ6*7JY%B18Z3RUV.* FOGOJG=BDC
ML*?QKU(*0R9%@FDT*H8[3$QO332GIRU-$^.V"S;;LC3C*^:+,#C-9G[RX3.\
M1C_,%SH@D[_J9,^? ^^5FK.]V'HPEKYDNY ?3.MZ3?:$4KG7BDY-F5I^:NP.
M$.2GMGTS/=QA;[2VL_K&9"&,G5!YBDL6O+M#STO.MO63K,Z%I9Z:U\#\,<0.
M%"=,&%VA^G!$;RO-1Q63YA-3G&EKS29JG:;M)9"D]"3N'=OJ0';D7%[JKB%B
MLEQ"ES6.U1/3BLA8O-VX(0E$OX'1$BSU9^5+OWEUJ6X?-V%C0K[C!/G0!:[;
M=FKX>#&S:9WFT%3=IMD+S2S*YLJJ8 A8BE7Q[V2S@LT*MAMB3):H=E%U,GRQ
M&?/0(,SE'V!I7%]M6[@287 ',#Z_ P 5+I]9G:IB,17-A6^\3?"BD\;(1UXB
M[6C:W8]/GXH&Y/N'[A$:J/<FUM'YDF\;0,TS(BRH?-=PMT8ENL[_ IQ[N;CJ
M,H-L^'K-7VE%#B$0H;LS S1$[1F+R.N\(63>;&\'JZVO6H<ZV,&^TYJ7L77=
MHT[-W2WV?5YZJVV?X6\,93'YI#9.R;DEV%]TNR<G8:MMB,=#K@/EB*W) J-2
M!3.G3S;TNCL:7]N *ND#C<_C4%>FW<?<-H.@(\+<P/PC>-[-Q!U N5YRV8MR
M\T]D8S[:FO7FLJY<= F$5%$[P/'D2:;B[=)-<6N@G%+&R>3PW6JK$E, AB[1
MV?!3#<<]$TA!9T;%G+>M41Z?S^7@?EG)+)Y96WI!G"[QT72X5IFV#]26J/]Y
M]:O^<,<U&YSJS5EVK9-;*FV'M6[?N$5,!S(QVFBPZ6;!>D;%EJ7-IU9<9VE!
M.)K*)/WKF(.&/7O]+.7!WK/&,GDCOUF/!0G=*XEVL<;BY-QTA@FO(-ZRPS?+
M:?M-U[=>XZCC(MY;&\\@KPF3Y"^(%;Z+-MLM?=YI-*\=WU 3>4$\CR!18IJ#
MWQ0U9\ZW1]?ZO[_ILVWL&R^['=SOGS&#1CN>F#ZC*6VH7MG"TX_I$ZE9X8DU
MUFD]M9OZO<)Z@?1Y&/*F,(G?>S5.\\6WAY\+]7?YEKD(Z-"7\GIHO(M4S^XL
M[K)!*3M"G7ZP@,H"QE94;H_>L7CH:K\$YYU>N:=M&T1G!VG4^KJ.;?K0:$%L
MMUD-.X%RG#BQJ%/VOHVCENXHDU==7/1<FASDOP-LZ<8ASPBG?N=10S6)\&^8
M@E13<HSYG)D](,3')U(JH@T*H_/@'Z8RK6):9Z2[-!Y"!$I_U3.ADA?%UU[/
MMUV?!^.E@7A$EG+51;W 32#,2640J;<GJJY\+*][QO75[$T9FNIV;?ADX=E6
MX\DEUXQ9Q2O0XC%7\AV@XIQB2L T/PF5.R$1>4+Y/\A[RZ@XNFY;F#@$"P[!
M@D-P=P@0(+AK(PG2N$/CD 2"T[A;<&VLL4:#TVAP&F@(#HV[DYOGG/<=XWWN
M=^XX9YPK?[Y=56/LJA\ENVKO6GNNM>8<,^W7FID;*)=*(PO '/D$T>_XUL*'
M-2;^KI'^%2%)[F,;JL*RI*)X*N!GAA!A>BQM]B>&'[W?--)A!BH_ME^NZE?Z
MC9;_&XVH?:=,6+N;CMAY(*]GD:/(Q((^P<5745PP*F^-88E'18&QP3 [@*ZK
M9CIQ)<;"4)5$08]^7L6Q>/"F*'VAV:8R5"NM2E/:>/\[Z(ED^<GQ+_<"\\P1
M%<+3_J@*1H'UK]5>"7!"M@F*)2QES6$\#-+WSSAQT!PIZ^,/-I:V&;VH'3WH
M*X='3V2E/2-#'?W [Z*7AQ[&)&FO!L;Z^G-2 F0)$8/%&PL.'F-)!XDP2_H+
M![[L!8%T.35<E>8YUK=%0V^6!CVZM(("<:P9F_T$N2)D3()#[]K+ULESBP^L
M%V=D5&U335]D]L()#;",3T@==817(GK8Z8U@@I$FUE8O'/7S8E5R0BUG-.W8
M]-IJB22[GP06_D:S27:C>NL2M3JU0E]()K\4E<_0:DG<J,KNH2*>CHJQ=W90
ML]()+X:JXJMY(/D;/5 Q'315<M)&COXN8=1Y<"VGWVC*G _?$+ZXN2> G+*:
M&U:9IV1(E<2(O2F7.,,J_>(8:EU (P6PD9X(\:OTZ61L8H4:A<5JSX/2M,6:
MCEL#XBVJDJ=VB''JD]&;C,PMICISTEY!QGD%]@4>KQN'"9NW#@YUR=,C!\OO
M4U0A[>%^JD0L@7MM&/0/ICK*2RD'9/L$"6_L2-OHOA"X7&\ZZ?2M8IGF<76J
MCPX/2YP0AT6W(KX,P8$2BSX"/A%6$2KFL#G;-[_1QG=VHA@6PZ^A;K_63R;7
M7L"OG9QP[E6Z;R6EYP-,(S)%HQJANKTIG>H;B9=7#C'D LNK%Z:\5KTK[-)]
M\3T-DCN$MDI;YV#)[E+](0+GY<IV%1&!$P'I9(G"UF]PX_2W[JPJKHN5JL,C
ME+:=;'T'JL/#:*H'>XNBY4,.3OF'U4UZ$<8RQ,4SIWU[JL)^]\,Z!#0KG8-%
M&6SOBX9-QF7Y8=_CVL(_"2T&%]I9BPI88S_2?VL-(2_FZ^&.#/+##2]6-;>B
MBF>!R)-4C-%G._%!1^BA!'&#<A:JQQ?U^W2%DR04%,JM<,A$4FMJW5UZ\L7B
M@\TD;L*5PTU@Z#4EY<RT=@#>$OR!W+?&-"+C[B4CR/% 81D)]V+7GU3[SI4@
MF:UEC!TE.PHF6UR9C"'8BEQ"LCMFH:]OI6[0F#'6J%ETR.=;G;'.PNU@]HZ5
M/H)@/:P1]7Z;#Y8O4#M!RMWB18VX>FKZP%KA#YO; 9_ +"];U)I/OH\R'[<8
M3R66?SO^T9^BQHHALCG;98 ]>-F\PX Q:]1FMY#;9K/('AX#70>-^._Z;W0,
M4KYI!Q3-]EP+L3W#,A:YNK-\FXHBHB5].YYK^#IQ5QJKZ]4LQ(@NA/2S0;!Y
MU--G?T&M_B8DB1I8!0L.#0N^#3<-RZ#E<F#?5UK.S_\=Z)I(]7!D;V).W#1\
M,=.=DO3>])79J1J%GSQ5;I\>$/)QP#\Y@2D\6+YPCF*,A*_BA"*^J?-Q^V\T
MAZ716,?L>5MCVN,^ PQ4_1UA<;>X_85HAA#\_?(-N1)SF_!0LEFY;<_[!XJ0
M,6D[HH(0!9ITG@AK"R%@A)1+/$L>$U@_RCBM9XW[#0W(RHS$RM'@T=6_QR&/
M+>T]3$0W *!?!A:SOO_8&G;O^\Z;T/WUM;#!RLO9+<]?K\4<W]G.)\N K,NB
M$U!K<7Z/U0X;9YV8G&8"XQZ*9]_9Q\I2W<\A"P/3@9,?JXQR>L=V+OQY2_0S
M_61:HM#[(+/ M;B!-=6L1HED)_WX8;9U]32QX/\ SZUV:U6KJSIEGX=(Y4 D
MOV0,/+'9%UC=FVAP8L5:>WKLNK^_ANIU8GQX>)[0H7"/\4C/Y-QDPG2$''1R
MJ#H6\WGBS8W>RW'XJEYLR1C+Q@G>\0^Q%%=Y-C4NZ%62C29./NGG;$&2$_9N
M7N\.:M:6EHY9SP!CY(.>IV=@TK7IQ#_P<H?;6%_^Y,)%S/E+&N,8W%Q4J]=)
MK##&N<0',9$Q,LG:PZA^'V2XT$67K_X)R5JIM)$+7NQG#+*_F(-=Y2SN:1]+
MLI")HC<.'@Q7N2#/$4V@1MNSI<QL+HJ1,&K^DG7B (L12^.*N6](1&8H-69G
M9/B-3-E;*1JT :L!LK+_5LS_O_JT*L[_IC+P3B/NGX')3@=KU.%*U(XW09=%
ME,KQ(4M_V_U?<&;'MZ&RTDP=!<TY&9BIQ$7+EU14@EVBNTCI&YGN:J+QG3XM
M):ML)--094?HL01!8_$2[<N+/>M 1@Y]\T.-UIVKMN*O+O@9*;Z$;V07\,.A
M7GW$6Y#*\>?97$ 4:QV+J"361_=J?"L@Z/3/%E@VMCGZ^>3?KBXFZK;^L'6B
M1W;@O6\[_QO-Z8F2)=LYRO\)D;+V"%N%UCH7#BX5"2W;^Q.E7[T8YNPY=6OB
M^H5IO0<RLZH>26T1MZHF\RK=G:CY#98UN4_]*!&-HX>.XH,/CV+#I)!I>S/$
MF&>F)5XP73Q::XO$#YC'>5?-3AJ:0VLEEBX-YC P?!(2$-VD &;EV^\B9E4C
M$XQ[6CWPG/,$6GO[X?^E]D"-78.IC2VY2B-LQ-1A5=3Y_92S=J$ "=SJ(#@(
M7/3D3),K5L%U(+2.SQ:0MBA-RSTHJYI])3'[&VWDA6ER0H_^,5]E4+8/-X4%
MPW,UC=@Z;_O/9Z?3E"2H'AVF .&0O?%3HAK:QTR\B%T88-8U351S"6X!073$
MM@A[C#GNP\&]Y?@)]W@C?*$TOAGQ*W^1!L/_R63F"O)!^(%7=AWX\[F_!M1D
M#\Z4\OUZZB!#.3-AR:-9W72W2QV#21S>_&W=J^]5(+%^[\7C[2SJF,DY/Q-,
M(K29OI5MG;[Q2JQA;IUB="ET;UY!-C2DZO!B"N=)V6\T3T(0X&VB&Z FZ4NZ
M4095SD2>_9Z4=&OE=6LD;R/.+/LW'R)XZP_FQ5.7VF$!YO]"-,*_TB,E^>C(
M5IXZQ;2-W KK'5$Q//H:]F]M7:#7K+<3N2"Y?]-R)3X]*)(8<:EXS^UK==^A
M%_BB&?;(L^X_/#V>QK+L\9-2B>$=SCYEUR(>V-C?R)/^(57QK_1(@_&#^^+C
MRZ_266]KKH GCQ7^XTB _T[U5?'2&'+C[N>QIN/SV*(-R!%?S J6OPL51"ND
M0H+I*TVW6%JFNYEE]#9C_/HS#K$0;W^IW)(=S,BF!*'8. P,WG ,S*;8V 3>
M<$QH#294J$54E!=:BZ H?[3\#(D\$KOT='H_'OCU0'5B5UG\@W$_N:T3[92'
M6703.+I4R+X)O7JFD=5T)3=]7/J9;]P_D^;,5+?:CY_WPV6L/2 SKWD2NG-/
MB0L$S^WPX0,[&:YI!-@V'T:.:@FJ]22O>0=I"_!F'0+?.7+T<$A+[TE+J]+3
M<P[$QK:\BFWYZZ8BH:*BHF\$Y&E# E 21YN+%>^LHXU=<DP^E@F6&]6P>C57
MX1D]]0^,_U4P-$'\<3"4$?0DGVE*ECVWBA?]?\KA\?V;XZG2=%GG&"/S5KQ0
M$D='^^<_&M2$O#EG)V AIN8ZL$]Y,'_P[WZIQ*??_M,^7.49\%!(6]Z8BA<(
M-#A%I#UKVSLWRY4C$=A:W <Y@@$C/Q;]>J>M71.;/$_6EBH>+1O$^HK&%6^[
M#:C_/-N#NHYV<\B+9F.0@X7QO8[/D<CEX0^4&?"IUT"7I=]HG.4G@9P/];ZM
MW!-^E123(AZUY1R!DB*W]FHW^!%W$9BKH,;-8X'RV4(]O?=ZW?#^(ACGJ$O&
MW6A:.I.5$:_&9/K.9)_>W7%<([8^ #7$]^6IB5&CV BSM^OBO:YQ5EQY=\>?
MYQQQ;I,L_=6SBRV>!-4XG.VR/"9CL<:*)E]\+;C2[)$NCV]]!XPRWW7AR/9>
M029O%<]R\C?UI^MT@>3$Q7?D../%0<86J\UU[38>XA0<^8XJCFK6,M[P.]KD
MA9L.C[I;I\E<[\I)?TA=E15VY>3Y7C (&ON1^:,[*)D,W=YBW^PX"14YY_4Y
MHH@QZ*EE;*LT=ZBV1ZYK([".2972H_*<:@7E5UDW(YA#DSDT. FHF="8K<)R
MF#2))D7?.%?V%[H*R9+BL?X"<Q5655 [<'I^9)LU-WW-;E?!09G1N,$$T>J)
M.[Y2MLYH,Y)[2Q"0?F;[I+H1:P*1M@&S+FP4J\T9GQ\IGP($E;HTD[__Z8N(
MBB/).)?73-+W\C40*_SRQ-8+]7GU5-7^7LY%+YBAW@S=HMO+8^6!$\?,."/#
MTG6T&;]%DL.!60MW@TG'+7FQKGO?0' &4>GM0&1$DWY,$E/K,=Q\-B+ ZUY:
MAJK$:&2\[[68.+1HD1;/):E%;6Y<7E";U\OMH,I>T\G.[&:[VK@*;EI=B6)$
MXUOO;=3*'QQ]?T+S%6VS%[;(JNL(=26O &GL514)A"IH3S3;O@ YLFV<-#R5
M>#5JJ?S4:F Y]BF@I-E/Y'P-+R3K([B5MHLBA7#/8&Y(9:\A,>99"%Y+2O-/
MQ%0S6/\Q*VPQ5G[BA"0MR\_?BN4)&?BX$)S)0]W('EXQE\%-9'+LU*O$O[ D
MP)KD8TQPT^0155M,E>T_E+]A[)>>,Q>Y&;^5H%%M0G)EI_HMJMA,UPI)#8$6
MM!:R9Y3AKG6<))C:0!(VE *QA@:9)0Z!AV_]6_(YD-M*_H:_T7BU0QD2*\Q^
MHW$W#>$)$G#SDJA^;R.,TI]+2RUY=YB0FB_XG=@\@'2E F(J4$$AY+9@M\LT
M0:3;CFP8JF)W-@:@%N9?:6;FD[S9-1R5>,Z?9L"[7EG?L:]H"GIE4INPG6(Y
MW9"7H3_^I_,L:= HQ"+:6MKWN7FG9GTB$BM[C2@"? N/DVE!.YF(.;?D7$'F
M)^7$]).4,R$=I'X6I(,C+&'0ZL9W1\-+*NMW@@-+F[_1=DU#GKSDSV?5_1 %
M'QC>8&)AB$4.C,K$+0X/9 VL,[G2>M)Z,GEJ>B ;YW .SJT6-%!"C)"&YH C
M['Y&H1P=TR_S\IWJ CN>^=1HB/(X BXY!SE8?2F#2,JAXJ1[)<ZX)0M<NLQ\
M+,Y-:70('H]PH+Q,2HA7+RJXJ"1G8L\7?:E28>L30XK:I0J^JW343@@PYI<]
MF$PI,&O;M6HX\4\^X!:=;<YH*3@_O_$MK"IQRR^9LSFK?+UH?XSR/2_\Y>I)
M$Y=5\$,C7=":EFM[$$!E/!CM_1P):3*5Q LOEX;8:I=W:V8)T4)T(5Y=S*RS
MGU\+?0IY T1?B^!^A4;\"0\(!%J>Z;Q>&Q4:G(46I\0NLH*/>OO5O,PGVU&L
MC7P;$[J(6K<42U*Y5]$]OP[P^\:KRWOZ(I#T!XT6A1X9'@E7LJ!@05ON<U?7
M!$[,P9XEQ#W$&<";>_*ZD6O-;%8BO_AHA.Y9U*:CUW#9SZ EF5?5E)$-I$:V
MDR$VD2.?E70GSVYK#\O)J6  _PNYYO*()<W,;+@?_KG#7EZC0T&&@%A%V7:E
M)X#_Y6YDYA9'!'<$LN,N'K7\/H/VL(.U+B"R=\<:=&#T/'.J>4MSBO;SR56Z
ML$%=P$L;*A8HEQ*0#"=$];B?W5ZTF]Z5+TZ_67I%_[EAWXZ?D'K%24HU$FM1
M$'NZ/T.0RN3P-&!^723#P*I^M&!HEUW/ZX2L%0GG-*GUBW(YEQRUG8Y&SK_4
MSCU"351*#!.M@B64FZ-JF6JM+/?ZSG?+?.0)-2>Z)JP/45$#<INDF<R*G4PA
MJDL$ZZXXO7ID>!V-@N&?NCZ\51WYV8ZS4J%*\G.#HCR%W6.(2>1:497*7"E-
MAPK59%]>A*>HJU3%F6:N&N^20P0\9H3J<F07)=I',4>!EK@UD<*2T#'QS J'
MICYQJJ/PF%8I6Q*2C^D8:V^X&%%/HGI[>C(VK$A C!HVS;X@+ZS>=)EIU+T*
M,+CUR$E_9)#$YD5,=I?,2ER,TE7<.127;<3]X4*B:TZ%N\A]LVY<*(P[=410
MC;P0FEC:.TFZ%AQ22< JJ>1W\D,_D7MF?^ATEPJJL,ESE-97W99WYKS<\_S=
MHU8_ Y@HU%=6TQ4OU7@A%!0U+PS(]C$H .V8,07*/SX&24 BL88MF6<MMK1W
M,TPL=:7VX1(FF:,</*:D!B2[-;3R./=TPJLFDUKJEVO-P5/)1[48YPLYZ8T=
MP,(CIGZ89WN#<NZ:0*CWR>HUSW9AWOF,G"[U-_3HKPU94\E*GRDBN?GT,^NR
M*3REN?+=[_U_99_7Z!:R'._=01M33M:0#\FG5J=ZB@=\AQ]3 -.E4-^$!&_^
M;)&6D.@Q9%:VL5Y$L?&ZF"R<D0-63\Q1QZ-*($RVX5*364 'C YG?[?$[R7U
M6J=Y-$F/7<F7MX8UIL6THK8DPIC5^*"2U?9F@;!<2SW-RRGL>M'E,*7U0D=_
M>3X@-B'0]YQZZ9;3VZ$M=1Q/)\'[OSA':%X&>;JI6ML_E]="54#L)0A('JG8
M;J1X;H5X@E_^#**XY-!G/"J;*"><@2BO87L5Q :;SBPYK$\V/U&Q] "6#?1&
M=:V^.:Y0HXLQBB>H\T!I1P^8C"PD)'J4Z;[83?=&>P$VGH\QAK5XV?H?3CGY
M7*M$3LSM6&(+%JYE1K0Q4R#3]R]P4BN!%7W=NP)A'^R@-Q")U&=+!H+=@=BN
M_+N+&4FDA IL45G)^_LCZQK-\WJ*H@+S+F7LJC:-Z :EQVJ$T\5ZM8K#:46H
M\H!PT"G;0ME7_Q1Y@08P7%%C_^$HX,18MHV,E=3GF02Y8^D"!G>JP"8KF2ND
M/RAARA'_%2*G#U6C1K6<6N)B="=\*+5;2)9\HJ[S(M[M%75"#@_3S6=V.,$#
M5')V!69DQUEB7H*D':$_6)(:BW4[\!8Z=8J; X2"UA;'!G?)DXMJG>C[-M7.
M30< -QI.SI%^48O^>GK%TC]=W.]LC[G?1I.>L^>35OFHY;EEMHS"]UOW$EQ3
M^O-8+T#&"$_%NW#8J%IY0.0$MW$^T7:*[#6TO:[P!WQH.,1CUW7O$7GUF"!\
MRJJ33VILV_QZ[?C^%0!^+<?IQ-<XPH%7;P03\=%5+A28$N2JP-_(ZR',FV4L
M7I.WZDFE]>3<YAWL&OO5S=:&E\*T=XV@<^$'QDS??BD^2D!,W' \JHFK4WE#
M.?'8O(WX-6-4#@TC8P;177&P"J7AZK"<%L'[I0:!80/%:/*FN+,3W"%)]L.5
M=NA=)'MT7$P"13I+,\<@H.@W&J,+:-QB5TNAPS>^%Z.T.UV<VF,\CW_5*.J>
M5Y":Q\2\!VHC#6-Y:VEDL;HQF+YE!.]S\I_WGYCK:/_AT!XUT2SS(FSA1G_>
M4)EY%AI^Q=YE.&MG&"*<#R>J<6,+OLQ_DPTX56"[R$R72809#Y>S+,(6"HX;
MNBWY_9>'3^%L&?ZQ]:R8,JPU(W:*F?$MKO@=.A5O/#SXJJPHR0DHF;^.V&4N
M^G<A?.1*$R)36!985) FR@M.;\OI%YU<D_='U3QL'9H6R/H]&PYVG%->K=EZ
M$5J:N_;AO.4I$_577DWA]^6 NSMO-P9%-0#V"!D]&SS=V]?,8ISKC*7] XNM
M<RK-=]%@J#O^3[OG'#&68_S@*'HQ*<SSA:C"OM1!*]E=E70V4ZQC1MV$#%40
MQ35[D7'V7?+, U*7?I8?Q!%O_-I7D8,WRJ+V]5*T7&ZT(X>R,*I!5#+*\M+J
MQ0YS>^G%F4UOW?G82BT-Z''YITR&%V]<XC)Q6!XMJ@JC-;VA871YPVB&;V4%
M!($T<Y ."Q?&N5/8N><.^0]6AA&_T;0%"KWI*1G2ZO;)C<.;<[J[+>BW[2O>
MB1,5@>!AT*2M#/K;E=L63&RSBU-K$8XI8%S1;.I;=5]^!@G2>AUF,R=@:^$$
M8CN8,C^QG?CD<;OYTW?J&V5"*<\XY5/$) $N!S>_T:Y9+X-2_M@](5,I_'K]
M\?.7JGMB)>PWXLT +5N/,4? FTD7Y\SO.P(@CMS.](F&AKM0"8N+ .,Z^+E#
M0,&$2Z;G$H%*4:9W=$3]%H8YACE7O/!3"_ '.%@8#1&&A67<\_G;7/ W9'A6
M5DZH:2TDQFW6*S$.K@3DWU_=C7K>_GG,.*O=EU2T>D<4JJRLQO=F[522+C&;
M[;%7H]=@NQA3K6L>A547F2&C?Y.P4H"I3X;F/!FAP#5[:, M/_/!(F/ABVE'
MHP>R53%_/9R*5ALG,D@Q]F62+CVL/&7$:?PBT3!^>_3[LD/4I&],8>V\I(Z&
M79-?FVN(',G'>DV0U;D]6*([G$@YFLS'JM2";$GXQ5>"J(*H4N[YTUK&TKEH
MPROE,1-YU74<!;Z&8M(>NTW;)QB4OF@X^UJ<"M'Y;<JI[Z_(=7Q0@^(D?<9D
M\TS0RB0D.[>G@NV=LVD?8%7?$OBJ+;*#-'5FT&RO*6ZR ] C /YH90Y6L!OF
MF4FW5K,_:NRY U/#UW/XYQU.U9@H/9P3%/QIH^<5YPH2UYJC?QK%SRO"N@''
MF-UW_FY$?8I<@\&&1;.[R&M=^T9GAS/_%4YO=]>H$BW-_3W_O8"\R=D*<U[2
M#/7E_N5\%AG;Z ',2I9?L?ZYH !9Q/63QT(%^(]I6#T\K2YCQY<HE';V/WAP
M9R0$5W#&%5*/LJ+>NO ^V:H^)J$=W>BVY!Y7H/F9F:Z.5VC6H?*Q10MD-"U*
M7D$_^3H<?, S%FZNBA+:3>3CO9KAR*Y>+P"W2U>](6.S&W:=XHF0<RL'5IRZ
M5XJRQ'>ON]QD**\[F/'JE^.9]*];*Q[-E]K2FCUY3$WW^!3C4UP$.1YAK#[X
M@T4\3Z.83:>/$_%.DK%*4HMQ /"YOYT_K/E$K2Z+-V"_7LEFEF]><4"HN;&+
M I#391A5#:43C-A;;RAM7PKO/1RLB-C%%-S(! &:ZH:GSK);1!K(G=U-MB:^
M=#74=F9G#@_0LN,!S\83YVZ?J^PG9:3:0;07VY*KOE70+M:<ZMR"Q'^C#?U&
MLW3E0!H7NU 6MS"C!CAD]<A:1-7U(9YNN .\EMQ-@$<Q4\+#3-"U; D'R80!
M?=C[9T.4"1$5!%=)_IKK4SU003V8&,.-CJ&R,^_*VU.^\KW.6OS=-N>-1JH!
M_@D/$?;@MYF>4?FF\LV6*<UW?FGRG,2V@SQFE5'YQ_Y,Q"U]M@JPWKU)?W_<
M+@-AC[0LI&B/X1-_ :A>39W+*K\#<9VJY2N?$%7AH^OGB3\^MW)J=H@.4"KW
M8?U2EE;E_-9:!0EJGW:<J#65,43:C,!VUC]ETC.B5J[691=2K':<^.FVS&1H
M(X\W&RMO[(OLUC _O=WL$(+GKS0D;.S0Y[!>*7!Z7HI'=SLK\J //)O"1T\E
M\ U32/VV<(ZX-JWM->E> !M"K2].A5E:&^QM_(SM)H2Y"=.P+$%])HE7EX0S
M92J"U'2D%>5&=5/.A=%Q 6(/2!* <D>6]@9&(&F\*I5B<UEE#**A2;\#HU<A
M\#D>GM?8N_\=K.N9<ON5XT@'5T:5';]B2V_0[+%:"2H5$XLFS2:5GTAJ!P^8
M,E-8E1#7! (-1M;$7051CA#:7$(N[-A[YY4[U2LN^)_'H:9)U=$'MG*F:"6_
MN1QQG5@R[ $0I+1XG*_7=<Q/MBK>%<QS/C:"BGI#&]GV#T"!;E7,_VYWI3QL
M<DS$Y'M*U=5?SXL1MU?.]>_26N^B7F:YK=C[W@!FTO;-QN+6"QK5,W^\860-
M@S@UM4+*B,M-\LT44VSTOVZ(JJ<H3T-F8JT@9K2GJQ\8T1*I0X$TCCJWM[1.
MYPZC"Q#.BEROD#XU:E++C^'7+]/*<M)<IV5A3*_ 9UIBM&JSOPA53?Z8</3_
M'^Q06ZU]LB[#%M('R6-6G5AU?\J 71R-7$O1V*#YVB<%VRI8IM::9FYIS!1H
M\WGQZP?"H+_NXEISP?])&7_A ;IS:@O!9.4!K9YK/%0J(I=:+T6G-;C^E^?*
M/!=OXGW84,036P=Y3][X <L3K:0*L.9^1?3M\X,M\2$H921^0DO+K>N X^)M
M1LBE\^>K?Y#G@!\>_$<.WRDTNB\#JS9#6X1:]-YX.XLP_)H6-GEOPN*@DY7S
M3$ZUP<6E)B&*38&@QFO:&A&-" [KVE5\>_O]EK_AZ[R/,"#ICNVBA9F?XWT4
M!5,,);VXT$O&GN'55^JQE5R2J6-QM0==FZL\)?\MJ!WS7Q4C=L5U_S5CZ">A
MQ3^;%W#;U+^JV;_0_OU^)U2+/K?Q;[O_BVL<_48S72S96C)&:#3DNYWHHXC
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M*^,\S#U78Q2PW/EE:#C-HD_"%2_XD4FNWFL%+)3W",S\V1S,1?P*_8?^.S1
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M<;]W*#6HB-)Q D5IU#]>;8N:NV</8\3#7@!9:RG;ORJWOZ'/^C_J9#4+M ^
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M>4S+X]MHK"SV3#<-EHV#Q)$*WY?1>)$S9%9D%IGRA79$**ZY;LM]9V!-H_Y
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M:J&;)]-!D!%8(8>XVBILT*LKS\V'COE?$FV+,%@MYC\()\MJ_9J1']=((I@
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M9R.%@S6EX<']K!XI1>X)B[P4BX,)_10KF$'X557*7,G$SL3!3%N.F:O/][3
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MX=#F/1( @1$U [XS8SJ\E&;^ 9+[5PN%^7T98"A_(2R>FZZN0?7P<6[(?.,
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M,(^2AYI 2_S\X^3=54 ZM:A,OY2MR1"B=<S5;#-Y8?')NJF0%WA2GEGK8G1
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M;^TI*GC=6.T@)_6,\F&;YLC#28D%8C[H)*'NFN'[?V/7_!TW8*:1VX?;)F^
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MYXH3;@+AA[,02^WY1QR\Z_R0C:@IJFHAPNCYB-(.\Q*!P/$42-)HQ\J?3K&
M[][YYEE@.9T<'TLK31-'&+C]G#:,<U H\DQ&Z>PZ4H26A8WPP@ _U6Q3ZQ+J
M-Z^=-+[$"BRM:#@J+W"R*TM9=FY(#?;\</+DGB _78W*)^EX%WH ++(&<M=X
M[9<<,M[)>9;OQ8T?(!/8ND"Y[(:6%."7Q/O_\)=1MZO[@@WBLQJ>T/;*&A6
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MZ;T4&__^ID>Z1I5E94OQ=<9D5?>Y$-&;B:A6[LKBD(#%L=T5*WC <$^[PYK
MW&Z+_H>4K<R@'UJ\=#G-+M@H(_==C=V'+(U;6HY(CK%WZNF5,<KR9C3R[^%U
M]8)[EE49@_45\HV_=8;+AZJ_6HSXJG8GB1V"J^NR=9&4T; :PT+<T][)BA='
MX<NRM@TT O1A?4YMXC%57[IL%NF.>"8?QY.YYZ48'DAOCP0B'(:ZO:;31LRB
MH[,7TG[WF900B#O_HG2>P#QX4T7PEIA4A:9:_8FP6B=9[^VAIP!^UJ&_2MN$
MKN]!MS;:'\L77$35,*_ SC['=[A6:\'E-NSMY<3>^"J:P@EQ*=XY?>[FIK+0
MXK+EGC!C<)56V9I<-,/3=C$P@*LA>Q+LNO3?%RTP&MA=VI[&3XQE%L54CO@0
MUHT4<6-6<NI6#-]4#=KNQ!(IU,<EQ>5HXLBHJ6YOUM1N6AW/\$/:1F?BU+'T
M!TS?>BSZDK+ 1HXIDOZI-NY"N09UOV>C<E17/II.A_9;/O+C;G9H':45$/W+
M/N>Z%:J2.^T$EO&D9WL2)4.O!A=W=R/G E]J(2I9[V!F+'7^,3!:T>G=NKLQ
MU7,Q N4_1)W3+C! \0=DSV9_KM!NVG_[:M%_SO?RA*]&^(%5F7%P&/>GY'-/
M/RG!R2IP^7=Y"P]5A[I]^!,ODQSA%-KGF?UA+X>TK=J6M[<L-IMRO9B=%#/E
M*^*TK:L/'!KP+Y\E^,#E:M\XTN:/P13K$7UWWW'UW/*..L3<+RL^SW_&,3-1
MO/A%H_!OX+JT?8KRFU@I#+7HU_XF,@ 5F!7J\-81BK=7GI]#_UA%,XZ,GQ=$
M+U"=D% 7_1"!OJNF&6"OB)5@]G;T-<4;OC\8%>^*J]0-EZRC#K@!."G_#M"'
M4L;5+*X==5<5O2--)9_JHZE+WPH;VM89B[7-(X/!^APN11H5*&!CM.F9 ZWI
M;<-'_Y9G&NBHZX1 1<<JDD550O!F%O6>3><U^U,VN(W.>E/U5 ?'!*?G_I^G
M[V;WSREE3Q,1G9! 7&EQS@(3_5,K3DDM%CH,-1UKG]G">O_RT82XUL/-IT=K
MZ&6].-5@+T<DV(S?6-&CJNRXW7K#Q\R%F/]F+*@QR?$ I30'ZSH.6 6;?9['
M;KB:!C=LGF&$_6IW_S]3OO__BE3_''V?]"__9R#_-^[^?XMK-)YXQG47Q#4&
M*5V,/2[44''_=\W_4'<O3GRG(" ^J!.B1&QQO O$(;,M;.%!X^3\\BV(K<\A
M^N[G<@+7_5>#<(;ZS*XPSXRT]RK\W.^GA"K$C(&Z]NZ+!].SOEGM(MW)[K:[
MRJ_,JL3LEK>?Z_SJ#?3ID@-YF$:&O6-/H 4@HLI^'>_MX,?HQZ("[BXM^50J
MU/1]&H]7NQX3E5:/'5:E]['N9<A9@P2\MHPU5Y,W5)$7/^FP%5=#._-E $UL
M.7KM2SH,B3H^&^-LH.^J;"M$Q:#<(\-#AGVKR"$O D."> #CR_]-28#;]ING
MKSH&]?_Z7'?6)L32;/%'VH5"07@NJE2CQLN3O\DB8FU"X.5@7?<5E&?F:5P1
M0?RM@,H!^;;C"U^GN*%KU>(US.?8X^3!+/$#(__GFF9//\=T<6A*"N9:_<!W
MRTG&/J,5<Q%O-E_<\X,W(>K!4K.0=W8\FJ)C;;I^?!9ESV#5".MN=O)NUVZ5
M<0+!Y1="_8DP9*IM^\5<PU/GQ490.6K.U]=H>6*ZB<UUXMU5VHSVB-Q#;G H
MZ8679?ZS%6*:Z-(5 =G6;^8\U)9N#CL;V6Z1'V3S#[Q%IS,9JBV_2PT^=3M\
MA:0_'#;^&1S;EK:<I:A.#YX[EODO@ZC/:*^4U"DU1]2YP)6*S+JL.>A96(]Y
MQ3OU]?P,OTBV2/H44!XGR"IS?GOPKNQ;Z/R2QW5CV(SYZ"9QFO0OSK+^KJ>+
MO+F,')R"WY](>)&K65;KB1KW-4=I4*SPP7U"A3,O9@Q5<2D,!_Y(:4-*BS#G
M^L@,RQ3-MR#S=E%F^K:R1-E]Y$<2!NTKKX$GKJL39KCZ^:5RJ$#E&[$R\U%_
M07<Z0I8P).TE3GE%"C%?N3U>9O9YH:\;LR*5I5TVTQ;,Y)\GZ]WH:+#EVGUV
M99;1EC-D"DJ$!QN+/$A']S[\_;[/.OL5%_1A/4M8DRS\HPKB8"KRCLC_GH/V
MR<PQ/^(1Y10NBK\G( %&*?.$I]-PIM'99B/V 6M,5O3 Y0(B_V[DT$>"S^]/
M%PET65E?O-AF?2JH]D+O9V0D+)Y,%O8@2A8.%Q5M@:E#H-Y=MCGABSL-8B1/
MY^\.R^:!NL:GQZAIWPPZT^B<ZU[($DYV:]''D%.EG%@5.4_((N$A+2GA\_4"
M;DVDDX,N1<S4C%$V]%(5?)/;BV]V!!BWM^Z(:GCV;/UF37C(Q"(ZG^+:])S^
M$C'XGU;U_T0"^W]EY1&]&(3?-9R7%]IJ:EJJJ!+#NHAL;,7^HK=;@NS;CZ$(
M6W,G*OH9_F2HL_2A)=-,W]:XVB<2/'?Y,/)F!R,XV[OBC%1G41X:WS6HI^^Q
M*6A9U=>S]ET88O^B])3E &0Q@&Z"GCF/R^_*HW/%G^!V<C[WP39= ]DXRWLF
M8BZUKWD+H/<&?S&X7@LZTA+HJW-7'RWTJG=E(M5:#2>\-;+39X>SFQW=O6 7
MV=FWL/^B!HJD%_<]5#HR.N6I)= -$-2[ ?RM)'[":'(CHM$1J@Q3]@16F*GU
MN)O=8MB[Q02H="Q7@MG+\R"R_TZ _C_$2U>3V'<KX::=I@6W8TWSR:16HGNZ
M,5\)L[2)K;H_IG?_G60CVR2D,<*K:SIEIW*&]R=YOZHCV_>6'V&W.:EY',<,
M7WKVW<IL%(K(ZKTO$F*00;5>>LRI"MNKHEY[AR)B>SAO=6P\)H_5V=<+MGC;
ML@!JK8V*7H*O)$$#ENK;[M._*AOL#[_P^12/,K/L,"='X0ZBYD507JK;,1#_
M*!W3$O%68R"SO,6SYJF.F('Q!-IE0:D$(F^<&B?)VJ\^,==+6?R\"W$C5RT'
M415'A;P4AI^BF9*V)8Z9K4.HFWUN6/\,CUFKWN\B]CR#;[_!"4]'N$N:PR_'
MEMZ+C';O&X[[3M&9#<8@614:;F/ <,4;@#,P=ABRDL46J^YTK[WM&SP-2J^=
M=2+FDY&Q1HYD4240I&E3(7:]C/9Z5</VIT%;L'/,$#XE3)@Y6B[(>KSVX=+M
MS\%KVZ HW<$ 'I-XH>+,&X#DU^-PY*@55@M:][H!W7EVR5CJE)C<!#(3.YDO
M:,VP2F[:31^XW%J;;=\_+-2%S3(< _K!3;/BH;FAM6P8@_CV<LB/S4]G)X?Q
MQ&%SPN\5$[9ZR\B^'A$'@^9'B61)A YU+[VZ BY;)S[YI(0/OA5 ?!DW#3B-
M^MZE%SN$V=:O'KIVQ9IO"].J!>\I)-P!/7B0CIJ4=*X<;E'DQ[(LAT=CD<C]
M\-?9Z!O B[T(\0?9E_TYCV%79#*9W!-YW+U6&/8L1XMY$3V87G#)I6% CJNU
MF ;>;HQ;PQM4/ZJ8Q3D6.]]^F-M_%D#?.,&-*>G1SY,*E$A>BROH]5)TULB*
M2 DN@F(B%E4_6@RD9^)V<U:G?MER9A9;OC?G_7TD^N28\/26PPE<,BM!-HC8
M1@\O*6_+[" WPDWLW=LXB+$1NIY(S_?-+5N!5L@]G7=?L:YT/PHN\^XMVRZK
M$M+"6"!>#;U<4 :O@*1A7CL.C<;"))6=EWX>(]=:LPR#,Q=!07Z->J=5.#;_
M4W5FOM?G(.LBG:9-4(]E60.< ^Y6<E EX(X:%$U!!*5:IT$3^G6<_<JG)1,"
MR+/&7NKN8-D_KNBM[G:!=X84EICNMF9^V@#7:@8/9,Q)W0 2-YGE;@ J_1,A
MG)CA,XFEW!5L\WG9806*RR(W<[2(WJOK-)UNN&]J\65NG&)\]MD:8B#PBK5C
M*F[WQ5Q]%GN"F=0&1ZUF/WN"%;G%>2#UBJV6X!GJT611X5J6^WB"_Z2N-),S
MFJF&[(/WGC*(C5U7P77(1C_5$$9M<7@L*%GC4)8^V]<87KS QU@F2B\Y2<.3
M1G& [1J4V[L.W@D0O3\-8O$,S/DA+8U)*]9_ -R":=DX9:5?-D$^,B]@D8_;
M$Q E0;AK#<DKB[0*H-&8T(]!H39-*H&,JJ'5]3%=D0KY#"<W..HXH#)NTX5I
M>EK/8$_XB?MT9E[H47QL.7^(L;+MUSFS]N?WH7B0>D[A+YX(X1*P(9+2Q8QO
MLF!3:F,R!>H(760#1.I] _B2.D(<'+#H2[3>KN/(ZI5*J35A-=PGH\-<-X&X
MO9BG)BV!W &2)!^T8=)\BZ3I6P58,M@LMVQ +\)1<-G26E"*<\IL!D=3YWX@
MFU=63Z<LL+IOBD 2&W,Y@NYV5BKDAF\'47&0D[L115Z:C'I/""D*-ELP[S^I
M]YF]+JML!ZG= ) RF LUT8]2SC1?]/^(#:7[5?EA'9"#43J['7(M([)'GJ6R
M[9E%@PV%CP>/;T_-(%F C";T=FXHB._^N#,B#9$&A_GXQU __1AXYE5C\S2F
M>3]'TM&AGNO-#4!=EC \(27$NR76-)KKD1P5'[J-Y1E>(+Y_:O/[<X+<F0_D
MY--0$#T//:P9I>[8<$=M_>&CF-%S*/V'<EQWGS%360JZZ7C7CI/'W3K^W*Q5
M"\+)^9;,D8R,:H?*J"CZZIL/\82,V'3K0XY6*Z1CJE1[-MW\$U"'$4KLV+-!
MEKPRM],@0$\!Z[5[Z&]811M8> -(;@LL3Z@X3G9CT%)9YQ=,[YGH=+JTXE?@
M3')C-*<YWY^JHA"5Y/A-C ;W7\^-]:^)X:6UQ")8R.3M+C8">"0H3 SG+*V@
M#-;5;XK2:7YER)RG9#T>5F0=8MMKD"&+1Z$B<7^:1>.3=D9GG+P=G02B>T%J
MT<,;Q'EWU!.KAK78Y9*)D\%.^R=Y$% A[V28B 2S-(O?6T%E ^H8*9(H^T+G
M\54+GI$RN\UAM^9!;S3'JLXN/&LK(091B4^2<)]W'.MFHC"O3 SFT(]VK^3=
M%OPB_.F("]LUJD:E.ICREQ)7M7Q_A#9X,OU]97_981;(LP^:.^,OG&.L[-^8
M:S>\DUIJ!/:-:A ^*<OT')7W\@#?AX":[)G2OR4%I7]+D [M)[8Z[YTG&K[L
M2,7?  : M&_4/*.7ZI:D>CVSS#V3[)KSN.M'>S4*,];'YKX9.8^0)W%F<1%J
M4GQ,^1.].&=/RS6A*:*CH8#,4Y/<G*/5LAI27_L:X-;EUW0='31WT59U?;)5
M.RRXY2&W>H93$+'6&_>A!=Z&@-WOD'P9L+?9#"8*_V*NKR:(Z_(BK2$9E=2>
MZ0RX2L$<M7:<X,\4?FSI4%? X"X5SS(:=4W]S;29-!D:>$'2D3FL&S"UGS>
M2<-&:XUBZXB4_>*9!$G/?6GWJ/V*QCNR]QKR0&J<1J\U XI[H8;VGJNSD#S:
M :T?[AU@O<4*"Z:MFK(VT#[8"5'DUMQ0ZIE='0>J_9*J9\2CV))>:T\E>*R
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M/._VK]RGB>6SZ8V@T%97R?7X^118'LHEH8,W2L8<3S.-B[LMX2$<K0H?';-
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M],PFIV='OQYL"XN>GE=H3>E)@>9,$>.!S+U)%@M.#A$5,C*UMC/:1$(W(3E
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M/2_I4QJ[17X'?5-X#UZ*3YL+VZ"H*2<]Z:H/H?#(@[?>AKG50T=B]S$IMW7
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MFI^DIF%H7 D8IT3IA#W-;9!NM%9ML&3,7&6-]7)N/94<3X#4F@@49+A@X@)
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M#B_U;/ELQ71M[ [D7ZS1P>,&]\R 4N?6J?4Q[[LU)$V)^M9>"NI^,'SEB24
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MNNGMQD$__@RIE6OJA-.]J^"G6LW$&?_1;K.KKX[40IG3DSU=:,VJ9*HB42+
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MC[1 5N+]^]NW;!9^GJU:WCG+!I,:NE\^N;/8EX:CW.&K:!$]8@H0?3E/J>[
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M I@U-FQX8HQI^;XJJ7LYKA= CP8G7*C@0*5R(Z))#/>)EYN%?VHQJ$) L[W
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ME3VN/(T0$":G<M<97G_UU$\]9"J[7<P*ZTEW3XQEG!$$V@*%YHQMV@/_S)-
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M5=P4^J>:BG5D7BR* FK?XORR+LR'&/,^_36E<,3Q<M.B#=TD?]*!>+W.8^;
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M]L#@PN\W(W\?0G9'B.)@^:;!E-='_U4^".%2C =12Z,H>_U)BW[1K/RC C]
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MQ903M4"ZN_+/03LM"F:C4LJFF8,G'T9E,U,7?U^9F:V+BT_C$Q>0"ABHM$]
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MIJM)C1"O$IK?;79H4,^6($XOM;/,'N%Q.HY&!8AI$:\M3U_M:%&#/B,NY)5
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M27[I'_^)0P_Q7U%\UG]R;;W*7Z)H7*Z[TQJ OOYG#KT%M-WN>^I;EEMJYT<
MQ*;K5\ R*R))OT<Q9S='6GC'94ORQ$L9#Z &.2N#V;7.7CBSM/4LGGO+M\Q
M+=!SHR2)%Z24("TM3E;Y(2;GFN;S?7NWJ.1RXY9O3J1Q7_0BS!)+<\>K$!(_
MO>:3EN-+@8/A\T)<$>,&V(.2Q$/]$L5<(\O>J#[D0T(>-+B\;RKTI(S+WP%
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M9K6LL4]2E;,D^6H7/KH>91 C.2SPH=?\0S-337ZMF*N[==HD]8)LY73]K-#
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M74$[_RVLTM)2JLL#\,,A:-FRK&N$/Y*CO";IR_>7&C+#L;UK3I.<?#(M!JY
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M;>X%]2-T,QD89&> M)&M\. O!ME@K#+'C*9)Y!ZCVM0S&=23;]1$$ +8L$]
M,@XURJI*/-]Z)X6CP::+6O2$,LZ(^%DM>AWI!==8XPGW%,/8I0R,A.0;5_->
M0O7SZ2J6X>3DT/3TQ5X%IM3'SRSD.QVNRPBLE4O)]6:LY,*WY@='10-0L.49
MYBGZX@;CB!>'8D]O1'2X)&O$^0\ ZYIP15N-;"=_C SVV" C5B>C4R?_*R+
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M481T@'V9,_-1; 1"!EG4Q..TNS<K+#\J,LZ_S*D\P2RIU#J:9PZG$>9OX1)
M@,9Y%&D?PG7SLS"T%X-L"!O<@MXV?CLX.J:,2ZHYRH/]TQM8VQ-X?$=;-W29
ML^1-K5TR_77CAR_7K35!1HX738W14$C'(9'*M9KCA"EDG8AR5>."MISE1SFA
M?4XN;8$AE(RFUT;]5KEX&1)1:VQ]\?,JX3KU;NAO><HE?&EJZJ<WI1R>_4(J
M%B*36GEDK8K4@/U&7?Q< _@V<1E<W&O1[$J"2G-HD5X>6JO;?X_L-!7*)%'
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MBH1H8L_ZPB,>O26([#JDFDL:=*%>8F;KQ1KP'K,7CL@AQ \&!0D&A34$)@R
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MJ6SL;%4=E@=N.R[A^I5,YR.]JK >_;^K%[$/SD?:*,%11[VD(1X#5CDZ>-Z
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M)%CR:>8Z-I4=<W,IJ-<*+E.P'%^F.\ W._;91DB(WYO!6^TG&%D$I:.(^O;
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MVY4/#9LG\\RY'(Z\@ O6>T!*'W?0X21E6!RPA:5G2+V018:A]L%[Y5"G5([
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M]W?OS??>6[NUM;6UVS4U=>K4_#%U3O?;_?;[Z><A\];,K]K,3@+:\?CP@,Z
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MO<)]<5JG++[[^6WA-VP"B9I[7 \2'DO$QZ C-9)7&0W>R!W>U?!\B&=T^*R
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MZIL!3^Z,_O'.U6*)8578T&99%[CW8UCVP$85:!@[0+#&A<3%'E8V#P??\9N
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M$'**9M=G*IVGSV:%")7N*E*M&K)&2*I205/N@JR:%B["JG.CQ_PD3WO(?=L
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M;LON)_J,J;4BZ/BN D@7,<@^G]3-0\C,7/O@RN*:HK\/;4F),C'_D?Q^%SM
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MX>U#/TB:M;6)^<7LT&;7W"A1?:E#D?G6<5#7$3\A( "P$1 !.#CX1CCX 'S
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MHKP]W!\YA5)R9=M):E'.+BX^[^[3P;0JR2D7$Z)67YMVYUMU("?Y:L!.'@L
MX*^FI@?-[L$'M@H&=!OC*]_B<R3;FNXC0>.#(J-2;4>%E(:/IIBW8%!>$966
MD1W*MZ[;>MW*38([#,J5 B@RB 3)&,"BZFZ:"\/8)SZNR>3>ES^,ON4EYP A
M',C9WZ-<6(P)RW8QZ?**=%=O:9F5Z&==F?2SM_56K2^IQ0!GR"GZWP, 5KW_
M:NC[Y^4DZQ+2NH^K\"XT]GHG0[?I+U ($MEL7YNXX1J2H_!>?=NKVNHYU+]
M(3'X%_\1,S&ZLE/J25.NQ9^Q'/DVRXYKPDU&SKCQB7#Y$8G_0UHOP0<3.5%V
M]/F25;P88P)PMR(W?_>>5AKG\"M1"^H#KP41;6OO]=VHBKF$YTDY4P1@E-0\
MMOS4GL$C>H8/:PHW)R?:W_3Q=U,RHM%>35MCPXHM7Y]4V60>]1Z:M8-*QG.
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MA;M:#K!X8J=[8<3*_!I]L-/1_A<?_M[/&%X_81VTZ&1CI&4'\W6#Q3F,$!"
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MI,5WHL+WS@5X9%_%W6J3:'^A[M^)"BM8JBCMR"\YDV<(4[:UKR,E"P;U.Q)
M](YE]A\+@X*9+1H2U(!6@\^>/W'U[!<<YIFJP0^L*H5<RM"VF)37)4V^ @1"
MR,N&G*%]\@0*F<-O>OK"XH<4,,4)M+-T7[XK-&B)DB=K\K2W:AV_BT^#'734
MDZ9:YT59@]ZDRA\+IW9H\J-3%!Y7*0",E%+ZS9A/H0O]NG$]2[2G\A,4: ?R
MBWWV5R5:W^?2L[^Q[I8I^L1<I"MA3_:I[3E&$P7VS'W*"^GIV&!7S<<PUF=A
MB:\R&W7J<T8$5+@F&QTH+K*Z.F=-[_AEX8[J,&G?3]N_@ISW)O15CF6.+?$2
M^.-7Z(8WK%;N$SAIG#1<]\J6/36+($82_<%MX(I5P#5*?^BJ8HD19:V$BQX5
M]*,E?D W-J]"M=:FRX5(1&6 ZBGW&A&S5MR;$WE*&Y?#-X=>O:"/2R;64Q\&
M;9=KB><N+KT+<<5E\UXT$8N@FZ^#Q3I6LF3UMCZ%G3;*EFW046#N=.FAV<V3
M14VEF^5R%2SO/*>)FA+@1(J<:I SWC CP]#7VNUV&K9576@TZ?+DM55RU(8Z
M6APL)&EOQ8D=;/QMEZLD?G+PUK[:T(D%\:[@BZ[4;+FR/--.YX#7<"W*89H?
MHDZ^Y9CXWD[.]'<'N/3U6-[,QYD2(:R*@A UKSX7BG7A:%'K[C_7><98MEG=
M:12U]+_RW3[#<2N^R&X;;I(3:?2-\T/'9D<PIXH10P+6#$?#5)HR\J>=$ZL1
MRX11=9LQHLU32JYOH+-]WG)!@4. D]7%@?VU,L&4$VY*&5$PY\>=)=41<DY5
M8P,EV6_P8SIPCQIU.IDWNMM-_RA4GIZ,I=GK7&@RS0H"6!@+/=Y>NV)5Z+&B
MJB=N^D3)["W3+?>97E5+HB!;\<<B94E<^3KKM^&9ZAD3SP1CDVE($U2[J):G
M8&Q[1#\,XC]#;,CDA)[5K?<$;7O#0NY$G@1:PU4I,\S#J!N=PJJ:UK+81^>^
MQH$$\:2ZK)U=(FE(<W*ZO*.<=J%/KU:5?G7$N>[$MX<Q85I)5$29A%L?.CAW
M,U(D,.__WG_C!?ZWN1@>>M#]$=H$6?Y=?7V>(Y>^;V3!1.VV990@\RJ]LHRE
M&Z>.AUY2]B!")4&8_A;80^.>+80N*JM K.8=S[-T[2='\/P#_M)SI328/EGA
M:19R"EQ?\$7:;(,N@MID_TRQ=YT\A3=ALZAE8X9-./S5*76ON.K,8'4?LQ-2
M)\I[5JQ#ETTW'Z<OO/RN2@],9&G>*R2\]V06/=E["(*%WHG@$1%[S/3'%[5K
M8^>(TH8>WVV?>V7QD!C:6H<@;9XT%+,W27W=;-_@!IM%4!2^.>?DER?<H =O
M%O5%#ZM;IY**/GLMDU[FF)5<:"<U2Y)7P$.!YK+9:6.-671AK4(BY'XQF]LG
M-5]$!SIE$O"17TJ]]1IO+4@A&U3*\7T>N'$ZYXA?9LJAR6S*H8VN8;=1C;_)
M?_"]7S_CP*#%TAWU:]K(D.J0<7>!A*,\52INHV"%)+[Z)?%^2=+RP_>ED>(N
M*3/AFNE:AZL?*%36H"S?K,>"(1FC U\3-CQ'_*"^14'$ISCWE^8+[6W*N8+S
MHEP\0YOUA>RB7Z:A/2Y=V*"<U_NSXP*6!XM\T8A?O8OV@-51<:,8?J]88K^X
M6>F#OO5%)]@T-!@L'5S2R%KLDR>UJX:0!$RE9("PL,2:C5Z].DGY%JN:KT.X
MAAU)$UR+TTN-0#TL+#:RT9C[+WNIKRMVPD'H%M^VO2>NY<HGUWL+EO9^A))\
M/;FT@37F<>(3RC8DE2L=RJ,(A82.NIVZI=!G4/=-AQ;9U@-!L_M5?LOPHCE/
M]6*J<#V-VG:=GN8X=)&B#=$\:,!0U[[LA!U:>C%X6#75=Y DX5.*1"A14E+4
MV%)D7=3T;;(T<,5CX8"FR,E#EQ<I(B0H:6I!4"LRE*TM'5VWF"E )#MX[2?"
M&Z1 %T+H*]6!IU_$:3D[[4C'%8G8N]YQ8#TC'>^G8>9 K^JC1(NH0A> L< @
M2\MMYJUC:4QZ8XXD B44VK5);8$8Y#I-8X@&M=HT-83)'R63RKA)[S'>D\BJ
ML1AHK1-&$EGL:-2=*WAZ_D3@;#D<L+ZTW1$OX$VKK",U8R.NO4)1GJX!DB[/
MU_31YW0^@QEJ#;((W?)9&F!,:07F()E-LF(T__,>]?.VK 2125FHB.EEV[76
MQ)MVRS]OO,94E=_:\OD]Q?(>FK;&W31F_Q;)&KE+I>2- ME=0\<-+3QTC\GP
MX.CY=[SW^MNLM2TLUR_"#P/_>U1[97M5 T+KNXR9+P/6.04BIE=IKK;@Q62(
M/\K.-IAO92/9F_%2/.'/YW=(5E @K$I%'Y>=>5K=ZRC1+( D\:B+Z4EBN\S+
M*-?+RQA5;T66T*<;NEH/'OB0)9>\K1/\'HVZ1@G&J9%%@\.W&=H=E-E@X ])
MSG> #]^9-3M?I2M-$M8"3EQ:33^A$)X(1D3ZM;XD0AF6(E,,!V.4.:'@7(N!
M+;ZB+LN-&1<7H2]Z4)*MK; 4>W+LRN<^H^@4.+(>[!X[V][*,)OUL*U,M^=X
M;VQ^P:U%$__C1'=TE"VD>(1V"G.'\RH"/&"-+"V[XA@M;7_E+]@DKNP!"0B@
M 4]U8_>5_EHQ4CJD-4[TZ&'8"/JJX%D7& =.R$Q)/=$9%N2]])M.5ZNH#=ZP
M0&?15=D>/F#>XMYPM+STTE%B6;=E\Y249I'87W];>6>C RO$C>P@>N'HVNL:
MNW@@V\*/V1W^W\A[RZ@XNG5;&"*0! @0$MR=8,$AC6OP ,%=&W<:"Q(\>""X
M)<%=FL:=QBTX#8T[=..N-^^[S]GGS=[[W/OC^^ZYX]S;@VZ*&FNL*E;5>N8S
M5\^:3YX,7NZ6\6&JC901I[.X1B6_CI'&WJO84NY3Z3-Y'OO;8E4Q[BA:&FE.
M7NME4B,I6R-J:NI!:I8.Z@6%CJ%.+K[>7[EC4XKC\ W@8&'Y'[4^*1GS22<E
M5%NP<U?\Z[-/W9M@UVZ?UEF&PA((10Q)AFV>!SUHC-A5_S8N3N&KWW.X V]T
M".'W^&_E4]0/3H1C[E'<:7TRO$6LKHCT/%7A9+XO3X>7K]IBRB8&S2I/9Z/3
MDV$#>:P<499.+26/E]"DCA(ERFP2&3(=ID,,_JYR^7_<I>12 (XDU0<(D&;,
MUB%\&)6Z!J9+)%0SY [Y/L3#P$:K 4],\9T%S-^@X+M36XCZF(?YU%R[V-4"
MFY_&PLF&1Z8[EG<:-;\KO*,?W"$M"9#2?)KOE&%JRIQ0U2'-LPN.\CH<\5I+
MV)H"6S!R[Q.?Y(-$K,3/,F?/[3:GG;@/^-HT5D/%EDNA=Q1$I1^@OHV4 R,;
M6 *Z3#35JEB-6AMOCQ3+@34C#CZ32.SBG*FTTL*-X36Q<%(-MFJ'F/&W]A&W
MST64C#JTF5>75J^$X@%$@",78>G;^L]#J+,9F[?KJ8L0MHVYZ5E(&DEX+NE%
M,VZ.S:#+^S$OQY*OHU.FSHZ0E%8HW@YFP2,)7_C[( X)N5Q^ZN@@@\EG^*PS
MY4H9-@3V\,K'<A\*VUF+D^QUOAH5*V5H/=H VT]LDKXJ%D?G/B:4(L2-Q_BT
M()0$X+%N7H$+T=6\I<XJM_8Q38@A$7TBNSOA;PK09H%L4O ?UMF:X5>YKSOC
M$D\J>$%[-=;L.YMC3Z8ZD1H1LZ6,9%I#="&ETC:;+QUGA\W#/MH.?^O%]!U8
M'%I; W\!=]9UNUS@.F&JA'6$9M?",^?3N8/F/M75[7#N6T#R1N>,MZNO\.05
M#F;*<PIA]-NV&874X7N%M9IAFPVO*K_(6V2^QN"U;?HW,]C_?VQ8_G"J-3\I
MO\Y&F 5>;H'N4?#'9KI_1H<<K%J)'>\2-DA@\ONXMN/<'!Q,BAZFADN<M3S%
MM.NACR$ R(HG-#L  G._9KN0?"DV.!.AT>@B.2F%XDW6R\$9#"9UW[SK(IU$
MB%%U<JL^??0E!94KHI%5U^?7C.J!&0P1%TTM688'NYA +/1HH((&+#6\UUP?
M:1-.\HP'2N_0,RWSA3B2F(CYPM\=\'8#(%8C"0_JGRWZ1H_D/'[^LP5@<E[+
M,FKW\=CC+86N8:JJ70O$PM<7=:C?E[(GFV6 0UZ94NJ1CH%&'$!(ZW.W@KH8
M0:@%:'DNT8\!> [PD40[T_.5;JZC@FAXV$Z"7[I,@PW>IV+@*&#1JHEQVZL,
M8%;&ICM+2Z(]@K(A$+MPG8KKS&;JYB[$#+>K$CB4KEY7@.A$+(#Y?6+QZ*CL
M0(KE3;2TY3=P](.E- 5S>\T>F<&8J.8(3UHBWK=G',C+ZHQOW#/6=D536D/R
M'VB"JK2VUJTO;S#' W$F1HPV'7M72B).9;J2=9AHHZ4#K)))8XFB_QHBLN]1
M:A<]AX=!-N/YF?-8:H\Q7#29*AK4R);7>$)R>#DCJ3J, MY7OB'M4"$7[U/O
M4M^*DT\JEL+,HS2_V]FK2?LYZ\)3?.IK0Y'O.IS9,]-O =;61=6)%HYZ[Y+J
MN<Y>,L@A14(ZWJ_2_LA9D=8IL<C@YN[2MM9ZWA-+@7"^$W$6">&R3*=+C&L>
MG!R+W(5-Z00TQE=[8E2F5ZQ4[K$>2+\6B[9@"8ZP@ .;IUNQ7;PUS%NPJL>V
MA@J[%@#\6,W?G=9MG+L_J@_:D/R,5$P?"#)!-\B.6'DS]K4\.EP7G6[;6 Q%
M_QSF#N:M6%#TR^,=%UO-HBD\-9!^S0U-3LT3KF71QES0, :>VDH3YW_VHQ)Y
MKHAI\.@A:WUQ.[N2U;Q0["^0J+.5(O'4ZP92*>.%=9DN ?B.4A2BPG9^]JB4
MD@@FLL+!+([M.'RT%@L;:VE6Z-E(>)H:F"U&R*KL]6AC\^PT*>ZFG>0=Y'ED
MFR(+:&G4(T*&U$^0)CRW6<49![?7?+=+0\!VM9)_._)I ()]9E7>%G_*BK5H
M]+!QI;J;WSCSYHO,JZ8%@W:A]&[0M33\%;Q&7!8YU-=[6/WIX3MCG(8!LS\)
M8 %!:^MV#Q+U;%WMT!2EYI95M/GV'D5)Q!*[]G56!.&C1Y+%[5<O%T]BJD-G
M]'-O;^M?QX3_@U#JP6U!F#\;25WKB3?@C(3INMMM, D+;G@EE'&-]?5V]>U#
MJ9"_5ZC=*L_X#XD4(U:!0?CTF,T/8=CI/<JJ@916O:;,J,Z5HJO,G'#KC4UO
M,<$_@%-Q:(X#/);D.G=]/@K2U74#.[%G$;?U,0ZIMR=/R9%B299';XML""1
M'1%.@PAP**T>D(*[=* OU*=D_E:Y_&6%(F;<?UZYG-2"V@0Q-SN)=LO0LOJS
MB]RT>F%TV32&@F.N;U\XI4=:=#(_-D#;G8! Z8U'*I,L0K8T._('*&%E O5E
ME7Q*BG]V:A5#]M"B"A ,@F"U3KO#:V3TUD6KXK7CU+!:)C3$BKN*MA]R5'M$
M;/ 46S>L=* ^<MSHW*Q&!O?/@^]1/#U FWVWO1BI5Q;U;\_=\8S8U#))U%F1
M9^5@C4G/!]9G-B-I[?*/#A1)OCIW<DN^D*+$1?WT%*.N\6V>SG[S))*G!-*2
M.)=!57CD]VP%5(R=.#[+N/F )40$-;'9X-)XLT8U?C8W.K'ZO0D-8UN!"FX>
MO6,/'K8X)7W/:-\5"$2 **N[>P99F?.%4'H)B"@-=]PF3%.T:S3I.OQA;HM?
MBBVWN]TS0>$RU'*+_*HK/_7[#E&-2YWCG_M70)X8N*G(Q>*/A/>3Y4+/[U'R
M7+1NN[GN4:*NF%"K1O^U\$,3;RP0P0=T;^19@SQ_EI[$8_%S3<+0E%F,J,_B
M[@4AW??BRI\R) (#?&T@^O[I(,EP;ZUDYD".8>@4P"!3@N)QP_$D!%/#&A:B
M\VN0" <>'2C\(BM#N)6/OL@3X<@217S^Q!\/ %0]E.PEP:G$J'S*Q1_;2HU
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M]\D98;D3R*)E$Y*>H%_ [FPQ_=L"S>K6("\DVH0 M&/)9M9#%O0)UE-P4$]
MQ=A?'1X])U:=<NM3S#T5.@8AW\N9O&P"979H;,<&'1$!4'68Z \"9*5+-3AK
MG44C%X@=E?EDN>T'7&M-RP:U6)-GD1B064?=I5*\O$,/1H2@*6D]B3HSRN*
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MH[;5:FT9'!9Q6,HD[$=O2F-J[S5\]E#CR 'FM[E-M\>#MW%QT,J)&XM6YL%
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MVW2)@<:C@T4RXZ!IH1^9L ZMO=\;=4"K#^@J!':W4."W1BDPBM'G#F.77.A
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M4(K43Z6$).4>1&'H0ZSO8X)0<IGZ?NBGPC0ZY_0T<SOF-)*"5M0KT @+E+1
MBVL>HM.#;#]5N,-K9)88"I55I,YY)"Z(U>D9?+)HG?,*=N-U#)ZV]_Z^S9?J
MQ[RH>RQL2PF]S8LG_3NQ3?A:2$]7,Q<4!C&IB]<B98L0 E/DA2'S0^Y+HWI
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M-%)'@-#W/(CBA,'42SV(<4!(R(1@H5&G2,<83UK4J)$8B%9D\ ,Y!-XR^\$
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MM*'ZEK(!/3.O,D=!/3SC:C"NI^A59N?(X_0Z4O1;:LWF62@E"WLD:\93A?D
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M2%31\N#-,JIY'!$&(YP0B*F*(*<HAHA$.HZS1 KB58;HXHA3X_/: 5JF?]V
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M86'\[Z6X$%%0"^S^778B>YFK0N$U,'-U0-6#RSHQ<V>V4-B-Q'-78>C%@"[
M=/!AY^VCL:.+$FVN=+J^;TQHH<Q-#[=+^4[]4(O5DWU=;*.)9:%F&L=2TRB%
M@MF(JI@P2*-<0D40RG%$\AQ[5KWL'&]Z-ETC+F!+">1>8-]HSRZ0W1QYP8 ;
MF$Y?(-:2%-2BAHSE=$ D; 1GUX CQVTZZ'X<K>ER4\\".5M>J']M[?-^F/^J
M%[R8,96C)(8Y1\QL '5NL^X%C&-E?HYH1#+E<Q!P<I3)V5X[(4$II6=!EY-
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M=O6VGQEC:B13N9G:<KJ[*L_!>-E)'0"<@6GC&)<>T2#G ')WM 8 :B0O:!_
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M/_8RUP:89YQKD(ESX\GQ)F-$_MPK< -V"D(C+"R8I=&66J#4"QS,V W@I6[
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M'?QI1?1M/W\65#>B"P+5P$3FA9)_!9%+" 2M#G)VL'$K?US2^:BJQ\4;KHT
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M[<;K!=[#R;U6X'VN[WOV2?M3+.>Y*+]Q1G_PZ\J<_;M]-$U 9RRD*<.!@BK
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M"!0T7=)G#,5Z;1A)J"B2$&OH899Q @.21B*-DBA.F)M:B:,%+@_-..HE+0?
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MPBB081QF@>1"]F^K>G;<J;%0J8&2MS105EO+P9,QW:P,:]NO:;!Z?B+L"&D
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MI0-M*>?2$[#<N0)^$W*Q?,P7AGS*-<5&LYJ>0%9.Y4*:7M[Z:AT-SY=%803
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MHYB(,%,*2IEE$"<QU^RJ,AA1%*1I'$A%W%1)SHTT->(L[6MI:CB(;5Y&U;;
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M!1-?%]_,^9>5?ON]H45>_+E8LD*NGLV^Q,?%TV:M_UD[6998Z*_1[J0JS5!
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M7%T#3>T9KFT%.V.K -K^A=H)Z^4HPQ=8 S_@YW#J$8%T F8?CO@";J38I#^
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MX!!A'*@PSG 8LEZ9@HY!IT:R[4WMMMGFJ$)M>,_\0!?RCOD!3WB.F!_86CE
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M__1__D?S&_T?HWGV?_['_P]02P,$%     @ ;GYI41Q&Q%IPK@  E\L' !0
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M?_N)N"ZX7&)^?::;>YG;<+8FZXJ;3PZA]_]U&I;TQ-GW]_AEL5Q/G)2^.!>
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MIE_Q15B'<[8FD@4I=+3@>$:*D>D/CXHLH'8HE2E6\"%.UA^B83>@=)_$'$#
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M4K)P5;S533H3[$;>N#7,HYG1@S75*0(O/)IWX7MU9VCUG9>]7K]0HE$6XK6
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MLUCCQ4VOB1%*VE0LZ.QXW0*(#W)#Z*M H99PQ:8F5Y_N(VC<6Z$CHFQOK72
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M#W<&/M!+KDU82MZ64#1813PKRSEX%2+]D7QAS'JFF]3?[D9>MZU>GH*7.Z4
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MFF1 *Z(X'3G?I4?P;MJ__N;Q&DL-HOV]A=A!/OF!/? JS>13])*; !(K3X'
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ML1?XI<;P%VN*ZQP,DE1B[28;2%(^H(/$)0;.BI*^R0;[ $WCIMO[@>! 6NL
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M>[/E-I(D7?B)_%CLRR5+2YM^4Y5DDKK;YMS 8O&0,$,":BRJTGGZWP,$%Y$
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M0>MSLGV'X.U1!6!C-?9VHGXN\W<CD"=^Y?@[T7[>V]:,'BN 04RM1!X$[<-
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M5R&O1D4*BKQF IP1+@;-DVHSY:B=]_QF1L]:UY9]UV7DRDEK2B(.:VJ?LBQ
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MTA?SY?6$GL"8*J8>D.I",C1"0 A10XI,>ED2.<2-C.%.>KJ![)E==YPN^5$
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M<AR3;6>_6$O>5[$%A N:D.0,V3 G282Q^**=B3*W\%W.-_O%ENA*D(YB(N-
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M;9L>*\^K4<]!VN[:J.<0T0^^3^TYTKK+Z%IAWO*UZ06?B:6D2YWF5ON[:F:
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M\,-U>^$KZ[G@6[N\<CZ(8GT%2[Y-D"T14%( []%Y4WFON4NITYYUC?J6?PS
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M0&N00Q=4V*4-;-XRA\H=G0A_A^MI,13N?(-_^(/V(]*J_-=__!]02P,$%
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MEVY]R .?3U77\#&7_ZSL]"]02P,$%     @ ;GYI4>\W*_A@"   BR<  !8
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M+3(P,C P.3,P+FAT;5!+ 0(4 Q0    ( &Y^:5%"8\8_E!0  (G;   0
M          "  9XI P!I;F\M,C R,# Y,S N>'-D4$L! A0#%     @ ;GYI
M40B;L_*]*0  A;8! !0              ( !8#X# &EN;RTR,#(P,#DS,%]C
M86PN>&UL4$L! A0#%     @ ;GYI4?F#:CW0D@  DD<& !0
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M2P$"% ,4    " !N?FE1NT2#'%0(  "Q)@  %@              @ 'CZPL
M:6YO+3DS,#(P>#$P<65X,S$Q+FAT;5!+ 0(4 Q0    ( &Y^:5'O-ROX8 @
M (LG   6              "  6OT"P!I;F\M.3,P,C!X,3!Q97@S,3(N:'1M
M4$L! A0#%     @ ;GYI4;R42U-N!@  >2(  !8              ( !__P+
M &EN;RTY,S R,'@Q,'%E>#,R,2YH=&U02P4&      H "@"1 @  H0,,

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
